

=> d his

(FILE 'HOME' ENTERED AT 14:08:54 ON 26 MAR 2002)

(FILE 'MEDLINE, CABA, CAPLUS, BIOTECHNO, CONFSCI, EMBASE, BIOTECHDS, WPIDS' ENTERED AT 14:09:39 ON 26 MAR 2002)

L1 2370 S MITCHELL W?/AU  
L2 592 S STRATTON C?/AU  
L3 32 S L1 AND L2  
L4 40243 S ?CHLAMYDI?  
L5 53 S L4 AND (L1 OR L2)  
L6 55 S L3 OR L5  
L7 30 DUP REM L6 (25 DUPLICATES REMOVED)

(=> d ibib-ab 17 1-30) fil hom

L7 ANSWER 1 OF 30 MEDLINE DUPLICATE 1  
ACCESSION NUMBER: 2001371246 MEDLINE  
DOCUMENT NUMBER: 21241020 PubMed ID: 11342681  
TITLE: CSF oligoclonal bands in MS include antibodies against Chlamydomydia antigens.  
COMMENT: Comment in: Neurology. 2001 May 8;56(9):1126-7  
Comment in: Neurology. 2001 May 8;56(9):1128-9  
Comment in: Neurology. 2001 May 8;56(9):1130  
AUTHOR: Yao S Y; Stratton C W; Mitchell W M; Sriram S  
CORPORATE SOURCE: Department of Neurology, Vanderbilt University School of Medicine, Nashville, TN, USA.  
SOURCE: NEUROLOGY, (2001 May 8) 56 (9) 1168-76.  
Journal code: NZO; 0401060. ISSN: 0028-3878.  
PUB. COUNTRY: United States  
Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals  
ENTRY MONTH: 200106  
ENTRY DATE: Entered STN: 20010702  
Last Updated on STN: 20010702  
Entered Medline: 20010628  
AB BACKGROUND: Considerable evidence suggests the role of an infectious agent in MS. The presence of Chlamydomydia pneumoniae in CSF from patients with MS was shown earlier; to further examine this association the reactivity of the oligoclonal antibody response in the CSF of patients with MS to C pneumoniae antigens was determined and compared with other antigens. METHODS: Seventeen patients with MS and 14 control subjects with other neurologic disease were studied. Affinity-driven immunoblot studies and solid-phase adsorption of CSF oligoclonal bands by elementary body antigens of C pneumoniae, viral antigens (measles and herpes simplex virus-1), bacterial antigen (Escherichia coli and Staphylococcus aureus), and heat shock protein-60 were performed. RESULTS: Affinity-driven immunoblot studies demonstrated reactivity of oligoclonal bands in CSF samples from 16 patients with MS against elementary body antigens of C pneumoniae. None of the control subjects showed a prominent reactivity to elementary body antigens of C pneumoniae. In 14 of 17 patients with MS examined, oligoclonal bands were adsorbed either partially or completely from the CSF by elementary body antigens of C pneumoniae, but not by myelin basic protein, heat shock protein-60, or bacterial or viral antigens. In three patients with subacute sclerosing panencephalitis, adsorption of oligoclonal bands was seen with measles virus antigens but not with elementary body antigens of C pneumoniae. CONCLUSIONS: Oligoclonal bands in CSF of patients with MS include antibodies against Chlamydomydia antigens.

L7 ANSWER 2 OF 30 MEDLINE DUPLICATE 2

ACCESSION NUMBER: 2001435272 MEDLINE  
DOCUMENT NUMBER: 21229846 PubMed ID: 11331036  
TITLE: Regulation by IFN-beta of inducible nitric oxide synthase and interleukin-12/p40 in murine macrophages cultured in the presence of *Chlamydia pneumoniae* antigens.  
AUTHOR: Yao S Y; Ljunggren-Rose A; Stratton C W; Mitchell W M; Sriram S  
CORPORATE SOURCE: Department of Neurology, Vanderbilt University School of Medicine, Nashville, TN 37212, USA.  
SOURCE: JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, (2001 Mar) 21 (3) 137-46.  
PUB. COUNTRY: Journal code: CD4; 9507088. ISSN: 1079-9907. United States  
LANGUAGE: Journal; Article; (JOURNAL ARTICLE) English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 200108  
ENTRY DATE: Entered STN: 20010806  
Last Updated on STN: 20010806  
Entered Medline: 20010802

AB *Chlamydia pneumoniae* has been demonstrated in the cerebrospinal fluid (CSF) of patients with multiple sclerosis (MS). Interferon-beta (IFN-beta) has favorable effects on the clinical course of MS. We investigated whether the beneficial effects of IFN-beta in MS may involve its role in regulating nitric oxide (NO) and interleukin-12 (IL-12) in macrophages, as these immune modulators form part of the innate immune response to intracellular pathogens, such as *C. pneumoniae*. Murine macrophages in cultures exposed to elementary body antigens or recombinant major outer membrane protein (rMOMP) of *C. pneumoniae* demonstrate a significant increase in NO as well as production of IL-12/p40 in culture supernatants compared with basal levels. Addition of murine IFN-beta increased NO activity in murine macrophages cultured with *chlamydial* antigens. Addition of neutralizing anti-IFN-beta antibody prevented the NO increase. In contrast to its effect on inducible NO synthase (iNOS), IFN-beta reduced induction of IL-12/p40 following culture with either elementary body antigens or rMOMP. Inhibition was reversed with anti-IFN-beta antibody. If *C. pneumoniae* infection is responsible for the inflammatory response in the pathogenesis of MS, the beneficial effects of IFN-beta in MS may be due to its enhancing intracellular NO activity while inhibiting secretion of the proinflammatory cytokine, IL-12.

L7 ANSWER 3 OF 30 MEDLINE DUPLICATE 5  
ACCESSION NUMBER: 2000111212 MEDLINE  
DOCUMENT NUMBER: 20111212 PubMed ID: 10642692  
TITLE: Pyoderma gangrenosum and *Chlamydia pneumoniae* infection in a diabetic man: pathogenic role or coincidence?  
AUTHOR: Vannucci S A; Mitchell W M; Stratton C W ; King L E Jr  
CORPORATE SOURCE: Department of Medicine, Division of Dermatology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-5227, USA.  
SOURCE: JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, (2000 Feb) 42 (2 Pt 1) 295-7.  
PUB. COUNTRY: Journal code: HVG; 7907132. ISSN: 0190-9622. United States  
LANGUAGE: Journal; Article; (JOURNAL ARTICLE) English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 200002  
ENTRY DATE: Entered STN: 20000309  
Last Updated on STN: 20000309

Entered Medline: 20000224

AB **Chlamydia** Pneumoniae is not a known cause of skin infections, but unusual pathogens cause chronic infections in diabetic patients. Multiple idiopathic pyoderma gangrenosum-like (PG-like) lesions were refractory to multiple therapeutic agents in a diabetic patient who had C pneumoniae identified by serologic tests and polymerase chain reaction. Based on complete resolution by prolonged anti-**chlamydial** antibiotic therapy and concomitant decrease in serologic and titers determined by polymerase chain reactions, the PG-like lesions were presumed to be due to C pneumoniae.

L7 ANSWER 4 OF 30 MEDLINE DUPLICATE 6  
ACCESSION NUMBER: 1999206606 MEDLINE  
DOCUMENT NUMBER: 99206606 PubMed ID: 10192388  
TITLE: Comparative genomes of **Chlamydia** pneumoniae and C. trachomatis.  
AUTHOR: Kalman S; **Mitchell W**; Marathe R; Lammel C; Fan J; Hyman R W; Olinger L; Grimwood J; Davis R W; Stephens R S  
CORPORATE SOURCE: Stanford DNA Sequencing and Technology Center, Stanford University, California 94305, USA.  
SOURCE: NATURE GENETICS, (1999 Apr) 21 (4) 385-9.  
Journal code: BRO; 9216904. ISSN: 1061-4036.  
PUB. COUNTRY: United States  
Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
OTHER SOURCE: GENBANK-AE001273; GENBANK-AE001363  
ENTRY MONTH: 199904  
ENTRY DATE: Entered STN: 19990511  
Last Updated on STN: 19990511  
Entered Medline: 19990426

AB **Chlamydia** are obligate intracellular eubacteria that are phylogenetically separated from other bacterial divisions. C. trachomatis and C. pneumoniae are both pathogens of humans but differ in their tissue tropism and spectrum of diseases. C. pneumoniae is a newly recognized species of **Chlamydia** that is a natural pathogen of humans, and causes pneumonia and bronchitis. In the United States, approximately 10% of pneumonia cases and 5% of bronchitis cases are attributed to C. pneumoniae infection. Chronic disease may result following respiratory-acquired infection, such as reactive airway disease, adult-onset asthma and potentially lung cancer. In addition, C. pneumoniae infection has been associated with atherosclerosis. C. trachomatis infection causes trachoma, an ocular infection that leads to blindness, and sexually transmitted diseases such as pelvic inflammatory disease, chronic pelvic pain, ectopic pregnancy and epididymitis. Although relatively little is known about C. trachomatis biology, even less is known concerning C. pneumoniae. Comparison of the C. pneumoniae genome with the C. trachomatis genome will provide an understanding of the common biological processes required for infection and survival in mammalian cells. Genomic differences are implicated in the unique properties that differentiate the two species in disease spectrum. Analysis of the 1,230,230-nt C. pneumoniae genome revealed 214 protein-coding sequences not found in C. trachomatis, most without homologues to other known sequences. Prominent comparative findings include expansion of a novel family of 21 sequence-variant outer-membrane proteins, conservation of a type-III secretion virulence system, three serine/threonine protein kinases and a pair of paralogous phospholipase-D-like proteins, additional purine and biotin biosynthetic capability, a homologue for aromatic amino acid (tryptophan) hydroxylase and the loss of tryptophan biosynthesis genes.

L7 ANSWER 5 OF 30 MEDLINE DUPLICATE 7  
ACCESSION NUMBER: 1999328202 MEDLINE

DOCUMENT NUMBER: 99328202 PubMed ID: 10401775  
TITLE: **Chlamydia** pneumoniae infection of the central nervous system in multiple sclerosis.  
COMMENT: Comment in: Ann Neurol. 1999 Jul;46(1):4-5  
Comment in: Ann Neurol. 2000 Mar;47(3):408-9; discussion 409-11  
Comment in: Ann Neurol. 2000 Mar;47(3):408; discussion 409-11  
Comment in: Ann Neurol. 2000 Sep;48(3):399  
Comment in: Ann Neurol. 2000 Sep;48(3):399-400  
Comment in: Ann Neurol. 2000 Sep;48(3):400  
Comment in: Ann Neurol. 2001 Jan;49(1):135  
AUTHOR: Sriram S; **Stratton C W**; Yao S; Tharp A; Ding L; Bannan J D; **Mitchell W M**  
CORPORATE SOURCE: Department of Neurology, Vanderbilt School of Medicine, Nashville, TN, USA.  
SOURCE: ANNALS OF NEUROLOGY, (1999 Jul) 46 (1) 6-14.  
Journal code: 7707449. ISSN: 0364-5134.  
PUB. COUNTRY: United States  
Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 199908  
ENTRY DATE: Entered STN: 19990816  
Last Updated-on-STN: 20020314  
Entered Medline: 19990802

AB Our identification of **Chlamydia** pneumoniae in the cerebrospinal fluid (CSF) of a patient with multiple sclerosis (MS) led us to examine the incidence of this organism in the CSF from 17 patients with relapsing-remitting MS, 20 patients with progressive MS, and 27 patients with other neurological diseases (OND). CSF samples were examined for C pneumoniae by culture, polymerase chain reaction assays, and CSF immunoglobulin (Ig) reactivity with C pneumoniae elementary body antigens. C pneumoniae was isolated from CSF in 64% of MS patients versus 11% of OND controls. Polymerase chain reaction assays demonstrated the presence of C pneumoniae MOMP gene in the CSF of 97% of MS patients versus 18% of OND controls. Finally, 86% of MS patients had increased CSF antibodies to C pneumoniae elementary body antigens as shown by enzyme-linked immunosorbent assay absorbance values that were 3 SD greater than those seen in OND controls. The specificity of this antibody response was confirmed by western blot assays of the CSF, using elementary body antigens. Moreover, CSF isoelectric focusing followed by western blot assays revealed cationic antibodies against C pneumoniae. Infection of the central nervous system with C pneumoniae is a frequent occurrence in MS patients. Although the organism could represent the pathogenetic agent of MS, it may simply represent a secondary infection of damaged central nervous system tissue. A therapeutic trial directed at eliminating C pneumoniae from the central nervous system may provide additional information on its role in MS.

L7 ANSWER 6 OF 30 MEDLINE DUPLICATE 10  
ACCESSION NUMBER: 1999000809 MEDLINE  
DOCUMENT NUMBER: 99000809 PubMed ID: 9784136  
TITLE: Genome sequence of an obligate intracellular pathogen of humans: **Chlamydia** trachomatis.  
COMMENT: Comment in: Science. 1998 Oct 23;282(5389):638-9  
AUTHOR: Stephens R S; Kalman S; Lammel C; Fan J; Marathe R; Aravind L; **Mitchell W**; Olinger L; Tatusov R L; Zhao Q; Koonin E V; Davis R W  
CORPORATE SOURCE: Program in Infectious Diseases, University of California, Berkeley, CA 94720, USA.. ctgenome@socrates.berkeley.edu  
CONTRACT NUMBER: AI 39258 (NIAID)  
SOURCE: SCIENCE, (1998 Oct 23) 282 (5389) 754-9.



Journal code: UJ7; 0404511. ISSN: 0036-8075.  
PUB. COUNTRY: United States  
Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
OTHER SOURCE: GENBANK-AE001275; GENBANK-AE001276; GENBANK-AE001277;  
GENBANK-AE001278; GENBANK-AE001279; GENBANK-AE001280;  
GENBANK-AE001281; GENBANK-AE001282; GENBANK-AE001283;  
GENBANK-AE001284; GENBANK-AE001285; GENBANK-AE001286;  
GENBANK-AE001287; GENBANK-AE001288; GENBANK-AE001289;  
GENBANK-AE001290; GENBANK-AE001291; GENBANK-AE001292;  
GENBANK-AE001293; GENBANK-AE001294; GENBANK-AE001295;  
GENBANK-AE001296; GENBANK-AE001297; GENBANK-AE001298;  
GENBANK-AE001299; GENBANK-AE001300; GENBANK-AE001301;  
GENBANK-AE001302; GENBANK-AE001303; GENBANK-AE001304  
ENTRY MONTH: 199811  
ENTRY DATE: Entered STN: 19990106  
Last Updated on STN: 20000303  
Entered Medline: 19981109

AB Analysis of the 1,042,519-base pair **Chlamydia** trachomatis genome revealed unexpected features related to the complex biology of **chlamydiae**. Although **chlamydiae** lack many biosynthetic capabilities, they retain functions for performing key steps and interconversions of metabolites obtained from their mammalian host cells. Numerous potential virulence-associated proteins also were characterized. Several eukaryotic chromatin-associated domain proteins were identified, suggesting a eukaryotic-like mechanism for **chlamydial** nucleoid condensation and decondensation. The phylogenetic mosaic of **chlamydial** genes, including a large number of genes with phylogenetic origins from eukaryotes, implies a complex evolution for adaptation to obligate intracellular parasitism.

L7 ANSWER 7 OF 30 MEDLINE DUPLICATE 11  
ACCESSION NUMBER: 1998145402 MEDLINE  
DOCUMENT NUMBER: 98145402 PubMed ID: 9484408  
TITLE: Multiple sclerosis associated with **Chlamydia** pneumoniae infection of the CNS.  
COMMENT: Comment in: Neurology. 2001 Aug 28;57(4):746  
AUTHOR: Sriram S; Mitchell W; Stratton C  
CORPORATE SOURCE: Department of Neurology, Vanderbilt University Medical Center, Nashville, TN 37212, USA.  
SOURCE: NEUROLOGY, (1998 Feb) 50 (2) 571-2.  
Journal code: 0401060. ISSN: 0028-3878.  
PUB. COUNTRY: United States  
Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals  
OTHER SOURCE: GENBANK-AF131889  
ENTRY MONTH: 199803  
ENTRY DATE: Entered STN: 19980326  
Last Updated on STN: 20020130  
Entered Medline: 19980316

L7 ANSWER 8 OF 30 MEDLINE DUPLICATE 13  
ACCESSION NUMBER: 92346653 MEDLINE  
DOCUMENT NUMBER: 92346653 PubMed ID: 1638577  
TITLE: Fluoroquinolone antibiotics: properties of the class and individual agents.  
AUTHOR: Stratton C  
CORPORATE SOURCE: Department of Pathology, Vanderbilt University Medical Center, Nashville, Tennessee.  
SOURCE: CLINICAL THERAPEUTICS, (1992 May-Jun) 14 (3) 348-75; discussion 347. Ref: 121

PUB. COUNTRY: Journal code: CPE; 7706726. ISSN: 0149-2918.  
United States  
Journal; Article; (JOURNAL ARTICLE)  
General Review; (REVIEW)  
(REVIEW, TUTORIAL)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 199209  
ENTRY DATE: Entered STN: 19920911  
Last Updated on STN: 19920911  
Entered Medline: 19920901

AB The broad spectrum of activity and bactericidal nature of the fluoroquinolones, together with their excellent absorption, rapid distribution, and high tissue concentration, make them excellent therapeutic agents for the management of a number of complicated community-acquired and nosocomial infections of the urinary tract, bone and soft tissue, gastrointestinal tract, and prostate, as well as some respiratory tract infections and sexually transmitted diseases. Data are presented and reviewed concerning the in vitro activity, pharmacology, and clinical use of ciprofloxacin, norfloxacin, and ofloxacin, which have been available for some time, and lomefloxacin and temafloxacin, which are recently approved agents. The comparable qualities and differences in activity and clinical applications of these agents are considered. For many infections in selected patients, quinolones are excellent substitutes for parenteral agents. In general, adverse effects have been infrequent and rarely require drug discontinuation. Significant interactions, such as with theophylline and caffeine, have occurred but are quinolone dependent. Antacids can markedly impair the absorption of all quinolones. Because emerging resistance to *Pseudomonas* and *Staphylococcus* species have been observed, the improper use of the quinolones must be avoided, and the clinician must be aware that an unfavorable response may signal resistance. The development of future agents with better gram-positive activity, improved gram-negative coverage, and activity against unusual pathogens such as *Chlamydia* species and *Mycobacterium* species, will make these oral agents invaluable. Assessing the usefulness and safety of these antibiotics in children is an ongoing challenge.

L7 ANSWER 9 OF 30 MEDLINE  
ACCESSION NUMBER: 2001314629 MEDLINE  
DOCUMENT NUMBER: 21244261 PubMed ID: 11346358  
TITLE: Diabetic foot ulcers and *Chlamydia pneumoniae*:  
innocent bystander or opportunistic pathogen?.  
AUTHOR: King L E Jr; Bushman T; Stratton C W;  
Mitchell W M  
SOURCE: ARCHIVES OF DERMATOLOGY, (2001 May) 137 (5) 671-2.  
Journal code: 6WU; 0372433. ISSN: 0003-987X.  
PUB. COUNTRY: United States  
Letter  
LANGUAGE: English  
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals  
ENTRY MONTH: 200106  
ENTRY DATE: Entered STN: 20010611  
Last Updated on STN: 20010611  
Entered Medline: 20010607

L7 ANSWER 10 OF 30 MEDLINE  
ACCESSION NUMBER: 2000092443 MEDLINE  
DOCUMENT NUMBER: 20092443 PubMed ID: 10628821  
TITLE: Does *Chlamydia pneumoniae* play a role in the  
pathogenesis of multiple sclerosis?.  
AUTHOR: Stratton C W; Mitchell W M; Sriram S  
SOURCE: JOURNAL OF MEDICAL MICROBIOLOGY, (2000 Jan) 49 (1) 1-3.  
Journal code: J2N; 0224131. ISSN: 0022-2615.

PUB. COUNTRY: ENGLAND: United Kingdom  
 Editorial  
 LANGUAGE: English  
 FILE SEGMENT: Priority Journals  
 ENTRY MONTH: 200001  
 ENTRY DATE: Entered STN: 20000124  
 Last Updated on STN: 20000124  
 Entered Medline: 20000113

L7 ANSWER 11 OF 30 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 3  
 ACCESSION NUMBER: 2000:688466 CAPLUS  
 DOCUMENT NUMBER: 133:249334  
 TITLE: Methods and reagents for the diagnosis and treatment  
 of multiple sclerosis caused by **Chlamydia**  
 INVENTOR(S): **Stratton, Charles W.; Mitchell, William**  
**M.; Yao, Song-yi; Bannan, Jason D.;**  
**Ljunggren-Rose, Asa; Sriram, Subramaniam**  
 PATENT ASSIGNEE(S): Vanderbilt University, USA  
 SOURCE: PCT Int. Appl., 102 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000057187	A2	20000928	WO 2000-US7226	20000317
WO 2000057187	A3	20010419		
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1166117	A2	20020102	EP 2000-916513	20000317
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
PRIORITY APPLN. INFO.:			US 1999-125598P	P 19990319
			US 2000-176662P	P 20000118
			US 2000-176784P	P 20000118
			US 2000-176940P	P 20000118
			WO 2000-US7226	W 20000317

AB The invention features methods and reagents for the diagnosis, monitoring, and treatment of multiple sclerosis. The invention is based in part on the discovery that **Chlamydia** is present in patients with multiple sclerosis, and that anti-**chlamydial** agents improve or sustain neurol. function in these patients.

L7 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 4  
 ACCESSION NUMBER: 2000:335519 CAPLUS  
 DOCUMENT NUMBER: 133:1493  
 TITLE: **Chlamydia pneumoniae** genome sequence  
 INVENTOR(S): **Stephens, Richard; Mitchell, Wayne; Kalman, Sue; Davis, Ronald**  
 PATENT ASSIGNEE(S): The Regents of the University of California, USA  
 SOURCE: PCT Int. Appl., 330 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000027994	A2	20000518	WO 1999-US26923	19991112
WO 2000027994	A3	20001123		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2000017223	A5	20000529	AU 2000-17223	19991112
EP 1133572	A2	20010919	EP 1999-960323	19991112
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

PRIORITY APPLN. INFO.:

US 1998-108279P P 19981112  
US 1999-128606P P 19990408  
WO 1999-US26923 W 19991112

AB The **Chlamydia** pneumoniae genome sequence and anal. of the encoded polypeptides and RNAs are provided. The *C. pneumoniae* genome contains 187,711 addnl. nucleotides compared to the *C. trachomatis* genome, and the 214 coding sequences not found in *C. trachomatis* account for most of the increased genome size. The majority of these addnl. genes lack identifiable homologs to genes from other organisms, and probably are essential for specific attributes that define the differential biol., tropism, and pathogenesis of *C. trachomatis* and *C. pneumoniae*. The *C. pneumoniae* gene nucleic acid compns. find use in identifying homologous or related proteins and the DNA sequences encoding such proteins; in producing compns. that modulate the expression or function of the protein; and in studying assocd. physiol. pathways. In addn., modulation of the gene activity in vivo is used for prophylactic and therapeutic purposes, such as identification of cell type based on expression, and the like.

L7 ANSWER 13 OF 30 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 8  
ACCESSION NUMBER: 1998:752291 CAPLUS  
DOCUMENT NUMBER: 130:10609  
TITLE: Diagnosis and management of infection caused by **Chlamydia**  
INVENTOR(S): Mitchell, William M.; Stratton, Charles W.  
PATENT ASSIGNEE(S): Vanderbilt University, USA  
SOURCE: PCT Int. Appl., 139 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 4  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9850074	A2	19981112	WO 1998-US9237	19980506
WO 9850074	A3	19990819		
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,				

FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,  
CM, GA, GN, ML, MR, NE, SN, TD, TG

US 2001002421 A1 20010531 US 1998-25176 19980218  
US 6258532 B1 20010710  
AU 9872899 A1 19981127 AU 1998-72899 19980506  
EP 981372 A2 20000301 EP 1998-920292 19980506

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, FI

ZA 9803798 A 20000307 ZA 1998-3798 19980506  
PRIORITY APPLN. INFO.: US 1997-45689P P 19970506  
US 1997-45739P P 19970506  
US 1997-45779P P 19970506  
US 1997-45780P P 19970506  
US 1997-45784P P 19970506  
US 1997-45787P P 19970506  
US 1997-911593 A 19970814  
US 1998-25176 A2 19980218  
US 1998-25521 A2 19980218  
US 1998-25174 A 19980218  
WO 1998-US9237 W 19980506

AB A combination of agents directed toward various stages of the **chlamydial** life cycle is effective in substantially reducing infection. These include agents targeted against the cryptic phase (e.g. nitroarom. compds.), elementary body phase (e.g. disulfide reducing agents), and replicating phase, probenecid, and antiporphyrin agents. **Chlamydia**-free cell lines and animals can be obtained, and **Chlamydia** infections can be treated, by use of .gtoreq.2 such agents. **Chlamydia** infections may be diagnosed or monitored by immunoassays (e.g. ELISA or antigen capture assay) for the cysteine-rich major outer membrane protein or for specific antigenic peptides, DNA amplification assays (e.g. PCR) for **chlamydial** genes, and Western blot assays. Thus, a multiple sclerosis patient showing progressive limb impairment was diagnosed with *C. pneumoniae* infection by cerebrospinal fluid PCR and culture; treatment with rifampin (300 mg twice a day for 2 mo against the elementary body/reticulate body transition), flagyl (500 mg twice a day for 5 mo against the stationary phase reticulate body), and ofloxacin (for 2 mo) and Bactrim (double strength twice a day) and levaquin (500 mg/day) for 5 mo against the replicating reticulate body resulted in marked improvement in all aspects of neurol. function and an ability to return to work and routine athletic activities.

L7 ANSWER 14 OF 30 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 9  
ACCESSION NUMBER: 1998:124043 CAPLUS  
DOCUMENT NUMBER: 128:201045  
TITLE: Compositions of **antichlamydial** agents for  
the diagnosis and management of infection caused by  
**chlamydia**  
INVENTOR(S): Mitchell, William M.; Stratton, Charles  
W.  
PATENT ASSIGNEE(S): Vanderbilt University, USA; Mitchell, William M.;  
Stratton, Charles W.  
SOURCE: PCT Int. Appl., 83 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 4  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9806435	A2	19980219	WO 1997-US14402	19970814
WO 9806435	A3	19980409		

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,

DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ,  
 LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL,  
 PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US,  
 UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR,  
 GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA,  
 GN, ML, MR, NE, SN, TD, TG

AU 9741516 A1 19980306 AU 1997-41516 19970814  
 PRIORITY APPLN. INFO.: US 1996-23921P P 19960814  
 WO 1997-US14402 W 19970814

AB The invention provides a unique approach for the diagnosis and management of infections by **Chlamydia** species, particularly *C. pneumoniae*. The invention is based, in part, on the discovery that a combination of agents directed toward the various stages of the **chlamydial** life cycle is effective in substantially reducing infection. Products comprising combination of **antichlamydial** agents, compns., and pharmaceutical packs are also described.

L7 ANSWER 15 OF 30 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:65982 CAPLUS  
 DOCUMENT NUMBER: 136:133602  
 TITLE: Identification of antigenic peptide sequences  
 INVENTOR(S): Mitchell, William M.; Stratton, Charles W.  
 PATENT ASSIGNEE(S): Vanderbilt University, USA  
 SOURCE: U.S., 40 pp., Cont.-in-part of U.S. Ser. No. 911,593, abandoned.  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 4  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6340463	B1	20020122	US 1998-25596	19980218
PRIORITY APPLN. INFO.:			US 1996-23921P	P 19960814
			US 1997-911593	B2 19970814

AB Identification of linear amino acid antigenic sequences for the prodn. of both polyclonal and monoclonal antibodies to defined antigenic domains is described. Also described are antigenic peptides identified by the described methods and antibodies thereto.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 16 OF 30 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:397834 CAPLUS  
 DOCUMENT NUMBER: 135:2559  
 TITLE: Methods for in vitro susceptibility testing of **Chlamydia**  
 INVENTOR(S): Stratton, Charles W.; Mitchell, William M.  
 PATENT ASSIGNEE(S): USA  
 SOURCE: U.S. Pat. Appl. Publ., 9 pp., Cont.-in-part of U.S. Ser. No. 911,593, abandoned.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 4  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

US 2001002421 A1 20010531 US 1998-25176 19980218  
 US 6258532 B1 20010710  
 US 2002009802 A1 20020124 US 1998-25174 19980218  
 WO 9850074 A2 19981112 WO 1998-US9237 19980506  
 WO 9850074 A3 19990819

W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

AU 9872899 A1 19981127 AU 1998-72899 19980506  
 EP 981372 A2 20000301 EP 1998-920292 19980506

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI

PRIORITY APPLN. INFO.:

US 1997-911593 B2 19970814  
 US 1997-45689P P 19970506  
 US 1997-45739P P 19970506  
 US 1997-45779P P 19970506  
 US 1997-45780P P 19970506  
 US 1997-45784P P 19970506  
 US 1997-45787P P 19970506  
 US 1998-25174 A 19980218  
 US 1998-25176 A2 19980218  
 US 1998-25521 A2 19980218  
 WO 1998-US9237 W 19980506

AB Methods for detg. the susceptibility of intracellular pathogens, particularly **Chlamydia**, to single or combination of test agents are described. The methods can be used for in vitro or in vivo evaluation of agents that can be used as therapeutic agents in the treatment/eradication of pathogen infection in general or to target a specific infected organ. Assays which utilize nucleic amplification techniques (e.g., PCR) to det. effectiveness of the agent(s) evaluated are also described.

L7 ANSWER 17 OF 30 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:607994 CAPLUS

DOCUMENT NUMBER: 136:84535

TITLE: Association of multiple sclerosis with **Chlamydia pneumoniae**: Demonstration of the 16S rRNA gene and immunoreactivity of CSF cationic antibodies against C. pneumoniae antigens

AUTHOR(S): Sriram, S.; Stratton, C. W.; Yao, S.; Bannan, J. D.; Mitchell, W. M.

CORPORATE SOURCE: Department of Neurology, Vanderbilt School of Medicine, Nashville, TN, USA

SOURCE: Genes and Viruses in Multiple Sclerosis (2001), 221-229. Editor(s): Hommes, Otto R.; Clanet, Michel; Wekerle, Hartmut. Elsevier Science B.V.: Amsterdam, Neth.

CODEN: 69BRQ7

DOCUMENT TYPE: Conference

LANGUAGE: English

AB The immunoreactivity of the cationic antibodies in the CSF of multiple sclerosis (MS) patients was evaluated using affinity-driven immunoblot assays. Among the 17 CSF samples from MS patients, 88% contained DNA specific for the 16S rRNA gene of **Chlamydia pneumoniae**. MS patients had an increased Igs in the CSF, and part of the increase was represented as oligoclonal bands on isoelec. focusing gels. The development of an intrathecal immune response to C. pneumoniae was found to be a common occurrence in patients with MS. The cationic anti-EB

antibodies were present in patients with MS and might represent in part the specificity of the oligoclonal bands. The results of IEF/affinity-driven assays showed that a CNS immune response specifically to *C. pneumoniae* EB antigens was present in patients with MS.

REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 18 OF 30 CONFSCI COPYRIGHT 2002 CSA

ACCESSION NUMBER: 85:2268 CONFSCI

DOCUMENT NUMBER: 85002357

TITLE: Clinical evaluation of the MicroTrak direct specimen test for the detection of *Chlamydia trachomatis* in genital specimens

AUTHOR: Peters, T.H.; Lefkowitz, L.B.; Ratner, H.B.; Davidson, T.L.; Stratton, C.W.

CORPORATE SOURCE: Vanderbilt Univ. Med. Cent. and Metropolitan Health Dep., Nashville-Davidson County, Nashville, TN, USA

SOURCE: 1985, Abstracts available: American Society for Microbiology, Publication Department, 1913 I St. NW, Washington, DC 20006, USA, Paper No. C 382. Meeting Info.: 851 5000: American Society for Microbiology, 85th Annual Meeting (8515000). Las Vegas, NV (USA). 3-7 Mar 85. American Society for Microbiology.

DOCUMENT TYPE: Conference

FILE SEGMENT: DCCP

LANGUAGE: UNAVAILABLE

L7 ANSWER 19 OF 30 CONFSCI COPYRIGHT 2002 CSA

ACCESSION NUMBER: 86:15890 CONFSCI

DOCUMENT NUMBER: 86043671

TITLE: *Chlamydia* screening of male patients with gonorrhea

AUTHOR: Lefkowitz, L.B.; Peters, T.H.; Ratner, H.B.; Davidson, T.L.; Stratton, C.W.

CORPORATE SOURCE: Vanderbilt Univ., Nashville, TN, USA

SOURCE: American Society for Microbiology, 1913 I Street, N.W., Washington, DC 20006 (USA), Poster Paper No. C30. Meeting Info.: 861 0146: American Society for Microbiology 86th Annual Meeting (8610146). Washington, DC (USA). 23-28 Mar 1986. American Society for Microbiology (ASM).

DOCUMENT TYPE: Conference

FILE SEGMENT: DCCP

LANGUAGE: UNAVAILABLE

L7 ANSWER 20 OF 30 CONFSCI COPYRIGHT 2002 CSA

ACCESSION NUMBER: 84:751 CONFSCI

DOCUMENT NUMBER: 84006418

TITLE: Comparison of immunoperoxidase staining with iodine staining for the detection of *Chlamydia*

AUTHOR: trachomatis inclusion bodies in McCoy cells  
Stratton, C.W.; Judson, F.N.; Simpson, E.B.; Jones, M.R.; Kasselberg, A.G.

CORPORATE SOURCE: Vanderbilt Univ. Hosp., Nashville, TN

SOURCE: Abstracts available: American Society for Microbiology, Publications Department, 1913 I St. NW, Washington, DC 20006, USA, Paper No. C105. Meeting Info.: 841 0195: American Society for Microbiology 84th Annual Meeting (8410195). St. Louis, MO (USA). 4-9 Mar 84. American Society for Microbiology (ASM).

DOCUMENT TYPE: Conference

FILE SEGMENT: DCCP

LANGUAGE: UNAVAILABLE



L7 ANSWER 21 OF 30 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.

ACCESSION NUMBER: 2002091023 EMBASE

TITLE: Pharmacokinetic, pharmacodynamic and tolerability profiles of telithromycin, the first ketolide antimicrobial agent.

AUTHOR: Stratton C.W.

CORPORATE SOURCE: Dr. C.W. Stratton, Clinical Microbiology Laboratory, Vanderbilt Clinic, 21st and Edgehill, Nashville, TN 37232, United States. Charles.Stratton@mcmail.Vanderbilt.edu

SOURCE: Today's Therapeutic Trends, (2002) 20/1 (37-58).

Refs: 102

ISSN: 0741-2320 CODEN: TTTRDH

COUNTRY: United States

DOCUMENT TYPE: Journal; General Review

FILE SEGMENT: 015 Chest Diseases, Thoracic Surgery and Tuberculosis  
017 Public Health, Social Medicine and Epidemiology  
030 Pharmacology  
037 Drug Literature Index  
038 Adverse Reactions Titles

LANGUAGE: English

SUMMARY LANGUAGE: English

AB The ketolides are the latest structural derivatives of erythromycin to be added to the macrolide family, with telithromycin being the first ketolide to undergo clinical evaluation. Telithromycin is a broad-spectrum and highly potent antimicrobial agent, which has a number of unique pharmacokinetic and pharmacodynamic properties that assure its clinical utility despite the increasing prevalence of macrolide resistance among the major respiratory tract pathogens. It appears that the most important factors in terms of structure-activity are the lack of the neutral sugar cladinose in position C3 as well as a C11/C12 carbamate group, which together markedly increase the affinity of telithromycin for its microbial target, the 23S ribosomal drug-binding pocket. This increased affinity is seen even in macrolide-resistant strains, and also results in concentration-dependent bactericidal activity and a prolonged post-antimicrobial effect against important respiratory tract pathogens. The microbiological spectrum of activity for telithromycin includes *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Haemophilus influenzae*, *Moraxella catarrhalis*, *Legionella* species, *Mycoplasma pneumoniae*, and *Chlamydia pneumoniae*, suggesting that telithromycin will play an important clinical role in the empirical treatment of community-acquired respiratory tract infections. The pharmacokinetic profile of telithromycin demonstrates that this drug can be administered once daily without regard for meals, and requires no dosage reduction in elderly patients or those with hepatic impairment. Telithromycin is well absorbed after oral administration, with rapid penetration into respiratory tissues and fluids, and as well is highly concentrated within white blood cells. Integration of pharmacokinetic and pharmacodynamic properties reveals that telithromycin has a high AUC/MIC ratio compared with macrolide antimicrobial agents, resulting in enhanced efficacy. Finally, telithromycin is well tolerated and has a low propensity for drug interactions. In summary, telithromycin promises to be a potent agent for the treatment of community-acquired respiratory tract infections.

L7 ANSWER 22 OF 30 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.

ACCESSION NUMBER: 2001185465 EMBASE

TITLE: Diabetic foot ulcers and *chlamydia pneumoniae*: Innocent bystander or opportunistic pathogen? [10].

AUTHOR: King L.E. Jr.; Bushman T.; Stratton C.W.; Mitchell W.M.

CORPORATE SOURCE: Dr. L.E. King Jr., Division of Dermatology, Vanderbilt Univ. Sch. of Med. 3983, Vanderbilt Clinic, Nashville, TN 37232-2556, United States. lloyd.king@amcmail.vanderbilt.edu

SOURCE: Archives of Dermatology, (2001) 137/5 (671-672).

Refs: 6  
ISSN: 0003-987X CODEN: ARDEAC  
COUNTRY: United States  
DOCUMENT TYPE: Journal; Letter  
FILE SEGMENT: 004 Microbiology  
006 Internal Medicine  
013 Dermatology and Venereology  
LANGUAGE: English

L7 ANSWER 23 OF 30 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.  
ACCESSION NUMBER: 2001241578 EMBASE  
TITLE: Association of **Chlamydia pneumoniae** with chronic human diseases.  
AUTHOR: Stratton C.W.  
CORPORATE SOURCE: Dr. C.W. Stratton, Vanderbilt Univ. School of Medicine, Nashville, TN 37232, United States  
SOURCE: Antimicrobics and Infectious Diseases Newsletter, (2000) 18/7 (49-55).  
Refs: 141

ISSN: 1069-417X CODEN: AIDIEX  
COUNTRY: United States  
DOCUMENT TYPE: Journal; General Review  
FILE SEGMENT: 004 Microbiology  
008 Neurology and Neurosurgery  
011 Otorhinolaryngology  
015 Chest Diseases, Thoracic Surgery and Tuberculosis  
017 Public Health, Social Medicine and Epidemiology  
LANGUAGE: English  
SUMMARY LANGUAGE: English

AB It is apparent from this review that *C. pneumoniae* has been implicated in many chronic diseases of humans. Whether the role is that of innocent bystander, cause, or perhaps something in between remains to be determined. Regardless of the role of *C. pneumoniae* in these or other chronic diseases, this microorganism is becoming a major health concern. Considerable resources will be needed to determine its role in human disease. If *C. pneumoniae* proves to play an important role in any or all of these chronic diseases, its eventual control or eradication may do much to improve the health of countless persons.

L7 ANSWER 24 OF 30 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.  
ACCESSION NUMBER: 2000017568 EMBASE  
TITLE: Does **Chlamydia pneumoniae** play a role in the pathogenesis of multiple sclerosis?.  
AUTHOR: Stratton C.W.; Mitchell W.M.; Sriram S.  
CORPORATE SOURCE: C.W. Stratton, Department of Pathology, Vanderbilt School of Medicine, Nashville, TN 37232, United States.  
Charles.Stratton@mcmail.Vanderbilt.edu  
SOURCE: Journal of Medical Microbiology, (2000) 49/1 (1-3).  
Refs: 28  
ISSN: 0022-2615 CODEN: JMMIAV  
COUNTRY: United Kingdom  
DOCUMENT TYPE: Journal; Editorial  
FILE SEGMENT: 004 Microbiology  
008 Neurology and Neurosurgery  
LANGUAGE: English

L7 ANSWER 25 OF 30 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.  
ACCESSION NUMBER: 1999287545 EMBASE  
TITLE: The role of **Chlamydia** in connective tissues diseases.  
AUTHOR: Stratton C.W.  
CORPORATE SOURCE: Dr. C.W. Stratton, Vanderbilt University School of Med., Nashville, TN 37232, United States

SOURCE: Antimicrobics and Infectious Diseases Newsletter, (1998)  
17/2 (9-15).  
Refs: 129  
ISSN: 1069-417X CODEN: AIDIEX

COUNTRY: United States  
DOCUMENT TYPE: Journal; General Review  
FILE SEGMENT: 004 Microbiology  
005 General Pathology and Pathological Anatomy  
006 Internal Medicine  
LANGUAGE: English  
SUMMARY LANGUAGE: English

AB In summary, **Chlamydia** species have been shown to infect synovial tissues. The synovial infection produced can be persistent and can cause a cell-mediated inflammatory response directed at **chlamydial** HSPs. Antimicrobial therapies of arthritis syndromes to date have demonstrated some success despite not being optimized for persistent **chlamydial** infection. Clearly, additional work is both needed and warranted to firmly establish the role of **Chlamydia** species in connective tissue diseases. Included in this is the need to optimize antimicrobial therapy against persistent infections caused by **Chlamydia**.

L7 ANSWER 26 OF 30 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.

ACCESSION NUMBER: 97374392 EMBASE

DOCUMENT NUMBER: 1997374392

TITLE: The importance of **Chlamydia pneumoniae** as a pathogen: The 1996 consensus conference on **Chlamydia pneumoniae** infections.

AUTHOR: File T.M. Jr.; Bartlett J.G.; Cassell G.H.; Gaydos C.A.; Grayston J.T.; Hammerschlag M.R.; Jones R.B.; Kahn J.B.; Marie T.J.; Ramirez J.A.; Saikku P.; Schachter J.; Schumacher H.R.; Stamm W.E.; **Stratton C.W.**; Yu V.L.

CORPORATE SOURCE: T.M. File Jr., Infectious Disease Section, SUMMA Health System, 75 Arch Street, Akron, OH 44304-1430, United States  
SOURCE: Infectious Diseases in Clinical Practice, (1997) 6/SUPPL. 2 (S28-S31).

Refs: 26

ISSN: 1056-9103 CODEN: IDCPEY

COUNTRY: United States

DOCUMENT TYPE: Journal; (Short Survey)

FILE SEGMENT: 004 Microbiology  
015 Chest Diseases, Thoracic Surgery and Tuberculosis  
018 Cardiovascular Diseases and Cardiovascular Surgery

LANGUAGE: English

L7 ANSWER 27 OF 30 BIOTECHDS COPYRIGHT 2002 DERWENT INFO AND ISI

ACCESSION NUMBER: 1996-11724 BIOTECHDS

TITLE: Inducing mucosal immune response by administration of antigen-encoding DNA; genetic immunization against disease caused by HIV virus, herpes virus, orthomyxo virus, mumps virus, hepatitis virus, Salmonella, Shigella, **Chlamydia** or **Helicobacter** sp.

AUTHOR: **Mitchell W M**

PATENT ASSIGNEE: Univ.Vanderbilt

LOCATION: Nashville, TN, USA.

PATENT INFO: WO 9621356 18 Jul 1996

APPLICATION INFO: WO 1995-US8374 3 Jul 1995

PRIORITY INFO: US 1995-372429 13 Jan 1995

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: WPI: 1996-341965 [34]

AB A new method for inducing a mucosal immune response in a subject involves

administering to the mucosa of the subject an amount of an antigen-encoding DNA effective to induce a mucosal immune response complexed to a transfection-facilitating lipospermine or lipospermidine. Preferably, administration is nasal, oral, rectal or vaginal and the lipospermine is dioctadecylamidoglycylspermine. The DNA encodes an envelope antigen or an envelope-associated antigen. Also new is a composition of the antigen-encoding DNA complexed to a transfection facilitating lipospermine or lipospermidine. The DNA induces both humoral and cellular responses and allows easy formulation of multiple sequence variants into a single genetic vaccine. The method provides the advantages of live, attenuated vaccines and lacks the threat of reversion to virulence. The antigen-encoding DNA may be cloned into a vector, e.g. plasmid pBR322-based plasmid pHenv. (82pp)

L7 ANSWER 28 OF 30 BIOTECHDS COPYRIGHT 2002 DERWENT INFO AND ISI

ACCESSION NUMBER: 2001-00586 BIOTECHDS

TITLE: Diagnosing and monitoring multiple sclerosis by assaying a test sample for **Chlamydia**, and treating multiple sclerosis by administering anti-**chlamydial** agents such as rifamycins, azalides, macrolides, ketolides; polymerase chain reaction for diagnosis and drug screening method

AUTHOR: Stratton C W; Mitchell W M; Yao S Y; Bannan J D; Ljunggren-Rose A; Sriram S

PATENT ASSIGNEE: Univ.Vanderbilt

LOCATION: Nashville, TN, USA.

PATENT INFO: WO 2000057187 28 Sep 2000

APPLICATION INFO: WO 2000-US7226 17 Mar 2000

PRIORITY INFO: US 2000-176784 18 Jan 2000; US 1999-125598 19 Mar 1999

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: WPI: 2000-602242 [57]

AB A new method (M1) for diagnosing or monitoring multiple sclerosis in an individual is claimed. It involves assaying a test sample (selected from blood, serum or cerebrospinal fluid) for the presence of **Chlamydia** selected from **Chlamydia pneumoniae** by contacting cultured **Chlamydia**-free indicator cells with the test sample. Also claimed are; a method (M2) for isolating elementary bodies from a receptacle by treating the receptacle with trypsin (EC-3.4.21.4)/EDTA(ethylene diamine tetraacetic acid); a method (M3) for releasing DNA from elementary bodies by incubating them under disulfide reducing conditions and digesting with a protease; a method (M4) for treating an individual with multiple sclerosis; a method (M5) for determining if a candidate compound is a potential drug for the treatment of **Chlamydial** infection-related disease by infecting a non-human animal with **Chlamydia**, administering a candidate compound to the animal, and assaying for the presence of a **chlamydial** infection. The methods are useful for diagnosing and treating multiple sclerosis and for identifying agents which may potentially be useful for treating the disease. (100pp)

L7 ANSWER 29 OF 30 BIOTECHDS COPYRIGHT 2002 DERWENT INFO AND ISI

ACCESSION NUMBER: 2000-10037 BIOTECHDS

TITLE: Isolated nucleic acid for use in diagnostic and analytical methods encodes genomic sequence of **Chlamydia pneumoniae**;

method is useful for prophylactic and therapeutic purpose

AUTHOR: Stephens R; Mitchell W; Kalman S; Davis R

PATENT ASSIGNEE: Univ.California

LOCATION: Oakland, CA, USA.

PATENT INFO: WO 2000027994 18 May 2000

APPLICATION INFO: WO 1999-US26923 12 Nov 1999

PRIORITY INFO: US 1999-128606 8 Apr 1999; US 1998-108279 12 Nov 1998

DOCUMENT TYPE: Patent  
LANGUAGE: English  
OTHER SOURCE: WPI: 2000-376516 [32]

AB A new isolated nucleic acid (N1) encoding a **Chlamydia** pneumoniae protein (P1) is claimed. Also claimed are: a probe containing a hybridizing fragment of N1; an isolated nucleic acid (N2) that hybridizes under stringent conditions to N1; an expression cassette containing N1 under the transcriptional regulation of an initiation region functional in an expression host, and a transcriptional termination region; a cell containing an expression cassette as part of an extrachromosomal element in the genome of a host cell, and the cellular progeny of the host cell; a method for producing a P1 by growing a cell where the protein is expressed and isolating protein free of other proteins; a purified protein composition containing at least 50 wt.% of P1; and a monoclonal antibody binding to the peptide. The isolated nucleic acid is useful for diagnosing and analytical methods, such as hybridization-based assays or amplification-based assays. The protein may be used for diagnostic purposes, for its enzymatic or structural activity, or as a vaccine. (330pp)

L7 ANSWER 30 OF 30 BIOTECHDS COPYRIGHT 2002 DERWENT INFO AND ISI

ACCESSION NUMBER: 1998-05630 BIOTECHDS

TITLE: Treating **chlamydia** infections using a combination of agents directed against different phases; disease diagnosis by DNA amplification

AUTHOR: Mitchell W M; Stratton C W

PATENT ASSIGNEE: Univ.Vanderbilt

LOCATION: Nashville, TN, USA.

PATENT INFO: WO 9806435 19 Feb 1998

APPLICATION INFO: WO 1997-US14402 14 Aug 1997

PRIORITY INFO: US 1996-23921 14 Aug 1996

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: WPI: 1998-159294 [14]

AB A new composition (A) comprises at least 2 antichlamydial agents (I) active against different phases in the **Chlamydia** sp. life cycle. Also new are: a method for identifying agents that inhibit **chlamydial** infection or are active against the cryptic forms of **Chlamydia** sp.; a method for identifying cells containing these cryptic forms; a method for activating macrophages and monocytes in which the ability to combat infection has been comprised by **chlamydial** infection; a method for detecting **chlamydial** elementary bodies in a sample, which involves treatment with a disulfide reducing agent prior to detecting **chlamydial** DNA by DNA amplification using the polymerase chain reaction; 12 specific peptides derived from various **Chlamydia** spp.; the therapeutic agents identified by the method; therapy of **Chlamydia** sp. infection; and determination of the status of a patient and monitoring treatment for **Chlamydia** sp. infection. (A) is used for therapy of **Chlamydia** pneumoniae disease and related diseases (autoimmune diseases, inflammation, and immunodeficiency conditions. **Chlamydia** spp. have been associated with multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, etc. (82pp)

FILE 'HOME' ENTERED AT 14:11:26 ON 26 MAR 2002

**THIS PAGE BLANK (USPTO)**

GenCore version 4.5  
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: March 26, 2002, 13:37:19 ; Search time 42.75 Seconds  
(without alignments)  
26.728 Million cell updates/sec

Title: US-09-709-201-97

Perfect score: 82

Sequence: 1 CFGVKGTFTVNAELP 15

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 219241 seqs, 76174552 residues

Total number of hits satisfying chosen parameters: 219241

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 10%

Listing first 45 summaries

Database : PIR\_68.\*

1: pir1.\*

2: pir2.\*

3: pir3.\*

4: pir4.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Match	Length	ID	Description
1	73	89.0	389	A43587	major outer membra
2	73	89.0	389	D86577	major outer membra
3	69	84.1	389	I40739	major outer membra
4	61	74.4	389	I40864	N utilization subs
5	45	54.9	500	B81060	N utilization subs
6	45	54.9	505	H81816	cell division prot
7	44	53.7	744	H71643	major outer membra
8	42	51.2	389	MMCWP3	hypothetical prote
9	42	51.2	455	F96817	peptide transport
10	42	51.2	708	A56163	ribosomal protein
11	41	50.0	93	R5R223	ribosomal protein
12	41	50.0	93	R5ZM23	probable 9-cis-epo
13	41	50.0	93	R5WT23	nine-cis-epoxycaro
14	41	50.0	604	T51936	probable actin ygg
15	41	50.0	605	T07123	hypothetical 26.6k
16	40	48.8	246	D85948	conserved hypotet
17	40	48.8	246	A65077	DNA-binding protei
18	40	48.8	365	IQQBEW4	p-type cation tran
19	40	48.8	1235	A44396	2k12.7 protein -
20	40	48.8	1984	C84887	phosphoglycolate p
21	39	47.6	215	C84098	histidine-containi
22	39	47.6	216	G70044	probable transcrip
23	39	47.6	235	E83302	hypothetical prote
24	39	47.6	235	E71520	tail protein pb5 -
25	39	47.6	335	E1YBPT5	hypothetical prote
26	39	47.6	640	T27382	galacturan 1,4-alp
27	39	47.6	773	T27382	cytochrome-c oxida
28	38.5	47.0	435	T52408	
29	38	46.3	168	T52480	

ALIGNMENTS

RESULT 1

A43587

major outer membrane protein, porin CP0051 precursor [imported] - Chlamydomophila pneum  
N: Alternate names: MOMP  
C: Species: Chlamydomophila pneumoniae, Chlamydia pneumoniae  
C: Date: 29-Jan-1993 #sequence revision 29-Jan-1993 #text\_change 11-May-2000  
C: Accession: A43587; A49751; A49216; G72044; F81619  
R: Perez-Melgosa, M.; Kuo, C.C.; Campbell, L.A.  
Infect. Immun. 59:2195-2199, 1991  
A: Title: Sequence analysis of the major outer membrane protein gene of Chlamydia pneu  
A: Reference number: A43587; MUID: 91244474  
A: Accession: A43587  
A: Molecule type: DNA  
A: Residues: 1-389 <PER>  
A: Cross-references: GB:M69230; NID: g144540; PIDN: AAA73071.i; PID: g144541  
R: Carter, M.W.; Al-Mahdawi, S.A.H.; Giles, I.G.; Trehan, J.D.; Ward, M.E.; Clarke, C.J. Gen. Microbiol. 137:465-475, 1991  
A: Title: Nucleotide sequence and taxonomic value of the major outer membrane protein  
A: Reference number: A49751; MUID: 91237311  
A: Accession: A49751  
A: Status: preliminary  
A: Molecule type: DNA  
A: Residues: 1-389 <CAR>  
A: Cross-references: GB:M64064; GB:M34942; NID: g144534; PIDN: AAA23143.1; PID: g144535  
A: Note: isolate IOL-207  
R: Gabor, C.A.; Quinn, T.C.; Bobot, L.D.; Eiden, J.J.  
Infect. Immun. 60:5319-5323, 1992  
A: Title: Similarity of Chlamydia pneumoniae strains in the variable domain IV region.  
A: Reference number: A49216; MUID: 93084388  
A: Accession: A49216  
A: Status: preliminary  
A: Molecule type: DNA  
A: Residues: 297-352 <GAV>  
A: Cross-references: GB:S50607; NID: g260972; PIDN: AAB24363.1; PID: g260973  
A: Note: sequence extracted from NCBI backbone (NCBI:120604, NCBIP:120605)  
R: Kalman, S.; Mitchell, W.; Marathe, R.; Lammel, C.; Fan, J.; Olinger, L.; Grimwood, N. Nature Genet. 21:385-389, 1999  
A: Title: Comparative genomes of Chlamydia pneumoniae and C. trachomatis.  
A: Reference number: A72000; MUID: 99206606  
A: Accession: G72044  
A: Molecule type: DNA  
A: Residues: 1-389 <ARN>  
A: Cross-references: GB:AE001652; GB:AE001363; NID: g4376997; PIDN: AAD18834.1; PID: g437  
A: Experimental source: strain CWL029  
R: Read, T.D.; Brunham, R.C.; Shen, C.; Gall, S.R.; Heidelberg, J.F.; White, O.; Hicke  
C.; Dodson, R.; Gwinn, M.; Nelson, W.; Deloy, R.; Kolonay, J.; McClarty, G.; Salzbe  
Nucleic Acids Res. 28, 1397-1406, 2000  
A: Title: Genome sequences of Chlamydia trachomatis Mopn and Chlamydia pneumoniae AR39  
A: Reference number: A81500; MUID: 20150255  
A: Accession: F81619  
A: Status: preliminary  
A: Molecule type: DNA

probable oxidoredu  
branched-chain ket  
vanH protein - Ent  
3-methyl-2-oxobuta  
hypothetical prote  
hypothetical prote  
transmembrane prot  
hypothetical prote  
phosphoglucosylase  
phosphoglucosylase  
Ca2+/calmodulin-de  
hypothetical prote  
outer layer protei  
hypothetical prote  
hypothetical prote  
probable helicase

A:Residues: 1-389 <REA>  
 A:Cross-references: GB:AE002168; GB:AE002161; NID:g7188982; PIDN:AAF37944.1; PID:g718899  
 A:Experimental source: strain AR39, HL cells  
 C:Genetics:

A:Gene: ompA; CP0051  
 C:Superfamily: Chlamydia major outer membrane protein  
 C:Keywords: membrane protein  
 F:1-23/Domain: signal sequence #status predicted <SIG>  
 F:24-389/Product: major outer membrane protein #status predicted <MAT>

Query Match 89.0%; Score 73; DB 2; Length 389;  
 Best Local Similarity 100.0%; Pred. No. 3e-05;  
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 FGKGTNNANELP 15  
 Db 158 FGKGTNNANELP 171

RESULT 2  
 D86577  
 major outer membrane protein [imported] - Chlamydia pneumoniae (strain J138)  
 C:Species: Chlamydia pneumoniae, Chlamydia pneumoniae  
 C:Date: 02-Mar-2001 #sequence\_revision 02-Mar-2001 #text\_change 23-Mar-2001  
 C:Accession: D86577  
 R:Shirai, M.; Hirakawa, H.; Kimoto, M.; Tabuchi, M.; Kishi, F.; Ouchi, K.; Shiba, T.; Is  
 Nucleic Acids Res. 28, 2311-2314, 2000  
 A:Title: Comparison of whole genome sequences of chlamydia pneumoniae J138.  
 A:Reference number: A86491; MUID:20330349  
 A:Accession: D86577  
 A:Status: preliminary  
 A:Molecule type: DNA  
 A:Residues: 1-389 <STO>  
 A:Cross-references: GB:BA000008; NID:g8979067; PIDN:BAA98902.1; GSPDB:GN00142  
 A:Experimental source: strain J138  
 C:Genetics:  
 A:Gene: ompA  
 C:Superfamily: Chlamydia major outer membrane protein

Query Match 89.0%; Score 73; DB 2; Length 389;  
 Best Local Similarity 100.0%; Pred. No. 3e-05;  
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 FGKGTNNANELP 15  
 Db 158 FGKGTNNANELP 171

RESULT 3  
 I40739  
 major outer membrane protein precursor - Chlamydia pneumoniae (strain equine/N16)  
 C:Species: Chlamydia pneumoniae, Chlamydia pneumoniae  
 A:Variety: strain equine/N16  
 C:Date: 16-Aug-1996 #sequence\_revision 16-Aug-1996 #text\_change 20-Apr-2000  
 C:Accession: I40739  
 R:Storey, C.; Lusher, M.; Yates, P.; Richmond, S.  
 J. Gen. Microbiol. 139, 2621-2626, 1993  
 A:Title: Evidence for Chlamydia pneumoniae of non-human origin.  
 A:Reference number: I40739; MUID:94103736  
 A:Accession: I40739  
 A:Status: translated from GB/EMBL/DBJ

A:Residues: 1-389 <STO>  
 A:Cross-references: GB:L04982; NID:g289840; PIDN:AAAL7397.1; PID:g289841  
 C:Comment: On the basis of the major outer membrane protein the authors classified the  
 the sequence of the genome strain CWL029 and strain IOL-207. See PIR:A43587.  
 C:Genetics:  
 A:Gene: ompA  
 C:Superfamily: Chlamydia major outer membrane protein  
 C:Keywords: membrane protein  
 F:1-23/Domain: signal sequence #status predicted <SIG>

F:24-389/Product: major outer membrane protein #status predicted <MAT>

Query Match 84.1%; Score 69; DB 2; Length 389;  
 Best Local Similarity 92.9%; Pred. No. 0.00016;  
 Matches 13; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 2 FGKGTNNANELP 15  
 Db 158 FGKGTNNANELP 171

RESULT 4  
 I40864  
 major outer membrane protein - Chlamydia psittaci  
 C:Species: Chlamydia psittaci, Chlamydia psittaci  
 C:Date: 16-Aug-1996 #sequence\_revision 16-Aug-1996 #text\_change 31-Mar-2000  
 C:Accession: I40864; S33465  
 R:Gijses, A.A.; Carrick, F.N.; Lavin, M.F.  
 Gene 138, 139-142, 1994  
 A:Title: Remarkable sequence relatedness in the DNA encoding the major outer membrane  
 A:Reference number: I40864; MUID:94117025  
 A:Accession: I40864  
 A:Status: preliminary; translated from GB/EMBL/DBJ  
 A:Molecule type: DNA  
 A:Residues: 1-389 <RES>  
 A:Cross-references: EMBL:X72023; NID:g313844; PIDN:CAA50906.1; PID:g313845  
 C:Superfamily: Chlamydia major outer membrane protein

Query Match 74.4%; Score 61; DB 2; Length 389;  
 Best Local Similarity 85.7%; Pred. No. 0.0044;  
 Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 2 FGKGTNNANELP 15  
 Db 158 FGKGTNNANELP 171

RESULT 5  
 B81060  
 N utilization substance protein A NMB1642 [imported] - Neisseria meningitidis (strain  
 C:Species: Neisseria meningitidis  
 C:Date: 31-Mar-2000 #sequence\_revision 31-Mar-2000 #text\_change 19-Jan-2001  
 C:Accession: B81060  
 R:Tetzelin, H.; Saunders, N.J.; Heidelberg, J.; Jeffries, A.C.; Nelson, K.E.; Eisen,  
 Hickey, E.K.; Haft, D.H.; Salzberg, S.L.; White, O.; Fleischmann, R.D.; Dougherty, B.  
 ri, H.; Qin, H.; Vamathevan, J.; Gill, J.; Scarlato, V.; Maignani, V.; Pizza, M.  
 Science 287, 1809-1815, 2000  
 A:Authors: Grandi, G.; Sun, L.; Smith, H.O.; Fraser, C.M.; Moxon, E.R.; Rappuoli, R.;  
 A:Title: Complete genome sequence of Neisseria meningitidis serogroup B strain MC58.  
 A:Reference number: A81000; MUID:20175755  
 A:Accession: B81060  
 A:Status: preliminary  
 A:Molecule type: DNA  
 A:Residues: 1-500 <TET>  
 A:Cross-references: GB:AE002514; GB:AE002098; NID:g7226886; PIDN:AAF41991.1; PID:g722  
 A:Experimental source: serogroup B, strain MC58  
 C:Genetics:  
 A:Gene: NMB1642  
 C:Superfamily: Escherichia coli transcription factor nusA; transcription termination

Query Match 54.9%; Score 45; DB 2; Length 500;  
 Best Local Similarity 62.5%; Pred. No. 4.3;  
 Matches 10; Conservative 2; Mismatches 2; Indels 2; Gaps 1;

QY 1 CFGKGTNNANEL 14  
 Db 259 CIGKGTNNANEL 274

RESULT 6



H81816  
 N utilisation substance protein A NMA1896 [imported] - Neisseria meningitidis (strain 224)  
 C:Species: Neisseria meningitidis  
 C>Date: 05-May-2000 #sequence\_revision 05-May-2000 #text\_change 02-Feb-2001  
 C:Accession: H81816  
 R:Parkhill, J.; Achtman, M.; James, K.D.; Bentley, S.D.; Churcher, C.; Klee, S.R.; Morel  
 ; Holroyd, S.; Jørgensen, K.; Leather, S.; Moule, S.; Mungall, K.; Quail, M.A.; Rajandream,  
 Nature 404, 502-506, 2000  
 A:Title: Complete DNA sequence of a serogroup A strain of Neisseria meningitidis 22491.  
 A:Reference number: A81775; MUID:20222556  
 A:Accession: H81816  
 A:Status: preliminary  
 A:Molecule type: DNA  
 A:Residues: 1-505 <PAR>  
 A:Cross-references: GB:AL162757; GB:AL157959; NID:g7380371; PIDN:CAB85117.1; PID:g738053  
 A:Experimental source: serogroup A, strain 22491  
 C:Genetics:  
 C:Superfamily: Escherichia coli transcription factor nusA; transcription termination fac  
 A:Gene: nusA; NMA1896  
 C:Superfamily: Escherichia coli transcription factor nusA; transcription termination fac

Query Match 54.98; Score 45; DB 2; Length 505;  
 Best Local Similarity 62.58; Pred. No. 4.3; Mismatches 2; Indels 2; Gaps 1;  
 Matches 10; Conservative 2; Mismatches 2; Indels 2; Gaps 1;

Qy 1 CFGVKGTTVNA--NEL 14  
 | | | | | | | | | |  
 Db 264 CIGVGRSRVNAVSNEL 279

RESULT 7  
 H71643  
 cell division protein ftsK homolog (ftsK) RP823 - Rickettsia prowazekii  
 C:Species: Rickettsia prowazekii  
 C>Date: 21-Nov-1998 #sequence\_revision 21-Nov-1998 #text\_change 02-Mar-2001  
 C:Accession: H71643  
 R:Andersson, S.G.E.; Zomorodipour, A.; Andersson, J.O.; Sichert-Ponten, T.; Alsmark, U  
 Nature 396, 133-140, 1998  
 A:Title: The genome sequence of Rickettsia prowazekii and the origin of mitochondria.  
 A:Reference number: A71630; MUID:99039499  
 A:Accession: H71643  
 A:Status: preliminary; nucleic acid sequence not shown; translation not shown  
 A:Molecule type: DNA  
 A:Residues: 1-744 <AND>  
 A:Cross-references: GB:AJ235273; GB:AJ235269; NID:g3861237; PIDN:CAA15248.1; PID:g386134  
 A:Experimental source: Strain Madrid E  
 C:Genetics:  
 A:Gene: ftsK; RP823  
 C:Superfamily: Bacillus subtilis DNA translocase spoIIIE

Query Match 53.78; Score 44; DB 2; Length 744;  
 Best Local Similarity 57.18; Pred. No. 9.9; Mismatches 4; Indels 0; Gaps 0;  
 Matches 8; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy 2 FGKVGTTVNANELP 15  
 | | | | | | | | | |  
 Db 288 FGKVGQIINQGP 301

RESULT 8  
 MMCWP3  
 major outer membrane protein precursor - Chlamydomophila psittaci (strain S26/3)  
 C:Species: Chlamydomophila psittaci, Chlamydia psittaci  
 C>Date: 31-Dec-1990 #sequence\_revision 31-Dec-1990 #text\_change 31-Mar-2000  
 C:Accession: S08770  
 R:Herrington, A.J.; Tan, T.W.; Baxter, S.; Inglis, N.F.; Dunbar, S.  
 FEMS Microbiol. Lett. 65, 153-158, 1989  
 A:Title: Sequence analysis of the major outer membrane protein gene of an ovine abortion  
 A:Reference number: S08770  
 A:Accession: S08770  
 A:Molecule type: DNA  
 A:Residues: 1-389 <HER>

A:Cross-references: EMBL:X51859; NID:g40600; PIDN:CAA36152.1; PID:g40601  
 C:Superfamily: Chlamydia major outer membrane protein  
 F:1-22/Domain: signal sequence #status predicted <SIG>  
 F:23-389/Product: major outer membrane protein #status predicted <MAT>

Query Match 51.24; Score 42; DB 1; Length 389;  
 Best Local Similarity 53.84; Pred. No. 11; Mismatches 5; Indels 0; Gaps 0;  
 Matches 7; Conservative 5; Mismatches 5; Indels 0; Gaps 0;

Qy 3 GVKGTTVNANELP 15  
 | | | | | | | | | |  
 Db 159 GVGSSIAADQLP 171

RESULT 9  
 F96817  
 hypothetical protein F9K20.12 [imported] - Arabidopsis thaliana  
 C:Species: Arabidopsis thaliana (mouse-ear cress)  
 C>Date: 02-Mar-2001 #sequence\_revision 02-Mar-2001 #text\_change 31-Mar-2001  
 C:Accession: F96817  
 R:Theologis, A.; Ecker, J.R.; Palm, C.J.; Federspiel, N.A.; Kaul, S.; White, O.; Alon  
 ; Chiu, C.W.; Chung, M.K.; Conn, L.; Conway, A.B.; Conway, A.R.; Creasy, T.H.; Dewar,  
 ansen, N.F.; Hughes, B.; Huizart, L.  
 Nature 408, 816-820, 2000  
 A:Authors: Hunter, J.L.; Jenkins, J.; Johnson-Hopson, C.; Khan, S.; Khaykin, E.; Kim,  
 C.A.; Li, J.H.; Li, Y.; Lin, X.; Liu, S.X.; Liu, Z.A.; Luros, J.S.; Maiti, R.; Marzia  
 Rizzo, M.; Rooney, T.; Rowley, D.; Sakano, H.  
 A:Authors: Salzberg, S.L.; Schwartz, J.R.; Shinn, P.; Southwick, A.M.; Sun, H.; Tallo  
 ker, M.; Wu, D.; Yu, G.; Fraser, C.M.; Venter, J.C.; Davis, R.W.  
 A:Title: Sequence and analysis of chromosome 1 of the plant Arabidopsis.  
 A:Reference number: A86141; MUID:21016719  
 A:Accession: F96817  
 A:Status: preliminary  
 A:Molecule type: DNA  
 A:Residues: 1-455 <SPTO>  
 A:Cross-references: GB:AE005173; NID:g3834313; PIDN:AAC83028.1; GSPDB:GN00141  
 C:Genetics:  
 A:Gene: F9K20.12  
 A:Map position: 1

Query Match 51.24; Score 42; DB 2; Length 455;  
 Best Local Similarity 80.04; Pred. No. 13; Mismatches 0; Indels 2; Gaps 0;  
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CFGVKGTTVN 10  
 | | | | | | | | | |  
 Db 374 CSGVKGTVN 383

RESULT 10  
 A56163  
 peptide transport protein hPEPT1 - human  
 C:Species: Homo sapiens (man)  
 C>Date: 28-Apr-1995 #sequence\_revision 28-Apr-1995 #text\_change 24-Sep-1999  
 C:Accession: A56163  
 R:Liang, R.; Fei, Y.J.; Prasad, P.D.; Ramamoorthy, S.; Han, H.; Yang-Feng, T.L.; Hedi  
 J. Biol. Chem. 270, 6456-6463, 1995  
 A:Title: Human intestinal H(+)/peptide cotransporter. Cloning, functional expression,  
 A:Reference number: A56163; MUID:95204429  
 A:Accession: A56163  
 A:Status: preliminary; not compared with conceptual translation  
 A:Molecule type: mRNA  
 A:Residues: 1-708 <LIA>  
 A:Cross-references: GB:U13173; NID:g773587; PIDN:AAB61693.1; PID:g773588  
 C:Superfamily: peptide transport protein PEPT1

Query Match 51.24; Score 42; DB 2; Length 708;  
 Best Local Similarity 46.24; Pred. No. 22; Mismatches 6; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 3 FGKGTNNANELP 15  
 ||| |:: |:  
 Db 524 GKGFTTSSTP 536

## RESULT 11

R5ZM23

Ribosomal protein L23 - rice chloroplast

C:Species: chloroplast Oryza sativa (rice)

C:Date: 31-Mar-1990 #sequence\_revision 31-Mar-1990 #text\_change 24-Sep-1999

C:Accession: J00271; S05151; JAA0092

R:Shimada, H.; Whittier, R.F.; Hiratsuka, J.; Maeda, Y.; Hirai, A.; Sugiura, M.

submitted to JPIB, December 1989

A:Reference number: J00200

A:Accession: J00271

A:Molecule type: DNA

A:Residues: 1-93 &lt;SHI&gt;

A:Experimental source: cv. Nihonbare

R:Hiratsuka, J.; Shimada, H.; Whittier, R.; Ishibashi, T.; Sakamoto, M.; Mori, M.; Kond

Mol. Gen. Genet. 217, 185-194, 1989

A:Title: The complete sequence of the rice (Oryza sativa) chloroplast genome: intermoled

of the cereals.

A:Reference number: S05080; MUID:89364698

A:Accession: S05151

A&gt;Status: nucleic acid sequence not shown; translation not shown

A:Molecule type: DNA

A:Residues: 1-14, A', 16-93 &lt;HIR&gt;

A:Experimental source: cv. Nihonbare

R:Moore, E.; Wu, R.

Gene 70, 1-12, 1988

A:Title: Organization and nucleotide sequence of genes at both junctions between the two

A:Reference number: JAA092; MUID:89196901

A:Accession: JAA092

A:Molecule type: DNA

A:Residues: 1-14, A', 16-45, X', 47-93 &lt;MOO&gt;

A:Cross-references: GB:M22826; NID:9710564; PIDN:AA84593.1; PID:g710565

A:Note: Genes located at the two inverted repeats (IRA and IRB) in the rice chloroplast

1 proteins L23 and L2 and S19, lies at the ends of the two IRS near the LSCK

A:Note: the 46th codon is the TAG stop codon in this publication

C:Genetics:

A:Gene: rpl23

A:Genome: chloroplast

C:Superfamily: Escherichia coli ribosomal protein L23

C:Keywords: chloroplast; protein biosynthesis; ribosome

Query Match 50.0%; Score 41; DB 1; Length 93;

Best Local Similarity 57.1%; Pred. No. 3.7;

Matches 8; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

QY 32 FGKGTNNANELP 15

||| |:: |:

Db 43 FGKVVAVNSHRLP 56

## RESULT 12

R5ZM23

Ribosomal protein L23 - maize chloroplast

C:Species: chloroplast Zea mays (maize)

C:Date: 31-Dec-1990 #sequence\_revision 31-Dec-1990 #text\_change 16-Jun-2000

C:Accession: S01396; S60127; S58596; S58638; S20058

R:McLoughlin, W.E.; Larinua, I.M.

Nucleic Acids Res. 16, 8183, 1988

A:Title: The sequence of the maize plastid encoded rpl23 locus.

A:Reference number: S01396; MUID:88335565

A:Accession: S01396

A:Molecule type: DNA

A:Residues: 1-93 &lt;MCL&gt;

A:Cross-references: EMBL:X07864; NID:g12417; PIDN:CAA30712.1; PID:g12418

A:Genetics: GENI

A:Accession: S60127

A:Molecule type: DNA  
 A:Residues: 1-93 <MCW>  
 A:Cross-references: EMBL:X07864; NID:g12417; PIDN:CAA30712.1; PID:g12418  
 A:Genetics: GEN2  
 R:Maier, R.M.; Neckermann, K.; Igloi, G.L.; Koessel, H.  
 J. Mol. Biol. 251, 614-628, 1995  
 A:Title: Complete sequence of the maize chloroplast genome: gene content, hotspots of  
 A:Reference number: S58531; MUID:95395841  
 A:Accession: S58596  
 A>Status: nucleic acid sequence not shown; translation not shown  
 A:Molecule type: DNA  
 A:Residues: 1-93 <MAI>  
 A:Cross-references: EMBL:X86563; NID:g902200; PIDN:CAA60330.1; PID:g902265  
 A:Genetics: GEN2  
 A:Note: the nucleotide sequence was submitted to the EMBL Data Library, April 1995  
 A:Accession: S58638  
 A:Molecule type: DNA  
 A:Residues: 1-93 <MAW>  
 A:Cross-references: EMBL:X86563; NID:g902200; PIDN:CAA60330.1; PID:g902265  
 A:Genetics: GEN1  
 A:Note: the nucleotide sequence was submitted to the EMBL Data Library, April 1995  
 R:Hoch, B.; Maier, R.M.; Appel, K.; Igloi, G.L.; Koessel, H.  
 Nature 353, 178-180, 1991  
 A:Title: Editing of a chloroplast mRNA by creation of an initiation codon.  
 A:Reference number: S17874; MUID:91367263  
 A:Accession: S20058  
 A:Molecule type: mRNA  
 A:Residues: 81-93 <HOC>  
 A:Cross-references: EMBL:X62070; NID:g12463; PIDN:CAA43984.1; PID:g12465  
 C:Genetics: <GEN1>  
 A:Gene: rpl23  
 A:Map position: IR(A); IR(II)  
 A:Genome: chloroplast  
 C:Genetics: <GEN2>  
 A:Gene: rpl23  
 A:Map position: IR(B); IR(I)  
 A:Genome: chloroplast  
 C:Superfamily: Escherichia coli ribosomal protein L23  
 C:Keywords: chloroplast; protein biosynthesis; ribosome

Query Match 50.0%; Score 41; DB 1; Length 93;  
 Best Local Similarity 57.1%; Pred. No. 3.7;  
 Matches 8; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

QY 2 FGKGTNNANELP 15

||| |:: |:

Db 43 FGKVVAVNSHRLP 56

## RESULT 13

R5WT23

Ribosomal protein L23 - wheat chloroplast

C:Species: chloroplast Triticum aestivum (common wheat)

C:Date: 31-Dec-1990 #sequence\_revision 31-Dec-1990 #text\_change 22-Jun-1999

C:Accession: S06026

R:Bowman, C.M.; Barker, R.F.; Dyer, T.A.

Curr. Genet. 14, 127-136, 1988

A:Title: In wheat tDNA, segments of ribosomal protein genes are dispersed repeats, p

A:Reference number: S06025; MUID:89028843

A:Accession: S06026

A:Molecule type: DNA

A:Residues: 1-93 &lt;BOW&gt;

A:Cross-references: EMBL:X12850; NID:g12369; PIDN:CAA31328.1; PID:g12370

C:Genetics:

A:Genome: chloroplast

C:Superfamily: Escherichia coli ribosomal protein L23

C:Keywords: chloroplast; protein biosynthesis; ribosome

Query Match 50.0%; Score 41; DB 1; Length 93;

Best Local Similarity 57.1%; Pred. No. 3.7;

Matches 8; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

QY 2 FGKGGTTVNANELP 15  
|||||  
Db 43 FGKGVAVNSHRLP 56

## RESULT 14

T51936

probable 9-cis-epoxycarotenoid dioxygenase [imported] - potato

C;Species: Solanum tuberosum (potato)

C;Date: 20-Oct-2000 #sequence\_revision 20-Oct-2000 #text\_change 20-Oct-2000

C;Accession: T51936

R;Burbidge, A.; Taylor, I.B.; Thompson, A.

submitted to the EMBL Data Library, March 2000

A;Description: Potato putative 9-cis-epoxycarotenoid dioxygenase 1 cDNA.

A;Reference number: Z25874

A;Accession: T51936

A;Status: preliminary; translated from GB/EMBL/DBJ

A;Molecule type: mRNA

A;Residues: 1-604 <BUR>

A;Cross-references: EMBL:AJ276244; PIDN:CAB76920.1

C;Genetics:

A;Gene: nced1

Query Match 50.0%; Score 41; DB 2; Length 604;

Best Local Similarity 53.8%; Pred. No. 27;

Matches 7; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 2 FGKGGTTVNANEL 14  
:| || :|||:  
Db 588 YGFHGTFINANDL 600

## RESULT 15

T07123

nine-cis-epoxycarotenoid dioxygenase - tomato

N;Alternate names: probable neoxanthin cleavage enzyme

C;Species: Lycopersicon esculentum (tomato)

C;Date: 30-Apr-1999 #sequence\_revision 30-Apr-1999 #text\_change 20-Jun-2000

C;Accession: T07123

R;Burbidge, A.

submitted to the EMBL Data Library, January 1998

A;Reference number: Z15934

A;Accession: T07123

A;Status: preliminary; translated from GB/EMBL/DBJ

A;Molecule type: mRNA

A;Residues: 1-605 <BUR>

A;Cross-references: EMBL:Z97215; PIDN:CAB10168.1

Query Match

50.0%; Score 41; DB 2; Length 605;

Best Local Similarity 53.8%; Pred. No. 28;

Matches 7; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 2 FGKGGTTVNANEL 14  
:| || :|||:  
Db 589 YGFHGTFINANDL 601

Search completed: March 26, 2002, 13:37:19

Job time: 53 sec



GenCore version 4.5  
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: March 26, 2002, 13:40:13 ; Search time 79.01 Seconds  
(without alignments)  
27.770 Million cell updates/sec

Title: US-09-709-201-97  
Perfect score: 82  
Sequence: 1 CFGVKGTTVNANELP 15

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 473505 seqs, 146272329 residues

Total number of hits satisfying chosen parameters: 473505

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : SPTREMBL\_17:\*

- 1: sp\_archaea:\*
- 2: sp\_bacteria:\*
- 3: sp\_fungi:\*
- 4: sp\_human:\*
- 5: sp\_invertebrate:\*
- 6: sp\_mammal:\*
- 7: sp\_mhc:\*
- 8: sp\_organelle:\*
- 9: sp\_phase:\*
- 10: sp\_plant:\*
- 11: sp\_rodent:\*
- 12: sp\_virus:\*
- 13: sp\_vertebrate:\*
- 14: sp\_unclassified:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	73	89.0	223	2 Q9RB77	Q9rb77 chlamydia p
2	73	89.0	223	2 Q9RB76	Q9rb76 chlamydia p
3	61	74.4	389	2 Q08085	Q08085 chlamydia p
4	47	57.3	388	2 Q9AIK1	Q9aik1 chlamydia p
5	45	54.9	500	2 Q9JYD3	Q9jyd3 neisseria p
6	45	54.9	505	2 Q9JTB6	Q9jtb6 neisseria m
7	44	53.7	744	2 Q9ZCD4	Q9zcd4 rickettsia
8	44	53.7	1059	2 P95633	P95633 rickettsia
9	43	52.4	389	2 Q9APM4	Q9apm4 chlamydophi
10	42	51.2	318	3 Q9HEU6	Q9heu6 emericella
11	42	51.2	341	2 Q9X717	Q9x717 chlamydophi
12	42	51.2	352	2 Q69306	Q69306 chlamydia p
13	42	51.2	352	2 Q69307	Q69307 chlamydia p
14	42	51.2	352	2 Q70085	Q70085 chlamydia p
15	42	51.2	353	2 Q69305	Q69305 chlamydia p
16	42	51.2	455	10 Q9ZVA2	Q9zva2 arabidopsis
17	42	51.2	605	4 Q9BZ21	Q9bz21 homo sapien
18	42	51.2	708	4 Q43641	Q43641 homo sapien
19	42	51.2	743	5 Q9VK47	Q9vk47 drosophila

ALIGNMENTS

RESULT 1	20	41	50.0	254	10	Q9SM99	Q9sm99 oryza sativ
Q9RB77	21	41	50.0	323	2	Q9AC82	Q9ac82 staphylococ
ID Q9RB77	22	41	50.0	604	10	Q9M3Z9	Q9m3z9 solanum tub
AC Q9RB77	23	41	50.0	605	10	O24023	O24023 lycopersico
DT 01-MAY-2000 (TRENBLrel. 13, Created)	24	40	48.8	355	2	O26021	O26021 helicobacte
DT 01-MAY-2000 (TRENBLrel. 13, Last sequence update)	25	40	48.8	1024	2	Q9AAJ9	Q9aaj9 caulobacter
DT 01-JUN-2001 (TRENBLrel. 17, Last annotation update)	26	40	48.8	3337	5	Q9TWY4	Q9twy4 caenorhabdi
DE MUTANT MAJOR OUTER MEMBRANE PROTEIN (FRAGMENT).	27	39	47.6	50	2	Q9Z476	Q9z476 bacillus su
GN MOMP.	28	39	47.6	143	4	Q04490	Q04490 homo sapien
OS Chlamydia pneumoniae (Chlamydophila pneumoniae).	29	39	47.6	215	2	Q9K6V7	Q9k6v7 bacillus ha
OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydophila.	30	39	47.6	216	2	Q9JMQ2	Q9jmq2 bacillus su
ON NCBI_TaxID=83558;	31	39	47.6	282	10	Q9FL72	Q9fl72 arabidopsis
RP SEQUENCE FROM N.A.	32	39	47.6	295	2	Q9I085	Q9i085 pseudomonas
RA Tharp A.C., Mitchell W.M., Stratton C.W., Ding L.-M.;	33	39	47.6	335	2	O84396	O84396 chlamydia t
RT "Presence of viable Chlamydia pneumoniae in fetal calf serum and in	34	39	47.6	381	10	O48576	O48576 arabidopsis
RL epithelial-derived cell lines."	35	39	47.6	605	5	Q9V7L8	Q9v7l8 drosophila
DR EMBL; AFI31230; AAD33511.1;	36	39	47.6	610	5	Q9U6Y9	Q9u6y9 drosophila
DR InterPro: IPR000604; Chlamydia_OMP.	37	39	47.6	773	5	Q9XW87	Q9xw87 caenorhabdi
DR Pfam: PF01308; Chlamydia_OMP; 1.	38	39	47.6	2478	5	Q9VXZ5	Q9vxz5 drosophila
DR ProDom: PD001717; Chlamydia_OMP; 1.	39	39	47.6	5233	5	Q9NB71	Q9nb71 drosophila
FT NON_TER	40	38	46.3	171	2	Q9RDE1	Q9rde1 streptomyce
FT NON_TER	41	38	46.3	223	10	Q9FMA6	Q9fma6 arabidopsis
SQ SEQUENCE 223 AA; 24171 MW; 6D19A6B4D8841496 CRC64;	42	38	46.3	224	2	O32906	O32906 mycobacteri
Query Match 89.0%; Score 73; DB 2; Length 223;	43	38	46.3	229	10	Q9SPV5	Q9spv5 nicotiana p
Best Local Similarity 100.0%; Pred. No. 6e-05;	44	38	46.3	273	3	Q9UQY4	Q9uqy4 aspergillus
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	45	38	46.3	295	2	Q50850	Q50850 myxococcus
QY 2 FGKGGTTVNANELP 15							
Db 58 FGKGGTTVNANELP 71							
RESULT 2							
Q9RB76							
ID Q9RB76							
AC Q9RB76							
DT 01-MAY-2000 (TRENBLrel. 13, Created)							
DT 01-MAY-2000 (TRENBLrel. 13, Last sequence update)							

01-JUN-2001 (Tremblrel. 17, Last annotation update)  
 DE MUTANT MAJOR OUTER MEMBRANE PROTEIN (FRAGMENT).  
 GN MOMP.  
 OS Chlamydia pneumoniae (Chlamydia pneumoniae).  
 OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydia.  
 OX NCBI\_TaxID=83558;  
 RN (1)  
 RP SEQUENCE FROM N.A.  
 RA Sharp A.C., Mitchell W.M., Stratton C.W., Ding L.-M.;  
 RT "Presence of viable Chlamydia pneumoniae in fetal calf serum and in  
 RL epithelial-derived cell lines.";  
 DR EMBL; AF131229; AAD33510.1;  
 DR InterPro; IPR000604; Chlamydia\_OMP.  
 DR Pfam; PF01308; Chlamydia\_OMP; 1.  
 DR ProDom; PD001717; Chlamydia\_OMP; 1.  
 FT NON\_TER 1 1  
 FT VARIANT 6 6 A -> P.  
 FT VARIANT 10 10 M -> K.  
 FT VARIANT 161 161 V -> A.  
 FT NON\_TER 223 223  
 SQ SEQUENCE 223 AA; 4B676047B947C00F CRC64;  
 Query Match 89.0%; Score 73; DB 2; Length 223;  
 Best Local Similarity 100.0%; Pred. No. 5e-05;  
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 2 FGKGTGVNANL 15  
 DB 158 FGKGTGVNANL 171  
 RESULT 3  
 ID Q08085 PRELIMINARY; PRT; 389 AA.  
 AC Q08085;  
 DT 01-NOV-1996 (Tremblrel. 01, Created)  
 DT 01-NOV-1996 (Tremblrel. 01, Last sequence update)  
 DE MAJOR OUTER MEMBRANE PROTEIN PRECURSOR (MOMP).  
 OS Chlamydia psittaci (Chlamydia psittaci).  
 OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydia.  
 OX NCBI\_TaxID=83554;  
 RN (1)  
 RP SEQUENCE FROM N.A.  
 RA Strain-KOALA TYPE 1;  
 RX MEDLINE=94171025; PubMed=8125292;  
 RA Gillespie A., Carrick F.N., Lavin M.F.;  
 RT "Remarkable sequence relatedness in the DNA encoding the major outer  
 RT membrane protein of Chlamydia psittaci (koala type I) and Chlamydia  
 RT pneumoniae."  
 RL Science 287:438-439 (1999).  
 CC -1 FUNCTION: STRUCTURAL RIGIDITY OF THE OUTER MEMBRANE OF ELEMENTARY  
 CC BODIES AND PORIN FORMING, PERMITTING DIFFUSION OF SOLUTES THROUGH  
 CC THE INTRACELLULAR RETICULATE BODY MEMBRANE.  
 CC -2 SUBUNIT: DISULFIDE BOND INTERACTIONS WITHIN AND BETWEEN MOMP  
 CC MOLECULES & OTHER COMPONENTS FORM HIGH MOLECULAR-WEIGHT OLIGOMERS.  
 CC -3 SUBCELLULAR LOCATION: INTEGRAL MEMBRANE PROTEIN. OUTER MEMBRANE.  
 DR EMBL; X72023; CAA50906.1;  
 DR InterPro; IPR000604; Chlamydia\_OMP.  
 DR Pfam; PF01308; Chlamydia\_OMP; 1.  
 DR ProDom; PD001334; CHLAMYDIA\_OMP.  
 DR ProDom; PD001717; Chlamydia\_OMP; 1.  
 KW Outer membrane; Transmembrane; Porin; Signal.  
 FT SIGNAL 1 23 BY SIMILARITY.  
 FT CHAIN 24 389 MAJOR OUTER MEMBRANE PROTEIN.  
 SQ SEQUENCE 389 AA; 41579 MW; 5DC50E85A6F4E50F CRC64;  
 Query Match 74.4%; Score 61; DB 2; Length 389;  
 Best Local Similarity 85.7%; Pred. No. 0.014;  
 Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

01-JUN-2001 (Tremblrel. 17, Last annotation update)  
 DE MAJOR OUTER MEMBRANE PROTEIN (FRAGMENT).  
 GN OMP.  
 OS Chlamydia psittaci (Chlamydia psittaci).  
 OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydia.  
 OX NCBI\_TaxID=83554;  
 RN (1)  
 RP SEQUENCE FROM N.A.  
 RA Strain-VS225;  
 RX MEDLINE=21078680; PubMed=11211261;  
 RA Bush R.M., Everett K.D.;  
 RT "Molecular evolution of the Chlamydiaceae";  
 RL Int. J. Syst. Evol. Microbiol. 51:203-220 (2001).  
 DR EMBL; AF269259; AAK00240.1;  
 KW Signal.  
 FT NON\_TER 1 1  
 FT SIGNAL <1 19 POTENTIAL.  
 FT CHAIN 20 388 MAJOR OUTER MEMBRANE PROTEIN.  
 SQ SEQUENCE 388 AA; 41573 MW; 8E232D22C9B9948D CRC64;  
 Query Match 57.3%; Score 47; DB 2; Length 388;  
 Best Local Similarity 69.2%; Pred. No. 4;  
 Matches 9; Conservative 3; Mismatches 1; Indels 0; Gaps 0;  
 QY 3 GVKGTGVNANL 15  
 DB 156 GVKGTGVNANL 168  
 RESULT 5  
 ID Q9JYD3 PRELIMINARY; PRT; 500 AA.  
 AC Q9JYD3;  
 DT 01-OCT-2000 (Tremblrel. 15, Created)  
 DT 01-OCT-2000 (Tremblrel. 15, Last sequence update)  
 DE N UTILIZATION SUBSTANCE PROTEIN A.  
 GN NMB1642.  
 OS Neisseria meningitidis (serogroup B).  
 OC Bacteria; Proteobacteria; beta subdivision; Neisseriaceae; Neisseria.  
 OX NCBI\_TaxID=491;  
 RN (1)  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=MC58 / SEROGROUP B;  
 RX MEDLINE=20175755; PubMed=10710307;  
 RA Tettelin H., Saunders N.J., Heidelberg J., Jeffries A.C., Nelson K.E.,  
 RA Nelson J.A., Ketchum K.A., Hood D.W., Peden J.F., Dodson R.J.,  
 RA Eisen W.C., Gwinn M.L., DeBoy R., Peterson J.D., Hickey E.K.,  
 RA Haft D.H., Salzberg S.L., White O., Fleischmann R.D., Dougherty B.A.,  
 RA Mason T., Clecko A., Parksey D.S., Blair E., Citton H., Clark E.B.,  
 RA Cotton M.D., Utterback T.R., Khouri H., Qin H., Vamathevan J.,  
 RA Gill J., Scarlato V., Masignani V., Pizzi M., Grandi G., Sun L.,  
 RA Smith H.O., Fraser C.M., Moxon E.R., Rappuoli R., Venter J.C.;  
 RT "Complete genome sequence of Neisseria meningitidis serogroup B strain  
 RT MC58";  
 RL Science 287:1809-1815 (2000).  
 DR EMBL; AE002514; AAF41991.1;  
 DR TIGR; NMB1642;  
 DR InterPro; IPR000958; KH.  
 DR InterPro; IPR003029; SI.

DR Pfam; PF00013; KH-domain; 1.  
 DR Pfam; PF00575; S1; 1.  
 DR SMART; SM00322; KH; 2.  
 DR SMART; SM00316; S1; 1.  
 KW Complete proteome.  
 SQ SEQUENCE 500 AA; 55751 MW; 753FA50DDEF5B774 CRC64;

Query Match 54.9%; Score 45; DB 2; Length 500;  
 Best Local Similarity 62.5%; Pred. No. 12;  
 Matches 10; Conservative 2; Mismatches 2; Indels 2; Gaps 1;

QY 1 CFGVGKGTTVNA--NEL 14  
 | | | | | | | | | |  
 Db 259 CIGVGRSRVNAVSNEL 274

## RESULT 6

Q9JTB6 PRELIMINARY; PRT; 505 AA.  
 AC Q9JTB6;  
 DT 01-OCT-2000 (TrEMBLrel. 15, Created)  
 DT 01-OCT-2000 (TrEMBLrel. 15, Last sequence update)  
 DT 01-JUN-2001 (TrEMBLrel. 17, Last annotation update)  
 DE N UTILISATION SUBSTANCE PROTEIN A.  
 GN NUSA OR NNA1896.  
 OS Neisseria meningitidis (serogroup A).  
 OC Bacteria; Proteobacteria; beta subdivision; Neisseriaceae; Neisseria.  
 OX NCBI\_TaxID=65699;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=22491 / SEROGROUP A / SEROTYPE 4A;  
 RX MEDLINE=20222556; PubMed=10761919;  
 RA Parkhill J., Achtman M., James K.D., Bentley S.D., Churcher C.,  
 RA Klee S.R., Morelli G., Basham D., Brown D., Chillingworth T.,  
 RA Davies R.M., Davis P., Devlin K., Feltwell T., Hamlin N., Holroyd S.,  
 RA Jagels K., Leather S., Moule S., Mungall K., Quail M.A.,  
 RA Rajandream M.A., Rutherford K.M., Simmonds M., Skelton J.,  
 RA Whitehead S., Spratt B.G., Barrell B.G.;  
 RT "Complete DNA sequence of a serogroup A strain of Neisseria  
 meningitidis 22491";  
 RL Nature 404:502-506(2000).  
 DR EMBL; AL162757; CAB85117.1;  
 DR InterPro; IPR000958; KH.  
 DR InterPro; IPR003029; S1.  
 DR Pfam; PF00013; KH-domain; 1.  
 DR Pfam; PF00575; S1; 1.  
 DR SMART; SM00322; KH; 2.  
 DR SMART; SM00316; S1; 1.  
 KW Complete proteome.  
 SQ SEQUENCE 505 AA; 56418 MW; 5A0F080DCA99E5D7 CRC64;

Query Match 54.9%; Score 45; DB 2; Length 505;  
 Best Local Similarity 62.5%; Pred. No. 12;  
 Matches 10; Conservative 2; Mismatches 2; Indels 2; Gaps 1;

QY 1 CFGVGKGTTVNA--NEL 14  
 | | | | | | | | | |  
 Db 264 CIGVGRSRVNAVSNEL 279

## RESULT 7

Q9ZCD4 PRELIMINARY; PRT; 744 AA.  
 AC Q9ZCD4;  
 DT 01-MAY-1999 (TrEMBLrel. 10, Created)  
 DT 01-MAY-1999 (TrEMBLrel. 10, Last sequence update)  
 DT 01-JUN-2001 (TrEMBLrel. 17, Last annotation update)  
 DE CELL DIVISION PROTEIN FTSK HOMOLOG (FTSK).  
 GN RP823.  
 OS Rickettsia prowazekii.  
 OC Bacteria; Proteobacteria; alpha subdivision; Rickettsiales;

OC Rickettsiaceae; Rickettsiae; Rickettsia.  
 OX NCBI\_TaxID=782;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=MADRID E;  
 RX MEDLINE=99039499; PubMed=9823893;  
 RA Andersson S.G.E., Zomorodipour A., Andersson J.O.,  
 RA Sicheritz-Ponten T., Alsmark U.C.M., Podowski R.M., Naeslund A.K.,  
 RA Eriksson A.-S., Winkler H.H., Kurland C.G.;  
 RT "The genome sequence of Rickettsia prowazekii and the origin of  
 mitochondria";  
 RL Nature 396:133-140(1998).  
 DR EMBL; AJ235273; CAAL5248.1;  
 DR InterPro; IPR002543; FtsK\_SpoIIIE.  
 DR Pfam; PF01580; FtsK\_SpoIIIE; 1.  
 KW Complete proteome.  
 SQ SEQUENCE 744 AA; 82819 MW; C8208B0A9D9E42AC CRC64;

Query Match 53.7%; Score 44; DB 2; Length 744;  
 Best Local Similarity 57.1%; Pred. No. 27;  
 Matches 8; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

QY 2 FGKVGTTVNANELP 15  
 | | | | | : | | | |  
 Db 288 FGKVGQIININQGP 301

## RESULT 8

P95633 PRELIMINARY; PRT; 1055 AA.  
 AC P95633;  
 DT 01-MAY-1997 (TrEMBLrel. 03, Created)  
 DT 01-MAY-1997 (TrEMBLrel. 03, Last sequence update)  
 DT 01-JUN-2001 (TrEMBLrel. 17, Last annotation update)  
 DE ROMPA (FRAGMENT).  
 GN OMPA.  
 OS Rickettsia montana.  
 OC Bacteria; Proteobacteria; alpha subdivision; Rickettsiales;  
 OC Rickettsiaceae; Rickettsiae; Rickettsia.  
 OX NCBI\_TaxID=33991;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=M5/6;  
 RA Raoult D., Fournier P.E., Roux V.;  
 RL Submitted (DEC-1996) to the EMBL/GenBank/DBJ databases.  
 DR EMBL; U83447; AAC35183.1;  
 DR InterPro; IPR003858; rOmpA\_rOmpB.  
 DR Pfam; PF02708; rOmpA\_rOmpB; 1.  
 FT NON\_TER 1  
 FT NON\_TER 1059 1059  
 SQ SEQUENCE 1059 AA; 110213 MW; DD9EECF128990632 CRC64;

Query Match 53.7%; Score 44; DB 2; Length 1059;  
 Best Local Similarity 61.5%; Pred. No. 40;  
 Matches 8; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 2 FGKVGTTVNANEL 14  
 | | | | | | | | | |  
 Db 301 FGKVGTTFNATDI 313

## RESULT 9

Q9APM4 PRELIMINARY; PRT; 369 AA.  
 AC Q9APM4;  
 DT 01-JUN-2001 (TrEMBLrel. 17, Created)  
 DT 01-JUN-2001 (TrEMBLrel. 17, Last sequence update)  
 DT 01-JUN-2001 (TrEMBLrel. 17, Last annotation update)  
 DE MAJOR OUTER MEMBRANE PROTEIN PRECURSOR.  
 GN OMP1.  
 OS Chlamydophila abortus.

```

OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydia.
OX NCBI_TaxID=83555;
RN [1]
RC STRAIN=LLG;
RX MEDLINE=20569239; PubMed=11119563;
RA Vreton E., Psarrou E., Kaisar M., Vilisidou I., Salti-Montesanto V.,
RA Longbottom D.;
RT "Identification of protective epitopes by sequencing of the major
RT outer membrane protein gene of a variant strain of Chlamydia psittaci
RT serotype 1.";
RL Infect. Immun. 69:607-612(2001).
RW EMBL; AF272945; AAG53881.1; -.
KW SIGNAL.
FT CHAIN 1 22 POTENTIAL.
FT CHAIN 23 389 MAJOR OUTER MEMBRANE PROTEIN.
SQ SEQUENCE 389 AA; 41897 MW; 20513C69C7DBAAF5 CRC64;

Query Match 52.4%; Score 43; DB 2; Length 389;
Best Local Similarity 61.5%; Pred. No. 20;
Matches 8; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy 3 GVKGTTVNANELP 15
Db 159 GVGSSVAADQLP 171

RESULT 10
Q9HEU6
ID Q9HEU6 PRELIMINARY; PRT; 318 AA.
AC Q9HEU6;
DT 01-MAR-2001 (TReMBLrel. 16; Created)
DT 01-MAR-2001 (TReMBLrel. 16; Last sequence update)
DT 01-MAR-2001 (TReMBLrel. 16; Last annotation update)
DE PTAC BETA (FRAGMENT).
GN PTAC.
OS Emericella nidulans (Aspergillus nidulans).
OC Eukaryota; Fungi; Ascomycota; Pezizomycotina; Eurotiomycetes;
OC Eutriales; Trichocomaceae; Emericella.
OX NCBI_TaxID=5072;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=89218944; PubMed=2651886;
RA Arst H.N. Jr., Tollervey D., Caddick M.X.;
RT "A translocation associated, loss-of-function mutation in the nitrogen
RT metabolite repression regulatory gene of Aspergillus nidulans can
RT revert intracistronically.";
RL Mol. Gen. Genet. 215:364-367(1989).
RN [2]
RP SEQUENCE FROM N.A.
RA Conlon H.E., Zadra I., Haas H., Jones M.G., Arst H.N. Jr.,
RA Caddick M.X.;
RT "The Aspergillus nidulans GATA transcription factor gene areB encodes
RT at least three proteins and features three classes of mutation.";
RL Submitted (NOV-2000) to the EMBL/GenBank/DBJ databases.
DR EMBL; AF320980; AAG49360.1; -.
FT NON_TER 1
FT SEQUENCE 318 AA; 34750 MW; 1F2F8776D1C46A3D CRC64;

Query Match 51.2%; Score 42; DB 3; Length 318;
Best Local Similarity 46.7%; Pred. No. 25;
Matches 7; Conservative 2; Mismatches 5; Indels 0; Gaps 0;

Qy 1 CFGVGKTTVNANELP 15
Db 237 CLGLSGQVNRNKP 251

RESULT 11
Q9X717
ID Q9X717 PRELIMINARY; PRT; 341 AA.

```

```

AC Q9X717;
DT 01-NOV-1999 (TReMBLrel. 12; Created)
DT 01-NOV-1999 (TReMBLrel. 12; Last sequence update)
DT 01-JUN-2001 (TReMBLrel. 17; Last annotation update)
DE MAJOR OUTER MEMBRANE PROTEIN PRECURSOR (FRAGMENT).
GN OMPA.
OS Chlamydia abortus.
OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydia.
OX NCBI_TaxID=83555;
RN [1]
RP SEQUENCE FROM N.A.
RX STRAIN=LW508;
RX MEDLINE=93123168; PubMed=8419295;
RA Kaltenboeck B., Kousoulas K.G., Storz J.;
RT "Structures of and allelic diversity and relationships among the major
RT outer membrane protein (ompA) genes of the four chlamydial species.";
RL J. Bacteriol. 175:487-502(1993).
DR EMBL; M73040; AAD29103.1; -.
DR InterPro; IPR000604; Chlamydia_OMP.
DR Pfam; PF01308; Chlamydia_OMP; 1.
DR ProDom; PD001717; Chlamydia_OMP; 1.
FT NON_TER 1
FT NON_TER 341
FT SEQUENCE 341 AA; 36762 MW; B5933C9BF6AAF171 CRC64;

Query Match 51.2%; Score 42; DB 2; Length 341;
Best Local Similarity 53.8%; Pred. No. 27;
Matches 7; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Qy 3 GVKGTTVNANELP 15
Db 123 GVGSSIAADQLP 135

RESULT 12
O69306
ID O69306 PRELIMINARY; PRT; 352 AA.
AC O69306;
DT 01-AUG-1998 (TReMBLrel. 07; Created)
DT 01-AUG-1998 (TReMBLrel. 07; Last sequence update)
DT 01-JUN-2001 (TReMBLrel. 17; Last annotation update)
DE OMP1 PROTEIN (FRAGMENT).
GN OMP1.
OS Chlamydia psittaci (Chlamydia psittaci).
OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydia.
OX NCBI_TaxID=83554;
RN [1]
RP SEQUENCE FROM N.A.
RX STRAIN=PM234;
RA Hoelzle L.E., Steinhausen G., Eggemann G., Schiller I.,
RA Wittenbrink M.M.;
RL Submitted (MAR-1998) to the EMBL/GenBank/DBJ databases.
DR EMBL; AJ004874; CAA06183.1; -.
DR InterPro; IPR000604; Chlamydia_OMP.
DR Pfam; PF01308; Chlamydia_OMP; 1.
DR ProDom; PD001717; Chlamydia_OMP; 1.
FT NON_TER 352
FT SEQUENCE 352 AA; 37868 MW; OAE9B1E099EED41 CRC64;

Query Match 51.2%; Score 42; DB 2; Length 352;
Best Local Similarity 53.8%; Pred. No. 28;
Matches 7; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Qy 3 GVKGTTVNANELP 15
Db 159 GVGSSIAADQLP 171

RESULT 13
O69307
ID O69307 PRELIMINARY; PRT; 352 AA.

```



AC O69307;  
 DT 01-AUG-1998 (TrEMBLrel. 07, Created)  
 DT 01-AUG-1998 (TrEMBLrel. 07, Last sequence update)  
 DT 01-JUN-2001 (TrEMBLrel. 17, Last annotation update)  
 DE OMP1 PROTEIN (FRAGMENT).  
 GN OMP1.  
 OS Chlamydia psittaci (Chlamydochloa psittaci).  
 OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydochloa.  
 OX NCBI\_TaxID=83554;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=PM326;  
 RA Hoelzle L.E., Steinhilber G., Eggemann G., Schiller I.,  
 RA Wittenbrink M.M.;  
 RL Submitted (MAR-1998) to the EMBL/GenBank/DBJ databases.  
 DR EMBL; AJ004875; CAA06184.1; -  
 DR InterPro: IPR000604; Chlamydia\_OMP.  
 DR Pfam: PF01308; Chlamydia\_OMP; 1.  
 DR ProDom: PD001717; Chlamydia\_OMP; 1.  
 FT NON\_TER 352  
 SQ SEQUENCE 352 AA; 37854 MW; 33589C6D1137CCDB CRC64;

Query Match 51.2%; Score 42; DB 2; Length 352;  
 Best Local Similarity 53.8%; Pred. No. 28;  
 Matches 7; Conservative 5; Mismatches 1; Indels 0; Gaps 0;  
 QY 3 GVKGTNNANL 15  
 |||||:|:|:  
 Db 159 GVGSSIAADQLP 171

RESULT 14  
 O70085  
 ID O70085 PRELIMINARY; PRT; 352 AA.  
 AC O70085;  
 DT 01-AUG-1998 (TrEMBLrel. 07, Created)  
 DT 01-AUG-1998 (TrEMBLrel. 07, Last sequence update)  
 DT 01-JUN-2001 (TrEMBLrel. 17, Last annotation update)  
 DE OMP1 (FRAGMENT).  
 GN OMP1.  
 OS Chlamydia psittaci (Chlamydochloa psittaci).  
 OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydochloa.  
 OX NCBI\_TaxID=83554;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=PM326;  
 RA Hoelzle L.E., Steinhilber G., Eggemann G., Schiller I.,  
 RA Wittenbrink M.M.;  
 RL Submitted (APR-1998) to the EMBL/GenBank/DBJ databases.  
 DR EMBL; AJ005618; CAA06625.1; -  
 DR EMBL; AJ005617; CAA06624.1; -  
 DR InterPro: IPR000604; Chlamydia\_OMP.  
 DR Pfam: PF01308; Chlamydia\_OMP; 1.  
 DR ProDom: PD001717; Chlamydia\_OMP; 1.  
 FT NON\_TER 352  
 SQ SEQUENCE 352 AA; 391914AD146072CB CRC64;

Query Match 51.2%; Score 42; DB 2; Length 352;  
 Best Local Similarity 53.8%; Pred. No. 28;  
 Matches 7; Conservative 5; Mismatches 1; Indels 0; Gaps 0;  
 QY 3 GVKGTNNANL 15  
 |||||:|:|:  
 Db 159 GVGSSIAADQLP 171

RESULT 15  
 O69305  
 ID O69305 PRELIMINARY; PRT; 353 AA.  
 AC O69305;  
 DT 01-AUG-1998 (TrEMBLrel. 07, Created)

DT 01-AUG-1998 (TrEMBLrel. 07, Last sequence update)  
 DT 01-JUN-2001 (TrEMBLrel. 17, Last annotation update)  
 DE OMP1 PROTEIN (FRAGMENT).  
 GN OMP1.  
 OS Chlamydia psittaci (Chlamydochloa psittaci).  
 OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydochloa.  
 OX NCBI\_TaxID=83554;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=OCLH196;  
 RA Hoelzle L.E., Steinhilber G., Eggemann G., Schiller I.,  
 RA Wittenbrink M.M.;  
 RL Submitted (MAR-1998) to the EMBL/GenBank/DBJ databases.  
 DR EMBL; AJ004873; CAA06182.1; -  
 DR InterPro: IPR000604; Chlamydia\_OMP.  
 DR Pfam: PF01308; Chlamydia\_OMP; 1.  
 DR ProDom: PD001717; Chlamydia\_OMP; 1.  
 FT NON\_TER 353  
 SQ SEQUENCE 353 AA; AC7D8FD9FA6E1728 CRC64;

Query Match 51.2%; Score 42; DB 2; Length 353;  
 Best Local Similarity 53.8%; Pred. No. 28;  
 Matches 7; Conservative 5; Mismatches 1; Indels 0; Gaps 0;  
 QY 3 GVKGTNNANL 15  
 |||||:|:|:  
 Db 159 GVGSSIAADQLP 171

Search completed: March 26, 2002, 13:40:14  
 Job time: 228 sec



GenCore version 4.5  
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: March 26, 2002, 13:40:43 ; Search time 24.63 Seconds  
(without alignments)  
22.329 Million cell updates/sec

Title: US-09-709-201-97  
Perfect score: 82  
Sequence: 1 CFGVKGTTVNANELP 15

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 100059 seqs, 36664827 residues

Total number of hits satisfying chosen parameters: 100059

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : SwissProt\_39:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	73	89.0	389	1	OMPL_CHLPN
2	69	84.1	389	1	OMIN_CHLPN
3	61	74.4	333	1	OM1K_CHLPN
4	42	51.2	389	1	OM1A_CHLPN
5	42	51.2	708	1	PETL_HUMAN
6	41	50.0	93	1	RK23_MAIZE
7	41	50.0	93	1	RK23_ORYZA
8	41	50.0	93	1	RK23_WHEAT
9	40	48.8	246	1	YGGI_ECOLI
10	40	48.8	1235	1	DNBI_HCMVA
11	40	48.8	1956	1	ATX1_PLAFA
12	40	48.8	3343	1	YOG7_CAEEL
13	39	47.6	640	1	TPB5_BPT5
14	38.5	47.0	435	1	PGLX_ASPTU
15	38	46.3	168	1	GLX2_THETH
16	38	46.3	223	1	CLIC_ARATH
17	38	46.3	229	1	NECL_NICPL
18	38	46.3	322	1	VANH_ENTFC
19	38	46.3	330	1	ODBA_BACSU
20	38	46.3	473	1	KCC4_HUMAN
21	38	46.3	776	1	VP4_ROT5
22	37	45.1	93	1	RK23_ARATH
23	37	45.1	93	1	RK23_TOBAC
24	37	45.1	232	1	PYRK_ARCFU
25	37	45.1	335	1	NAG2_XYLFA
26	37	45.1	395	1	NUSA_HELPJ
27	37	45.1	395	1	NUSA_HELPJ
28	37	45.1	2731	1	RRPB_CVMJH
29	36	43.9	202	1	YJ72_YEAST
30	36	43.9	246	1	PSA6_CAEEL
31	36	43.9	413	1	COBL_PSEDE
32	36	43.9	425	1	SYH_STREQ
33	36	43.9	474	1	LCND_LACLA

#### RESULT 1

ID	OMPL_CHLPN	STANDARD;	PRT;	389 AA.
AC	P27455: Q9JOF6;			
DT	01-AUG-1992 (Rel. 23, Created)			
DT	01-AUG-1992 (Rel. 23, Last sequence update)			
DE	20-AUG-2001 (Rel. 40, Last annotation update)			
DE	MAJOR OUTER MEMBRANE PROTEIN PRECURSOR (MOMP).			
GN	OMPA OR OMPI OR CPN0695 OR CP0051.			
OS	Chlamydia pneumoniae (Chlamydia pneumoniae).			
OC	Bacteria; Chlamydiales; Chlamydiales; Chlamydiales.			
OX	NCBI_TaxID=83558;			
RN	[1]			
RP	SEQUENCE FROM N.A.			
RC	STRAIN=IOL-207;			
RX	MEDLINE=91237311; PubMed=2033374;			
RA	Carter M.W., Al-Mahdawi S.A.H., Giles I.G., Trehan J.D.,			
RA	Ward M.E., Clarke I.N.;			
RT	"Nucleotide sequence and taxonomic value of the major outer membrane protein gene of Chlamydia pneumoniae IOL-207.";			
RL	J. Gen. Microbiol. 137:465-475(1991).			
RN	[2]			
RP	SEQUENCE FROM N.A.			
RC	STRAIN=TWAR;			
RX	MEDLINE=91244474; PubMed=1840574;			
RA	Perez Melgosa M., Kuo C.-C., Campbell L.A.;			
RT	"Sequence analysis of the major outer membrane protein gene of Chlamydia pneumoniae.";			
RL	Infect. Immun. 59:2195-2199(1991).			
RN	[3]			
RP	SEQUENCE FROM N.A.			
RA	Mitchell W.M., Tharp A.C., Stratton C.W., Srinam S.;			
RL	Submitted (FEB-1995) to the EMBL/GenBank/DBJ databases.			
RN	[4]			
RP	SEQUENCE FROM N.A.			
RC	STRAIN=CWL029;			
RX	MEDLINE=99206606; PubMed=10192388;			
RA	Kalman S., Mitchell W., Marathe R., Lamel C., Fan J., Hyman R.W.,			
RA	Olinger L., Grimwood J., Davis R.W., Stephens R.S.;			
RT	"Comparative genomes of Chlamydia pneumoniae and C. trachomatis.";			
RL	Nat. Genet. 21:385-389(1999).			
RN	[5]			
RP	SEQUENCE FROM N.A.			
RC	STRAIN=AR39;			
RX	MEDLINE=20150255; PubMed=10684935;			
RA	Read T.D., Brunham R.C., Shen C., Gill S.R., Heidelberg J.F., Bass S.,			
RA	White O., Hickey E.K., Peterson J., Utterback T., Berry K., Dadd S.,			
RA	Linher K., Weidman J., Khouri H., Craven B., Bowman C., Dodson R.,			
RA	Gwin M., Nelson J., DeBoy R., Kolonay J., McClarty G., Salzberg S.L.,			
RT	"Genome sequences of Chlamydia trachomatis MOPn and Chlamydia pneumoniae AR39.";			
RL	Nucleic Acids Res. 28:1397-1406(2000).			
RN	[6]			
RP	SEQUENCE FROM N.A.			
RC	STRAIN=J138;			

34	36	43.9	539	1	VLL_HPVA5
35	36	43.9	556	1	FTHS_CLOCY
36	36	43.9	916	1	CAD4_HUMAN
37	36	43.9	964	1	PMPE_CHLTR
38	36	43.9	976	1	PMPE_CHLMU
39	36	43.9	1178	1	YNI7_YEAST
40	36	43.9	1208	1	RCQ4_HUMAN
41	36	43.9	1242	1	CY41_TRYBB
42	36	43.9	1271	1	Y338_MYCGE
43	36	43.9	2733	1	RRPB_CVMA5
44	35.5	43.3	215	1	HP27_TAMAS
45	35.5	43.3	238	1	Y097_CAEEL

#### ALIGNMENTS

P36741	human papill
Q07064	clostridium
P55283	homo sapien
O84877	chlamydia t
Q9p147	chlamydia m
P48231	saccharomyc
Q99279	trypanosoma
P47580	mycoplasma
P16342	murine coro
Q06577	tamias asia
P41847	caenorhabdi

RX MEDLINE=20330349; PubMed=10871362;  
 RA Shirai M., Hirakawa H., Kimoto M., Tabuchi M., Kishi F., Ouchi K.,  
 RA Shiba T., Ishii K., Hattori M., Kuhara S., Nakazawa T.;  
 RT "Comparison of whole genome sequences of Chlamydia pneumoniae J138  
 from Japan and CWL029 from USA.";  
 RL Nucleic Acids Res. 28:2311-2314(2000).  
 RN [7]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=J138;  
 RX MEDLINE=20298986; PubMed=10839753;  
 RA Shirai M., Hirakawa H., Ouchi K., Tabuchi M., Kishi F., Kimoto M.,  
 RA Takeuchi H., Nishida J., Shibata K., Fujinaga R., Yoneda H.,  
 RA Matsushina H., Tanaka C., Furukawa S., Miura K., Nakazawa A.,  
 RA Ishii K., Shiba T., Hattori M., Kuhara S., Nakazawa T.;  
 RT "Comparison of outer membrane protein genes omp and pmp in the whole  
 genome sequences of Chlamydia pneumoniae isolates from Japan and the  
 United States";  
 RL J. Infect. Dis. 181 Suppl 3:S524-S527(2000).  
 CC -1- FUNCTION: STRUCTURAL RIGIDITY OF THE OUTER MEMBRANE OF ELEMENTARY  
 CC BODIES AND PORIN FORMING. PERMITTING DIFFUSION OF SOLUTES THROUGH  
 CC THE INTRACELLULAR RETICULATE BODY MEMBRANE.  
 CC -1- SUBUNIT: DISULFIDE BOND INTERACTIONS WITHIN AND BETWEEN MOMP  
 CC MOLECULES & OTHER COMPONENTS FORM HIGH MOLECULAR-WEIGHT OLIGOMERS.  
 CC -1- SUBCELLULAR LOCATION: INTEGRAL MEMBRANE PROTEIN. OUTER MEMBRANE.  
 CC -1- SIMILARITY: BELONGS TO THE CHLAMYDIAL OMP FAMILY.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC -----  
 DR EMBL; M64064; AAA23143.1; -;  
 DR EMBL; M69230; AAA73071.1; -;  
 DR EMBL; AF131889; AAD22492.1; -;  
 DR EMBL; AE001652; AAD18834.1; -;  
 DR EMBL; AE002167; AAF37944.1; -;  
 DR EMBL; AP002547; BAA98902.1; -;  
 DR EMBL; AB033787; BAA85940.1; -;  
 DR PIR; A43587; A43587.  
 DR PIR; A49751; A49751.  
 DR TIGR; CP0051; -;  
 DR InterPro; IPR000604; Chlamydia\_OMP.  
 DR Pfam; PF01308; Chlamydia\_OMP; 1.  
 DR ProDom; PD001717; Chlamydia\_OMP; 1.  
 KW Outer membrane; Transmembrane; Porin; Signal; Complete proteome.  
 FT SIGNAL 1 23  
 FT CHAIN 24 389 MAJOR OUTER MEMBRANE PROTEIN.  
 SQ SEQUENCE 389 AA; 41620 MW; 15D984151E41F8F2 CRC64;

Query Match 89.08; Score 73; DB 1; Length 389;  
 Best Local Similarity 100.0%; Pred. No. 1.4e-05;  
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 FGKGTNNANL 15  
 Db 158 FGKGTNNANL 171

RESULT 2  
 OM1N\_CHLPN STANDARD; PRT; 389 AA.  
 AC Q07430;  
 DT 30-MAY-2000 (Rel. 39, Created)  
 DT 30-MAY-2000 (Rel. 39, Last sequence update)  
 DE 20-AUG-2001 (Rel. 40, Last annotation update)  
 DE MAJOR OUTER MEMBRANE PROTEIN PRECURSOR (MOMP).  
 GN OMPA OR OMP1  
 OS Chlamydia pneumoniae (Chlamydia pneumoniae).  
 OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydia.

OX NCBI\_TaxID=83558;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=N16;  
 RX MEDLINE=94103736; PubMed=8277245;  
 RA Storey C., Lusher M., Yates P., Richmond S.;  
 RT "Evidence for Chlamydia pneumoniae of non-human origin.";  
 RL J. Gen. Microbiol. 139:2621-2626(1993).  
 CC -1- FUNCTION: STRUCTURAL RIGIDITY OF THE OUTER MEMBRANE OF ELEMENTARY  
 CC BODIES AND PORIN FORMING. PERMITTING DIFFUSION OF SOLUTES THROUGH  
 CC THE INTRACELLULAR RETICULATE BODY MEMBRANE.  
 CC -1- SUBUNIT: DISULFIDE BOND INTERACTIONS WITHIN AND BETWEEN MOMP  
 CC MOLECULES & OTHER COMPONENTS FORM HIGH MOLECULAR-WEIGHT OLIGOMERS.  
 CC -1- SUBCELLULAR LOCATION: INTEGRAL MEMBRANE PROTEIN. OUTER MEMBRANE.  
 CC -1- SIMILARITY: BELONGS TO THE CHLAMYDIAL OMP FAMILY.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC -----  
 DR EMBL; L04982; AAA17397.1; -;  
 DR InterPro; IPR000604; Chlamydia\_OMP.  
 DR Pfam; PF01308; Chlamydia\_OMP; 1.  
 DR ProDom; PD001717; Chlamydia\_OMP; 1.  
 KW Outer membrane; Transmembrane; Porin; Signal.  
 FT SIGNAL 1 23 BY SIMILARITY  
 FT CHAIN 24 389 MAJOR OUTER MEMBRANE PROTEIN.  
 SQ SEQUENCE 389 AA; 41628 MW; 801622F05D841967 CRC64;

Query Match 84.1%; Score 69; DB 1; Length 389;  
 Best Local Similarity 92.9%; Pred. No. 7.2e-05;  
 Matches 13; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 2 FGKGTNNANL 15  
 Db 158 FGKGTNNANL 171

RESULT 3  
 OM1K\_CHLPN STANDARD; PRT; 333 AA.  
 AC Q9XB4;  
 DT 30-MAY-2000 (Rel. 39, Created)  
 DT 30-MAY-2000 (Rel. 39, Last sequence update)  
 DE 20-AUG-2001 (Rel. 40, Last annotation update)  
 DE MAJOR OUTER MEMBRANE PROTEIN (MOMP) (FRAGMENT).  
 GN OMPA OR OMP1.  
 OS Chlamydia pneumoniae (Chlamydia pneumoniae).  
 OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydia.

OX NCBI\_TaxID=83558;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=KOALA TYPE I;  
 RX MEDLINE=93123168; PubMed=8419295;  
 RA Kaltenboeck B., Kousoulas K.G., Storz J.;  
 RT "Structures of and allelic diversity and relationships among the major  
 outer membrane protein (ompA) genes of the four chlamydial species.";  
 RL J. Bacteriol. 175:487-502(1993).  
 CC -1- FUNCTION: STRUCTURAL RIGIDITY OF THE OUTER MEMBRANE OF ELEMENTARY  
 CC BODIES AND PORIN FORMING. PERMITTING DIFFUSION OF SOLUTES THROUGH  
 CC THE INTRACELLULAR RETICULATE BODY MEMBRANE.  
 CC -1- SUBUNIT: DISULFIDE BOND INTERACTIONS WITHIN AND BETWEEN MOMP  
 CC MOLECULES & OTHER COMPONENTS FORM HIGH MOLECULAR-WEIGHT OLIGOMERS.  
 CC -1- SUBCELLULAR LOCATION: INTEGRAL MEMBRANE PROTEIN. OUTER MEMBRANE.  
 CC -1- SIMILARITY: BELONGS TO THE CHLAMYDIAL OMP FAMILY.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -

CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announcement/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).

DR EMBL; M73038; AAD38210.1; -  
 DR InterPro; IPR000604; Chlamydia\_OMP.  
 DR Pfam; PF01308; Chlamydia\_OMP; 1.  
 DR ProDom; PD001717; Chlamydia\_OMP; 1.  
 KW Outer membrane; Transmembrane; Porin.  
 FT NON\_TER 1 1  
 FT NON\_TER 333 333  
 SQ SEQUENCE 333 AA; 35811 MW; 204604512C4C3B3F CRC64;

Query Match 74.48; Score 61; DB 1; Length 333;  
 Best Local Similarity 85.78; Pred. No. 0.0017;  
 Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Oy 2 FGKGTNNANL 15  
 |||||:|||||  
 Db 114 FGKGTNNANL 127

RESULT 4  
 OM1A\_CHLPS STANDARD; PRT; 389 AA.  
 AC P16567;  
 DT 01-AUG-1990 (Rel. 15, Created)  
 DT 01-AUG-1990 (Rel. 15, Last sequence update)  
 DT 20-AUG-2001 (Rel. 40, Last annotation update)  
 DE MAJOR OUTER MEMBRANE PROTEIN PRECURSOR (MOMP).  
 GN OMPA OR OMP.  
 OS Chlamydia psittaci (Chlamydia psittaci).  
 OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydia phila.  
 OC NCBI\_TaxID=83554;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN-OVINE ENZOOTIC ABORTION ISOLATE S26/3;  
 RA MEDLINE=96189695; PubMed=8605581;  
 RA Griffiths P.C., Plater J.M., Martin T.C., Hughes S.L.,  
 RA Hughes K.J., Hewinson R.G., Dawson M.;  
 RT "Epizootic bovine abortion in a dairy herd: characterization of a  
 RT ovine abortion strain of Chlamydia psittaci.";  
 RL FEMS Microbiol. Lett. 53:153-158(1989).  
 RN [2]

RP SEQUENCE FROM N.A.  
 RC STRAIN-BOVINE ABORTION ISOLATE BAI;  
 RA MEDLINE=96189695; PubMed=8605581;  
 RA Griffiths P.C., Plater J.M., Martin T.C., Hughes S.L.,  
 RA Hughes K.J., Hewinson R.G., Dawson M.;  
 RT "Epizootic bovine abortion in a dairy herd: characterization of a  
 RT Chlamydia psittaci isolate and antibody response.";  
 RL Br. Vet. J. 151:683-693(1995).  
 CC -1- FUNCTION: STRUCTURAL RIGIDITY OF THE OUTER MEMBRANE OF ELEMENTARY  
 CC BODIES AND PORIN FORMING, PERMITTING DIFFUSION OF SOLUTES THROUGH  
 CC THE INTRACELLULAR RETICULATE BODY MEMBRANE.  
 CC -1- SUBUNIT: DISULFIDE BOND INTERACTIONS WITHIN AND BETWEEN MOMP  
 CC MOLECULES & OTHER COMPONENTS FORM HIGH MOLECULAR-WEIGHT OLIGOMERS.  
 CC -1- SUBCELLULAR LOCATION: INTEGRAL MEMBRANE PROTEIN. OUTER MEMBRANE.  
 CC -1- SIMILARITY: BELONGS TO THE CHLAMYDIAL OMP FAMILY.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announcement/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).

CC EMBL; X51859; CAA36152.1; -  
 DR EMBL; L39020; AAB02850.1; -  
 DR PIR; S08770; MMCWP3.

DR InterPro; IPR000604; Chlamydia\_OMP.  
 DR Pfam; PF01308; Chlamydia\_OMP; 1.  
 DR ProDom; PD001717; Chlamydia\_OMP; 1.  
 KW Outer membrane; Transmembrane; Porin; Signal.  
 FT SIGNAL 1 22  
 FT CHAIN 23 389 MAJOR OUTER MEMBRANE PROTEIN.  
 SQ SEQUENCE 389 AA; 41883 MW; 741B5A23ACDBB447 CRC64;

Query Match 51.28; Score 42; DB 1; Length 389;  
 Best Local Similarity 53.88; Pred. No. 5.1;  
 Matches 7; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Oy 3 GVKGTNNANL 15  
 |||||:|:|:|  
 Db 159 GVKGTNNANL 171

RESULT 5  
 PET1\_HUMAN STANDARD; PRT; 708 AA.  
 ID PET1\_HUMAN STANDARD; PRT; 708 AA.  
 AC P46059;  
 DT 01-NOV-1995 (Rel. 32, Created)  
 DT 01-NOV-1995 (Rel. 32, Last sequence update)  
 DT 20-AUG-2001 (Rel. 40, Last annotation update)  
 DE OLIGOPEPTIDE TRANSPORTER, SMALL INTESTINE ISOFORM (PEPTIDE TRANSPORTER  
 DE 1) (INTESTINAL H+/PEPTIDE COTRANSPORTER) (SOLUTE CARRIER FAMILY 15,  
 DE MEMBER 1).  
 GN SLC15A1 OR PEPT1.  
 OS Homo sapiens (Human).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 OX NCBI\_TaxID=9606;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC TISSUE=Intestine;  
 RX MEDLINE=95204429; PubMed=7896779;  
 RA Liang R., Fei Y.-J., Prasad P.D., Ramamoorthy S., Han H.,  
 RA Yang-Feng T.L., Hediger M.A., Ganapathy V., Leibach F.H.;  
 RT "Human intestinal H+/peptide cotransporter: Cloning, functional  
 RT expression, and chromosomal localization.";  
 RL J. Biol. Chem. 270:6456-6463(1995).  
 CC -1- FUNCTION: PROTON-COUPLED INTAKE OF OLIGOPEPTIDES OF 2 TO 4  
 CC AMINO ACIDS WITH A PREFERENCE FOR DIPEPTIDES. MAY CONSTITUTE  
 CC A MAJOR ROUTE FOR THE ABSORPTION OF PROTEIN DIGESTION END-  
 CC PRODUCTS.

CC -1- SUBCELLULAR LOCATION: INTEGRAL MEMBRANE PROTEIN.  
 CC -1- SIMILARITY: BELONGS TO THE PTR2 FAMILY OF TRANSPORTERS.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announcement/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).

EMBL; U13173; AAB61693.1; -  
 DR EMBL; U21936; AAA63797.1; -  
 DR MIM; 600544; -  
 DR InterPro; IPR000109; PTR2.  
 DR Pfam; PF00854; PTR2; 2.  
 DR PROSITE; PS01022; PTR2\_1; 1.  
 DR PROSITE; PS01023; PTR2\_2; 1.  
 KW Peptide transport; Transport; Transmembrane; Symport; Glycoprotein.  
 FT TRANSMEM 1 21 POTENTIAL.  
 FT DOMAIN 22 53 EXTRACELLULAR (POTENTIAL).  
 FT TRANSMEM 54 74 POTENTIAL.  
 FT DOMAIN 75 82 CYTOPLASMIC (POTENTIAL).  
 FT TRANSMEM 83 103 POTENTIAL.  
 FT DOMAIN 104 118 EXTRACELLULAR (POTENTIAL).  
 FT TRANSMEM 119 139 POTENTIAL.  
 FT DOMAIN 140 161 CYTOPLASMIC (POTENTIAL).

```

FT TRANSMEM 162 POTENTIAL.
FT DOMAIN 183 EXTRACELLULAR (POTENTIAL).
FT TRANSMEM 199 POTENTIAL.
FT DOMAIN 220 CYTOPLASMIC (POTENTIAL).
FT TRANSMEM 277 POTENTIAL.
FT DOMAIN 298 EXTRACELLULAR (POTENTIAL).
FT TRANSMEM 328 POTENTIAL.
FT DOMAIN 348 CYTOPLASMIC (POTENTIAL).
FT TRANSMEM 362 POTENTIAL.
FT DOMAIN 383 EXTRACELLULAR (POTENTIAL).
FT TRANSMEM 585 POTENTIAL.
FT DOMAIN 606 POTENTIAL.
FT TRANSMEM 620 CYTOPLASMIC (POTENTIAL).
FT DOMAIN 641 EXTRACELLULAR (POTENTIAL).
FT TRANSMEM 646 POTENTIAL.
FT DOMAIN 667 POTENTIAL.
FT CARBOHYD 50 CYTOPLASMIC (POTENTIAL).
FT CARBOHYD 404 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 408 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 439 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 509 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 514 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 562 N-LINKED (GLCNAC. . .) (POTENTIAL).
SQ SEQUENCE 708 AA; 78805 MW; A75475789177A907 CRC64;

Query Match 51.2%; Score 42; DB 1; Length 708;
Best Local Similarity 46.2%; Pred. NO. 9.7;
Matches 6; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 3 GVKGTTVNANELP 15
I::I I::: I::I
DB 524 GIKGTTISTEIP 536

RESULT 6
RK23_MAIZE STANDARD; PRT; 93 AA.
ID RK23_MAIZE
AC P09387;
DT 01-MAR-1989 (Rel. 10, Created)
DT 01-MAR-1989 (Rel. 10, Last sequence update)
DT 01-FEB-1996 (Rel. 33, Last annotation update)
DE CHLOROPLAST 50S RIBOSOMAL PROTEIN L23.
GN RPL23.
OS Zea mays (Maize).
OC Chloroplast.
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; PACC clade;
OC Panicoidae; Andropogoneae; Zea.
OX NCBI_TaxID=4577;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=88335565; PubMed=3419911;
RA McLaughlin W.E., Larrinua I.M.;
RT "The sequence of the maize plastid encoded rpl 23 locus.";
RL Nucleic Acids Res. 16:8183-8183(1988).
RN [2]
RP SEQUENCE FROM N.A.
RX MEDLINE=95395841; PubMed=7666415;
RA Maier R.M., Neckermann K., Igloi G.L., Koessel H.;
RT "Complete sequence of the maize chloroplast genome: gene content, hotspots of divergence and fine tuning of genetic information by transcript editing.";
RL J. Mol. Biol. 251:614-628(1995).
RN [3]
RP SEQUENCE OF 81-93 FROM N.A.
RX MEDLINE=91367263; PubMed=1653905;
RA Hoch B., Maier R.M., Appel K., Igloi G.L., Koessel H.;
RT "Editing of a chloroplast mRNA by creation of an initiation codon.";
RL Nature 353:178-180(1991).
CC -!- SIMILARITY: BELONGS TO THE L23P FAMILY OF RIBOSOMAL PROTEINS.
CC This SWISS-PROT entry is copyright. It is produced through a collaboration

```

```

CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL: X07864; CAA30712.1; -
DR EMBL: X86563; CAA60330.1; -
DR EMBL: X86563; CAA60370.1; -
DR EMBL: X62070; CAA43984.1; -
DR PIR: S01396; R52M23.
DR MaizeDB: 66085; -
DR Mendel: 4720; ZEAmA:rpl23:1.
DR InterPro: IPR001014; Ribosomal_L23.
DR Pfam: PF00276; Ribosomal_L23; 1.
DR PRODOM: PD001141; Ribosomal_L23; 1.
DR PROSITE: PS00050; RIBOSOMAL_L23; 1.
KW Ribosomal protein; Chloroplast; rRNA-binding.
SQ SEQUENCE 93 AA; 10737 MW; 720C2D893CF77566 CRC64;

Query Match 50.0%; Score 41; DB 1; Length 93;
Best Local Similarity 57.1%; Pred. NO. 1.7;
Matches 8; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

QY 2 FGKVTTVNANELP 15
I::I I::: I::I
DB 43 FGKVVAVNSHRLP 56

RESULT 7
RK23_ORYZA STANDARD; PRT; 93 AA.
ID RK23_ORYZA
AC P12097;
DT 01-OCT-1989 (Rel. 12, Created)
DT 01-OCT-1989 (Rel. 12, Last sequence update)
DT 01-OCT-1996 (Rel. 34, Last annotation update)
DE CHLOROPLAST 50S RIBOSOMAL PROTEIN L23.
GN RPL23.
OS Oryza sativa (Rice).
OC Chloroplast.
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
OC Ehrhartoideae; Oryzeae; Oryza.
OX NCBI_TaxID=4530;
RN [1]
RP SEQUENCE FROM N.A.
RX STRAIN=CV. NIPPONBARE;
RA Sugiyura M.;
RL Submitted (JUL-1989) to the EMBL/GenBank/DBJ databases.
RN [2]
RP COMPLETE GENOME.
RX MEDLINE=89364698; PubMed=2770692;
RA Hiratsuka J., Shimada H., Whittier R., Ishibashi T., Sakamoto M.,
RA Mori M., Kondo C., Honji Y., Sun C.-R., Meng B.-Y., Li Y.-Q.,
RA Kanno A., Nishizawa Y., Hirai A., Shinozaki K., Sugiyura M.;
RT "The complete sequence of the rice (Oryza sativa) chloroplast genome: intermolecular recombination between distinct trna genes accounts for a major plastid DNA inversion during the evolution of the cereals.";
RL Mol. Gen. Genet. 217:185-194(1989).
RN [3]
RP SEQUENCE FROM N.A.
RX STRAIN=CV. LABELLE; TISSUE=Seedling;
RX MEDLINE=89196901; PubMed=3240862;
RA Moon E., Wu R.;
RT "Organization and nucleotide sequence of genes at both junctions between the two inverted repeats and the large single-copy region in the rice chloroplast genome.";
RL Gene 70:1-12(1988).
CC -!- SIMILARITY: BELONGS TO THE L23P FAMILY OF RIBOSOMAL PROTEINS.
CC This SWISS-PROT entry is copyright. It is produced through a collaboration

```

CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).

DR EMBL; X15901; CAA33938.1; -;  
 DR EMBL; X15901; CAA33923.1; -;  
 DR EMBL; X22826; AAB84593.1; -;  
 DR EMBL; L40578; AAD15253.1; -;  
 DR PIR; J00271; R5R223.  
 DR Mende1; 5010; ORYSA; rpl23; 2.  
 DR InterPro; IPR001014; Ribosomal\_L23.  
 DR Pfam; PF00276; Ribosomal\_L23; 1.  
 DR ProDom; PD001141; Ribosomal\_L23; 1.  
 DR PROSITE; PS00050; Ribosomal\_L23; 1.  
 DR Ribosomal protein; Chloroplast; rRNA-binding.  
 FT CONFLICT 15 15 R -> A (IN REF. 3).  
 SQ SEQUENCE 93 AA; 10764 MW; 721EBD893CF77566 CRC64;

Query Match 50.0%; Score 41; DB 1; Length 93;  
 Best Local Similarity 57.1%; Pred. No. 1.7;  
 Matches 8; Conservative 2; Mismatches 4; Indels 0; Gaps 0;  
 QY 2 FGVKGTNNANLPL 15  
 ||||| ||::||  
 DB 43 FGVKVVAVNSHRLP 56

RESULT 8  
 RK23.WHEAT  
 ID RK23.WHEAT STANDARD; PRT; 93 AA.  
 AC P11535; P41097;  
 DT 01-OCT-1989 (Rel. 12, Created)  
 DT 01-OCT-1989 (Rel. 12, Last sequence update)  
 DT 01-FEB-1996 (Rel. 33, Last annotation update)  
 DE CHLOROPLAST 50S RIBOSOMAL PROTEIN L23.  
 GN RPL23.  
 OS Triticum aestivum (Wheat), and Hordeum vulgare (Barley).  
 OG Chloroplast.  
 OC Eukaryota; Viridiplantae; Streptophyta; Tracheophyta;  
 OC Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;  
 OC Triticeae; Triticum.  
 OX NCBI\_TaxID=4565, 4513;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC SPECIES=T.aestivum;  
 RX MEDLINE=89028843; PubMed=3180271;  
 RA Bowman C.M., Barker R.F., Dyer T.A.;  
 RT "In wheat cDNA, segments of ribosomal protein genes are dispersed  
 RT repeats, probably conserved by nonreciprocal recombination.";  
 RL Curr. Genet. 14:127-136(1988).  
 RN [2]  
 RP SEQUENCE FROM N.A.  
 RC SPECIES=H.vulgare; STRAIN=CV. HAISA;  
 RX MEDLINE=95086380; PubMed=7994178;  
 RA Hess W.R., Hoch B., Zeltz P., Huebschmann T., Koessel H.,  
 RA Boerner T.;  
 RT "Inefficient rpl2 splicing in barley mutants with ribosome-deficient  
 RT plastids.";  
 RL Plant Cell 6:1455-1465(1994).

CC -1- SIMILARITY: BELONGS TO THE L23P FAMILY OF RIBOSOMAL PROTEINS.  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).

DR EMBL; X12850; CAA31328.1; -;  
 DR EMBL; X78185; CAA55027.1; -;  
 DR PIR; S06026; R5WT23.  
 DR InterPro; IPR001014; Ribosomal\_L23.  
 DR Pfam; PF00276; Ribosomal\_L23; 1.  
 DR ProDom; PD001141; Ribosomal\_L23; 1.  
 DR PROSITE; PS00050; Ribosomal\_L23; 1.  
 DR Ribosomal protein; Chloroplast; rRNA-binding.  
 SQ SEQUENCE 93 AA; 10746 MW; 1E747D893CF77562 CRC64;

Query Match 50.0%; Score 41; DB 1; Length 93;  
 Best Local Similarity 57.1%; Pred. No. 1.7;  
 Matches 8; Conservative 2; Mismatches 4; Indels 0; Gaps 0;  
 QY 2 FGVKGTNNANLPL 15  
 ||||| ||::||  
 DB 43 FGVKVVAVNSHRLP 56

RESULT 9  
 YGGE.ECOLI  
 ID YGGE.ECOLI STANDARD; PRT; 246 AA.  
 AC P11668;  
 DT 01-OCT-1989 (Rel. 12, Created)  
 DT 01-NOV-1995 (Rel. 32, Last sequence update)  
 DT 20-AUG-2001 (Rel. 40, Last annotation update)  
 DE HYPOTHETICAL PROTEIN YGGE.  
 GN YGGE OR B2922 OR Z4259 OR ECS3793.  
 OS Escherichia coli, and  
 OS Escherichia coli O157:H7.  
 OC Bacteria; Proteobacteria; gamma subdivision; Enterobacteriaceae;  
 OC Escherichia.  
 OX NCBI\_TaxID=562, 83334;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=K12 / MG1655;  
 RX MEDLINE=97426617; PubMed=9278503;  
 RA Blattner F.R., Plunkett G. III, Bloch C.A., Perna N.T., Burland V.,  
 RA Riley M., Colliado-Vides J., Glasner J.D., Rode C.K., Mayhew G.F.,  
 RA Gregor J., Davis N.W., Kirkpatrick H.A., Goeden M.A., Rose D.J.,  
 RA Mau B., Shao Y.;  
 RT "The complete genome sequence of Escherichia coli K-12.";  
 RL Science 277:1453-1474(1997).  
 RN [2]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=O157:H7 / EDL933 / ATCC 700927;  
 RX MEDLINE=21074935; PubMed=11206551;  
 RA Perna N.T., Plunkett G. III, Burland V., Mau B., Glasner J.D.,  
 RA Rose D.J., Mayhew G.F., Evans P.S., Gregor J., Kirkpatrick H.A.,  
 RA Postel G., Hackett J., Klink S., Boutin A., Shao Y., Miller L.,  
 RA Grobeck E.J., Davis N.W., Lim A., Dinalanta E.T., Potamouis K.,  
 RA Apodaca T., Anantharaman T.S., Lin J., Yen G., Schwartz D.C.,  
 RA Welch R.A., Blattner F.R.;  
 RT "Genome sequence of enterohaemorrhagic Escherichia coli O157:H7.";  
 RL Nature 409:529-533(2001).

CC SEQUENCE FROM N.A.  
 RC STRAIN=O157:H7 / RIMD 0509952;  
 RX MEDLINE=21156231; PubMed=11258796;  
 RA Hayashi T., Makino K., Ohnishi M., Murata T., Tanaka M., Tohe T.,  
 RA Han C.-G., Ohsubo E., Nakayama K., Kurokawa K., Ishii K., Yokoyama K.,  
 RA Ikeda T., Takami H., Honda T., Sasaki C., Ogasawara N., Yasunaga T.,  
 RA Kuhara S., Shiba T., Hattori M., Shingawa H.;  
 RT "Complete genome sequence of enterohaemorrhagic Escherichia coli  
 RT O157:H7 and genomic comparison with a laboratory strain K-12.";  
 RL DNA Res. 8:11-22(2001).  
 RN [4]  
 RP SEQUENCE OF 1-155 FROM N.A.  
 RC STRAIN=K12 / CS520;  
 RX MEDLINE=89313302; PubMed=2546007;  
 RA Alefounder P.R., Baldwin S.A., perham S.A., Short N.J.;  
 RT "Identification, molecular cloning and sequence analysis of a gene

RT cluster encoding the class II fructose 1,6-bisphosphate aldolase, 3-phosphoglycerate kinase and a putative second glyceraldehyde 3-phosphate dehydrogenase of *Escherichia coli*.";  
 RL Mol. Microbiol. 3:723-732(1989).  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC -----  
 DR EMBL; U28377; AAC69089.1;  
 DR EMBL; AF000375; AAC75959.1;  
 DR EMBL; AF005522; AAG58048.1;  
 DR EMBL; AP002563; BAB37216.1;  
 DR EMBL; X14436; CAA32608.1;  
 DR PIR; S04737; S04737.  
 DR EcoGene; EG11244; Y99B.  
 KW Hypothetical protein; Complete proteome.  
 SQ SEQUENCE 246 AA; 26635 MW; 92436CA0B3DFA891 CRC64;  
 CC -----  
 Query Match 48.8%; Score 40; DB 1; Length 246;  
 Best Local Similarity 53.8%; Pred. No. 7.3;  
 Matches 7; Conservative 1; Mismatches 5; Indels 0; Gaps 0;  
 QY 3 GVKGTIVNANLP 15  
 I: |  
 DQ 13 GISGMAQAANLP 25  
 -----  
 RESULT 10  
 ID DMBI\_HCMVA STANDARD; PRT; 1235 AA.  
 AC DMBI\_HCMVA  
 DT 01-AUG-1990 (Rel. 15, Created)  
 DT 01-AUG-1990 (Rel. 15, Last sequence update)  
 DT 20-AUG-2001 (Rel. 40, Last annotation update)  
 DE MAJOR DNA-BINDING PROTEIN (MDBP).  
 GN 157 OR DBP.  
 OS Human cytomegalovirus (strain Ad169).  
 OC Viruses; GSDNA viruses, no RNA stage; Herpesviridae;  
 OC Betaherpesvirinae; Cytomegalovirus.  
 OC NCBI\_TaxID=10360;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=90269039; PubMed=2161319;  
 RA Chee M.S., Bankier A.T., Beck S., Bohni R., Brown C.M., Cerny R.,  
 RA Horsnell T., Hutchison C.A. III, Kouzarides T., Martignetti J.A.,  
 RA Reddick E., Satchwell S.C., Tomlinson P., Weston K.M., Barrell B.G.;  
 RT Analysis of the protein-coding content of the sequence of human  
 RT cytomegalovirus strain Ad169.  
 RL Curr. Top. Microbiol. Immunol. 154:125-169(1990).  
 CC FUNCTION: SINGLE-STRAND DNA-BINDING PROTEIN REQUIRED FOR DNA  
 CC REPLICATION.  
 CC SUBCELLULAR LOCATION: NUCLEAR (PROBABLE).  
 CC SIMILARITY: BELONGS TO THE HERPESVIRUSES DNA-BINDING PROTEIN  
 CC FAMILY.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC -----  
 DR EMBL; X17403; CAA35372.1;  
 DR PIR; S09820; Q0BEM4.  
 DR InterPro; IPR000635; viral\_DNA\_bind.  
 DR Pfam; PF00747; viral\_DNA\_bp. 1.

KW DNA-binding; DNA replication; Zinc-finger; Nuclear protein;  
 KW Early protein.  
 FT ZN\_FING 467 481 C2HC-TYPE.  
 SQ SEQUENCE 1235 AA; 133878 MW; 94E8D4F8D3BB2CB6 CRC64;  
 CC -----  
 Query Match 48.8%; Score 40; DB 1; Length 1235;  
 Best Local Similarity 52.6%; Pred. No. 40;  
 Matches 10; Conservative 0; Mismatches 3; Indels 6; Gaps 1;  
 QY 1 CFGVKCTT-----VNANE 13  
 I: | | | | |  
 DQ 1191 CFGVPGTGGGCFVNVAGE 1209  
 -----  
 RESULT 11  
 ID ATXI\_PLAFA STANDARD; PRT; 1956 AA.  
 AC Q04956;  
 DT 30-MAY-2000 (Rel. 39, Created)  
 DT 30-MAY-2000 (Rel. 39, Last sequence update)  
 DT 20-AUG-2001 (Rel. 40, Last annotation update)  
 DE PROBABLE CATION-TRANSPORTING ATPASE 1 (EC 3.6.3.-).  
 OS Plasmodium falciparum.  
 OC Eukaryota; Alveolata; Apicomplexa; Haemosporida; Plasmodium.  
 OC NCBI\_TaxID=5833;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=T9/96;  
 RX MEDLINE=93132070; PubMed=8421054;  
 RA Krishna S., Cowan G., Meade J.C., Wells R.A., Stringer J.R.,  
 RA Robson K.J.;  
 RT "A family of cation ATPase-like molecules from Plasmodium  
 RT falciparum".  
 RL J. Cell Biol. 120:385-398(1993).  
 CC CATALYTIC ACTIVITY: ATP + H(2)O = ADP + PHOSPHATE.  
 CC SUBCELLULAR LOCATION: INTEGRAL MEMBRANE PROTEIN.  
 CC SIMILARITY: BELONGS TO THE CATION TRANSPORT ATPASES FAMILY (E1-E2  
 CC ATPASES). SUBFAMILY V.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC -----  
 DR EMBL; X65738; CAA46646.1;  
 DR InterPro; IPR001757; E1-E2\_ATPase.  
 DR Pfam; PF00122; E1-E2\_ATPase. 1.  
 DR PROSITE; PS00154; ATPASE\_E1\_E2; 1.  
 KW Hydrolase; Transmembrane; Phosphorylation; Magnesium; ATP-binding.  
 FT DOMAIN 1 35  
 FT TRANSMEM 36 58  
 FT DOMAIN 59 61  
 FT TRANSMEM 62 80  
 FT DOMAIN 81 407  
 FT TRANSMEM 408 427  
 FT DOMAIN 428 440  
 FT TRANSMEM 441 462  
 FT DOMAIN 463 1818  
 FT TRANSMEM 1819 1837  
 FT DOMAIN 1838 1845  
 FT TRANSMEM 1846 1863  
 FT DOMAIN 1864 1881  
 FT TRANSMEM 1882 1905  
 FT DOMAIN 1906 1928  
 FT TRANSMEM 1929 1952  
 FT DOMAIN 1953 1956  
 FT MOD\_RES 496 496  
 FT METAL 1760 1760  
 FT METAL 1764 1764



FT DOMAIN 246 251 POLY-ASN.  
 FT DOMAIN 252 256 POLY-LYS.  
 FT DOMAIN 937 941 POLY-ASN.  
 FT DOMAIN 1344 1347 POLY-LYS.  
 FT DOMAIN 1363 1372 POLY-ASN.  
 FT DOMAIN 1680 1684 POLY-ASN.  
 SQ SEQUENCE 1956 AA; 230285 MW; AE708AAE99009335 CRC64;

Query Match 48.8%; Score 40; DB 1; Length 1956;  
 Best Local Similarity 53.8%; Pred. No. 65;  
 Matches 7; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 4 VKGTVNANEL 14  
 |||| :|:|:|  
 Db 263 VKGTIYNSDL 273

RESULT 12  
 YOG7\_CAEEL STANDARD; PRT; 3343 AA.  
 AC P34616;  
 DT 01-FEB-1994 (Rel. 28, Created)  
 DT 01-FEB-1994 (Rel. 28, Last sequence update)  
 DT 20-AUG-2001 (Rel. 40, Last annotation update)  
 DE HYPOTHETICAL 375.7 KDA PROTEIN ZK112.7 IN CHROMOSOME III PRECURSOR.  
 GN ZK112.7.  
 OS Caenorhabditis elegans.  
 OC Eukaryota; Metazoa; Nematoda; Chromadorea; Rhabditida; Rhabditidae;  
 OC Rhabditidae; Peloderinae; Caenorhabditis.  
 OX NCBI\_TaxID=6239;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=BRISTOL N2;  
 RX MEDLINE=94150718; PubMed=7906398;  
 RA Wilson R., Ainscough R., Anderson K., Baynes C., Berks M.,  
 RA Bonfield J., Burton J., Connell M., Copsey T., Cooper J., Coulson A.,  
 RA Craxton M., Dear S., Du Z., Durbin R., Favello A., Fraser A.,  
 RA Fulton L., Gardner A., Green P., Hawkins T., Hillier L., Jier M.,  
 RA Johnston L., Jones M., Kershaw J., Kirsten J., Laister N.,  
 RA Latreille P., Lightning J., Lloyd C., Mortimore B., O'Callaghan M.,  
 RA Parsons J., Percy C., Rifken L., Roopra A., Saunders D., Showkeen R.,  
 RA Sims M., Smaldon N., Smith A., Smith M., Sonhammer E., Staden R.,  
 RA Sulston J., Thierry-Mieg J., Thomas K., Vaudin M., Vaughan K.,  
 RA Watson R., Watson A., Weinstock L., Wilkinson-Sproat J.,  
 RA Wohlschlag P.;  
 RT "2.2 Mb of contiguous nucleotide sequence from chromosome III of C.  
 elegans.";  
 RL Nature 368:32-38(1994).  
 CC -!- SUBCELLULAR LOCATION: TYPE I MEMBRANE PROTEIN (POTENTIAL).  
 CC -!- SIMILARITY: CONTAINS 11 CADHERIN DOMAINS.  
 CC -!- SIMILARITY: CONTAINS 1 LAMININ G-LIKE DOMAIN.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (see <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC -----  
 CC EMBL: L14324; AAA28182.1;  
 DR PIR: S44887; S44887.  
 DR WormPep; ZK112.7; CE00378.  
 DR InterPro; IPR002126; Cadherin.  
 DR InterPro; IPR000561; EGF-like.  
 DR InterPro; IPR001791; Laminin\_G.  
 DR Pfam; PF00028; cadherin; 11.  
 DR Pfam; PF00054; laminin\_G; 1.  
 DR PRINTS; PR00205; CADHERIN.  
 DR SMART; SM00112; CA; 12.  
 DR SMART; SM00181; EGF; 1.  
 DR SMART; SM00282; LamG; 1.

DR PROSITE; PS00232; CADHERIN\_1; 8.  
 DR PROSITE; PS0268; CADHERIN\_2; 11.  
 DR PROSITE; PS01186; EGF\_2; UNKNOWN 1.  
 KW Hypothetical protein; Cell adhesion; Signal; Transmembrane;  
 KW Cytoskeleton; Glycoprotein; Calcium-binding; Repeat.  
 FT SIGNAL 1 26 POTENTIAL.  
 FT CHAIN 27 3343 HYPOTHETICAL PROTEIN ZK112.7.  
 FT DOMAIN 27 3228 EXTRACELLULAR (POTENTIAL).  
 FT TRANSMEM 3229 3250 POTENTIAL.  
 FT DOMAIN 3251 3343 CYTOPLASMIC (POTENTIAL).  
 FT DOMAIN 28 117 CADHERIN 1.  
 FT DOMAIN 118 229 CADHERIN 2.  
 FT DOMAIN 242 330 CADHERIN 3.  
 FT DOMAIN 632 738 CADHERIN 4.  
 FT DOMAIN 1279 1368 CADHERIN 5.  
 FT DOMAIN 1545 1648 CADHERIN 6.  
 FT DOMAIN 1676 1756 CADHERIN 7.  
 FT DOMAIN 1757 1857 CADHERIN 8.  
 FT DOMAIN 1954 2045 CADHERIN 9.  
 FT DOMAIN 2046 2145 CADHERIN 10.  
 FT DOMAIN 2146 2245 CADHERIN 11.  
 FT CARBOHYD 22 22 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 149 149 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 250 250 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 288 288 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 369 369 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 467 467 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 612 612 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 752 752 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 806 806 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 941 941 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 966 966 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 970 970 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 985 985 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 1042 1042 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 1335 1335 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 1425 1425 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 1429 1429 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 1557 1557 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 1563 1563 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 1597 1597 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 1624 1624 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 1695 1695 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 1702 1702 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 1895 1895 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 1900 1900 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 2053 2053 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 2129 2129 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 2203 2203 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 2382 2382 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 2391 2391 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 2410 2410 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 2414 2414 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 2431 2431 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 2527 2527 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 2530 2530 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 2564 2564 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 2621 2621 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 2665 2665 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 2712 2712 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 2798 2798 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 2809 2809 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 2927 2927 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 2976 2976 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 3045 3045 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 3222 3222 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 3225 3225 N-LINKED (GLCNAC... ) (POTENTIAL).  
 SQ SEQUENCE 3343 AA; 375745 MW; 063E6F17FCC15D18 CRC64;

Query Match 48.8%; Score 40; DB 1; Length 3343;  
 Best Local Similarity 50.0%; Pred. No. 11e+02;  
 Matches 7; Conservative 3; Mismatches 4; Indels 0; Gaps 0;



Search completed: March 26, 2002, 13:40:44  
Job time: 258 sec

DE SUBUNIT II) (CYTOCHROME CBA3 SUBUNIT 2).  
GN CBAB OR CTAC.  
OS Thermus aquaticus (subsp. thermophilus).  
OC Bacteria; Thermus/Deinococcus group; Thermus group; Thermus.  
OX NCBI\_TaxID=274;  
RN [1]  
RP SEQUENCE FROM N.A., AND SEQUENCE OF 1-30.  
RC STRAIN=HB8 / ATCC 27634;  
RA MEDLINE=95386472; PubMed=7657607;  
RX Keightley J.A., Zimmermann B.H., Mather M.W., Springer P.,  
RA Pastuszyn A., Lawrence D.M., Fee J.A.;  
RT "Molecular genetic and protein chemical characterization of the  
cytochrome ba3 from Thermus thermophilus HB8.";  
RL J. Biol. Chem. 270:20345-20358(1995).  
RN [2]  
RP X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS).  
RX MEDLINE=99287095; PubMed=10360350;  
RA Williams P.A., Blackburn N.J., Sanders D., Bellamy H., Stura E.A.,  
RA Fee J.A., McRee D.E.;  
RT "The Cua domain of Thermus thermophilus ba3-type cytochrome c oxidase  
at 1.6-A resolution.";  
RL Nat. Struct. Biol. 6:509-516(1999).  
RN [3]  
RP X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS).  
RC STRAIN=HB8 / ATCC 27634;  
RA MEDLINE=20237613; PubMed=10775261;  
RX Soulimane T., Buse G., Bourenkov G.P., Bartunik H.D., Huber R.,  
RA Than M.E.;  
RT "Structure and mechanism of the aberrant ba3-cytochrome c oxidase  
from Thermus thermophilus.";  
RL EMBO J. 19:1766-1776(2000).  
CC -1- FUNCTION: SUBUNIT I AND II FORM THE FUNCTIONAL CORE OF THE ENZYME  
COMPLEX. ELECTRONS ORIGINATING IN CYTOCHROME C ARE TRANSFERRED VIA  
HEME A AND CU(A) TO THE BINUCLEAR CENTER FORMED BY HEME A3 AND  
CU(B).  
CC -1- CATALYTIC ACTIVITY: 4 FERROCYTOCHROME C + O(2) = 2 H(2)O +  
4 FERRICYTOCHROME C.  
CC -1- SUBCELLULAR LOCATION: MEMBRANE-BOUND.  
CC -1- SIMILARITY: BELONGS TO THE CYTOCHROME C OXIDASE SUBUNIT 2 FAMILY.  
CC -----  
CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
between the Swiss Institute of Bioinformatics and the EMBL outstation -  
the European Bioinformatics Institute. There are no restrictions on its  
use by non-profit institutions as long as its content is in no way  
modified and this statement is not removed. Usage by and for commercial  
entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
CC -----  
DR EMBL; L09121; AAB00369.1; -  
DR PDB; 2CUA; 28-MAY-99.  
DR InterPro; IPR001505; COX2.  
DR PRODOM; PD000131; COX2; 1.  
DR PROSITE; PS000078; COX2; 1.  
KW Oxidoreductase; Respiratory chain; Electron transport; Transmembrane;  
KW Copper; 3D-structure.  
FT DOMAIN 1 3 PERIPLASMIC (POTENTIAL).  
FT TRANSMEM 4 38  
FT DOMAIN 39 69 CYTOPLASMIC (POTENTIAL).  
FT METAL 114 114 COPPER A.  
FT METAL 149 149 COPPER A.  
FT METAL 153 153 COPPER A.  
FT METAL 157 157 COPPER A.  
SQ SEQUENCE 168 AA; 18563 MW; FE5689FB7672CF05 CRC64;  
  
Query Match 46.3%; Score 38; DB 1; Length 168;  
Best Local Similarity 50.0%; Pred. No. 11;  
Matches 7; Conservative 2; Mismatches 5; Indels 0; Gaps 0;  
  
QY 2 FGVKGTNNANELP 15  
| | | | : | |  
DB 116 FHVEGTNNVEVLP 129



GenCore version 4.5  
Copyright (c) 1993 - 2000 Compugen Ltd.

OM protein - protein search, using sw model

Run on: March 26, 2002, 13:38:46 : Search time 81.51 Seconds  
(without alignments)  
13.631 Million cell updates/sec

Title: US-09-709-201-97

Perfect score: 82

Sequence: 1 CFGVGKGTIVNANELP 15

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 522463 seqs, 74073290 residues

Total number of hits satisfying chosen parameters: 522463

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

A\_Geneseq\_1101.\*  
1: /SID88/gcgdata/geneseq/geneseq/AA1980.DAT.\*  
2: /SID88/gcgdata/geneseq/geneseq/AA1981.DAT.\*  
3: /SID88/gcgdata/geneseq/geneseq/AA1982.DAT.\*  
4: /SID88/gcgdata/geneseq/geneseq/AA1983.DAT.\*  
5: /SID88/gcgdata/geneseq/geneseq/AA1984.DAT.\*  
6: /SID88/gcgdata/geneseq/geneseq/AA1985.DAT.\*  
7: /SID88/gcgdata/geneseq/geneseq/AA1986.DAT.\*  
8: /SID88/gcgdata/geneseq/geneseq/AA1987.DAT.\*  
9: /SID88/gcgdata/geneseq/geneseq/AA1988.DAT.\*  
10: /SID88/gcgdata/geneseq/geneseq/AA1989.DAT.\*  
11: /SID88/gcgdata/geneseq/geneseq/AA1990.DAT.\*  
12: /SID88/gcgdata/geneseq/geneseq/AA1991.DAT.\*  
13: /SID88/gcgdata/geneseq/geneseq/AA1992.DAT.\*  
14: /SID88/gcgdata/geneseq/geneseq/AA1993.DAT.\*  
15: /SID88/gcgdata/geneseq/geneseq/AA1994.DAT.\*  
16: /SID88/gcgdata/geneseq/geneseq/AA1995.DAT.\*  
17: /SID88/gcgdata/geneseq/geneseq/AA1996.DAT.\*  
18: /SID88/gcgdata/geneseq/geneseq/AA1997.DAT.\*  
19: /SID88/gcgdata/geneseq/geneseq/AA1998.DAT.\*  
20: /SID88/gcgdata/geneseq/geneseq/AA1999.DAT.\*  
21: /SID88/gcgdata/geneseq/geneseq/AA2000.DAT.\*  
22: /SID88/gcgdata/geneseq/geneseq/AA2001.DAT.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	82	100.0	15	AAW95324	Peptide fragment o
2	73	89.0	100	AAW95295	Chlamydia major o
3	73	89.0	343	AAV56771	C. trachomatis ser
4	67	81.7	391	AAV35319	Chlamydia pneumoni
5	61	74.4	20	AAW84463	Peptide Cp2A deriv
6	61	74.4	20	AAW84457	Peptide C.p.2A der
7	42	51.2	257	AAV30954	Arabidopsis thalia
8	42	51.2	365	AAV30953	Arabidopsis thalia
9	42	51.2	389	AAW98188	Arabidopsis thalia
10	42	51.2	455	AAV30952	Arabidopsis thalia
11	42	51.2	708	AAW74088	Human hPEPT1 prote

12	42	51.2	708	20	AAW74087	Gastro-intestinal
13	42	51.2	708	20	AAW83394	Human protein-coup
14	41	50.0	605	22	AAE04789	Lycopersicon escul
15	41	50.0	605	22	AAW72308	Neoxanthin cleavag
16	40	48.8	246	21	AAV15923	E. coli proliferat
17	39	47.6	352	20	AAV36781	Chlamydia trachoma
18	38.5	47.0	452	15	AAW59792	Aspergillus tubige
19	38	46.3	15	20	AAW95325	Peptide fragment o
20	38	46.3	146	22	AAV18041	Peptide #4475 enco
21	38	46.3	146	22	AAW30554	Peptide #4591 enco
22	38	46.3	146	22	AAW05680	Peptide #4362 enco
23	38	46.3	322	13	AAW24297	Glycopeptide resis
24	38	46.3	380	18	AAW09406	Transforming growt
25	38	46.3	395	20	AAV35621	Chlamydia pneumoni
26	38	46.3	989	20	AAV37242	Chlamydia trachoma
27	38	46.3	2408	13	AAW24307	Translation of ORF
28	37	45.1	89	18	AAW20662	H. pylori secreted
29	37	45.1	97	21	AAV16756	Bacteriophage Dp-1
30	37	45.1	98	18	AAW20457	H. pylori secreted
31	37	45.1	158	22	AAW76134	Human colon cancer
32	37	45.1	395	19	AAW98760	H. pylori GHPO 108
33	37	45.1	463	22	AAW90216	C. glutamicum prote
34	37	45.1	469	12	AAV15510	Tomato ACC synthas
35	37	45.1	469	22	AAE00987	Tomato 1-aminocycl
36	37	45.1	469	22	AAW59726	Tomato ACC synthas
37	37	45.1	583	22	AAE04782	Arabidopsis thalia
38	37	45.1	1073	21	AAV01837	Haemophilus influe
39	37	45.1	1079	21	AAV01836	Haemophilus influe
40	36.5	44.5	537	22	AAE05684	Arabidopsis thalia
41	36	43.9	54	13	AAW20077	Sequence encoded b
42	36	43.9	144	20	AAV08240	Human cadherin-4 p
43	36	43.9	144	21	AAV08240	Zea mays protein f
44	36	43.9	147	21	AAV49588	Arabidopsis thalia
45	36	43.9	158	21	AAV49587	Arabidopsis thalia

#### ALIGNMENTS

RESULT 1  
AAW95324  
ID AAW95324 standard; Protein; 15 AA.  
XX  
AC AAW95324;  
XX  
DT 15-MAR-1999 (first entry)  
XX  
DE Peptide fragment of C. pneumoniae CPN1:8-171.  
XX  
KW Chlamydia; cryptic phase; elementary body phase; replicating; probenidic;  
KW antiporphyrilic acid; immune response; infection; diagnostic; assay; MOMP;  
KW major outer membrane protein; autoimmune; inflammatory; porphyria;  
KW Epstein Barr virus; antioxidant.  
XX  
OS Chlamydia pneumoniae.  
XX  
PN W09850074-A2.  
XX  
PD 12-NOV-1998.  
XX  
PF 06-MAY-1998; 98W0-US09237.  
XX  
PR 18-FEB-1998; 98US-0025521.  
PR 06-MAY-1997; 97US-0045889.  
PR 06-MAY-1997; 97US-0045739.  
PR 06-MAY-1997; 97US-0045779.  
PR 06-MAY-1997; 97US-0045780.  
PR 06-MAY-1997; 97US-0045784.  
PR 06-MAY-1997; 97US-0045787.  
PR 14-AUG-1997; 97US-0911593.  
PR 18-FEB-1998; 98US-0025174.  
PR 18-FEB-1998; 98US-0025176.  
XX

PA (UYVA-) UNIV VANDERBILT.  
 XX Mitchell WM, Stratton CW;  
 PI WPI; 1999-059653/05.  
 XX  
 XX Composition with two agents effective against different stages of  
 PT Chlamydia life cycle - comprises agent targeted against cryptic  
 PT phase, against elementary body phase, against replicating phase,  
 PT probedicid and antiporphyric  
 XX  
 PS Claim 4; Fig 4; 138pp; English.  
 XX  
 CC The invention relates to the diagnosis and management of infections by  
 CC Chlamydia species. The invention provides a composition that comprises  
 CC at least two agents, where each of the agents is effective against a  
 CC different phase of the chlamydial life cycle. The agents are selected  
 CC from: (a) agents targeted against cryptic phase of chlamydial life  
 CC cycle; (b) agents targeted against elementary body phase of chlamydial  
 CC life cycle; (c) agents targeted against replicating phase of chlamydial  
 CC life cycle; (d) probedicid, and (e) antiporphyric acid. The composition  
 CC is used to elicit a protective immune response to Chlamydia infection in  
 CC an animal or human and is applied until the animal or human tests  
 CC negative for Chlamydia infection. It is also used to treat biological  
 CC material infected with Chlamydia. Diagnostic kits for antibody assays  
 CC against recombinant major outer membrane protein (MOMP), and for DNA  
 CC amplification assays for chlamydial genes, are used to diagnose disease,  
 CC e.g. autoimmune disease, an inflammatory disease or a disease that  
 CC occurs in an immuno-compromised individual, associated with Chlamydia  
 CC infection. The kits are used to detect chlamydial elementary bodies in a  
 CC sample. They are also used to monitor and/or modify the course of therapy  
 CC in a patient. The treatment reduces the acellular load of infectious  
 CC Ebsstein Barr virus. The method is also used to treat porphyria, by  
 CC reducing the number of elementary bodies and applying a drug, e.g.  
 CC cimetidine, and antioxidants, to reduce the adverse effects associated  
 CC with porphyria. Sequences AAW95324 to AAW95327 represent peptides  
 CC employed for the construction of peptide based ELISAs with species  
 CC specificity for variable domain 1 (VD1).  
 XX  
 SQ Sequence 15 AA;  
 XX  
 Query Match 100.0%; Score 82; DB 20; Length 15;  
 Best Local Similarity 100.0%; Pred. No. 2.7e-08;  
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 CFGVKGTTVNANELP 15  
 DB 1 CFGVKGTTVNANELP 15  
 |||||  
 RESULT 2  
 AAW95295  
 ID AAW95295 standard; Protein: 100 AA.  
 XX  
 AC AAW95295;  
 XX  
 DT 15-MAR-1999 (first entry)  
 XX  
 DE Chlamydia major outer membrane protein (MOMP) PN fragment.  
 XX  
 KW Chlamydia; cryptic phase; elementary body phase; replicating; probedicid;  
 KW antiporphyric acid; immune response; infection; diagnostic; assay; MOMP;  
 KW major outer membrane protein; autoimmune; inflammatory; porphyria,  
 KW Ebsstein Barr virus; antioxidant.  
 XX  
 OS Chlamydia sp.  
 XX  
 PN WO9850074-A2.  
 XX  
 PD 12-NOV-1998.  
 XX  
 PF 06-MAY-1998; 98WO-0509237.  
 XX

XX 18-FEB-1998; 98US-0025521.  
 PR 06-MAY-1997; 97US-0045689.  
 PR 06-MAY-1997; 97US-0045739.  
 PR 06-MAY-1997; 97US-0045779.  
 PR 06-MAY-1997; 97US-0045780.  
 PR 06-MAY-1997; 97US-0045784.  
 PR 06-MAY-1997; 97US-0045787.  
 PR 14-AUG-1997; 97US-0911593.  
 PR 18-FEB-1998; 98US-0025174.  
 PR 18-FEB-1998; 98US-0025176.  
 XX  
 XX (UYVA-) UNIV VANDERBILT.  
 PA Mitchell WM, Stratton CW;  
 PI WPI; 1999-059653/05.  
 XX  
 XX Composition with two agents effective against different stages of  
 PT Chlamydia life cycle - comprises agent targeted against cryptic  
 PT phase, against elementary body phase, against replicating phase,  
 PT probedicid and antiporphyric  
 XX  
 PS Disclosure; Fig 1A; 138pp; English.  
 XX  
 CC The invention relates to the diagnosis and management of infections by  
 CC Chlamydia species. The invention provides a composition that comprises  
 CC at least two agents, where each of the agents is effective against a  
 CC different phase of the chlamydial life cycle. The agents are selected  
 CC from: (a) agents targeted against cryptic phase of chlamydial life  
 CC cycle; (b) agents targeted against elementary body phase of chlamydial  
 CC life cycle; (c) agents targeted against replicating phase of chlamydial  
 CC life cycle; (d) probedicid, and (e) antiporphyric acid. The composition  
 CC is used to elicit a protective immune response to Chlamydia infection in  
 CC an animal or human and is applied until the animal or human tests  
 CC negative for Chlamydia infection. It is also used to treat biological  
 CC material infected with Chlamydia. Diagnostic kits for antibody assays  
 CC against recombinant major outer membrane protein (MOMP), and for DNA  
 CC amplification assays for chlamydial genes, are used to diagnose disease,  
 CC e.g. autoimmune disease, an inflammatory disease or a disease that  
 CC occurs in an immuno-compromised individual, associated with Chlamydia  
 CC infection. The kits are used to detect chlamydial elementary bodies in a  
 CC sample. They are also used to monitor and/or modify the course of therapy  
 CC in a patient. The treatment reduces the acellular load of infectious  
 CC Ebsstein Barr virus. The method is also used to treat porphyria, by  
 CC reducing the number of elementary bodies and applying a drug, e.g.  
 CC cimetidine, and antioxidants, to reduce the adverse effects associated  
 CC with porphyria. Sequences AAW95272 to AAW95319 represent peptide  
 CC fragments of various Chlamydia MOMPs.  
 XX  
 SQ Sequence 100 AA;  
 XX  
 Query Match 89.0%; Score 73; DB 20; Length 100;  
 Best Local Similarity 100.0%; Pred. No. 1e-05;  
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 2 FGKVGTTVNANELP 15  
 DB 62 FGKVGTTVNANELP 75  
 |||||  
 RESULT 3  
 AAY56771  
 ID AAY56771 standard; Protein: 343 AA.  
 XX  
 AC AAY56771;  
 XX  
 DT 22-FEB-2000 (first entry)  
 XX  
 DE C. trachomatis serovar HuPn MOMP sequence;  
 XX  
 KW Major outer membrane protein; MOMP; Chlamydia; vaccine; immune response;

KW cellular response; immunogen; Th1-like CD4 response; mucosal immunity.

OS Chlamydia trachomatis.

PN WO9951745-A2.

XX 14-OCT-1999.

PD 07-APR-1999; 99WO-CA00292.

PF 07-APR-1998; 98US-0055765.

PR (UYMA-) UNIV MANITOBA.

XX Bruhnam RC;

XX WPI; 1999-620205/53.

XX Non-replicating vector encoding fragments of the outer membrane protein  
PT of Chlamydia, useful in vaccines and as immunogen

XX Disclosure; Fig 10 A-F; 52pp; English.

XX The invention provides a non-replicating vector that comprises, linked  
CC to a promoter, a nucleotide sequence that encodes a region containing at  
CC least one of the conserved domains 2, 3 and 5 of a major outer membrane  
CC protein (MOMP) of a Chlamydia strain. The vector is used: (a) in  
CC vaccines to generate a protective immune response (mainly cellular)  
CC against MOMP, and (b) as immunogens to raise anti-MOMP antibodies, useful  
CC in standard immunoassays. Immunization with the vector induces a broad  
CC spectrum of immune responses, including Th1-like CD4 responses and  
CC mucosal immunity, providing significant protection against subsequent  
CC challenge. Sequences AAY56757-71 represent MOMP sequences from a variety  
CC of serovars of *C. trachomatis*.

XX Sequence 343 AA;

Query Match 89.0%; Score 73; DB 20; Length 343;

Best Local Similarity 100.0%; Pred. No. 4.1e-05;

Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 FGVRGTTVNANELP 15

Db 158 fgvggtvnanelp 171

RESULT 4

AAAY35319  
ID AAY35319 standard; Protein; 391 AA.

XX AC AAY35319;

DT 13-SEP-1999 (first entry)

XX Chlamydia pneumoniae transmembrane protein sequence.

XX Respiratory disease; pneumonia; bronchitis; heart disease; sarcoidosis;  
KW sinusitis; purulent otitis media; erythema nodosum; pharyngitis;  
KW vaccine; neutralising epitope.

XX Chlamydia pneumoniae.

XX WO9927105-A2.

XX 03-JUN-1999.

XX 20-NOV-1998; 98WO-IB01890.

XX 04-NOV-1998; 98US-0107078.

XX 21-NOV-1997; 97FR-0014673.

XX (GEST ) GENSET.

XX Griffais R;

XX WPI; 1999-357842/30.

XX Genome sequence of Chlamydia pneumoniae

XX Page 1130-1131; Disclosure; 1912pp; English.

XX AAY34584-Y35879 represent the proteins encoded by all the open reading  
CC frames in the complete genome (see AAX91990) of Chlamydia pneumoniae.  
CC C. pneumoniae causes respiratory disease such as pneumonia and  
CC bronchitis and is thought to be a contributing factor in heart  
CC disease, sarcoidosis, sinusitis, purulent otitis media, erythema  
CC nodosum or pharyngitis. The polypeptides encoded by the open reading  
CC frames of the C. pneumoniae genome (see AAY34584-Y35879) can be used in  
CC immunogenic compositions as vaccines. Vectors containing C. pneumoniae  
CC nucleotide sequences can also be used as immunogenic compositions,  
CC especially where the vector directs the expression of a neutralising  
CC epitope of C. pneumoniae.

XX Sequence 391 AA;

Query Match 81.7%; Score 67; DB 20; Length 391;

Best Local Similarity 92.9%; Pred. No. 0.00058;

Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2 FGVRGTTVNANELP 15

Db 160 fgvggtvnanelp 173

RESULT 5

AAW84463  
ID AAW84463 standard; peptide; 20 AA.

XX AC AAW84463;

DT 23-MAR-1999 (first entry)

XX Peptide Cp2A derived from a major outer membrane protein.

XX Variable domain; major outer membrane protein; MOMP;

XX Chlamydia; detection; infection; vaccine.

XX Synthetic.

XX Chlamydia pneumoniae.

XX WO9857981-A2.

XX 23-DEC-1998.

XX 15-JUN-1998; 98WO-IL00277.

XX 19-JUN-1997; 97IL-0121114.

XX (SAVY-) SAVYON DIAGNOSTICS LTD.

XX Ohana B;

XX WPI; 1999-080945/07.

XX New peptides derived from Chlamydia pneumoniae MOMP protein - useful  
PT to detect C. pneumoniae infection

XX Claim 2; Page 53; 39pp; English.

XX The present peptide is derived from the variable domain of the  
CC major outer membrane protein (MOMP) of Chlamydia pneumoniae. The  
CC peptide is able to react with antibodies formed during C. pneumoniae  
CC infection and characterised by having essentially very low  
CC cross-reactivity towards antibodies against other Chlamydia species.

CC A mixture of such peptides (see also AAW84462-68) is used to detect  
 CC C. pneumoniae infection, and in the preparation of vaccines.

SQ Sequence 20 AA;

Query Match 74.4%; Score 61; DB 20; Length 20;

Best Local Similarity 100.0%; Pred. No. 0.00024;

Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 VKGTTVNANELP 15

Db 1 vkgttvanelp 12

RESULT 6

AAW84557  
 ID AAW84557 standard; peptide; 20 AA.

XX AC AAW84557;

XX DT 26-MAR-1999 (first entry)

XX DE Peptide C.p.2A derived from the major outer membrane protein.

XX KW Variable domain; immunodominant; major outer membrane protein; MOMP;  
 anti-MOMP antibody; Chlamydia; vaccine; C. trachomatis.

XX OS Chlamydia pneumoniae.

XX PN WO9900414-A1.

XX PD 07-JAN-1999.

XX PF 15-JUN-1998; 98WO-IL00276.

XX PR 19-JUN-1997; 97IL-0121115.

XX PA (SAVY-) SAVYON DIAGNOSTICS LTD.

XX PI Ohana B;

XX DR WPI; 1999-095677/08.

XX CC Chlamydia trachomatis specific peptides useful in diagnostic assays  
 PT - derived from major outer membrane protein variable domains and  
 PT useful in mixtures to detect infection with or immunise against all  
 PT serovars

XX PS Example 1; Page 24; 78pp; English.

XX CC The present sequence represents a peptide derived from variable  
 CC domain 2 (VDII) of the Chlamydia pneumoniae major outer membrane  
 CC protein (MOMP). The specification also describes C. trachomatis  
 CC MOMP derived peptides which have specificity only to C. trachomatis  
 CC anti-MOMP antibodies and are non-cross reactive with anti-MOMP  
 CC antibodies of other Chlamydia species. Such peptides are useful to  
 CC detect C. trachomatis infections in humans. Mixtures of MOMP peptide  
 CC mixtures allow detection of and vaccination against all C. trachomatis  
 CC serovars, which is not possible with existing MOMP-derived peptides  
 CC for C. trachomatis-specific detection.

XX SQ Sequence 20 AA;

Query Match 74.4%; Score 61; DB 20; Length 20;

Best Local Similarity 100.0%; Pred. No. 0.00024;

Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 VKGTTVNANELP 15

Db 1 vkgttvanelp 12

RESULT 7

AAAG30954

ID AAG30954 standard; Protein; 257 AA.

XX XX

AC AAG30954;

XX DT 17-OCT-2000 (first entry)

XX DE Arabidopsis thaliana protein fragment SEQ ID NO: 37095.

XX KW Protein identification; signal transduction pathway; metabolic pathway;  
 KW hybridisation assay; genetic mapping; gene expression control; promoter;  
 KW termination sequence.

XX OS Arabidopsis thaliana.

XX PN EP1033405-A2.

XX PD 06-SEP-2000.

XX PF 25-FEB-2000; 2000EP-0301439.

XX PR 25-FEB-1999; 99US-0121825.

XX PR 05-MAR-1999; 99US-0123180.

XX PR 23-MAR-1999; 99US-0123548.

XX PR 23-MAR-1999; 99US-0125788.

XX PR 25-MAR-1999; 99US-0126264.

XX PR 29-MAR-1999; 99US-0126785.

XX PR 01-APR-1999; 99US-0127462.

XX PR 06-APR-1999; 99US-0128234.

XX PR 08-APR-1999; 99US-0128714.

XX PR 16-APR-1999; 99US-0129845.

XX PR 19-APR-1999; 99US-0130077.

XX PR 21-APR-1999; 99US-0130449.

XX PR 23-APR-1999; 99US-0130510.

XX PR 28-APR-1999; 99US-0131449.

XX PR 30-APR-1999; 99US-0132048.

XX PR 04-MAY-1999; 99US-0132484.

XX PR 05-MAY-1999; 99US-0132485.

XX PR 06-MAY-1999; 99US-0132486.

XX PR 06-MAY-1999; 99US-0132487.

XX PR 07-MAY-1999; 99US-0132863.

XX PR 11-MAY-1999; 99US-0134256.

XX PR 14-MAY-1999; 99US-0134218.

XX PR 14-MAY-1999; 99US-0134219.

XX PR 14-MAY-1999; 99US-0134221.

XX PR 14-MAY-1999; 99US-0134370.

XX PR 18-MAY-1999; 99US-0134768.

XX PR 19-MAY-1999; 99US-0134941.

XX PR 20-MAY-1999; 99US-0135124.

XX PR 21-MAY-1999; 99US-0135353.

XX PR 24-MAY-1999; 99US-0135629.

XX PR 25-MAY-1999; 99US-0136021.

XX PR 27-MAY-1999; 99US-0136392.

XX PR 28-MAY-1999; 99US-0136782.

XX PR 01-JUN-1999; 99US-0137222.

XX PR 03-JUN-1999; 99US-0137528.

XX PR 04-JUN-1999; 99US-0137502.

XX PR 07-JUN-1999; 99US-0137724.

XX PR 08-JUN-1999; 99US-0138094.

XX PR 10-JUN-1999; 99US-0138540.

XX PR 10-JUN-1999; 99US-0138847.

XX PR 14-JUN-1999; 99US-0139119.

XX PR 16-JUN-1999; 99US-0139452.

XX PR 16-JUN-1999; 99US-0139453.

XX PR 17-JUN-1999; 99US-0139492.

XX PR 18-JUN-1999; 99US-0139454.

XX PR 18-JUN-1999; 99US-0139455.

XX PR 18-JUN-1999; 99US-0139456.

XX PR 18-JUN-1999; 99US-0139457.







PR 27-AUG-1999; 99US-0151066.  
PR 27-AUG-1999; 99US-0151080.  
PR 30-AUG-1999; 99US-0151303.  
PR 31-AUG-1999; 99US-0151438.  
PR 01-SEP-1999; 99US-0151930.  
PR 07-SEP-1999; 99US-0152363.  
PR 10-SEP-1999; 99US-0153070.  
PR 13-SEP-1999; 99US-0153758.  
PR 15-SEP-1999; 99US-0154018.  
PR 16-SEP-1999; 99US-0154039.  
PR 20-SEP-1999; 99US-0154779.  
PR 22-SEP-1999; 99US-0155139.  
PR 23-SEP-1999; 99US-0155486.  
PR 24-SEP-1999; 99US-0155659.  
PR 28-SEP-1999; 99US-0156458.  
PR 29-SEP-1999; 99US-0156596.  
PR 04-OCT-1999; 99US-0157117.  
PR 05-OCT-1999; 99US-0157753.  
PR 06-OCT-1999; 99US-0157865.  
PR 07-OCT-1999; 99US-0158029.  
PR 08-OCT-1999; 99US-0158232.  
PR 12-OCT-1999; 99US-0158369.  
PR 13-OCT-1999; 99US-0159293.  
PR 13-OCT-1999; 99US-0159294.  
PR 13-OCT-1999; 99US-0159295.  
PR 14-OCT-1999; 99US-0159329.  
PR 14-OCT-1999; 99US-0159330.  
PR 14-OCT-1999; 99US-0159331.  
PR 14-OCT-1999; 99US-0159637.  
PR 14-OCT-1999; 99US-0159638.  
PR 18-OCT-1999; 99US-0159584.  
PR 21-OCT-1999; 99US-0160741.  
PR 21-OCT-1999; 99US-0160767.  
PR 21-OCT-1999; 99US-0160768.  
PR 21-OCT-1999; 99US-0160770.  
PR 21-OCT-1999; 99US-0160814.  
PR 21-OCT-1999; 99US-0160815.  
PR 22-OCT-1999; 99US-0160980.  
PR 22-OCT-1999; 99US-0160981.  
PR 22-OCT-1999; 99US-0160989.  
PR 25-OCT-1999; 99US-0161404.  
PR 25-OCT-1999; 99US-0161405.  
PR 25-OCT-1999; 99US-0161406.  
PR 26-OCT-1999; 99US-0161359.  
PR 26-OCT-1999; 99US-0161360.  
PR 26-OCT-1999; 99US-0161361.  
PR 28-OCT-1999; 99US-0161920.  
PR 28-OCT-1999; 99US-0161992.  
PR 28-OCT-1999; 99US-0161993.  
PR 29-OCT-1999; 99US-0162142.

Query Match 51.2%; Score 42; DB 21; Length 365;  
Best Local Similarity 80.08; Pred. No. 18;  
Matches 8; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 CFGVKGTTVN 10  
| |||||  
Db 284 csqvkgtktn 293

RESULT 9  
AAW98188  
ID AAW98188 standard; Protein; 389 AA.  
XX  
AC AAW98188;

DT 05-JUL-1999 (first entry)  
XX  
XX Chlamydia psittaci major outer membrane protein.  
DE  
XX Major outer membrane protein; MOMP; psittacosis; infection;  
KW  
KW vaccine; genetic immunisation.  
XX

OS Chlamydia psittaci.  
XX  
PN WO9910005-A1.  
XX  
PD 04-MAR-1999.  
XX  
PF 28-AUG-1998; 98WO-US17943.  
XX  
PR 28-AUG-1997; 97US-0057147.  
XX  
PA (LOUV ) UNIV LOUISIANA & AGRIC & MECH COLLEGE.  
XX  
PI Baghian A, Chouljenko VN, Kousoulas K3, Tully TN;  
XX  
DR WPI: 1999-254214/21.  
DR N-PSDB: AAX25047.  
XX  
XX A new vaccine for Chlamydia psittaci infections  
PT  
XX  
PS Disclosure; Page 60-61; 72pp; English.  
XX

CC The present sequence is the major outer membrane protein (MOMP) of Chlamydia psittaci strain B577. A claimed MOMP polypeptide (see AA98184) comprises regions VD3 and VD4 of B577 MOMP, i.e. it lacks regions VD1 and VD2. A claimed vaccine composition includes MOMP polypeptide lacking VD1 and VD2, optionally fused to a maltose binding protein. Also claimed are an isolated nucleic acid encoding the polypeptide, a vector, and a method of preventing C. psittaci infection by administering the vaccine containing the MOMP polypeptide. Vectors encoding MOMP polypeptides lacking regions VD1 and VD2 are useful for genetic vaccination. The vaccines are used to prevent C. psittaci infection, especially in birds.

SQ Sequence 389 AA;

Query Match 51.2%; Score 42; DB 20; Length 389;  
Best Local Similarity 53.8%; Pred. No. 20;  
Matches 7; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Qy 3 GVKGTVMNANELP 15  
| |||::: |::|  
Db 159 gvkgsstaadglp 171

RESULT 10  
AAG30952  
ID AAG30952 standard; Protein; 455 AA.  
XX  
AC AAG30952;

DT 17-OCT-2000 (first entry)  
XX  
DE Arabidopsis thaliana protein fragment 389 ID NO: 370933.

XX Protein identification; signal transduction pathway; metabolic pathway;  
KW hybridisation assay; genetic mapping; gene expression control; promoter;  
KW termination sequence.

XX Arabidopsis thaliana.  
XX  
XX EPI033405-A2.  
XX  
XX 06-SEP-2000.

XX 25-FEB-2000; 2000EP-0301439.  
XX  
XX 25-FEB-1999; 99US-0121825.  
PR 05-MAR-1999; 99US-0123180.  
PR 09-MAR-1999; 99US-0123548.  
PR 23-MAR-1999; 99US-0125788.  
PR 25-MAR-1999; 99US-0126264.

PR 29-MAR-1999; 99US-0126785.  
PR 01-APR-1999; 99US-0127462.  
PR 06-APR-1999; 99US-0128234.  
PR 08-APR-1999; 99US-0128714.  
PR 16-APR-1999; 99US-0129845.  
PR 19-APR-1999; 99US-0130077.  
PR 21-APR-1999; 99US-0130449.  
PR 23-APR-1999; 99US-0130510.  
PR 28-APR-1999; 99US-0130891.  
PR 30-APR-1999; 99US-0131449.  
PR 30-APR-1999; 99US-0132048.  
PR 04-MAY-1999; 99US-0132407.  
PR 05-MAY-1999; 99US-0132484.  
PR 05-MAY-1999; 99US-0132485.  
PR 06-MAY-1999; 99US-0132486.  
PR 07-MAY-1999; 99US-0132487.  
PR 07-MAY-1999; 99US-0132863.  
PR 11-MAY-1999; 99US-0134256.  
PR 14-MAY-1999; 99US-0134218.  
PR 14-MAY-1999; 99US-0134219.  
PR 14-MAY-1999; 99US-0134221.  
PR 14-MAY-1999; 99US-0134370.  
PR 16-MAY-1999; 99US-0134768.  
PR 16-MAY-1999; 99US-0134941.  
PR 20-MAY-1999; 99US-0135124.  
PR 20-MAY-1999; 99US-0135353.  
PR 20-MAY-1999; 99US-0135629.  
PR 25-MAY-1999; 99US-0136021.  
PR 27-MAY-1999; 99US-0136392.  
PR 28-MAY-1999; 99US-0136782.  
PR 01-JUN-1999; 99US-0137222.  
PR 03-JUN-1999; 99US-0137528.  
PR 04-JUN-1999; 99US-0137502.  
PR 07-JUN-1999; 99US-0137724.  
PR 08-JUN-1999; 99US-0138094.  
PR 10-JUN-1999; 99US-0138540.  
PR 10-JUN-1999; 99US-0138847.  
PR 14-JUN-1999; 99US-0139119.  
PR 16-JUN-1999; 99US-0139452.  
PR 16-JUN-1999; 99US-0139453.  
PR 17-JUN-1999; 99US-0139454.  
PR 18-JUN-1999; 99US-0139454.  
PR 18-JUN-1999; 99US-0139455.  
PR 18-JUN-1999; 99US-0139456.  
PR 18-JUN-1999; 99US-0139457.  
PR 18-JUN-1999; 99US-0139458.  
PR 18-JUN-1999; 99US-0139459.  
PR 18-JUN-1999; 99US-0139460.  
PR 18-JUN-1999; 99US-0139461.  
PR 18-JUN-1999; 99US-0139462.  
PR 18-JUN-1999; 99US-0139463.  
PR 18-JUN-1999; 99US-0139750.  
PR 18-JUN-1999; 99US-0139763.  
PR 22-JUN-1999; 99US-0139817.  
PR 22-JUN-1999; 99US-0139899.  
PR 23-JUN-1999; 99US-0140353.  
PR 23-JUN-1999; 99US-0140354.  
PR 24-JUN-1999; 99US-0140695.  
PR 24-JUN-1999; 99US-0140823.  
PR 24-JUN-1999; 99US-0140991.  
PR 30-JUN-1999; 99US-0141287.  
PR 01-JUL-1999; 99US-0141842.  
PR 01-JUL-1999; 99US-0142154.  
PR 02-JUL-1999; 99US-0142055.  
PR 06-JUL-1999; 99US-0142390.  
PR 06-JUL-1999; 99US-0142803.  
PR 09-JUL-1999; 99US-0142920.  
PR 12-JUL-1999; 99US-0142977.  
PR 13-JUL-1999; 99US-0143542.  
PR 14-JUL-1999; 99US-0143624.  
PR 15-JUL-1999; 99US-0144005.  
PR 16-JUL-1999; 99US-0144085.  
PR 16-JUL-1999; 99US-0144086.  
PR 19-JUL-1999; 99US-0144325.  
PR 19-JUL-1999; 99US-0144331.  
PR 19-JUL-1999; 99US-0144332.  
PR 19-JUL-1999; 99US-0144333.  
PR 19-JUL-1999; 99US-0144334.  
PR 19-JUL-1999; 99US-0144335.  
PR 20-JUL-1999; 99US-0144352.  
PR 20-JUL-1999; 99US-0144632.  
PR 20-JUL-1999; 99US-0144884.  
PR 21-JUL-1999; 99US-0144814.  
PR 21-JUL-1999; 99US-0145086.  
PR 21-JUL-1999; 99US-0145088.  
PR 22-JUL-1999; 99US-0145085.  
PR 22-JUL-1999; 99US-0145087.  
PR 22-JUL-1999; 99US-0145089.  
PR 22-JUL-1999; 99US-0145192.  
PR 23-JUL-1999; 99US-0145145.  
PR 23-JUL-1999; 99US-0145218.  
PR 23-JUL-1999; 99US-0145224.  
PR 26-JUL-1999; 99US-0145276.  
PR 27-JUL-1999; 99US-0145913.  
PR 27-JUL-1999; 99US-0145918.  
PR 27-JUL-1999; 99US-0145919.  
PR 28-JUL-1999; 99US-0145951.  
PR 02-AUG-1999; 99US-0146386.  
PR 02-AUG-1999; 99US-0146388.  
PR 02-AUG-1999; 99US-0146389.  
PR 03-AUG-1999; 99US-0147038.  
PR 04-AUG-1999; 99US-0147204.  
PR 04-AUG-1999; 99US-0147302.  
PR 05-AUG-1999; 99US-0147192.  
PR 05-AUG-1999; 99US-0147260.  
PR 06-AUG-1999; 99US-0147303.  
PR 06-AUG-1999; 99US-0147416.  
PR 09-AUG-1999; 99US-0147493.  
PR 09-AUG-1999; 99US-0147935.  
PR 10-AUG-1999; 99US-0148171.  
PR 11-AUG-1999; 99US-0148319.  
PR 12-AUG-1999; 99US-0148341.  
PR 13-AUG-1999; 99US-0148565.  
PR 13-AUG-1999; 99US-0148684.  
PR 16-AUG-1999; 99US-0149368.  
PR 17-AUG-1999; 99US-0149175.  
PR 18-AUG-1999; 99US-0149426.  
PR 20-AUG-1999; 99US-0149722.  
PR 20-AUG-1999; 99US-0149723.  
PR 20-AUG-1999; 99US-0149929.  
PR 23-AUG-1999; 99US-0149902.  
PR 23-AUG-1999; 99US-0149930.  
PR 25-AUG-1999; 99US-0150566.  
PR 26-AUG-1999; 99US-0150884.  
PR 27-AUG-1999; 99US-0151065.  
PR 27-AUG-1999; 99US-0151066.  
PR 27-AUG-1999; 99US-0151080.  
PR 30-AUG-1999; 99US-0151303.  
PR 31-AUG-1999; 99US-0151438.  
PR 01-SEP-1999; 99US-0151930.  
PR 07-SEP-1999; 99US-0152363.  
PR 10-SEP-1999; 99US-0153070.  
PR 13-SEP-1999; 99US-0153758.  
PR 15-SEP-1999; 99US-0154039.  
PR 16-SEP-1999; 99US-0154039.  
PR 20-SEP-1999; 99US-0154779.  
PR 22-SEP-1999; 99US-0155139.  
PR 23-SEP-1999; 99US-0155486.  
PR 24-SEP-1999; 99US-0155659.  
PR 28-SEP-1999; 99US-0156458.  
PR 29-SEP-1999; 99US-0156596.  
PR 04-OCT-1999; 99US-0157117.  
PR 05-OCT-1999; 99US-0157753.  
PR 06-OCT-1999; 99US-0157865.  
PR 07-OCT-1999; 99US-0158029.  
PR 08-OCT-1999; 99US-0158232.

PR 12-OCT-1999; 99US-0158369.  
 PR 13-OCT-1999; 99US-0159293.  
 PR 13-OCT-1999; 99US-0159294.  
 PR 13-OCT-1999; 99US-0159295.  
 PR 14-OCT-1999; 99US-0159329.  
 PR 14-OCT-1999; 99US-0159330.  
 PR 14-OCT-1999; 99US-0159331.  
 PR 14-OCT-1999; 99US-0159637.  
 PR 14-OCT-1999; 99US-0159638.  
 PR 18-OCT-1999; 99US-0159584.  
 PR 21-OCT-1999; 99US-0160741.  
 PR 21-OCT-1999; 99US-0160767.  
 PR 21-OCT-1999; 99US-0160768.  
 PR 21-OCT-1999; 99US-0160770.  
 PR 21-OCT-1999; 99US-0160814.  
 PR 21-OCT-1999; 99US-0160815.  
 PR 22-OCT-1999; 99US-0160980.  
 PR 22-OCT-1999; 99US-0160981.  
 PR 22-OCT-1999; 99US-0160989.  
 PR 25-OCT-1999; 99US-0161404.  
 PR 25-OCT-1999; 99US-0161405.  
 PR 25-OCT-1999; 99US-0161406.  
 PR 26-OCT-1999; 99US-0161359.  
 PR 26-OCT-1999; 99US-0161360.  
 PR 28-OCT-1999; 99US-0161361.  
 PR 28-OCT-1999; 99US-0161920.  
 PR 28-OCT-1999; 99US-0161992.  
 PR 28-OCT-1999; 99US-0161993.  
 PR 29-OCT-1999; 99US-0162142.

Query Match 51.2%; Score 42; DB 21; Length 455;  
 Best Local Similarity 80.0%; Pred. No. 23;  
 Matches 8; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 CFGVKGTIVN 10  
 | | | | | | | |  
 Db 374 csqvkgtivn 383

RESULT 11  
 AAW74088  
 ID AAW74088 standard; Protein; 708 AA.  
 AC AAW74088;  
 XX  
 XX  
 XX 04-MAY-1999 (first entry)  
 XX  
 XX Human hPEPT1 protein.

XX Gastro-intestinal transport receptor; binding protein; hSI; HPT1;  
 KW D2H; hPEPT1; human; GI tract receptor; sucrose-isomaltase complex;  
 KW intestinal peptide-associated transporter; hypertension; diabetes;  
 KW osteoporosis; haemophilia; anaemia; cancer; migraine; angina pectoris;  
 KW therapeutic agent delivery; therapy; probe.

XX Homo sapiens.  
 OS  
 XX  
 XX WO9851325-A2.  
 PN  
 XX  
 XX 19-NOV-1998.  
 PD  
 XX  
 XX 15-MAY-1998; 98WO-US10088.  
 PF  
 XX  
 XX 15-MAY-1997; 97US-0046595.  
 PR  
 XX  
 XX (CYTO-) CYTOGEN CORP.  
 PA  
 XX (ELAN-) ELAN CORP PLC.

XX Alvarez VL, Belinka BA, Cagney GM, Carter JM, Lambkin IJ;  
 PI Omahony DJ, Patterson CA, Singleton J;  
 XX WPI; 1999-009568/01.  
 DR  
 XX

PT New proteins that bind specifically to receptors in the  
 PT gastro-intestinal tract and related nucleic acid - chimaeras and  
 PT antibodies, used to deliver therapeutic or diagnostic agents to, or  
 PT through, the gastrointestinal tract, e.g. insulin or leuprolide  
 XX  
 PS Disclosure; Fig 1; 294pp; English.

XX This sequence is the human hPEPT1 protein. The invention relates to  
 CC purified proteins (I) that bind specifically to at least one of the  
 CC gastro-intestinal (GI) tract receptors human intestinal  
 CC peptide-associated transporter (HPT1), hPEPT1, D2H and human  
 CC sucrose-isomaltase complex (hSI). (I) provide active transport of  
 CC therapeutic agents through human and animal GI tissue (into the blood)  
 CC for in vivo delivery, particularly for treatment or prevention  
 CC of hypertension, diabetes, osteoporosis, haemophilia, anaemia, cancer,  
 CC migraine, or angina pectoris. Specifically they are used to deliver  
 CC insulin or leuprolide, but many other suitable therapeutic agents are  
 CC disclosed, including genes or inhibitory nucleic acid, imaging agents and  
 CC antigens. (I) may also provide targeting to the GI tract. Other uses of  
 CC (I) are: (i) to determine the level of specified receptors in a sample  
 CC (in a binding assay); and (ii) to screen for molecules that bind (I).  
 CC Immunogenic analogues or derivatives of (I) are used to raise antibodies  
 CC and in immunoassays. The antibodies are used to locate, detect and  
 CC measure (I), e.g. for imaging, monitoring treatment, tissue analysis  
 CC etc., also for peptide purification and immobilisation.

XX Sequence 708 AA;

Query Match 51.2%; Score 42; DB 20; Length 708;  
 Best Local Similarity 46.2%; Pred. No. 39;  
 Matches 6; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 3 GVKGTIVNANELP 15  
 | | | | | | | | | | | | | | | |  
 Db 524 gikgftissteip 536

RESULT 12  
 AAW74087  
 ID AAW74087 standard; peptide; 708 AA.  
 XX  
 AC AAW74087;  
 XX  
 XX 04-MAY-1999 (first entry)  
 XX  
 XX Gastro-intestinal transport receptor binding protein.

XX Gastro-intestinal transport receptor; binding protein; hSI; HPT1;  
 KW D2H; hPEPT1; human; GI tract receptor; sucrose-isomaltase complex;  
 KW intestinal peptide-associated transporter; hypertension; diabetes;  
 KW osteoporosis; haemophilia; anaemia; cancer; migraine; angina pectoris;  
 KW therapeutic agent delivery; therapy.

XX Homo sapiens.  
 OS  
 XX  
 XX WO9851325-A2.  
 PN  
 XX  
 XX 19-NOV-1998.  
 PD  
 XX  
 XX 15-MAY-1998; 98WO-US10088.  
 PF  
 XX  
 XX 15-MAY-1997; 97US-0046595.  
 PR  
 XX  
 XX (CYTO-) CYTOGEN CORP.  
 PA  
 XX (ELAN-) ELAN CORP PLC.

XX Alvarez VL, Belinka BA, Cagney GM, Carter JM, Lambkin IJ;  
 PI Omahony DJ, Patterson CA, Singleton J;  
 XX WPI; 1999-009568/01.  
 DR  
 XX

PT New proteins that bind specifically to receptors in the

xx The present sequence represents human proton-coupled peptide transporter  
cc (PCPT). Transforming cells with a nucleic acid molecule encoding PCPT  
cc allows transport of peptides or their mimics across a cellular membrane.  
cc Any di- or tri-peptide (and structurally similar compounds such as  
cc beta-lactam antibiotics) can be transported into cells of the  
cc gastrointestinal tract, brain, the blood-brain barrier, kidney and  
cc liver. Chemicals (particularly therapeutic agents) can be coupled to  
cc the peptides for delivery across membranes (with subsequent release of  
cc active drug by enzymatic hydrolysis). Sequences antisense to the nucleic  
cc acid molecule encoding PCPT may be used to inhibit PCPT expression.  
xx Sequence 708 AA:  
SQ

RESULT	14
AAE04789	
ID	AAE04
XX	
AC	AAE04
XX	
DT	10-SEP

XX  
DE Lycopersicon esculentum neoxanthin cleavage enzyme, LencEDI.  
XX  
XX Tomato; neoxanthin cleavage enzyme; LencEDI; abscisic acid; ABA;  
KW stress tolerance; transgenic plant; plant breeding; antisense-therapy;  
KW plant growth protectant; herbicide.

11-JAN-2001; 2001EP-0300218.  
13-JAN-2000; 2000JP-0010056.  
11-JAN-2001; 2001JP-0003476.

(RIKE ) RIKEN KK.  
Iuchi S, Kobayashi M, Shinozaki K;  
WPI; 2001-400081/43.  
N-PSDB; AAD09401.  
A DNA encoding a protein with a neoxanthin cleavage activity for  
producing transgenic plants with improved or decreased stress tolerance  
Claim 3; Fig 2; 101pp; English.

The invention relates to neoxanthin cleavage enzymes and their corresponding cDNA molecules. Neoxanthin cleavage enzyme plays a key role in endogenous abscisic acid (ABA) biosynthesis under drought stress. Neoxanthin cleavage enzyme is used for improving stress tolerance in a plant when expressed in a plant cell. The invention also relates to methods for increasing or decreasing stress tolerance in a plant by introducing the DNA into the plant, and a transgenic plant into which a neoxanthin cleavage enzyme is introduced. The improvement of stress tolerance in plants is useful, for example in plant breeding. Neoxanthin cleavage enzyme genes are useful for producing transgenic plants. An arid land can be improved by growing transformant weed for several years and

CC then removing the weed by specifically lowering stress tolerance in the  
 CC weed by inducing an inducible promoter. The present sequence is  
 CC Lycopersicon esculentum neoxanthin cleavage enzyme, LeNCE1 protein  
 CC related to the invention.

XX SQ Sequence 605 AA;

Query Match 50.0%; Score 41; DB 22; Length 605;  
 Best Local Similarity 53.8%; Pred. No. 49;  
 Matches 7; Conservative 3; Mismatches 3; Indels 0; Gaps 0;  
 QY 2 FGVKGTTVNANEL 14  
 :| || :|||:  
 Db 589 ygfhtfinandl 601

# RESULT 15

AAB72308  
 ID AAB72308 standard; Protein; 605 AA.

XX AC AAB72308;

XX DT 16-MAY-2001 (first entry)

XX DE Neoxanthin cleavage enzyme-like protein amino acid sequence.

XX KW Defence-related signalling gene; sunflower; neoxanthin cleavage enzyme;  
 KW NCE; amino acid permease; AAP; glutamic acid rich protein; GRP;  
 KW pathogen resistance; abscisic acid metabolism.

XX OS Lycopersicon esculentum.

XX PN W0200112801-A2.

XX PD 22-FEB-2001.

XX PF 17-AUG-2000; 2000WO-US22961.

XX PR 18-AUG-1999; 99US-0149656.

XX PR 23-MAY-2000; 2000US-0206405.

XX PA (PION-) PIONEER HI-BRED INT INC.

XX PA (CURA-) CURAGEN CORP.

XX PI Bidney DL, Crasta OR, Hu X, Lu G;

XX DR WPI; 2001-211215/21.

XX Novel isolated defence-related signalling gene isolated from sunflower  
 PT encoding neoxanthin cleavage enzyme, amino acid permease or glutamic  
 PT acid-rich protein useful for increasing resistance of plant to a  
 PT pathogen

XX PS Disclosure; Fig 1; 135pp; English.

XX This invention relates to defence-related signalling genes isolated from  
 CC the sunflower (*Helianthus annuus*). The genes encode a neoxanthin cleavage  
 CC enzyme (NCE), an amino acid permease (AAP) and a glutamic acid rich  
 CC protein (GRP). The signalling gene is useful for increasing the  
 CC resistance of a plant to a pathogen such as fungus, virus, bacterium,  
 CC nematode or insect (e.g. European corn borer), preferably  
 CC *Sclerotinia* spp., *Phoma* spp., or *Phomopsis* spp. by stably incorporating a  
 CC construct containing the gene into the genome of the plant. The gene is  
 CC useful for regulating gene expression in a plant, in response to a  
 CC stimulus such as infection with a pathogen, damage from a pathogen,  
 CC hydrogen peroxide, jasmonic acid, methyl jasmonate, salicylic acid,  
 CC oxalic acid or expression of a gene encoding oxalic acid oxidase. The  
 CC genes are also useful for stem-preferred regulation of gene expression in  
 CC a plant. The genes are useful in agriculture, particularly in the  
 CC breeding of crop plants with improved agronomic traits, for modifying  
 CC abscisic acid (ABA) metabolism and for modifying amino acid transport and  
 CC content in plants. The present sequence represents a neoxanthin cleavage

CC enzyme-like protein from Lycopersicon esculentum used in the  
 CC characterisation of sunflower NCE.

XX SQ Sequence 605 AA;

Query Match 50.0%; Score 41; DB 22; Length 605;  
 Best Local Similarity 53.8%; Pred. No. 49;  
 Matches 7; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 2 FGVKGTTVNANEL 14  
 :| || :|||:  
 Db 589 ygfhtfinandl 601

Search completed: March 26, 2002, 13:38:47  
 Job time: 141 sec





GenCore version 4.5  
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: March 26, 2002, 13:41:27 ; Search time 37.72 Seconds  
(without alignments)  
8.949 Million cell updates/sec

Title: US-09-709-201-97

Perfect score: 82  
Sequence: 1 CFGVKGTTVNANLNP 15

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 212252 seqs, 22503292 residues

Total number of hits satisfying chosen parameters: 212252

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Issued\_Patents\_AA:\*

- 1: /cgn2\_6/ptodata/2/1aa/5A\_COMB.pep:\*
- 2: /cgn2\_6/ptodata/2/1aa/5B\_COMB.pep:\*
- 3: /cgn2\_6/ptodata/2/1aa/6A\_COMB.pep:\*
- 4: /cgn2\_6/ptodata/2/1aa/6B\_COMB.pep:\*
- 5: /cgn2\_6/ptodata/2/1aa/PTUS\_COMB.pep:\*
- 6: /cgn2\_6/ptodata/2/1aa/backfiles1.pep:\*

pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	42	51.2	708	US-08-576-165-2	Sequence 2, Appli
2	38.5	47.0	452	US-08-290-978A-5	Sequence 5, Appli
3	38.5	47.0	452	US-08-780-869-5	Sequence 5, Appli
4	38	46.3	322	US-08-286-819A-2	Sequence 2, Appli
5	38	46.3	322	US-08-980-357-2	Sequence 2, Appli
6	38	46.3	380	US-08-468-846-2	Sequence 2, Appli
7	38	46.3	380	US-08-915-096A-2	Sequence 2, Appli
8	38	46.3	2291	US-08-286-819A-29	Sequence 29, Appli
9	38	46.3	2291	US-08-980-357-29	Sequence 29, Appli
10	37	45.1	469	US-08-378-313-33	Sequence 33, Appli
11	36	43.9	916	US-08-188-228-48	Sequence 48, Appli
12	36	43.9	916	US-08-332-643-42	Sequence 42, Appli
13	36	43.9	916	US-08-332-638-48	Sequence 48, Appli
14	35.5	43.3	185	US-08-463-911-3	Sequence 3, Appli
15	35.5	43.3	236	US-09-140-804-6	Sequence 6, Appli
16	35	42.7	664	US-08-421-661-6	Sequence 1, Appli
17	35	42.7	992	US-08-890-865A-1	Sequence 1, Appli
18	34.5	42.1	200	US-09-282-146-2	Sequence 2, Appli
19	34	41.5	121	US-08-560-003-8	Sequence 8, Appli
20	34	41.5	121	US-09-418-540-8	Sequence 8, Appli
21	34	41.5	263	US-08-776-059-43	Sequence 43, Appli
22	34	41.5	264	US-08-776-059-33	Sequence 33, Appli
23	34	41.5	564	US-08-776-059-35	Sequence 35, Appli
24	34	41.5	953	US-08-500-857A-2	Sequence 2, Appli
25	34	41.5	1147	US-08-131-365B-38	Sequence 38, Appli
26	34	41.5	1147	US-08-668-123-38	Sequence 38, Appli
27	34	41.5	1297	US-09-540-245A-17	Sequence 17, Appli

28	34	41.5	2556	1	US-08-185-432-17	Sequence 17, Appli
29	34	41.5	2556	1	US-08-083-590A-20	Sequence 20, Appli
30	34	41.5	2556	3	US-08-532-384-20	Sequence 20, Appli
31	33.5	40.9	559	1	US-08-030-096-6	Sequence 6, Appli
32	33	40.2	31	2	US-08-023-980B-30	Sequence 30, Appli
33	33	40.2	31	2	US-08-486-953A-25	Sequence 25, Appli
34	33	40.2	79	1	US-08-154-916-12	Sequence 12, Appli
35	33	40.2	151	2	US-08-722-050-8	Sequence 8, Appli
36	33	40.2	237	4	US-08-861-774E-68	Sequence 68, Appli
37	33	40.2	317	6	5340934-11	Patent No. 5340934
38	33	40.2	369	1	US-07-854-596B-31	Sequence 31, Appli
39	33	40.2	385	2	US-08-892-715-2	Sequence 2, Appli
40	33	40.2	385	2	US-09-145-917-2	Sequence 2, Appli
41	33	40.2	403	2	US-08-533-659A-10	Sequence 10, Appli
42	33	40.2	403	2	US-08-607-509-2	Sequence 2, Appli
43	33	40.2	403	2	US-08-454-036-2	Sequence 2, Appli
44	33	40.2	403	2	US-08-634-612-2	Sequence 2, Appli
45	33	40.2	403	3	US-08-989-370-2	Sequence 2, Appli

ALIGNMENTS

RESULT 1  
US-08-576-165-2  
; Sequence 2, Application US/08576165  
; Patent No. 5849525  
; GENERAL INFORMATION:  
; APPLICANT: HEDIGER, MATTHIAS  
; TITLE OF INVENTION: COMPOSITIONS CORRESPONDING TO A  
; TITLE OF INVENTION: PROTON-COUPLED PEPTIDE TRANSPORTER AND METHODS OF MAKING  
; TITLE OF INVENTION: AND USING SAME  
; NUMBER OF SEQUENCES: 4  
; CORRESPONDENCE ADDRESSES:  
; ADDRESSEE: WOLF, GREENFIELD & SACKS, P.C.  
; STREET: 600 ATLANTIC AVENUE  
; CITY: BOSTON  
; STATE: MASSACHUSETTS  
; COUNTRY: USA  
; ZIP: 02210  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/576,165  
; FILING DATE:  
; CLASSIFICATION: 514  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US/08/208,645  
; FILING DATE:  
; ATTORNEY/AGENT INFORMATION:  
; NAME: JANIUK, ANTHONY J.  
; REGISTRATION NUMBER: 29,809  
; REFERENCE/DOCKET NUMBER: B0801/7022  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 617-720-3500  
; TELEFAX: 617-720-2441  
; INFORMATION FOR SEQ ID NO: 2:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 708 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
US-08-576-165-2

Query Match 51.2%; Score 42; DB 2; Length 708;  
Best Local Similarity 46.2%; Pred. No.: 11;  
Matches 6; Conservative 5; Mismatches 2; Indels 0; Gaps 0;  
QY 3 GVKGTTVNANLNP 15

Db 524 GIKGTISSTEIP 536

## RESULT 2

US-08-290-978A-5  
; Sequence 5, Application US/08290978A  
; Patent No. 5624834  
; GENERAL INFORMATION:  
; APPLICANT: KUSTERS-VAN SOMEREN, MARGO A.  
; APPLICANT: MULLER, YVONNE  
; APPLICANT: KESTER, HERMANUS C.M.  
; APPLICANT: VISSER, JACOB  
; APPLICANT: VAN COYEN, ALBERT J.J.  
; APPLICANT: ROLIN, CLAUD  
; TITLE OF INVENTION: CLONING AND EXPRESSION OF THE  
; TITLE OF INVENTION: EXO-POLYGALACTURONASE GENE FROM ASPERGILLUS  
; NUMBER OF SEQUENCES: 15  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: MORRISON & FOERSTER  
; STREET: 2000 Pennsylvania Avenue N.W.  
; CITY: Washington  
; STATE: DC  
; COUNTRY: USA  
; ZIP: 20006-1812  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/290,978A  
; FILING DATE: 17-OCT-1994  
; CLASSIFICATION: 435  
; PRIOR APPLICATION INFORMATION:  
; NAME: MURASHIGE, KATE H.  
; REGISTRATION NUMBER: 29,959  
; REFERENCE/DOCKET NUMBER: 4615-0044.00  
; TELEPHONE: (202) 887-1500  
; TELEFAX: (202) 887-0763  
; TELEX: 90-4030  
; INFORMATION FOR SEQ ID NO: 5:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 452 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
US-08-290-978A-5

Query Match 47.0%; Score 38.5; DB 1; Length 452;  
Best Local Similarity 53.3%; Pred. No. 30;  
Matches 8; Conservative 2; Mismatches 4; Indels 1; Gaps 1;  
QY 1 CFGVKGTIVNANL 15  
Db 365 CYGQKNTTL-CNEYP 378  
RESULT 3  
US-08-290-978A-5  
; Sequence 5, Application US/08780869  
; Patent No. 5830737  
; GENERAL INFORMATION:  
; APPLICANT: KUSTERS-VAN SOMEREN, MARGO A.  
; APPLICANT: MULLER, YVONNE  
; APPLICANT: KESTER, HERMANUS C.M.  
; APPLICANT: VISSER, JACOB  
; APPLICANT: VAN COYEN, ALBERT J.J.  
; APPLICANT: ROLIN, CLAUD  
; TITLE OF INVENTION: CLONING AND EXPRESSION OF THE  
; TITLE OF INVENTION: EXO-POLYGALACTURONASE GENE FROM ASPERGILLUS

NUMBER OF SEQUENCES: 15  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: MORRISON & FOERSTER  
; STREET: 2000 Pennsylvania Avenue N.W.  
; CITY: Washington  
; STATE: DC  
; COUNTRY: USA  
; ZIP: 20006-1812  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/780,869  
; FILING DATE: 24-JAN-1997  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/290,978  
; FILING DATE: 17-OCT-1994  
; ATTORNEY/AGENT INFORMATION:  
; NAME: MURASHIGE, KATE H.  
; REGISTRATION NUMBER: 29,959  
; REFERENCE/DOCKET NUMBER: 4615-0044.00  
; TELEPHONE: (202) 887-1500  
; TELEFAX: (202) 887-0763  
; TELEX: 90-4030  
; INFORMATION FOR SEQ ID NO: 5:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 452 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
US-08-780-869-5

Query Match 47.0%; Score 38.5; DB 2; Length 452;  
Best Local Similarity 53.3%; Pred. No. 30;  
Matches 8; Conservative 2; Mismatches 4; Indels 1; Gaps 1;  
QY 1 CFGVKGTIVNANL 15  
Db 365 CYGQKNTTL-CNEYP 378  
RESULT 4  
US-08-286-819A-2  
; Sequence 2, Application US/08286819A  
; Patent No. 5871910  
; GENERAL INFORMATION:  
; APPLICANT: ARTHUR, MICHEL  
; APPLICANT: DUKTA-MALEN, SYLVIE  
; APPLICANT: MOLINAS, CATHERINE  
; APPLICANT: COURVALIN, PATRICE  
; TITLE OF INVENTION: POLYPEPTIDES IMPLICATED IN THE  
; TITLE OF INVENTION: EXPRESSION OF RESISTANCE TO GLYCOPOLYMERES, IN PARTICULAR  
; TITLE OF INVENTION: IN GRAM-POSITIVE BACTERIA, NUCLEOTIDE SEQUENCE CODING FOR  
; TITLE OF INVENTION: THESE POLYPEPTIDES AND USE FOR DIAGNOSIS  
; NUMBER OF SEQUENCES: 54  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT,  
; STREET: 1755 S. Jefferson Davis Highway, Suite 400  
; CITY: Arlington  
; STATE: Virginia  
; COUNTRY: U.S.A.  
; ZIP: 22202  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25

Query Match 47.0%; Score 38.5; DB 2; Length 452;  
Best Local Similarity 53.3%; Pred. No. 30;  
Matches 8; Conservative 2; Mismatches 4; Indels 1; Gaps 1;  
QY 1 CFGVKGTIVNANL 15  
Db 365 CYGQKNTTL-CNEYP 378  
RESULT 4  
US-08-286-819A-2  
; Sequence 2, Application US/08286819A  
; Patent No. 5871910  
; GENERAL INFORMATION:  
; APPLICANT: ARTHUR, MICHEL  
; APPLICANT: DUKTA-MALEN, SYLVIE  
; APPLICANT: MOLINAS, CATHERINE  
; APPLICANT: COURVALIN, PATRICE  
; TITLE OF INVENTION: POLYPEPTIDES IMPLICATED IN THE  
; TITLE OF INVENTION: EXPRESSION OF RESISTANCE TO GLYCOPOLYMERES, IN PARTICULAR  
; TITLE OF INVENTION: IN GRAM-POSITIVE BACTERIA, NUCLEOTIDE SEQUENCE CODING FOR  
; TITLE OF INVENTION: THESE POLYPEPTIDES AND USE FOR DIAGNOSIS  
; NUMBER OF SEQUENCES: 54  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT,  
; STREET: 1755 S. Jefferson Davis Highway, Suite 400  
; CITY: Arlington  
; STATE: Virginia  
; COUNTRY: U.S.A.  
; ZIP: 22202  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25

Query Match 47.0%; Score 38.5; DB 2; Length 452;  
Best Local Similarity 53.3%; Pred. No. 30;  
Matches 8; Conservative 2; Mismatches 4; Indels 1; Gaps 1;  
QY 1 CFGVKGTIVNANL 15  
Db 365 CYGQKNTTL-CNEYP 378  
RESULT 4  
US-08-286-819A-2  
; Sequence 2, Application US/08286819A  
; Patent No. 5871910  
; GENERAL INFORMATION:  
; APPLICANT: ARTHUR, MICHEL  
; APPLICANT: DUKTA-MALEN, SYLVIE  
; APPLICANT: MOLINAS, CATHERINE  
; APPLICANT: COURVALIN, PATRICE  
; TITLE OF INVENTION: POLYPEPTIDES IMPLICATED IN THE  
; TITLE OF INVENTION: EXPRESSION OF RESISTANCE TO GLYCOPOLYMERES, IN PARTICULAR  
; TITLE OF INVENTION: IN GRAM-POSITIVE BACTERIA, NUCLEOTIDE SEQUENCE CODING FOR  
; TITLE OF INVENTION: THESE POLYPEPTIDES AND USE FOR DIAGNOSIS  
; NUMBER OF SEQUENCES: 54  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT,  
; STREET: 1755 S. Jefferson Davis Highway, Suite 400  
; CITY: Arlington  
; STATE: Virginia  
; COUNTRY: U.S.A.  
; ZIP: 22202  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25

Query Match 47.0%; Score 38.5; DB 2; Length 452;  
Best Local Similarity 53.3%; Pred. No. 30;  
Matches 8; Conservative 2; Mismatches 4; Indels 1; Gaps 1;  
QY 1 CFGVKGTIVNANL 15  
Db 365 CYGQKNTTL-CNEYP 378  
RESULT 4  
US-08-286-819A-2  
; Sequence 2, Application US/08286819A  
; Patent No. 5871910  
; GENERAL INFORMATION:  
; APPLICANT: ARTHUR, MICHEL  
; APPLICANT: DUKTA-MALEN, SYLVIE  
; APPLICANT: MOLINAS, CATHERINE  
; APPLICANT: COURVALIN, PATRICE  
; TITLE OF INVENTION: POLYPEPTIDES IMPLICATED IN THE  
; TITLE OF INVENTION: EXPRESSION OF RESISTANCE TO GLYCOPOLYMERES, IN PARTICULAR  
; TITLE OF INVENTION: IN GRAM-POSITIVE BACTERIA, NUCLEOTIDE SEQUENCE CODING FOR  
; TITLE OF INVENTION: THESE POLYPEPTIDES AND USE FOR DIAGNOSIS  
; NUMBER OF SEQUENCES: 54  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT,  
; STREET: 1755 S. Jefferson Davis Highway, Suite 400  
; CITY: Arlington  
; STATE: Virginia  
; COUNTRY: U.S.A.  
; ZIP: 22202  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25

Query Match 47.0%; Score 38.5; DB 2; Length 452;  
Best Local Similarity 53.3%; Pred. No. 30;  
Matches 8; Conservative 2; Mismatches 4; Indels 1; Gaps 1;  
QY 1 CFGVKGTIVNANL 15  
Db 365 CYGQKNTTL-CNEYP 378  
RESULT 4  
US-08-286-819A-2  
; Sequence 2, Application US/08286819A  
; Patent No. 5871910  
; GENERAL INFORMATION:  
; APPLICANT: ARTHUR, MICHEL  
; APPLICANT: DUKTA-MALEN, SYLVIE  
; APPLICANT: MOLINAS, CATHERINE  
; APPLICANT: COURVALIN, PATRICE  
; TITLE OF INVENTION: POLYPEPTIDES IMPLICATED IN THE  
; TITLE OF INVENTION: EXPRESSION OF RESISTANCE TO GLYCOPOLYMERES, IN PARTICULAR  
; TITLE OF INVENTION: IN GRAM-POSITIVE BACTERIA, NUCLEOTIDE SEQUENCE CODING FOR  
; TITLE OF INVENTION: THESE POLYPEPTIDES AND USE FOR DIAGNOSIS  
; NUMBER OF SEQUENCES: 54  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT,  
; STREET: 1755 S. Jefferson Davis Highway, Suite 400  
; CITY: Arlington  
; STATE: Virginia  
; COUNTRY: U.S.A.  
; ZIP: 22202  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25

Query Match 47.0%; Score 38.5; DB 2; Length 452;  
Best Local Similarity 53.3%; Pred. No. 30;  
Matches 8; Conservative 2; Mismatches 4; Indels 1; Gaps 1;  
QY 1 CFGVKGTIVNANL 15  
Db 365 CYGQKNTTL-CNEYP 378  
RESULT 4  
US-08-286-819A-2  
; Sequence 2, Application US/08286819A  
; Patent No. 5871910  
; GENERAL INFORMATION:  
; APPLICANT: ARTHUR, MICHEL  
; APPLICANT: DUKTA-MALEN, SYLVIE  
; APPLICANT: MOLINAS, CATHERINE  
; APPLICANT: COURVALIN, PATRICE  
; TITLE OF INVENTION: POLYPEPTIDES IMPLICATED IN THE  
; TITLE OF INVENTION: EXPRESSION OF RESISTANCE TO GLYCOPOLYMERES, IN PARTICULAR  
; TITLE OF INVENTION: IN GRAM-POSITIVE BACTERIA, NUCLEOTIDE SEQUENCE CODING FOR  
; TITLE OF INVENTION: THESE POLYPEPTIDES AND USE FOR DIAGNOSIS  
; NUMBER OF SEQUENCES: 54  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT,  
; STREET: 1755 S. Jefferson Davis Highway, Suite 400  
; CITY: Arlington  
; STATE: Virginia  
; COUNTRY: U.S.A.  
; ZIP: 22202  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25

Query Match 47.0%; Score 38.5; DB 2; Length 452;  
Best Local Similarity 53.3%; Pred. No. 30;  
Matches 8; Conservative 2; Mismatches 4; Indels 1; Gaps 1;  
QY 1 CFGVKGTIVNANL 15  
Db 365 CYGQKNTTL-CNEYP 378  
RESULT 4  
US-08-286-819A-2  
; Sequence 2, Application US/08286819A  
; Patent No. 5871910  
; GENERAL INFORMATION:  
; APPLICANT: ARTHUR, MICHEL  
; APPLICANT: DUKTA-MALEN, SYLVIE  
; APPLICANT: MOLINAS, CATHERINE  
; APPLICANT: COURVALIN, PATRICE  
; TITLE OF INVENTION: POLYPEPTIDES IMPLICATED IN THE  
; TITLE OF INVENTION: EXPRESSION OF RESISTANCE TO GLYCOPOLYMERES, IN PARTICULAR  
; TITLE OF INVENTION: IN GRAM-POSITIVE BACTERIA, NUCLEOTIDE SEQUENCE CODING FOR  
; TITLE OF INVENTION: THESE POLYPEPTIDES AND USE FOR DIAGNOSIS  
; NUMBER OF SEQUENCES: 54  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT,  
; STREET: 1755 S. Jefferson Davis Highway, Suite 400  
; CITY: Arlington  
; STATE: Virginia  
; COUNTRY: U.S.A.  
; ZIP: 22202  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25

;; CURRENT APPLICATION DATA:  
;; APPLICATION NUMBER: US/08/286,819A  
;; FILING DATE: 05-AUG-1994  
;; CLASSIFICATION: 435  
;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: US 08/174,682  
;; FILING DATE: 28-DEC-1993  
;; CLASSIFICATION: 435  
;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: US 07/917,146  
;; FILING DATE: 10-AUG-1992  
;; CLASSIFICATION: 435  
;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: PCT/FR/91/00855  
;; FILING DATE: 29-OCT-1991  
;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: FR 9013579  
;; FILING DATE: 31-OCT-1990  
;; CLASSIFICATION: 435  
;; ATTORNEY/AGENT INFORMATION:  
;; NAME: Oblon, No. 5871910man F.  
;; REGISTRATION NUMBER: 24,618  
;; REFERENCE/DOCKET NUMBER: 560-060-0 PCT  
;; TELECOMMUNICATION INFORMATION:  
;; TELEPHONE: (703) 413-3000  
;; TELEFAX: (703) 413-2220  
;; TELEX: 248855 OPAT UR  
;; INFORMATION FOR SEQ ID NO: 2:  
;; SEQUENCE CHARACTERISTICS:  
;; LENGTH: 322 amino acids  
;; TYPE: amino acid  
;; TOPOLOGY: linear  
;; MOLECULE TYPE: protein  
;; US-08-286-819A-2

Query Match 46.3%; Score 38; DB 2; Length 322;  
Best Local Similarity 63.6%; Pred. No. 24;  
Matches 7; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

Qy 2 FGVKGTNNAN 12  
||| | :|||  
Db 26 FGVNATINAN 36

RESULT 5  
US-08-980-357-2  
; Sequence 2, Application US/08980357  
; Patent No. 6013508  
; GENERAL INFORMATION:  
; APPLICANT: ARTHUR, MICHEL  
; APPLICANT: DUKTA-MALEN, SYLVIE  
; APPLICANT: MOLINAS, CATHERINE  
; APPLICANT: COURVALIN, PATRICE  
; TITLE OF INVENTION: POLYPEPTIDES IMPLICATED IN THE  
; TITLE OF INVENTION: EXPRESSION OF RESISTANCE TO GLYCOPROTEINS, IN PARTICULAR  
; TITLE OF INVENTION: IN GRAM-POSITIVE BACTERIA, NUCLEOTIDE SEQUENCE CODING FOR  
; TITLE OF INVENTION: THESE POLYPEPTIDES AND USE FOR DIAGNOSIS  
; NUMBER OF SEQUENCES: 54  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT,  
; ADDRESSEE: P.C.  
; STREET: 1755 S. Jefferson Davis Highway, Suite 400  
; CITY: Arlington  
; STATE: Virginia  
; COUNTRY: U.S.A.  
; ZIP: 22202  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:

;; APPLICATION NUMBER: US/08/980,357  
;; FILING DATE:  
;; CLASSIFICATION: 435  
;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: US 08/286,819  
;; FILING DATE: 05-AUG-1994  
;; APPLICATION NUMBER: US 08/174,682  
;; FILING DATE: 28-DEC-1993  
;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: US 07/917,146  
;; FILING DATE: 10-AUG-1992  
;; CLASSIFICATION: 435  
;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: PCT/FR/91/00855  
;; FILING DATE: 29-OCT-1991  
;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: FR 9013579  
;; FILING DATE: 31-OCT-1990  
;; ATTORNEY/AGENT INFORMATION:  
;; NAME: Oblon, No. 6013508man F.  
;; REGISTRATION NUMBER: 24,618  
;; REFERENCE/DOCKET NUMBER: 560-060-0 PCT  
;; TELECOMMUNICATION INFORMATION:  
;; TELEPHONE: (703) 413-3000  
;; TELEFAX: (703) 413-2220  
;; TELEX: 248855 OPAT UR  
;; INFORMATION FOR SEQ ID NO: 2:  
;; SEQUENCE CHARACTERISTICS:  
;; LENGTH: 322 amino acids  
;; TYPE: amino acid  
;; TOPOLOGY: linear  
;; MOLECULE TYPE: protein  
;; US-08-980-357-2

Query Match 46.3%; Score 38; DB 3; Length 322;  
Best Local Similarity 63.6%; Pred. No. 24;  
Matches 7; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

Qy 2 FGVKGTNNAN 12  
||| | :|||  
Db 26 FGVNATINAN 36

RESULT 6  
US-08-468-846-2  
; Sequence 2, Application US/08468846  
; Patent No. 6074839  
; GENERAL INFORMATION:  
; APPLICANT: Weissner, Paul  
; APPLICANT: Fuldner, Rebecca  
; APPLICANT: Fel-wel, Ying  
; APPLICANT: Adams, Mark  
; TITLE OF INVENTION: TRANSFORMING GROWTH FACTOR ALPHA HI  
; NUMBER OF SEQUENCES: 15  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: CARELLA, BYRNE, BAIN, GILFILLAN, CECCHI,  
; ADDRESSEE: STUART & OLSTEIN  
; STREET: 6 Becker Farm Road  
; CITY: Roseland  
; STATE: New Jersey  
; COUNTRY: USA  
; ZIP: 07068  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/468,846  
; FILING DATE: 06-JUN-1995  
; CLASSIFICATION: 514  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/208,008

COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/915.096A  
FILING DATE: 20-AUG-1997  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
PRIOR APPLICATION NUMBER: US 08/468,846  
FILING DATE: 06-JUN-1995  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/208,008  
FILING DATE: 08-MAR-1994  
ATTORNEY/AGENT INFORMATION:  
NAME: Brookes, A. Anders  
REGISTRATION NUMBER: 36,373  
REFERENCE/DOCKET NUMBER: PFI1001  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 301-309-8504  
TELEX: 301-309-8439  
INFORMATION FOR SEQ ID NO.: 2:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 380 amino acids  
TYPE: amino acid  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
US-08-915-096A-2

US-08-286-819A-29

Query Match 46.3%; Score 38; DB 2; Length 2291;  
Best Local Similarity 63.6%; Pred. No. 2.6e+02;  
Matches 7; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

Qy 2 FGVKGTNNAN 12  
| | | | : | | |  
Db 1138 FGVMTIINAN 1148

RESULT 9  
US-08-980-357-29  
; Sequence 29, Application US/08980357  
; Patent No. 6013508  
; GENERAL INFORMATION:  
; APPLICANT: ARTHUR, MICHEL  
; APPLICANT: DUKTA-MALEN, SYLVIE  
; APPLICANT: MOLINAS, CATHERINE  
; APPLICANT: COURVALIN, PATRICE  
; TITLE OF INVENTION: POLYPEPTIDES IMPLICATED IN THE  
; TITLE OF INVENTION: EXPRESSION OF RESISTANCE TO GLYCOPROTEINS, IN PARTICULAR  
; TITLE OF INVENTION: IN GRAM-POSITIVE BACTERIA, NUCLEOTIDE SEQUENCE CODING FOR  
; TITLE OF INVENTION: THESE POLYPEPTIDES AND USE FOR DIAGNOSIS  
; NUMBER OF SEQUENCES: 54  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT,  
; ADDRESSEE: P.C.  
; STREET: 1755 S. Jefferson Davis Highway, Suite 400  
; CITY: Arlington  
; STATE: Virginia  
; COUNTRY: U.S.A.  
; ZIP: 22202  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patentin Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/980.357  
; FILING DATE:  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/286.819  
; FILING DATE: 05-AUG-1994  
; APPLICATION NUMBER: US 08/174.682  
; FILING DATE: 28-DEC-1993  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/917.146  
; FILING DATE: 10-AUG-1992  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: PCT/FR/91/00855  
; FILING DATE: 29-OCT-1991  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: FR 9013579  
; FILING DATE: 31-OCT-1990  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Oblon, No. 6013508man F.  
; REGISTRATION NUMBER: 24,618  
; REFERENCE/DOCKET NUMBER: 660-060-0 PCT  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (703) 413-3000  
; TELEFAX: (703) 413-2220  
; TELEX: 248855 OPAT UR  
; INFORMATION FOR SEQ ID NO: 29:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 2291 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
US-08-980-357-29

Query Match 46.3%; Score 38; DB 3; Length 2291;  
Best Local Similarity 63.6%; Pred. No. 2.6e+02;

Matches 7; Conservative 1; Mismatches 3; Indels 0; Gaps 0;  
Qy 2 FGVKGTNNAN 12  
| | | | : | | |  
Db 1138 FGVMTIINAN 1148

RESULT 10  
US-08-378-313-33  
; Sequence 33, Application US/08378313  
; Patent No. 6207881  
; GENERAL INFORMATION:  
; APPLICANT: THEOLOGIS, ATHANASIOS  
; APPLICANT: SATO, TAKAHIDO  
; TITLE OF INVENTION: CONTROL OF FRUIT RIPENING THROUGH  
; TITLE OF INVENTION: GENETIC CONTROL OF ACC SYNTHASE SYNTHESIS  
; NUMBER OF SEQUENCES: 34  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: MORRISON & FOERSTER  
; STREET: 755 Page Mill Road  
; CITY: Palo Alto  
; STATE: California  
; COUNTRY: USA  
; ZIP: 94304-1018  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patentin Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/378.313  
; FILING DATE:  
; CLASSIFICATION: 800  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/862.493  
; FILING DATE: 02-APR-1992  
; ATTORNEY/AGENT INFORMATION:  
; NAME: MURASHIGE, KATE H.  
; REGISTRATION NUMBER: 29,959  
; REFERENCE/DOCKET NUMBER: 29190-20003.20  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (415) 856-5600  
; TELEFAX: (415) 494-0792  
; TELEX: 706141  
; INFORMATION FOR SEQ ID NO: 33:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 469 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
US-08-378-313-33

Query Match 45.1%; Score 37; DB 4; Length 469;  
Best Local Similarity 77.8%; Pred. No. 59;  
Matches 7; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 6 GTTVNANEL 14  
| | | | : | | |  
Db 205 GTTLNREL 213

RESULT 11  
US-08-188-228-48  
; Sequence 48, Application US/08188228  
; Patent No. 5597725  
; GENERAL INFORMATION:  
; APPLICANT: Suzuki, Shintaro  
; TITLE OF INVENTION: CADHERIN MATERIALS AND METHODS  
; NUMBER OF SEQUENCES: 62  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray &  
; ADDRESSEE: Borun

STREET: 6300 Sears Tower, 233 S. Wacker Drive  
CITY: Chicago  
STATE: Illinois  
COUNTRY: USA  
ZIP: 60606  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent In Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/188,228  
FILING DATE:  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/049,460  
FILING DATE: 19 APR 1993  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/872,643  
FILING DATE: 17 APR 1992  
ATTORNEY/AGENT INFORMATION:  
NAME: No. 559772Sand, Greta E.  
REGISTRATION NUMBER: 35,302  
REFERENCE/DOCKET NUMBER: 31340  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (312) 474-6300  
TELEFAX: (312) 474-0448  
TELEX: 25-3856  
INFORMATION FOR SEQ ID NO: 48:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 916 amino acids  
TYPE: amino acid  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
US-08-188-228-48

Query Match 43.9%; Score 36; DB 1; Length 916;  
Best Local Similarity 42.9%; Pred. No. 2e+02;  
Matches 6; Conservative 1; Mismatches 7; Indels 0; Gaps 0;

Qy 1 CFGVKGTTVNANEL 14  
| | | | |  
Db 62 CVGTGKTQYETNSM 75

RESULT: 12  
US-08-332-643-42  
Sequence 42, Application US/08332643  
Patent No. 5639634  
GENERAL INFORMATION:  
APPLICANT: Suzuki, Shintaro  
TITLE OF INVENTION: CADHERIN MATERIALS AND METHODS  
NUMBER OF SEQUENCES: 56  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Marshall, O'Toole, Gerstein, Murray &  
ADDRESSEE: Bicknell  
STREET: Two First National Plaza, 20 South Clark  
STREET: Street  
CITY: Chicago  
STATE: Illinois  
COUNTRY: USA  
ZIP: 60603  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent In Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/332,643  
FILING DATE:  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:

APPLICATION NUMBER: US/07/872,643  
FILING DATE:  
ATTORNEY/AGENT INFORMATION:  
NAME: No. 5639634and, Greta E.  
REGISTRATION NUMBER: 35,302  
REFERENCE/DOCKET NUMBER: 27866/30795  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (312) 346-5750  
TELEFAX: (312) 984-9740  
TELEX: 25-3856  
INFORMATION FOR SEQ ID NO: 42:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 916 amino acids  
TYPE: amino acid  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
US-08-332-643-42

Query Match 43.9%; Score 36; DB 1; Length 916;  
Best Local Similarity 42.9%; Pred. No. 2e+02;  
Matches 6; Conservative 1; Mismatches 7; Indels 0; Gaps 0;

Qy 1 CFGVKGTTVNANEL 14  
| | | | |  
Db 62 CVGTGKTQYETNSM 75

RESULT 13  
US-08-332-638-48  
Sequence 48, Application US/08332638  
Patent No. 5646250  
GENERAL INFORMATION:  
APPLICANT: Suzuki, Shintaro  
TITLE OF INVENTION: CADHERIN MATERIALS AND METHODS  
NUMBER OF SEQUENCES: 62  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Marshall, O'Toole, Gerstein, Murray &  
ADDRESSEE: Borun  
STREET: 6300 Sears Tower, 233 S. Wacker Drive  
CITY: Chicago  
STATE: Illinois  
COUNTRY: USA  
ZIP: 60606  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent In Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/332,638  
FILING DATE: 01-NOV-1994  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/872,643  
FILING DATE: 17 APR 1992  
APPLICATION NUMBER: US/08/049,460  
FILING DATE:  
ATTORNEY/AGENT INFORMATION:  
NAME: No. 5646250and, Greta E.  
REGISTRATION NUMBER: 35,302  
REFERENCE/DOCKET NUMBER: 31340  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (312) 474-6300  
TELEFAX: (312) 474-0448  
TELEX: 25-3856  
INFORMATION FOR SEQ ID NO: 48:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 916 amino acids  
TYPE: amino acid  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
US-08-332-638-48

Query Match 43.9%; Score 36; DB 1; Length 916;  
Best Local Similarity 42.9%; Pred. No. 2e+02;  
Matches 6; Conservative 1; Mismatches 7; Indels 0; Gaps 0;

QY 1 CFGVKGTTVNANEL 14  
| | | | |  
DB 62 CVGTRGTQYETNSM 75

## RESULT 14

US-08-463-911-3  
; Sequence 3, Application US/08463911  
; Patent No. 5869330  
; GENERAL INFORMATION:  
; APPLICANT: Scherer, Philipp E.  
; APPLICANT: Lodish, Harvey F.  
; TITLE OF INVENTION: A NOVEL SERUM PROTEIN PRODUCED  
; TITLE OF INVENTION: EXCLUSIVELY IN ADIPOCYTES  
; NUMBER OF SEQUENCES: 7  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Hamilton, Brook, Smith & Reynolds, P.C.  
; STREET: Two Militia Drive  
; CITY: Lexington  
; STATE: Massachusetts  
; COUNTRY: USA  
; ZIP: 02173  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/463,911  
; FILING DATE:  
; CLASSIFICATION: 530  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Granahan, Patricia  
; REGISTRATION NUMBER: 32,227  
; REFERENCE/DOCKET NUMBER: WHI95-05  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (617) 861-6240  
; TELEFAX: (617) 861-9540  
; INFORMATION FOR SEQ ID NO: 3:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 185 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: DNA (genomic)  
US-08-463-911-3

Query Match 43.3%; Score 35.5; DB 2; Length 185;  
Best Local Similarity 64.3%; Pred. No. 37;  
Matches 9; Conservative 1; Mismatches 1; Indels 3; Gaps 1;

QY 5 KGTT---VNANELP 15  
| | | | |  
DB 57 KCTSAFAVKANELP 70

## RESULT 15

US-09-140-804-6  
; Sequence 6, Application US/09140804  
; Patent No. 6197930  
; GENERAL INFORMATION:  
; APPLICANT: Sheppard, Paul O.  
; APPLICANT: Humes, Jacqueline M.  
; TITLE OF INVENTION: ADIPOCYTE-SPECIFIC PROTEIN HOMOLOGS  
; FILE REFERENCE: 97-49  
; CURRENT APPLICATION NUMBER: US/09/140,804

; CURRENT FILING DATE: 1998-08-26  
; EARLIER APPLICATION NUMBER: 60/056,983  
; EARLIER FILING DATE: 1997-08-26  
; NUMBER OF SEQ ID NOS: 47  
; SOFTWARE: FastSEQ for Windows Version 3.0  
; SEQ ID NO 6  
; LENGTH: 236  
; TYPE: PRT  
; ORGANISM: Tamias sibiricus  
US-09-140-804-6

Query Match 43.3%; Score 35.5; DB 4; Length 236;  
Best Local Similarity 64.3%; Pred. No. 50;  
Matches 9; Conservative 1; Mismatches 1; Indels 3; Gaps 1;

QY 5 KGTT---VNANELP 15  
| | | | |  
DB 108 KCTSAFAVKANELP 121

Search completed: March 26, 2002, 13:41:28  
Job time: 302 sec





GenCore version 4.5  
Copyright (c) 1993 - 2000 Compugen Ltd.

OM protein - protein search, using sw model

Run on: March 26, 2002, 13:36:26 ; Search time 81.51 seconds  
(without alignments)  
15.449 Million cell updates/sec

Title: US-09-709-201-93

Perfect score: 91

Sequence: 1 CTGSAANYTTAVDRPN 17

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 522463 seqs, 74073290 residues

Total number of hits satisfying chosen parameters: 522463

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

1: /SID88/gcgdata/geneseq/geneseq/AA1980.DAT.\*  
2: /SID88/gcgdata/geneseq/geneseq/AA1981.DAT.\*  
3: /SID88/gcgdata/geneseq/geneseq/AA1982.DAT.\*  
4: /SID88/gcgdata/geneseq/geneseq/AA1983.DAT.\*  
5: /SID88/gcgdata/geneseq/geneseq/AA1984.DAT.\*  
6: /SID88/gcgdata/geneseq/geneseq/AA1985.DAT.\*  
7: /SID88/gcgdata/geneseq/geneseq/AA1986.DAT.\*  
8: /SID88/gcgdata/geneseq/geneseq/AA1987.DAT.\*  
9: /SID88/gcgdata/geneseq/geneseq/AA1988.DAT.\*  
10: /SID88/gcgdata/geneseq/geneseq/AA1989.DAT.\*  
11: /SID88/gcgdata/geneseq/geneseq/AA1990.DAT.\*  
12: /SID88/gcgdata/geneseq/geneseq/AA1991.DAT.\*  
13: /SID88/gcgdata/geneseq/geneseq/AA1992.DAT.\*  
14: /SID88/gcgdata/geneseq/geneseq/AA1993.DAT.\*  
15: /SID88/gcgdata/geneseq/geneseq/AA1994.DAT.\*  
16: /SID88/gcgdata/geneseq/geneseq/AA1995.DAT.\*  
17: /SID88/gcgdata/geneseq/geneseq/AA1996.DAT.\*  
18: /SID88/gcgdata/geneseq/geneseq/AA1997.DAT.\*  
19: /SID88/gcgdata/geneseq/geneseq/AA1998.DAT.\*  
20: /SID88/gcgdata/geneseq/geneseq/AA1999.DAT.\*  
21: /SID88/gcgdata/geneseq/geneseq/AA2000.DAT.\*  
22: /SID88/gcgdata/geneseq/geneseq/AA2001.DAT.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	ID	Description
1	91	100.0	17 20 AAW95320	Costant and variab
2	82	90.1	29 20 AAW84462	Peptide CplA deriv
3	82	90.1	29 20 AAW84556	Peptide C.p.IA der
4	82	90.1	343 20 AAY56771	C. trachomatis ser
5	82	90.1	391 20 AAY35319	Chlamydia pneumoni
6	69	75.8	23 20 AAW84468	Peptide CplAmp de
7	64	70.3	389 20 AAW98188	Chlamydia psittaci
8	55	60.4	10 20 AAW84466	Peptide CpVDI deri
9	55	60.4	10 20 AAW84553	Peptide C.pVDI deri
10	49	53.8	100 20 AAW95295	Chlamydial major o
11	48	52.7	1241 22 AAW25606	Human protein sequ

12	48	52.7	1330	22	AAW65630	Novel protein kina
13	47	51.6	343	20	AAW56769	C. trachomatis ser
14	43	47.3	17	20	AAW95323	Costant and variab
15	43	47.3	250	21	AAW06126	Arabidopsis thalia
16	43	47.3	250	21	AAW06126	Arabidopsis thalia
17	43	47.3	263	21	AAW06125	Arabidopsis thalia
18	43	47.3	263	21	AAW06125	Arabidopsis thalia
19	41	45.1	345	22	AAW85128	Carica cysteine pr
20	41	45.1	345	22	AAW85128	Human betal-adreno
21	41	45.1	1736	22	AAW70765	Hepatitis C virus
22	41	45.1	2813	19	AAW36932	Canine von Willebr
23	41	45.1	2813	21	AAW70557	Canine von Willebr
24	41	45.1	3910	14	AAW38470	ALL-1 protein. Ho
25	41	45.1	3910	16	AAW66462	ALL-1 (acute lymph
26	41	45.1	3969	15	AAW52971	Product of the cDN
27	40	44.0	3011	16	AAW67588	Hepatitis C virus
28	39	42.9	205	22	AAW92148	C glutamicum prote
29	39	42.9	217	22	AAW79574	Corynebacterium gl
30	39	42.9	356	22	AAW99749	Oryza sativa perox
31	39	42.9	375	20	AAW30532	A G protein-couple
32	39	42.9	375	21	AAW71298	Human orphan G pro
33	39	42.9	375	21	AAW02832	Human G protein co
34	39	42.9	377	20	AAW30536	A G protein-couple
35	39	42.9	411	19	AAW80938	Human kidney lecti
36	39	42.9	414	19	AAW80941	Human kidney lecti
37	39	42.9	444	19	AAW80943	Human kidney lecti
38	38	41.8	158	21	AAW78913	Androgen independe
39	38	41.8	272	13	AAW29871	HCY NS4-NS5 peptid
40	38	41.8	374	22	AAW90207	C glutamicum prote
41	38	41.8	422	21	AAW28827	Arabidopsis thalia
42	38	41.8	422	21	AAW32115	Arabidopsis thalia
43	38	41.8	438	21	AAW51345	Arabidopsis thalia
44	38	41.8	459	19	AAW38456	Schizosaccharomyce
45	38	41.8	643	22	AAW97666	Zea mays ZmEIN3-1

#### ALIGNMENTS

RESULT 1

AAW95320  
ID AAW95320 standard; Protein; 17 AA.

XX AC AAW95320;

XX DT 15-MAR-1999 (first entry)

XX DE Costant and variable domain sequence of C. pneumoniae CPN90-105.

XX KW Chlamydia; cryptic phase; elementary body phase; replicating; probedicid;  
KW antiporphyrin acid; immune response; infection; diagnostic; assay; MOMP;  
KW major outer membrane protein; autoimmunity; inflammatory; porphyria;  
KW Ebstein Barr virus; antioxidant.

XX OS Chlamydia pneumoniae.

XX PN WO9850074-A2.

XX PD 12-NOV-1998.

XX PF 06-MAY-1998; 98WO-US09237.

XX PR 18-FEB-1998; 98US-0025521.

XX PR 06-MAY-1997; 97US-0045689.

XX PR 06-MAY-1997; 97US-0045739.

XX PR 06-MAY-1997; 97US-0045779.

XX PR 06-MAY-1997; 97US-0045780.

XX PR 06-MAY-1997; 97US-0045784.

XX PR 06-MAY-1997; 97US-0045787.

XX PR 14-AUG-1997; 97US-0911593.

XX PR 18-FEB-1998; 98US-0025174.

XX PR 18-FEB-1998; 98US-0025176.

PA (UYVA-) UNIV VANDERBILT.  
 XX Mitchell WM, Stratton CW;  
 XX WPI; 1999-059653/05.  
 XX Composition with two agents effective against different stages of  
 PT Chlamydial life cycle - comprises agent targetted against cryptic  
 PT phase, against elementary body phase, against replicating phase,  
 PT prohenicid and antiporphyria  
 XX Claim 4; Fig 3; 138pp; English.  
 XX The invention relates to the diagnosis and management of infections by  
 CC Chlamydia species. The invention provides a composition that comprises  
 CC at least two agents, where each of the agents is effective against a  
 CC different phase of the chlamydial life cycle. The agents are selected  
 CC from: (a) agents targetted against cryptic phase of chlamydial life  
 CC cycle; (b) agents targetted against elementary body phase of chlamydial  
 CC life cycle; (c) agents targetted against replicating phase of chlamydial  
 CC life cycle; (d) prohenicid, and (e) antiporphyria acid. The composition  
 CC is used to elicit a protective immune response to Chlamydia infection in  
 CC an animal or human and is applied until the animal or human tests  
 CC negative for Chlamydia infection. It is also used to treat biological  
 CC material infected with Chlamydia. Diagnostic kits for antibody assays  
 CC against recombinant major outer membrane protein (MOMP), and for DNA  
 CC amplification assays for chlamydial genes, are used to diagnose disease,  
 CC e.g. autoimmune disease, an inflammatory disease or a disease that  
 CC occurs in an immuno-compromised individual, associated with Chlamydia  
 CC infection. The kits are used to detect chlamydial elementary bodies in a  
 CC sample. They are also used to monitor and/or modify the course of therapy  
 CC in a patient. The treatment reduces the acellular load of infectious  
 CC Ebsstein Barr virus. The method is also used to treat porphyria, by  
 CC reducing the number of elementary bodies and applying a drug, e.g.  
 CC cimetidine, and antioxidants, to reduce the adverse effects associated  
 CC with porphyria. Sequences: AAW95320 to AAW95323 represent constant and  
 CC variable domain sequences of various Chlamydia species.  
 XX Sequence 17 AA:  
 QY 1 CTGSAANYTTTAVDRPN 17  
 Db 1 ctgsaanytttavrpn 17  
 RESULT 2  
 AAW84462  
 ID AAW84462 standard; peptide; 29 AA.  
 AC AAW84462;  
 XX 23-MAR-1999 (first entry)  
 DE Peptide CplA derived from a major outer membrane protein.  
 DE Variable domain; major outer membrane protein; MOMP;  
 KW Chlamydia; detection; infection; vaccine.  
 XX Synthetic.  
 OS Chlamydia pneumoniae.  
 XX WO9857981-A2.  
 XX 23-DEC-1998.  
 XX 15-JUN-1998; 98WO-IL00277.  
 XX 19-JUN-1997; 97IL-0121114.

(SAVY-) SAVYON DIAGNOSTICS LTD.  
 XX Ohana B;  
 XX WPI; 1999-080945/07.  
 XX New peptides derived from Chlamydia pneumoniae MOMP protein - useful  
 PT to detect C. pneumoniae infection  
 XX Claim 2; Page 53; 39pp; English.  
 XX The present peptide is derived from the variable domain of the  
 CC major outer membrane protein (MOMP) of Chlamydia pneumoniae. The  
 CC peptide is able to react with antibodies formed during C. pneumoniae  
 CC infection and characterised by having essentially very low  
 CC cross-reactivity towards antibodies against other Chlamydia species.  
 CC A mixture of such peptides (see also AAW84462-68) is used to detect  
 CC C. pneumoniae infection, and in the preparation of vaccines.  
 XX Sequence 29 AA;  
 QY 2 TGSAAANYTTTAVDRPN 17  
 Db 9 tgsaanytttavrpn 24  
 RESULT 3  
 AAW84556  
 ID AAW84556 standard; peptide; 29 AA.  
 AC AAW84556;  
 XX 26-MAR-1999 (first entry)  
 DE Peptide C.P.1A derived from the major outer membrane protein.  
 DE Variable domain; immunodominant; major outer membrane protein; MOMP;  
 KW anti-MOMP antibody; Chlamydia; vaccine; C. trachomatis.  
 XX Chlamydia pneumoniae.  
 OS WO9900414-A1.  
 XX 07-JAN-1999.  
 XX 15-JUN-1998; 98WO-IL00276.  
 XX 19-JUN-1997; 97IL-0121115.  
 XX (SAVY-) SAVYON DIAGNOSTICS LTD.  
 XX Ohana B;  
 XX WPI; 1999-095677/08.  
 XX Chlamydia trachomatis specific peptides useful in diagnostic assays  
 PT - derived from major outer membrane protein variable domains and  
 PT useful in mixtures to detect infection with or immunise against all  
 PT serovars  
 XX Example 1; Page 24; 78pp; English.  
 XX The present sequence represents a peptide derived from variable  
 CC domain 1 (VD1) of the Chlamydia pneumoniae major outer membrane  
 CC protein (MOMP). The specification also describes C. trachomatis  
 CC MOMP derived peptides which have specificity only to C. trachomatis  
 CC anti-MOMP antibodies and are non-cross reactive with anti-MOMP

CC antibodies of other Chlamydia species. Such peptides are useful to  
 CC detect C. trachomatis infections in humans. Mixtures of MOMP peptide  
 CC mixtures allow detection of and vaccination against all C. trachomatis  
 CC serovars, which is not possible with existing MOMP-derived peptides  
 CC for C. trachomatis-specific detection.

XX SQ Sequence 29 AA;

Query Match 90.1%; Score 82; DB 20; Length 29;  
 Best Local Similarity 100.0%; Pred. No. 8.2e-07;  
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 TGSAAANYTTAVDRPN 17  
 |||||  
 Db 9 tgsaaanyttavdrpn 24

RESULT 4

AAV56771  
 ID AAY56771 standard; Protein; 343 AA.

XX AC AAY56771;

XX DT 22-FEB-2000 (first entry)

XX C. trachomatis serovar HuPn MOMP sequence.

XX Major outer membrane protein; MOMP; Chlamydia; vaccine; immune response;  
 KW cellular response; immunogen; Th1-like CD4 response; mucosal immunity.

XX Chlamydia trachomatis.

XX WO9951745-A2.

XX PD 14-OCT-1999.

XX PF 07-APR-1999; 99WO-CA00292.

XX PR 07-APR-1998; 98US-0055765.

XX PA (UYMA-) UNIV MANITOBA.

XX PI Bruham RC;

XX DR WPI; 1999-620205/53.

XX Non-replicating vector encoding fragments of the outer membrane protein  
 PT of Chlamydia, useful in vaccines and as immunogen

XX Disclosure; Fig 10 A-F; 52pp; English.

XX The invention provides a non-replicating vector that comprises, linked  
 CC to a promoter, a nucleotide sequence that encodes a region containing at  
 CC least one of the conserved domains 2, 3 and 5 of a major outer membrane  
 CC protein (MOMP) of a Chlamydia strain. The vector is used: (a) in  
 CC vaccines to generate a protective immune response (mainly cellular)  
 CC against MOMP, and (b) as immunogens to raise anti-MOMP antibodies, useful  
 CC in standard immunoassays. Immunization with the vector induces a broad  
 CC spectrum of immune responses, including Th1-like CD4 responses and  
 CC mucosal immunity, providing significant protection against subsequent  
 CC challenge. Sequences AAY56757-71 represent MOMP sequences from a variety  
 CC of serovars of C. trachomatis.

XX SQ Sequence 343 AA;

Query Match 90.1%; Score 82; DB 20; Length 343;  
 Best Local Similarity 100.0%; Pred. No. 1.1e-05;  
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 TGSAAANYTTAVDRPN 17  
 |||||

Db 90 tgsaaanyttavdrpn 105

RESULT 5

AAV5319  
 ID AAY35319 standard; Protein; 391 AA.

XX AC AAY35319;

XX DT 13-SEP-1999 (first entry)

XX Chlamydia pneumoniae transmembrane protein sequence.

XX Respiratory disease; pneumonia; bronchitis; heart disease; sarcoidosis;  
 KW sinusitis; purulent otitis media; erythema nodosum; pharyngitis;  
 KW vaccine; neutralising epitope.

XX Chlamydia pneumoniae.

XX WO9927105-A2.

XX PD 03-JUN-1999.

XX PF 20-NOV-1998; 98WO-IB01890.

XX PR 04-NOV-1998; 98US-0107078.

XX PR 21-NOV-1997; 97FR-0014673.

XX PA (GEST ) GENSET.

XX PI Griffais R;

XX WPI; 1999-357842/30.

XX Genome sequence of Chlamydia pneumoniae

XX Page 1130-1131; Disclosure; 1912pp; English.

XX AAY34584-Y35879 represent the proteins encoded by all the open reading  
 CC frames in the complete genome (see AAX91990) of Chlamydia pneumoniae.  
 CC C. pneumoniae causes respiratory disease such as pneumonia and  
 CC bronchitis and is thought to be a contributing factor in heart  
 CC disease, sarcoidosis, sinusitis, purulent otitis media, erythema  
 CC nodosum or pharyngitis. The polypeptides encoded by the open reading  
 CC frames of the C. pneumoniae genome (see AAY34584-Y35879) can be used in  
 CC immunogenic compositions as vaccines. Vectors containing C. pneumoniae  
 CC nucleotide sequences can also be used as immunogenic compositions,  
 CC especially where the vector directs the expression of a neutralising  
 CC epitope of C. pneumoniae.

XX SQ Sequence 391 AA;

Query Match 90.1%; Score 82; DB 20; Length 391;  
 Best Local Similarity 100.0%; Pred. No. 1.2e-05;  
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 TGSAAANYTTAVDRPN 17  
 |||||

Db 92 tgsaaanyttavdrpn 107

RESULT 6

AAW84468  
 ID AAW84468 standard; peptide; 23 AA.

XX AC AAW84468;

XX DT 23-MAR-1999 (first entry)

XX Peptide CpiAimp derived from a major outer membrane protein.

XX Variable domain; major outer membrane protein; MOMP;

KW Chlamydia; detection; infection; vaccine.  
 XX Synthetic.  
 OS Chlamydia pneumoniae.  
 XX  
 PN WO9857981-A2.  
 XX  
 PD 23-DEC-1998.  
 XX  
 PF 15-JUN-1998; 98WO-IL00277.  
 XX  
 PR 19-JUN-1997; 97IL-0121114.  
 XX  
 PA (SAVY-) SAVYON DIAGNOSTICS LTD.  
 XX  
 PI Ohana B;  
 XX  
 DR WPI; 1999-080945/07.  
 XX  
 PT New peptides derived from Chlamydia pneumoniae MOMP protein - useful  
 to detect C. pneumoniae infection  
 XX  
 PS Claim 2; Page 54; 39pp; English.  
 XX  
 CC The present peptide is derived from the variable domain of the  
 major outer membrane protein (MOMP) of Chlamydia pneumoniae. The  
 peptide is able to react with antibodies formed during C. pneumoniae  
 infection and characterised by having essentially very low  
 cross-reactivity towards antibodies against other Chlamydia species.  
 CC A mixture of such peptides (see also AAW84462-68) is used to detect  
 C. pneumoniae infection, and in the preparation of vaccines.  
 XX  
 SQ Sequence 23 AA;

Query Match 75.8%; Score 69; DB 20; Length 23;  
 Best Local Similarity 100.0%; Pred. No. 9.3e-05;  
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 TGSAAANYTTAVDR 15  
 DB 9 tgsaaanyttavdr 22  
 |||||

RESULT 7  
 AAW98188  
 ID AAW98188 standard; Protein; 389 AA.  
 XX  
 AC AAW98188;  
 XX  
 DT 05-JUL-1999 (first entry);  
 XX  
 DE Chlamydia psittaci major outer membrane protein.  
 XX  
 KW Major outer membrane protein; MOMP; psittacosis; infection;  
 vaccine; genetic immunisation.  
 XX  
 OS Chlamydia psittaci.  
 XX  
 PN WO9910005-A1.  
 XX  
 PD 04-MAR-1999.  
 XX  
 PF 28-AUG-1998; 98WO-US17943.  
 XX  
 PR 28-AUG-1997; 97US-0057147.  
 XX  
 PA (LOU ) UNIV LOUISIANA & AGRIC & MECH COLLEGE.  
 XX  
 PI Baghian A, Chouljenko VN, Kousoulas KG, Tully TN;  
 XX  
 DR WPI; 1999-254214/21.  
 DR N-PSDB; AAX25047.

XX A new vaccine for Chlamydia psittaci infections  
 PT  
 XX Disclosure; Page 60-61; 72pp; English.  
 PS  
 XX  
 CC The present sequence is the major outer membrane protein (MOMP)  
 of Chlamydia psittaci strain B577. A claimed MOMP polypeptide (see  
 CC AAW98184) comprises regions VD3 and VD4 of B577 MOMP, i.e. it lacks  
 CC regions VD1 and VD2. A claimed vaccine composition includes MOMP  
 CC polypeptide lacking VD1 and VD2, optionally fused to a maltose  
 CC binding protein. Also claimed are an isolated nucleic acid  
 CC encoding the polypeptide, a vector, and a method of preventing C.  
 CC psittaci infection by administering the vaccine containing the  
 CC MOMP polypeptide. Vectors encoding MOMP polypeptides lacking  
 CC regions VD1 and VD2 are useful for genetic vaccination. The  
 CC vaccines are used to prevent C. psittaci infection, especially in  
 CC birds.  
 XX  
 SQ Sequence 389 AA;

Query Match 70.3%; Score 64; DB 20; Length 389;  
 Best Local Similarity 75.0%; Pred. No. 0.012;  
 Matches 12; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 2 TGSAAANYTTAVDRPN 17  
 DB 90 tgsaaanyktptdrpn 105  
 ||:||||| |||||

RESULT 8  
 AAW84466  
 ID AAW84466 standard; peptide; 10 AA.  
 XX  
 AC AAW84466;  
 XX  
 DT 23-MAR-1999 (first entry)  
 XX  
 DE Peptide CpVDI derived from a major outer membrane protein.  
 XX  
 KW Variable domain; major outer membrane protein; MOMP;  
 KW Chlamydia; detection; infection; vaccine.  
 XX  
 OS Synthetic.  
 OS Chlamydia pneumoniae.  
 XX  
 PN WO9857981-A2.  
 XX  
 PD 23-DEC-1999  
 XX  
 PF 15-JUN-1998; 98WO-IL00277.  
 XX  
 PR 19-JUN-1997; 97IL-0121114.  
 XX  
 PA (SAVY-) SAVYON DIAGNOSTICS LTD.  
 XX  
 PI Ohana B;  
 XX  
 DR WPI; 1999-080945/07.  
 XX  
 PT New peptides derived from Chlamydia pneumoniae MOMP protein - useful  
 to detect C. pneumoniae infection  
 XX  
 PS Claim 2; Page 53; 39pp; English.  
 XX  
 CC The present peptide is derived from the variable domain of the  
 CC major outer membrane protein (MOMP) of Chlamydia pneumoniae. The  
 CC peptide is able to react with antibodies formed during C. pneumoniae  
 CC infection and characterised by having essentially very low  
 CC cross-reactivity towards antibodies against other Chlamydia species.  
 CC A mixture of such peptides (see also AAW84462-68) is used to detect  
 CC C. pneumoniae infection, and in the preparation of vaccines.  
 XX

SQ Sequence 10 AA;

Query Match 60.4%; Score 55; DB 20; Length 10;  
 Best Local Similarity 100.0%; Pred. No. 0.0082;  
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 8 NYTTAVDRPN 17  
 |||||  
 Db 1 nyttavdrpn 10

RESULT 9

AAW84553  
 ID AAW84553 standard; peptide; 10 AA.

XX AC AAW84553;

XX DT 26-MAR-1999 (first entry)

XX PE Peptide C.pVDI derived from the major outer membrane protein.

XX DE Variable domain; immunodominant; major outer membrane protein; MOMP;  
 KW anti-MOMP antibody; Chlamydia; vaccine; C. trachomatis.

XX OS Chlamydia pneumoniae.

XX PN WO9900414-A1.

XX XX

XX PD 07-JAN-1999.

XX PF 15-JUN-1998; 98WO-IL00276.

XX PR 19-JUN-1997; 97IL-0121115.

XX PA (SAVY-) SAVYON DIAGNOSTICS LTD.

XX PI Ohana B;

XX DR WPI; 1999-095677/08.

XX PT Chlamydia trachomatis specific peptides useful in diagnostic assays  
 PT - derived from major outer membrane protein variable domains and  
 PT useful in mixtures to detect infection with or immunise against all  
 PT serovars

XX PS Example 1; Page 21; 78pp; English.

XX CC The present sequence represents a peptide derived from variable  
 CC domain 1 (VBI) of the Chlamydia pneumoniae major outer membrane  
 CC protein (MOMP). The specification also describes C. trachomatis  
 CC MOMP derived peptides which have specificity only to C. trachomatis  
 CC anti-MOMP antibodies and are non-cross reactive with anti-MOMP  
 CC antibodies of other Chlamydia species. Such peptides are useful to  
 CC detect C. trachomatis infections in humans. Mixtures of MOMP peptide  
 CC mixtures allow detection of and vaccination against all C. trachomatis  
 CC serovars, which is not possible with existing MOMP-derived peptides  
 CC for C. trachomatis-specific detection.

XX SQ Sequence 10 AA;

Query Match 60.4%; Score 55; DB 20; Length 10;  
 Best Local Similarity 100.0%; Pred. No. 0.0082;  
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 8 NYTTAVDRPN 17  
 |||||  
 Db 1 nyttavdrpn 10

RESULT 10

AAW95295

ID AAW95295 standard; Protein; 100 AA.

XX AC AAW95295;

XX DT 15-MAR-1999 (first entry)

XX DE Chlamydial major outer membrane protein (MOMP) PN fragment.

XX KW Chlamydia; cryptic phase; elementary body phase; replicating; prohenicid;  
 KW antiporphyric acid; immune response; infection; diagnostic; assay; MOMP;  
 KW major outer membrane protein; autoimmune; inflammatory; porphyria;  
 KW Epstein Barr virus; antioxidant.

XX OS Chlamydia sp.

XX PN WO9850074-A2.

XX PD 12-NOV-1998.

XX PF 06-MAY-1998; 98WO-US09237.

XX PR 18-FEB-1998; 98US-0025521.

XX PR 06-MAY-1997; 97US-0045689.

XX PR 06-MAY-1997; 97US-0045739.

XX PR 06-MAY-1997; 97US-0045779.

XX PR 06-MAY-1997; 97US-0045780.

XX PR 06-MAY-1997; 97US-0045784.

XX PR 06-MAY-1997; 97US-0045787.

XX PR 14-AUG-1997; 97US-0911593.

XX PR 18-FEB-1998; 98US-0025174.

XX PR 18-FEB-1998; 98US-0025176.

XX PA (UYVA-) UNIV VANDERBILT.

XX PI Mitchell WM, Stratton CW;

XX DR WPI; 1999-059653/05.

XX CC Composition with two agents effective against different stages of  
 PT chlamydial life cycle - comprises agent targetted against cryptic  
 PT phase, against elementary body phase, against replicating phase,  
 PT prohenicid and antiporphyric

XX PS Disclosure; Fig 1A; 138pp; English.

XX CC The invention relates to the diagnosis and management of infections by  
 CC Chlamydia species. The invention provides a composition that comprises  
 CC at least two agents, where each of the agents is effective against a  
 CC different phase of the chlamydial life cycle. The agents are selected  
 CC from: (a) agents targetted against cryptic phase of chlamydial life  
 CC cycle; (b) agents targetted against elementary body phase of chlamydial  
 CC life cycle; (c) agents targetted against replicating phase of chlamydial  
 CC life cycle; (d) prohenicid, and (e) antiporphyric acid. The composition  
 CC is used to elicit a protective immune response to Chlamydia infection in  
 CC an animal or human and is applied until the animal or human tests  
 CC negative for Chlamydia infection. It is also used to treat biological  
 CC material infected with Chlamydia. Diagnostic kits for antibody assays  
 CC against recombinant major outer membrane protein (MOMP), and for DNA  
 CC amplification assays for chlamydial genes, are used to diagnose disease,  
 CC e.g. autoimmune disease, an inflammatory disease or a disease that  
 CC occurs in an immuno-compromised individual, associated with Chlamydia  
 CC infection. The kits are used to detect chlamydial elementary bodies in a  
 CC sample. They are also used to monitor and/or modify the course of therapy  
 CC in a patient. The treatment reduces the acellular load of infectious  
 CC Epstein Barr virus. The method is also used to treat porphyria, by  
 CC reducing the number of elementary bodies and applying a drug, e.g.  
 CC cimetidine, and antioxidants, to reduce the adverse effects associated  
 CC with porphyria. Sequences AAW95272 to AAW95319 represent peptide  
 CC fragments of various Chlamydial MOMPs.

XX SQ Sequence 100 AA;

Query Match 53.8%; Score 49; DB 20; Length 100;  
 Best Local Similarity 100.0%; Pred. No. 0.9;  
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 9 YTTAVDRPN 17  
 Db 1 yttavdrpn 9  
 |||||

RESULT 11  
 AAM25606  
 ID AAM25606 standard; Protein; 1241 AA.  
 XX AC AAM25606;  
 XX 16-OCT-2001 (first entry)  
 XX Human protein sequence SEQ ID NO:1121.  
 XX  
 KW Human; cancer; ulcer; HIV infection; human immunodeficiency virus;  
 KW antiinflammatory; antirheumatic; antiarthritic; immunosuppressive;  
 KW antibacterial; endocrine; cardiant; central nervous system; virucide;  
 KW anti-HIV; fungicide; antimutagen; cardiovascular; antianaemic; anaemia;  
 KW antiaggregant; haemostatic; vulnery; antiulcer; osteopathic; eczema;  
 KW dermatological; antiallergic; antiasthmatic; antidiabetic; cytostatic;  
 KW neuroprotective; antidepressant; nootropic; antiparkinsonian; infection;  
 KW immunostimulant; gene therapy; antisenese therapy; vaccine; inflammation;  
 KW antianaphylactic; rheumatoid arthritis; septic shock; pancreatitis;  
 KW cardiac dysfunction; neuropathology; cardiac anaphylaxis; autoimmunity;  
 KW genetic disease; haematopoietic disorder; platelet disorder; asthma;  
 KW thrombocytopaenia; osteoporosis; severe combined immunodeficiency;  
 KW allergic rhinitis; diabetes; multiple sclerosis; depression;  
 KW Alzheimer's disease; Parkinson's disease; neurodegenerative disorder;  
 KW neurological disorder.  
 XX  
 OS Homo sapiens.  
 XX WO200153455-A2.  
 XX 26-JUL-2001.  
 XX  
 XX 22-DEC-2000; 2000WO-US35017.  
 XX  
 XX 23-DEC-1999; 99US-0471275.  
 XX 21-JAN-2000; 2000US-0488725.  
 XX 25-APR-2000; 2000US-0552317.  
 XX  
 XX (HYSE-) HYSEQ INC.  
 XX  
 XX Tang YT, Liu C, Drmanac RT;  
 XX WPI; 2001-457603/49.  
 XX N-PSDB; AAH99547.  
 XX  
 PT Isolated human polynucleotides encoding polypeptides, useful for the  
 PT treatment and diagnosis of e.g. cancer, ulcers and HIV infection.  
 XX  
 PS Claim 20; Page 232; 1217pp; English.  
 XX  
 XX AAH99166 to AAH99904 encode the human proteins given in AAM25225 to  
 XX AAM25963. The proteins can have activities based on the tissues and  
 XX cells they are expressed in, such as: antiinflammatory; antirheumatic;  
 XX antiarthritic; immunosuppressive; antibacterial; endocrine; cardiant;  
 XX central nervous system; virucide; anti-HIV; fungicide; antimutagen;  
 XX cardiovascular; antianaemic; antiaggregant; haemostatic; vulnery;  
 XX antiulcer; osteopathic; dermatological; antiallergic; antidiabetic;  
 XX antidiabetic; cytostatic; neuroprotective; antidepressant; nootropic;  
 XX antiparkinsonian; and immunostimulant. The proteins and polynucleotides  
 XX encoding them can be used in gene therapy, antisense therapy and vaccine  
 XX production. The proteins and polynucleotides are useful for screening for  
 XX agonists or antagonists of a protein and for the treatment and diagnosis  
 XX of disorders associated with the activity of a protein e.g. inflammation,  
 XX rheumatoid arthritis, septic shock, pancreatitis, cardiac dysfunction,

CC neuropathology, cardiac anaphylaxis, viral, bacterial, HIV and fungal  
 CC infections, autoimmunity, genetic diseases, haematopoietic disorders,  
 CC anaemia, platelet disorders, thrombocytopaenia, wounds, burns, ulcers,  
 CC osteoporosis, severe combined immunodeficiency, eczema, allergic  
 CC rhinitis, asthma, diabetes, cancer, multiple sclerosis, depression,  
 CC Alzheimer's disease, Parkinson's disease, neurodegenerative and  
 CC neurological disorders.  
 XX  
 SQ Sequence 1241 AA;  
 Query Match 52.7%; Score 48; DB 22; Length 1241;  
 Best Local Similarity 56.2%; Pred. No. 18;  
 Matches 9; Conservative 2; Mismatches 5; Indels 0; Gaps 0;

QY 1 CTGSAANYYTTAVDRP 16  
 Db 619 ctgssacayalatdp 634  
 |||||

RESULT 12  
 AAB65630  
 ID AAB65630 standard; Protein; 1330 AA.  
 XX AC AAB65630;  
 XX 27-MAR-2001 (first entry)  
 XX  
 XX Novel protein kinase, SEQ ID NO: 156.  
 XX Human; mouse; protein kinase; antiarthritic; antisclerotic; osteopathic;  
 KW immunosuppressive; cardiant; renal; antiinflammatory; antiasthmatic;  
 KW dermatological; antidiabetic; antiinfertility; gene therapy; vaccine;  
 KW immune disorder; cardiovascular disease; neurodegenerative disease;  
 KW cancer; autoimmune disorder; stroke; inflammatory bowel disease;  
 KW inflammatory pelvic disease; multiple sclerosis; psoriasis.  
 XX  
 OS Homo sapiens.  
 XX WO200073469-A2.  
 XX 07-DEC-2000.  
 XX  
 XX 26-MAY-2000; 2000WO-US14842.  
 XX  
 XX 28-MAY-1999; 99US-0136503.  
 XX  
 XX (SUGE-) SUGEN INC.  
 XX  
 XX Plowman GD, Martinez R, Whyte D, Sudersanam S;  
 XX WPI; 2001-032161/04.  
 XX N-PSDB; AAF44656.  
 XX  
 PT Nucleic acids encoding kinase polypeptides, useful for diagnosing and  
 PT treating immune-related diseases and disorders, cardiovascular disease,  
 PT neurodegenerative diseases and/or cancers.  
 XX  
 PS Claim 10; Fig 1; 310pp; English.  
 XX  
 XX The present sequence is a novel protein kinase. The novel protein kinases  
 CC and the nucleic acids that encode them may be used in the treatment and  
 CC diagnosis of diseases associated with inappropriate kinase expression  
 CC such as immune-related diseases and disorders, cardiovascular disease,  
 CC neurodegenerative diseases and/or cancers. The nucleic acids and  
 CC complementary sequences may also be used as DNA probes in diagnostic  
 CC assays. The kinase polypeptides may be used as antigens in the production  
 CC of antibodies of kinase expression and activity. Anti-kinase antibodies  
 CC and kinase antagonists may also be used to down regulate kinase  
 CC expression and activity. Diseases related to kinase expression and  
 CC activity include rheumatoid arthritis, atherosclerosis, autoimmune  
 CC disorders, complications of organ transplantation, myocardial infarction,  
 CC immune disorders, cardiomyopathies, strokes, renal failure,

CC oxidative-stress related disorders, chronic inflammatory bowel disease,  
 CC chronic inflammatory pelvic disease, multiple sclerosis, asthma,  
 CC osteoarthritis, psoriasis, rhinitis, autoimmunity, diabetes, cancers and  
 CC reproductive disorders.

XX Sequence 1330 AA;

Query Match 52.7%; Score 48; DB 22; Length 1330;  
 Best Local Similarity 56.2%; Pred. No. 20;  
 Matches 9; Conservative 2; Mismatches 5; Indels 0; Gaps 0;

QY 1 CTGSAANTTAVDRP 16  
 ||||:| | | |  
 Db 708 ctgssacvalatdlp 723

# RESULT 13

AA56769  
 ID AAY56769 standard; Protein; 343 AA.

XX AC AAY56769;

XX DT 22-FEB-2000 (first entry)

XX DE C. trachomatis serovar GPIC MOMP sequence.

XX KW Major outer membrane protein; MOMP; Chlamydia; vaccine; immune response;  
 XX KX cellular response; immunogen; Th1-like CD4 response; mucosal immunity.

XX OS Chlamydia trachomatis.

XX PN W09951745-A2.

XX PD 14-OCT-1999.

XX PF 07-APR-1999; 99WO-CA00292.

XX PR 07-APR-1998; 98US-0055765.

XX PA (UYMA-) UNIV MANITOBA.

XX PI Bruham RC;

XX DR WPI; 1999-620205/53.

XX PT Non-replicating vector encoding fragments of the outer membrane protein  
 XX of Chlamydia, useful in vaccines and as immunogen

XX PS Disclosure; Fig 10 A-F; 52pp; English.

XX CC The invention provides a non-replicating vector that comprises, linked  
 CC to a promoter, a nucleotide sequence that encodes a region containing at  
 CC least one of the conserved domains 2, 3 and 5 of a major outer membrane  
 CC protein (MOMP) of a Chlamydia strain. The vector is used: (a) in  
 CC vaccines to generate a protective immune response (mainly cellular)  
 CC against MOMP, and (b) as immunogens to raise anti-MOMP antibodies, useful  
 CC in standard immunoassays. Immunization with the vector induces a broad  
 CC spectrum of immune responses, including Th1-like CD4 responses and  
 CC mucosal immunity, providing significant protection against subsequent  
 CC challenge. Sequences AAY56757-71 represent MOMP sequences from a variety  
 CC of serovars of C. trachomatis.

XX Sequence 343 AA;

Query Match 51.6%; Score 47; DB 20; Length 343;  
 Best Local Similarity 56.2%; Pred. No. 7;  
 Matches 9; Conservative 3; Mismatches 4; Indels 0; Gaps 0;

QY 2 TGSAAANTTAVDRPN 17  
 ||||:| | | |  
 Db 89 tgnaaadftvdrnn 104

## RESULT 14

AAW95323

ID AAW95323 standard; Protein; 17 AA.

XX AC AAW95323;

XX DT 15-MAR-1999 (first entry)

XX DE Costant and variable domain sequence of C. psittaci CP592-106.

XX KW Chlamydia; cryptic phase; elementary body phase; replicating; probenicid;  
 XX KX antiporphyrin acid; immune response; infection; diagnostic; assay; MOMP;  
 XX KW major outer membrane protein; autoimmune; inflammatory; porphyria;  
 XX Ebstain Barr virus; antioxidant.

XX OS Chlamydia psittaci.

XX PN W09850074-A2.

XX PD 12-NOV-1998.

XX PF 06-MAY-1998; 98WO-US09237.

XX PR 18-FEB-1998; 98US-0025521.

XX PR 06-MAY-1997; 97US-0045689.

XX PR 06-MAY-1997; 97US-0045739.

XX PR 06-MAY-1997; 97US-0045779.

XX PR 06-MAY-1997; 97US-0045780.

XX PR 06-MAY-1997; 97US-0045784.

XX PR 14-AUG-1997; 97US-0911593.

XX PR 18-FEB-1998; 98US-0025174.

XX PR 18-FEB-1998; 98US-0025176.

XX PA (UYMA-) UNIV VANDERBILT.

XX PI Mitchell W. Stratton CW;

XX DR WPI; 1999-059653/05.

XX CC Composition with two agents effective against different stages of  
 XX Chlamydia life cycle - comprises agent targeted against cryptic  
 XX phase, against elementary body phase, against replicating phase,  
 XX probenicid and antiporphyrin

XX PS Claim 4; Fig 3; 138pp; English.

XX CC The invention relates to the diagnosis and management of infections by  
 XX Chlamydia species. The invention provides a composition that comprises  
 XX at least two agents, where each of the agents is effective against a  
 XX different phase of the chlamydial life cycle. The agents are selected  
 XX from: (a) agents targeted against cryptic phase of chlamydial life  
 XX cycle; (b) agents targeted against elementary body phase of chlamydial  
 XX life cycle; (c) agents targeted against replicating phase of chlamydial  
 XX life cycle; (d) probenicid, and (e) antiporphyrin acid. The composition  
 XX is used to elicit a protective immune response to Chlamydia infection in  
 XX an animal or human and is applied until the animal or human tests  
 XX negative for Chlamydia infection. It is also used to treat biological  
 XX material infected with Chlamydia. Diagnostic kits for antibody assays  
 XX against recombinant major outer membrane protein (MOMP), and for DNA  
 XX amplification assays for chlamydial genes, are used to diagnose disease,  
 XX e.g. autoimmune disease, an inflammatory disease or a disease that  
 XX occurs in an immuno-compromised individual, associated with Chlamydia  
 XX infection. The kits are used to detect chlamydial elementary bodies in a  
 XX sample. They are also used to monitor and/or modify the course of therapy  
 XX in a patient. The treatment reduces the cellular load of infectious  
 XX Ebstain Barr virus. The method is also used to treat porphyria, by  
 XX reducing the number of elementary bodies and applying a drug, e.g.  
 XX cimetidine, and antioxidants, to reduce the adverse effects associated  
 XX with porphyria. Sequences AAW95320 to AAW95323 represent constant and  
 XX variable domain sequences of various Chlamydia species.

```
XX SQ Sequence 17 AA;
Query Match 47.38; Score 43; DB 20; Length 17;
Best Local Similarity 47.18; Pred. No. 1.4;
Matches 8; Conservative 1; Mismatches 8; Indels 0; Gaps 0;
QY 1 CTGSAANYTTAVDRPN 17
Db 1 casgtasnttvaadrsn 17
RESULT: 15
AAG06126
ID AAG06126 standard; Protein; 250 AA.
XX AC AAG06126;
XX DT 17 OCT-2000 (first entry)
XX DE Arabidopsis thaliana protein fragment SEQ ID NO: 2786.
XX KW Protein identification; signal transduction pathway; metabolic pathway;
KW hybridisation assay; genetic mapping; gene expression control; promoter;
KW termination sequence.
XX OS Arabidopsis thaliana.
XX PN EPI033405-A2.
XX PD 06 SEP-2000.
XX PF 25 FEB-2000; 2000EP-0301439.
XX PR 25 FEB-1999; 99US-0121825.
PR 05 MAR-1999; 99US-0123180.
PR 09 MAR-1999; 99US-0123548.
PR 23 MAR-1999; 99US-0125788.
PR 25 MAR-1999; 99US-0126564.
PR 29 MAR-1999; 99US-0126785.
PR 01 APR-1999; 99US-0127462.
PR 06 APR-1999; 99US-0128234.
PR 08 APR-1999; 99US-0128714.
PR 16 APR-1999; 99US-0129845.
PR 19 APR-1999; 99US-0130077.
PR 21 APR-1999; 99US-0130449.
PR 23 APR-1999; 99US-0130510.
PR 28 APR-1999; 99US-0130891.
PR 30 APR-1999; 99US-0131449.
PR 30 APR-1999; 99US-0132048.
PR 04 MAY-1999; 99US-0132407.
PR 05 MAY-1999; 99US-0132484.
PR 06 MAY-1999; 99US-0132485.
PR 06 MAY-1999; 99US-0132486.
PR 07 MAY-1999; 99US-0132487.
PR 11 MAY-1999; 99US-0132863.
PR 14 MAY-1999; 99US-0134256.
PR 14 MAY-1999; 99US-0134218.
PR 14 MAY-1999; 99US-0134219.
PR 14 MAY-1999; 99US-0134221.
PR 14 MAY-1999; 99US-0134370.
PR 18 MAY-1999; 99US-0134768.
PR 19 MAY-1999; 99US-0134941.
PR 20 MAY-1999; 99US-0135124.
PR 21 MAY-1999; 99US-0135353.
PR 24 MAY-1999; 99US-0135629.
PR 25 MAY-1999; 99US-0136021.
PR 27 MAY-1999; 99US-0136392.
PR 28 MAY-1999; 99US-0136782.
PR 01 JUN-1999; 99US-0137222.
PR 03 JUN-1999; 99US-0137528.
PR 04 JUN-1999; 99US-0137528.
PR 07 JUN-1999; 99US-0137724.
PR 08 JUN-1999; 99US-0138094.
PR 10 JUN-1999; 99US-0138540.
PR 10 JUN-1999; 99US-0138847.
PR 14 JUN-1999; 99US-0139119.
PR 16 JUN-1999; 99US-0139452.
PR 16 JUN-1999; 99US-0139453.
PR 17 JUN-1999; 99US-0139492.
PR 18 JUN-1999; 99US-0139454.
PR 18 JUN-1999; 99US-0139455.
PR 18 JUN-1999; 99US-0139456.
PR 18 JUN-1999; 99US-0139457.
PR 18 JUN-1999; 99US-0139458.
PR 18 JUN-1999; 99US-0139459.
PR 18 JUN-1999; 99US-0139460.
PR 18 JUN-1999; 99US-0139461.
PR 18 JUN-1999; 99US-0139462.
PR 18 JUN-1999; 99US-0139463.
PR 18 JUN-1999; 99US-0139750.
PR 18 JUN-1999; 99US-0139763.
PR 21 JUN-1999; 99US-0139817.
PR 22 JUN-1999; 99US-0139899.
PR 23 JUN-1999; 99US-0140353.
PR 23 JUN-1999; 99US-0140354.
PR 24 JUN-1999; 99US-0140695.
PR 28 JUN-1999; 99US-0140823.
PR 29 JUN-1999; 99US-0140991.
PR 30 JUN-1999; 99US-0141287.
PR 01 JUL-1999; 99US-0141842.
PR 02 JUL-1999; 99US-0142154.
PR 06 JUL-1999; 99US-0142055.
PR 06 JUL-1999; 99US-0142390.
PR 08 JUL-1999; 99US-0142803.
PR 09 JUL-1999; 99US-0142920.
PR 12 JUL-1999; 99US-0142977.
PR 13 JUL-1999; 99US-0143542.
PR 14 JUL-1999; 99US-0143624.
PR 15 JUL-1999; 99US-0144005.
PR 16 JUL-1999; 99US-0144085.
PR 16 JUL-1999; 99US-0144086.
PR 19 JUL-1999; 99US-0144325.
PR 19 JUL-1999; 99US-0144331.
PR 19 JUL-1999; 99US-0144332.
PR 19 JUL-1999; 99US-0144333.
PR 19 JUL-1999; 99US-0144334.
PR 19 JUL-1999; 99US-0144335.
PR 20 JUL-1999; 99US-0144352.
PR 20 JUL-1999; 99US-0144632.
PR 20 JUL-1999; 99US-0144884.
PR 21 JUL-1999; 99US-0144814.
PR 21 JUL-1999; 99US-0145086.
PR 21 JUL-1999; 99US-0145088.
PR 22 JUL-1999; 99US-0145085.
PR 22 JUL-1999; 99US-0145087.
PR 22 JUL-1999; 99US-0145089.
PR 22 JUL-1999; 99US-0145192.
PR 23 JUL-1999; 99US-0145145.
PR 23 JUL-1999; 99US-0145218.
PR 23 JUL-1999; 99US-0145224.
PR 26 JUL-1999; 99US-0145276.
PR 27 JUL-1999; 99US-0145913.
PR 27 JUL-1999; 99US-0145918.
PR 27 JUL-1999; 99US-0145919.
PR 28 JUL-1999; 99US-0145951.
PR 02 AUG-1999; 99US-0146386.
PR 02 AUG-1999; 99US-0146388.
PR 02 AUG-1999; 99US-0146389.
PR 03 AUG-1999; 99US-0147038.
PR 04 AUG-1999; 99US-0147204.
PR 04 AUG-1999; 99US-0147302.
PR 05 AUG-1999; 99US-0147192.
PR 05 AUG-1999; 99US-0147260.
PR 06 AUG-1999; 99US-0147303.
```



PR 06-AUG-1999; 99US-0147416.  
PR 09-AUG-1999; 99US-0147493.  
PR 09-AUG-1999; 99US-0147935.  
PR 10-AUG-1999; 99US-0148171.  
PR 11-AUG-1999; 99US-0148319.  
PR 12-AUG-1999; 99US-0148341.  
PR 13-AUG-1999; 99US-0148565.  
PR 13-AUG-1999; 99US-0148684.  
PR 16-AUG-1999; 99US-0149368.  
PR 17-AUG-1999; 99US-0149175.  
PR 18-AUG-1999; 99US-0149426.  
PR 20-AUG-1999; 99US-0149722.  
PR 20-AUG-1999; 99US-0149723.  
PR 20-AUG-1999; 99US-0149929.  
PR 23-AUG-1999; 99US-0149902.  
PR 23-AUG-1999; 99US-0149930.  
PR 25-AUG-1999; 99US-0150566.  
PR 26-AUG-1999; 99US-0150884.  
PR 27-AUG-1999; 99US-0151065.  
PR 27-AUG-1999; 99US-0151066.  
PR 27-AUG-1999; 99US-0151080.  
PR 30-AUG-1999; 99US-0151303.  
PR 31-AUG-1999; 99US-0151438.  
PR 01-SEP-1999; 99US-0151930.  
PR 07-SEP-1999; 99US-0152363.  
PR 10-SEP-1999; 99US-0153070.  
PR 13-SEP-1999; 99US-0153758.  
PR 15-SEP-1999; 99US-0154018.  
PR 16-SEP-1999; 99US-0154039.  
PR 20-SEP-1999; 99US-0154779.  
PR 22-SEP-1999; 99US-0155139.  
PR 23-SEP-1999; 99US-0155486.  
PR 24-SEP-1999; 99US-0155659.  
PR 28-SEP-1999; 99US-0156458.  
PR 29-SEP-1999; 99US-0156596.  
PR 04-OCT-1999; 99US-0157117.  
PR 05-OCT-1999; 99US-0157753.  
PR 06-OCT-1999; 99US-0157865.  
PR 07-OCT-1999; 99US-0158029.  
PR 08-OCT-1999; 99US-0158232.  
PR 12-OCT-1999; 99US-0158369.  
PR 13-OCT-1999; 99US-0159293.  
PR 13-OCT-1999; 99US-0159294.  
PR 13-OCT-1999; 99US-0159295.  
PR 14-OCT-1999; 99US-0159329.  
PR 14-OCT-1999; 99US-0159330.  
PR 14-OCT-1999; 99US-0159331.  
PR 14-OCT-1999; 99US-0159637.  
PR 14-OCT-1999; 99US-0159638.  
PR 18-OCT-1999; 99US-0159584.  
PR 21-OCT-1999; 99US-0160741.  
PR 21-OCT-1999; 99US-0160767.  
PR 21-OCT-1999; 99US-0160768.  
PR 21-OCT-1999; 99US-0160770.  
PR 21-OCT-1999; 99US-0160814.  
PR 21-OCT-1999; 99US-0160815.  
PR 22-OCT-1999; 99US-0160980.  
PR 22-OCT-1999; 99US-0160981.  
PR 22-OCT-1999; 99US-0160989.  
PR 25-OCT-1999; 99US-0161404.  
PR 25-OCT-1999; 99US-0161405.  
PR 25-OCT-1999; 99US-0161406.  
PR 26-OCT-1999; 99US-0161359.  
PR 26-OCT-1999; 99US-0161360.  
PR 26-OCT-1999; 99US-0161361.  
PR 28-OCT-1999; 99US-0161920.  
PR 28-OCT-1999; 99US-0161992.  
PR 28-OCT-1999; 99US-0161993.  
PR 29-OCT-1999; 99US-0162142.

Query Match 47.3%; Score 43; DB 21; Length 250;  
Best Local Similarity 66.7%; Pred. No. 23;  
Matches 8; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Oy 4 SAAANYTTAVDR 15  
| | | | | | | | | |  
Db 47 sralnystaidr 58

Search completed: March 26, 2002, 13:38:45  
Job time: 139 sec



GenCore version 4.5  
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: March 26, 2002, 13:36:26 : Search time 37.72 Seconds  
(without alignments)  
10.142 Million cell updates/sec

Title: US-09-709-201-93

Perfect score: 91  
Sequence: 1 CTGSAANYTTAVDRPN 17

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 212252 seqs, 22503292 residues

Total number of hits satisfying chosen parameters: 212252

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Issued\_Patents\_AA.\*

- 1: /cgn2\_6/ptodata/2/iaa/5A-COMB.pep.\*
- 2: /cgn2\_6/ptodata/2/iaa/5B-COMB.pep.\*
- 3: /cgn2\_6/ptodata/2/iaa/6A-COMB.pep.\*
- 4: /cgn2\_6/ptodata/2/iaa/6B-COMB.pep.\*
- 5: /cgn2\_6/ptodata/2/iaa/PCTUS-COMB.pep.\*
- 6: /cgn2\_6/ptodata/2/iaa/backfiles1.pep.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	41	45.1	345	3	US-09-120-365-73
2	41	45.1	345	4	US-09-515-039-73
3	41	45.1	345	4	US-08-827-171B-7
4	41	45.1	468	2	US-08-390-000A-7
5	41	45.1	477	1	US-08-444-734A-4
6	41	45.1	477	1	US-08-087-772A-16
7	41	45.1	2813	3	US-08-896-449A-2
8	41	45.1	2813	3	US-09-132-652-2
9	41	45.1	3969	4	US-08-061-376-5
10	40	44.0	472	1	US-08-194-338-6
11	38	41.8	459	2	US-08-870-518-4
12	38	41.8	918	4	US-09-041-886-11
13	37	40.7	505	4	US-09-382-256-8
14	37	40.7	505	4	US-09-395-115-8
15	37	40.7	997	1	US-08-324-977-50
16	37	40.7	997	2	US-08-384-616-50
17	37	40.7	997	2	US-08-904-686A-50
18	37	40.7	997	4	US-09-315-850-50
19	37	40.7	2620	1	US-08-324-977-32
20	37	40.7	2620	2	US-08-384-616-32
21	37	40.7	2620	2	US-08-904-686A-32
22	37	40.7	2620	4	US-09-315-850-32
23	37	40.7	2621	1	US-08-324-977-36
24	37	40.7	2621	2	US-08-384-616-36
25	37	40.7	2621	2	US-08-904-686A-36
26	37	40.7	2621	4	US-09-315-850-36
27	37	40.7	3010	1	US-08-324-977-2

28	37	40.7	3010	1	US-08-324-977-14	Sequence 14, Appl
29	37	40.7	3010	2	US-08-384-616-2	Sequence 2, Appl
30	37	40.7	3010	2	US-08-384-616-14	Sequence 14, Appl
31	37	40.7	3010	2	US-08-904-686A-2	Sequence 2, Appl
32	37	40.7	3010	2	US-08-904-686A-14	Sequence 14, Appl
33	37	40.7	3010	4	US-09-014-416-3	Sequence 3, Appl
34	37	40.7	3010	4	US-09-315-850-2	Sequence 2, Appl
35	37	40.7	3010	4	US-09-315-850-14	Sequence 14, Appl
36	36	39.6	120	1	US-08-539-304A-6	Sequence 6, Appl
37	36	39.6	304	4	US-09-088-651-2	Sequence 2, Appl
38	36	39.6	329	2	US-08-781-802-8	Sequence 8, Appl
39	36	39.6	329	4	US-08-694-078-8	Sequence 8, Appl
40	36	39.6	329	4	US-09-058-260-8	Sequence 8, Appl
41	36	39.6	366	3	US-08-945-056-6	Sequence 6, Appl
42	36	39.6	366	3	US-08-945-056-8	Sequence 8, Appl
43	36	39.6	374	2	US-08-915-107-2	Sequence 2, Appl
44	36	39.6	374	2	US-08-915-107-4	Sequence 4, Appl
45	36	39.6	374	4	US-09-273-C13-4	Sequence 4, Appl

#### ALIGNMENTS

RESULT 1  
US-09-120-365-73  
; Sequence 73, Application US/09120365  
; Patent No. 6103514  
; GENERAL INFORMATION:  
; APPLICANT: Natori, Shunji  
; TITLE OF INVENTION: NEW PROTEASE  
; FILE REFERENCE: 32290-144749  
; CURRENT APPLICATION NUMBER: US/09/120,365;  
; EARLIER FILING DATE: 1998-07-22  
; EARLIER APPLICATION NUMBER: JP 9-333 474  
; EARLIER FILING DATE: 1997-11-18  
; NUMBER OF SEQ ID NOS: 101  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 73  
; LENGTH: 345  
; TYPE: PRT  
; ORGANISM: Papain  
US-09-120-365-73

Query Match 45.1%; Score 41; DB 3; Length 345;  
Best Local Similarity 80.0%; Pred. No. 31;  
Matches 8; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2 TGSAAANYTT 11  
||| | |||  
Db 109 TGSIAAGNYTT 118

RESULT 2  
US-09-515-039-73  
; Sequence 73, Application US/09515039  
; Patent No. 6214599  
; GENERAL INFORMATION:  
; APPLICANT: Natori, Shunji  
; TITLE OF INVENTION: NEW PROTEASE  
; FILE REFERENCE: 32290-144749  
; CURRENT APPLICATION NUMBER: US/09/515,039  
; EARLIER FILING DATE: 2000-03-06  
; EARLIER APPLICATION NUMBER: JP 9-333 474  
; EARLIER FILING DATE: 1997-11-18  
; NUMBER OF SEQ ID NOS: 101  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 73  
; LENGTH: 345  
; TYPE: PRT  
; ORGANISM: Papain  
US-09-515-039-73

Tue Mar 26 15:55:37 2002

us-09-709-201-93.rai

Query Match 45.1%; Score 41; DB 4; Length 345;  
Best Local Similarity 80.0%; Pred. No. 31;  
Matches 8; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 2 TGSAAANYTT 11  
Db 109 TGSAGNYTT 118

RESULT 3  
US-08-827-171B-7  
Sequence 7, Application US/08827171B  
Patent No. 6254869  
GENERAL INFORMATION:  
APPLICANT: CAROLYN PETERSEN  
TITLE OF INVENTION: JIN-XING HUANG  
TITLE OF INVENTION: CRYPTOPOIN VACCINES, ANTIBODIES, PROTEINS,  
TITLE OF INVENTION: PEPTIDES, DNA AND RNAs FOR PROPHYLAXIS,  
TITLE OF INVENTION: TREATMENT, DIAGNOSIS AND  
TITLE OF INVENTION: DETECTION OF  
TITLE OF INVENTION: CRYPTOSPORIDIUM PARVUM  
NUMBER OF SEQUENCES: 16  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: PETERS, VERNY, JONES & BIK A  
STREET: 385 Sherman Avenue, Suite 6  
CITY: Palo Alto  
STATE: California  
COUNTRY: United States of America  
ZIP: 94306-1840

COMPUTER READABLE FORM:  
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Kb storage  
COMPUTER: PC  
OPERATING SYSTEM: WINDOWS  
SOFTWARE: Wordperfect 6.0a WINDOWS  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/827,171B  
FILING DATE:  
CLASSIFICATION: 536  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 60/014,233  
FILING DATE: March 27, 1996  
ATTORNEY/AGENT INFORMATION:  
NAME: Hana VERNY  
REGISTRATION NUMBER: 30,518  
REFERENCE/DOCKET NUMBER: (HV)  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (415) 324-1677  
TELEFAX: (415) 324-1678

INFORMATION FOR SEQ ID NO: 7:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 345 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
ORIGINAL SOURCE:  
ORGANISM: Carica

US-08-827-171B-7

Query Match 45.1%; Score 41; DB 4; Length 345;  
Best Local Similarity 80.0%; Pred. No. 31;  
Matches 8; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 2 TGSAAANYTT 11  
Db 109 TGSAGNYTT 118

RESULT 4  
US-08-390-000A-7  
Sequence 7, Application US/08390000A

Patent No. 5985583  
GENERAL INFORMATION:  
APPLICANT: Sealton, Stuart C.  
TITLE OF INVENTION: Cloning and Expression of  
TITLE OF INVENTION: Gonadotropin-Releasing Hormone Receptor  
NUMBER OF SEQUENCES: 8  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Pennie & Edmonds LLP  
STREET: 1155 Avenue of the Americas  
CITY: New York  
STATE: New York  
COUNTRY: U.S.A.  
ZIP: 10036-2711  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/390,000A  
FILING DATE: 17-FEB-1995  
CLASSIFICATION: 435  
ATTORNEY/AGENT INFORMATION:  
NAME: Mistrock, S. Leslie  
REGISTRATION NUMBER: 18,872  
REFERENCE/DOCKET NUMBER: 6923-052  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 212 790-9090  
TELEFAX: 212 869-8864/9741  
TELEX: 66141 PENNIE  
INFORMATION FOR SEQ ID NO: 7:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 468 amino acids  
TYPE: amino acid  
TOPOLOGY: unknown  
MOLECULE TYPE: protein  
US-08-390-000A-7

Query Match 45.1%; Score 41; DB 2; Length 468;  
Best Local Similarity 43.8%; Pred. No. 43;  
Matches 7; Conservative 4; Mismatches 5; Indels 0; Gaps 0;

Oy 1 CTGSAANYTTAVDRP 16  
Db 442 CNGGAADSDSSLDPE 457

RESULT 5  
US-08-444-734A-4  
Sequence 4, Application US/08444734A  
Patent No. 5610282  
GENERAL INFORMATION:  
APPLICANT: Sibley, David R.  
APPLICANT: Monsma, Frederick J.  
APPLICANT: Mahan, Lawrence C.  
APPLICANT: McVittie, Loris D.  
TITLE OF INVENTION: cDNA encoding the rat D1 dopamine  
TITLE OF INVENTION: receptor linked to adenylyl cyclase activation and  
TITLE OF INVENTION: expression of the receptor protein in plasmid-transfected  
TITLE OF INVENTION: cell lines  
NUMBER OF SEQUENCES: 13  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Knobbe, Martens, Olson and Bear  
STREET: 620 Newport Center Drive, Sixteenth Floor  
CITY: Newport Beach  
STATE: CA  
COUNTRY: USA  
ZIP: 92660

COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: PatentIn Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/444,734A  
FILING DATE:  
CLASSIFICATION: 530  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/029,917  
FILING DATE: 03-MAR-1993  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/548,714  
FILING DATE: 06-JUL-1990  
ATTORNEY/AGENT INFORMATION:  
NAME: Altman, Daniel E.  
REGISTRATION NUMBER: 34,115  
REFERENCE/DOCKET NUMBER: NIH065.001FW1  
TELEPHONE: (714) 760-0404  
TELEFAX: (714) 760-9502  
INFORMATION FOR SEQ ID NO: 4:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 477 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
HYPOTHETICAL: NO  
ANTI-SENSE: NO  
FRAGMENT TYPE: internal  
US-08-444-734A-4

Query Match 45.1%; Score 41; DB 1; Length 477;  
Best Local Similarity 43.8%; Pred. No. 44;  
Matches 7; Conservative 4; Mismatches 5; Indels 0; Gaps 0;

QY 1 CTGSAANYTTAVDRP 16  
| | | | | : : : |  
Db 451 CNGGAAADSSSLDEP 466

RESULT 6  
US-08-087-772A-16  
Sequence 16, Application US/08087772A  
Patent No. 5691155  
GENERAL INFORMATION:  
APPLICANT: Nahmias, Clara L.  
APPLICANT: Emorine, Jean L.  
APPLICANT: Strosberg, Donny A.  
TITLE OF INVENTION: Nucleotide Sequences Encoding the Murine  
TITLE OF INVENTION: Beta3-Adrenergic Receptor and Their Applications  
NUMBER OF SEQUENCES: 17  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Bell, Seltzer, Park & Gibson  
STREET: Post Office Drawer 34009  
CITY: Charlotte  
STATE: No. 5691155th Carolina  
COUNTRY: USA  
ZIP: 28234  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/087,772A  
FILING DATE:  
CLASSIFICATION: 800  
ATTORNEY/AGENT INFORMATION:  
NAME: Linker, Raymond O.  
REGISTRATION NUMBER: 26,419  
REFERENCE/DOCKET NUMBER: 3339-195  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 919-881-3140

TELEFAX: 919-881-3175  
INFORMATION FOR SEQ ID NO: 16:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 477 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
US-08-087-772A-16

Query Match 45.1%; Score 41; DB 1; Length 477;  
Best Local Similarity 43.8%; Pred. No. 44;  
Matches 7; Conservative 4; Mismatches 5; Indels 0; Gaps 0;

QY 1 CTGSAANYTTAVDRP 16  
| | | | | : : : |  
Db 451 CNGGAAADSSSLDEP 466

RESULT 7  
US-08-896-449A-2  
Sequence 2, Application US/08896449A  
Patent No. 6040143  
GENERAL INFORMATION:  
APPLICANT: Venta, Patrick J.  
APPLICANT: Yuzbasiyan-Gurkan, Vilma  
APPLICANT: Schall, William D.  
APPLICANT: Brewer, George J.  
TITLE OF INVENTION: DNA ENCODING CANINE VON WILLEBRAND  
TITLE OF INVENTION: FACTOR AND METHODS OF USE  
NUMBER OF SEQUENCES: 11  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Harness, Dickey & Pierce, P.L.C.  
STREET: 5445 Corporate Drive  
CITY: Troy  
STATE: Michigan  
COUNTRY: USA  
ZIP: 48098  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/896,449A  
FILING DATE: 18-JUL-1997  
CLASSIFICATION: 435  
ATTORNEY/AGENT INFORMATION:  
NAME: Smith, Deann F.  
REFERENCE/DOCKET NUMBER: 2115-001226  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 248-641-1600  
TELEFAX: 248-641-0270  
TELEX: 287637  
INFORMATION FOR SEQ ID NO: 2:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 2813 amino acids  
TYPE: amino acid  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
US-08-896-449A-2

Query Match 45.1%; Score 41; DB 3; Length 2813;  
Best Local Similarity 60.0%; Pred. No. 3.1e+02;  
Matches 9; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 1 CTGSAANYTTAVDR 15  
| | | | | : : : |  
Db 621 CLCSAVANAAVAAR 635

```
RESULT 8
US-09-132-652-2
; Sequence 2, Application US/09132652
; Patent No. 6074832
; GENERAL INFORMATION:
; APPLICANT: Venta, Patrick J
; APPLICANT: Yuzbasiyan-Gurkan, Vilma
; APPLICANT: Schall, William D
; APPLICANT: Brewer, George J
; APPLICANT: Duffendeck, John
; TITLE OF INVENTION: DNA ENCODING CANINE VON WILLEBRAND FACTOR AND METHODS
; FILE REFERENCE: 2115S-001226CPB
; CURRENT APPLICATION NUMBER: US/09/132.652
; CURRENT FILING DATE: 1998-08-11
; EARLIER APPLICATION NUMBER: 08/896.449
; EARLIER FILING DATE: 1997-07-18
; NUMBER OF SEQ ID NOS: 29
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 2
; LENGTH: 2813
; TYPE: PRT
; ORGANISM: Canis familiaris
US-09-132-652-2

Query Match 45.1%; Score 41; DB 3; Length 2813;
Best Local Similarity 60.0%; Pred. No. 3.1e+02;
Matches 9; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

Qy 1 CTGSAANNTTAVDR 15
| | | | | | | |
Db 621 CLCSAVANYAAVAR 635

RESULT 9
US-08-061-376-5
; Sequence 5, Application US/08061376
; Patent No. 6175000
; GENERAL INFORMATION:
; APPLICANT: Evans, Glen A.
; APPLICANT: Djabali, Malek
; APPLICANT: Selleri, Licia
; APPLICANT: Parry, Pauline
; TITLE OF INVENTION: CHARACTERIZATION OF A CHROMOSOME 11Q23
; TITLE OF INVENTION: TRANSLOCATION BREAKPOINT ASSOCIATED WITH ACUTE LEUKEMIAS
; NUMBER OF SEQUENCES: 12
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Pretty, Schroeder, Brueggemann & Clark
; STREET: 444 South Flower Street, Suite 2000
; CITY: Los Angeles
; STATE: California
; COUNTRY: USA
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/061,376
; FILING DATE: 13-MAY-1993
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Reiter, Stephen E.
; REGISTRATION NUMBER: 31,192
; REFERENCE/DOCKET NUMBER: P41 9387
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (619)546-4737
; TELEFAX: (619)546-9392
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 3969 amino acids
```

```
; TYPE: amino acid
; STRANDEDNESS: unknown
; TOPOLOGY: unknown
; MOLECULE TYPE: protein
US-08-061-376-5

Query Match 45.1%; Score 41; DB 4; Length 3969;
Best Local Similarity 43.8%; Pred. No. 4.6e+02;
Matches 7; Conservative 3; Mismatches 6; Indels 0; Gaps 0;

Qy 2 TGSAAANVTAVDRPN 17
| | | | | | | |
Db 3475 SGPOVSNETQTVDPN 3490

RESULT 10
US-08-194-338-6
; Sequence 6, Application US/08194338
; Patent No. 5474898
; GENERAL INFORMATION:
; APPLICANT: Venter, John C.
; APPLICANT: Fraser, Claire M.
; APPLICANT: McCombie, William R.
; TITLE OF INVENTION: OCTOPAMINE RECEPTOR
; NUMBER OF SEQUENCES: 16
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Knobbe, Martens, Olson and Bear
; STREET: 620 Newport Center Drive, Sixteenth Floor
; CITY: Newport Beach
; STATE: CA
; COUNTRY: USA
; ZIP: 92660
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/194,338
; FILING DATE: 08-FEB-1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/676,174
; FILING DATE: 28-MAR-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Israelsen, Ned A.
; REGISTRATION NUMBER: 29,655
; REFERENCE/DOCKET NUMBER: NIH101.001DV1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (619) 235-8550
; TELEFAX: (619) 235-0176
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 472 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; FRAGMENT TYPE: internal
US-08-194-338-6

Query Match 44.0%; Score 40; DB 1; Length 472;
Best Local Similarity 43.8%; Pred. No. 64;
Matches 7; Conservative 4; Mismatches 5; Indels 0; Gaps 0;

Qy 1 CTGSAANVTAVDRPN 16
| | | | | | | |
Db 446 CNGCAADSDSLDEP 461
```

RESULT 11  
US-08-870-518-4  
; Sequence 4, Application US/08870518  
; Patent No. 5925566  
; GENERAL INFORMATION:  
; APPLICANT: Davis, Roger J.  
; APPLICANT: Galcheva-Gargova, Zoya  
; TITLE OF INVENTION: NON-ACTIVATED RECEPTOR COMPLEX  
; TITLE OF INVENTION: PROTEINS AND USES THEREOF  
; NUMBER OF SEQUENCES: 35  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Fish & Richardson P.C.  
; STREET: 225 Franklin Street  
; CITY: Boston  
; STATE: MA  
; COUNTRY: US  
; ZIP: 02110-2804  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Diskette  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: Windows95  
; SOFTWARE: FASTSEQ for Windows Version 2.0  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/870,518  
; FILING DATE: 06-JUN-1997  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 60/019,219  
; FILING DATE: 06-JUN-1996  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Fasse, Peter J.  
; REGISTRATION NUMBER: 32,983  
; REFERENCE/DOCKET NUMBER: 04020/102001  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 617/542-5070  
; TELEFAX: 617/542-8906  
; TELEX: 200154  
; INFORMATION FOR SEQ ID NO: 4:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 459 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
US-08-870-518-4

Query Match 41.8%; Score 38; DB 2; Length 459;  
Best Local Similarity 61.5%; Pred. No. 1.3e+02;  
Matches 8; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

Qy 3 GSAANVTAVDR 15  
Db 14 GNAAQNVSTAE 26

RESULT 12  
US-09-041-886-11  
; Sequence 11, Application US/09041886  
; Patent No. 6235872  
; GENERAL INFORMATION:  
; APPLICANT: Bredesen, Dale E.  
; APPLICANT: Rabizadeh, Sharoz  
; TITLE OF INVENTION: Proapoptotic Peptides, Dependence  
; TITLE OF INVENTION: Polypeptides and Methods of Use  
; NUMBER OF SEQUENCES: 72  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Campbell & Flores LLP  
; STREET: 4370 La Jolla Village Drive, Suite 700  
; CITY: San Diego  
; STATE: California  
; COUNTRY: United States  
; ZIP: 92122  
; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/041,886  
; FILING DATE:  
; CLASSIFICATION:  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Campbell, Cathryn A.  
; REGISTRATION NUMBER: 31,815  
; REFERENCE/DOCKET NUMBER: P-LJ 2626  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (619) 535-9001  
; TELEFAX: (619) 535-8949  
; INFORMATION FOR SEQ ID NO: 11:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 918 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
US-09-041-886-11

Query Match 41.8%; Score 38; DB 4; Length 918;  
Best Local Similarity 41.2%; Pred. No. 2.8e+02;  
Matches 7; Conservative 5; Mismatches 5; Indels 0; Gaps 0;

Qy 1 CTGSAANVTAVDRPN 17  
Db 321 CSGSAAGSGTLELPS 337

RESULT 13  
US-09-382-256-8  
; Sequence 8, Application US/09382256A  
; Patent No. 6207814  
; GENERAL INFORMATION:  
; APPLICANT: MIYAZONO, Kohel  
; TEN DIJKE, Peter  
; FRANZEN, Petra  
; YAMASHITA, Hidetoshi  
; HELDIN, Carl-Henrik  
; TITLE OF INVENTION: ACTIVIN RECEPTOR LIKE KINASES, PROTEINS  
; HAVING SERINE THREONINE KINASE DOMAINS,  
; AND THEIR USE  
; NUMBER OF SEQUENCES: 29  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Fulbright & Jaworski L.L.P.  
; STREET: 666 Fifth Avenue  
; CITY: New York City  
; STATE: New York  
; COUNTRY: USA  
; ZIP: 10103  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Diskette, 3.25 inch, 1.44mb  
; COMPUTER: IBM PS/2  
; OPERATING SYSTEM: PC-DOS  
; SOFTWARE: Wordperfect  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/382,256A  
; FILING DATE: 24-Aug-1999  
; CLASSIFICATION: 514  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: PCT/GB93/02367  
; FILING DATE: No. 6207814ember 17, 1993  
; APPLICATION NUMBER: GB 9224057.1  
; FILING DATE: No. 6207814ember 17, 1992  
; APPLICATION NUMBER: GB 9304677.9  
; FILING DATE: March 8, 1993  
; APPLICATION NUMBER: GB 9304680.3  
; FILING DATE: March 8, 1993  
; APPLICATION NUMBER: 9311047.6

;; FILING DATE: May 28, 1993  
;; APPLICATION NUMBER: 9313763.6  
;; FILING DATE: July 2, 1993  
;; APPLICATION NUMBER: 9316099.2  
;; FILING DATE: August 3, 1993  
;; APPLICATION NUMBER: 321344.5  
;; FILING DATE: October 15, 1993  
;; ATTORNEY/AGENT INFORMATION:  
;; NAME: No. 6207814man D. Hanson  
;; REGISTRATION NUMBER: 30,946  
;; REFERENCE/DOCKET NUMBER: LUD 5298.1  
;; TELECOMMUNICATION INFORMATION:  
;; TELEPHONE: (212) 318-3000  
;; TELEFAX: (212) 752-5958  
;; INFORMATION FOR SEQ ID NO: 8:  
;; SEQUENCE CHARACTERISTICS:  
;; LENGTH: 505 amino acids  
;; TYPE: amino acid  
;; TOPOLOGY: linear  
;; MOLECULE TYPE: protein  
;; SEQUENCE DESCRIPTION: SEQ ID NO: 8:  
US-09-382-256-8

Query Match 40.7%; Score 37; DB 4; Length 505;  
Best Local Similarity 50.0%; Pred. No. 2.1e+02;  
Matches 7; Conservative 0; Mismatches 7; Indels 0; Gaps 0;  
QY 1 CTGSAANYTTAVD 14  
|| |||||  
Db 36 CTSCLOANYTCETD 49

RESULT 14  
US-09-395-115-8  
; Sequence 8, Application US/09395115  
; Patent No. 6271365  
; GENERAL INFORMATION:  
; APPLICANT: Miyazono, Kohei; Dijke, Peter Ten;  
; APPLICANT: Franzen, Petra; Yamashita, Hidetoshi; Heldin, Carl-Henrik  
; TITLE OF INVENTION: Activin Receptor-Like Kinase, Proteins  
; TITLE OF INVENTION: Having Serine Threonine Kinase Domains And Their Use  
; NUMBER OF SEQUENCES: 29  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Felfe & Lynch  
; STREET: 805 Third Avenue  
; CITY: New York City  
; STATE: New York  
; ZIP: 10022  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Diskette, 3.5 inch, 360 kb storage  
; COMPUTER: IBM  
; OPERATING SYSTEM: PC-DOS  
; SOFTWARE: Wordperfect  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/395,115  
; FILING DATE:  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US/08/436,265  
; FILING DATE: 30-October-1995  
; APPLICATION NUMBER: PCT/GB93/02367  
; FILING DATE: 17-No. 6271365ember-1993  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 9224057.1  
; FILING DATE: 17-No. 6271365ember-1992  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 9304677.9  
; FILING DATE: 8-March-1993  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 9304680.3  
; FILING DATE: 8-March-1993  
; PRIOR APPLICATION DATA:

;; APPLICATION NUMBER: 9311047.6  
;; FILING DATE: 28-May-1993  
;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: 9313763.6  
;; FILING DATE: 2-July-1993  
;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: 9136099.2  
;; FILING DATE: 3-August-1993  
;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: 9321344.5  
;; FILING DATE: 15-October-1993  
;; ATTORNEY/AGENT INFORMATION:  
;; NAME: Kohlei Vineet  
;; REGISTRATION NUMBER: 37,003  
;; REFERENCE/DOCKET NUMBER: LUD 5298  
;; TELECOMMUNICATION INFORMATION:  
;; TELEPHONE: (212) 688-9200  
;; TELEFAX: (212) 838-3884  
;; INFORMATION FOR SEQ ID NO: 8:  
;; SEQUENCE CHARACTERISTICS:  
;; LENGTH: 505 amino acids  
;; TYPE: amino acid  
;; TOPOLOGY: linear  
;; MOLECULE TYPE: protein  
;; US-09-395-115-8

Query Match 40.7%; Score 37; DB 4; Length 505;  
Best Local Similarity 50.0%; Pred. No. 2.1e+02;  
Matches 7; Conservative 0; Mismatches 7; Indels 0; Gaps 0;  
QY 1 CTGSAANYTTAVD 14  
|| |||||  
Db 36 CTSCLOANYTCETD 49

RESULT 15  
US-08-324-977-50  
; Sequence 50, Application US/08324977  
; Patent No. 5747339  
; GENERAL INFORMATION:  
; APPLICANT: OKAYAMA, Hiroto  
; APPLICANT: FUKU, Isao  
; APPLICANT: MORI, Chisato  
; APPLICANT: TAKAMIZAWA, Akahisa  
; APPLICANT: YOSHIDA, Iwao  
; TITLE OF INVENTION: NON-A, NON-B HEPATITIS VIRUS GENOMIC  
; TITLE OF INVENTION: CDNA AND ANTIGEN POLYPEPTIDE  
; NUMBER OF SEQUENCES: 50  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Armstrong, Westerman, Hattori, Mclelland &  
; ADDRESSEE: Naughton  
; STREET: 1725 K St. N.W. Suite 1000  
; CITY: Washington  
; STATE: D.C.  
; COUNTRY: U.S.A.  
; ZIP: 20006  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Diskette, 3.5 in, 1.44mb  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS, Version 5.0  
; SOFTWARE: ASCII  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/324,977  
; FILING DATE: 18-OCT-1994  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: JP 2-167466  
; FILING DATE: 25-JUN-1990  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: JP 2-230921  
; FILING DATE: 31-AUG-1990  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: JP 2-305605



;; FILING DATE: 09-NOV-1990  
;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: US 08/099,706  
;; FILING DATE: 30-JUL-1993  
;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: US 07/769,996  
;; FILING DATE: 02-OCT-1991  
;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: US 07/635,451  
;; FILING DATE: 28-DEC-1990  
;; ATTORNEY/AGENT INFORMATION:  
;; NAME: Stevens-Smith, Theresa M.  
;; REGISTRATION NUMBER: 36,281  
;; REFERENCE/DOCKET NUMBER: 900703D  
;; TELECOMMUNICATION INFORMATION:  
;; TELEPHONE: (202) 659-2930  
;; TELEFAX: (202) 887-0357  
;; TELEX: 440142  
;; INFORMATION FOR SEQ ID NO: 50:  
;; SEQUENCE CHARACTERISTICS:  
;; LENGTH: 997 amino acids  
;; TYPE: amino acid  
;; TOPOLOGY: linear  
;; MOLECULE TYPE: protein  
;; US-08-324-977-50

Query Match 40.7%; Score 37; DB 1; Length 997;  
Best Local Similarity 53.3%; Pred. No. 4.5e+02;  
Matches 8; Conservative 2; Mismatches 5; Indels 0; Gaps 0;  
QY 1 CTGSAANYTTAVDR 15  
Db 57 CTPSPAPNYSRALWR 71

Search completed: March 26, 2002, 13:41:27  
Job time: 301 sec



GenCore version 4.5  
Copyright (c) 1993 - 2000 Compugen Ltd.

OM protein - protein search, using sw model

Run on: March 26, 2002, 13:36:26 ; Search time 42.75 Seconds  
(without alignments)  
30.292 Million cell updates/sec.

Title: US-09-709-201-93

Perfect score: 91

Sequence: 1 CTGSAANNTTAVDRPN 17

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 219241 seqs, 76174552 residues

Total number of hits satisfying chosen parameters: 219241

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

PIR\_68:\*  
1: pir1:\*  
2: pir2:\*  
3: pir3:\*  
4: pir4:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Match	Length	ID	Description
1	82	90.1	389	2 A43587	major outer membra
2	82	90.1	389	2 D86577	major outer membra
3	78	85.7	389	2 I40864	major outer membra
4	78	85.7	389	2 I40739	major outer membra
5	64	70.3	389	1 MMCP3	major outer membra
6	48	52.7	662	2 T17211	hypothetical prote
7	47	51.6	56	2 D71349	probable ribosomal
8	47	51.6	389	2 A60109	major outer membra
9	46	50.5	168	2 A84156	single-strand DNA-
10	46	50.5	1325	2 T25753	hypothetical prote
11	45	49.5	3300	2 D70575	probable PPE prote
12	44	48.4	584	1 I39710	cellulose biosynth
13	43	47.3	429	2 T01009	hypothetical prote
14	42	46.2	306	2 S59540	heat shock transcr
15	42	46.2	422	2 D84403	dihydroorotase [lm
16	42	46.2	1005	2 C71513	hypothetical prote
17	41	45.1	229	2 E70978	hypothetical prote
18	41	45.1	273	2 G81952	HemK protein NMA03
19	41	45.1	310	2 JC7275	acid nuclease Lel
20	41	45.1	345	1 PPPA	papain (EC 3.4.22.
21	41	45.1	423	2 E81010	hemK protein NMB20
22	41	45.1	431	2 JW0098	carbazole dioxygen
23	41	45.1	477	1 QRHUB1	beta-1-adrenergic
24	41	45.1	480	2 I53053	beta 1 adrenergic
25	41	45.1	693	2 JN0573	ubiquitin-like fus
26	41	45.1	3968	2 A44265	trithorax homolog
27	40	44.0	87	1 BXSNA6	antibacterial subs
28	40	44.0	280	2 G36808	hypothetical prote
29	40	44.0	337	2 B84335	hypothetical prote

ALIGNMENTS

RESULT 1

A43587

major outer membrane protein, porin CP0051 precursor [imported] - Chlamydomophila pneum  
N; Alternate names: MOMP  
C: Species: Chlamydomophila pneumoniae, Chlamydia pneumoniae  
C: Date: 29-Jan-1993 #sequence\_revision 29-Jan-1993 #text\_change 11-May-2000  
C: Accession: A43587; A49751; A49216; G72044; F81619  
R: Perez Meigosa, M.; Kuo, C.C.; Campbell, L.A.  
Infected. Immun. 59, 2195-2199, 1991  
A: Title: Sequence analysis of the major outer membrane protein gene of Chlamydia pneu  
A: Reference number: A43587; MUID: 91244474  
A: Accession: A43587  
A: Molecule type: DNA  
A: Residues: 1-389 <PER>  
A: Cross-references: GB:M69230; NID: g144540; PIDN: AAA75071.1; PID: g144541  
R: Carter, M.W.; Al-Mahdawi, S.A.H.; Giles, I.G.; Trehan, J.D.; Ward, M.E.; Clarke, J. Gen. Microbiol. 137, 465-475, 1991  
A: Title: Nucleotide sequence and taxonomic value of the major outer membrane protein  
A: Reference number: A49751; MUID: 91237311  
A: Accession: A49751  
A: Status: preliminary  
A: Molecule type: DNA  
A: Residues: 1-389 <CAR>  
A: Cross-references: GB:M64064; GB:M34942; NID: g144534; PIDN: AAA23143.1; PID: g144535  
R: Gaydos, C.A.; Quinn, T.C.; Bobo, L.D.; Eiden, J.J.  
Infect. Immun. 60, 5319-5323, 1992  
A: Title: Similarity of Chlamydia pneumoniae strains in the variable domain IV region  
A: Reference number: A49216; MUID: 93084388  
A: Accession: A49216  
A: Status: preliminary  
A: Molecule type: DNA  
A: Residues: 297-352 <GAY>  
A: Cross-references: GB:S50607; NID: g260972; PIDN: AAB24363.1; PID: g260973  
A: Note: sequence extracted from NCBI backbone (NCBIN:120604, NCBIP:120605)  
R: Kalman, S.; Mitchell, W.; Marathe, R.; Lammel, C.; Fan, J.; Olinger, L.; Grimwood, Nature Genet. 21, 385-389, 1999  
A: Title: Comparative genomes of Chlamydia pneumoniae and C. trachomatis.  
A: Reference number: A72000; MUID: 99206606  
A: Accession: G72044  
A: Molecule type: DNA  
A: Residues: 1-389 <ARN>  
A: Cross-references: GB:AE001652; GB:AE001365; NID: g4376997; PIDN: AAD18834.1; PID: g437  
R: Read, T.D.; Brunham, R.C.; Shen, C.; Gill, S.R.; Heidelberg, J.F.; White, O.; Hicke  
C.; Dodson, R.; Winn, M.; Nelson, W.; Deboy, R.; Kolonay, J.; McClarty, G.; Salzbe  
Nucleic Acids Res. 28, 1397-1406, 2000  
A: Title: Genome sequences of Chlamydia trachomatis Mopn and Chlamydia pneumoniae AR39  
A: Reference number: A81500; MUID: 20150255  
A: Accession: F81619  
A: Status: preliminary  
A: Molecule type: DNA

hypothetical prote  
hypothetical prote  
hypothetical prote  
dihydrodipicolinat  
G-protein coupled  
hypothetical prote  
hypothetical-CoA syn  
probable lpg2 prot  
dihydroorotase (EC  
dihydroorotase - M  
hypothetical prote  
very hypothetical  
ferredoxin--NADP r

```
C:species: homo_sapiens (man)
C:date: 15-Oct-1999 #sequence_revision 15-Oct-1999 #text_change 15-Oct-1999
C:Accession: T17211
```

R.Poustka, A.; Klein, M.; Mewes, H.W.; Gassenhuber, J.; Wiemann, S.  
submitted to the Protein Sequence Database, September 1999  
A:Reference number: Z18723  
A:Accession: T17211  
A>Status: preliminary  
A:Molecule type: mRNA  
A:Residues: 1-662 <POU>  
A:Cross-references: EMBL:AL117400  
A:Experimental source: adult testis; clone DKFzp4340051  
C:Genetics:  
A:Note: DKFzp4340051.1

Query Match 52.7%; Score 48; DB 2; Length 662;

Best Local Similarity 56.2%; Pred. No. 3.8;

Matches 9; Conservative 2; Mismatches 5; Indels 0; Gaps 0;

QY 1 CTGSAANVTAVDRP 16

||||:| | | |

Db 251 CTGSSACVATDLP 266

RESULT 7

D71349

probable ribosomal protein L33 (rpmG) - syphilis spirochete

C:Species: Treponema pallidum subsp. pallidum (syphilis spirochete)

C:Date: 24-Jul-1998 #sequence\_revision 24-Jul-1998 #text\_change 13-Aug-1999

C:Accession: D71349

R:Fraser, C.M.; Norris, S.J.; Weinstock, G.M.; White, O.; Sutton, G.G.; Dodson, R.; Gwin

son, J.; Khalak, H.; Richardson, D.; Howell, J.K.; Chidambaram, M.; Utterback, T.; McG

they, L.; Weidman, J.; Smith, H.O.; Venter, J.C.

A:Title: Complete genome sequence of Treponema pallidum, the syphilis spirochete.

A:Reference number: A71250; MUID:98332770

A:Accession: D71349

A>Status: preliminary; nucleic acid sequence not shown; translation not shown

A:Molecule type: DNA

A:Residues: 1-56 <COL>

A:Cross-references: GB:AE001205; GB:AE000520; NID:g3322501; PID:g332250

A:Experimental source: strain Nichols

C:Genetics:

A:Gene: TP0234

C:Superfamily: Escherichia coli ribosomal protein L33

Query Match

Best Local Similarity 51.6%; Score 47; DB 2; Length 56;

Matches 9; Conservative 2; Mismatches 6; Indels 0; Gaps 0;

QY 1 CTGSAANVTAVDRP 17

||||:| | | |

Db 14 CTGCKRRNTTSNRN 30

RESULT 8

A60109

major outer membrane protein precursor - Chlamydia psittaci (strain Guinea pig inclu

C:Species: Chlamydia psittaci, Chlamydia psittaci

C:Date: 10-Nov-1992 #sequence\_revision 10-Nov-1992 #text\_change 31-Mar-2000

C:Accession: A60109

R:Zhang, Y.X.; Morrison, S.G.; Caldwell, H.D.; Baehr, W.

Infect. Immun. 57, 1621-1625, 1989

A:Title: Cloning and sequence analysis of the major outer membrane protein genes of two

A:Reference number: A60109; MUID:89212917

A:Accession: A60109

A>Status: not compared with conceptual translation

A:Molecule type: DNA

A:Residues: 1-389 <ZHA>

C:Superfamily: Chlamydia major outer membrane protein

C:Keywords: membrane protein

F:1-22/Domain: signal sequence #status predicted <SIG>

F:23-389/Product: major outer membrane protein #status predicted <MAT>

Query Match 51.6%; Score 47; DB 2; Length 389;

Best Local Similarity 56.2%; Pred. No. 3.2;

Matches 9; Conservative 3; Mismatches 4; Indels 0; Gaps 0;

QY 2 TGSAAANYTTAVDRP 17

||||:| | | |

Db 89 TGNAAADFXTVADRN 104

RESULT 9

A84156

single-strand DNA-binding protein (phage-related protein) ssb [imported] - Bacillus h

C:Species: Bacillus halodurans

C:Date: 01-Dec-2000 #sequence\_revision 01-Dec-2000 #text\_change 08-Dec-2000

C:Accession: A84156

R:Takami, H.; Nakasone, K.; Takaki, Y.; Maeno, G.; Sasaki, R.; Masui, N.; Fujii, F.; H

Nucleic Acids Res. 28, 4317-4331, 2000

A:Title: Complete genome sequence of the alkaliphilic bacterium Bacillus halodurans a

A:Reference number: A83650; MUID:20263314

A:Accession: A84156

A>Status: preliminary

A:Molecule type: DNA

A:Residues: 1-168 <STO>

A:Cross-references: GB:AP001520; GB:BA000004; NID:g10176401; PIDN:BAB07768.1; GSPDB:G

A:Experimental source: strain C-125

C:Genetics:

A:Gene: ssb

C:Superfamily: bacterial single-stranded DNA-binding protein; single-stranded DNA-bin

Query Match

Best Local Similarity 50.5%; Score 46; DB 2; Length 168;

Matches 9; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 3 GSAANVTAVDRP 16

||||:| | | |

Db 23 GVAVANFTLAVNRP 36

RESULT 10

T25753

hypothetical protein F45E4.3 - Caenorhabditis elegans

C:Species: Caenorhabditis elegans

C:Date: 15-Oct-1999 #sequence\_revision 15-Oct-1999 #text\_change 15-Oct-1999

C:Accession: T25753

R:Wilson, R.

submitted to the EMBL Data Library, September 1996

A:Description: The sequence of C. elegans cosmid F45E4.

A:Reference number: 220082

A:Accession: T25753

A>Status: preliminary; translated from GB/EM3L/DBDJ

A:Molecule type: DNA

A:Residues: 1-1325 <WIL>

A:Cross-references: EMBL:U70852; PIDN:AAB09134.1; GSPDB:GN00022; CESP:F45E4.3

A:Experimental source: strain Bristol N2; clone F45E4

C:Genetics:

A:Gene: CESP:F45E4.3

A:Map position: 4

A:Introns: 25/3; 859/1; 928/1; 966/1; 1002/2; 1106/2; 1167/1; 1255/1; 1274/2

Query Match

Best Local Similarity 50.5%; Score 46; DB 2; Length 1325;

Matches 9; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 3 GSAANVTTA 12

||||:| | | |

Db 156 GSAASNYTTA 165

RESULT 11

D70575

probable PPE protein - Mycobacterium tuberculosis (strain H37RV)  
 C:Species: Mycobacterium tuberculosis  
 C>Date: 17-Jul-1998 #sequence\_revision 17-Jul-1998 #text\_change 22-Oct-1999  
 C:Accession: D70575  
 R:Cole, S.T.; Brosch, R.; Parkhill, J.; Garnier, T.; Churcher, C.; Harris, D.; Gordon, S.; Connor, R.; Davies, R.; Devlin, K.; Feltwell, T.; Gentles, S.; Hamlin, N.; Holroyd, S.; Rajandream, M.A.; Rogers, J.; Rutter, S.; Seeger, K.; Skelton, S.; Squares, S.; Nature 393, 537-544, 1998  
 A:Authors: Squares, R.; Sulston, J.E.; Taylor, K.; Whitehead, S.; Barrell, B.G.  
 A:Title: Deciphering the biology of Mycobacterium tuberculosis from the complete genome  
 A:Reference number: A70500; MUID:98293987  
 A:Accession: D70575  
 A>Status: Preliminary; nucleic acid sequence not shown; translation not shown  
 A:Molecule type: DNA  
 A:Residues: 1-3300 <COL>  
 A:Cross-references: GB:Z95324; GB:AL123456; NID:g3261760; PIDN:CAB08587.1; PID:el299834  
 A:Experimental source: strain H37RV  
 C:Genetics:  
 A:Gene: PPE

Query Match 49.5%; Score 45; DB 2; Length 3300;  
 Best Local Similarity 57.1%; Pred. No. 61;  
 Matches 8; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

QY 3 GSAANYTTAVDRP 16  
 | | | | | : | |  
 Db 2792 GLLAANYTTIERP 2805

## RESULT 12

I39710  
 cellulose biosynthesis protein celd - Agrobacterium tumefaciens  
 C:Species: Agrobacterium tumefaciens  
 C>Date: 03-Dec-1999 #sequence\_revision 03-Dec-1999 #text\_change 03-Dec-1999  
 C:Accession: I39710  
 R:Matthysse, A.G.; White, S.; Lightfoot, R.  
 J. Bacteriol. 177, 1069-1075, 1995  
 A:Title: Genes required for cellulose synthesis in Agrobacterium tumefaciens.  
 A:Reference number: I39709; MUID:95164506  
 A:Accession: I39710  
 A>Status: translated from GB/EMBL/DBJ  
 A:Molecule type: DNA  
 A:Residues: 1-584 <RES>  
 A:Cross-references: GB:I39609; NID:g710486; PIDN:AAC41431.1; PID:g710488  
 C:Comment: This protein is required for cellulose biosynthesis.  
 C:Genetics:  
 A:Gene: celd  
 C:Superfamily: Agrobacterium tumefaciens cellulose biosynthesis protein celd

Query Match 48.4%; Score 44; DB 1; Length 584;  
 Best Local Similarity 53.3%; Pred. No. 16;  
 Matches 8; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

QY 3 GSAANYTTAVDRPN 17  
 | | | | | : | |  
 Db 89 GNAADYTGFSRPD 103

## RESULT 13

T01009  
 hypothetical protein At2g39790 [imported] - Arabidopsis thaliana  
 N:Alternate names: hypothetical protein T517.9  
 C:Species: Arabidopsis thaliana (mouse-ear cress)  
 C>Date: 05-Feb-1999 #sequence\_revision 05-Feb-1999 #text\_change 23-Mar-2001  
 C:Accession: T01009; E84821  
 R:Rounsley, S.D.; Lin, X.; Ketchum, K.A.; Crosby, M.L.; Brandon, R.C.; Sykes, S.M.; Kaul  
 submitted to the EMBL Data Library, November 1997  
 A:Description: Arabidopsis thaliana chromosome II BAC T517 genomic sequence.  
 A:Reference number: Z14162  
 A:Accession: T01009  
 A>Status: translated from GB/EMBL/DBJ

A:Molecule type: DNA  
 A:Residues: 1-429 <ROU>  
 A:Cross-references: EMBL:AC003000; NID:g2642152; PID:g2642161  
 A:Experimental source: cultivar Columbia  
 R:Lin, X.; Kaul, S.; Rounsley, S.D.; Shea, T.P.; Benito, M.I.; Town, C.D.; Fujii, C.Y.; M.; Koo, H.; Moffat, K.S.; Cronin, L.A.; Shen, M.; VanAken, S.E.; Umayam, L.; Tallon, E.; D.; Nierman, W.C.; White, O.; Eisen, J.A.; Salzberg, S.L.; Fraser, C.M.; Venter Nature 402, 761-768, 1999  
 A:Title: Sequence and analysis of chromosome 2 of the plant Arabidopsis thaliana.  
 A:Reference number: A84420; MUID:20083487  
 A:Accession: E84821  
 A>Status: preliminary  
 A:Molecule type: DNA  
 A:Residues: 1-429 <STO>  
 A:Cross-references: GB:AE002093; NID:g2642161; PIDN:AAB87138.1; GSPDB:GNO0139  
 C:Genetics:  
 A:Gene: T517.9; At2g39790  
 A:Map position: 2  
 A:Introns: 82/3; 189/2; 263/3; 377/2

Query Match 47.3%; Score 43; DB 2; Length 429;  
 Best Local Similarity 66.7%; Pred. No. 17;  
 Matches 8; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 4 SAAANYTTAVDR 15  
 | | | | | : | |  
 Db 226 SRALNYSTAIR 237

## RESULT 14

S59540  
 heat shock transcription factor HSF31 - soybean (fragment)  
 C:Species: Glycine max (soybean)  
 C>Date: 15-Feb-1996 #sequence\_revision 01-Mar-1996 #text\_change 03-Nov-2000  
 C:Accession: S59540  
 R:Czarnecka-Verner, E.; Yuan, C.X.; Fox, P.C.; Gurley, W.B.  
 Plant Mol. Biol. 29, 37-51, 1995  
 A:Title: Isolation and characterization of six heat shock transcription factor cDNA c  
 A:Reference number: S59537; MUID:96017612  
 A:Accession: S59540  
 A>Status: nucleic acid sequence not shown  
 A:Molecule type: mRNA  
 A:Residues: 1-306 <CZA>  
 A:Cross-references: EMBL:Z46955; NID:g662926; PIDN:CAA87079.1; PID:g671867  
 A:Note: constitutively expressed  
 C:Genetics:  
 A:Gene: HSF31  
 C:Superfamily: tomato heat shock transcription factor HSF8; HSF DNA-binding domain ho  
 C:Keywords: DNA binding; leucine zipper; nucleus; transcription factor  
 F:1-63/Domain: HSF DNA-binding domain homology (fragment) <HSF>

Query Match 46.2%; Score 42; DB 2; Length 306;  
 Best Local Similarity 72.7%; Pred. No. 18;  
 Matches 8; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 3 GSAANYTTAV 13  
 | | | | | : | |  
 Db 122 GAAANYNTSV 132

## RESULT 15

D84403  
 dihydroorotase [imported] - Halobacterium sp. NRC-1  
 C:Species: Halobacterium sp. NRC-1  
 C>Date: 02-Feb-2001 #sequence\_revision 02-Feb-2001 #text\_change 16-Feb-2001  
 C:Accession: D84403  
 R:Ng, W.V.; Kennedy, S.P.; Mahairas, G.G.; Berquist, B.; Pan, M.; Shukla, H.D.; Lesky  
 ; Leithausen, B.; Keller, K.; Cruz, R.; Danson, M.J.; Hough, D.W.; Maddocks, D.G.; Ja  
 Jung, K.H.; Alam, M.; Freitas, T.  
 Proc. Natl. Acad. Sci. U.S.A. 97, 12176-12181, 2000  
 A:Authors: Hou, S.; Daniels, C.J.; Dennis, P.P.; Omer, A.D.; Ebhardt, H.; Lowe, T.M.;

A;Title: Genome sequence of Halobacterium species NRC-1.  
A;Reference number: A84160; MUID:20504483  
A;Accession: D84403  
A;Status: preliminary  
A;Molecule type: DNA  
A;Residues: 1-422 <STO>  
A;Cross-references: GB:AE004437; NID:g10581925; PIDN:AAG20592.1; GSPDB:GN00138  
C;Genetics:  
A;Gene: pvrC  
C;Superfamily: Bacillus dihydroorotase; Bacillus dihydroorotase homology

Query Match 46.2%; Score 42; DB 2; Length 422;  
Best Local Similarity 57.1%; Pred. No. 24;  
Matches 8; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

QY 4 SAAANYTTAVDRPN 17  
:|:| | | | | | |  
Db 74 AAAGGVTTVVDQPN 87

Search completed: March 26, 2002, 13:37:18  
Job time: 52 sec





GenCore version 4.5  
Copyright (c) 1993 - 2000 Compugen Ltd.

OM protein - protein search, using sw model

Run on: March 26, 2002, 13:36:26 ; Search time 24.63 Seconds  
(without alignments)  
25.307 Million cell updates/sec

Title: US-09-709-201-93

Perfect score: 91

Sequence: 1 CTGSAANYTTAVDRPN 17

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 100059 seqs, 36664827 residues

Total number of hits satisfying chosen parameters: 100059

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : SwissProt\_39:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	82	90.1	389	1 OMPL_CHLPN	P27455 chlamydia p
2	78	85.7	333	1 OM1K_CHLPN	Q9xbi4 chlamydia p
3	78	85.7	389	1 OM1N_CHLPN	Q07430 chlamydia p
4	64	70.3	389	1 OM1A_CHLPN	PI6567 chlamydia p
5	47	51.6	56	1 RL33_TREPA	O83262 treponema p
6	43	47.3	429	1 YB90_ARATH	O22288 arabidopsis
7	42	46.2	1005	1 Y456_CHLTR	O84462 chlamydia t
8	41	45.1	345	1 PAPA_CARPA	P00784 carica papa
9	41	45.1	477	1 BIAR_HUMAN	P08588 homo sapien
10	41	45.1	480	1 BIAR_MACMU	P47899 macaca mula
11	41	45.1	3969	1 HRX_HUMAN	Q03164 homo sapien
12	40	44.0	87	1 ANSA_STRCZ	P01548 streptomyce
13	40	44.0	280	1 VG27_HSVSA	Q00998 herpesvirus
14	40	44.0	722	1 PALY_CITLI	Q42667 citrus limo
15	39.5	43.4	268	1 DAPB_PSEAE	P38103 pseudomonas
16	39	42.9	375	1 GPRS_HUMAN	Q9ns67 homo sapien
17	39	42.9	377	1 GPRS_RAT	O91ih3 rattus norv
18	39	42.9	379	1 GPRS_MOUSE	O54897 mus musculu
19	39	42.9	414	1 Y878_METJA	Q58288 methanococc
20	39	42.9	2037	1 FAS1_CANAL	P34731 c fatty aci
21	38.5	42.3	454	1 PYRC_METTH	O27199 methanobact
22	38	41.8	116	1 Y243_MYCGE	P47485 mycoplasma
23	38	41.8	278	1 YFOL_STRTR	P96051 streptococc
24	38	41.8	309	1 J1L1_HCMVA	PI7143 human cytom
25	38	41.8	346	1 CRL1_CANAL	P33153 candida alb
26	38	41.8	459	1 ZPRI_SCHPO	O13724 schizosacch
27	38	41.8	538	1 DAC_ACTSP	P39045 actinomader
28	38	41.8	557	1 YP85_MYCTU	Q50636 mycobacteri
29	38	41.8	580	1 MEND_BACSU	P23970 b menaquin
30	38	41.8	713	1 CDGT_BACSP	P30921 bacillus sp
31	38	41.8	895	1 ANDR_MACFA	O97952 macaca fasc
32	38	41.8	895	1 ANDR_PAPHA	O97960 papio hamad
33	38	41.8	911	1 ANDR_PANTR	O97775 pan troglod

#### RESULT 1

ID	OMPL_CHLPN	STANDARD;	PRT;	369 AA.
AC	P27455; Q9JQF6;			
DT	01-AUG-1992 (Rel. 23, Created)			
DT	01-AUG-1992 (Rel. 23, Last sequence update)			
DT	20-AUG-2001 (Rel. 40, Last annotation update)			
DE	MAJOR OUTER MEMBRANE PROTEIN PRECURSOR (MOMP).			
GN	OMPA OR OMPI OR CPN0695 OR CP0051.			
OS	Chlamydia pneumoniae (Chlamydia pneumoniae).			
OC	Bacteria; Chlamydiales; Chlamydiaceae; Chlamydia.			
OX	NCBI_TaxID=83558;			
RN	[1]			
RP	SEQUENCE FROM N.A.			
RC	STRAIN=IOL-207;			
RX	MEDLINE=91237311; PubMed=2033374;			
RA	Cartier M.W., Al-Mahdawi S.A.H., Giles I.G., Trehan J.D.,			
RA	Ward M.E., Clarke I.N.;			
RT	"Nucleotide sequence and taxonomic value of the major outer membrane			
RT	protein gene of Chlamydia pneumoniae IOL-207."			
RL	J. Gen. Microbiol. 137:465-475(1991).			
RN	[2]			
RP	SEQUENCE FROM N.A.			
RC	STRAIN=TWAR;			
RX	MEDLINE=91244474; PubMed=1840574;			
RA	Perez Melgosa M., Kuo C.-C., Campbell L.A.;			
RT	"Sequence analysis of the major outer membrane protein gene of			
RT	Chlamydia pneumoniae."			
RL	Infect. Immun. 59:2195-2199(1991).			
RN	[3]			
RP	SEQUENCE FROM N.A.			
RC	Mitchell W.M., Tharp A.C., Stratton C.W., Sriram S.;			
RL	Submitted (FEB-1999) to the EMBL/GenBank/DBJ databases.			
RN	[4]			
RP	SEQUENCE FROM N.A.			
RC	STRAIN=CWL029;			
RX	MEDLINE=99206606; PubMed=10192388;			
RA	Kalinger S., Mitchell W., Marathe R., Laumel C., Fan J., Hyman R.W.,			
RA	Ollinger L., Grimwood J., Davis R.W., Stephens R.S.;			
RT	"Comparative genomes of Chlamydia pneumoniae and C. trachomatis."			
RL	Nat. Genet. 21:385-389(1999).			
RN	[5]			
RP	SEQUENCE FROM N.A.			
RC	STRAIN=AR39;			
RX	MEDLINE=20150255; PubMed=10684935;			
RA	Read T.D., Brunham R.C., Shen C., Gill S.R., Heidelberg J.F.,			
RA	White O., Hickey E.K., Peterson J., Utterback T., Berry K., Bass S.,			
RA	Linher K., Weidman J., Khouri H., Cravan B., Bowman C., Dodson R.,			
RA	Gwin M., Nelson W., DeBoy R., Kolonay J., McClarty G., Salzberg S.L.,			
RA	Eisen J., Fraser C.M.;			
RT	"Genome sequences of Chlamydia trachomatis MOPN and Chlamydia			
RT	pneumoniae AR39."			
RL	Nucleic Acids Res. 28:1397-1406(2000).			
RN	[6]			
RP	SEQUENCE FROM N.A.			
RC	STRAIN=JI38;			

34 38 41.8 919 1 ANDR\_HUMAN  
35 38 41.8 1318 1 VP14\_EBV  
36 38 41.8 1790 1 VIT\_ANTGR  
37 37.5 41.2 1142 1 ENAM\_PIG  
38 37 40.7 270 1 NUP1\_PENCI  
39 37 40.7 270 1 NUP3\_PENSQ  
40 37 40.7 280 1 YTA2\_AGRVI  
41 37 40.7 341 1 COA2\_POVMK  
42 37 40.7 505 1 KIR2\_HUMAN  
43 37 40.7 718 1 YSO2\_CABEL  
44 37 40.7 754 1 SULX\_YEAST  
45 37 40.7 884 1 CADB\_XENLA

P10275 homo sapien  
P03179 epstein-bar  
Q05808 anthonomus  
O97939 sus scrofa  
P24289 penicillium  
P24504 penicillium  
P70796 agrobacteri  
P24596 mouse polyo  
P36896 mouse polyo  
Q10128 caenorhabdi  
P53394 saccharomyc  
P33152 xenopus lae

#### ALIGNMENTS

RX MEDLINE-20330349; PubMed=10871362;  
 RA Shirai M., Hirakawa H., Kimoto M., Tabuchi M., Kishi F., Ouchi K.,  
 RA Shiba T., Ishii K., Hattori M., Kuhara S., Nakazawa T.,  
 RT "Comparison of whole genome sequences of Chlamydia pneumoniae J138  
 RL from Japan and CML029 from USA.",  
 Nucleic Acids Res. 28:2311-2314(2000).  
 [7]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN-J138;  
 RX MEDLINE-20298986; PubMed=10839753;  
 RA Shirai M., Hirakawa H., Ouchi K., Tabuchi M., Kishi F., Kimoto M.,  
 RA Takeuchi H., Nishida J., Shibata K., Fujinaga R., Yoneda H.,  
 RA Matsushima H., Tanaka C., Furukawa S., Miura K., Nakazawa A.,  
 RA Ishii K., Shiba T., Hattori M., Kuhara S., Nakazawa T.,  
 RT "Comparison of outer membrane protein genes omp and pmp in the whole  
 RT genome sequences of Chlamydia pneumoniae isolates from Japan and the  
 RT United States.",  
 J. Infect. Dis. 181 Suppl 3:S524-S527(2000).  
 RL J. Infect. Dis. 181 Suppl 3:S524-S527(2000).  
 CC -!- FUNCTION: STRUCTURAL RIGIDITY OF THE OUTER MEMBRANE OF ELEMENTARY  
 CC BODIES AND PORIN FORMING, PERMITTING DIFFUSION OF SOLUTES THROUGH  
 CC THE INTRACELLULAR RETICULATE BODY MEMBRANE.  
 CC -!- SUBUNIT: DISULFIDE BOND INTERACTIONS WITHIN AND BETWEEN MOMP  
 CC MOLECULES & OTHER COMPONENTS FORM HIGH MOLECULAR-WEIGHT OLIGOMERS.  
 CC -!- SUBCELLULAR LOCATION: INTEGRAL MEMBRANE PROTEIN. OUTER MEMBRANE.  
 CC -!- SIMILARITY: BELONGS TO THE CHLAMYDIAL OMP FAMILY.  
 CC  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announcement/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC  
 DR EMBL; M64064; AAA23143.1;  
 DR EMBL; M69230; AAA73071.1;  
 DR EMBL; AF131889; AAD22492.1;  
 DR EMBL; AE001652; AAD18834.1;  
 DR EMBL; AE002167; AAF37944.1;  
 DR EMBL; AP002547; BAA98902.1;  
 DR EMBL; AB033787; BAA85940.1;  
 DR PIR; A43587; A43587.  
 DR PIR; A49751; A49751.  
 DR TIGR; CP0051;  
 DR InterPro; IPR000604; Chlamydia\_OMP.  
 DR Pfam; PF01308; Chlamydia\_OMP; 1.  
 DR ProDom; PD001717; Chlamydia\_OMP; 1.  
 KW Outer membrane; Transmembrane; Porin; Signal; Complete proteome.  
 FT SIGNAL 1 23  
 FT CHAIN 24 389 MAJOR OUTER MEMBRANE PROTEIN.  
 FT SEQUENCE 389 AA; 41620 MW; 15D984151E41F8F2 CRC64;  
 CC  
 Query Match 90.1%; Score 82; DB 1; Length 389;  
 Best Local Similarity 100.0%; Pred. No. 1.5e-06;  
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 Qy 2 TGSAAANYTTAVDRPN 17  
 Db 90 TGSAAANYTTAVDRPN 105  
 [1]  
 RESULT 2  
 ID OMIK\_CHLPN STANDARD; PRT; 333 AA.  
 AC Q9XB4;  
 DT 30-MAY-2000 (Rel. 39, Created)  
 DT 30-MAY-2000 (Rel. 39, Last sequence update)  
 DT 20-AUG-2001 (Rel. 40, Last annotation update)  
 DE MAJOR OUTER MEMBRANE PROTEIN (MOMP) (FRAGMENT).  
 GN OMPA OR OMP1.  
 OS Chlamydia pneumoniae (Chlamydia pneumoniae).  
 OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydia phila.

OX NCBI\_TaxID=83558;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN-KOALA TYPE I;  
 RX MEDLINE-93123168; PubMed=8419295;  
 RA Kaltenboeck B., Kousoulas K.G., Storz J.,  
 RT "Structures of and allelic diversity and relationships among the major  
 RL outer membrane protein (OmpA) genes of the four chlamydial species.",  
 J. Bacteriol. 175:487-502(1993).  
 CC -!- FUNCTION: STRUCTURAL RIGIDITY OF THE OUTER MEMBRANE OF ELEMENTARY  
 CC BODIES AND PORIN FORMING, PERMITTING DIFFUSION OF SOLUTES THROUGH  
 CC THE INTRACELLULAR RETICULATE BODY MEMBRANE.  
 CC -!- SUBUNIT: DISULFIDE BOND INTERACTIONS WITHIN AND BETWEEN MOMP  
 CC MOLECULES & OTHER COMPONENTS FORM HIGH MOLECULAR-WEIGHT OLIGOMERS.  
 CC -!- SUBCELLULAR LOCATION: INTEGRAL MEMBRANE PROTEIN. OUTER MEMBRANE.  
 CC -!- SIMILARITY: BELONGS TO THE CHLAMYDIAL OMP FAMILY.  
 CC  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announcement/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC  
 DR EMBL; M73038; AAD38210.1;  
 DR InterPro; IPR000604; Chlamydia\_OMP.  
 DR Pfam; PF01308; Chlamydia\_OMP; 1.  
 DR ProDom; PD001717; Chlamydia\_OMP; 1.  
 KW Outer membrane; Transmembrane; Porin.  
 FT NON\_TER 1 1  
 FT NON\_TER 333 333  
 FT SEQUENCE 333 AA; 35811 MW; 204604512C4C3B3F CRC64;  
 CC  
 Query Match 85.7%; Score 78; DB 1; Length 333;  
 Best Local Similarity 93.8%; Pred. No. 6.2e-06;  
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 Qy 2 TGSAAANYTTAVDRPN 17  
 Db 46 TGSAAANYTTAVDRPN 61  
 [1]  
 RESULT 3  
 ID OMIN\_CHLPN STANDARD; PRT; 389 AA.  
 AC Q07430;  
 DT 30-MAY-2000 (Rel. 39, Created)  
 DT 30-MAY-2000 (Rel. 39, Last sequence update)  
 DT 20-AUG-2001 (Rel. 40, Last annotation update)  
 DE MAJOR OUTER MEMBRANE PROTEIN PRECURSOR (MOMP).  
 GN OMPA OR OMP1.  
 OS Chlamydia pneumoniae (Chlamydia pneumoniae).  
 OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydia phila.  
 OX NCBI\_TaxID=83558;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN-N16;  
 RX MEDLINE-94103736; PubMed=8277245;  
 RA Storey C., Lusher M., Yates P., Richmond S.,  
 RT "Evidence for Chlamydia pneumoniae of non-human origin.",  
 J. Gen. Microbiol. 139:2621-2626(1993).  
 CC -!- FUNCTION: STRUCTURAL RIGIDITY OF THE OUTER MEMBRANE OF ELEMENTARY  
 CC BODIES AND PORIN FORMING, PERMITTING DIFFUSION OF SOLUTES THROUGH  
 CC THE INTRACELLULAR RETICULATE BODY MEMBRANE.  
 CC -!- SUBUNIT: DISULFIDE BOND INTERACTIONS WITHIN AND BETWEEN MOMP  
 CC MOLECULES & OTHER COMPONENTS FORM HIGH MOLECULAR-WEIGHT OLIGOMERS.  
 CC -!- SUBCELLULAR LOCATION: INTEGRAL MEMBRANE PROTEIN. OUTER MEMBRANE.  
 CC -!- SIMILARITY: BELONGS TO THE CHLAMYDIAL OMP FAMILY.  
 CC  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -

CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).

DR EMBL; L04982; AAA17397.1; -  
 DR InterPro; IPR000604; Chlamydia\_OMP.  
 DR Pfam; PF01308; Chlamydia\_OMP; 1.  
 DR ProDom; PD001717; Chlamydia\_OMP; 1.  
 KW Outer membrane; Transmembrane; Porin; Signal.  
 FT SIGNAL 1 23 BY SIMILARITY.  
 FT CHAIN 24 389 MAJOR OUTER MEMBRANE PROTEIN.  
 SQ SEQUENCE 389 AA; 41628 MW; 801622F05D841967 CRC64;

Query Match 85.7%; Score 78; DB 1; Length 389;  
 Best Local Similarity 93.8%; Pred. No. 7.3e-06;  
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2 TGSAAANYTTTAVDRPN 17  
 ||| ||||| |||||  
 DB 90 TGSATANYTTTAVDRPN 105

## RESULT 4

OM1A\_CHLPS STANDARD; PRT; 389 AA.  
 AC P16567;  
 DT 01-AUG-1990 (Rel. 15, Created)  
 DT 01-AUG-1990 (Rel. 15, Last sequence update)  
 DT 20-AUG-2001 (Rel. 40, Last annotation update)  
 DE MAJOR OUTER MEMBRANE PROTEIN PRECURSOR (MOMP).  
 GN OMPA OR OMP1.  
 OS Chlamydia psittaci (Chlamydophila psittaci).  
 OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydophila.  
 OX NCBI\_TaxID=83554;  
 [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=OVINE ENZOOTIC ABORTION ISOLATE S26/3;  
 RX MEDLINE=90128177; PubMed=2612883;  
 RA Herring A.J., Tan T.W., Baxter S., Inglis N.F., Dunbar S.;  
 RT "Sequence analysis of the major outer membrane protein gene of an  
 RT ovine abortion strain of Chlamydia psittaci.";  
 RL FEMS Microbiol. Lett. 53:153-158(1989).  
 RN [2]

RP SEQUENCE FROM N.A.  
 RC STRAIN=BOVINE ABORTION ISOLATE BAL;  
 RX MEDLINE=96189695; PubMed=8605581;  
 RA Griffiths P.C., Plater J.M., Martin T.C., Hughes S.L.,  
 RA Hughes K.J., Hewinson R.G., Dawson M.;  
 RT "Epizootic bovine abortion in a dairy herd: characterization of a  
 RT Chlamydia psittaci isolate and antibody response.";  
 RL Br. Vet. J. 151:683-693(1995).

CC -!- FUNCTION: STRUCTURAL RIGIDITY OF THE OUTER MEMBRANE OF ELEMENTARY  
 CC BODIES AND PORIN FORMING, PERMITTING DIFFUSION OF SOLUTES THROUGH  
 CC THE INTRACELLULAR RETICULATE BODY MEMBRANE.  
 CC -!- SUBUNIT: DISULFIDE BOND INTERACTIONS WITHIN AND BETWEEN MOMP  
 CC MOLECULES & OTHER COMPONENTS FORM HIGH MOLECULAR-WEIGHT OLIGOMERS.  
 CC -!- SUBCELLULAR LOCATION: INTEGRAL MEMBRANE PROTEIN. OUTER MEMBRANE.  
 CC -!- SIMILARITY: BELONGS TO THE CHLAMYDIAL OMP FAMILY.

CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).

DR EMBL; X51859; CAA36152.1; -  
 DR EMBL; L39020; AAB02850.1; -  
 DR PIR; S08770; MMCWP3.

DR InterPro; IPR000604; Chlamydia\_OMP.  
 DR Pfam; PF01308; Chlamydia\_OMP; 1.  
 DR ProDom; PD001717; Chlamydia\_OMP; 1.  
 KW Outer membrane; Transmembrane; Porin; Signal.  
 FT SIGNAL 1 22  
 FT CHAIN 23 389 MAJOR OUTER MEMBRANE PROTEIN.  
 SQ SEQUENCE 389 AA; 41883 MW; 741B5A23ACDDB447 CRC64;

Query Match 70.3%; Score 64; DB 1; Length 389;  
 Best Local Similarity 75.0%; Pred. No. 0.0017;  
 Matches 12; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 2 TGSAAANYTTTAVDRPN 17  
 ||| ||||| |||||  
 DB 90 TGTAAANYKTPTDRPN 105

## RESULT 5

RL33\_TREPA STANDARD; PRT; 56 AA.  
 ID RL33\_TREPA  
 AC O83262;  
 DT 15-DEC-1998 (Rel. 37, Created)  
 DT 15-DEC-1998 (Rel. 37, Last sequence update)  
 DT 20-AUG-2001 (Rel. 40, Last annotation update)  
 DE 50S RIBOSOMAL PROTEIN L33.  
 GN RPMG OR TP0234.  
 OS Treponema pallidum.  
 OC Bacteria; Spirochaetales; Spirochaetaceae; Treponema.  
 OX NCBI\_TaxID=160;  
 [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=NICHOLS;  
 RX MEDLINE=98332770; PubMed=9665876;  
 RA Fraser C.M., Norris S.J., Weinstock G.K., White O., Sutton G.G.,  
 RA Dodson R., Gwinn M., Hickey E.K., Clayton R., Ketchum K.A.,  
 RA Sodergren E., Hardham J.M., McLeod M.P., Salzberg S., Peterson J.,  
 RA Khalak H., Richardson D., Howell J.K., Chidambaram M., Utterback T.,  
 RA McDonald L., Attiach P., Bowman C., Cotton M.D., Fujii C., Garland S.,  
 RA Hatch B., Horst K., Roberts K., Sandusky M., Weidman J., Smith H.O.,  
 RA Venter J.C.;  
 RT "Complete genome sequence of Treponema pallidum, the syphilis  
 RT spirochete.";  
 RL Science 281:375-388(1998).  
 CC -!- SIMILARITY: BELONGS TO THE L33P FAMILY OF RIBOSOMAL PROTEINS.

CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).

DR EMBL; AE001205; AAC65222.1; -  
 DR TIGR; TP0234; -  
 DR InterPro; IPR001705; Ribosomal\_L33.  
 DR Pfam; PF004711; Ribosomal\_L33; 1.  
 DR ProDom; PD002595; Ribosomal\_L33; 1.  
 DR PROSITE; PS00582; RIBOSOMAL\_L33; 1.  
 KW Ribosomal protein; Complete proteome.  
 SQ SEQUENCE 56 AA; 6820 MW; 1636DC3500D1F4B1 CRC64;

Query Match 51.6%; Score 47; DB 1; Length 56;  
 Best Local Similarity 52.9%; Pred. No. 0.2;  
 Matches 9; Conservative 2; Mismatches 6; Indels 0; Gaps 0;

QY 1 CTGSAANYTTTAVDRPN 17  
 ||| ||||| |||||  
 DB 14 CTGCKRRNYTTSNRN 30

RA Stephens R.S., Kalman S., Lammel C.J., Fan J., Marathe R., Aravind L.,  
RA Mitchell W.P., Olinger L., Tatusov R.L., Zhao Q., Koonin E.V.,

RA Kamphuis I.G., Kalk K.H., Swarte M.B.A., Drenth J.;  
RT "Structure of papain refined at 1.65-A resolution.";  
RL J. Mol. Biol. 179:233-256(1984).  
RN [6]  
RX X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS).  
RA MEDLINE-90269230; PubMed-2347312;  
RA Stubbs M.T., Labor B., Bode W., Huber R., Jerala R., Lenarcic B.,  
RA Turk V.;  
RT "The refined 2.4 A X-ray crystal structure of recombinant human  
RT stefin B in complex with the cysteine proteinase papain: a novel type  
RT of proteinase inhibitor interaction.";  
RL EMBO J. 9:1939-1947(1990).  
RN [7]  
RX X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS).  
RA MEDLINE-93075728; PubMed-1445868;  
RA Yamamoto A., Tomoo K., Doi M., Ohishi H., Inoue M., Ishida T.,  
RA Yamamoto D., Tsuboi S., Okamoto H., Okada Y.;  
RT "Crystal structure of  
RT papain-succinyl-Gln-Val-Ala-p-nitroanilide complex at 1.7-A  
RT resolution: noncovalent binding mode of a common sequence of  
RT endogenous thiol protease inhibitors.";  
RL Biochemistry 31:11305-11309(1992).  
RN [8]  
RX X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS).  
RA Pickersgill R.W., Harris G.W., Garman E.;  
RT "Structure of monoclinal papain at 1.60-A resolution.";  
RL Acta Crystallogr. B 48:59-67(1992).  
CC -|- CATALYTIC ACTIVITY: PREFERENTIAL CLEAVAGE: ARG-, LYS-, PHE-XAA-  
CC -|- SIMILARITY: BELONGS TO PEPTIDASE FAMILY C1; ALSO KNOWN AS THE  
CC PAPAINE FAMILY OF THIOL PROTEASES.  
CC -|- DATABASE: NAME=worthington-enzyme manual;  
CC WWW="http://www.worthington-biochem.com/manual/P/PAP.html".  
CC -----  
CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
CC the European Bioinformatics Institute. There are no restrictions on its  
CC use by non-profit institutions as long as its content is in no way  
CC modified and this statement is not removed. Usage by and for commercial  
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
CC -----  
DR EMBL; M15203; AAB02650.1; -;  
DR PIR; A26466; PPPA.  
DR PDB; 1PAD; 17-FEB-84.  
DR PDB; 2PAD; 17-FEB-84.  
DR PDB; 4PAD; 04-MAR-85.  
DR PDB; 5PAD; 17-FEB-84.  
DR PDB; 6PAD; 17-FEB-84.  
DR PDB; 9PAD; 15-JAN-95.  
DR PDB; 1PE6; 15-APR-93.  
DR PDB; 1PIP; 31-OCT-93.  
DR PDB; 1POP; 31-OCT-93.  
DR PDB; 1PPD; 02-JAN-85.  
DR PDB; 1PPN; 31-JAN-94.  
DR PDB; 1PPP; 31-JAN-94.  
DR PDB; 1STF; 31-JAN-94.  
DR MEROPS; C01.001; -;  
DR InterPro; IPR000668; Peptidase\_C1.  
DR InterPro; IPR000189; Thiolprot\_act\_site.  
DR Pfam; PF00112; Peptidase\_C1; 1.  
DR PRINTS; PR00705; PAPAINE.  
DR PROSITE; PS00139; THIOL\_PROTEASE\_CYS; 1.  
DR PROSITE; PS00639; THIOL\_PROTEASE\_HIS; 1.  
DR PROSITE; PS00640; THIOL\_PROTEASE\_ASN; 1.  
KW Hydrolase; Thiol protease; Zymogen; Signal; 3D-structure.  
FT SIGNAL  
FT 1 18  
FT PROPEP 19 133  
FT CHAIN 134 345  
FT ACT\_SITE 158 158  
FT ACT\_SITE 292 292  
FT ACT\_SITE 308 308  
FT ACT\_SITE 155 196  
FT DISULFID 189 228

FT DISULFID 286 333  
FT CONFLICT 180  
FT CONFLICT 219 220  
FT CONFLICT 251 251  
FT CONFLICT 268 268  
FT STRAND 138 139  
FT TURN 140 144  
FT STRAND 151 151  
FT TURN 153 154  
FT STRAND 156 156  
FT HELIX 158 175  
FT STRAND 181 181  
FT HELIX 183 189  
FT TURN 191 192  
FT TURN 195 196  
FT STRAND 197 197  
FT STRAND 199 199  
FT HELIX 201 210  
FT TURN 211 211  
FT STRAND 213 213  
FT STRAND 215 215  
FT TURN 216 218  
FT HELIX 231 233  
FT STRAND 238 238  
FT STRAND 242 245  
FT HELIX 251 260  
FT STRAND 263 267  
FT HELIX 272 276  
FT STRAND 281 282  
FT STRAND 292 299  
FT STRAND 303 307  
FT STRAND 310 310  
FT TURN 312 313  
FT TURN 315 315  
FT STRAND 316 316  
FT TURN 317 318  
FT STRAND 319 323  
FT HELIX 332 334  
FT TURN 335 336  
FT STRAND 340 343  
SQ SEQUENCE 345 AA; 38922 MW; 82D9FB35EDCAL2EF CRC64;  
  
Query Match 45.1%; Score 41; DB 1; Length 345;  
Best Local Similarity 80.0%; Pred. No. 12;  
Matches 8; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 2 TGSAAANYTT 11  
||| |  
Db 109 TGSAGNYTT 118  
  
RESULT 9  
BIAR\_HUMAN STANDARD; PRT; 477 AA.  
ID BIAR\_HUMAN AC P08588; O9UGX8; O9UKG7;  
DT 01-AUG-1988 (Rel. 08, Created)  
DT 01-AUG-1988 (Rel. 08, Last sequence update)  
DT 20-AUG-2001 (Rel. 40, Last annotation update)  
DE BETA-1 ADRENERGIC RECEPTOR.  
GN ADRB1 OR ADRB1R OR BIAR.  
OS Homo sapiens (Human).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
RN NCBI\_TaxID=9606;  
RP SEQUENCE FROM N.A.  
RC TISSUE=Placenta;  
RX MEDLINE-88068509; PubMed-2825170;  
RA Frielle T., Collins S., Daniel K.W., Lefkowitz R.J.,  
RA Kobilka B.;  
RT "Cloning of the cDNA for the human beta 1-adrenergic receptor.";  
RL Proc. Natl. Acad. Sci. U.S.A. 84:7920-7924(1987).



FT DOMAIN 121 131 EXTRACELLULAR (POTENTIAL).  
 FT TRANSSEM 132 155 3 (POTENTIAL).  
 FT DOMAIN 156 175 CYTOPLASMIC (POTENTIAL).  
 FT TRANSSEM 176 199 4 (POTENTIAL).  
 FT DOMAIN 200 221 EXTRACELLULAR (POTENTIAL).  
 FT TRANSSEM 222 245 5 (POTENTIAL).  
 FT DOMAIN 246 328 CYTOPLASMIC (POTENTIAL).  
 FT TRANSSEM 329 352 6 (POTENTIAL).  
 FT DOMAIN 353 359 EXTRACELLULAR (POTENTIAL).  
 FT TRANSSEM 360 383 7 (POTENTIAL).  
 FT DOMAIN 384 480 CYTOPLASMIC (POTENTIAL).  
 FT CARBOHYD 15 15 N-LINKED (GLYCAC. . .) (PROBABLE).  
 FT DISULFID 131 209 BY SIMILARITY.  
 FT MOD\_RES 315 315 PHOSPHORYLATION (BY CAPK) (POTENTIAL).  
 FT MOD\_RES 415 415 PHOSPHORYLATION (BY CAPK) (POTENTIAL).  
 FT LIPID 395 395 PALMITATE (BY SIMILARITY).  
 SQ SEQUENCE 480 AA; 51608 MW; 25CB18FA03128084 CRC64;

Query Match 45.1%; Score 41; DB 1; Length 480;  
 Best Local Similarity 43.8%; Pred. No. 17;  
 Matches 7; Conservative 4; Mismatches 5; Indels 0; Gaps 0;

QY 1 CTGSAANYTTAVDRP 16  
 I I I I I : : : I I  
 Db 454 CNGGAADSDSLDEP 469

RESULT 11  
 HRX\_HUMAN  
 ID HRX\_HUMAN STANDARD; PRT; 3969 AA.  
 AC Q03164; Q16364; Q13743; Q13744; Q9UMA3;  
 DT 01-OCT-1993 (Rel. 27, Created)  
 DT 01-NOV-1995 (Rel. 32, Last sequence update)  
 DT 20-AUG-2001 (Rel. 40, Last annotation update)  
 DE ZINC FINGER PROTEIN HRX (ALL-1) (TRITHORAX-LIKE PROTEIN).  
 GN MLL OR HRX OR ALL1 OR TRX1 OR HTRX.  
 OS Homo sapiens (Human).  
 OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 OX NCBI\_TaxID=9606;  
 [1]  
 SEQUENCE FROM N.A.  
 RX MEDLINE-93046667; PubMed-1423624;  
 RA Tkachuk D.C., Kohler S., Cleary M.L.;  
 RT "Involvement of a homolog of Drosophila trithorax by 11q23  
 chromosomal translocations in acute leukemias.";  
 RL Cell 71:691-700(1992).  
 [2]  
 SEQUENCE FROM N.A.  
 RX MEDLINE-96290553; PubMed-8703835;  
 RA Nilsson I., Loechner K., Slegler G., Greil J., Beck J.D., Fey G.H.,  
 RA Marschalek R.;  
 RT "Exon/intron structure of the human ALL-1 (MLL) gene involved in  
 translocations to chromosomal region 11q23 and acute leukemias.";  
 RL Br. J. Haematol. 93:966-972(1996).  
 [3]  
 SEQUENCE OF 1-1909 FROM N.A.  
 RX MEDLINE-93390935; PubMed-8378076;  
 RA Yamamoto K., Seto M., Komatsu H., Iida S., Akao Y., Kojima S.,  
 RA Kodera Y., Nakazawa S., Ariyoshi Y., Takahashi T., Ueda R.;  
 RT "Two distinct portions of LTR19/ENL at 19p13 are involved in t(11;19)  
 leukemia.";  
 RL Oncogene 8:2617-2625(1993).  
 [4]  
 SEQUENCE OF 1317-2328 FROM N.A.  
 RX MEDLINE-93265134; PubMed-1303259;  
 RA Diabali M., Salleri L., Parry P., Bower M., Young B.D., Evans G.A.;  
 RT "A trithorax-like gene is interrupted by chromosome 11q23  
 translocations in acute leukemias.";  
 RL Nat. Genet. 2:113-118(1992).  
 [5]

RP SEQUENCE OF 1251-1538 FROM N.A.  
 RX MEDLINE-94215165; PubMed-8162575;  
 RA Gu Y., Alder H., Nakamura T., Schichman S.A., Prasad R., Canaani O.,  
 RA Saito H., Croce C.M., Canaani E.;  
 RT "Sequence analysis of the breakpoint cluster region in the ALL-1 gene  
 involved in acute leukemia.";  
 RL Cancer Res. 54:2326-2330(1994).  
 [6]  
 RP SEQUENCE OF 1251-1654 FROM N.A. (ISOFORM 14P-18B).  
 RX MEDLINE-95322025; PubMed-7598802;  
 RA Mbangkollo D., Burnett R., McCabe N., Thirman M., Gill H., Yu H.,  
 RA Rowley J.D., Diaz M.O.;  
 RT "The human MLL gene: nucleotide sequence, homology to the Drosophila  
 trz zinc-finger domain, and alternative splicing.";  
 RL DNA Cell Biol. 14:475-483(1995).  
 [7]  
 RP SEQUENCE OF 1212-1603 FROM N.A.  
 RX MEDLINE-95315013; PubMed-7794749;  
 RA Marschalek R., Greil J., Lochner K., Nilsson I., Slegler G.,  
 RA Zweckbronner I., Beck J.D., Fey G.H.;  
 RT "Molecular analysis of the chromosomal breakpoint and fusion  
 transcripts in the acute lymphoblastic SEM cell line with chromosomal  
 translocation t(4;11).";  
 RL Br. J. Haematol. 90:308-320(1995).  
 [8]  
 RP SEQUENCE OF 1421-1540 FROM N.A.  
 RX MEDLINE-94020842; PubMed-8414518;  
 RA Forster A., Rabbitts T.H.;  
 RT "A method for identifying genes within yeast artificial chromosomes:  
 application to isolation of MLL fusion cDNAs from acute leukaemia  
 translocations.";  
 RL Oncogene 8:3157-3160(1993).  
 [9]  
 RP CHROMOSOMAL TRANSLOCATION WITH CAS7.  
 RX MEDLINE-20183971; PubMed-10706619;  
 RA Megonigal M.D., Cheung N.-K.V., Rappaport E.F., Nowell P.C.,  
 RA Willson R.B., Jones D.H., Addya K., Leonard D.G.B., Kushner B.H.,  
 RA Williams T.M., Lange B.J., Felix C.A.;  
 RT "Detection of leukemia-associated MLL-CAS7 translocation early during  
 chemotherapy with DNA topoisomerase II inhibitors.";  
 RL Proc. Natl. Acad. Sci. U.S.A. 97:2814-2819(2000).  
 CC -1- FUNCTION: POSSIBLY ACTS AS A TRANSCRIPTIONAL REGULATORY FACTOR.  
 CC -1- SUBCELLULAR LOCATION: NUCLEAR.  
 CC -1- TISSUE SPECIFICITY: HEART, LUNG, BRAIN AND T AND B LYMPHOCYTES.  
 CC -1- DISEASE: INVOLVED IN ACUTE LEUKEMIAS BY CHROMOSOMAL TRANSLOCATIONS  
 T(11;19)(Q23;P13.3) THAT INVOLVES MLL AND MLLT1/ENL;  
 CC T(4;11)(Q21;Q23) THAT INVOLVES MLL AND MLLT2/AF4; T(9;11)(P22;Q23)  
 CC THAT INVOLVES MLL AND MLLT3/AF9; T(6;11)(Q27;Q23) THAT INVOLVES  
 CC MLL AND MLLT4/AF6; T(11;17)(Q23;Q21) THAT INVOLVES MLL AND  
 CC MLLT6/AF17; T(X;11)(Q13;Q23) THAT INVOLVES MLL AND MLLT7/AFX1;  
 CC T(10;11)(P12;Q23) THAT INVOLVES MLL AND MLLT10/AF10;  
 CC T(1;11)(Q21;Q23) THAT INVOLVES MLL AND AF10; T(11;19)(Q23;P13.3)  
 CC THAT INVOLVES MLL AND ELL; AND T(11;19)(Q23;P23) THAT INVOLVES MLL  
 CC AND GAS7.  
 CC -1- SIMILARITY: BELONGS TO THE TRITHORAX FAMILY OF TRANSCRIPTION  
 CC FACTORS.  
 CC -1- SIMILARITY: CONTAINS 1 BROMODOMAIN.  
 CC -1- SIMILARITY: CONTAINS 1 SET DOMAIN.  
 CC -1- SIMILARITY: CONTAINS 3 PHD-TYPE ZINC FINGERS.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@sib-sib.ch](mailto:license@sib-sib.ch)).  
 CC -----  
 DR EMBL; L04284; AAA58669.1; -;  
 DR EMBL; Z69744; CAA93625.1; -;  
 DR EMBL; Z69745; CAA93625.1; JOINED.  
 DR EMBL; Z69746; CAA93625.1; JOINED.  
 DR EMBL; Z69747; CAA93625.1; JOINED.

```
DR EMBL; Z69748; CAA93625.1; JOINED.
DR EMBL; Z69749; CAA93625.1; JOINED.
DR EMBL; Z69750; CAA93625.1; JOINED.
DR EMBL; Z69751; CAA93625.1; JOINED.
DR EMBL; Z69752; CAA93625.1; JOINED.
DR EMBL; Z69753; CAA93625.1; JOINED.
DR EMBL; Z69754; CAA93625.1; JOINED.
DR EMBL; Z69755; CAA93625.1; JOINED.
DR EMBL; Z69756; CAA93625.1; JOINED.
DR EMBL; Z69757; CAA93625.1; JOINED.
DR EMBL; Z69758; CAA93625.1; JOINED.
DR EMBL; Z69759; CAA93625.1; JOINED.
DR EMBL; Z69760; CAA93625.1; JOINED.
DR EMBL; Z69761; CAA93625.1; JOINED.
DR EMBL; Z69762; CAA93625.1; JOINED.
DR EMBL; Z69763; CAA93625.1; JOINED.
DR EMBL; Z69764; CAA93625.1; JOINED.
DR EMBL; Z69765; CAA93625.1; JOINED.
DR EMBL; Z69766; CAA93625.1; JOINED.
DR EMBL; Z69767; CAA93625.1; JOINED.
DR EMBL; Z69768; CAA93625.1; JOINED.
DR EMBL; Z69769; CAA93625.1; JOINED.
DR EMBL; Z69770; CAA93625.1; JOINED.
DR EMBL; Z69771; CAA93625.1; JOINED.
DR EMBL; Z69772; CAA93625.1; JOINED.
DR EMBL; Z69773; CAA93625.1; JOINED.
DR EMBL; Z69774; CAA93625.1; JOINED.
DR EMBL; Z69775; CAA93625.1; JOINED.
DR EMBL; Z69776; CAA93625.1; JOINED.
DR EMBL; Z69777; CAA93625.1; JOINED.
DR EMBL; Z69778; CAA93625.1; JOINED.
DR EMBL; Z69779; CAA93625.1; JOINED.
DR EMBL; Z69780; CAA93625.1; JOINED.
DR EMBL; D14540; BAA03407.1; JOINED.
DR EMBL; L01986; AAA92511.1; JOINED.
DR EMBL; U04737; AAA18644.1; JOINED.
DR EMBL; S78570; AAB34770.1; JOINED.
DR EMBL; X83604; CAA58584.1; JOINED.
DR EMBL; S66432; AAB28545.1; JOINED.
DR EMBL; AF231998; AAG26332.2; ALT_TERM.
DR TRANSFAC; T02337; -.
DR MIN; 159555; -.
DR InterPro; IPR001487; Bromodomain.
DR InterPro; IPR003889; FYRICH_C.
DR InterPro; IPR003888; FYRICH_N.
DR InterPro; IPR001965; PHD.
DR InterPro; IPR003616; PostSET.
DR InterPro; IPR001214; SET.
DR InterPro; IPR002857; Znf-CXXC.
DR Pfam; PF00628; PHD; 3.
DR Pfam; PF00856; SET; 1.
DR Pfam; PF02008; zf-CXXC; 1.
DR SMART; SM00297; BROMO; 1.
DR SMART; SM00542; FYRC; 1.
DR SMART; SM00541; FYRN; 1.
DR SMART; SM00249; PHD; 4.
DR SMART; SM00508; PostSET; 1.
DR SMART; SM00317; SET; 1.
DR PROSITE; PS50014; BROMODOMAIN_2; 1.
DR PROSITE; PS50280; SET; 1.
DR PANTO-oncogene; Chromosomal translocation; DNA-binding; Bromodomain;
DR Nuclear protein; Zinc-finger; Metal-binding; Transcription regulation;
DR Alternative splicing.
DR DOMAIN; 17 102
DR DNABIND; 169 180
DR DNABIND; 217 227
DR DNABIND; 301 309
DR ZNFING; 1431 1482
DR ZNFING; 1484 1533
DR ZNFING; 1566 1627
DR DOMAIN; 1703 1748
DR DOMAIN; 3840 3969
DR DOMAIN; 137 143
DR DOMAIN; 561 564
```

```
FT DOMAIN 568 571 POLY-PRO.
FT SITE 1444 1445 BREAKPOINT FOR TRANSLOCATION TO FORM MLL-
FT VARSPLIC 1407 1444 GAS7 ONCOGENE.
FT CONFLICT 144 144 MISSING (IN ISOFORM 14P-18B).
FT CONFLICT 317 379 E -> ELTQPCSWRTKGHIHDKRTEPFRLLASWCUN
FT CONFLICT 556 556 (IN REF. 2).
GLINSELEKPKVKRDKKEGTPPLTKEDKTVVRSPPRIKP
VRIIPSSKRTDIAKOLLORA -> VSSLILNWKSPKRSK
KTRKEHLHLQKKIRQLSDKALEGLSQLGLFLQKQOMQPLL
SNSYRGQ (IN REF. 1).
Q -> E (IN REF. 2).

Query Match 45.1%; Score 41; DB 1; Length 3969;
Best Local Similarity 43.8%; Pred. No. 1.4e+02;
Matches 7; Conservative 3; Mismatches 6; Indels 0; Gaps 0;

QY 2 TGSAAANYTTAVDRPN 17
DB 3476 SGPOVSNETQIVDAPN 3491

RESULT 12
ANSA_STRCZ
ID ANSA_STRCZ STANDARD; PRT; 87 AA.
AC P01548;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 20-MAR-1987 (Rel. 04, Last annotation update)
DE ANTI-BACTERIAL SUBSTANCE A.
OS Streptomyces carzinostaticus.
OC Bacteria; Firmicutes; Actinobacteria; Actinobacteridae;
OC Actinomycetales; Streptomycetales; Streptomycetaceae; Streptomycetes.
OX NCBI_TaxID=1897;
RN [ ]
RP SEQUENCE.
RC STRAIN=F41;
RX MEDLINE=700391118; PubMed=5353565;
RA Sato H., Tanimura T., Nakajima T., Tamura Z.;
RT "The total amino acid sequence of substance A produced by
ST Streptomyces carzinostaticus.";
RL Chem. Pharm. Bull. 17:2188-2191(1969).
RW PIR; A01811; BXSMAc.
KW Antibiotic.
FT DISULFID 42 50
SQ SEQUENCE 87 AA; 8477 MW; C9A114BE1534029B CRC64;

Query Match 44.0%; Score 40; DB 1; Length 87;
Best Local Similarity 66.7%; Pred. No. 4.7;
Matches 8; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 2 TGSAAANYTTAV 13
DB 8 TGCATATYSTAV 19

RESULT 13
VG27_HSVSA
ID VG27_HSVSA STANDARD; PRT; 280 AA.
AC Q00998;
DT 01-APR-1993 (Rel. 25, Created)
DT 01-APR-1993 (Rel. 25, Last sequence update)
DT 01-APR-1993 (Rel. 25, Last annotation update)
DE HYPOTHETICAL GENE 27 PROTEIN.
GN 27.
OS Herpesvirus saimiri (strain 11).
OC Viruses; dsDNA viruses, no RNA stage; Herpesviridae;
OC Gammaherpesvirinae; Rhadinovirus.
OX NCBI_TaxID=10383;
RN [ ]
RP SEQUENCE FROM N.A.
RX MEDLINE=92333688; PubMed=1321287;
RA Albrecht J.-C., Nicholas J., Biller D., Cameron K.R., Biesinger B.,
```



RA Newman C., Wittmann S., Craxton M.A., Coleman H., Fleckenstein B.,  
 RA Honess R.W.;  
 RT "Primary structure of the herpesvirus saimiri genome.";  
 RL J. Virol. 66:5047-5058(1992).  
 CC  
 CC -!- SIMILARITY: LOW, TO EBV BDLF2.  
 CC  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC  
 CC EMBL: X64346; CAA45650.1; -  
 DR PIR: G36808; G36808.  
 KW Hypothetical protein.  
 SQ SEQUENCE 280 AA; 32372 MW; 6B470950E93E9ABF CRC64;  
 Query Match 44.0%; Score 40; DB 1; Length 280;  
 Best Local Similarity 50.0%; Pred. No. 15;  
 Matches 7; Conservative 4; Mismatches 3; Indels 0; Gaps 0;  
 OY 2 TGSAAANYTTAVDR 15  
 DB 146 TGSSANYKLALER 159  
 || :||| |::|  
 RESULT 14  
 ID PALY\_CITLI STANDARD; PRT; 722 AA.  
 AC Q42667;  
 DT 15-JUL-1998 (Rel. 36, Created)  
 DT 15-JUL-1998 (Rel. 36, Last sequence update)  
 DT 20-AUG-2001 (Rel. 40, Last annotation update)  
 DE PHENYLALANINE AMMONIA-LYASE (EC 4.3.1.5).  
 GN PAL6.  
 OS Citrus limon (Lemon).  
 OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;  
 OC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; Rosidae;  
 OC eurosids II; Sapindales; Rutaceae; Citrus.  
 OX NCBI\_TaxID=2708;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RA Seelenfreund D., Chiong M., Lobos S., Perez L.M.;  
 RT "A full-length cDNA coding for phenylalanine ammonia-lyase from Citrus  
 RT limon.";  
 RL (in) Plant Gene Register PGR96-026.  
 CC -!- FUNCTION: THIS IS A KEY ENZYME OF PLANT METABOLISM CATALYZING THE  
 CC FIRST REACTION IN THE BIOSYNTHESIS FROM L-PHENYLALANINE OF A WIDE  
 CC VARIETY OF NATURAL PRODUCTS BASED ON THE PHENYLPROPANE SKELETON.  
 CC -!- CATALYTIC ACTIVITY: L-PHENYLALANINE - TRANS-CINNAMATE + NH(3).  
 CC -!- PATHWAY: KEY ENZYME OF PHENYLPROPANOID METABOLISM.  
 CC -!- SUBCELLULAR LOCATION: CYTOPLASMIC (PROBABLE).  
 CC -!- PTM: CONTAINS AN ACTIVE SITE 4-METHYLIDENE-IMIDAZOLE-5-ONE (MIO),  
 CC WHICH IS FORMED AUTOCATALYTICALLY BY CYCLIZATION AND DEHYDRATION  
 CC OF RESIDUES ALA-SER-GLY (BY SIMILARITY).  
 CC -!- SIMILARITY: BELONGS TO THE PAL / HISTIDASE FAMILY.  
 CC  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC  
 CC EMBL: U43338; AAB67733.1; -  
 DR InterPro: IPR001106; PAL.  
 DR Pfam: PF00221; PAL; 1.  
 DR PROSITE: PS00488; PAL\_HISTIDASE; 1.  
 KW Lyase; Phenylpropanoid metabolism; Multigene family.

FT SITE 206 208 MODIFIED TO FORM 4-METHYLIDENE-IMIDAZOLE-  
 FT 5-ONE (BY SIMILARITY).  
 SQ SEQUENCE 722 AA; 78490 MW; C96893196530D9E5 CRC64;  
 Query Match 44.0%; Score 40; DB 1; Length 722;  
 Best Local Similarity 50.0%; Pred. No. 38;  
 Matches 7; Conservative 2; Mismatches 5; Indels 0; Gaps 0;  
 OY 1 CTGSAANYTTAVD 14  
 DB 25 CTGTDPLNWTVAAD 38  
 ||| :||| |  
 RESULT 15  
 ID DAPB\_PSEAE STANDARD; PRT; 268 AA.  
 AC P38103;  
 DT 01-OCT-1994 (Rel. 30, Created)  
 DT 20-AUG-2001 (Rel. 40, Last sequence update)  
 DT 20-AUG-2001 (Rel. 40, Last annotation update)  
 DE DIHYDRODIPICOLINATE REDUCTASE (EC 1.3.1.26) (DHPR).  
 GN DAPB OR PA4759.  
 OS Pseudomonas aeruginosa.  
 OC Bacteria; Proteobacteria; gamma subdivision; Pseudomonadaceae;  
 OC Pseudomonas.  
 OX NCBI\_TaxID=287;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RA STRAIN=ATCC 15692 / PA01;  
 RX MEDLINE=20437337; PubMed=10984043;  
 RA Stover C.K., Pham X.-O.T., Erwin A.L., Mizoguchi S.D., Warren P.,  
 RA Hickey M.J., Brinkman F.S.L., Hufnagle W.O., Kowalik D.J., Lagrou M.,  
 RA Garber R.L., Goltzy L., Tolentino E., Westbrock-Wadman S., Yuan Y.,  
 RA Brody L.L., Coulter S.N., Folger K.R., Kas A., Larbig K., Lim R.M.,  
 RA Smith K.A., Spencer D.H., Wong G.K.-S., Wu Z., Paulsen I.T.,  
 RA Reizer J., Sailer M.H., Hancock R.E.W., Lory S., Olson M.V.;  
 RT "Complete genome sequence of Pseudomonas aeruginosa PA01, an  
 RT opportunistic pathogen.";  
 RL Nature 406:959-964 (2000).  
 RN [2]  
 RP SEQUENCE OF 135-268 FROM N.A.  
 RX STRAIN=ATCC 15692 / PA01;  
 RX MEDLINE=94222830; PubMed=8169201;  
 RA Kwon D.-H., Lu C.-D., Walthall D.A., Brown T.M., Houghton J.E.,  
 RA Abdelal A.T.;  
 RT "Structure and regulation of the carAB operon in Pseudomonas  
 RT aeruginosa and Pseudomonas stutzeri: no untranslated region exists.";  
 RL J. Bacteriol. 176:2532-2542(1994).  
 CC -!- CATALYTIC ACTIVITY: 2,3,4,5-TETRAHYDRODIPICOLINATE + NAD(P)(+) -  
 CC 2,3-DIHYDRODIPICOLINATE + NAD(P)H.  
 CC -!- PATHWAY: BIOSYNTHESIS OF DIAMINOPIMELATE AND LYSINE FROM ASPARTATE  
 CC SEMIALDEHYDE; SECOND STEP.  
 CC -!- SUBCELLULAR LOCATION: CYTOPLASMIC (BY SIMILARITY).  
 CC -!- SIMILARITY: BELONGS TO THE DIHYDRODIPICOLINATE REDUCTASE FAMILY.  
 CC  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC  
 CC EMBL: AE004889; AAG08145.1; -  
 DR EMBL: U04992; AAA19045.1; -  
 DR EMBL: U81259; AAB39249.1; -  
 DR HSP: P04036; LDRV.  
 DR InterPro: IPR000846; DapB.  
 DR Pfam: PF01113; DapB; 1.  
 DR ProDom: PD004105; DapB; 1.  
 DR PROSITE: PS01298; DAPB; 1.  
 KW Diaminopimelate biosynthesis; Lysine biosynthesis; Oxidoreductase;

KW NADP; Complete proteome.  
SQ SEQUENCE 268 AA; 28324 MW; 0B37EAF688419254 CRC64;

Query Match 43.48; Score 39.5; DB 1; Length 268;  
Best Local Similarity 62.5%; Pred. No. 17;  
Matches 10; Conservative 1; Mismatches 4; Indels 1; Gaps 1;

QY 2 TGSAAANYTTAVDRPN 17  
Db 24 TG-GAAGLTAAVDRPD 38

Search completed: March 26, 2002, 13:40:42  
Job time: 256 sec

GenCore version 4.5  
Copyright (c) 1993 - 2000 CompuGen Ltd.

# OM protein - protein search, using sw model

Run on: March 26, 2002, 13:36:26 ; Search time 79.01 Seconds  
(without alignments)  
31.472 Million cell updates/sec

Title: US-09-709-201-93  
Perfect score: 91  
Sequence: 1 CTGSAANYTTAVDRPN 17

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 473505 seqs, 146272329 residues

Total number of hits satisfying chosen parameters: 473505

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

## Database :

SPTREMBL\_17.\*  
1: sp\_archaea.\*  
2: sp\_bacteria.\*  
3: sp\_fungi.\*  
4: sp\_human.\*  
5: sp\_invertebrate.\*  
6: sp\_mammal.\*  
7: sp\_mhc.\*  
8: sp\_organelle.\*  
9: sp\_phase.\*  
10: sp\_plant.\*  
11: sp\_rodent.\*  
12: sp\_virus.\*  
13: sp\_vertebrate.\*  
14: sp\_unclassified.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	78	85.7	389	2 Q08085	Q08085 chlamydia p
2	64	70.3	341	2 Q9X717	Q9X717 chlamydia p
3	64	70.3	352	2 Q69306	Q69306 chlamydia p
4	64	70.3	352	2 Q69307	Q69307 chlamydia p
5	64	70.3	352	2 Q70050	Q70050 chlamydia p
6	64	70.3	352	2 Q70085	Q70085 chlamydia p
7	64	70.3	353	2 Q69305	Q69305 chlamydia p
8	62	68.1	388	2 Q9AIK1	Q9AIK1 chlamydia p
9	59	64.8	389	2 Q9APM4	Q9APM4 chlamydia p
10	48	52.7	557	2 Q99V50	Q99V50 staphylococ
11	48	52.7	662	4 Q9URF7	Q9URF7 homo sapien
12	48	52.7	1241	4 Q14148	Q14148 homo sapien
13	47	51.6	326	2 Q9K5C5	Q9K5C5 chlamydia p
14	47	51.6	389	2 Q9AIH9	Q9AIH9 chlamydia p
15	46	50.5	168	2 Q9K5N9	Q9K5N9 bacillus ha
16	46	50.5	836	5 Q9BI65	Q9BI65 caenorhabdi
17	46	50.5	1231	5 Q9BI66	Q9BI66 caenorhabdi
18	45	49.5	3300	2 Q06304	Q06304 mycobacteri
19	44.5	48.9	356	2 Q52924	Q52924 chlamydia p

20 44.5 48.9 390 2 Q9AIJ5  
21 44.5 48.9 392 2 Q9AIJ4  
22 44 48.4 584 2 Q59152  
23 43 47.3 1459 3 Q9HG03  
24 42 46.2 306 10 Q43456  
25 42 46.2 388 2 Q9AIK0  
26 42 46.2 391 2 Q46235  
27 42 46.2 422 1 Q9HMH9  
28 42 46.2 499 5 Q9VVM1  
29 42 46.2 618 2 Q9A9F7  
30 42 46.2 1583 12 Q90304  
31 41 45.1 218 2 Q34189  
32 41 45.1 229 2 P96873  
33 41 45.1 273 2 Q9JWH6  
34 41 45.1 310 3 Q9P356  
35 41 45.1 385 12 Q39888  
36 41 45.1 423 2 Q9JXG1  
37 41 45.1 431 2 Q85283  
38 41 45.1 589 3 Q9HE13  
39 41 45.1 626 2 Q45877  
40 41 45.1 693 13 Q91889  
41 41 45.1 834 3 Q9P978  
42 41 45.1 1682 5 Q9V693  
43 41 45.1 3010 12 Q9PJ3G2  
44 40 44.0 337 1 Q9HP24  
45 40 44.0 375 2 Q9HXE3

## ALIGNMENTS

RESULT 1

Q08085 Q08085 PRELIMINARY: PRT: 389 AA.  
AC Q08085;  
DT 01-NOV-1996 (Tremblrel. 01, Created)  
DT 01-NOV-1996 (Tremblrel. 01, Last sequence update)  
DT 01-JUN-2001 (Tremblrel. 17, Last annotation update)  
DE MAJOR OUTER MEMBRANE PROTEIN PRECURSOR (MOMP).  
OS Chlamydia psittaci (Chlamydia psittaci).  
OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydia.   
OX NCBI\_TaxID=83554;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN-KOALA TYPE 1;  
RX MEDLINE=84171025; Pubmed=8125292;  
RA Girjes A.A., Carrick F.N., Lavin M.F.;  
RT "Remarkable sequence relatedness in the DNA encoding the major outer  
RT membrane protein of Chlamydia psittaci (koala type I) and Chlamydia  
RT pneumoniae.";  
RL Gene J38.139-142(1994).  
CC -1- FUNCTION: STRUCTURAL RIGIDITY OF THE OUTER MEMBRANE OF ELEMENTARY  
CC BODIES AND PORIN FORMING, PERMITTING DIFFUSION OF SOLUTES THROUGH  
CC THE INTRACELLULAR RETICULATE BODY MEMBRANE.  
CC -1- SUBUNIT: DISULFIDE BOND INTERACTIONS WITHIN AND BETWEEN MOMP  
CC MOLECULES & OTHER COMPONENTS FORM HIGH MOLECULAR-WEIGHT OLIGOMERS.  
CC -1- SUBCELLULAR LOCATION: INTEGRAL MEMBRANE PROTEIN. OUTER MEMBRANE.  
DR EMBL: X72023; CAA50906.1;  
DR InterPro: IPR000604; Chlamydia\_OMP.  
DR Pfam: PF01308; Chlamydia\_OMP; 1.  
DR PRINTS: PR01334; CHLAMIDI\_OMP.  
DR ProDom: PD001717; Chlamydia\_OMP; 1.  
DR Outer membrane; Transmembrane; Porin; Signal.  
FT SIGNAL 1 23 BY SIMILARITY.  
FT CHAIN 24 389 MAJOR OUTER MEMBRANE PROTEIN.  
SQ SEQUENCE 389 AA; 41579 MW; 5DC50E8FA6F4E50F CRC64;

Query Match 85.7%; Score 78; DB 2; Length 389;  
Best Local Similarity 93.8%; Pred. No. 3.6e-05;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2 TGSAANYTTAVDRPN 17

db 90 TGSATANYTTAVDRPN 105

[illegible]

Query Match 70.3%; Score 64; DB 2; Length 341;  
Best Local Similarity 75.0%; Pred. No. 0.0073;  
Matches 12: Conservative 1; Mismatches 3; Indels

Qy 2 TGSAAANYTTAVDRPN 17  
||:||||| | ||||  
Db 54 TGTAAANYKTPTDRPN 69

```

RESULT      3
069306
ID          PRELIMINARY; PRT; 352 AA.
AC          069306;
DT          01-AUG-1998 (TRENBLrel. 07, Created)
DT          01-AUG-1998 (TRENBLrel. 07, Last sequence update)
DT          01-JUN-2001 (TRENBLrel. 17, Last annotation update)
DE          OMP1 PROTEIN (FRAGMENT).
DI          OMP1.
GN          Chlamydia psittaci (Chlamydophila psittaci).
OC          Bacteria; Chlamydiales; Chlamydiaceae; Chlamydophila.
OX          NCBI_TaxID=83554;
RN          [1]
RP          SEQUENCE FROM N.A.
RC          STRAIN=PM234;
RA          Hoelzle L.E., Steinhausen G., Eggemann G., Schiller I.,
RA          Wittenbrink M.M.;
RL          Submitted (MAR-1998) to the EMBL/GenBank/DBJ databases.
DR          EMBL; AJ004874; CAAG6183.1; ---
DR          RefSeq; IPRO000604; Chlamydia_OMP.
DR          Pfam; PF01308; Chlamydia_OMP; 1.
DR          ProDom; PD001717; Chlamydia_OMP; 1.
FT          NON_TER 352
SO          SEQUENCE 352 AA: 37868 MW: 0AEA9B1E099EEED41 CRC64;

```

Query Match 70.3%; Score 64; DB 2; Length 352;  
Best Local Similarity 75.0%; Pred. No. 0.0075;  
Matches 12: Conservative 1; Mismatches 3; Indels

Qy 2 TGSAAANYTTAVDRPN 17

Db 90 TGTAAANYKTPTDRPN 105

```

RESULT      4
ID          069307
PRELIMINARY;          PRT:      352 AA.
AC          069307;
DT          01-AUG-1998 (TREMBlrel. 07, Created)
DT          01-AUG-1998 (TREMBlrel. 07, Last sequence update)
DT          01-JUN-2001 (TREMBlrel. 17, Last annotation update)
DE          OMPI PROTEIN (FRAGMENT).
GN          OMPI.
OS          Chlamydia psittaci (Chlamydomphila psittaci).
OC          Bacteria; Chlamydiales; Chlamydiaceae; Chlamydomphila.
OX          NCBI_TaxID=83554;
RN          [1]
SEQUENCE FROM N.A.
RP          STRAIN=PM326;
RA          Hoelzle L.E., Steinhausen G., Eggemann G., Schiller I.,
RA          Wittenbrink M.M.;
RL          Submitted (MAR-1998) to the EMBL/GenBank/DBJ databases.
DR          EMBL: AJ004875; CAA06184.1;
DR          InterPro: IPR000504; Chlamydia_OMP.
DR          Pfam: PF01308; Chlamydia_OMP; I.
DR          ProDom: PD001717; Chlamydia_OMP; 1.
FT          NON_TER      352
          SEQUENCE      352 AA; 37854 MW; 33589C6D1137CCDB CRC64;

```

Query Match 70.3%; Score 64; DB 2; Length 352;  
Best Local Similarity 75.0%; Pred. NO. 0.0075;  
Matches 12: Conservative 1; Mismatches 3; Indels

QY 2 TGSAAANYTTAVDRPN 17  
||:||||| | ||||  
Db 90 TGTAAANYKTPTDRPN 105

```

RESULT      5
ID00050
ID 070050      PRELIMINARY;      PRT: 352 AA.
AC 070050;
DT 01-AUG-1998 (TRENBLrel. 07, Created)
DT 01-AUG-1998 (TRENBLrel. 07, Last sequence update)
DT 01-JUN-2001 (TRENBLrel. 17, Last annotation update)
DE OMP1 (FRAGMENT).
GN OMP1.
OS Chlamydia psittaci (Chlamydophila psittaci).
OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydophila.
OX NCBI_TaxID=83554;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=PM623, PM112, PM364;
RA Hoelzle L.E., Steinhäuser G., Eggemann G., Schiller I.,
RA Wittenbrink M.M.
RL Submitted (APR-1998) to the EMBL/GenBank/DBJ databases.
RL EMBL; AJ005615; CAA06622.1; -.
DR EMBL; AJ005613; CAA06620.1; -.
DR EMBL; AJ005614; CAA06621.1; -.
DR InterPro: IPR000604; Chlamydia_OMP.
DR Pfam: PF01308; Chlamydia_OMP; 1.
DR ProDom: PD001717; Chlamydia_OMP; 1.
FT NON_TER 352
SO SEQUENCE 352 AA: 37826 MW: 2F9D092492E462D4 CRC64;

```

Query Match 70.3%; Score 64; DB 2; Length 352;  
Best Local Similarity 75.0%; Pred. No. 0.0075;  
Matches 12; Conservative 1; Mismatches 3; Indels

QY 2 TGSAAANYTTAVDRPN 17  
||:|||||

Db 90 TGTAANYKTPTDRPN 105

RESULT 6  
070085 PRELIMINARY; PRT; 352 AA.  
ID 070085  
AC 070085  
DT 01-AUG-1998 (TReMBLrel. 07, Created)  
DT 01-AUG-1998 (TReMBLrel. 07, Last sequence update)  
DT 01-JUN-2001 (TReMBLrel. 17, Last annotation update)  
DE OMP1 (FRAGMENT).  
GN OMP1.  
OS Chlamydia psittaci (Chlamydothila psittaci).  
OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydothila.  
OX NCBI\_TaxID=83554;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN=PM225;  
RA Hoelzle L.E., Steinhausen G., Eggemann G., Schiller I.,  
Wittenbrink M.M.;  
RL Submitted (APR-1998) to the EMBL/GenBank/DBJ databases.  
DR EMBL: AJ005618; CAA06625.1; -  
DR EMBL: AJ005617; CAA06624.1; -  
DR InterPro: IPR000604; Chlamydia\_OMP.  
DR Pfam: PF01308; Chlamydia\_OMP; 1.  
DR ProDom: PD001717; Chlamydia\_OMP; 1.  
FT NON\_TER 352 352  
SQ SEQUENCE 352 AA; 37854 MW; 391914AD146072CB CRC64;

Query Match 70.3%; Score 64; DB 2; Length 352;  
Best Local Similarity 75.0%; Pred. No. 0.0075;  
Matches 12; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 2 TGSAANYTTAVDRPN 17  
||:||||| | ||||  
Db 90 TGTAANYKTPTDRPN 105

RESULT 7  
069305 PRELIMINARY; PRT; 353 AA.  
ID 069305  
AC 069305  
DT 01-AUG-1998 (TReMBLrel. 07, Created)  
DT 01-AUG-1998 (TReMBLrel. 07, Last sequence update)  
DT 01-JUN-2001 (TReMBLrel. 17, Last annotation update)  
DE OMP1 PROTEIN (FRAGMENT).  
GN OMP1.  
OS Chlamydia psittaci (Chlamydothila psittaci).  
OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydothila.  
OX NCBI\_TaxID=83554;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN=OCLH196;  
RA Hoelzle L.E., Steinhausen G., Eggemann G., Schiller I.,  
Wittenbrink M.M.;  
RL Submitted (MAR-1998) to the EMBL/GenBank/DBJ databases.  
DR EMBL: AJ004873; CAA06182.1; -  
DR InterPro: IPR000604; Chlamydia\_OMP.  
DR Pfam: PF01308; Chlamydia\_OMP; 1.  
DR ProDom: PD001717; Chlamydia\_OMP; 1.  
FT NON\_TER 353 353  
SQ SEQUENCE 353 AA; 37933 MW; AC7D8FD9FA6E1728 CRC64;

Query Match 70.3%; Score 64; DB 2; Length 353;  
Best Local Similarity 75.0%; Pred. No. 0.0076;  
Matches 12; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 2 TGSAANYTTAVDRPN 17  
||:||||| | ||||  
Db 90 TGTAANYKTPTDRPN 105

RESULT 8

09AIK1 PRELIMINARY; PRT; 388 AA.  
ID 09AIK1  
AC 09AIK1  
DT 01-JUN-2001 (TReMBLrel. 17, Created)  
DT 01-JUN-2001 (TReMBLrel. 17, Last sequence update)  
DT 01-JUN-2001 (TReMBLrel. 17, Last annotation update)  
DE MAJOR OUTER MEMBRANE PROTEIN PRECURSOR (FRAGMENT).  
GN OMPA.  
OS Chlamydia psittaci (Chlamydothila psittaci).  
OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydothila.  
OX NCBI\_TaxID=83554;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN=VS225;  
RA Bush R.M., Everett K.D.;  
RL "Molecular evolution of the Chlamydiaceae.";  
Int. J. Syst. Evol. Microbiol. 51:203-220(2001).  
DR EMBL: AF269259; AAK00240.1; -  
KW Signal.  
FT NON\_TER 1 1  
FT SIGNAL <1 19 POTENTIAL.  
FT CHAIN 20 388 MAJOR OUTER MEMBRANE PROTEIN.  
SQ SEQUENCE 388 AA; 41573 MW; 8E232D22C9B9948D CRC64;

Query Match 68.1%; Score 62; DB 2; Length 388;  
Best Local Similarity 75.0%; Pred. No. 0.018;  
Matches 12; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 2 TGSAANYTTAVDRPN 17  
|||||:| | ||||  
Db 87 TGSAADYKTPTDRPN 102

RESULT 9  
09APM4 PRELIMINARY; PRT; 389 AA.  
ID 09APM4  
AC 09APM4  
DT 01-JUN-2001 (TReMBLrel. 17, Created)  
DT 01-JUN-2001 (TReMBLrel. 17, Last sequence update)  
DT 01-JUN-2001 (TReMBLrel. 17, Last annotation update)  
DE MAJOR OUTER MEMBRANE PROTEIN PRECURSOR.  
GN OMP1.  
OS Chlamydothila abortus.  
OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydothila.  
OX NCBI\_TaxID=83555;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN=LLG;  
RA Vretou E., Psarrou E., Kaisar M., Vlisidou I., Salti-Montesanto V.,  
Longbottom D.;  
RT "Identification of protective epitopes by sequencing of the major  
outer membrane protein gene of a variant strain of Chlamydia psittaci  
serotype 1.";  
RL Infect. Immun. 69:607-612(2001).  
DR EMBL: AF272945; AAG53881.1; -  
KW Signal.  
FT SIGNAL 1 22 POTENTIAL.  
FT CHAIN 23 389 MAJOR OUTER MEMBRANE PROTEIN.  
SQ SEQUENCE 389 AA; 41897 MW; 20513C65C7DBAAF5 CRC64;

Query Match 64.8%; Score 59; DB 2; Length 389;  
Best Local Similarity 68.8%; Pred. No. 0.059;  
Matches 11; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 2 TGSAANYTTAVDRPN 17  
||:||||| | ||||  
Db 90 TGTAADYKTPTDRPN 105

```

RESULT 10
ID Q99V50 PRELIMINARY; PRT; 557 AA.
AC Q99V50;
DT 01-JUN-2001 (TrEMBLrel. 17, Created)
DT 01-JUN-2001 (TrEMBLrel. 17, Last sequence update)
DE MENAQUINONE BIOSYNTHESIS PROTEIN.
GN MEND OR SA0896.
OS Staphylococcus aureus subsp. aureus N315.
OC Bacteria; Firmicutes; Bacillus/Clostridium group;
OC Bacillus/Staphylococcus group; Staphylococcus.
OX NCBI_TaxID=158879;
RN [1]
RP SEQUENCE FROM N.A.
RA Kuroda M., Ohta T., Uchiyama I., Baba T., Yuzawa H., Kobayashi I.,
RA Cui L., Oguchi A., Aoki K.I., Nagai Y., Lian J., Ito T., Kanamori M.,
RA Matsumaru H., Maruyama A., Murakami H., Hosoyama A., Mizutani-Ui Y.,
RA Takahashi N.K., Sawano T., Inoue R.I., Kaito C., Sekimizu K.,
RA Hirakawa H., Kuhara S., Goto S., Yabuzaki J., Kanehisa M.,
RA Yamashita A., Oshima K., Furuya K., Yoshino C., Shiba T., Hattori M.,
RA Ogasawara N., Hayashi H., Hiramatsu K.;
RT "Whole genome sequencing of methicillin-resistant Staphylococcus
RT aureus.";
RL Lancet 357:1225-1240(2001).
DR EMBL; AP003132; BAB42141.1;
KW Complete proteome.
SQ SEQUENCE 557 AA; 63091 MW; B38C5DA274972483 CRC64;

Query Match 52.7%; Score 48; DB 2; Length 557;
Best Local Similarity 39.4%; Pred. No. 6.2;
Matches 13; Conservative 3; Mismatches 1; Indels 16; Gaps 2;

QY 1 CT-GSAANYTTAV-----DRPN 17
|||:|||||:|
DB 78 CTGTAANYTPTAIAESQISRIPLIVLTSRPH 110
|||||:|

RESULT 11
ID Q9UR7 PRELIMINARY; PRT; 662 AA.
AC Q9UR7;
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DE HYPOTHETICAL 71.0 KDA PROTEIN.
GN DKF2P4340051.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RA TISSUE-TESTIS;
RA Poustka A., Klein M., Meves H.W., Gassenhuber J., Wiemann S.;
RA Submitted (SEP-1999) to the EMBL/GenBank/DBJ databases.
DR EMBL; AL117400; CAB55901.1;
DR InterPro; IPR000719; Euk_pkinase.
DR Pfam; PF00069; pkinase; 1.
DR PROSITE; PS00107; PROTEIN_KINASE_ATP; UNKNOWN_1.
DR PROSITE; PS00111; PROTEIN_KINASE_DOM; 1.
KW ATP-binding; Hypothetical protein; Transferase.
SQ SEQUENCE 662 AA; 71003 MW; 8756E82919F6093D CRC64;

Query Match 52.7%; Score 48; DB 4; Length 662;
Best Local Similarity 56.2%; Pred. No. 7.4;
Matches 9; Conservative 2; Mismatches 5; Indels 0; Gaps 0;

QY 1 CTGSAANYTTAVDRP 16
||||:|

```

```

||||:| | | |
DB 251 CTGSSSACYALATDLP 266

RESULT 12
Q14148 PRELIMINARY; PRT; 1241 AA.
ID Q14148;
AC Q14148;
DT 01-NOV-1996 (TrEMBLrel. 01, Created)
DT 01-NOV-1996 (TrEMBLrel. 01, Last sequence update)
DE KIAA0135 PROTEIN (FRAGMENT).
GN KIAA0135.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RA MEDLINE=96127530; PubMed=8590280;
RA Nagase T., Seki N., Tanaka A., Ishikawa K., Nomura N.;
RT "Prediction of the coding sequences of unidentified human genes. IV.
RT analysis of cDNA clones from human cell line KG-1.";
RL DNA Res. 2:167-174(1995).
RN [2]
RP SEQUENCE OF 1-54 FROM N.A.
RA Ceulemans H., Van Bynde A., Perez-Callejon E., Stalmans W., Bollen M.;
RT "Structure and splice products of the human gene encoding sds22, a
RT putative mitotic regulator of protein phosphatase-1.";
RL Submitted (MAY-1998) to the EMBL/GenBank/DBJ databases.
CC -1- SIMILARITY: TO THE SER/THR FAMILY OF PROTEIN KINASES.
DR EMBL; D50925; BAA09484.1;
DR EMBL; AF067137; AAC23506.1;
DR InterPro; IPR000719; Euk_pkinase.
DR InterPro; IPR000014; PAS.
DR InterPro; IPR002290; Ser_thr_kin_actsite.
DR InterPro; IPR001245; Tyr_kin.
DR Pfam; PF00989; PAS; 3.
DR Pfam; PF00069; pkinase; 1.
DR PRINTS; P00109; TYRKINASE.
DR SMART; SM00091; PAS; 2.
DR PROSITE; PS00107; PROTEIN_KINASE_ATP; UNKNOWN_1.
DR PROSITE; PS00111; PROTEIN_KINASE_DOM; 1.
DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
KW ATP-binding; Hypothetical protein; Serine/threonine-protein kinase;
KW Transferase.
FT NON_TER 1
SQ SEQUENCE 1241 AA; 134103 MW; B651937986664A84 CRC64;

Query Match 52.7%; Score 48; DB 4; Length 1241;
Best Local Similarity 56.2%; Pred. No. 14;
Matches 9; Conservative 2; Mismatches 5; Indels 0; Gaps 0;

QY 1 CTGSAANYTTAVDRP 16
||||:| | | |
DB 619 CTGSSSACYALATDLP 634

RESULT 13
Q9K5C5 PRELIMINARY; PRT; 326 AA.
ID Q9K5C5;
AC Q9K5C5;
DT 01-OCT-2000 (TrEMBLrel. 15, Created)
DT 01-OCT-2000 (TrEMBLrel. 15, Last sequence update)
DE OUTER MEMBRANE PROTEIN 1 (FRAGMENT).
GN OMP1.
OS Chlamydia psittaci (Chlamydia phila psittaci).
OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydia phila.
OX NCBI_TaxID=83554;
RN [1]

```

```
RP SEQUENCE FROM N.A.
RC STRAIN-R54;
RX PubMed-10919838;
RA Herrmann B., Rahman R., Bergstrom S., Bonnedahl J., Olsen B.;
RT "Chlamydomophila abortus in a Brown Skua (Catharacta antarctica
lonnbergi) from a Subantarctic Island.";
RL Appl. Environ. Microbiol. 66:3654-3656(2000).
DR EMBL; AJ243525; CAB96859.1; -.
DR InterPro; IPR000604; Chlamydia_OMP.
DR PRINTS; PR01308; Chlamydia_OMP; 1.
DR ProDom; PD001717; Chlamydia_OMP; 1.
FT NON_TER 1
FT NON_TER 326
FT CHAIN 326
SQ SEQUENCE 326 AA; 35345 MW; 6C5A20C8913743C8 CRC64;

Query Match 51.6%; Score 47; DB 2; Length 326;
Best Local Similarity 62.3%; Pred. No. 5.3;
Matches 10; Conservative 1; Mismatches 5; Indels 0; Gaps 0;

QY 2 TGSAAANYTTAVDRPN 17
   ||||| . | | | |
Db 36 TGSAAQDYKAAEDRAN 51

RESULT 14
Q9AIH9 PRELIMINARY; PRT; 389 AA.
AC Q9AIH9;
DT 01-JUN-2001 (TrEMBLrel. 17, Created)
DE 01-JUN-2001 (TrEMBLrel. 17, Last sequence update)
DE 01-JUN-2001 (TrEMBLrel. 17, Last annotation update)
DT MAJOR OUTER MEMBRANE PROTEIN PRECURSOR.
GN OMPA.
OS Chlamydomophila caviae.
OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydomophila.
NCBI_TaxID=83557;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN-GUINEA PIG INCLUSION CONJUNCTIVITIS, GPIC, ATCC VR813;
RX MEDLINE-89212917; PubMed-2707861;
RA Zhang Y.X., Morrison S.G., Caldwell H.D., Baehr W.;
RT "Cloning and sequence analysis of the major outer membrane protein
genes of two Chlamydia psittaci strains.";
RL Infect. Immun. 57:1621-1625(1989).
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN-GUINEA PIG INCLUSION CONJUNCTIVITIS, GPIC, ATCC VR813;
RX MEDLINE-21078680; PubMed-11211261;
RA Bush R.M., Everett K.D.;
RT "Molecular evolution of the Chlamydiaceae.";
RL Int. J. Syst. Evol. Microbiol. 51:203-220(2001).
DR EMBL; AF269282; AAK00263.1; -.
KW Signal.
FT SIGNAL 1 22 POTENTIAL.
FT CHAIN 23 389 MAJOR OUTER MEMBRANE PROTEIN.
SQ SEQUENCE 389 AA; 41932 MW; 2527A820C76F8310 CRC64;

Query Match 51.6%; Score 47; DB 2; Length 389;
Best Local Similarity 56.2%; Pred. No. 6.3;
Matches 9; Conservative 3; Mismatches 4; Indels 0; Gaps 0;

QY 2 TGSAAANYTTAVDRPN 17
   ||||| . | | | |
Db 89 TGSAAADFKTVADRNN 104

RESULT 15
Q9K5N9 PRELIMINARY; PRT; 168 AA.
ID Q9K5N9
AC Q9K5N9;
```

```
DT 01-OCT-2000 (TrEMBLrel. 15, Created)
DT 01-OCT-2000 (TrEMBLrel. 15, Last sequence update)
DT 01-JUN-2001 (TrEMBLrel. 17, Last annotation update)
DE SINGLE-STRAND DNA-BINDING PROTEIN (PHAGE-RELATED PROTEIN).
GN SSB OR BH4049.
OS Bacillus halodurans.
OC Bacteria; Firmicutes; Bacillus/Clostridium group;
OC Bacillus/Staphylococcus group; Bacillus.
OX NCBI_TaxID=86665;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN-C-125 / JCM 9153;
RX MEDLINE-20512582; PubMed-11058132;
RA Takami H., Nakasone K., Takaki Y., Maeno G., Sasaki R., Masui N.,
RA Fuji F., Hiramata C., Nakamura Y., Ogasawara N., Kuhara S.,
RA Horikoshi K.;
RT "Complete genome sequence of the alkaliphilic bacterium Bacillus
halodurans and genomic sequence comparison with Bacillus subtilis.";
RL Nucleic Acids Res. 28:4317-4331(2000).
DR EMBL; AF001520; BAB07768.1; -.
DR InterPro; IPR000424; SSB.
DR Pfam; PF00436; SSB; 1.
DR PROSITE; PS00735; SSB_1; 1.
KW DNA-binding; Complete proteome.
SQ SEQUENCE 168 AA; 18220 MW; 0D7C702E656232F6 CRC64;

Query Match 50.5%; Score 46; DB 2; Length 168;
Best Local Similarity 64.3%; Pred. No. 3.9;
Matches 9; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 3 GSAAANYTTAVDRP 16
   | | | | | | | | | |
Db 23 GVAVANFTLAVNRP 36

Search completed: March 26, 2002, 13:40:11
Job time: 225 sec
```





GenCore version 4.5  
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: March 26, 2002, 13:38:45 ; Search time 81.51 seconds  
(without alignments)  
15.449 Million cell updates/sec

Title: US-09-709-201-96

Perfect score: 85

Sequence: 1 CASOTASNTTVAADRSN 17

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 522463 seqs, 74073290 residues

Total number of hits satisfying chosen parameters: 522463

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Maximum Match 0%

Listing first 45 summaries

Database :

- A\_Geneseq\_1101.\*
- 1: /SID88/gcgdata/geneseq/geneseq/AA1980.DAT.\*
  - 2: /SID88/gcgdata/geneseq/geneseq/AA1981.DAT.\*
  - 3: /SID88/gcgdata/geneseq/geneseq/AA1982.DAT.\*
  - 4: /SID88/gcgdata/geneseq/geneseq/AA1983.DAT.\*
  - 5: /SID88/gcgdata/geneseq/geneseq/AA1984.DAT.\*
  - 6: /SID88/gcgdata/geneseq/geneseq/AA1985.DAT.\*
  - 7: /SID88/gcgdata/geneseq/geneseq/AA1986.DAT.\*
  - 8: /SID88/gcgdata/geneseq/geneseq/AA1987.DAT.\*
  - 9: /SID88/gcgdata/geneseq/geneseq/AA1988.DAT.\*
  - 10: /SID88/gcgdata/geneseq/geneseq/AA1989.DAT.\*
  - 11: /SID88/gcgdata/geneseq/geneseq/AA1990.DAT.\*
  - 12: /SID88/gcgdata/geneseq/geneseq/AA1991.DAT.\*
  - 13: /SID88/gcgdata/geneseq/geneseq/AA1992.DAT.\*
  - 14: /SID88/gcgdata/geneseq/geneseq/AA1993.DAT.\*
  - 15: /SID88/gcgdata/geneseq/geneseq/AA1994.DAT.\*
  - 16: /SID88/gcgdata/geneseq/geneseq/AA1995.DAT.\*
  - 17: /SID88/gcgdata/geneseq/geneseq/AA1996.DAT.\*
  - 18: /SID88/gcgdata/geneseq/geneseq/AA1997.DAT.\*
  - 19: /SID88/gcgdata/geneseq/geneseq/AA1998.DAT.\*
  - 20: /SID88/gcgdata/geneseq/geneseq/AA1999.DAT.\*
  - 21: /SID88/gcgdata/geneseq/geneseq/AA2000.DAT.\*
  - 22: /SID88/gcgdata/geneseq/geneseq/AA2001.DAT.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	85	100.0	17	20 AAW95323	Costant and variab
2	46	54.1	163	21 AAY94712	Tumour necrosis fa
3	46	54.1	165	21 AAB00014	Peptide fragment o
4	46	54.1	183	16 AAR77421	BamTP delta53 nerv
5	46	54.1	198	21 AAY94720	Human type 2 tumou
6	46	54.1	225	21 AAY77463	Primate protein se
7	46	54.1	227	22 AAB66981	Tnfr2 protein. Un
8	46	54.1	235	19 AAW59665	Human soluble tumo
9	46	54.1	235	19 AAW52270	Tumour necrosis fa
10	46	54.1	235	20 AAW89234	Tumour necrosis in
11	46	54.1	235	21 AAY54440	Amino acid sequenc

12	46	54.1	235	21 AAY54441	Amino acid sequenc
13	46	54.1	235	21 AAY54442	A K108R/K120R muta
14	46	54.1	235	21 AAY54443	Wild type N-termina
15	46	54.1	235	22 AAB37685	Human 40 kDa TNF i
16	46	54.1	248	21 AAY94718	Human type 2 tumou
17	46	54.1	392	12 AAR11605	Human 75kD TNF-bin
18	46	54.1	392	20 AAY30935	Human tumour necro
19	46	54.1	461	12 AAR11001	40kD TNF inhibitor
20	46	54.1	461	12 AAR11141	Human TNF-R deduce
21	46	54.1	461	14 AAR42058	Fibroblast derived
22	46	54.1	461	16 AAR72504	p75 Tumour Necrosi
23	46	54.1	461	21 AAB37801	Human tumour necro
24	46	54.1	461	21 AAB18717	A human tumour nec
25	46	54.1	461	21 AAB01342	Death receptor. H
26	46	54.1	461	22 AAB35331	Human TNF receptor
27	46	54.1	461	22 AAB36698	Human tumour necro
28	46	54.1	461	22 AAB37686	Human 40 kDa TNF i
29	46	54.1	485	13 AAR24016	Fusion protein TNF
30	46	54.1	518	15 AAR51003	Sequence of a reco
31	46	54.1	518	22 AAB70001	STNFR(075):Fc fusi
32	46	54.1	518	22 AAB50080	TNFR:Fc fusion pro
33	43	50.6	17	20 AAW95320	Costant and variab
34	43	50.6	287	22 AAB94116	Human protein sequ
35	43	50.6	427	21 AAB43107	Human OREX ORF2871
36	42	49.4	389	21 AAY59209	B. halodurans clon
37	41	48.2	227	21 AAY77462	Rodent protein seq
38	41	48.2	258	22 AAB50082	Rat TNFR (p80) ext
39	41	48.2	474	12 AAR11142	TNFR-R deduced from
40	41	48.2	487	22 AAB50084	TNFR:Fc fusion pro
41	40	47.1	213	22 AAB62541	B. melitensis viru
42	40	47.1	604	21 AAB27324	B. vulgaris NIM1 h
43	40	47.1	802	16 AAR70111	TBP11-GBP 130 fusi
44	40	47.1	802	16 AAR70112	TNFR-R-GBP 130 fusi
45	40	47.1	826	21 AAG38474	Arabidopsis thalia

ALIGNMENTS

RESULT 1

AAW95323  
ID AAW95323 standard; Protein; 17 AA.

AC AAW95323;

XX AC

DT 15-MAR-1999 (first entry)

XX Costant and variable domain sequence of C. psitacaci CPS92-106.

DE Chlamydia; cryptic phase; elementary body phase; replicating; probedicid;  
KW antiporphyrin acid; immune response; infection; diagnostic; assay; MOMP;  
KW major outer membrane protein; autoimmunity; inflammatory; porphyria;  
KW Ebstein Barr virus; antioxidant.

XX Chlamydia psitacaci.

XX WO9850074-A2.

PN 12-NOV-1998.

PD 06-MAY-1998;

PF 98WO-US09237.

XX 18-FEB-1998;

PR 98US-0025521.

PR 97US-0045689.

PR 97US-0045739.

PR 97US-0045779.

PR 97US-0045780.

PR 97US-0045784.

PR 97US-0045787.

PR 97US-0911593.

PR 98US-0025174.

PR 98US-0025176.

PA (UYVA-) UNIV VANDERBILT.  
 XX Mitchell WM, Stratton CW;  
 PI WPI; 1999-059653/05.  
 XX  
 XX Composition with two agents effective against different stages of  
 PT chlamydial life cycle - comprises agent targetted against cryptic  
 PT phase, against elementary body phase, against replicating phase,  
 PT probenicid and antiporphyrin  
 XX  
 PS Claim 4; Fig 3; 138pp; English.  
 XX  
 CC The invention relates to the diagnosis and management of infections by  
 CC Chlamydia species. The invention provides a composition that comprises  
 CC at least two agents, where each of the agents is effective against a  
 CC different phase of the chlamydial life cycle. The agents are selected  
 CC from: (a) agents targetted against cryptic phase of chlamydial life  
 CC cycle; (b) agents targetted against elementary body phase of chlamydial  
 CC life cycle; (c) agents targetted against replicating phase of chlamydial  
 CC life cycle; (d) probenicid; and (e) antiporphyrin acid. The composition  
 CC is used to elicit a protective immune response to Chlamydia infection in  
 CC an animal or human and is applied until the animal or human tests  
 CC negative for Chlamydia infection. It is also used to treat biological  
 CC material infected with Chlamydia. Diagnostic kits for antibody assays  
 CC against recombinant major outer membrane protein (MOMP), and for DNA  
 CC amplification assays for chlamydial genes, are used to diagnose disease,  
 CC e.g. autoimmune disease, an inflammatory disease or a disease that  
 CC occurs in an immuno-compromised individual, associated with Chlamydia  
 CC infection. The kits are used to detect chlamydial elementary bodies in a  
 CC sample. They are also used to monitor and/or modify the course of therapy  
 CC in a patient. The treatment reduces the acellular load of infectious  
 CC Ebsstein Barr virus. The method is also used to treat porphyria, by  
 CC reducing the number of elementary bodies and applying a drug, e.g.  
 CC cimetidine, and antioxidants, to reduce the adverse effects associated  
 CC with porphyria. Sequences AA95320 to AA95333 represent constant and  
 CC variable domain sequences of various Chlamydia species.  
 XX  
 XX Sequence 17 AA;  
 XX  
 Query Match 100.0%; Score 85; DB 20; Length 17;  
 Best Local Similarity 100.0%; Pred. No. 1.3e-07;  
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 CASGTASNTTVAADRSN 17  
 DB 1 casgtasntttvaadrsn 17  
 |||||  
 RESULT 2  
 ID AAY94712  
 XX AAY94712 standard; Protein; 163 AA.  
 AC AAY94712;  
 XX  
 XX 29-JAN-2001 (first entry)  
 XX  
 XX Tumour necrosis factor receptor (TNFR) domain of TNFR-II.  
 XX  
 KW Tumour necrosis factor-receptor related protein; TR2; human; cancer;  
 KW chromosome p36.2-p36.3; arthritis; inflammation; autoimmune disease;  
 KW immunodeficiency; metastasis; haemolytic anaemia; asthma; X-linked SCID;  
 KW severely combined immunodeficiency; apoptosis inhibition;  
 KW Alzheimer's disease; Parkinson's disease; Crohn's disease.  
 XX  
 OS Homo sapiens.  
 PN WO200056405-A2.  
 XX  
 PD 28-SEP-2000.  
 XX  
 XX 22-MAR-2000; 2000WO-US07521.  
 PF

XX 22-MAR-1999; 99US-0125683.  
 PR 26-MAR-1999; 99US-0126522.  
 PR 20-MAY-1999; 99US-0135169.  
 PR 06-AUG-1999; 99US-0147383.  
 XX  
 XX (NIJJ/) NI J.  
 PA (ROSE/) ROSEN C A.  
 PA (GENTZ/) GENTZ R L.  
 XX  
 PI Ni J, Rosen CA, Gentz RL;  
 XX  
 DR WPI; 2000-594519/56.  
 XX  
 XX Nucleic acid molecule encoding a human tumor necrosis factor receptor 2  
 PT and its two splice variants, useful for treating arthritis or  
 PT inflammation, cancer (such as follicular lymphomas) and  
 PT immunodeficiency disorders -  
 XX  
 PS Disclosure; Fig 16; 373pp; English.  
 XX  
 CC This invention relates to an isolated nucleic acid molecule encoding a  
 CC human tumour necrosis factor (TNF)-receptor related protein TR2. Included  
 CC in the invention are the two splice variants of TR2, TR2-SV1 and TR2-SV2.  
 CC The TR2 gene is located on chromosome 1 at position p36.2-p36.3. TR2 is a  
 CC member of the TNFR superfamily. The invention includes a method for the  
 CC treatment of arthritis or inflammation using an antibody directed against  
 CC a fragment of the TR2 protein. TR2 its agonists, antagonists and  
 CC antibodies exhibit cytostatic, dermatological, antianemic,  
 CC immunosuppressive, anti-allergic, antiarthritic, antiparkinsonian, and  
 CC antiinflammatory, neuroprotective, nootropic, antiparkinsonian, and  
 CC cerebroprotective activity. The methods are useful for treating arthritis  
 CC or inflammation, cancer (such as follicular lymphomas, carcinoma with p53  
 CC mutations, cardiac tumours, pancreatic, breast, or prostate cancer), an  
 CC immunodeficiency or for enhancing an in vivo leukocyte response to an  
 CC antigen. Anti-TR2 antibodies are useful for treating, inhibiting or  
 CC preventing autoimmune diseases (such as autoimmune haemolytic anaemia,  
 CC dermatitis, allergic encephalomyelitis, rheumatoid arthritis, asthma, and  
 CC inflammatory myopathies) and immunodeficiency disorders (such as severely  
 CC combined immunodeficiency (SCID)-X linked, B cell lymphoproliferative  
 CC disorder, or Nezelof syndrome-combined immunodeficiency with IgS). TR2,  
 CC TR2-SV1 and/or TR2-SV2 polynucleotides and polypeptides, agonists or  
 CC antagonists are useful for treating or preventing autoimmune diseases and  
 CC inhibit the growth, progression and/or metastasis of cancers. They are  
 CC also used to activate, differentiate or proliferate cancerous cells or  
 CC tissues, and can be used to treat diseases associated with increased cell  
 CC survival, or the inhibition of apoptosis, e.g. Alzheimer's disease,  
 CC Parkinson's disease, or Crohn's disease. The TR2 polypeptides are useful  
 CC as sources for generating antibodies, as molecular weight markers.  
 CC This sequence represents the tumour necrosis factor receptor (TNFR)  
 CC domain of the human TNFR-II protein. The sequence was used in the  
 CC characterisation of the TR2 receptor protein of the invention.  
 XX  
 XX Sequence 163 AA;  
 XX  
 Query Match 54.1%; Score 46; DB 21; Length 163;  
 Best Local Similarity 64.3%; Pred. No. 4.6;  
 Matches 9; Conservative 1; Mismatches 4; Indels 0; Gaps 0;  
 QY 1 CASGTASNTTVAAD 14  
 DB 126 capgtftsntssd 139  
 |||||  
 RESULT 3  
 ID AAB00014  
 XX AAB00014 standard; Peptide; 165 AA.  
 AC AAB00014;  
 XX  
 XX 20-OCT-2000 (first entry)  
 XX

DE Peptide fragment of TNFR2.  
 XX Tumour necrosis factor receptor homologue; TRH1; TNF; arthritis;  
 KW transplant rejection; activation; proliferation; differentiation;  
 KW apoptosis; immunosuppression; antiinflammatory; immunostimulation;  
 KW probe; primer; human.  
 XX Homo sapiens.  
 OS  
 XX W0200034294-A2.  
 PN  
 XX 15-JUN-2000.  
 PD  
 XX 10-DEC-1999; 99WO-US29400.  
 XX  
 XX 11-DEC-1998; 98US-0111826.  
 XX  
 XX (BRIM ) BRISTOL-MYERS SQUIBB CO.  
 XX  
 XX Bowen MA, Siemers N;  
 PI  
 XX WPI: 2000-423364/36.  
 DR  
 XX Novel tumor necrosis factor receptor homologue-1 useful as a target for  
 PT immunosuppressive, antiinflammatory and/or immunostimulatory drug  
 PT development  
 PT  
 XX Disclosure; Fig 5; 42pp; English.  
 PS  
 XX The tumour necrosis factor receptor homologue TRH1 can be used for  
 CC treating a mammal e.g. a human, at risk for a disorder characterized  
 CC by an aberrant or unwanted level or biological activity of TRH1,  
 CC e.g. rheumatoid arthritis and transplant rejection. TRH1 may also be  
 CC useful to leach out or block a ligand which is found to bind to the  
 CC TRH1. TRH1 may be used in various drug screening techniques and to  
 CC identify fragments and analogs of a protein or peptide (agonist or  
 CC antagonist) which bind to TRH1. The TRH1 protein plays a role in  
 CC cellular function, cell activation, proliferation, differentiation,  
 CC and apoptosis. The interaction between the novel TNF protein of the  
 CC present invention and intracellular signaling molecules and/or its  
 CC potential co-receptor may serve as a novel target for  
 CC immunosuppressive, antiinflammatory and/or immunostimulatory drug  
 CC development. Gene constructs can also be used as part of a gene  
 CC therapy protocol to deliver nucleic acids encoding the TRH1, or an  
 CC agonist or antagonist form of a TRH1 protein or peptide. Antibody  
 CC directed against TRH1 can be used to reject TRH1 in tissues  
 CC and cells. They can also be used to make targeted antibody that  
 CC destroy TRH1 expressing cells. Fragments of the TRH1 gene can be  
 CC used as diagnostic probes or as PCR primers. Fragments of the full  
 CC length gene may be used as hybridization probes for a cDNA library to  
 CC isolate the full length gene and to isolate other genes which have a  
 CC high sequence similarity. The probes may be used to identify a cDNA  
 CC clone corresponding to a full length transcript and a genomic clone  
 CC or clones that contain the complete gene including regulatory and  
 CC promoter regions, exons, and introns. This peptide fragment  
 CC corresponds to amino acids 38-202 of TNFR2 was used in a  
 CC homology comparison with TRH1. This cysteine rich motif was aligned  
 CC with the extracellular region of TRH1 (See GENESEQ record AAB00012).  
 XX  
 SQ Sequence 165 AA;  
 Query Match 54.1%; Score 46; DB 21; Length 165;  
 Best Local Similarity 64.3%; Pred. No. 4.6;  
 Matches 9; Conservative 1; Mismatches 4; Indels 0; Gaps 0;  
 Qy 1 CASGTASNTTVAAD 14  
 |||||:  
 Db 127 capgtfsnttsstd 140  
 RESULT 4  
 AAR77421

ID AAR77421 standard; Protein; 183 AA.  
 XX  
 AC AAR77421;  
 XX  
 DT 10-FEB-1996 (first entry)  
 XX  
 DE BamTP delta53 nerve growth factor sequence.  
 XX  
 XX Nerve growth factor; neurotrophic factor; therapeutic;  
 KW protein refolding; NGF; plasmid pT3XI-2.  
 XX  
 OS Synthetic.  
 XX  
 PN W09530686-A1.  
 XX  
 PD 16-NOV-1995.  
 XX  
 XX 02-MAY-1995; 95WO-US05423.  
 XX  
 XX 27-JUN-1994; 94US-0266080.  
 PR  
 XX 09-MAY-1994; 94US-0240122.  
 XX  
 XX (SYNT ) SYNTX-SYNERGEN NEUROSCIENCE JOINT VENTU.  
 PA  
 XX Bonam D, Kohno T, Lille J, Rosendahl MS;  
 PI  
 XX WPI: 1995-404080/51.  
 XX  
 DR N-PSDB; AAT05443.  
 DR  
 XX Process for bacterial expression of recombinant neurotrophic factor  
 PT - useful for promoting the survival and maintaining phenotypic  
 PT differentiation of nerve and glial cells.  
 PT  
 XX Example 1; Page 36-37; 57pp; English.  
 PS  
 XX The synthetic nerve growth factor (NGF) gene isolated from Bam TP  
 CC delta 53 plasmid pT3XI-2 is designed to optimize codons for  
 CC expression in Escherichia coli as well as create unique sites for  
 CC subsequent cloning steps. The recombinant protein is solubilized  
 CC and sulfonlated and allowed to refold in the presence of PEG and  
 CC urea. Biologically active NGF, used for promoting the survival of  
 CC and maintaining the phenotypic differentiation of nerve and glial  
 CC cells, is isolated and purified. This method breaks incorrectly  
 CC formed disulphide bonds and allows refolding of the factor into  
 CC the correct tertiary structure required for maximum yield of full  
 CC active protein.  
 XX  
 SQ Sequence 183 AA;  
 Query Match 54.1%; Score 46; DB 16; Length 183;  
 Best Local Similarity 64.3%; Pred. No. 5.2;  
 Matches 9; Conservative 1; Mismatches 4; Indels 0; Gaps 0;  
 Qy 1 CASGTASNTTVAAD 14  
 |||||:  
 Db 143 capgtfsnttsstd 156  
 RESULT 5  
 AAY94720  
 ID AAY94720 standard; Protein; 198 AA.  
 XX  
 AC AAY94720;  
 XX  
 DT 29-JAN-2001 (first entry)  
 XX  
 DE Human type 2 tumour necrosis factor receptor protein fragment.  
 XX  
 XX Tumour necrosis factor-receptor related protein; TR2; human; cancer;  
 KW chromosome p36.2-p36.3; arthritis; inflammation; autoimmune disease;  
 KW immunodeficiency; metastasis; haemolytic anaemia; asthma; X-linked SCID;  
 KW severely combined immunodeficiency; apoptosis inhibition;

KW Alzheimer's disease; Parkinson's disease; Crohn's disease.

XX Homo sapiens.

XX WO200056405-A2.

XX 28-SEP-2000.

XX 22-MAR-2000; 2000WO-US07521.

XX 22-MAR-1999; 99US-0125683.

XX 26-MAR-1999; 99US-0126522.

XX 20-MAY-1999; 99US-0135169.

XX 06-AUG-1999; 99US-0147383.

XX (NIJJ/) NI J.

XX (ROSE/) ROSEN C A.

XX (GENTZ/) GENTZ R L.

XX NI J, Rosen CA, Gentz RL;

XX WPI; 2000-594519/56.

XX Disclosure; Fig 8; 373pp; English.

XX This invention relates to an isolated nucleic acid molecule encoding a human tumor necrosis factor (TNF)-receptor related protein TR2. Included in the invention are the two splice variants of TR2, TR2-SV1 and TR2-SV2. The TR2 gene is located on chromosome 1 at position p36.2-p36.3. TR2 is a member of the TNFR superfamily. The invention includes a method for the treatment of arthritis or inflammation using an antibody directed against a fragment of the TR2 protein. TR2 is an agonist, antagonist and antibodies exhibit cytostatic, dermatological, antineoplastic, immunosuppressive, antiallergic, antiarthritic, antiasthmatic, antiinflammatory, neuroprotective, neurotropic, antiparkinsonian, and cerebroprotective activity. The methods are useful for treating arthritis or inflammation, cancer (such as follicular lymphomas, carcinoma with p53 mutations, cardiac tumors, pancreatic, breast, or prostate cancer), an immunodeficiency or for enhancing an in vivo leukocyte response to an antigen. Anti-TR2 antibodies are useful for treating, inhibiting or preventing autoimmune diseases (such as autoimmune hemolytic anemia, dermatitis, allergic encephalomyelitis, rheumatoid arthritis, asthma, and inflammatory myopathies) and immunodeficiency disorders (such as severely combined immunodeficiency (SCID)-X linked, B cell lymphoproliferative disorder, or Nezelof syndrome-combined immunodeficiency with Igs). TR2, TR2-SV1 and/or TR2-SV2 polynucleotides and polypeptides, agonists or antagonists are useful for treating or preventing autoimmune diseases and inhibit the growth, progression and/or metastasis of cancers. They are also used to activate, differentiate or proliferate cancerous cells or tissues, and can be used to treat diseases associated with increased cell survival, or the inhibition of apoptosis, e.g. Alzheimer's disease, Parkinson's disease, or Crohn's disease. The TR2 polypeptides are useful as sources for generating antibodies, as molecular weight markers.

XX This sequence represents a fragment of the type 2 human tumor necrosis factor receptor protein. The sequence is used in the characterization of the TR2 receptor protein of the invention.

XX Sequence 198 AA;

XX Query Match 54.18; Score 46; DB 21; Length 198;

XX Best Local Similarity 64.39; Pred. No. 5.7;

XX Matches 9; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

QY 1 CASGTASNTTVAAD 14

DB 164 capgfsntstsd 177

# RESULT 6

AA777463

ID AAY77463 standard; Protein; 225 AA.

XX AAY77463;

XX 05-JUN-2000 (first entry)

XX Primate protein sequence, SEQ ID NO:14.

XX Immune disorder; inflammation; allergy; immunosuppressant; antiarthritic; antirheumatoid; antiinflammatory; dermatological; antithyroid.

XX Primates.

XX WO200001817-A2.

XX 13-JAN-2000.

XX 06-JUL-1999; 99WO-US12366.

XX 06-JUL-1998; 98US-0110938.

XX 13-JUL-1998; 98US-0114466.

XX 23-JUL-1998; 98US-0093897.

XX 12-AUG-1998; 98US-0132968.

XX 18-AUG-1998; 98US-0136214.

XX 11-SEP-1998; 98US-0099999.

XX (SCHE ) SCHERING CORP.

XX Bates EEM, Lebecque SJE, Murphy EE, Mattson JD, Gorman DM;

XX Hedrick JA, Wang L, Zlotnick A, Murgolo NJ, Greene JR, Johnston JA;

XX Bazan JF, Mahony D, Lees EM;

XX WPI; 2000-171015/15.

XX New isolated mammalian genes, used to develop products for treating e.g. immune, inflammatory or allergic abnormalities, cancers or degenerative conditions

XX Disclosure; Page 170-171; 218pp; English.

XX The invention relates to a number of primate and/or rodent proteins, and the genes which encode them. The invention encompasses human dendritic cell prostaglandin transporter (DC-PGT); the TNF (tumour necrosis factor) receptor family-related proteins HDTEA84, HSLJP37R and RANKL; human CC chemokine HCC5; human deubiquitinating proteins Dub11 and Dub 12; human MD-1 and human and murine MD-2 proteins, which exhibit the properties of ligands for proteins comprising a leucine-rich motif (LRR); human cyclin E2; cDNAs encoding these proteins; and antibodies against these proteins. The proteins can be used for modulating the physiology or development of a cell. They can be used to mediate uptake of substrates (e.g., prostaglandin-like molecules), to modulate or mediate cellular interactions (e.g., induce or prevent trafficking, proliferation, or differentiation of cells), or are intracellular proteins which are important in various cellular processes such as the deubiquitination of proteins or cell cycle regulation. The products can be used for treating medical conditions such as immune, inflammatory or allergic disorders, or abnormal cellular proliferation, for example, cancers or degenerative conditions. They can be used to modulate immune responses in disease states e.g., autoimmune disorders, including rheumatoid arthritis, systemic lupus erythematosus, Hashimoto's autoimmune thyroiditis, as well as acute and chronic inflammatory responses in which T cell activation, expansion, and/or immunological T cell memory play an important role. Sequences AAY77463-Y77464, AAY77474-Y77475 and AAY77484 represent primate proteins of undefined function, AAY77462 and AAY77481 are rodent proteins of undefined function, and AAY77482 is an avian protein of undefined function. These sequences are given in the sequence listing but are not referred to in the remainder of the specification.

XX

SQ Sequence 225 AA;

Query Match 54.1%; Score 46; DB 21; Length 225;  
Best Local Similarity 64.3%; Pred. No. 6.6;  
Matches 9; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

QY 1 CASGTASNTTVAAD 14  
||| ||||| : I  
Db 164 capgtfsnttsstd 177

RESULT 7

AA866981  
ID AAB66981 standard; Protein; 227 AA.

XX AC AAB66981;

XX DT 19-APR-2001 (first entry)

XX DE Tnfr2 protein.

XX KW Bone loss; osteoprotegerin; OPG; rheumatoid arthritis; hyperalgesia;  
XX KW multiple sclerosis; osteoporosis; osteomyelitis; asthma; inflammation;  
XX KW systemic lupus erythematosus; graft-versus-host disease; septic shock;  
XX KW acute pancreatitis; Alzheimer's disease; anorexia; atherosclerosis; pain;  
XX KW coronary condition; myocardial infarction; cancer; diabetes; psoriasis;  
XX KW endometriosis; fever; glomerulonephritis; inflammatory bowel disease;  
XX KW ischaemia; Parkinson's disease.

XX OS Unidentified.

XX PN W0200103719-A2.

XX PD 18-JAN-2001.

XX PF 07-JUL-2000; 2000WO-US18667.

XX PR 09-JUL-1999; 99US-0350670.

XX PR 09-DEC-1999; 99US-0457647.

XX PA (AMGE-) AMGEN INC.

XX PI Boyle WJ, Lacey DL, Calzone FJ, Chang M, Senaldi G;

XX PS WPI; 2001-103031/11.

XX PT Treating conditions leading to bone loss such as rheumatoid arthritis,  
XX PT multiple sclerosis and asthma, comprises administering an  
XX PT osteoprotegerin protein in conjunction with e.g. inhibitors of  
XX PT interleukin and tumor necrosis factor alpha

XX PS Disclosure; Fig 2; 316pp; English.

XX CC The present invention relates to a method for treating conditions leading  
XX CC to bone loss. The method comprises administering a purified and isolated  
XX CC osteoprotegerin (OPG) protein (AAF57836-AAF57838 and AAB66974-AAB66976)  
XX CC in conjunction with other substances such as tumour necrosis factor-alpha  
XX CC (TNF-alpha) inhibitors, interleukin (IL)-6, -8 and -18 inhibitors, ICE  
XX CC modulators, fibroblast growth factor (FGF)1-10 modulators and/or platelet  
XX CC activating factor (PAF) antagonists. The method is useful for treating  
XX CC conditions leading to bone loss such as rheumatoid arthritis, multiple  
XX CC sclerosis, osteoporosis, osteomyelitis and asthma. The method is also  
XX CC useful for treating inflammation, systemic lupus erythematosus (SLE) and  
XX CC graft-versus-host disease (GVHD). Other diseases that can be treated  
XX CC include acute pancreatitis, Alzheimer's disease, anorexia,  
XX CC atherosclerosis, coronary conditions (e.g. myocardial infarction),  
XX CC cancer, diabetes, endometriosis, fever, glomerulonephritis, hyperalgesia,  
XX CC inflammatory bowel disease, ischaemia, pain, Parkinson's disease,  
XX CC psoriasis and septic shock. The present sequence was used in a sequence  
XX CC homology comparison.

XX SQ Sequence 227 AA;

Query Match 54.1%; Score 46; DB 22; Length 227;  
Best Local Similarity 64.3%; Pred. No. 6.7;  
Matches 9; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

QY 1 CASGTASNTTVAAD 14  
||| ||||| : I  
Db 164 capgtfsnttsstd 177

RESULT 8

AAW59665

ID AAW59665 standard; Protein; 235 AA.

XX AC AAW59665;

XX DT 28-SEP-1998 (first entry)

XX DE Human soluble tumour necrosis factor receptor type II.

XX KW Human; tumour necrosis factor; TNF; TNF receptor type II;  
XX KW inflammatory disease; leukaemia; TNF binding protein;  
XX KW anti-inflammatory drug; methotrexate.

XX OS Homo sapiens.

XX PN W09824463-A2.

XX PD 11-JUN-1998.

XX PF 08-DEC-1997; 97WO-US22733.

XX PR 09-JUL-1997; 97US-0052023.

XX PR 06-DEC-1996; 96US-0032587.

XX PR 23-JAN-1997; 97US-0036355.

XX PR 07-FEB-1997; 97US-0039315.

XX PA (AMGE-) AMGEN INC.

XX PI Bendele AM, Edwards CK, Sennello RM;

XX DR WPI; 1998-333039/29.

XX DR N-PSDB; AAV41549.

XX PT Treatment of acute or chronic inflammatory disease, e.g. leukaemia -  
XX PT by administering tumour necrosis factor binding protein and at least  
XX PT one additional anti-inflammatory drug, e.g. methotrexate

XX PS Disclosure; Fig 2; 104pp; English.

XX CC This is the amino acid sequence of the human tumour necrosis factor  
XX CC receptor type II, used in the method of the invention involving the  
XX CC treatment of acute or chronic inflammatory disease such as leukaemia  
XX CC by administering tumour necrosis factor binding protein and at least  
XX CC one additional anti-inflammatory drug, e.g. methotrexate.

XX SQ Sequence 235 AA;

Query Match 54.1%; Score 46; DB 19; Length 235;  
Best Local Similarity 64.3%; Pred. No. 6.9;  
Matches 9; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

QY 1 CASGTASNTTVAAD 14  
||| ||||| : I  
Db 142 capgtfsnttsstd 155

RESULT 9

AAW52270

ID AAW52270 standard; Protein; 235 AA.

XX

AC AAW52270;  
 XX  
 DT 29-JUN-1998 (first entry)  
 XX  
 DE Tumour necrosis factor inhibitor.  
 XX  
 KW Soluble tumour necrosis factor receptor; sTNFR; TNF-mediated disease;  
 KW tumour necrosis factor binding protein; autoimmune disease; arthritis;  
 KW adult respiratory distress syndrome; cachexia/anorexia; cancer; therapy;  
 KW tumour necrosis factor inhibitor; Alzheimer's disease; TNBP.  
 XX  
 OS Homo sapiens.  
 XX  
 PN W09801555-A2.  
 XX  
 PD 15-JAN-1998.  
 XX  
 PF 09-JUL-1997; 97WO-0512244.  
 XX  
 PR 04-MAR-1997; 97US-0039792.  
 PR 09-JUL-1996; 96US-0021443.  
 PR 06-DEC-1996; 96US-0032534.  
 PR 23-JAN-1997; 97US-0037737.  
 PR 07-FEB-1997; 97US-0039314.  
 XX  
 PA (AMGE-) AMGEN INC.  
 XX  
 PI Edwards CK, Fisher EF, Kieft GL;  
 XX  
 DR WPI; 1998-101052/09.  
 DR N-PSDB; AAV19802.  
 XX  
 PT Truncated and soluble forms of tumour necrosis factor receptor -  
 PT useful for treating diseases involving factor, e.g. arthritis and  
 PT adult respiratory distress syndrome  
 XX  
 PS Claim 3; Fig 8; 205pp; English.  
 XX  
 CC This sequence is the human tumour necrosis factor inhibitor. The protein  
 CC was used to make the truncated soluble tumour necrosis factor receptor  
 CC (sTNFR) proteins of the invention. The truncated sTNFR proteins and  
 CC tumour necrosis factor binding proteins (TNBP) are used to treat any  
 CC TNF-mediated disease, e.g. arthritis, adult respiratory distress  
 CC syndrome, cachexia/anorexia, cancer, chronic fatigue syndrome, graft  
 CC rejection, Alzheimer's disease and other autoimmune diseases. Cells  
 CC transformed with a vector containing DNA encoding the protein may be used  
 CC for production of recombinant sTNFR, which may also be used for measuring  
 CC the amount of sTNFR in samples and to raise antibodies against sTNFR.  
 CC TNBP may also be used in preparation of therapeutic compositions for  
 CC treating the above diseases. The sTNFR proteins are well suited to large  
 CC scale production (since they lack the deamidation site in region 111-126,  
 CC so are more stable in vivo); contain fewer disulphide bonds and fewer  
 CC epitopes, making them less antigenic than full-length proteins.  
 XX  
 SQ Sequence 235 AA;  
 Query Match 54.1%; Score 46; DB 19; Length 235;  
 Best Local Similarity 64.3%; Pred. No. 6.9;  
 Matches 9; Conservative 1; Mismatches 4; Indels 0; Gaps 0;  
 QY 1 CASGTASNTTVAAD 14  
 DB 142 capgtfsnttsstd 155  
 RESULT 10  
 AAW89234  
 ID AAW89234 standard; Protein: 235 AA.  
 XX  
 AC AAW89234;  
 XX  
 DT 04-MAR-1999 (first entry)

XX Tumour necrosis inhibitor 40 kDa protein.  
 DE  
 XX  
 KW Tumour necrosis factor receptor 1; TNFR-1; inhibitor; osteoprotegerin;  
 KW OpG; chimeric; fusion; dimerisation domain; autoimmune disease;  
 KW inflammation; apoptosis.  
 XX  
 OS Homo sapiens.  
 XX  
 PN W09849305-A1.  
 XX  
 PD 05-NOV-1998.  
 XX  
 PF 29-APR-1998; 98WO-US08631.  
 XX  
 PR 01-MAY-1997; 97US-0850188.  
 XX  
 PA (AMGE-) AMGEN INC.  
 XX  
 PI Boyle WJ, Wooden S;  
 XX  
 DR WPI; 1999-034661/03.  
 DR N-PSDB; AAV81733.  
 XX  
 PT New chimeric osteoprotegerin polypeptides - contain the  
 PT osteoprotegerin dimerisation domain and a heterologous sequence,  
 PT useful to treat TNF and TNFR-mediated disorders  
 XX  
 PS Disclosure; Fig 3; 92pp; English.  
 XX  
 CC The present invention describes a chimeric polypeptide (A1), comprising  
 CC an osteoprotegerin (OPG) dimerisation domain fused to a heterologous  
 CC amino acid sequence. Also described are: (1) a multimer polypeptide  
 CC comprising covalently associated A1 monomers; (2) an isolated nucleic  
 CC acid encoding A1; (3) an expression vector comprising the nucleic acid  
 CC sequence; and (4) a host cell transformed or transfected with the  
 CC expression vector so that the nucleic acid is expressible. The products  
 CC from the present invention are useful to treat a variety of disorders  
 CC including those related to receptor binding. Compositions comprising  
 CC tumour necrosis factor (TNF)/OPG and TNF receptor (TNFR)/OPG chimeras  
 CC are used to treat TNF and TNFR-mediated disorders such as inflammation,  
 CC autoimmune diseases and disorders related to excessive apoptosis. The  
 CC chimeras are also useful for detecting molecules which interact with  
 CC fused heterologous sequences to identify potential new receptors and  
 CC ligands. The present sequence represents the TNF inhibitor 40 kDa  
 CC protein.  
 XX  
 SQ Sequence 235 AA;  
 Query Match 54.1%; Score 46; DB 20; Length 235;  
 Best Local Similarity 64.3%; Pred. No. 6.9;  
 Matches 9; Conservative 1; Mismatches 4; Indels 0; Gaps 0;  
 QY 1 CASGTASNTTVAAD 14  
 DB 142 capgtfsnttsstd 155  
 RESULT 11  
 AAY54440  
 ID AAY54440 standard; Protein: 235 AA.  
 XX  
 AC AAY54440;  
 XX  
 DT 25-APR-2000 (first entry)  
 XX  
 DE Amino acid sequence of a K108R mutant of soluble p75 TNF receptor.  
 XX  
 KW p75 tumour necrosis factor receptor; mutant; PEG conjugated protein;  
 KW polyethylene glycol conjugation; PEG conjugation; protein activity.  
 XX  
 OS Homo sapiens.

```

OS Synthetic.
XX Key Location/Qualifiers
FH Misc-difference 108
FT /note= "wild type Lys replaced with Arg"
XX
XX WO9967291-A2.
XX
XX 29-DEC-1999.
XX
XX 18-JUN-1999; 99WO-US13953.
XX
XX 22-JUN-1998; 98US-0102530.
XX
XX (IMMV ) IMMUNEX CORP.
XX
XX Pettit DK;
XX
XX WPI; 2000-160577/14.
XX
XX N-PSDB; AA245759.
XX
XX Novel methods for site-specific protein modification by mutagenesis by
XX replacing polyethylene glycol reacting sites
XX
XX Claim 17; Page 29; 36pp; English.
XX
XX The present sequence represents a N-terminal fragment of a mutant of
XX the soluble tumour necrosis factor (TNF) receptor, where the wild
XX type Lys residue at position 108 is replaced with Arg. Lys108 (and
XX Lys120) make contact between the p75 receptor and ligand. These
XX residues are also potential polyethylene glycol (PEG) conjugation
XX sites. The wild type p75 TNF receptor protein was mutated and conjugated
XX to PEG, using the method of the invention. The specification describes
XX a method for conjugating proteins with PEG to result in
XX PEG-conjugated proteins having little or no reduction in a desired
XX activity. Specifically, one or more amino acid residues that are
XX critical for protein bioactivity and which are capable of reacting
XX with PEG sites are deleted, prior to conjugation of the protein to PEG.
XX The methods provide PEG conjugated proteins that are more homogeneous
XX and present in higher yields. Conjugation does not take place at amino
XX acid residues that are critical to the proteins bioactivity, thus
XX maintaining the activity of the protein. The methods are used to
XX produce PEG conjugated proteins.
XX
XX Sequence 235 AA;

Query Match 54.1%; Score 46; DB 21; Length 235;
Best Local Similarity 64.3%; Pred. No. 6.9;
Matches 9; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

QY 1 CASGTSNTTVAAD 14
Db 142 capgtfsnttsstd 155
|| || || || || : |

RESULT 12
AAV54441
ID AAV54441 standard; Protein; 235 AA.
XX
XX AC AAV54441;
XX
XX 25-APR-2000 (first entry)
XX
XX Amino acid sequence of a K120R mutant of soluble p75 TNF receptor.
XX
XX p75 tumour necrosis factor receptor; mutant; PEG conjugated protein;
XX polyethylene glycol conjugation; PEG conjugation; protein activity.
XX
XX Homo sapiens.
XX Synthetic.
XX
XX Key Location/Qualifiers

```

```

FT Misc-difference 120
FT /note= "wild type Lys replaced with Arg"
XX
XX WO9967291-A2.
XX
XX 29-DEC-1999.
XX
XX 18-JUN-1999; 99WO-US13953.
XX
XX 22-JUN-1998; 98US-0102530.
XX
XX (IMMV ) IMMUNEX CORP.
XX
XX Pettit DK;
XX
XX WPI; 2000-160577/14.
XX
XX N-PSDB; AA245760.
XX
XX Novel methods for site-specific protein modification by mutagenesis by
XX replacing polyethylene glycol reacting sites
XX
XX Claim 16; Page 31; 36pp; English.
XX
XX The present sequence represents a N-terminal fragment of a mutant of
XX the soluble tumour necrosis factor (TNF) receptor, where the wild
XX type Lys residue at position 120 is replaced with Arg. Lys120 (and
XX Lys108) make contact between the p75 receptor and ligand. These
XX residues are also potential polyethylene glycol (PEG) conjugation
XX sites. The wild type p75 TNF receptor protein was mutated and conjugated
XX to PEG, using the method of the invention. The specification describes
XX a method for conjugating proteins with PEG to result in
XX PEG-conjugated proteins having little or no reduction in a desired
XX activity. Specifically, one or more amino acid residues that are
XX critical for protein bioactivity and which are capable of reacting
XX with PEG sites are deleted, prior to conjugation of the protein to PEG.
XX The methods provide PEG conjugated proteins that are more homogeneous
XX and present in higher yields. Conjugation does not take place at amino
XX acid residues that are critical to the proteins bioactivity, thus
XX maintaining the activity of the protein. The methods are used to
XX produce PEG conjugated proteins.
XX
XX Sequence 235 AA;

Query Match 54.1%; Score 46; DB 21; Length 235;
Best Local Similarity 64.3%; Pred. No. 5.9;
Matches 9; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

QY 1 CASGTSNTTVAAD 14
Db 142 capgtfsnttsstd 155
|| || || || || : |

RESULT 13
AAV54442
ID AAV54442 standard; Protein; 235 AA.
XX
XX AC AAV54442;
XX
XX 25-APR-2000 (first entry)
XX
XX A K108R/K120R mutant of soluble p75 TNF receptor.
XX
XX p75 tumour necrosis factor receptor; mutant; PEG conjugated protein;
XX polyethylene glycol conjugation; PEG conjugation; protein activity.
XX
XX Homo sapiens.
XX Synthetic.
XX
XX Key Location/Qualifiers
XX Misc-difference 108
FT /note= "wild type Lys replaced with Arg"
FT Misc-difference 120

```

/note= "wild type Lys replaced with Arg"

FT XX WO967291-A2.  
 PN XX 29-DEC-1999.  
 PD XX  
 XX XX 18-JUN-1999; 99WO-US13953.  
 PF XX  
 XX XX 22-JUN-1998; 98US-0102530.  
 PR XX  
 XX XX (IMMV ) IMMUNEX CORP.  
 PA XX  
 XX XX Pettit DK;  
 PI XX  
 XX XX WPI: 2000-160577/14.  
 DR XX N-PSDB; AA54761.  
 DR XX  
 XX XX Novel methods for site-specific protein modification by mutagenesis by  
 PT replacing polyethylene glycol reacting sites -  
 XX  
 XX Claim 16; Page 33-34; 36pp; English.  
 XX  
 CC The present sequence represents a N-terminal fragment of a mutant of the  
 CC soluble tumour necrosis factor (TNF) receptor, where the wild type Lys  
 CC residues at positions 108 and 120 are replaced with Arg. Lys120 and  
 CC Lys108 make contact between the p75 receptor and ligand. These  
 CC residues are also potential polyethylene glycol (PEG) conjugation  
 CC sites. The wild type p75 TNF receptor protein was mutated and conjugated  
 CC to PEG, using the method of the invention. The specification describes  
 CC a method for conjugating proteins with PEG to result in  
 CC PEG-conjugated proteins having little or no reduction in a desired  
 CC activity. Specifically, one or more amino acid residues that are  
 CC critical for protein bioactivity and which are capable of reacting  
 CC with PEG sites are deleted, prior to conjugation of the protein to PEG.  
 CC The methods provide PEG conjugated proteins that are more homogeneous  
 CC and present in higher yields. Conjugation does not take place at amino  
 CC acid residues that are critical to the proteins bioactivity, thus  
 CC maintaining the activity of the protein. The methods are used to  
 CC produce PEG conjugated proteins.  
 XX Sequence 235 AA;  
 SQ

Query Match 54.1%; Score 46; DB 21; Length 235;  
 Best Local Similarity 64.3%; Pred. No. 6.9;  
 Matches 9; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

QY 1 CASGTASNTTVAAD 14  
 || || || || || :  
 Db 142 capgtfnttsstd 155

RESULT 14  
 AAY5443  
 ID AAY54443 standard; Protein; 235 AA.  
 XX  
 AC AAY54443;

DT 25-APR-2000 (first entry)

DE Wild type N-terminal fragment of the soluble p75 TNF receptor.

KW p75 tumour necrosis factor receptor; mutant; PEG conjugated protein;  
 KW polyethylene glycol conjugation; PEG conjugation; protein activity.

OS Homo sapiens.

PN WO967291-A2.

XX 29-DEC-1999.

PF 18-JUN-1999; 99WO-US13953.

XX

PR 22-JUN-1998; 98US-0102530.

XX (IMMV ) IMMUNEX CORP.

PI Pettit DK;

XX WPI: 2000-160577/14.  
 DR N-PSDB; AA245762.

XX Novel methods for site-specific protein modification by mutagenesis by  
 PT replacing polyethylene glycol reacting sites -

XX Claim 16; Page 35-36; 36pp; English.

XX The present sequence represents a N-terminal fragment of the soluble  
 CC tumour necrosis factor (TNF) receptor. The wild type Lys residues at  
 CC positions 108 and 120 are replaced with Arg (see AAY54441-42). Lys120  
 CC and Lys108 make contact between the p75 receptor and ligand. These  
 CC residues are also potential polyethylene glycol (PEG) conjugation  
 CC sites. The wild type p75 TNF receptor protein was mutated and conjugated  
 CC to PEG, using the method of the invention. The specification describes  
 CC a method for conjugating proteins with PEG to result in  
 CC PEG-conjugated proteins having little or no reduction in a desired  
 CC activity. Specifically, one or more amino acid residues that are  
 CC critical for protein bioactivity and which are capable of reacting  
 CC with PEG sites are deleted, prior to conjugation of the protein to PEG.  
 CC The methods provide PEG conjugated proteins that are more homogeneous  
 CC and present in higher yields. Conjugation does not take place at amino  
 CC acid residues that are critical to the proteins bioactivity, thus  
 CC maintaining the activity of the protein. The methods are used to  
 CC produce PEG conjugated proteins.

XX Sequence 235 AA;

Query Match 54.1%; Score 46; DB 21; Length 235;  
 Best Local Similarity 64.3%; Pred. No. 6.9;  
 Matches 9; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

QY 1 CASGTASNTTVAAD 14  
 || || || || || :  
 Db 142 capgtfnttsstd 155

RESULT 15  
 AAB37685  
 ID AAB37685 standard; Protein; 235 AA.

XX AAB37685;

XX 02-MAR-2001 (first entry)

XX Human 40 kDa TNF inhibitor.

XX TNF inhibitor; antinflammatory; Tumour Necrosis Factor; Interleukin;  
 KW IL-1; inflammatory disease; degenerative disease; human; lymphotoxin.

XX Homo sapiens.

XX US6143866-A.

XX 07-NOV-2000.

XX 19-JAN-1995; 95US-0375242.

XX 19-JUL-1990; 90US-0555274.

XX 09-JUL-1993; 93US-0090366.

XX 18-JUL-1989; 89US-0381080.

XX 11-DEC-1989; 89US-0450329.

XX 07-FEB-1990; 90US-0479661.

XX (AMGE-) AMGEN INC.

XX



PI Squires C, King MW, Hale KK, Brewer MT, Thompson RC;  
 PI Vanderslice RW, Vannice J, Kohno T;  
 XX WPI; 2001-006443/01.  
 DR  
 XX Novel 30 kDa tumor necrosis factor inhibitor analog comprising a  
 PT non-native cysteine residue cross-linked with polyethylene glycol,  
 PT useful for treating inflammatory and degenerative diseases mediated by  
 PT TNF -  
 XX  
 PS Example 12; Fig 38; 82pp; English.  
 XX  
 CC The present invention relates to Tumour Necrosis Factor (TNF) inhibitors  
 CC (see AAB37676 and AAB37685), which have TNF inhibitory activity. The  
 CC novel TNF inhibitors of the present invention are useful as therapeutic  
 CC agents for inhibiting the activity of TNF and interleukin (IL-1) and  
 CC for treating inflammatory and degenerative diseases mediated by TNF. The  
 CC present sequence is 40 kDa TNF inhibitor. The 40 kDa TNF inhibitor can  
 CC inhibit both TNF alpha and beta (lymphotoxin).  
 XX  
 SQ Sequence 235 AA;

Query Match 54.1%; Score 46; DB 22; Length 235;  
 Best Local Similarity 64.3%; Pred. No. 6.9;  
 Matches 9; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

OY 1 CASGTASNTTVAAD 14  
 || || || || || : |  
 Db 142 capgtfsnttsstd 155

Search completed: March 26, 2002, 13:38:46  
 Job time: 140 sec



GenCore version 4.5  
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: March 26, 2002, 13:41:27 ; Search time 37.72 Seconds  
(without alignments)  
10.142 Million cell updates/sec

Title: US-09-709-201-96  
Perfect score: 85  
Sequence: 1 CASGTASNTTVAADRSN 17

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 212252 seqs, 22503292 residues

Total number of hits satisfying chosen parameters: 212252

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : Issued\_Patents\_AA.\*  
1: /cgn2\_6/ptodata/2/iaa/5A.COMB.pep.\*  
2: /cgn2\_6/ptodata/2/iaa/5B.COMB.pep.\*  
3: /cgn2\_6/ptodata/2/iaa/6A.COMB.pep.\*  
4: /cgn2\_6/ptodata/2/iaa/6B.COMB.pep.\*  
5: /cgn2\_6/ptodata/2/iaa/PCTUS.COMB.pep.\*  
6: /cgn2\_6/ptodata/2/iaa/backfiles1.pep.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	46	54.1	39	1	US-08-050-319B-41
2	46	54.1	39	2	US-08-465-982-41
3	46	54.1	163	2	US-08-219-237B-5
4	46	54.1	163	4	US-08-477-347-13
5	46	54.1	163	4	US-08-476-862-4
6	46	54.1	163	4	US-08-468-560C-5
7	46	54.1	164	2	US-08-232-087A-9
8	46	54.1	227	3	US-08-974-022-48
9	46	54.1	227	4	US-08-795-445A-48
10	46	54.1	227	4	US-08-795-447A-48
11	46	54.1	227	4	US-08-974-186-48
12	46	54.1	227	4	US-08-795-446B-48
13	46	54.1	235	4	US-08-326-394-4
14	46	54.1	461	1	US-08-385-229-2
15	46	54.1	461	2	US-08-650-000-2
16	46	54.1	461	4	US-09-042-785A-7
17	46	54.1	461	4	US-08-477-347-3
18	46	54.1	461	4	US-09-006-353A-4
19	46	54.1	461	4	US-08-476-862-2
20	46	54.1	461	6	5395760-2
21	46	54.1	486	1	US-08-243-010-1
22	46	54.1	518	1	US-08-385-229-4
23	41	48.2	474	2	US-08-650-000-4
24	41	48.2	474	4	US-09-042-785A-8
25	41	48.2	474	6	5395760-4
26	40	47.1	223	1	US-08-278-091-13
27	40	47.1	223	1	US-08-483-859-13

28	40	47.1	223	1	US-08-472-173-13	Sequence 13, Appl
29	40	47.1	223	2	US-08-487-167-13	Sequence 13, Appl
30	40	47.1	223	2	US-08-482-316-13	Sequence 13, Appl
31	40	47.1	223	2	US-08-296-149-13	Sequence 13, Appl
32	40	47.1	223	2	US-08-801-199-13	Sequence 13, Appl
33	40	47.1	223	2	US-08-615-371-13	Sequence 13, Appl
34	40	47.1	223	3	US-09-074-659-13	Sequence 13, Appl
35	40	47.1	223	3	US-09-074-659-13	Sequence 13, Appl
36	40	47.1	223	3	US-09-106-468-13	Sequence 13, Appl
37	40	47.1	223	4	US-09-106-468A-13	Sequence 13, Appl
38	40	47.1	223	4	US-09-106-467-13	Sequence 13, Appl
39	39.5	46.5	1038	4	US-09-541-782-4	Sequence 4, Appl
40	39	45.9	1319	2	US-08-290-731C-2	Sequence 2, Appl
41	39	45.9	1336	2	US-08-290-731C-6	Sequence 6, Appl
42	38	44.7	327	1	US-08-240-049B-13	Sequence 13, Appl
43	38	44.7	327	1	US-08-240-049B-14	Sequence 14, Appl
44	38	44.7	327	1	US-08-259-148A-15	Sequence 15, Appl
45	38	44.7	327	1	US-08-259-148A-16	Sequence 16, Appl

ALIGNMENTS

RESULT 1  
US-08-050-319B-41  
; Sequence 41, Application US/08050319B  
; Patent No. 5633145  
; GENERAL INFORMATION:  
; APPLICANT: M.Feldmann, P.W. Gray,  
; APPLICANT: M.J.C. Turner, F.M Brennan  
; TITLE OF INVENTION: Modified human TNFalpha (Tumor  
; TITLE OF INVENTION: Necrosis Factor alpha) Receptor  
; NUMBER OF SEQUENCES: 57  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Reed & Robbins  
; STREET: 635 Bryant Street  
; CITY: Palo Alto  
; STATE: California  
; COUNTRY: USA  
; ZIP: 94301  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/050,319B  
; FILING DATE: 10-May-1993  
; CLASSIFICATION: 435  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Robbins, Roberta L.  
; REGISTRATION NUMBER: 33,208  
; REFERENCE/DOCKET NUMBER: 5150-0030  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (415) 617-8999  
; TELEFAX: (415) 327-3231  
; INFORMATION FOR SEQ ID NO: 41:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 39 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
; US-08-050-319B-41

Query Match 54.1%; Score 46; DB 1; Length 39;  
Best Local Similarity 64.3%; Pred. No. 0.45;  
Matches 9; Conservative 1; Mismatches 4; Indels 0; Gaps 0;  
QY 1 CASGTASNTTVAAD 14  
||| ||||| :  
Db 2 CAPGTFSTSTSTD 15

RESULT 2  
US-08-465-982-41  
; Sequence 41, Application US/08465982  
; Patent No. 5863786  
; GENERAL INFORMATION:  
; APPLICANT: M.Feldmann, P.W. Gray,  
; APPLICANT: M.J.C. Turner, F.M. Brennan  
; TITLE OF INVENTION: Modified human TNFalpha (Tumor  
; NUMBER OF SEQUENCES: 57  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Reed & Robbins  
; STREET: 635 Bryant Street  
; CITY: Palo Alto  
; STATE: California  
; COUNTRY: USA  
; ZIP: 94301  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/465,982  
; FILING DATE:  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US/08/050,319  
; FILING DATE: 10-May-1993  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Robbins, Roberta L.  
; REGISTRATION NUMBER: 33,208  
; REFERENCE/DOCKET NUMBER: 5150-0030  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (415) 617-8999  
; TELEFAX: (415) 327-3231  
; INFORMATION FOR SEQ ID NO: 41:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 39 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
US-08-465-982-41

Query Match 54.1%; Score 46; DB 2; Length 39;  
Best Local Similarity 64.3%; Pred. No. 0.45;  
Matches 9; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

Qy 1 CASGTASNTTVAAD 14  
||| ||||| :|  
Db 2 CAPGTFSTTSSTD 15

RESULT 3  
US-08-219-237B-5  
; Sequence 5, Application US/08219237B  
; Patent No. 5874546  
; GENERAL INFORMATION:  
; APPLICANT: NAGATA, Shigekazu  
; APPLICANT: ITOH, Naoto  
; APPLICANT: YONEHARA, Shin  
; TITLE OF INVENTION: DNA Coding for Human Cell Surface Antigen  
; NUMBER OF SEQUENCES: 11  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: James W. Hellwege  
; STREET: P.O. Box 2266 Eads Station  
; CITY: Arlington  
; STATE: Virginia  
; COUNTRY: USA

ZIP: 22202  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/219,237B  
; FILING DATE: 28-MAR-1994  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/872,129  
; FILING DATE: 22-APR-1992  
; CLASSIFICATION: 435  
; ATTORNEY/AGENT INFORMATION:  
; NAME: James W. Hellwege  
; REGISTRATION NUMBER: 28,808  
; REFERENCE/DOCKET NUMBER: 516762  
; INFORMATION FOR SEQ ID NO: 5:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 163 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
US-08-219-237B-5

Query Match 54.1%; Score 46; DB 2; Length 163;  
Best Local Similarity 64.3%; Pred. No. 2.3;  
Matches 9; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

Qy 1 CASGTASNTTVAAD 14  
||| ||||| :|  
Db 126 CAPGTFSTTSSTD 139

RESULT 4  
US-08-477-347-13  
; Sequence 13, Application US/08477347  
; Patent No. 6232446  
; GENERAL INFORMATION:  
; APPLICANT: WALLACH, David  
; APPLICANT: BIGDA, Jacek  
; APPLICANT: BELETSKY, Igor  
; APPLICANT: METT, Igor  
; TITLE OF INVENTION: TNF LIGANDS  
; NUMBER OF SEQUENCES: 17  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: BROWDY AND NEIMARK  
; STREET: 419 Seventh Street, N.W.  
; CITY: Washington  
; STATE: D.C.  
; COUNTRY: USA  
; ZIP: 20004  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/477,347  
; FILING DATE:  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 08/115,685  
; FILING DATE:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: IL 106271  
; FILING DATE: 08-JUL-1993  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Townsend, G. Kevin  
; REGISTRATION NUMBER: 34,033  
; REFERENCE/DOCKET NUMBER: WALLACH-10

TELECOMMUNICATION INFORMATION:  
TELEPHONE: 202-628-5197  
TELEFAX: 202-737-3528  
TELEX: 248633  
INFORMATION FOR SEQ ID NO: 13:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 163 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
US-08-477-347-13

Query Match 54.1% Score 46; DB 4; Length 163;  
Best Local Similarity 64.3%; Pred. No. 2.3;  
Matches 9; Conservative 1; Mismatches 4; Indels 0; Gaps 0;  
QY 1 CASGTASNTTVAAD 14  
||| ||||| :  
Db 126 CAPGTFSTTSSTD 139

RESULT 5  
US-08-476-862-4  
; Sequence 4, Application US/08476862  
; Patent No. 6262239  
; GENERAL INFORMATION:  
; APPLICANT: WALLACH, David  
; APPLICANT: BIGDA, Jacek  
; APPLICANT: BELETSKY, Igor  
; APPLICANT: METT, Igor  
; APPLICANT: ENGELMANN, Hartmut  
; TITLE OF INVENTION: TNF INHIBITORS  
; NUMBER OF SEQUENCES: 8  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: BROWDY AND NEIMARK  
; STREET: 419 Seventh Street, N.W.  
; CITY: Washington  
; STATE: D.C.  
; COUNTRY: USA  
; ZIP: 20004  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/476,862  
; FILING DATE: 07-JUN-1995  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: IL 107267  
; FILING DATE: 12-OCT-1993  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: IL 94039  
; FILING DATE: 06-APR-1990  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: IL 91229  
; FILING DATE: 06-AUG-1989  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: IL 90339  
; FILING DATE: 18-MAY-1989  
; ATTORNEY/AGENT INFORMATION:  
; NAME: BROWDY, Roger L.  
; REGISTRATION NUMBER: 25,618  
; REFERENCE/DOCKET NUMBER: WALLACH-12A  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 202-628-5197  
; TELEFAX: 202-737-3528  
; INFORMATION FOR SEQ ID NO: 4:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 163 amino acids

TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
US-08-476-862-4

Query Match 54.1% Score 46; DB 4; Length 163;  
Best Local Similarity 64.3%; Pred. No. 2.3;  
Matches 9; Conservative 1; Mismatches 4; Indels 0; Gaps 0;  
QY 1 CASGTASNTTVAAD 14  
||| ||||| :  
Db 126 CAPGTFSTTSSTD 139

RESULT 6  
US-08-468-560C-5  
; Sequence 5, Application US/08468560C  
; Patent No. 6270998  
; GENERAL INFORMATION:  
; APPLICANT: NAGATA, Shigekazu  
; APPLICANT: ITOH, Naoto  
; APPLICANT: YONEHARA, Shin  
; TITLE OF INVENTION: DNA CODING FOR HUMAN CELL SURFACE  
; TITLE OF INVENTION: ANTIGEN  
; NUMBER OF SEQUENCES: 11  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: BIRCH, STEWART, KOLASCH & BIRCH, LLP.  
; STREET: P.O. BOX 747  
; CITY: FALLS CHURCH  
; STATE: VA.  
; COUNTRY: USA  
; ZIP: 22040-0747  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/468,560C  
; FILING DATE: 06-JUN-1995  
; CLASSIFICATION: 435  
; ATTORNEY/AGENT INFORMATION:  
; NAME: MURPHY JR., GERLAD M.  
; REGISTRATION NUMBER: 28,977  
; REFERENCE/DOCKET NUMBER: 20-4393P  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 703-205-8000  
; TELEFAX: 703-205-8050  
; INFORMATION FOR SEQ ID NO: 5:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 163 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
US-08-468-560C-5

Query Match 54.1% Score 46; DB 4; Length 163;  
Best Local Similarity 64.3%; Pred. No. 2.3;  
Matches 9; Conservative 1; Mismatches 4; Indels 0; Gaps 0;  
QY 1 CASGTASNTTVAAD 14  
||| ||||| :  
Db 126 CAPGTFSTTSSTD 139

RESULT 7  
US-08-232-087A-9  
; Sequence 9, Application US/08232087A  
; Patent No. 5866372

```

1  ZIP: 91320-1789
2  COMPUTER READABLE FORM:
3  MEDIUM TYPE: Floppy disk
4  COMPUTER: IBM PC compatible
5  SOFTWARE: PC-DOS/MS-DOS
6  OPERATING SYSTEM: PatentIn Release #1.0, Version #1.30
7  CURRENT APPLICATION DATA:
8  APPLICATION NUMBER: US/08/795,445A
9  FILING DATE:
10 CLASSIFICATION:
11 PRIOR APPLICATION DATA:
12 APPLICATION NUMBER: 08/577,788
13 FILING DATE:
14 ATTORNEY/AGENT INFORMATION:
15 NAME: Winter, Robert B.
16 REFERENCE/DOCKET NUMBER: A-378
17 INFORMATION FOR SEQ ID NO: 48:
18 SEQUENCE CHARACTERISTICS:
19 LENGTH: 227 amino acids
20 TYPE: amino acid
21 STRANDEDNESS: single
22 TOPOLOGY: linear

```

; MOLECULE TYPE: protein  
US-08-795-445A-48

Query Match 54.1%; Score 46; DB 4; Length 227;  
Best Local Similarity 64.3%; Pred. No. 3.3;  
Matches 9; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

QY 1 CASGTASNTTVAAD 14  
|| || || || || :  
Db 164 CAPGTFSTNTSSTD 177

## RESULT 10

US-08-795-447A-48  
; Sequence 48, Application US/08795447A

; Patent No. 6284728

; GENERAL INFORMATION:

; APPLICANT: Boyle, William J.

; APPLICANT: Lacey, David L.

; APPLICANT: Calzone, Frank J.

; APPLICANT: Chang, Ming-Shi

; TITLE OF INVENTION: Osteoprotegerin

; NUMBER OF SEQUENCES: 53

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Amgen Inc.

; STREET: One Amgen Center Drive

; CITY: Thousand Oaks

; STATE: California

; COUNTRY: USA

; ZIP: 91320-1789

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: PatentIn Release #1.0, Version #1.30

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/795,447A

; FILING DATE:

; CLASSIFICATION: 514

; ATTORNEY/AGENT INFORMATION:

; NAME: Winter, Robert B.

; REFERENCE/DOCKET NUMBER: A-378D2

; INFORMATION FOR SEQ ID NO: 48:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 227 amino acids

; TYPE: amino acid

; STRANDEDNESS: single

; TOPOLOGY: linear

; MOLECULE TYPE: protein

US-08-795-447A-48

## Query Match

54.1%; Score 46; DB 4; Length 227;  
Best Local Similarity 64.3%; Pred. No. 3.3;  
Matches 9; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

QY 1 CASGTASNTTVAAD 14  
|| || || || || :  
Db 164 CAPGTFSTNTSSTD 177

## RESULT 11

US-08-974-186-48

; Sequence 48, Application US/08974186

; Patent No. 6284740

; GENERAL INFORMATION:

; APPLICANT: Boyle, William J.

; APPLICANT: Lacey, David L.

; APPLICANT: Calzone, Frank J.

; APPLICANT: Chang, Ming-Shi

; TITLE OF INVENTION: OSTEOPTROGERIN

; NUMBER OF SEQUENCES: 53

; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Amgen Inc.  
; STREET: 1840 Dehavilland Drive  
; CITY: Thousand Oaks  
; STATE: California  
; COUNTRY: USA  
; ZIP: 91320-1789  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/974,186  
; FILING DATE:  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 08/577,788  
; FILING DATE:  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Winter, Robert B.  
; REFERENCE/DOCKET NUMBER: A-378  
; INFORMATION FOR SEQ ID NO: 48:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 227 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
; US-08-974-186-48

Query Match 54.1%; Score 46; DB 4; Length 227;  
Best Local Similarity 64.3%; Pred. No. 3.3;  
Matches 9; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

QY 1 CASGTASNTTVAAD 14  
|| || || || || :  
Db 164 CAPGTFSTNTSSTD 177

## RESULT 12

US-08-795-446B-48

; Sequence 48, Application US/08795446B

; Patent No. 6288032

; GENERAL INFORMATION:

; APPLICANT: Boyle, William J.

; APPLICANT: Lacey, David L.

; APPLICANT: Calzone, Frank J.

; APPLICANT: Chang, Ming-Shi

; TITLE OF INVENTION: OSTEOPTROGERIN

; NUMBER OF SEQUENCES: 53

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Amgen Inc.

; STREET: 1840 Dehavilland Drive

; CITY: Thousand Oaks

; STATE: California

; COUNTRY: USA

; ZIP: 91320-1789

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: PatentIn Release #1.0, Version #1.30

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/795,446B

; FILING DATE:

; CLASSIFICATION:

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 08/577,788

; FILING DATE:

; ATTORNEY/AGENT INFORMATION:

; NAME: Winter, Robert B.

REFERENCE/DOCKET NUMBER: A-378  
; INFORMATION FOR SEQ ID NO: 48:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 227 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
US-08-795-446B-48

Query Match 54.1%; Score 46; DB 4; Length 227;  
Best Local Similarity 64.3%; Pred. No. 3.3;  
Matches 9; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

Qy 1 CASGTASNTTVAAD 14  
|| || || || || : |  
Db 164 CAPGTFSTTSSTD 177

RESULT 13  
US-09-326-394-4  
; Sequence 4, Application US/09326394  
; Patent No. 6306820  
; GENERAL INFORMATION:  
; APPLICANT: Bendele, Alison M.  
; APPLICANT: Sennello, Regina M.  
; APPLICANT: Edwards, Carl K.  
; TITLE OF INVENTION: COMBINATION THERAPY USING A TNF BINDING  
; TITLE OF INVENTION: PROTEIN FOR TREATING TNF-MEDIATED DISEASES  
; NUMBER OF SEQUENCES: 4  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Amgen Inc.  
; STREET: 1840 DeHavilland Drive  
; CITY: Thousand Oaks  
; STATE: CA  
; COUNTRY: US  
; ZIP: 91320-1789  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/326,394  
; FILING DATE: 08-DEC-1997  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 60/032,587  
; FILING DATE: 06-DEC-1996  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 60/036,355  
; FILING DATE: 23-JAN-1997  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 60/039,315  
; FILING DATE: 07-FEB-1997  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 60/052,023  
; FILING DATE: 09-JUL-1997  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Zindrick, Thomas K.  
; REGISTRATION NUMBER: 32,185  
; REFERENCE/DOCKET NUMBER: A-430D  
; INFORMATION FOR SEQ ID NO: 4:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 235 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
US-09-326-394-4

Query Match 54.1%; Score 46; DB 4; Length 235;

Best Local Similarity 64.3%; Pred. No. 3.4;  
Matches 9; Conservative 1; Mismatches 4; Indels 0; Gaps 0;  
Qy 1 CASGTASNTTVAAD 14  
|| || || || || : |  
Db 142 CAPGTFSTTSSTD 155

RESULT 14  
US-08-385-229-2  
; Sequence 2, Application US/08385229  
; Patent No. 5605690  
; GENERAL INFORMATION:  
; APPLICANT: Jacobs, Cindy A.  
; APPLICANT: Smith, Craig A.  
; TITLE OF INVENTION: Method of Treating TNF-Dependent  
; TITLE OF INVENTION: Inflammation Using Tumor Necrosis Factor Antagonists  
; NUMBER OF SEQUENCES: 5  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Immunex Corporation  
; STREET: 51 University Street  
; CITY: Seattle  
; STATE: Washington  
; COUNTRY: U.S.A.  
; ZIP: 98101  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/385,229  
; FILING DATE:  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US/07/946,236  
; FILING DATE:  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Wight, Christopher L.  
; REGISTRATION NUMBER: 31,680  
; REFERENCE/DOCKET NUMBER: 2503  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (206) 587-0430  
; TELEFAX: (206) 587-0606  
; INFORMATION FOR SEQ ID NO: 2:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 461 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
US-08-385-229-2

Query Match 54.1%; Score 46; DB 1; Length 461;  
Best Local Similarity 64.3%; Pred. No. 7.4;  
Matches 9; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

Qy 1 CASGTASNTTVAAD 14  
|| || || || || : |  
Db 164 CAPGTFSTTSSTD 177

RESULT 15  
US-08-650-000-2  
; Sequence 2, Application US/08650000  
; Patent No. 5945397  
; GENERAL INFORMATION:  
; APPLICANT: Smith, Craig A.  
; APPLICANT: Goodwin, Raymond G.  
; APPLICANT: Beckmann, W. Patricia  
; TITLE OF INVENTION: Tumor Necrosis Factor Receptors  
; NUMBER OF SEQUENCES: 4  
; CORRESPONDENCE ADDRESS:  
US-08-650-000-2



ADDRESSEE: Immunex Corporation  
STREET: 51 University Street  
CITY: Seattle  
STATE: Washington  
COUNTRY: U.S.A.  
ZIP: 98101  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
OPERATING SYSTEM: IBM PC compatible  
SOFTWARE: PatentIn Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/650,000  
FILING DATE:  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US/08/468,453  
FILING DATE:  
APPLICATION NUMBER: US/08/038,765  
FILING DATE:  
APPLICATION NUMBER: US 403,241  
FILING DATE: 05-SEP-1989  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 405,370  
FILING DATE: 11-SEP-1989  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 421,417  
FILING DATE: 13-OCT-1989  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 523,635  
FILING DATE: 10-MAY-1990  
ATTORNEY/AGENT INFORMATION:  
NAME: Wight, Christopher L.  
REGISTRATION NUMBER: 31,680  
REFERENCE/DOCKET NUMBER: 2501-D  
TELEPHONE: (206) 587-0430  
TELEFAX: (206) 233-0644  
INFORMATION FOR SEQ ID NO: 2:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 461 amino acids  
TYPE: amino acid  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
US-08-650-000-2

Query Match 54.1%; Score 46; DB 2; Length 461;  
Best Local Similarity 64.3%; Pred. NO. 7.4;  
Matches 9; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

OY 1 CASGTASNTTVAAD 14  
Db 164 CAPGTFSTSTSD 177

Search completed: March 26, 2002, 13:41:27  
Job time: 301 sec



GenCore version 4.5  
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: March 26, 2002, 13:37:18 ; Search time 42.75 Seconds  
(without alignments)  
30.292 Million cell updates/sec

Title: US-09-709-201-96  
Perfect score: 85  
Sequence: 1 CASGTASNTTVAADRSN 17

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 219241 seqs, 76174552 residues

Total number of hits satisfying chosen parameters: 219241

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : PIR\_68:\*  
1: pir1:\*  
2: pir2:\*  
3: pir3:\*  
4: pir4:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	76	89.4	392	2 A40371	major outer membra
2	46	54.1	461	1 A35356	tumor necrosis fac
3	46	54.1	1518	2 T28880	hypothetical prote
4	46	54.1	4753	1 A47437	IDL-receptor-relat
5	45	52.9	390	2 T25642	hypothetical prote
6	45	52.9	767	2 S55618	hypothetical prote
7	45	52.9	942	2 T13014	cytochrome b245 be
8	43	50.6	425	2 S41099	protein kinase (EC
9	43	50.6	427	2 T46265	hypothetical prote
10	43	50.6	1462	2 T06819	DNA topoisomerase
11	42	49.4	390	2 E84066	hypothetical prote
12	42	49.4	518	2 F70831	probable PPE prote
13	42	49.4	621	2 S35092	plakoglobin - mous
14	41	48.2	459	2 I48854	gene murine tumour
15	41	48.2	474	2 B38634	tumor necrosis fac
16	41	48.2	1237	2 H81660	DNA polymerase III
17	40	47.1	226	2 B41378	cytochrome c553i p
18	40	47.1	259	1 TRSMG	trypsin (EC 3.4.21
19	40	47.1	490	2 T49096	hypothetical prote
20	40	47.1	492	2 T47720	pyruvate kinase-II
21	40	47.1	510	2 T47704	pyruvate kinase-II
22	40	47.1	760	2 S18686	Sc/SvM protein -
23	39	45.9	202	2 JX0228	multicatalytic end
24	39	45.9	205	2 S17522	multicatalytic end
25	39	45.9	226	2 T40487	proteasome compone
26	39	45.9	239	2 B54589	proteasome subunit
27	39	45.9	323	2 B83757	sodium-dependent t
28	39	45.9	527	2 T04329	importin alpha - t
29	39	45.9	644	2 T37800	probable lysophosp

30 39 45.9 710 2 E69665 nitrate reductase  
31 39 45.9 1181 2 T30578 myosin IC - slime  
32 39 45.9 1181 2 T19736 hypothetical prote  
33 39 45.9 1336 2 S25716 Ras guanine nucleo  
34 39 45.9 1975 2 B81192 hemagglutinin/hemo  
35 39 45.9 1995 2 G81044 hemagglutinin/hemo  
36 38 44.7 85 2 S60856 M protein precursor  
37 38 44.7 97 2 S60846 M protein precursor  
38 38 44.7 117 1 J01745 glycoprotein J - c  
39 38 44.7 174 2 A86358 Similar to blue co  
40 38 44.7 215 2 S61337 multicatalytic end  
41 38 44.7 315 2 E81937 probable transmem  
42 38 44.7 315 2 B81168 transporter NMB070  
43 38 44.7 334 2 T50139 GNS1/SUR4 family p  
44 38 44.7 335 2 S71796 centrosome-binding  
45 38 44.7 356 2 T27052 hypothetical prote

ALIGNMENTS

RESULT 1  
A40371.

major outer membrane protein precursor - Chlamydia psittaci (strain Fpn/pring)  
C:Species: Chlamydia psittaci, Chlamydia psittaci  
C:Date: 27-Nov-1991 #sequence.revision 27-Nov-1991 #text\_change 31-Mar-2000  
C:Accession: I40859; A40371; S16137  
R:Storey, C.; Lusher, M.; Yates, P.; Richmond, S.  
J. Gen. Microbiol. 139, 2621-2626, 1993  
A:Title: Evidence for Chlamydia pneumoniae of non-human origin.  
A:Reference number: I40739; MUID:94103736  
A:Accession: I40859  
A:Status: nucleic acid sequence not shown; translation not shown; translated from GB/  
A:Molecule type: DNA  
A:Residues: 1-392 <RES>  
A:Cross-references: EMBL:X61096; NID:g40564; PIDN:CAA43409.1; PID:g40565  
A:Experimental source: strain Fpn  
C:Genetics:  
A:Gene: MOMP  
C:Superfamily: Chlamydia major outer membrane protein  
C:Keywords: membrane protein  
F:1-22/Domain: signal sequence #status predicted <SIG>  
F:23-392/Product: major outer membrane protein #status predicted <MAY>

Query Match 89.4%; Score 76; DB 2; Length 392;  
Best Local Similarity 100.0%; Pred. No. 7.5e-05;  
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 ASGTASNTTVAADRSN 17  
DB 92 ASGTASNTTVAADRSN 107

RESULT 2  
A35356

tumor necrosis factor receptor 2 precursor [validated] - human  
N:Alternate names: 75K tumor necrosis factor receptor; TNF receptor type 2  
C:Species: Homo sapiens (man)  
C:Date: 10-Sep-1999 #sequence.revision 10-Sep-1999 #text\_change 08-Dec-2000  
C:Accession: A35356; A36475; A48416; A36007; A23666; B35010; I38094  
R:Smith, C.A.; Davis, T.; Anderson, D.; Solam, L.; Beckmann, M.P.; Jerzy, R.; Dover, Science 248, 1019-1023, 1990  
A:Title: A receptor for tumor necrosis factor defines an unusual family of cellular a  
A:Reference number: A35356; MUID:90260639  
A:Accession: A35356  
A:Status: preliminary  
A:Molecule type: mRNA  
A:Residues: 1-461 <SMI>  
A:Cross-references: GB:M32315; NID:g189185; PIDN:AAA59929.1; PID:g189186  
R:Kohn, T.; Brewer, M.T.; Baker, S.L.; Schwartz, P.E.; King, M.W.; Hale, K.K.; Squir Proc. Natl. Acad. Sci. U.S.A. 87, 8331-8335, 1990  
A:Title: A second tumor necrosis factor receptor gene product can shed a naturally oc

```
Query Match          54.1%; Score 46; DB 1; Length 461;
Best Local Similarity 64.3%; Pred. NO. 6.8;
Matches 9; Conservative 1; Mismatches 4; Indels 0; Gaps 0;
```

Query Match	54.1%	Score 46;	DB 2;	Length 1518;
Best Local Similarity	52.9%	Pred. No. 21;		
Matches	9;	Conservative	1;	Mismatches
			7;	Indels
				Gaps
				0;

4  
RESULT  
A47437  
LDL-receptor-related protein - Caenorhabditis elegans  
C:Species: Caenorhabditis elegans  
C:Date: 10-Sep-1999 #sequence revision 10-Sep-1999 #text\_change 18-Aug-2000  
C:Accession: A47437; S27801; T21547  
R:Vochem, J.; Greenwald, I.  
Proc. Natl. Acad. Sci. U.S.A. 90, 4572-4576, 1993  
A:Title: A gene for a low density lipoprotein receptor-related protein in the nematode  
A:Reference number: A47437; MUID:93281621  
A:Accession: A47437  
A:Molecule type: DNA  
A:Residues: 1-4753 <YOC>  
A:Cross-references: MG96150; NID:g156359; PIDN:AAA28105.1; PID:g156360  
A:Note: nucleotide sequence not given; translation not complete in this paper  
R:Vochem, J.; Greenwald, I.  
submitted to the EMBL Data Library, July 1992  
A:Description: A gene for an LDL receptor-related protein (LPR) in the nematode C. elegans  
A:Reference number: S27801  
A:Accession: S27801  
A:Molecule type: DNA  
A:Residues: 1-4753 <YO2>  
A:Cross-references: EMBL:M96150; NID:g156359; PIDN:AAA28105.1; PID:g156360  
R:Wilkinson, J.  
submitted to the EMBL Data Library, June 1996  
A:Reference number: Z19439  
A:Accession: T21547  
A>Status: preliminary; translated from GB/EMBL/DDBJ  
A:Molecule type: DNA  
A:Residues: 1-4753 <WIL>  
A:Cross-references: EMBL:Z73907; PIDN:CAA98124.1; GSPDB:GN00019; CESP:F29D11.1  
C:Genetics:  
A:Gene: LPR  
A:Map position: 1

A; Introns: 31/1; 88/1; 132/1; 172/3; 219/1; 298/1; 463/2; 526/2; 585/3; 780/2; 874/2; 974/1

C; Superfamily: alpha-2-macroglobulin receptor; EGF homology; LDL receptor ligand-binding

C; Keywords: tandem repeat; transmembrane protein

F:53-87/Domain: LDL receptor ligand-binding repeat homology <LDL1>

F:92-131/Domain: LDL receptor ligand-binding repeat homology <LDL2>

F:138-175/Domain: LDL receptor ligand-binding repeat homology <LDL3>

F:182-218/Domain: LDL receptor ligand-binding repeat homology <LDL4>

F:223-257/Domain: LDL receptor ligand-binding repeat homology <LDL5>

F:262-297/Domain: LDL receptor ligand-binding repeat homology <LDL6>

F:302-336/Domain: EGF homology <EGF1>

F:1054-1095/Domain: LDL receptor ligand-binding repeat homology <LDL7>

F:1101-1138/Domain: LDL receptor ligand-binding repeat homology <LDL8>

F:1146-1182/Domain: LDL receptor ligand-binding repeat homology <LDL9>

F:1187-1223/Domain: LDL receptor ligand-binding repeat homology <LDL10>

F:1228-1263/Domain: LDL receptor ligand-binding repeat homology <LDL11>

F:1270-1307/Domain: LDL receptor ligand-binding repeat homology <LDL12>

F:1313-1350/Domain: LDL receptor ligand-binding repeat homology <LDL13>

F:1359-1396/Domain: LDL receptor ligand-binding repeat homology <LDL14>

F:1441-1475/Domain: EGF homology <EGF>

F:1611-1654/Domain: LDL receptor WYTD-containing repeat homology <YW33>

F:1799-1829/Domain: LDL receptor ligand-binding repeat homology <LDL15>

F:2834-2868/Domain: LDL receptor ligand-binding repeat homology <LDL16>

F:2874-2912/Domain: LDL receptor ligand-binding repeat homology <LDL17>

F:2919-2956/Domain: LDL receptor ligand-binding repeat homology <LDL18>

F:2961-2997/Domain: LDL receptor ligand-binding repeat homology <LDL19>

F:3006-3044/Domain: LDL receptor ligand-binding repeat homology <LDL20>

F:3049-3093/Domain: LDL receptor ligand-binding repeat homology <LDL21>

F:3100-3135/Domain: LDL receptor ligand-binding repeat homology <LDL22>

F:3140-3174/Domain: LDL receptor ligand-binding repeat homology <LDL23>

F:3187-3222/Domain: LDL receptor ligand-binding repeat homology <LDL24>

F:3586-3623/Domain: EGF homology <EGX1>

F:3627-3666/Domain: LDL receptor ligand-binding repeat homology <LDL25>

F:3671-3705/Domain: LDL receptor ligand-binding repeat homology <LDL26>

F:3709-3746/Domain: LDL receptor ligand-binding repeat homology <LDL27>

F:3753-3788/Domain: LDL receptor ligand-binding repeat homology <LDL28>

F:3793-3830/Domain: LDL receptor ligand-binding repeat homology <LDL29>

F:3833-3871/Domain: LDL receptor ligand-binding repeat homology <LDL30>

F:3878-3912/Domain: LDL receptor ligand-binding repeat homology <LDL31>

F:3917-3951/Domain: LDL receptor ligand-binding repeat homology <LDL32>

F:3959-3995/Domain: LDL receptor ligand-binding repeat homology <LDL33>

F:4000-4040/Domain: LDL receptor ligand-binding repeat homology <LDL34>

F:4049-4083/Domain: LDL receptor ligand-binding repeat homology <LDL35>

F:4092-4130/Domain: EGF homology <EGF2>

F:4343-4386/Domain: LDL receptor WYTD-containing repeat homology <YW38>

Query Match 54.1%; Score 46; DB 1; Length 4753;

Best Local Similarity 52.9%; Pred. No. 64;

Matches 9; Conservative 2; Mismatches 6; Indels 0; Gaps 0;

QY 1 CASGTASNTTVAADRSN 17

Db 4056 CANGKCVGTACDRKD 4072

||||| ||||| |||

RESULT 5

T25642

hypothetical protein C46H11.8 - Caenorhabditis elegans

C; Species: Caenorhabditis elegans

C; Date: 15-Oct-1999 #sequence\_revision 15-Oct-1999 #text\_change 15-Oct-1999

C; Accession: T25642

R; Miller, N.; Bradshaw, H.; Wamsley, P.

submitted to the EMBL Data Library, February 1997

A; Description: the sequence of C. elegans cosmid C46H11.

A; Reference number: Z20061

A; Accession: T25642

A; Status: preliminary; translated from GB/EMBL/DDBJ

A; Molecule type: DNA

A; Residues: 1-390 <ML>

A; Cross-references: EMBL:U08314; PIDN:AAB42362.1; GSPDB:GN00019; CESP:C46H11.8

A; Experimental source: strain Bristol N2; clone C46H11

C; Genetics:

A; Gene: CESP:C46H11.8

A; Map position: 1

A; Introns: 26/1; 51/1; 189/1; 345/1

Query Match 52.9%; Score 45; DB 2; Length 390;

Best Local Similarity 56.2%; Pred. No. 8.5;

Matches 9; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

QY 2 ASGTASNTTVAADRSN 17

Db 182 SSTSSSTTCADRSN 197

|||||

RESULT 6

S55618

hypothetical protein 24 - equine herpesvirus 2

C; Species: equine herpesvirus 2

C; Date: 27-Oct-1995 #sequence\_revision 03-Nov-1995 #text\_change 08-Oct-1999

C; Accession: S55618

R; Telford, E.A.R.; Watson, M.S.; Aird, H.C.; Perry, J.; Davison, A.J.

A; Title: The DNA sequence of equine herpesvirus 2.

A; Reference number: S55618

A; Accession: S55618

A; Molecule type: DNA

A; Residues: 1-767 <TEL>

A; Cross-references: GB:U20824; NID:G695172; PIDN:AAC13811.1; PID:G695196

A; Note: the nucleotide sequence was submitted to the EMBL Data Library, February 1995

Query Match 52.9%; Score 45; DB 2; Length 767;

Best Local Similarity 57.1%; Pred. No. 16;

Matches 8; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

QY 1 CASGTASNTTVAAD 14

Db 511 CASGTAINMNISGD 524

||||| |::|

RESULT 7

T13014

cytochrome b245 beta chain homolog F8L21.20 - Arabidopsis thaliana

C; Species: Arabidopsis thaliana (mouse-ear cress)

C; Date: 13-Aug-1999 #sequence\_revision 13-Aug-1999 #text\_change 29-Oct-1999

C; Accession: T13014

R; Bevan, M.; Peters, S.A.; van Staveren, M.; Dirkse, W.; Stiekema, W.; Bancroft, I.;

submitted to the Protein Sequence Database, July 1999

A; Reference number: Z17587

A; Accession: T13014

A; Molecule type: DNA

A; Residues: 1-942 <BEV>

A; Cross-references: EMBL:AL096882; GSPDB:GN00062; ATSP:F8L21.20

A; Experimental source: cultivar Columbia; BAC clone F8L21

C; Genetics:

A; Gene: ATSP:F8L21.20

A; Map position: 4

A; Introns: 211/1; 282/3; 322/3; 458/3; 587/3; 619/3; 658/2; 714/2; 767/3; 837/3; 880/

Query Match 52.9%; Score 45; DB 2; Length 942;

Best Local Similarity 43.8%; Pred. No. 20;

Matches 7; Conservative 5; Mismatches 4; Indels 0; Gaps 0;

QY 1 CASGTASNTTVAADRS 16

Db 769 CIGSCSNISSDHS 784

||||| |::|

RESULT 8

S41099

protein kinase (EC 2.7.1.37), CAMP-dependent, catalytic chain C - fungus (Blastocladi

C:Species: Blastocladia emersonii  
 C:Date: 19-Mar-1997 #sequence\_revision 06-Jun-1997 #text\_change 28-May-1999  
 C:Accession: S41099; S77890  
 R:Franco de Oliveira, J.C.; Cantisani Borges, A.C.; do Valle Marques, M.; Lopes Gomes, S.  
 Eur. J. Biochem. 219, 555-562, 1994  
 A:Title: Cloning and characterization of the gene for the catalytic subunit of cAMP-dephosphorylase  
 A:Reference number: S41099; MUID:94139736  
 A:Accession: S41099  
 A:Molecule type: DNA  
 A:Residues: 1-425 <FRA>  
 A:Cross-references: GB:L17008; NID:g304272; PIDN:AAA20074.1; PID:g304273  
 A:Accession: S77889  
 A:Molecule type: mRNA  
 A:Residues: 22-425 <FRB>  
 A:Cross-references: GB:M81709; GB:L17038; NID:g507140; PIDN:AAAL9440.1; PID:g507141  
 A:Accession: S77890  
 A:Molecule type: protein  
 A:Residues: 2-16 <FRC>  
 C:Genetics:  
 A:Introns: 209/3; 243/3; 315/1  
 C:Superfamily: kinase-related transforming protein; protein kinase homology  
 C:Keywords: ATP; cAMP binding; magnesium; phosphoprotein; phosphotransferase; serine/threonine kinase  
 F:2-425/Product: protein kinase, cAMP-dependent, catalytic chain C #status experimental  
 F:114-370/Domain: protein kinase homology <KIN>  
 F:122-130/Region: protein kinase ATP-binding motif  
 F:127-128, 194, 200, 243, 256/Binding site: Mg-ATP (Phe, Gly, Glu, Thr) #status predicted  
 F:145, 164, 239, 241/Active site: Lys, Glu, Asp, Lys #status predicted  
 F:244, 257/Binding site: magnesium (Asn, Asp) #status predicted  
 F:270/Binding site: phosphate (Thr) (covalent) #status predicted

Query Match 50.6%; Score 43; DB 2; Length 425;  
 Best Local Similarity 62.5%; Pred. No. 19;  
 Matches 10; Conservative 1; Mismatches 5; Indels 0; Gaps 0;

QY 2 ASGTASNTTVAADRSN 17  
 |||||  
 Db 40 ASSTASSTTTAAASGN 55

RESULT 9  
 T46265  
 hypothetical protein DKFZp761A052.1 - human (fragment)  
 C:Species: Homo sapiens (man)  
 C:Date: 04-Feb-2000 #sequence\_revision 04-Feb-2000 #text\_change 04-Feb-2000  
 C:Accession: T46265  
 R:Ottewaelde, B.; Obermayer, B.; Mewes, H.W.; Gassenhuber, J.; Wiemann, S.  
 submitted to the Protein Sequence Database, January 2000  
 A:Reference number: Z23031  
 A:Accession: T46265  
 A:Status: preliminary  
 A:Molecule type: mRNA  
 A:Residues: 1-427 <AAA>  
 A:Cross-references: EMBL:AL137509  
 A:Experimental source: adult amygdala; clone DKFZp761A052  
 C:Genetics:  
 A:Note: DKFZp761A052.1

Query Match 50.6%; Score 43; DB 2; Length 427;  
 Best Local Similarity 50.0%; Pred. No. 20;  
 Matches 8; Conservative 3; Mismatches 5; Indels 0; Gaps 0;

QY 1 CASGTASNTTVAADRS 16  
 |||||  
 Db 347 CAPGTSQFSAGADRA 362

RESULT 10  
 T06819  
 DNA topoisomerase (ATP-hydrolyzing) (EC 5.99.1.3) II - garden pea  
 C:Species: Pisum sativum (garden pea)  
 C:Date: 23-Apr-1999 #sequence\_revision 23-Apr-1999 #text\_change 20-Jun-2000

C:Accession: T06819  
 R:Reddy, M.K.; Nair, S.; Tewari, K.K.  
 submitted to the EMBL Data Library, August 1997  
 A:Reference number: Z15832  
 A:Accession: T06819  
 A:Status: preliminary; translated from GB/EMBL/DDBJ  
 A:Molecule type: mRNA  
 A:Residues: 1-1462 <RED>  
 A:Cross-references: EMBL:Y14559; PIDN:CAA74891.1  
 C:Genetics:  
 A:Note: TOP11  
 C:Function:  
 A:Description: involved in DNA replication and chromosome condensation  
 C:Superfamily: eukaryotic type II DNA topoisomerase; phage T4 DNA topoisomerase (ATP-ATPase)  
 C:Keywords: ATP; DNA binding; isomerase

Query Match 50.6%; Score 43; DB 2; Length 1462;  
 Best Local Similarity 50.0%; Pred. No. 64;  
 Matches 7; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1 CASGTASNTTVAAD 14  
 |||||  
 Db 1400 CSAGSASNTPLSD 1413

RESULT 11  
 E84066  
 hypothetical protein BH3333 [imported] - Bacillus halodurans (strain C-125)  
 C:Species: Bacillus halodurans  
 C:Date: 01-Dec-2000 #sequence\_revision 01-Dec-2000 #text\_change 31-Dec-2000  
 C:Accession: E84066  
 R:Takami, H.; Nakasone, K.; Takaki, Y.; Maeno, G.; Sasaki, R.; Masui, N.; Fujii, F.; H.  
 Nucleic Acids Res. 28, 4317-4331, 2000  
 A:Title: Complete genome sequence of the alkaliphilic bacterium Bacillus halodurans a  
 A:Reference number: A83650; MUID:20263314  
 A:Accession: E84066  
 A:Status: preliminary  
 A:Molecule type: DNA  
 A:Residues: 1-390 <STO>  
 A:Cross-references: GB:AP001518; GB:BA000004; NID:g10175792; PIDN:BAB07052.1; GSPDB:G  
 A:Experimental source: strain C-125  
 C:Genetics:  
 A:Gene: BH3333

Query Match 49.4%; Score 42; DB 2; Length 390;  
 Best Local Similarity 61.5%; Pred. No. 26;  
 Matches 8; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 5 TASNTTVAADRSN 17  
 |||||  
 Db 122 TVSNLTIDADRTN 134

RESULT 12  
 F70831  
 probable PPE protein - Mycobacterium tuberculosis (strain H37RV)  
 C:Species: Mycobacterium tuberculosis  
 C:Date: 17-Jul-1998 #sequence\_revision 17-Jul-1998 #text\_change 22-Oct-1999  
 C:Accession: F70831  
 R:Cole, S.T.; Brosch, R.; Parkhill, J.; Garnier, T.; Churcher, C.; Harris, D.; Gordon  
 ; Connor, R.; Davies, R.; Devlin, K.; Feltwell, T.; Gentles, S.; Hamlin, N.; Holroyd,  
 Rajandream, M.A.; Rogers, R.; Rutter, S.; Seeger, K.; Skelton, S.; Squares, S.  
 Nature 393, 537-544, 1998  
 A:Authors: Squares, R.; Sulston, J.E.; Taylor, K.; Whitehead, S.; Barrell, B.G.  
 A:Title: Deciphering the biology of Mycobacterium tuberculosis from the complete geno  
 A:Reference number: A70500; MUID:9825987  
 A:Accession: F70831  
 A:Status: preliminary; nucleic acid sequence not shown; translation not shown  
 A:Molecule type: DNA  
 A:Residues: 1-518 <COL>  
 A:Cross-references: GB:AL021932; GB:AL123456; NID:g3261527; PIDN:CAAL7410.1; PID:e125

A:Experimental source: strain H37Rv  
 C:Genetics:  
 A:Gene: PPE

Query Match 49.48; Score 42; DB 2; Length 518;  
 Best Local Similarity 81.8%; Pred. No. 34;  
 Matches 9; Conservative 1; Mismatches 0; Gaps 0;

Qy 3 SGTASNTTVA 13  
 :|||||  
 Db 474 AGTASNETVA 484

## RESULT 13

Plakoglobin - mouse (fragment)  
 C:Species: Mus musculus (house mouse)  
 C:Date: 06-Jan-1995 #sequence\_revision 06-Jan-1995 #text\_change 17-Mar-1999  
 C:Accession: S35092  
 R:Butz, S.; Stappert, J.; Weissig, H.; Kemler, R.  
 Science 257, 1142-1144, 1992  
 A:Title: Plakoglobin and beta-catenin: distinct but closely related.  
 A:Reference number: S35091; MUID:92376536  
 A:Accession: S35092  
 A:Status: preliminary  
 A:Molecule type: mRNA  
 A:Residues: 1-621 <BUT>  
 A:Cross-references: EMBL:M90365  
 C:Keywords: cytoskeleton

Query Match 49.48; Score 42; DB 2; Length 621;  
 Best Local Similarity 72.7%; Pred. No. 41;  
 Matches 8; Conservative 1; Mismatches 0; Gaps 0;

Qy 1 CASGTASNTTV 11  
 :|||||  
 Db 286 CATGTLNRTV 296

## RESULT 14

148854  
 gene murine tumour necrosis factor receptor 2 protein - mouse (fragment)  
 C:Species: Mus musculus (house mouse)  
 C:Date: 02-Jul-1996 #sequence\_revision 02-Jul-1996 #text\_change 23-Jul-1999  
 C:Accession: I48854  
 R:Powell, E.E.; Wicker, L.S.; Peterson, L.B.; Todd, J.A.  
 Mamm. Genome 5, 726-727, 1994  
 A:Title: Allelic variation of the type 2 tumor necrosis factor receptor gene.  
 A:Reference number: I48854; MUID:95178848  
 A:Accession: I48854  
 A:Status: preliminary; translated from GB/EMBL/DBJ  
 A:Molecule type: mRNA  
 A:Residues: 1-459 <RES>  
 A:Cross-references: EMBL:X76401; NID:9433830; PIDN:CAA53981.1; PID:9433831  
 C:Superfamily: tumor necrosis factor receptor type 2; NGF receptor repeat homology  
 F:151-188/Domain: NGF receptor repeat homology <NGF>

Query Match 48.2%; Score 41; DB 2; Length 459;  
 Best Local Similarity 57.1%; Pred. No. 44;  
 Matches 8; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

Qy 1 CASGTASNTTVAAD 14  
 :|||||  
 Db 151 CAPGTFSDTSTD 164

## RESULT 15

B38634  
 tumor necrosis factor receptor type 2 precursor - mouse  
 C:Species: Mus musculus (house mouse)

C:Date: 30-Jun-1992 #sequence\_revision 30-Jun-1992 #text\_change 23-Jul-1999  
 C:Accession: B38634; A40254; S54816  
 R:Lewis, M.; Tartaglia, L.A.; Lee, A.; Bennett, G.L.; Rice, G.C.; Wong, G.H.W.; Chen, Proc. Natl. Acad. Sci. U.S.A. 88, 2830-2834, 1991  
 A:Title: Cloning and expression of cDNAs for two distinct murine tumor necrosis facto

A:Reference number: A38634; MUID:91187885

A:Accession: B38634

A:Molecule type: mRNA

A:Residues: 1-474 <LEW>

A:Cross-references: GB:M60469; NID:9199827; PIDN:AAA39752.1; PID:9199828

R:Goodwin, R.G.; Anderson, D.; Jerzy, R.; Davis, T.; Brannan, C.L.; Copeland, N.G.; J Mol. Cell. Biol. 11, 3020-3026, 1991

A:Title: Molecular cloning and expression of the type 1 and type 2 murine receptors f

A:Reference number: A40254; MUID:91246168

A:Accession: A40254

A:Molecule type: mRNA

A:Residues: 1-474 <GOO>

A:Cross-references: GB:M60469; NID:9199827; PIDN:AAA39752.1; PID:9199828

R:Kisssonerghis, M.; Fellows, R.; Feldmann, M.; Chernaiovsky, Y.

submitted to the EMBL Data Library, May 1995

A:Description: Characterization of the promoter region of the murine p75-TNF receptor

A:Reference number: S54816

A:Accession: S54816

A:Status: preliminary

A:Molecule type: DNA

A:Residues: 1-22 <KIS>

A:Cross-references: EMBL:X87128; NID:9809043; PIDN:CAA60618.1; PID:9809044

C:Superfamily: tumor necrosis factor receptor type 2; NGF receptor repeat homology

C:Keywords: cytokine receptor; transmembrane protein

F:1-22/Domain: signal sequence #status predicted <SIG>

F:23-474/Product: tumor necrosis factor receptor type 2 #status predicted <MAT>

F:40-77/Domain: NGF receptor repeat homology <NG1>

F:79-120/Domain: NGF receptor repeat homology <NG2>

F:166-203/Domain: NGF receptor repeat homology <NG4>

Query Match 48.2%; Score 41; DB 2; Length 474;  
 Best Local Similarity 57.1%; Pred. No. 46;  
 Matches 8; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

Qy 1 CASGTASNTTVAAD 14  
 :|||||  
 Db 166 CAPGTFSDTSTD 179

Search completed: March 26, 2002, 13:37:19  
 Job time: 53 sec







RESULT 2  
 ID TNF2\_HUMAN STANDARD; PRT; 461 AA.  
 AC P20333;  
 DT 01-FEB-1991 (Rel. 17, Created)  
 DT 01-AUG-1991 (Rel. 19, Last sequence update)  
 DE 20-AUG-2001 (Rel. 40, Last annotation update)  
 DE TUMOR NECROSIS FACTOR RECEPTOR 2 PRECURSOR (TUMOR NECROSIS FACTOR  
 DE BINDING PROTEIN 2) (TBPII) (P80) (TNF-R2) (P75) (CD120B) (ETANERCEPT).  
 GN TNFRSF1B OR TNFR2 OR TNFR.  
 OS Homo sapiens (human).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 OX NCBI\_TaxID=9606;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=90260639; PubMed=2160731;  
 RA Smith C.A., Davis T., Anderson D., Solam L., Beckmann M.P., Jerzy R.,  
 RA Dower S.K., Cosman D., Goodwin R.G.;  
 RT "A receptor for tumor necrosis factor defines an unusual family of  
 RT cellular and viral proteins.";  
 RT Science 248:1019-1023(1990).  
 RN [2]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=91045991; PubMed=2172983;  
 RA Kohno T., Brewer M.T., Baker S.L., Schwartz P.E., King M.W.,  
 RA Hale K.K., Squires C.H., Thompson R.C., Vannice J.L.;  
 RT "A second tumor necrosis factor receptor gene product can shed a  
 RT naturally occurring tumor necrosis factor inhibitor.";  
 RT Proc. Natl. Acad. Sci. U.S.A. 87:8331-8335(1990).  
 RN [3]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=96299745; PubMed=8661109;  
 RA Baltinger C.P., White P.S., Maris J.M., Sulman E.P., Jensen S.J.,  
 RA Lepaslier D., Stallard B.J., Goeddel D.V., Desauvage F.J.,  
 RA Brodeur G.M.;  
 RT "Physical mapping and genomic structure of the human TNFR2 gene.";  
 RT Genomics 35:94-100(1996).  
 RN [4]  
 RP SEQUENCE OF 116-461 FROM N.A., AND PARTIAL SEQUENCE.  
 RX MEDLINE=90349572; PubMed=2166946;  
 RA Heller R.A., Song K., Onasch M.A., Fischer W.H., Chang D.,  
 RA Ringold G.M.;  
 RT "Complementary DNA cloning of a receptor for tumor necrosis factor  
 RT and demonstration of a shed form of the receptor.";  
 RT Proc. Natl. Acad. Sci. U.S.A. 87:6151-6155(1990).  
 RN [5]  
 RP SEQUENCE OF 27-31.  
 RX MEDLINE=90110215; PubMed=2153136;  
 RA Engelmann H., Novick D., Wallach D.;  
 RT "Two tumor necrosis factor-binding proteins purified from human  
 RT urine. Evidence for immunological cross-reactivity with cell surface  
 RT tumor necrosis factor receptors.";  
 RT J. Biol. Chem. 265:1531-1536(1990).  
 RN [6]  
 RP SEQUENCE OF 23-40; 65-69; 136-141; 300-306 AND 346-362.  
 RX MEDLINE=91056048; PubMed=2173696;  
 RA Loetscher H., Schlaeger E.J., Lahm H.-W., Pan Y.-C.E., Lesslauer W.,  
 RA Brockhaus M.;  
 RT "Purification and partial amino acid sequence analysis of two  
 RT distinct tumor necrosis factor receptors from HL60 cells.";  
 RT J. Biol. Chem. 265:20131-20138(1990).  
 RN [7]  
 RP CHARACTERIZATION.  
 RX MEDLINE=93016040; PubMed=1328224;  
 RA Pennica D., Lam V.T., Mize N.K., Weber R.F., Lewis M., Fendly B.M.,  
 RA Lipari M.T., Goeddel D.V.;  
 RT "Biochemical properties of the 75-kDa tumor necrosis factor receptor.  
 RT Characterization of ligand binding, internalization, and receptor  
 RT phosphorylation.";  
 RT J. Biol. Chem. 267:21172-21178(1992).  
 RN [8]  
 RP X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 419-428 IN TRAF2 COMPLEX.

RX MEDLINE=99221490; PubMed=10206649;  
 RA Park Y.C., Burkitt V., Villa A.R., Tong L., Wu H.;  
 RT "Structural basis for self-association and receptor recognition of  
 RT human TRAF2.";  
 RL Nature 398:533-538(1999).  
 CC -!- FUNCTION: RECEPTOR FOR TNF-ALPHA. HIGH AFFINITY FOR TNF-ALPHA AND  
 CC APPROXIMATELY 5-FOLD LOWER AFFINITY FOR TNF-BETA.  
 CC -!- SUBCELLULAR LOCATION: TYPE I MEMBRANE PROTEIN.  
 CC -!- PTM: PHOSPHORYLATED; MAINLY ON SERINE RESIDUES WITH A VERY LOW  
 CC LEVEL ON THREONINE RESIDUES.  
 CC -!- PHARMACEUTICAL: AVAILABLE UNDER THE NAME ENBREL (IMMUNEX AND  
 CC WYETH-AYERST). USED TO TREAT MODERATE TO SEVERE RHEUMATOID  
 CC ARTHRITIS (RA). ENBREL CONSIST OF THE EXTRACELLULAR LIGAND-BINDING  
 CC PORTION OF TNFR2 LINKED TO AN IMMUGLOBULIN FC CHAIN. IT BINDS TO  
 CC TNF-ALPHA AND BLOCKS ITS INTERACTIONS WITH RECEPTORS.  
 CC -!- SIMILARITY: CONTAINS A LA-NGFR/TNFR-TYPE CYSTEINE-RICH REGION.  
 CC -!- DATABASE: NAME=PROW; NOTE=CD guide CD120b entry;  
 CC WWW="http://www.ncbi.nlm.nih.gov/prov/cd/cd120b.htm".  
 CC -!- DATABASE: NAME=Enbrel; NOTE=Clinical information on Enbrel;  
 CC WWW="http://www.enbrelinfo.com/".  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See http://www.isb-sib.ch/announce/  
 CC or send an email to license@sib-sib.ch).  
 CC -----  
 DR EMBL; M32315; AAA59929.1; -;  
 DR EMBL; M35857; AAC63262.1; -;  
 DR EMBL; U52165; AAC50622.1; -;  
 DR EMBL; U52157; AAC50622.1; JOINED.  
 DR EMBL; U52156; AAC50622.1; JOINED.  
 DR EMBL; U52158; AAC50622.1; JOINED.  
 DR EMBL; U52159; AAC50622.1; JOINED.  
 DR EMBL; U52160; AAC50622.1; JOINED.  
 DR EMBL; U52161; AAC50622.1; JOINED.  
 DR EMBL; U52162; AAC50622.1; JOINED.  
 DR EMBL; U52163; AAC50622.1; JOINED.  
 DR EMBL; U52164; AAC50622.1; JOINED.  
 DR EMBL; M55994; AAA36755.1; -;  
 DR PIR; A33356; A35356.  
 DR PIR; A36007; A36007.  
 DR PIR; A36475; A36475.  
 DR PIR; B35010; B35010.  
 DR PIR; A23666; A23666.  
 DR PDB; 1CA9; 12-APR-99.  
 DR MIM; I91191; -;  
 DR InterPro; IPR001368; TNFR\_c6.  
 DR Pfam; PF00020; TNFR\_c6; 4.  
 DR ProDom; PD000771; TNFR\_c6; 1.  
 DR SMART; SM00208; TNFR; 4.  
 DR PROSITE; PS00652; TNFR\_NGFR\_1; 2.  
 DR PROSITE; PS50050; TNFR\_NGFR\_2; 4.  
 KW Receptor; Transmembrane; Glycoprotein; Repeat; Signal;  
 KW Phosphorylation; Pharmaceutical; 3D-structure.  
 FT SIGNAL 1 22  
 FT CHAIN 23 461 TUMOR NECROSIS FACTOR RECEPTOR 2.  
 FT DOMAIN 23 257 EXTRACELLULAR (POTENTIAL).  
 FT TRANSMEM 258 287 POTENTIAL.  
 FT DOMAIN 288 461 CYTOPLASMIC (POTENTIAL).  
 FT DOMAIN 39 201 4 X TNFR-CYS.  
 FT REPEAT 39 76 TNFR-CYS 1.  
 FT REPEAT 77 118 TNFR-CYS 2.  
 FT REPEAT 119 162 TNFR-CYS 3.  
 FT REPEAT 163 201 TNFR-CYS 4.  
 FT DISULFID 40 53 BY SIMILARITY.  
 FT DISULFID 54 67 BY SIMILARITY.  
 FT DISULFID 57 75 BY SIMILARITY.  
 FT DISULFID 78 93 BY SIMILARITY.  
 FT DISULFID 96 110 BY SIMILARITY.  
 FT DISULFID 100 118 BY SIMILARITY.

```

FT  DISULFID 120 126 BY SIMILARITY.
FT  FT 134 143 BY SIMILARITY.
FT  FT 137 161 BY SIMILARITY.
FT  FT 164 179 BY SIMILARITY.
FT  CARBOHYD 171 171 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT  CARBOHYD 193 193 R -> P (IN REF. 4).
FT  CONFLICT 141 141 R -> M (IN REF. 1 AND 3).
FT  CONFLICT 196 196 A -> T (IN REF. 4).
FT  CONFLICT 363 363 A -> T (IN REF. 4).
SQ  SEQUENCE 461 AA; 48316 MW; 603B580ECD67636F CRC64;

Query Match 54.1%; Score 46; DB 1; Length 461;
Best Local Similarity 64.3%; Pred. No. 3;
Matches 9; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

QY 1 CASGTASNTTVAAD 14
    || || || || |
Db 164 CARGTFSNTTSSD 177

RESULT 3
LRP_CAEEEL STANDARD; PRT; 4753 AA.
AC Q04833;
DT 01-OCT-1996 (Rel. 34, Created)
DT 01-OCT-1996 (Rel. 34, Last sequence update)
DT 20-AUG-2001 (Rel. 40, Last annotation update)
DE LOW-DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN PRECURSOR (LRP).
GN LRP OR F29D11.1.
OS Caenorhabditis elegans.
OC Eukaryota; Metazoa; Nematoda; Chromadorea; Rhabditida; Rhabditidae;
OC Rhabditidae; Peloderinae; Caenorhabditis.
OX NCBI_TaxID=6239;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=93281621; PubMed=8506301;
RA Vochem J.; Greenwald I.;
RT "A gene for a low density lipoprotein receptor-related protein in the
RT nematode Caenorhabditis elegans."
RL Proc. Natl. Acad. Sci. U.S.A. 90:4572-4576(1993).
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN=BRISTOL N2;
RA Wilkinson J.;
RL Submitted (MAY-1996) to the EMBL/GenBank/DBJ databases.
CC -1- FUNCTION: MAY ACT AS A RECEPTOR FOR THE ENDOCYTOSIS OF
CC EXTRACELLULAR LIGANDS SUCH AS CHYLOMICRON REMNANTS, PROTEASE-
CC INHIBITOR COMPLEXES AND VITELLOGENIN.
CC -1- SUBCELLULAR LOCATION: TYPE I MEMBRANE PROTEIN.
CC -1- SIMILARITY: CONTAINS 35 LDL-RECEPTOR CLASS A DOMAINS.
CC -1- SIMILARITY: CONTAINS 17 EGF-LIKE DOMAINS.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (see http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
CC EMBL; M96150; A028105.1; -
CC HSP; P07204; IEGT.
CC WormPep; F29D11.1; CE05765.
CC InterPro; IPR000152; Asx_hydroxyl.
CC InterPro; IPR000561; EGF-like.
CC InterPro; IPR001881; EGF_Ca.
CC InterPro; IPR002172; LDL_recept_A.
CC InterPro; IPR000033; ldl_recept_a; 35.
CC Pfam; PF00058; ldl_recept_b; 26.
CC PRINTS; PR00261; LDLRECEPTOR.

```

```

DR SMART; SM00179; EGF_CA; 2.
DR SMART; SM00001; EGF_Like; 15.
DR SMART; SM00192; LDLA; 34.
DR SMART; SM00135; LY; 30.
DR PROSITE; PS00010; ASX_HYDROXYL; 6.
DR PROSITE; PS00022; EGF_1; 1.
DR PROSITE; PS01186; EGF_2; 3.
DR PROSITE; PS01187; EGF_CA; 3.
DR PROSITE; PS01209; LDLRA_1; 27.
DR PROSITE; PS00088; LDLRA_2; 34.
KW Receptor; Transmembrane; Repeat; Endocytosis; Glycoprotein;
KW Signal; Calcium-binding; EGF-like domain; Coated pits.
FT SIGNAL 1 18 POTENTIAL.
FT CHAIN 19 4753 LOW-DENSITY LIPOPROTEIN RECEPTOR-RELATED
FT PROTEIN.
FT DOMAIN 19 4570 EXTRACELLULAR (POTENTIAL).
FT TRANSMEM 4571 4596 POTENTIAL.
FT DOMAIN 4597 4753 CYTOPLASMIC (POTENTIAL).
FT DOMAIN 51 89 LDL-RECEPTOR CLASS A 1.
FT DOMAIN 90 133 LDL-RECEPTOR CLASS A 2.
FT DOMAIN 136 177 LDL-RECEPTOR CLASS A 3.
FT DOMAIN 180 220 LDL-RECEPTOR CLASS A 4.
FT DOMAIN 221 259 LDL-RECEPTOR CLASS A 5.
FT DOMAIN 260 298 LDL-RECEPTOR CLASS A 6.
FT DOMAIN 299 337 EGF-LIKE 1.
FT DOMAIN 338 368 EGF-LIKE 2. CALCIUM-BINDING (POTENTIAL).
FT DOMAIN 369 712 EGF-LIKE 3.
FT DOMAIN 997 1043 EGF-LIKE 4.
FT DOMAIN 1052 1097 LDL-RECEPTOR CLASS A 7.
FT DOMAIN 1099 1140 LDL-RECEPTOR CLASS A 8.
FT DOMAIN 1144 1184 LDL-RECEPTOR CLASS A 9.
FT DOMAIN 1185 1225 LDL-RECEPTOR CLASS A 10.
FT DOMAIN 1226 1265 LDL-RECEPTOR CLASS A 11.
FT DOMAIN 1268 1309 LDL-RECEPTOR CLASS A 12.
FT DOMAIN 1311 1352 LDL-RECEPTOR CLASS A 13.
FT DOMAIN 1357 1397 LDL-RECEPTOR CLASS A 14.
FT DOMAIN 1398 1436 EGF-LIKE 5.
FT DOMAIN 1437 1476 EGF-LIKE 6.
FT DOMAIN 1747 1786 EGF-LIKE 7.
FT DOMAIN 2080 2120 EGF-LIKE 8.
FT DOMAIN 2396 2439 EGF-LIKE 9.
FT DOMAIN 2728 2780 EGF-LIKE 10.
FT DOMAIN 2831 2870 LDL-RECEPTOR CLASS A 15.
FT DOMAIN 2832 2870 LDL-RECEPTOR CLASS A 16.
FT DOMAIN 2872 2914 LDL-RECEPTOR CLASS A 17.
FT DOMAIN 2917 2958 LDL-RECEPTOR CLASS A 18.
FT DOMAIN 2959 2999 LDL-RECEPTOR CLASS A 19.
FT DOMAIN 3004 3046 LDL-RECEPTOR CLASS A 20.
FT DOMAIN 3047 3095 LDL-RECEPTOR CLASS A 21.
FT DOMAIN 3098 3137 LDL-RECEPTOR CLASS A 22.
FT DOMAIN 3138 3176 LDL-RECEPTOR CLASS A 23.
FT DOMAIN 3185 3223 LDL-RECEPTOR CLASS A 24.
FT DOMAIN 3224 3265 EGF-LIKE 11.
FT DOMAIN 3266 3306 EGF-LIKE 12. CALCIUM-BINDING (POTENTIAL).
FT DOMAIN 3582 3624 EGF-LIKE 13.
FT DOMAIN 3625 3668 LDL-RECEPTOR CLASS A 25.
FT DOMAIN 3669 3707 LDL-RECEPTOR CLASS A 26.
FT DOMAIN 3707 3748 LDL-RECEPTOR CLASS A 27.
FT DOMAIN 3751 3790 LDL-RECEPTOR CLASS A 28.
FT DOMAIN 3791 3832 LDL-RECEPTOR CLASS A 29.
FT DOMAIN 3831 3873 LDL-RECEPTOR CLASS A 30.
FT DOMAIN 3876 3914 LDL-RECEPTOR CLASS A 31.
FT DOMAIN 3915 3953 LDL-RECEPTOR CLASS A 32.
FT DOMAIN 3957 3997 LDL-RECEPTOR CLASS A 33.
FT DOMAIN 4042 4085 LDL-RECEPTOR CLASS A 34.
FT DOMAIN 4088 4131 EGF-LIKE 14. CALCIUM-BINDING (POTENTIAL).
FT DOMAIN 4132 4176 EGF-LIKE 15.
FT DOMAIN 4477 4515 EGF-LIKE 16.
FT DOMAIN 4526 4554 EGF-LIKE 17.
FT DOMAIN 4653 4658 ENDOCYTOSIS SIGNAL (POTENTIAL).
FT SITE 4744 4744 CRITICAL FOR ENDOCYTOSIS (BY SIMILARITY).
FT DISULFID 53 65 BY SIMILARITY.

```

```
FT DISULFID 60 78 BY SIMILARITY.
FT DISULFID 72 87 BY SIMILARITY.
FT DISULFID 92 109 BY SIMILARITY.
FT DISULFID 99 122 BY SIMILARITY.
FT DISULFID 116 131 BY SIMILARITY.
FT DISULFID 138 152 BY SIMILARITY.
FT DISULFID 146 165 BY SIMILARITY.
FT DISULFID 159 175 BY SIMILARITY.
FT DISULFID 182 195 BY SIMILARITY.
FT DISULFID 189 208 BY SIMILARITY.
FT DISULFID 202 218 BY SIMILARITY.
FT DISULFID 223 235 BY SIMILARITY.
FT DISULFID 230 248 BY SIMILARITY.
FT DISULFID 242 257 BY SIMILARITY.
FT DISULFID 262 275 BY SIMILARITY.
FT DISULFID 269 288 BY SIMILARITY.
FT DISULFID 282 297 BY SIMILARITY.
FT DISULFID 302 311 BY SIMILARITY.
FT DISULFID 307 320 BY SIMILARITY.
FT DISULFID 322 336 BY SIMILARITY.
FT DISULFID 342 352 BY SIMILARITY.
FT DISULFID 348 361 BY SIMILARITY.
FT DISULFID 363 367 BY SIMILARITY.
FT DISULFID 673 682 BY SIMILARITY.
FT DISULFID 678 697 BY SIMILARITY.
FT DISULFID 699 711 BY SIMILARITY.
FT DISULFID 1001 1010 BY SIMILARITY.
FT DISULFID 1006 1026 BY SIMILARITY.
FT DISULFID 1028 1042 BY SIMILARITY.
FT DISULFID 1054 1068 BY SIMILARITY.
FT DISULFID 1063 1081 BY SIMILARITY.
FT DISULFID 1075 1095 BY SIMILARITY.
FT DISULFID 1101 1114 BY SIMILARITY.
FT DISULFID 1108 1127 BY SIMILARITY.
FT DISULFID 1121 1138 BY SIMILARITY.
FT DISULFID 1146 1158 BY SIMILARITY.
FT DISULFID 1153 1171 BY SIMILARITY.
FT DISULFID 1165 1182 BY SIMILARITY.
FT DISULFID 1187 1199 BY SIMILARITY.
FT DISULFID 1194 1212 BY SIMILARITY.
FT DISULFID 1206 1223 BY SIMILARITY.
FT DISULFID 1228 1241 BY SIMILARITY.
FT DISULFID 1235 1254 BY SIMILARITY.
FT DISULFID 1248 1263 BY SIMILARITY.
FT DISULFID 1270 1283 BY SIMILARITY.
FT DISULFID 1277 1296 BY SIMILARITY.
FT DISULFID 1290 1307 BY SIMILARITY.
FT DISULFID 1313 1325 BY SIMILARITY.
FT DISULFID 1320 1338 BY SIMILARITY.
FT DISULFID 1332 1350 BY SIMILARITY.
FT DISULFID 1359 1373 BY SIMILARITY.
FT DISULFID 1366 1386 BY SIMILARITY.
FT DISULFID 1380 1396 BY SIMILARITY.
FT DISULFID 1401 1412 BY SIMILARITY.
FT DISULFID 1408 1421 BY SIMILARITY.
FT DISULFID 1423 1435 BY SIMILARITY.
FT DISULFID 1441 1451 BY SIMILARITY.
FT DISULFID 1447 1460 BY SIMILARITY.
FT DISULFID 1462 1475 BY SIMILARITY.
FT DISULFID 1751 1760 BY SIMILARITY.
FT DISULFID 1756 1770 BY SIMILARITY.
FT DISULFID 1772 1785 BY SIMILARITY.
FT DISULFID 2084 2095 BY SIMILARITY.
FT DISULFID 2091 2105 BY SIMILARITY.
FT DISULFID 2107 2119 BY SIMILARITY.
FT DISULFID 2400 2415 BY SIMILARITY.
FT DISULFID 2411 2426 BY SIMILARITY.
FT DISULFID 2428 2438 BY SIMILARITY.
FT DISULFID 2732 2743 BY SIMILARITY.
FT DISULFID 2739 2759 BY SIMILARITY.
FT DISULFID 2761 2779 BY SIMILARITY.
FT DISULFID 2792 2805 BY SIMILARITY.
FT DISULFID 2800 2818 BY SIMILARITY.

Query Match 54.1% Score 46; DB 1; Length 4753;
Best Local Similarity 52.9%; Pred. No. 33;
Matches 9; Conservative 2; Mismatches 6; Indels 0; Gaps 0;

QY 1 CASGTASNTTVAADRSN 17
Db 4056 CANGKCVNGTVACDRKD 4072

RESULT 4:
TOP2_PEA ID TOP2_PEA STANDARD; PRT; 1462 AA.
AC 024308;
DT 15-DEC-1998 (Rel. 37, Created)
DT 15-DEC-1998 (Rel. 37, Last sequence update)
DT 30-MAY-2000 (Rel. 39, Last annotation update)
DE DNA TOPOISOMERASE II (EC 5.99.1.3).
GN TOP2 OR TOP11.
OS Pisum sativum (Garden pea).
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; Rosidae;
OC eurosids I; Fabales; Fabaceae; Papilionoideae; Viciaeae; Pisum.
OX NCBI_TaxID=3888;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Leaf;
RA Reddy M.K., Nair S., Tewari K.K.;
RL Submitted (AUG-1997) to the EMBL/GenBank/DBJ databases.
CC -1- FUNCTION: CONTROL OF TOPOLOGICAL STATES OF DNA BY TRANSIENT
CC BREAKAGE AND SUBSEQUENT REJOINING OF DNA STRANDS. TOPOISOMERASE II
CC MAKES DOUBLE-STRAND BREAKS.
CC -1- CATALYTIC ACTIVITY: ATP-DEPENDENT BREAKAGE, PASSAGE AND REJOINING
CC OF DOUBLE-STRANDED DNA.
CC -1- SUBUNIT: HOMODIMER (BY SIMILARITY).
CC -1- MISCELLANEOUS: EUKARYOTIC TOPOISOMERASE I AND II CAN RELAX BOTH
CC NEGATIVE AND POSITIVE SUPERCOILS,
CC RELAX ONLY NEGATIVE SUPERCOILS.
CC -1- SIMILARITY: BELONGS TO THE TYPE II TOPOISOMERASE FAMILY.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC
CC EMBL: Y14559; CAA74891.1;
CC InterPro: IPR000947; CBFA_NFYB.
CC InterPro: IPR001241; DNA_topoisoII.
CC InterPro: IPR002205; DNA_topoisoIV.
CC InterPro: IPR003594; HATPase_c.
CC Pfam: PF00204; DNA_topoisoII; 1.
CC Pfam: PF00521; DNA_topoisoIV; 2.
CC Pfam: PF02518; HATPase_c; 1.
CC PRINTS; PR00418; TP12FAMILY.
CC PRINTS; PR00615; CCAATSUBUNTA.
CC PRINTS; PR01158; TOPISMRASEII.
CC ProDom; PD000616; DNA_topoisoII; 1.
CC SMART; SM00433; TOP2c; 1.
CC SMART; SM00434; TOP4c; 1.
CC PROSITE; PS00177; TOPOISOMERASE_II; 1.
CC Isomerase; Topoisomerase; DNA-binding; ATP-binding.
CC NP_BIND 149 154 ATP (POTENTIAL).
CC ACT_SITE 761 761 DNA CLEAVAGE (BY SIMILARITY).
CC SEQUENCE 1462 AA; 164205 MW; D9212C54AE0F8B2E CRC64;
```

Query Match 50.6%; Score 43; DB 1; Length 1462;  
 Best Local Similarity 50.0%; Pred. No. 31;  
 Matches 7; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1 CASGTASNTTVAAD 14  
 DB 1400 CSASASNTPLSD 1413

RESULT 5  
 TNFR2\_MOUSE STANDARD; PRT; 474 AA.  
 AC P25119; P97893;  
 DT 01-MAY-1992 (Rel. 22, Created)  
 DT 01-MAY-1992 (Rel. 22, Last sequence update)  
 DT 15-JUL-1999 (Rel. 38, Last annotation update)  
 DE TUMOR NECROSIS FACTOR RECEPTOR 2 PRECURSOR (TNF-R2) (P75).  
 GN TNFRSF1B OR TNFR2 OR TNFR-2.  
 OS Mus musculus (Mouse).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
 OX NCBI\_TaxID=10090;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=91187885; PubMed=1849278;  
 RA Lewis M., Tartaglia L.A., Lee A., Bennett G.L., Rice G.C.,  
 Wong G.H., Chen E.Y., Goeddel D.V.;  
 RT "Cloning and expression of cDNAs for two distinct murine tumor  
 RT necrosis factor receptors demonstrate one receptor is species  
 RT specific."  
 RL Proc. Natl. Acad. Sci. U.S.A. 88:2830-2834(1991).  
 RN [2]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=91246168; PubMed=1645445;  
 RA Goodwin R.G., Anderson D., Jerzy R., Davis T., Brannan C.I.,  
 Copeland N.G., Jenkins N.A., Smith C.A.;  
 RT "Molecular cloning and expression of the type 1 and type 2 murine  
 RT receptors for tumor necrosis factor."  
 RL Mol. Cell. Biol. 11:3020-3026(1991).  
 RN [3]  
 RP SEQUENCE OF 1-26 FROM N.A.  
 RC STRAIN=NOD;  
 RA Jacob C.O., Liu J.;  
 RL Submitted (JAN-1996) to the EMBL/GenBank/DBJ databases.  
 RN [4]  
 RP SEQUENCE OF 1-22 FROM N.A.  
 RC TISSUE=Liver;  
 RA Kissinger M., Fellowes R., Feldmann M., Chernajovsky Y.;  
 RL Submitted (MAY-1995) to the EMBL/GenBank/DBJ databases.  
 CC -1- FUNCTION: RECEPTOR FOR TNF-ALPHA.  
 CC -1- SUBCELLULAR LOCATION: TYPE I MEMBRANE PROTEIN.  
 CC -1- SIMILARITY: CONTAINS A LA-NGFR/TNFR-TYPE CYSTEINE-RICH REGION.  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed, usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC -----  
 DR EMBL; M50469; AAA39752.1; -  
 DR EMBL; M59378; AAA40463.1; -  
 DR EMBL; U39488; AAA5021.1; -  
 DR EMBL; X87128; CAA60618.1; -  
 DR PIR; B38634; B38634.  
 DR HSSP; P19438; 1NCF.  
 DR MGD; MGI:1314883; Tnfrsf1b.  
 DR InterPro; IPR001368; TNFR\_c6.  
 DR Pfam; PF00020; TNFR\_c6; 4.  
 DR ProDom; PD000771; TNFR\_c6; 1.  
 DR SMART; SM00208; TNFR; 4.  
 DR PROSITE; PS00652; TNFR\_NGFR\_1; 2.

DR PROSITE; PS00652; TNFR\_NGFR\_2; 3.  
 KW Receptor; Transmembrane; Glycoprotein; Repeat; Signal.  
 FT SIGNAL 1 22  
 FT CHAIN 23 474 TUMOR NECROSIS FACTOR RECEPTOR 2.  
 FT DOMAIN 23 258 EXTRACELLULAR (POTENTIAL).  
 FT TRANSMEM 259 288 POTENTIAL.  
 FT DOMAIN 289 474 CYTOPLASMIC (POTENTIAL).  
 FT DOMAIN 39 203 4 X TNFR-CYS.  
 FT REPEAT 39 77 TNFR-CYS 3.  
 FT REPEAT 78 119 TNFR-CYS 2.  
 FT REPEAT 120 164 TNFR-CYS 3.  
 FT REPEAT 165 203 TNFR-CYS 4.  
 FT DISULFID 40 54 BY SIMILARITY.  
 FT DISULFID 55 68 BY SIMILARITY.  
 FT DISULFID 58 76 BY SIMILARITY.  
 FT DISULFID 79 94 BY SIMILARITY.  
 FT DISULFID 97 111 BY SIMILARITY.  
 FT DISULFID 101 119 BY SIMILARITY.  
 FT DISULFID 121 127 BY SIMILARITY.  
 FT DISULFID 136 145 BY SIMILARITY.  
 FT DISULFID 139 163 BY SIMILARITY.  
 FT DISULFID 166 181 BY SIMILARITY.  
 FT CARBOHYD 69 69 N-LINKED (GLCNAC... ) (POTENTIAL).  
 FT CARBOHYD 195 195 N-LINKED (GLCNAC... ) (POTENTIAL).  
 SQ SEQUENCE 474 AA; 50319 MW; 462EAE398C4D6563 CRC64;

Query Match 48.2%; Score 41; DB 1; Length 474;  
 Best Local Similarity 57.1%; Pred. No. 21;  
 Matches 8; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

QY 1 CASGTASNTTVAAD 14  
 DB 166 CAPGTSDDTSTSD 179  
 RESULT 6  
 DP3A\_CHLMU STANDARD; PRT; 1237 AA.  
 ID DP3A\_CHLMU STANDARD; PRT; 1237 AA.  
 AC G9PJU7;  
 DT 20-AUG-2001 (Rel. 40, Created)  
 DT 20-AUG-2001 (Rel. 40, Last sequence update)  
 DT 20-AUG-2001 (Rel. 40, Last annotation update)  
 DE DNA POLYMERASE III ALPHA SUBUNIT (EC 2.7.7.7).  
 GN DNAE OR TC0832.  
 OS Chlamydia muridarum.  
 OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydia.  
 OX NCBI\_TaxID=22560;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=M22; Nigg.  
 RX MEDLINE=20150235; PubMed=10684935;  
 RA Read T.D., Bruhman R.C., Shen C., Gill S.R., Heidelberg J.F.,  
 White O., Hickey E.K., Peterson J., Utterback T., Berry K., Bass S.,  
 Linher K., Weidman J., Khouri H., Craven B., Bowman C., Dodson R.,  
 Gwin M., Nelson W., DeBoy R., Kolonay J., McClarty G., Salzberg S.L.,  
 Eisen J., Fraser C.M.;  
 RA "Genome sequences of Chlamydia trachomatis MoPn and Chlamydia  
 RA pneumoniae AR39."  
 RT Nucleic Acids Res. 28:1397-1406(2000).  
 CC -1- FUNCTION: DNA POLYMERASE III IS A COMPLEX, MULTICHAIN ENZYME  
 CC RESPONSIBLE FOR MOST OF THE REPLICATIVE SYNTHESIS IN BACTERIA.  
 CC THIS DNA POLYMERASE ALSO EXHIBITS 3' TO 5' EXONUCLEASE ACTIVITY.  
 CC THE ALPHA CHAIN IS THE DNA POLYMERASE (BY SIMILARITY).  
 CC -1- CATALYTIC ACTIVITY: N DEOXYNUCLEOSIDE TRIPHOSPHATE -  
 CC N PYROPHOSPHATE + DNA(N).  
 CC -1- SUBUNIT: CONTAINS A CORE (COMPOSED OF ALPHA, EPSILON, AND THETA  
 CC CHAINS) THAT ASSOCIATES WITH A TAU SUBUNIT WHICH ALLOW THE CORE  
 CC DIMERIZATION TO FORM THE POLIII' COMPLEX. POLIII' ASSOCIATES WITH  
 CC THE GAMMA COMPLEX (COMPOSED OF CHAINS GAMMA, DELTA, DELTA', PSI,  
 CC AND CHI) AND WITH THE BETA CHAIN (BY SIMILARITY).  
 CC -1- SUBCELLULAR LOCATION: CYTOPLASMIC (BY SIMILARITY).  
 CC -1- SIMILARITY: BELONGS TO DNA POLYMERASE TYPE-C FAMILY. DNAE

```

CC SUBFAMILY.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL: AE002349; AAF39632.1; -
DR TIGR: TC0832; -
DR InterPro: IPR003141; PHP_N.
DR Pfam: PF02231; PHP_N; 1.
DR SMART: SM00481; POLIITAC; 1.
DR Transferrase: DNA-directed DNA polymerase; DNA replication;
KW Complete proteome.
SQ SEQUENCE 1237 AA; 139892 MW; 5839DAF98D4CA223 CRC64;

Query Match 48.2%; Score 41; DB 1; Length 1237;
Best Local Similarity 61.5%; Pred. No. 55;
Matches 8; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

QY 5 TASNTTVAADRSN 17
   | | | | |
DB 289 TISNTLIVADRCN 301

RESULT 7
C553_PARDE STANDARD; PRT; 226 AA.
AC P29967;
DT 01-APR-1993 (Rel. 25, Created)
DT 01-APR-1993 (Rel. 25, Last sequence update)
DT 01-NOV-1997 (Rel. 35, Last annotation update)
DE CYTOCHROME C-553I PRECURSOR (C553I).
GN CYCB.
OS Paracoccus denitrificans.
OC Bacteria; Proteobacteria; alpha subdivision; Rhodobacter group;
OC Paracoccus.
OX NCBI_TaxID=266;
RN [1]
RP SEQUENCE FROM N.A., AND PARTIAL SEQUENCE.
RC STRAIN=PD 1235;
RX MEDLINE=92041583; PubMed=1657873;
RA Ras J., Reijnders W.N.M., van Spanning R.J.M., Harms N., Oltmann L.F.,
RA Stouthamer A.H.;
RT "Isolation, sequencing, and mutagenesis of the gene encoding
RT cytochrome c553i of Paracoccus denitrificans and characterization of
RL J. Bacteriol. 173:6971-6979(1991).
CC -|- SUBCELLULAR LOCATION: PERIPLASMIC.
CC -|- INDUCTION: DURING GROWTH ON METHANOL.
CC -|- PTM: BINDS ONE HEME GROUP PER MOLECULE.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL: M75583; AAA25575.1; -
DR PIR: B41378; B41378.
DR InterPro: IPR000345; CytC_heme_bind.
DR InterPro: IPR003088; Cyt_C1.
DR Pfam: PF00034; cytochrome_c; 1.
DR PROSITE: PS00190; CYTOCHROME_C; FALSE_NEG.
KW Electron transport; Heme; Signal; Methanol utilization; Periplasmic.
FT SIGNAL 1 22 POTENTIAL.
FT CHAIN 23 226 CYTOCHROME C-553I.

```

```

FT BINDING 125 125 HEME (COVALENT) (BY SIMILARITY).
FT BINDING 128 128 HEME (COVALENT) (BY SIMILARITY).
FT METAL 129 129 IRON (HEME AXIAL LIGAND) (BY SIMILARITY).
FT METAL 173 173 IRON (HEME AXIAL LIGAND) (BY SIMILARITY).
FT DOMAIN 37 44 POLY-ALA.
FT DOMAIN 60 64 POLY-GLU.
SQ SEQUENCE 226 AA; 23879 MW; C1D5DA803702AEC7 CRC64;

Query Match 47.1%; Score 40; DB 1; Length 226;
Best Local Similarity 41.2%; Pred. No. 14;
Matches 7; Conservative 3; Mismatches 7; Indels 0; Gaps 0;

QY 1 CASGTASNTTVAADRSN 17
   | | | | |
DB 16 CAASATAGTALCADRRN 32

RESULT 8
TRYP_STRGR STANDARD; PRT; 259 AA.
AC P00775;
DT 21-JUL-1986 (Rel. 01, Created)
DT 01-FEB-1994 (Rel. 28, Last sequence update)
DT 01-NOV-1995 (Rel. 32, Last annotation update)
DE TRYP SIN PRECURSOR (EC 3.4.21.4) (SGT).
GN SPRT.
OS Streptomyces griseus.
OC Bacteria; Firmicutes; Actinobacteria; Actinobacteridae.
OC Actinomycetales; Streptomyces; Streptomycetaceae; Streptomyces.
OX NCBI_TaxID=1911;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=ATCC 10137;
RX MEDLINE=92095977; PubMed=1755852;
RA Kim J.C., Cha S.H., Jeong S.T., Oh S.K., Byun S.M.;
RT "Molecular cloning and nucleotide sequence of Streptomyces griseus
RT trypsin gene."
RT Biochem. Biophys. Res. Commun. 181:707-713(1991).
RN [2]
RP SEQUENCE OF 37-259.
RX MEDLINE=75127940; PubMed=804314;
RA Olafson R.W., Jurasek L., Carpenter M.R., Smillie L.B.;
RT "Amino acid sequence of Streptomyces griseus trypsin. Cyanogen
RT bromide fragments and complete sequence."
RL Biochemistry 14:1168-1177(1975).
RN [3]
RP X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS).
RX MEDLINE=88286735; PubMed=3135412;
RA Read R.J., James M.N.G.;
RT "Refined crystal structure of Streptomyces griseus trypsin at 1.7-A
RT resolution."
RL J. Mol. Biol. 200:523-551(1988).
CC -|- CATALYTIC ACTIVITY: PREFERENTIAL CLEAVAGE: ARG-, LYS-.
CC -|- SIMILARITY: BELONGS TO PEPTIDASE FAMILY S1; ALSO KNOWN AS THE
CC TRYP SIN FAMILY.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL: M64471; AAA26820.1; ALT_SEQ.
DR PIR: A00962; TRSMG.
DR PIR: JQ1302; JQ1302.
DR PDB: 1SGT; 16-JUL-88.
DR MEROPS: S01.101; -.
DR InterPro: IPR001314; Chymotrypsin.
DR InterPro: IPR001254; Trypsin.
DR Pfam: PF00089; trypsin; 1.

```

DR PRINTS; PR00722; CHYMOTRYPSIN.  
DR SMART; SM00020; TRYP\_SPC; 1.  
DR PROSITE; PS02040; TRYPSIN\_DOM; 1.  
DR PROSITE; PS00134; TRYPSIN\_HIS; 1.  
DR PROSITE; PS00135; TRYPSIN\_SER; 1.  
KW Hydrolase; Serine protease; Zymogen; Signal; 3D-structure.  
FT SIGNAL 1 32  
FT PROPEP 33 36 ACTIVATION PEPTIDE.  
FT CHAIN 37 259 TRYPSIN.  
FT ACT\_SITE 73 73 CHARGE RELAY SYSTEM.  
FT ACT\_SITE 118 118 CHARGE RELAY SYSTEM.  
FT ACT\_SITE 208 208 CHARGE RELAY SYSTEM.  
FT DISULFID 58 74  
FT DISULFID 177 192  
FT DISULFID 204 233  
FT SITE 202 202 REQUIRED FOR SPECIFICITY.  
FT SITE 202 202 MISSING (IN REF. 2).  
FT CONFLICT 95 96  
FT STRAND 38 38  
FT TURN 39 39  
FT STRAND 41 42  
FT TURN 45 46  
FT TURN 49 50  
FT STRAND 51 54  
FT TURN 55 57  
FT STRAND 58 64  
FT TURN 65 66  
FT STRAND 67 70  
FT STRAND 72 74  
FT HELIX 79 80  
FT STRAND 85 88  
FT STRAND 92 92  
FT TURN 93 94  
FT TURN 96 97  
FT STRAND 99 108  
FT TURN 110 111  
FT STRAND 120 124  
FT STRAND 134 135  
FT TURN 140 141  
FT STRAND 145 150  
FT TURN 156 157  
FT STRAND 163 163  
FT STRAND 165 172  
FT HELIX 174 184  
FT TURN 187 189  
FT STRAND 190 193  
FT TURN 196 198  
FT STRAND 202 202  
FT TURN 205 206  
FT TURN 208 209  
FT STRAND 211 215  
FT TURN 217 218  
FT STRAND 221 229  
FT TURN 236 237  
FT STRAND 240 244  
FT HELIX 245 257  
FT TURN 258 258  
SQ SEQUENCE 259 AA; 26776 MW; 050233AFF1F64823 CRC64;

Query Match 47.1%; Score 40; DB 1; Length 259;  
Best Local Similarity 46.2%; Pred. No. 16;  
Matches 6; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

QY 1 CASGTASNTTVA 13  
Db 74 CVSGSGNNTSITA 86

RESULT 9  
PRCD\_RAT STANDARD; PRT; 237 AA.  
ID PRCD\_RAT  
AC P28073;  
DT 01-AUG-1992 (Rel. 23, Created)

DT 01-FEB-1994 (Rel. 28, Last sequence update)  
DT 20-AUG-2001 (Rel. 40, Last annotation update)  
DE PROTEASOME DELTA CHAIN PRECURSOR (EC 3.4.99.46) (MACROPAIN DELTA  
DE CHAIN) (MULTICATALYTIC ENDOPEPTIDASE COMPLEX DELTA CHAIN) (PROTEASOME  
DE SUBUNIT Y) (PROTEASOME CHAIN 5) (FRAGMENT).  
GN PSMB6.  
OS Rattus norvegicus (Rat).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.  
OX NCBI\_TaxID=10116;  
RN [1]  
RP SEQUENCE FROM N.A.  
RX MEDLINE=93147071; PubMed=1491007;  
RA Tamura T., Shimbara N., Aki M., Ishida N., Bey F., Scherrer K.,  
RA Tanaka K., Ichihara A.;  
RT "Molecular cloning of cDNAs for rat proteasomes: deduced primary  
RT structures of four other subunits.",  
RL J. Biochem. 112:530-534(1992).  
RN [2]  
RP SEQUENCE OF 33-50.  
RX MEDLINE=90242957; PubMed=2335214;  
RA Lilley K.S., Davison M.D., Rivett A.J.;  
RT "N-terminal sequence similarities between components of the  
RT multicatalytic proteinase complex.",  
RL FEBS Lett. 262:327-329(1990).  
CC -!- FUNCTION: THE PROTEASOME IS A MULTICATALYTIC PROTEINASE COMPLEX  
CC WHICH IS CHARACTERIZED BY ITS ABILITY TO CLEAVE PEPTIDES WITH  
CC ARG. PHE, TYR, LEU, AND GLU ADJACENT TO THE LEAVING GROUP AT  
CC NEUTRAL OR SLIGHTLY BASIC PH. THE PROTEASOME HAS AN ATP-DEPENDENT  
CC PROTEOLYTIC ACTIVITY.  
CC -!- PATHWAY: INVOLVED IN AN ATP/UBIQUITIN-DEPENDENT NON-LYSOSOMAL  
CC PROTEOLYTIC PATHWAY.  
CC -!- SUBUNIT: THE PROTEASOME IS COMPOSED OF AT LEAST 15 NON IDENTICAL  
CC SUBUNITS WHICH FORM A HIGHLY ORDERED RING-SHAPED STRUCTURE.  
CC -!- SUBCELLULAR LOCATION: PROTEASOMES ARE FOUND IN THE CYTOPLASM AND  
CC ALSO IN THE NUCLEUS.  
CC -!- SIMILARITY: BELONGS TO PEPTIDASE FAMILY T1B; ALSO KNOWN AS THE  
CC PROTEASOME B-TYPE FAMILY. DELTA SUBFAMILY.  
CC -----  
CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
CC the European Bioinformatics Institute. There are no restrictions on its  
CC use by non-profit institutions as long as its content is in no way  
CC modified and this statement is not removed. Usage by and for commercial  
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
CC -----  
DR EMBL; D10754; BAA01586.1; ALT\_INIT.  
DR PIR; S09086; S09086.  
DR MEROPS; T01.010; -.  
DR InterPro; IPR001353; Proteasome.  
DR InterPro; IPR000243; Proteasome\_B.  
DR Pfam; PF00227; proteasome; 1.  
DR PROSITE; PS00854; PROTEASOME\_B; 1.  
DR KW Proteasome; Hydrolase; Protease; Zymogen.  
FT NON\_TER 1 1  
FT PROPEP <1 32  
FT CHAIN 33 237 PROTEASOME DELTA CHAIN.  
SQ SEQUENCE 237 AA; 25158 MW; C215AC2A70D9AA5F CRC64;

Query Match 45.9%; Score 39; DB 1; Length 237;  
Best Local Similarity 50.0%; Pred. No. 21;  
Matches 7; Conservative 3; Mismatches 4; Indels 0; Gaps 0;

QY 1 CASGTASNTTVAAD 14  
Db 76 CRSGSAADTOAVAD 89

RESULT 10  
PRCD\_HUMAN STANDARD; PRT; 239 AA.  
ID PRCD\_HUMAN





OS Lycopersicon esculentum ('Tomato').  
 OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;  
 OC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;  
 OC Asteridae; euasterids I; Solanales; Solanaceae; Solanum.  
 OX NCBI\_TaxID=4081;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RA Kunik T., Mizrahy L., Citovsky V., Gafni Y.;  
 RL Submitted (JUN-1998) to the EMBL/GenBank/DBJ databases.  
 CC -1- FUNCTION: BINDS SPECIFICALLY AND DIRECTLY TO SUBSTRATES CONTAINING  
 CC EITHER A SIMPLE OR BIPARTITE NLS MOTIF. PROMOTES DOCKING OF IMPORT  
 CC SUBSTRATES TO THE NUCLEAR ENVELOPE. SEEMS TO ACT AS A CYTOSOLIC  
 CC RECEPTOR FOR BOTH SIMPLE AND BIPARTITE NLS MOTIFS (BY SIMILARITY).  
 CC -1- SUBUNIT: FORMS A COMPLEX WITH IMPORTIN BETA-1 SUBUNIT (BY  
 CC SIMILARITY).  
 CC -1- SUBCELLULAR LOCATION: CYTOPLASMIC (BY SIMILARITY).  
 CC -1- SIMILARITY: BELONGS TO THE IMPORTIN ALPHA FAMILY.  
 CC -1- SIMILARITY: CONTAINS 8 ARM REPEATS.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC -----  
 DR EMBL; AF017252; AAC23722.1; -;  
 DR InterPro; IPR000225; Armadillo.  
 DR Pfam; PF00514; Armadillo\_seg; 8.  
 DR Pfam; PF01749; IBB; 1.  
 DR SMART; SM00185; ARM; 8.  
 DR PROSITE; PS50176; ARM\_REPEAT; 5.  
 KW Transport; Protein transport; Repeat.  
 FT DOMAIN 12 51 IBB.  
 FT REPEAT 109 151 ARM 1.  
 FT REPEAT 152 196 ARM 2.  
 FT REPEAT 197 234 ARM 3.  
 FT REPEAT 235 279 ARM 4.  
 FT REPEAT 280 319 ARM 5.  
 FT REPEAT 320 362 ARM 6.  
 FT REPEAT 363 403 ARM 7.  
 FT REPEAT 403 445 ARM 8.  
 FT DOMAIN 446 527 ASP/GLU-RICH (ACIDIC).  
 FT SEQUENCE 527 AA; 58605 MW; 4A3F01691CE4817 CRC64;  
 Query Match 45.9%; Score 39; DB 1; Length 527;  
 Best Local Similarity 61.5%; Pred. No. 49;  
 Matches 8; Conservative 1; Mismatches 4; Indels 0; Gaps 0;  
 Qy 2 ASGTASNTTVAAD 14  
 Db 145 ASGTSNTKVVID 157  
 RESULT 13  
 NASC\_BACSU STANDARD; PRT; 710 AA.  
 ID P42434;  
 AC P42434;  
 DT 01-NOV-1995 (Rel. 32, Created)  
 DT 01-NOV-1997 (Rel. 35, Last sequence update)  
 DT 20-AUG-2001 (Rel. 40, Last annotation update)  
 DE ASSIMILATORY NITRATE REDUCTASE SUBUNIT (EC 1.7.99.4).  
 GN NASC OR NARB OR NASBB.  
 OS Bacillus subtilis.  
 OC Bacteria; Firmicutes; Bacillus/Clostridium group;  
 OC Bacillus/Staphylococcus group; Bacillus.  
 OX NCBI\_TaxID=1423;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=168;

RX MEDLINE=97124189; PubMed=8969502;  
 RA Yamane K., Kumano M., Kurita K.;  
 RT "The 25 degrees-36 degrees region of the Bacillus subtilis  
 RT chromosome: determination of the sequence of a 146 kb segment and  
 RT identification of 113 genes.";  
 RL Microbiology 142:3047-3056(1996).  
 RN [2]  
 RP SEQUENCE OF 35-710 FROM N.A.  
 RC STRAIN=168;  
 RX MEDLINE=95173124; PubMed=7868621;  
 RA Ogawa K.-I., Akagawa E., Yamane K., Sun Z.-W., Lacelle M., Zuber P.,  
 RA Nakano M.M.;  
 RT "The nasB operon and nasA gene are required for nitrate/nitrite  
 RT assimilation in Bacillus subtilis.";  
 RL J. Bacteriol. 177:1409-1413(1995).  
 CC -1- FUNCTION: NITRATE REDUCTASE IS A KEY ENZYME INVOLVED IN THE FIRST  
 CC STEP OF NITRATE ASSIMILATION IN PLANTS, FUNGI AND BACTERIA.  
 CC -1- CATALYTIC ACTIVITY: NITRATE + ACCEPTOR -> NITRATE + REDUCED  
 CC ACCEPTOR.  
 CC -1- COFACTOR: MOLYBDENUM (MOLYBDOPTERIN); MAY BIND A 4FE-4S CLUSTER.  
 CC -1- PATHWAY: NITRATE ASSIMILATORY PATHWAY.  
 CC -1- SIMILARITY: BELONGS TO THE PROKARYOTIC MOLYBDOPTERIN-CONTAINING  
 CC OXIDOREDUCTASE FAMILY.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC -----  
 DR EMBL; D50453; BAA08965.1; -;  
 DR EMBL; D30689; BAA06353.1; -;  
 DR EMBL; Z99105; CAB12125.1; -;  
 DR HSSP; P07658; IFDI.  
 DR Subtilist; BG11095; nasC.  
 DR InterPro; IPR001467; Molybdopterin.  
 DR Pfam; PF00384; molybdopterin; 1.  
 DR Pfam; PF01568; Molybdop\_binding; 1.  
 DR PROSITE; PS00551; MOLYBDOPTERIN\_PROK\_1; 1.  
 DR PROSITE; PS00490; MOLYBDOPTERIN\_PROK\_2; 1.  
 DR PROSITE; PS00932; MOLYBDOPTERIN\_PROK\_3; FALSE\_NEG.  
 KW Oxidoreductase; Molybdenum; Nitrate assimilation; Iron-sulfur; 4Fe-4S;  
 KW Complete proteome.  
 FT METAL 26 26 IRON-SULFUR (4FE-4S) (POTENTIAL).  
 FT METAL 29 29 IRON-SULFUR (4FE-4S) (POTENTIAL).  
 FT METAL 33 33 IRON-SULFUR (4FE-4S) (POTENTIAL).  
 FT METAL 63 63 IRON-SULFUR (4FE-4S) (POTENTIAL).  
 SQ SEQUENCE 710 AA; 78575 MW; 625E8864A1552AA2 CRC64;  
 Query Match 45.9%; Score 39; DB 1; Length 710;  
 Best Local Similarity 57.1%; Pred. No. 66;  
 Matches 8; Conservative 2; Mismatches 4; Indels 0; Gaps 0;  
 Qy 2 ASGTASNTTVAADR 15  
 Db 157 AAATAAQTGADR 170  
 RESULT 14  
 MYSC\_DICDI STANDARD; PRT; 1181 AA.  
 ID MYSC\_DICDI  
 AC P42522;  
 DT 01-NOV-1995 (Rel. 32, Created)  
 DT 01-NOV-1995 (Rel. 32, Last sequence update)  
 DT 20-AUG-2001 (Rel. 40, Last annotation update)  
 DE MYOSIN IC HEAVY CHAIN.  
 GN MYOC OR DMIC.  
 OS Dictyostelium discoideum (Slime mold).  
 OC Eukaryota; Mycetozoa; Dictyosteliida; Dictyostelium.  
 OX NCBI\_TaxID=44689;

```

RN  SEQUENCE FROM N.A.
RP  STRAIN-AX2:
RX  MEDLINE-95348228; PubMed-762596;
RA  Peterson M.D.; Novak K.D.; Reedy M.C.; Ruman J.I.; Titus M.A.;
RT  "Molecular genetic analysis of myoC, a Dictyostellium myosin I.";
RL  J. Cell Sci. 108:1103-1103(1995).
CC  -!- FUNCTION: MYOSIN IS A PROTEIN THAT BINDS TO ACTIN & HAS ATPASE
CC  ACTIVITY THAT IS ACTIVATED BY ACTIN.
CC  -!- SUBUNIT: MYOSIN I HEAVY CHAIN IS SINGLE-HEADED. DIMER OF A HEAVY
CC  AND A LIGHT CHAIN. INABILITY TO SELF-ASSEMBLE INTO FILAMENTS.
CC  -!- SIMILARITY: CONTAINS 1 MYOSIN-LIKE GLOBULAR HEAD DOMAIN.
CC  -!- SIMILARITY: CONTAINS 1 SH3 DOMAIN.
CC  -----
CC  This SWISS-PROT entry is copyright. It is produced through a collaboration
CC  between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC  the European Bioinformatics Institute. There are no restrictions on its
CC  use by non-profit institutions as long as its content is in no way
CC  modified and this statement is not removed. Usage by and for commercial
CC  entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC  or send an email to license@isb-sib.ch).
CC  -----
DR  EMBL; L35323; AAC37427.1;
DR  HSSP; P08799; 1MND.
DR  DictyDb; DD01090; myoC.
DR  InterPro; IPR001452; SH3.
DR  InterPro; IPR001609; myosin_head.
DR  Pfam; PF00063; myosin_head; 2.
DR  Pfam; PF00018; SH3; 1.
DR  PRINTS; PR00193; MYOSINHEAVY.
DR  PRINTS; PR00452; SH3DOMAIN.
DR  ProDom; PD000355; myosin_head; 1.
DR  SMART; SM00242; MYSC; 1.
DR  SMART; SM00326; SH3; 1.
DR  PROSITE; PS00002; SH3; 1.
KW  Myosin; Actin-binding; ATP-binding; Chemotaxis; SH3 domain;
FT  DOMAIN 1 ? MYOSIN HEAD-LIKE.
FT  DOMAIN ? 1181 NON ALPHA-HELICAL, C-TERMINAL DOMAIN.
FT  NP_BIND 109 116 ATP (POTENTIAL).
FT  DOMAIN 1122 1181 SH3.
SQ  SEQUENCE 1181 AA; 132915 MW; 5B1EE47F0CA8803 CRC64;

Query Match 45.9%; Score 39; DB 1; Length 1181;
Best Local Similarity 56.2%; Pred. No. 1.1e+02;
Matches 9; Conservative 2; Mismatches 5; Indels 0; Gaps 0;

Qy 2 ASGTASNTTVAADRSN 17
    ||| :||| |
Db 951 ASGLPASTTVAKVRKN 966

RESULT 15
SOS1_MOUSE
ID  SOS1_MOUSE STANDARD; PRT; 1319 AA.
AC  O62245; O62244;
DT  15-JUL-1999 (Rel. 38, Created)
DT  15-JUL-1999 (Rel. 38, Last sequence update)
DT  30-MAY-2000 (Rel. 39, Last annotation update)
DE  SON OF SEVENLESS PROTEIN HOMOLOG 1 (SOS-1) (MSOS-1).
GN  SOS1.
OS  Mus musculus (Mouse).
OC  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC  Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX  NCBI_TaxID=10090;
RN  [1]
RP  SEQUENCE FROM N.A.
RX  STRAIN-SWISS: TISSUE-EYE;
RA  MEDLINE-9233328; PubMed-1631150;
RA  Bowtell D., Fu P., Simon M., Senior P.;
RT  "Identification of murine homologues of the Drosophila son of
RT  sevenless gene: potential activators of ras.";

```

```

Proc. Natl. Acad. Sci. U.S.A. 89:6511-6515(1992).
[2]
RP  STRUCTURE BY NMR OF 415-548.
RX  MEDLINE-97360334; PubMed-9217262;
RA  Koshiba S., Kigawa T., Kim J.-H., Shirouzu M., Bowtell D.,
RA  Yokoyama S.;
RT  "The solution structure of the pleckstrin homology domain of mouse
RT  Son-of-sevenless 1 (MSOS1).";
RL  J. Mol. Biol. 269:579-591(1997).
CC  -!- FUNCTION: PROMOTES THE EXCHANGE OF RAS-BOUND GDP BY GTP (BY
CC  SIMILARITY).
CC  -!- TISSUE SPECIFICITY: EXPRESSED IN MOST EMBRYONIC AND ADULT TISSUES.
CC  -!- SIMILARITY: CONTAINS 1 DBL-HOMOLOGY DOMAIN (DH).
CC  -!- SIMILARITY: CONTAINS 1 PH DOMAIN.
CC  -!- SIMILARITY: CONTAINS 1 RASGEF DOMAIN.
CC  -----
CC  This SWISS-PROT entry is copyright. It is produced through a collaboration
CC  between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC  the European Bioinformatics Institute. There are no restrictions on its
CC  use by non-profit institutions as long as its content is in no way
CC  modified and this statement is not removed. Usage by and for commercial
CC  entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC  or send an email to license@isb-sib.ch).
CC  -----
DR  EMBL; Z11574; CAA77662.1;
DR  EMBL; Z11578; CAA77665.1;
DR  PDB; 1PMS; 15-MAY-97.
DR  MGD; MGI:98354; Sosl.
DR  InterPro; IPR00166; Histone_core.
DR  InterPro; IPR001849; PH.
DR  InterPro; IPR000651; RasGEFN.
DR  InterPro; IPR001895; RasGEF_CDC25.
DR  InterPro; IPR000219; RhoGEF.
DR  Pfam; PF00169; PH; 1.
DR  Pfam; PF00617; RasGEF; 1.
DR  Pfam; PF00618; RasGEFN; 1.
DR  Pfam; PF00621; RhoGEF; 1.
DR  SMART; SM00233; PH; 1.
DR  SMART; SM00147; RasGEF; 1.
DR  SMART; SM00229; RasGEFN; 1.
DR  SMART; SM00325; RhoGEF; 1.
DR  PROSITE; PS00720; GDS_CDC25; 1.
DR  PROSITE; PS50003; PH_DOMAIN; 1.
KW  Guanine-nucleotide releasing factor; 3D-structure.
FT  DOMAIN 202 443 DH.
FT  DOMAIN 444 548 PH.
FT  DOMAIN 777 963 RASGEF.
FT  DOMAIN 1244 1247 POLY-PRO.
SQ  SEQUENCE 1319 AA; 150882 MW; 3286088A5BA04A6 CRC64;

Query Match 45.9%; Score 39; DB 1; Length 1319;
Best Local Similarity 66.7%; Pred. No. 1.2e+02;
Matches 8; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy 2 ASGTASNTTVA 13
    |||:|:| |
Db 1092 ASGTSNTDVCS 1103

Search completed: March 26, 2002, 13:40:43
Job time: 257 sec

```

GenCore version 4.5  
Copyright (c) 1993 - 2000 Compugen Ltd.

OM protein - protein search, using sw model

Run on: March 26, 2002, 13:40:11 ; Search time 79.01 Seconds  
(without alignments)  
31.472 Million cell updates/sec

Title: US-09-709-201-96

Perfect score: 85

Sequence: 1 CASGTASNTTVAADRSN 17

Scoring table:

BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 473505 seqs, 146272329 residues

Total number of hits satisfying chosen parameters: 473505

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

- SPTREMBL\_17:\*
- 1: sp-archaea:\*
  - 2: sp-bacteria:\*
  - 3: sp-fungi:\*
  - 4: sp-human:\*
  - 5: sp-invertebrate:\*
  - 6: sp-mammal:\*
  - 7: sp-mhc:\*
  - 8: sp-organelle:\*
  - 9: sp-phase:\*
  - 10: sp-plant:\*
  - 11: sp-rodent:\*
  - 12: sp-virus:\*
  - 13: sp-vertebrate:\*
  - 14: sp-unclassified:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	76	89.4	392	2 Q99QB0	Q99qb0 chlamydomphi
2	54	63.5	356	2 O52924	O52924 chlamydia p
3	54	63.5	390	2 Q9AIJ5	Q9aij5 chlamydia p
4	54	63.5	392	2 Q9AIJ4	Q9aij4 chlamydia p
5	46	54.1	30	4 Q9UIH1	Q9uih1 homo sapien
6	46	54.1	425	4 Q16042	Q16042 homo sapien
7	46	54.1	1518	5 Q21850	Q21850 caenorhabdi
8	45	52.9	390	5 Q9GYJ3	Q9gyj3 caenorhabdi
9	45	52.9	767	12 Q66627	Q66627 equine herp
10	45	52.9	942	10 Q9SUT8	Q9sut8 arabidopsis
11	44	51.8	341	2 Q9X653	Q9x653 streptomyce
12	44	51.8	2911	5 Q9BLV4	Q9blv4 leishmania
13	44	51.8	3040	5 Q9GNY4	Q9gny4 leishmania
14	43	50.6	287	4 Q9H9U0	Q9h9u0 homo sapien
15	43	50.6	376	4 Q9H650	Q9h650 homo sapien
16	43	50.6	425	3 Q12741	Q12741 blastoclad
17	43	50.6	427	4 Q9NT65	Q9nt65 homo sapien
18	43	50.6	4899	5 Q9VR91	Q9vr91 drosophila
19	42	49.4	165	5 Q9N3E7	Q9n3e7 caenorhabdi

20	42	49.4	236	1 Q9HHV1	Q9hhv1 halobacteri
21	42	49.4	390	2 Q9K7M8	Q9k7m8 bacillus ha
22	42	49.4	518	2 O53738	O53738 mycobacteri
23	41.5	48.8	473	2 Q9RK75	Q9rk75 streptomyce
24	41	48.2	119	5 O61034	O61034 trypanosoma
25	41	48.2	175	11 Q9WUL4	Q9wul4 rattus norv
26	41	48.2	217	2 Q9X6X0	Q9x6x0 streptococc
27	41	48.2	338	5 Q9BLA4	Q9bla4 leishmania
28	41	48.2	459	11 Q62327	Q62327 mus musculu
29	41	48.2	482	11 Q88734	Q88734 mus musculu
30	41	48.2	3257	5 Q9V736	Q9v736 drosophila
31	40	47.1	226	2 Q51672	Q51672 paracoccus
32	40	47.1	259	2 Q54168	Q54168 streptomyce
33	40	47.1	355	10 Q9ATT5	Q9att5 coix lachry
34	40	47.1	490	10 Q9SUY8	Q9suy8 arabidopsis
35	40	47.1	492	10 Q9M044	Q9m044 arabidopsis
36	40	47.1	510	10 Q9M057	Q9m057 arabidopsis
37	40	47.1	760	2 Q47429	Q47429 escherichia
38	39	45.9	126	5 Q9GXD5	Q9gxd5 leishmania
39	39	45.9	166	11 Q9CV50	Q9cv50 mus musculu
40	39	45.9	190	11 Q9CV36	Q9cv36 mus musculu
41	39	45.9	202	5 Q9CZ03	Q9cz03 caenorhabdi
42	39	45.9	202	11 Q60692	Q60692 mus musculu
43	39	45.9	216	2 Q9X6H6	Q9x6h6 streptococc
44	39	45.9	226	3 Q43063	Q43063 schizosacch
45	39	45.9	231	13 Q12992	Q12992 lampetra ja

ALIGNMENTS

RESULT 1	
Q99QB0	
ID Q99QB0	PRELIMINARY; PRT; 392 AA.
AC Q99QB0	
DT 01-JUN-2001 (TREMBLrel. 17, Created)	
DT 01-JUN-2001 (TREMBLrel. 17, Last sequence update)	
DT 01-JUN-2001 (TREMBLrel. 17, Last annotation update)	
DE MAJOR OUTER MEMBRANE PROTEIN PRECURSOR.	
GN OMPA.	
OS Chlamydomophila felis.	
OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydomophila.	
OX NCBI_TaxID=83556;	
RN [1]	
RP SEQUENCE FROM N.A.	
RC STRAIN-PP BAKER, ATCC VR120, AND PP CHLLO;	
RX MEDLINE=21078580; PubMed=11211261;	
RA Bush R.M., Everett K.D.;	
RT "Molecular evolution of the Chlamydiaceae.;"	
RL Int. J. Syst. Evol. Microbiol. 51:203-220(2001).	
DR EMBL; AF269257; AAK00238.1; --	
DR EMBL; AF269258; AAK00239.1; --	
KW Signal.	
FT SIGNAL	1 22 POTENTIAL.
FT CHAIN	23 392 MAJOR OUTER MEMBRANE PROTEIN.
SQ SEQUENCE	392 AA; 42051 MW; 88B3C0%CIFEE26DB CRC64;

Query Match 89.4%; Score 76; DB 2; Length 392;  
Best Local Similarity 100.0%; Pred. No. 0.0003;  
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2	ASGTASNTTVAADRSN 17
DB 92	ASGTASNTTVAADRSN 107

RESULT 2	
O52924	
ID O52924	PRELIMINARY; PRT; 356 AA.
AC O52924	
DT 01-JUN-1998 (TREMBLrel. 06, Created)	
DT 01-JUN-1998 (TREMBLrel. 06, Last sequence update)	

DT 01-JUN-2001 (TRENBLrel. 17, Last annotation update)  
DE OUTER MEMBRANE PROTEIN 1 (FRAGMENT).  
GN OMP1.  
OS Chlamydia psittaci (Chlamydoiphila psittaci).  
OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydoiphila.  
OX NCBI\_TaxID=83554;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN=92-1293, AVIAN SEROVAR D;  
RA Vanrompay D., Cox E., Goddeeris B.M., Volckaert G.;  
RL Submitted (FEB-1998) to the EMBL/GenBank/DBJ databases.  
DR EMBL; Y16562; CAA76286.1; -  
DR InterPro; IPR000604; Chlamydia\_OMP.  
DR Pfam; PF01308; Chlamydia\_OMP; 1.  
DR ProDom; PD001717; Chlamydia\_OMP; 1.  
KW Outer membrane.  
FT NON\_TER 356  
SQ SEQUENCE 356 AA; 38396 MW; D51DE06FB46EGF13 CRC64;

Query Match 63.5%; Score 54; DB 2; Length 356;  
Best Local Similarity 68.8%; Pred. No. 0.79; 3; Indels 0; Gaps 0;  
Matches 11; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 2 ASGTASNTTVAADRSN 17  
1:||||| ||| |||:  
Db 92 ATGTASATTAVDRTN 107

RESULT 3

Q9AIJ5 PRELIMINARY; PRT; 390 AA.  
AC Q9AIJ5;  
DT 01-JUN-2001 (TRENBLrel. 17, Created)  
DT 01-JUN-2001 (TRENBLrel. 17, Last sequence update)  
DE MAJOR OUTER MEMBRANE PROTEIN PRECURSOR (FRAGMENT).  
GN OMPA.  
OS Chlamydia psittaci (Chlamydoiphila psittaci).  
OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydoiphila.  
OX NCBI\_TaxID=83554;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN=NEW JERSEY 1, NJ1;  
RX MEDLINE=21078680; Pubmed=11211261;  
RA Bush R.M., Everett K.D.;  
RT "Molecular evolution of the Chlamydiaceae.";  
RL Int. J. Syst. Evol. Microbiol. 51:203-220(2001).  
DR EMBL; AF269266; AAK00247.1; -  
KW Signal.  
FT NON\_TER 1 1  
FT SIGNAL <1 20 POTENTIAL.  
FT CHAIN 21 390 MAJOR OUTER MEMBRANE PROTEIN.  
SQ SEQUENCE 390 AA; 42042 MW; B62858403DBFA4E6 CRC64;

Query Match 63.5%; Score 54; DB 2; Length 390;  
Best Local Similarity 68.8%; Pred. No. 0.85; 3; Indels 0; Gaps 0;  
Matches 11; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 2 ASGTASNTTVAADRSN 17  
1:||||| ||| |||:  
Db 90 ATGTASATTAVDRTN 105

RESULT 4

Q9AIJ4 PRELIMINARY; PRT; 392 AA.  
AC Q9AIJ4;  
DT 01-JUN-2001 (TRENBLrel. 17, Created)  
DT 01-JUN-2001 (TRENBLrel. 17, Last sequence update)  
DE MAJOR OUTER MEMBRANE PROTEIN PRECURSOR.

GN OMPA.  
OS Chlamydia psittaci (Chlamydoiphila psittaci).  
OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydoiphila.  
OX NCBI\_TaxID=83554;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN=TEXAS TURKEY 3, TT3;  
RA MEDLINE=21078680; Pubmed=11211261;  
RA Bush R.M., Everett K.D.;  
RT "Molecular evolution of the Chlamydiaceae.";  
RL Int. J. Syst. Evol. Microbiol. 51:203-220(2001).  
DR EMBL; AF269267; AAK00248.1; -  
KW Signal.  
FT SIGNAL 1 22 POTENTIAL.  
FT CHAIN 23 392 MAJOR OUTER MEMBRANE PROTEIN.  
SQ SEQUENCE 392 AA; 42293 MW; FC31FC051955246C CRC64;

Query Match 63.5%; Score 54; DB 2; Length 392;  
Best Local Similarity 68.8%; Pred. No. 0.86; 3; Indels 0; Gaps 0;  
Matches 11; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 2 ASGTASNTTVAADRSN 17  
1:||||| ||| |||:  
Db 92 ATGTASATTAVDRTN 107

RESULT 5

Q9UIH1 PRELIMINARY; PRT; 30 AA.  
AC Q9UIH1;  
DT 01-MAY-2000 (TRENBLrel. 13, Created)  
DT 01-MAY-2000 (TRENBLrel. 13, Last sequence update)  
DE 01-MAY-2000 (TRENBLrel. 13, Last annotation update)  
DE TUMOR NECROSIS FACTOR RECEPTOR 2 (FRAGMENT).  
GN TNFR2.  
OS Homo sapiens (Human).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
OX NCBI\_TaxID=9606;  
RN [1]  
RP SEQUENCE FROM N.A.  
RA Komata T., Tsuchiya N., Matsushita M., Tokunaga K.;  
RT "New polymorphism within the extracellular region of TNFR2.";  
RL Submitted (AUG-1999) to the EMBL/GenBank/DBJ databases.  
DR EMBL; AB030950; BAA89033.1; -  
KW Receptor.  
FT NON\_TER 1 1  
FT NON\_TER 30 30  
SQ SEQUENCE 30 AA; 3183 MW; 942C00239B909DF5 CRC64;

Query Match 54.1%; Score 46; DB 4; Length 30;  
Best Local Similarity 64.3%; Pred. No. 1.5; 4; Indels 0; Gaps 0;  
Matches 9; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

QY 1 CASGTASNTTVAAD 14  
1:||||| |||:  
Db 11 CAPGTFSTSTSD 24

RESULT 6

Q16042 PRELIMINARY; PRT; 425 AA.  
AC Q16042;  
DT 01-NOV-1996 (TRENBLrel. 01, Created)  
DT 01-JUN-2001 (TRENBLrel. 17, Last sequence update)  
DT 01-JUN-2001 (TRENBLrel. 17, Last annotation update)  
DE TUMOR NECROSIS FACTOR RECEPTOR (FRAGMENT).  
OS Homo sapiens (Human).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
OX NCBI\_TaxID=9606;

Query Match	54.1%	Score 46;	DB 5;	Length 1518;	
Best Local Similarity	52.9%	Pred. No. 53;			
Matches	9;	Conservative	1;	Mismatches	7; Indels 0; Gaps 0;
QY	1	CASGTASNTTVAADRSN	17		
DB	1275	CVYGLOSNIKIADRSN	1291		
RESULT	8				
Q9GYJ3		PRELIMINARY;	PRT;	390 AA.	
ID	Q9GYJ3				
AC	Q9GYJ3;				
DT	01-MAR-2001 (TrEMBLrel. 16, Created)				
DT	01-MAR-2001 (TrEMBLrel. 16, Last sequence update)				
DT	01-JUN-2001 (TrEMBLrel. 17, Last annotation update)				
DE	C46H11.8 PROTEIN.				
GN	C46H11.8.				
OS	Caenorhabditis elegans.				
OC	Eukaryota; Metazoa; Nematoda; Chromadorea; Rhabditida; Rhabditoidea;				
OC	Rhabditidae; Pelodierinae; Caenorhabditis.				
OC	NCBI_TaxID=6239;				
RN	[1]				
RP	SEQUENCE FROM N.A.				
RC	STRAIN=BRISTOL N2;				
RX	MEDLINE=99069613; PubMed=9851916;				
RA	None.				
RT	"Genome sequencing of the nematode C. elegans: a platform for				
RT	investigating biology. The C. elegans Sequencing Consortium.";				
RL	Science 282:2012-2018 (1998).				
RN	[2]				
RP	SEQUENCE FROM N.A.				
RC	STRAIN=BRISTOL N2;				
RA	Miller N., Bradshaw H., Wamsley P.;				
RT	"The sequence of C. elegans cosmid C46H11.";				
RL	Submitted (FEB-1997) to the EMBL/GenBank/DBJ databases.				
RN	[3]				
RP	SEQUENCE FROM N.A.				
RC	STRAIN=BRISTOL N2;				
RA	Waterston R.;				
RL	Submitted (AUG-2000) to the EMBL/GenBank/DBJ databases.				
DR	EMBL; U88314; AAF99887.1; -.				
DR	InterPro; IPR002526; DUF18.				
DR	InterPro; IPR003582; SHKT.				
DR	Pfam; PF01549; DUF18; 1.				
DR	SMART; SM00254; SHKT; 5.				
SQ	SEQUENCE 390 AA; 40714 MW; 6158969H40C4B161 CRC64;				
Query Match	52.9%	Score 45;	DB 5;	Length 390;	
Best Local Similarity	56.2%	Pred. No. 22;			
Matches	9;	Conservative	4;	Mismatches	3; Indels 0; Gaps 0;
QY	2	ASGTASNTTVAADRSN	17		
DB	182	SSTSSSTTCADRSN	197		
RESULT	9				
Q66627		PRELIMINARY;	PRT;	757 AA.	
ID	Q66627				
AC	Q66627;				
DT	01-NOV-1996 (TrEMBLrel. 01, Created)				
DT	01-NOV-1996 (TrEMBLrel. 01, Last sequence update)				
DT	01-MAR-2001 (TrEMBLrel. 16, Last annotation update)				
DE	ORF 24.				
OS	Equine herpesvirus type 2 (strain 86/87).				
OC	Viruses; dsDNA viruses, no RNA stage; Herpesviridae;				
OC	Gammaherpesvirinae.				
OC	NCBI_TaxID=82831;				
RN	[1]				
RP	SEQUENCE FROM N.A.				
RX	MEDLINE=95302501; PubMed=7783207;				

RA Telford E.A., Watson M.S., Aird H.C., Perry J., Davison A.J.;  
 RT "The DNA sequence of equine herpesvirus 2.";  
 J. Mol. Biol. 249:520-528(1995).  
 RN [2]  
 RP SEQUENCE FROM N.A.  
 RA Telford E.A.R.;  
 RL Submitted (FEB-1995) to the EMBL/GenBank/DBJ databases.  
 DR EMBL; U20824; AAC13811.1; -  
 SQ SEQUENCE 767 AA; 84112 MW; 6DB41AA51B5B8EDA CRC64;

Query Match 52.9%; Score 45; DB 12; Length 767;  
 Best Local Similarity 57.1%; Pred. No. 41;  
 Matches 8; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

QY 1 CASGTASNTTVAAD 14  
 ||||| :|||  
 Db 511 CASGTAINMNISGD 524

RESULT 10

ID Q9SUT8 PRELIMINARY; PRT; 942 AA.  
 AC Q9SUT8;  
 DT 01-MAY-2000 (TrEMBLrel. 13, Created)  
 DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)  
 DT 01-JUN-2001 (TrEMBLrel. 17, Last annotation update)  
 DE RESPIRATORY BURST OXIDASE HOMOLOG F-LIKE PROTEIN.  
 GN F8121.20 OR AT4G11230.  
 OS Arabidopsis thaliana (Mouse-ear cress).  
 OC Eukaryota; Viridiplantae; Streptophyta; Tracheophyta;  
 OC Spermatophyta; Magnoliophyta; eudicotyledons; Core eudicots; Rosidae;  
 OC eurosids II; Brassicales; Brassicaceae; Arabidopsis.  
 OX NCBI\_TaxID=3702;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RA Bevan M., Peters S.A., van Staveren M., Dirkse W., Stiekema W.,  
 Bancroft I., Mewes H.W., Mayer K.F.X., Lemcke K., Schueller C.;  
 RL Submitted (JUL-1999) to the EMBL/GenBank/DBJ databases.  
 RN [2]  
 RP SEQUENCE FROM N.A.  
 RA EU Arabidopsis sequencing project;  
 RL Submitted (AUG-1999) to the EMBL/GenBank/DBJ databases.  
 RN [3]  
 RP SEQUENCE FROM N.A.  
 RA Peters S.A., van Staveren M., Dirkse W., Stiekema W., Mewes H.W.,  
 Lemcke K., Mayer K.F.X.;  
 RL Submitted (MAR-2000) to the EMBL/GenBank/DBJ databases.  
 RN [4]  
 RP SEQUENCE FROM N.A.  
 RA EU Arabidopsis sequencing project;  
 RL Submitted (MAR-2000) to the EMBL/GenBank/DBJ databases.  
 DR EMBL; AL095882; CAB51407.1; -  
 DR EMBL; AL161531; CAB81224.1; -  
 DR InterPro; IPR002916; Ferric\_reduct.  
 DR InterPro; IPR000778; Gp91phox.  
 DR Pfam; PF01794; Ferric\_reduct; 1.  
 DR PRINTS; PR00466; GP91PHOX.  
 SQ SEQUENCE 942 AA; 107211 MW; 70672D6E2A9BCCD3 CRC64;

Query Match 52.9%; Score 45; DB 10; Length 942;  
 Best Local Similarity 43.8%; Pred. No. 49;  
 Matches 7; Conservative 5; Mismatches 4; Indels 0; Gaps 0;

QY 1 CASGTASNTTVAADRS 16  
 ||||| :|||  
 Db 769 CIGSCSNISDHS 784

RESULT 11

Q9X653 PRELIMINARY; PRT; 341 AA.  
 ID Q9X653

AC Q9X653;  
 DT 01-NOV-1999 (TrEMBLrel. 12, Created)  
 DT 01-NOV-1999 (TrEMBLrel. 12, Last sequence update)  
 DT 01-JUN-2001 (TrEMBLrel. 17, Last annotation update)  
 DE NAPG OXIDOREDUCTASE.  
 GN NAPG;  
 OS Streptomyces collinus.  
 OC Bacteria; Firmicutes; Actinobacteria; Actinobacteridae;  
 OC Actinomycetales; Streptomycetaceae; Streptomyces.  
 OX NCBI\_TaxID=42684;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=TU 1892;  
 MEDLINE=39203506; PubMed=10103039;  
 RA Chen S., von Bamberg D., Hale V., Breuer M., Hardt B., Mlier R.,  
 Floss H.G., Reynolds K.A., Leistner E.;  
 RT "Biosynthesis of ansatrienin (mycotrienin) and naphthomycin.  
 RT Identification and analysis of two separate biosynthetic gene clusters  
 RT in Streptomyces collinus Tu 1892.";  
 RL Eur. J. Biochem. 261:98-107(1999).  
 DR EMBL; AF131877; AAD31829.1; -  
 DR InterPro; IPR000683; GFO\_IDH\_Moca.  
 DR InterPro; IPR002965; P\_rich\_extensn.  
 DR Pfam; PF01408; GFO\_IDH\_MOCA; 1.  
 DR PRINTS; PR01217; PRICHEXTENS.  
 SQ SEQUENCE 341 AA; 34598 MW; 8809EE179285291E CRC64;

Query Match 51.8%; Score 44; DB 2; Length 341;  
 Best Local Similarity 50.0%; Pred. No. 28;  
 Matches 8; Conservative 4; Mismatches 4; Indels 0; Gaps 0;

QY 1 CASGTASNTTVAADRS 16  
 ||||| :|||  
 Db 97 CLSGTEADTLAAERA 112

RESULT 12

Q9BLV4 PRELIMINARY; PRT; 2911 AA.  
 ID Q9BLV4  
 AC Q9BLV4;  
 DT 01-JUN-2001 (TrEMBLrel. 17, Created)  
 DT 01-JUN-2001 (TrEMBLrel. 17, Last sequence update)  
 DT 01-JUN-2001 (TrEMBLrel. 17, Last annotation update)  
 DE POSSIBLE HIGH MOLECULAR MASS NUCLEAR ANTIGEN (FRAGMENT).  
 GN L2230.01.  
 OS Leishmania major.  
 OC Eukaryota; Euklenozoa; Kinetoplastida; Trypanosomatidae; Leishmania.  
 OX NCBI\_TaxID=5664;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=FRIEDLIN;  
 RA Zimmermann W., Wambutt R., Ivens A.C., Quail M., Rajandream M.A.,  
 Barrell B.G.;  
 RL Submitted (JAN-2001) to the EMBL/GenBank/DBJ databases.  
 RN [2]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=FRIEDLIN;  
 RX MEDLINE=98146435; PubMed=9477341;  
 RA Ivens A.C., Lewis S.M., Bagherzadeh A., Zhang L., Chan H.M.,  
 Smith D.F.;  
 RT "A physical map of the Leishmania major Friedlin genome.";  
 RL Genome Res. 8:135-145(1998).  
 DR EMBL; AL513062; CAC24680.1; -  
 FT NON\_TER 2911 2911  
 SQ SEQUENCE 2911 AA; 305079 MW; 45CD9DC05BC57091 CRC64;

Query Match 51.8%; Score 44; DB 5; Length 2911;  
 Best Local Similarity 60.0%; Pred. No. 2e+02;  
 Matches 9; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 3 SGTASNTTVAADRSN 17

Db 939 TGSASSTAAAGRSN 953  
:|||||: || |||

## RESULT 13

Q9GNY4 ID Q9GNY4 PRELIMINARY; PRT: 3040 AA.  
AC Q9GNY4;  
DT 01-MAR-2001 (TREMBlrel. 16, Created)  
DT 01-MAR-2001 (TREMBlrel. 16, Last sequence update)  
DT 01-MAR-2001 (TREMBlrel. 16, Last annotation update)  
DE POSSIBLE KINETOPLAST-ASSOCIATED PROTEIN (FRAGMENT).  
GN L5852.01.  
OS Leishmania major.  
OC Eukaryota; Eulenzooza; Kinetoplastida; Trypanosomatidae; Leishmania.  
OX NCBI\_TaxID=5664;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN=FRIEDLIN;  
RA Reinhardt R., Klages S., Beck A., Ivens A.C., Murphy L., Quail M.,  
RA Rajandream M.A., Barrell B.G.;  
RL Submitted (DEC-2000) to the EMBL/GenBank/DBJ databases.  
RN [2]  
RP SEQUENCE FROM N.A.  
RC STRAIN=FRIEDLIN;  
RX MEDLINE=98146435; PubMed=9477341;  
RA Ivens A.C., Lewis S.M., Bagherzadeh A., Zhang L., Chan H.M.,  
RA Smith D.F.;  
RT "A physical map of the Leishmania major Friedlin genome.";  
RT Genome Res. 8:135-145(1998).  
DR EMBL; AL499614; CAC18858.1; -  
FT NON\_TER 1 1  
FT NON\_TER 3040 3040  
SQ SEQUENCE 3040 AA; 323433 MW; 8F2AD28D3C4021ED CRC64;

Query Match 51.8%; Score 44; DB 5; Length 3040;  
Best Local Similarity 60.0%; Pred. No. 2e+02;  
Matches 9; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

Qy 3 SGTASNTTVAADRSN 17  
:|||||: || |||

Db 216 TGSASSTAAAGRSN 230

## RESULT 14

Q9H9U0 ID Q9H9U0 PRELIMINARY; PRT: 287 AA.  
AC Q9H9U0;  
DT 01-MAR-2001 (TREMBlrel. 16, Created)  
DT 01-MAR-2001 (TREMBlrel. 16, Last sequence update)  
DT 01-MAR-2001 (TREMBlrel. 16, Last annotation update)  
DE CDNA FLJ12550 FIS, CLONE NT2RM4000698.  
OS Homo sapiens (Human).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.  
OX NCBI\_TaxID=9606;  
RN [1]  
RP SEQUENCE FROM N.A.  
RA Isogai T., Ota T., Hayashi K., Sugiyama T., Otsuki T., Suzuki Y.,  
RA Nishikawa T., Nagai K., Sugano S., Shiratori A., Sudo H.,  
RA Wagatsuma M., Hosoi T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,  
RA Takahashi M., Chiba Y., Ishida S., Murakawa K., Ono Y., Takiguchi S.,  
RA Watanabe S., Kimura K., Murakami K., Ishii S., Kawai Y., Saito K.,  
RA Yamamoto J., Wakamatsu A., Nakamura Y., Nagahari K., Masuho Y.,  
RA Ninomiya K., Iwayanagi T.;  
RT "NEDO human cDNA sequencing project.";  
RT Submitted (AUG-2000) to the EMBL/GenBank/DBJ databases.  
DR EMBL; AK022612; BAB14131.1; -  
SQ SEQUENCE 287 AA; 31637 MW; 66A71B40BFC53F77 CRC64;

Query Match 50.6%; Score 43; DB 4; Length 287;

Best Local Similarity 50.0%; Pred. No. 35;  
Matches 8; Conservative 3; Mismatches 5; Indels 0; Gaps 0;

Qy 1 CASGTASNTTVAADRS 16  
:|||||: || |||

Db 207 CAPGTSSQFSAGADRA 222

## RESULT 15

Q9H650 ID Q9H650 PRELIMINARY; PRT: 375 AA.  
AC Q9H650;  
DT 01-MAR-2001 (TREMBlrel. 16, Created)  
DT 01-MAR-2001 (TREMBlrel. 16, Last sequence update)  
DT 01-JUN-2001 (TREMBlrel. 17, Last annotation update)  
DE CDNA: FLJ22607 FIS, CLONE HSI04846.  
OS Homo sapiens (Human).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.  
OX NCBI\_TaxID=9606;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC TISSUE=HUMAN SMALL INTESTINE;  
RA Watanabe K., Kumagai A., Itakura S., Yamazaki M., Tashiro H., Ota T.,  
RA Suzuki Y., Obayashi M., Nishi T., Shibahara T., Tanaka T.,  
RA Nakamura Y., Isogai T., Sugano S.;  
RT "NEDO human cDNA sequencing project.";  
RT Submitted (AUG-2000) to the EMBL/GenBank/DBJ databases.  
DR EMBL; AK026260; BAB15416.1; -  
DR InterPro; IPR003323; OTU.  
DR Pfam; PF02338; OTU; 1.  
DR PROSITE; PS50802; OTU; 1.  
SQ SEQUENCE 375 AA; 42440 MW; 911A1020341BC66E CRC64;

Query Match 50.6%; Score 43; DB 4; Length 376;  
Best Local Similarity 50.0%; Pred. No. 44;  
Matches 8; Conservative 3; Mismatches 5; Indels 0; Gaps 0;

Qy 1 CASGTASNTTVAADRS 16  
:|||||: || |||

Db 296 CAPGTSSQFSAGADRA 311

Search completed: March 26, 2002, 13:40:13  
Job time: 227 sec





GenCore version 4.5  
Copyright (c) 1993 - 2000 Compugen Ltd.

# OM protein - protein search, using sw model

Run on: March 26, 2002, 13:38:47 ; Search time 81.51 Seconds  
(without alignments)  
12.723 Million cell updates/sec

Title: US-09-709-201-100

Perfect score: 77

Sequence: 1 CIGLAGTDFANQRP 14

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 522463 seqs, 74073290 residues

Total number of hits satisfying chosen parameters: 522463

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

## Database :

A\_Geneseq\_1101.\*  
1: /SID88/gcgdata/geneseq/geneseq/AA1980.DAT.\*  
2: /SID88/gcgdata/geneseq/geneseq/AA1981.DAT.\*  
3: /SID88/gcgdata/geneseq/geneseq/AA1982.DAT.\*  
4: /SID88/gcgdata/geneseq/geneseq/AA1983.DAT.\*  
5: /SID88/gcgdata/geneseq/geneseq/AA1984.DAT.\*  
6: /SID88/gcgdata/geneseq/geneseq/AA1985.DAT.\*  
7: /SID88/gcgdata/geneseq/geneseq/AA1986.DAT.\*  
8: /SID88/gcgdata/geneseq/geneseq/AA1987.DAT.\*  
9: /SID88/gcgdata/geneseq/geneseq/AA1988.DAT.\*  
10: /SID88/gcgdata/geneseq/geneseq/AA1989.DAT.\*  
11: /SID88/gcgdata/geneseq/geneseq/AA1990.DAT.\*  
12: /SID88/gcgdata/geneseq/geneseq/AA1991.DAT.\*  
13: /SID88/gcgdata/geneseq/geneseq/AA1992.DAT.\*  
14: /SID88/gcgdata/geneseq/geneseq/AA1993.DAT.\*  
15: /SID88/gcgdata/geneseq/geneseq/AA1994.DAT.\*  
16: /SID88/gcgdata/geneseq/geneseq/AA1995.DAT.\*  
17: /SID88/gcgdata/geneseq/geneseq/AA1996.DAT.\*  
18: /SID88/gcgdata/geneseq/geneseq/AA1997.DAT.\*  
19: /SID88/gcgdata/geneseq/geneseq/AA1998.DAT.\*  
20: /SID88/gcgdata/geneseq/geneseq/AA1999.DAT.\*  
21: /SID88/gcgdata/geneseq/geneseq/AA2000.DAT.\*  
22: /SID88/gcgdata/geneseq/geneseq/AA2001.DAT.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	77	100.0	14	20	AAW95327
2	41	53.2	112	20	AA148247
3	40	51.9	98	11	AAW06602
4	40	51.9	1096	21	AA192323
5	39	50.6	16	7	AA161750
6	39	50.6	99	16	AAW85208
7	39	50.6	126	17	AAW95230
8	39	50.6	201	17	AAW95232
9	39	50.6	320	21	AAW44529
10	39	50.6	348	21	AAW44528
11	39	50.6	351	21	AAW44527

12	39	50.6	355	21	AAW53884	A suppressor of cy
13	39	50.6	462	19	AAW73012	Cobra venom protea
14	39	50.6	496	22	AAW06222	Booroola sheep mut
15	39	50.6	502	13	AAW53374	Mouse Activin rece
16	39	50.6	502	16	AAW70238	Bone morphogenetic p
17	39	50.6	502	16	AAW85209	Mouse ALK-6. Mus
18	39	50.6	502	17	AAW95226	Chick BMP type I r
19	39	50.6	502	17	AAW96202	Bone morphogenetic
20	39	50.6	502	20	AAW33307	Human ALK-6 clone
21	39	50.6	502	20	AAW86249	Mouse BMP receptor
22	39	50.6	502	22	AAW06221	Wild-type sheep BM
23	39	50.6	502	22	AAW06225	Human BMP1B recept
24	39	50.6	521	19	AAW73010	Cobra venom protea
25	39	50.6	592	19	AAW73011	Cobra venom protea
26	38	49.4	277	21	AAW10705	Arabidopsis thalia
27	38	49.4	290	21	AAW34779	Arabidopsis thalia
28	38	49.4	352	21	AAW10704	Arabidopsis thalia
29	38	49.4	356	21	AAW10703	Arabidopsis thalia
30	38	49.4	356	22	AAW01908	Arabidopsis thalia
31	38	49.4	365	21	AAW34778	Arabidopsis thalia
32	38	49.4	369	21	AAW34777	Arabidopsis thalia
33	37.5	48.7	288	18	AAW21776	Protein encoded by
34	37	48.1	135	18	AAW27804	Staphylococcus aur
35	36.5	47.4	319	10	AAW91951	Polypeptide with 1
36	36.5	47.4	319	17	AAW09624	Pseudomonas glumae
37	36.5	47.4	319	17	AAW09625	Pseudomonas glumae
38	36.5	47.4	319	17	AAW88018	Mature Pseudomonas
39	36.5	47.4	319	17	AAW88010	Mature Pseudomonas
40	36.5	47.4	319	17	AAW88011	Mature Pseudomonas
41	36.5	47.4	319	17	AAW88012	Mature Pseudomonas
42	36.5	47.4	319	17	AAW88013	Mature Pseudomonas
43	36.5	47.4	319	17	AAW88014	Mature Pseudomonas
44	36.5	47.4	319	17	AAW88015	Mature Pseudomonas
45	36.5	47.4	319	17	AAW88016	Mature Pseudomonas

## ALIGNMENTS

### RESULT 1

AAW95327  
ID AAW95327 standard; Protein; 14 AA.  
XX  
AC AAW95327;  
XX  
DT 15-MAR-1999 (first entry)  
XX  
DE Peptide fragment of C. psittaci CPS160-172.  
XX  
KW Chlamydia: cryptic phase; elementary body phase; replicating; probenidicid;  
KW antiporphyrin acid; immune response; infection; diagnostic; assay; MOMP;  
KW major outer membrane protein; autolysins; inflammatory; porphyria;  
KW Epstein Barr virus; antioxidant.

OS Chlamydia psittaci.

PN WO9850074-A2.

XX

PD 12-NOV-1998.

XX

PF 06-MAY-1998; 98WO-US09237.

XX

PR 18-FEB-1998; 98US-0025521.

PR 06-MAY-1997; 97US-0045689.

PR 06-MAY-1997; 97US-0045739.

PR 06-MAY-1997; 97US-0045779.

PR 06-MAY-1997; 97US-0045780.

PR 06-MAY-1997; 97US-0045784.

PR 06-MAY-1997; 97US-0045787.

PR 14-AUG-1997; 97US-0911593.

PR 18-FEB-1998; 98US-0025174.

PR 18-FEB-1998; 98US-0025176.

XX

PA (UYVA-) UNIV VANDERBILT.  
XX  
XX Mitchell WM, Stratton CW;  
XX WPI: 1999-059653/05.  
XX  
XX Composition with two agents effective against different stages of  
PT Chlamydial life cycle - comprises agent targetted against cryptic  
PT phase, against elementary body phase, against replicating phase,  
PT prohenicid and antiporphyric  
XX  
XX Claim 4; Fig 4; 138pp; English.  
PS  
XX  
XX The invention relates to the diagnosis and management of infections by  
CC Chlamydia species. The invention provides a composition that comprises  
CC at least two agents, where each of the agents is effective against a  
CC different phase of the chlamydial life cycle. The agents are selected  
CC from: (a) agents targetted against cryptic phase of chlamydial life  
CC cycle; (b) agents targetted against replicating phase of chlamydial  
CC life cycle; (c) agents targetted against elementary body phase of chlamydial  
CC life cycle; (d) prohenicid, and (e) antiporphyric acid. The composition  
CC is used to elicit a protective immune response to Chlamydia infection in  
CC an animal or human and is applied until the animal or human tests  
CC negative for Chlamydia infection. It is also used to treat biological  
CC material infected with Chlamydia. Diagnostic kits for antibody assays  
CC against recombinant major outer membrane protein (MOMP), and for DNA  
CC amplification assays for chlamydial genes, are used to diagnose disease,  
CC e.g. autoimmune disease, an inflammatory disease or a disease that  
CC occurs in an immuno-compromised individual, associated with Chlamydia  
CC infection. The kits are used to detect chlamydial elementary bodies in a  
CC sample. They are also used to monitor and/or modify the course of therapy  
CC in a patient. The treatment reduces the acellular load of infectious  
CC Ebsstein Barr virus. The method is also used to treat porphyria, by  
CC reducing the number of elementary bodies and applying a drug, e.g.  
CC cimetidine, and antioxidants, to reduce the adverse effects associated  
CC with porphyria. Sequences AA95324 to AA95327 represent peptides  
CC employed for the construction of peptide based ELISAs with species  
XX specificity for variable domain 1 (VD1).  
XX  
XX Sequence 14 AA;  
SQ

Query Match 100.0%; Score 77; DB 20; Length 14;  
Best Local Similarity 100.0%; Pred. No. 3e-08;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 1 CIGLAGTDFANQRP 14  
Db | | | | | | | | | | | | | | | |  
1 ciglagnatdfrnp 14  
  
RESULT 2  
AA48247  
ID AAY48247 standard; Protein: 112 AA.  
XX  
XX AAY48247;  
XX  
XX 08-DEC-1999 (first entry)  
XX  
XX Human prostate cancer-associated protein 33.  
XX  
XX Expressed sequence tag; EST; prostate tumor; antitumor; treatment;  
KW gene therapy; tissue specificity human.  
XX  
XX Homo sapiens.  
OS  
XX DEL9811193-A1.  
PN  
XX  
XX 16-SEP-1999.  
PD  
XX  
XX 10-MAR-1998; 98DE-1011193.  
PF  
XX  
XX 10-MAR-1998; 98DE-1011193.  
PR

XX PA (META-) METAGEN GES GENOMFORSCHUNG MBH.  
XX  
XX Specht T, Hinzmann B, Schmitt A, Pillarsky C, Dahl E, Rosenthal A;  
XX  
XX WPI: 1999-519628/44.  
DR N-PSDB: AAZ33449.  
XX  
XX New nucleic acid expressed at high level in prostatic tumor tissue and  
PT encoded polypeptides, useful for treating cancer and screening for  
PT therapeutic agents -  
XX  
XX Claim 22; 127; 166pp; German.  
PS  
XX This invention describes novel nucleic acid sequences (A) that are  
CC expressed at high level in prostatic tumor tissue and encode gene  
CC products or their fragments. The products of the invention have  
CC antitumor activity. Polypeptides (f) encoded by (A) are used: (i) for  
CC identifying agents for treatment of prostatic cancer and (ii) for  
CC therapy of prostate cancer, optionally where expressed by gene therapy  
CC methods. (A) is also used to isolate full-length genes (for gene therapy)  
CC and for recombinant production of (f), which can be used to raise  
CC specific antibodies. (A) are identified by assembly of ESTs (expressed  
CC sequence tags) before they are analyzed for expression pattern (tissue  
CC specificity). This approach eliminates many of the false results, as  
CC regards tissue specificity, associated with known methods that use  
CC single (usually short) ESTs. AAY48215-Y48303 represent protein fragments  
CC encoded by the expressed sequence tags described in the method of the  
CC invention.  
XX  
XX Sequence 112 AA;  
SQ

Query Match 53.2%; Score 41; DB 20; Length 112;  
Best Local Similarity 50.0%; Pred. No. 2.9;  
Matches 7; Conservative 2; Mismatches 5; Indels 0; Gaps 0;  
  
QY 1 CIGLAGTDFANQRP 14  
Db | | | | | | | | | | | | | | | |  
15 cmgvagtalgrarp 28  
  
RESULT 3  
AAR06602  
ID AAR06602 standard; protein: 98 AA.  
XX  
XX AAR06602;  
XX  
XX 11-JAN-1991 (first entry)  
XX  
XX Cytochrome C-552.  
XX  
XX Cytochrome C-552; recombinant expression systems; myocardial;  
KW infarction; cerebrovascular disease;  
KW  
XX Hydrogenobacter thermophilus.  
OS  
XX  
XX Key Location/Qualifiers  
FH Peptide 1..18  
FT /label=signal\_peptide  
FT  
XX  
XX EP385451-A.  
PN  
XX  
XX 05-SEP-1990.  
PD  
XX  
XX 28-FEB-1990; 90EP-0103928.  
PF  
XX  
XX 28-FEB-1989; 89JP-0047427.  
PR  
XX  
XX (SUNR ) SUNTORY LTD.  
PA  
XX  
XX Kodama T, Igarashi Y;  
PI  
XX

DR WPI; 1990-269480/36.  
 DR N-PSDB; AAQ05835.  
 XX  
 PT New DNA sequence for cytochrome C-552 of Hydrogenobacter  
 PT thermophilus - and heterologous recombinant expression systems,  
 PT useful e.g. for treating myocardial infarction and reducing  
 PT mutagenicity of foods  
 XX  
 XX Claim 1; Page 10; 25pp; English.  
 PS  
 CC The amino acid sequence of C-552 has been reported and from this  
 CC information oligonucleotides were synthesised (See AAQ06573-76).  
 CC The probes were used to isolate a 2.5 kb fragment from a  
 CC H. thermophilus digest. The C-552 gene was further localised  
 CC to a 1.1 kb fragment and this was subcloned in pUC14, forming  
 CC pHTC 135, and then sequenced. The sequence was inserted into a  
 CC yeast expression vector, and the recombinants used to transform  
 CC the yeast strain X3-39-2delta CYC1 (deficient in iso-1  
 CC cytochrome C so unable to use lactic acid). The gene may also be  
 CC incorporated into E. coli.  
 CC The gene product is expected to be useful in treatment of  
 CC myocardial infarction and cerebrovascular diseases, and, compared  
 CC with equine cytochrome C, has lower mol. wt. and better stability.  
 CC It can also be used to reduce mutagenicity of food prods.  
 XX  
 XX Sequence 98 AA;  
 SQ

Query Match 51.9%; Score 40; DB 11; Length 98;  
 Best Local Similarity 58.3%; Pred. No. 3.9;  
 Matches 7; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 2 IGLAGTDFANOR 13  
 :||||| |||:  
 Db 10 vglagitfaneq 21

RESULT 4  
 AAY92323  
 ID AAY92323 standard; Protein; 1096 AA.  
 AC AAY92323;  
 XX  
 XX 10-AUG-2000 (first entry)  
 DT  
 DE Human alpha-2-delta-D polypeptide from splice variant 1.  
 XX  
 KW alpha-2-delta-D; calcium channel; l2p13.3; gabapentin; cytostatic;  
 KW anticonvulsant; antimigrane; antiparkinsonian; antidepressant;  
 KW splice variant.  
 XX  
 OS Homo sapiens.  
 XX  
 FH Key Location/Qualifiers  
 FT Misc-difference 310  
 FT /note= "encoded by RTT"  
 XX  
 XX WO200020450-A2.  
 XX  
 PD 13-APR-2000.  
 XX  
 XX 07-OCT-1999; 99WO-US23519.  
 XX  
 PR 07-OCT-1998; 98US-0103322.  
 PR 30-OCT-1998; 98US-0106473.  
 PR 29-DEC-1998; 98US-0114088.  
 XX  
 XX (WARN ) WARNER LAMBERT CO.  
 PA  
 XX  
 XX Johns MA, Moldover B, Offord JD;  
 PI  
 XX  
 XX WPI; 2000-303744/26.  
 DR  
 DR N-PSDB; AAA09278.

XX New human nucleic acids encoding the alpha2delta-C and alpha2delta-D  
 PT proteins, useful in the treatment of epilepsy, migraine, chronic pain,  
 PT anxiety, multiple sclerosis or cancer  
 XX  
 PS Example 3; Page 84; 88pp; English.  
 XX  
 CC The alpha-2-delta-D gene encodes a calcium channel subunit polypeptide.  
 CC The gene has been mapped to chromosome l2p13.1. This gene and the related  
 CC alpha-2-delta-C and -B genes are useful for protecting mammalian cells  
 CC from abnormal calcium flux by introducing expression vectors containing  
 CC the respective gene into mammalian cells. The antisense genes are also  
 CC useful for treating or preventing epilepsy. The alpha-delta-2-A protein  
 CC is a high-affinity binding target of the anti-convulsant drug gabapentin.  
 CC Therefore, alpha-delta-2 proteins may also be targeted to treat  
 CC seizure-related syndromes, migraine, ataxia, vestibular defects, chronic  
 CC pain, sleep interference, anxiety, amyotrophic lateral sclerosis (ALS),  
 CC multiple sclerosis, mania, tremor, parkinsonism, substance abuse or  
 CC addiction syndromes, mood, depression or cancer.  
 XX  
 SQ Sequence 1096 AA;  
 CC

Query Match 51.9%; Score 40; DB 21; Length 1096;  
 Best Local Similarity 50.0%; Pred. No. 50;  
 Matches 7; Conservative 1; Mismatches 6; Indels 0; Gaps 0;

QY 1 CIGLAGTDFANORP 14  
 :|:|:|:|:|:|:  
 Db 1013 clpigtllnqsp 1026

RESULT 5  
 AAP61750  
 ID AAP61750 standard; Protein; 16 AA.  
 XX  
 AC AAP61750;  
 XX  
 XX 11-JUL-1991 (first entry)  
 DT  
 XX  
 DE Plasmid pSYC720 encoded penP mature protein fragment.  
 XX  
 KW Large exopenicillinase; protein secretion.  
 XX  
 OS Bacillus licheniformis.  
 XX  
 PN ES8506800-A.  
 XX  
 PD 16-NOV-1985.  
 XX  
 XX 08-MAR-1984; 84ES-0530399.  
 PF  
 XX 02-MAR-1984; 84US-0583472.  
 PR  
 PR 09-MAR-1983; 83US-0473820.  
 PR 22-AUG-1982; 89US-0407701.  
 XX  
 XX (CETU ) CETUS CORP.  
 PA  
 XX  
 XX Shing C;  
 PI  
 XX  
 XX WPI; 1986-057082/09.  
 DR N-PSDB; AAN60990.  
 DR  
 XX Recombinant plasmid vector prodn. - by combining single chain DNA  
 PT fragments of different lengths.  
 PT  
 XX Disclosure; Fig 6; 26pp; English.  
 PS  
 XX By removing the Cys residue from the gene product, the membrane  
 CC binding ability of the secretion signal is interfered with, whilst  
 CC the transport signal remains active. Thus the secretion of a  
 CC desired protein may be facilitated at increased levels by  
 CC attachment of the signal in a suitable host.

XX Sequence 16 AA;  
SQ

Query Match 50.6%; Score 39; DB 7; Length 16;  
Best Local Similarity 46.2%; Pred. No. 0.8;  
Matches 6; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

QY 1 CIGLAGTDFANOR 13  
I: |||: ||: |  
Db 1 cvalagsafsnq 13

## RESULT 6

AAR85208  
ID -AAR85208 standard; Protein; 99 AA.

XX AC  
XX AAR85208;

DT 13-FEB-1996 (first entry)

XX Mouse ALK-6 extracellular domain.

DE ALK-3; Opl binding receptor; osteogenic protein 1; morphogenesis;  
KW morphogen; agonist; antagonist.

XX OS  
XX Mus sp.

XX WO9530003-A2.

PN 09-NOV-1995.

XX 28-APR-1995; 95WO-US05467.

PF 29-APR-1994; 94US-0236428.

XX {CREA-} CREATIVE BIOMOLECULES INC.  
PA {LUDW-} LUDWIG INST CANCER RES.

XX DIjke PT, Heldin C, Miyazano K, Sampath KT;

XX WPI; 1995-393076/50.

DR N-PSDB; AAT06032.

XX Identifying osteogenic protein-1 receptor-binding analogue - useful  
PT in the design of morphogen agonists and antagonists for therapeutic,  
PT diagnostic and experimental purposes

XX Claim 1; Page 73-74; 95pp; English.

XX The Type-I cell surface receptors ALK-2, ALK-3 and ALK-6 (given in  
CC AAR85206, AAR85207 and AAR85209) have specific binding affinity for  
CC osteogenic protein 1 (Opl) and Opl-related analogues. The  
CC receptors, and the extracellular domain of ALK-6 (AAR85208), are used  
CC to identify novel morphogen receptor binding analogues useful in  
CC drug design.

XX Sequence 99 AA;

Query Match 50.6%; Score 39; DB 16; Length 99;  
Best Local Similarity 66.7%; Pred. No. 6.2;  
Matches 6; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1 CIGLAGTDF 9  
I: ||| |:  
Db 48 clglegsdf 56

## RESULT 7

AAR95230  
ID AAR95230 standard; Protein; 126 AA.

XX

AC AAR95230;

XX 31-DEC-1996 (first entry)

XX Chick soluble BMP type I receptor kinase protein (BRK-2).

XX BMP type II receptor kinase-3; BRK-3; bone morphogenetic protein;

KW BMP type I receptor kinase; BRK-2; BMP receptor.

XX OS  
XX Gallus sp.

XX WO9614579-A1.

PN 17-MAY-1996.

XX 30-OCT-1995; 95WO-US14027.

XX 05-JUN-1995; 95US-0462467.

PR 04-NOV-1994; 94US-0334178.

XX (PROC ) PROCTER & GAMBLE CO.

XX Rosenbaum JS;

XX WPI; 1996-251887/25.

DR N-PSDB; AAT28026.

XX Assays for bone morphogenetic protein activities - using complex of  
PT BMP type I receptor kinase protein and BMP receptor kinase protein  
PT BRK-3

XX Claim 9; Page 73-74; 101pp; English.

XX Chick soluble bone morphogenetic protein (BMP) type I receptor  
CC kinase protein-2 (BRK-2) (AAR95230) lacks the regions of the full-  
CC length receptor (AAR95226) not required for BMP binding. A BMP  
CC receptor kinase protein complex formed of full-length, incomplete  
CC or soluble BMP type I receptor kinase protein and full-length,  
CC incomplete or soluble BMP type II receptor kinase-3 (BRK-3) (see  
CC also AAR95222-29 and AAR95231-34) is useful for screening cpds. for BMP  
CC receptor affinity or for determining the concentration of a BMP  
CC receptor ligand in a clinical sample. The complex can be expressed  
CC by host cells co-transfected with vectors carrying the appropriate  
CC DNA sequences (see also AAT28018-30).

XX Sequence 126 AA;

Query Match 50.6%; Score 39; DB 17; Length 126;  
Best Local Similarity 66.7%; Pred. No. 8.2;  
Matches 6; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1 CIGLAGTDF 9  
I: ||| |:  
Db 71 clglegsdf 79

## RESULT 8

AAR95232  
ID AAR95232 standard; Protein; 201 AA.

XX AC  
XX AAR95232;

XX 31-DEC-1996 (first entry)

XX Chick incomplete BMP type I receptor kinase protein (BRK-2).

XX BMP type II receptor kinase-3; BRK-3; bone morphogenetic protein;

KW BMP type I receptor kinase; BRK-2; BMP receptor.

XX OS  
XX Gallus sp.

XX WO9614579-A1.

PN

XX 17-MAY-1996.  
 PD 30-OCT-1995; 95WO-US14027.  
 PF 05-JUN-1995; 95US-0462467.  
 XX 04-NOV-1994; 94US-0334178.  
 XX (PROC ) PROCTER & GAMBLE CO.  
 PA Rosenbaum JS;  
 XX WPI; 1996-251887/25.  
 PI N-PSDB; AAT28028.  
 XX Assays for bone morphogenetic protein activities - using complex of  
 PT BMP type I receptor kinase protein and BMP receptor kinase protein  
 PT BRK-3  
 XX Disclosure; Page 77; 101pp; English.  
 XX Chick incomplete bone morphogenetic protein (BMP) type I receptor  
 CC Kinase protein-1 (BRK-1) (AAR95232) lacks the intracellular kinase  
 CC domain of the full-length receptor (AAR95226) and is incapable of  
 CC signal transduction. A BMP receptor kinase protein complex formed  
 CC of full-length, incomplete or soluble BMP type I receptor kinase  
 CC protein and full-length, incomplete or soluble BMP type II receptor  
 CC kinase-3 (BRK-3) (see also AAR95222-31 and AAR95233-34) is useful for  
 CC screening cpds. for BMP receptor affinity or for determining the  
 CC concentration of a BMP receptor ligand in a clinical sample. The  
 CC complex can be expressed by host cells co-transfected with vectors  
 CC carrying the appropriate DNA sequences (see also AAT28018-30).  
 XX Sequence 201 AA;  
 SQ

Query Match 50.6%; Score 39; DB 17; Length 201;  
 Best Local Similarity 66.7%; Pred. No. 14;  
 Matches 6; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1 CIGLAGTDF 9  
 :|||:|  
 Db 71 clglegsdff 79

RESULT 9  
 AAG44529  
 ID AAG44529 standard; Protein; 320 AA.  
 XX AAG44529;  
 AC AAG44529;  
 XX DT 18-OCT-2000 (first entry)  
 XX DE Arabidopsis thaliana protein fragment SEQ ID NO: 55790.  
 XX KW Protein identification; signal transduction pathway; metabolic pathway;  
 KW hybridisation assay; genetic mapping; gene expression control; promoter;  
 KW termination sequence.  
 XX OS Arabidopsis thaliana.  
 XX PN EP1033405-A2.  
 XX PD 06-SEP-2000.  
 XX PF 25-FEB-2000; 2000EP-0301439.  
 XX 25-FEB-1999; 99US-0121825.  
 PR 05-MAR-1999; 99US-0123180.  
 PR 09-MAR-1999; 99US-0123548.  
 PR 23-MAR-1999; 99US-0125788.  
 PR 25-MAR-1999; 99US-0126264.  
 PR 29-MAR-1999; 99US-0126785.

PR 01-APR-1999; 99US-0127462.  
 PR 06-APR-1999; 99US-0128234.  
 PR 08-APR-1999; 99US-0128714.  
 PR 16-APR-1999; 99US-0129845.  
 PR 19-APR-1999; 99US-0130077.  
 PR 21-APR-1999; 99US-0130449.  
 PR 23-APR-1999; 99US-0130510.  
 PR 23-APR-1999; 99US-0130891.  
 PR 28-APR-1999; 99US-0131449.  
 PR 30-APR-1999; 99US-0132048.  
 PR 30-APR-1999; 99US-0132407.  
 PR 04-MAY-1999; 99US-0132484.  
 PR 05-MAY-1999; 99US-0132485.  
 PR 06-MAY-1999; 99US-0132486.  
 PR 06-MAY-1999; 99US-0132487.  
 PR 07-MAY-1999; 99US-0132863.  
 PR 11-MAY-1999; 99US-0134256.  
 PR 14-MAY-1999; 99US-0134218.  
 PR 14-MAY-1999; 99US-0134219.  
 PR 14-MAY-1999; 99US-0134221.  
 PR 14-MAY-1999; 99US-0134370.  
 PR 18-MAY-1999; 99US-0134768.  
 PR 19-MAY-1999; 99US-0134941.  
 PR 20-MAY-1999; 99US-0135124.  
 PR 21-MAY-1999; 99US-0135353.  
 PR 24-MAY-1999; 99US-0135629.  
 PR 25-MAY-1999; 99US-0136021.  
 PR 27-MAY-1999; 99US-0136392.  
 PR 28-MAY-1999; 99US-0136782.  
 PR 01-JUN-1999; 99US-0137222.  
 PR 03-JUN-1999; 99US-0137528.  
 PR 04-JUN-1999; 99US-0137502.  
 PR 07-JUN-1999; 99US-0137724.  
 PR 08-JUN-1999; 99US-0138094.  
 PR 10-JUN-1999; 99US-0138540.  
 PR 10-JUN-1999; 99US-0138847.  
 PR 14-JUN-1999; 99US-0139119.  
 PR 16-JUN-1999; 99US-0139452.  
 PR 16-JUN-1999; 99US-0139453.  
 PR 17-JUN-1999; 99US-0139492.  
 PR 18-JUN-1999; 99US-0139454.  
 PR 18-JUN-1999; 99US-0139455.  
 PR 18-JUN-1999; 99US-0139456.  
 PR 18-JUN-1999; 99US-0139457.  
 PR 18-JUN-1999; 99US-0139458.  
 PR 18-JUN-1999; 99US-0139459.  
 PR 18-JUN-1999; 99US-0139460.  
 PR 18-JUN-1999; 99US-0139461.  
 PR 18-JUN-1999; 99US-0139462.  
 PR 18-JUN-1999; 99US-0139463.  
 PR 18-JUN-1999; 99US-0139750.  
 PR 18-JUN-1999; 99US-0139763.  
 PR 21-JUN-1999; 99US-0139817.  
 PR 22-JUN-1999; 99US-0139899.  
 PR 23-JUN-1999; 99US-0140353.  
 PR 23-JUN-1999; 99US-0140354.  
 PR 24-JUN-1999; 99US-0140595.  
 PR 28-JUN-1999; 99US-0140823.  
 PR 29-JUN-1999; 99US-0140991.  
 PR 30-JUN-1999; 99US-0141287.  
 PR 01-JUL-1999; 99US-0141842.  
 PR 01-JUL-1999; 99US-0142154.  
 PR 02-JUL-1999; 99US-0142055.  
 PR 06-JUL-1999; 99US-0142390.  
 PR 08-JUL-1999; 99US-0142803.  
 PR 09-JUL-1999; 99US-0142920.  
 PR 12-JUL-1999; 99US-0142977.  
 PR 13-JUL-1999; 99US-0143542.  
 PR 14-JUL-1999; 99US-0143824.  
 PR 15-JUL-1999; 99US-0144005.  
 PR 16-JUL-1999; 99US-0144085.  
 PR 16-JUL-1999; 99US-0144086.  
 PR 19-JUL-1999; 99US-0144325.

PR 19-JUL-1999; 99US-0144331.  
PR 19-JUL-1999; 99US-0144332.  
PR 19-JUL-1999; 99US-0144333.  
PR 19-JUL-1999; 99US-0144334.  
PR 19-JUL-1999; 99US-0144335.  
PR 20-JUL-1999; 99US-0144352.  
PR 20-JUL-1999; 99US-0144632.  
PR 20-JUL-1999; 99US-0144884.  
PR 21-JUL-1999; 99US-0144814.  
PR 21-JUL-1999; 99US-0145086.  
PR 21-JUL-1999; 99US-0145088.  
PR 22-JUL-1999; 99US-0145085.  
PR 22-JUL-1999; 99US-0145087.  
PR 22-JUL-1999; 99US-0145089.  
PR 22-JUL-1999; 99US-0145192.  
PR 23-JUL-1999; 99US-0145145.  
PR 23-JUL-1999; 99US-0145218.  
PR 23-JUL-1999; 99US-0145224.  
PR 26-JUL-1999; 99US-0145276.  
PR 27-JUL-1999; 99US-0145913.  
PR 27-JUL-1999; 99US-0145918.  
PR 27-JUL-1999; 99US-0145919.  
PR 28-JUL-1999; 99US-0145951.  
PR 02-AUG-1999; 99US-0146386.  
PR 02-AUG-1999; 99US-0146388.  
PR 02-AUG-1999; 99US-0146389.  
PR 03-AUG-1999; 99US-0147038.  
PR 04-AUG-1999; 99US-0147204.  
PR 04-AUG-1999; 99US-0147302.  
PR 05-AUG-1999; 99US-0147192.  
PR 05-AUG-1999; 99US-0147260.  
PR 06-AUG-1999; 99US-0147303.  
PR 06-AUG-1999; 99US-0147416.  
PR 06-AUG-1999; 99US-0147493.  
PR 08-AUG-1999; 99US-0147935.  
PR 10-AUG-1999; 99US-0148171.  
PR 11-AUG-1999; 99US-0148319.  
PR 12-AUG-1999; 99US-0148341.  
PR 13-AUG-1999; 99US-0148565.  
PR 13-AUG-1999; 99US-0148684.  
PR 16-AUG-1999; 99US-0149368.  
PR 17-AUG-1999; 99US-0149175.  
PR 18-AUG-1999; 99US-0149426.  
PR 20-AUG-1999; 99US-0149722.  
PR 20-AUG-1999; 99US-0149723.  
PR 20-AUG-1999; 99US-0149829.  
PR 23-AUG-1999; 99US-0149902.  
PR 23-AUG-1999; 99US-0149930.  
PR 25-AUG-1999; 99US-0150566.  
PR 26-AUG-1999; 99US-0150884.  
PR 27-AUG-1999; 99US-0151065.  
PR 27-AUG-1999; 99US-0151066.  
PR 27-AUG-1999; 99US-0151080.  
PR 30-AUG-1999; 99US-0151303.  
PR 31-AUG-1999; 99US-0151438.  
PR 01-SEP-1999; 99US-0151930.  
PR 07-SEP-1999; 99US-0152363.  
PR 10-SEP-1999; 99US-0153070.  
PR 13-SEP-1999; 99US-0153758.  
PR 15-SEP-1999; 99US-0154018.  
PR 16-SEP-1999; 99US-0154039.  
PR 20-SEP-1999; 99US-0154779.  
PR 22-SEP-1999; 99US-0155139.  
PR 23-SEP-1999; 99US-0155486.  
PR 24-SEP-1999; 99US-0155659.  
PR 28-SEP-1999; 99US-0156458.  
PR 29-SEP-1999; 99US-0156596.  
PR 01-OCT-1999; 99US-0157117.  
PR 05-OCT-1999; 99US-0157753.  
PR 06-OCT-1999; 99US-0157865.  
PR 07-OCT-1999; 99US-0158029.  
PR 08-OCT-1999; 99US-0158232.  
PR 12-OCT-1999; 99US-0158369.

PR 13-OCT-1999; 99US-0159293.  
PR 13-OCT-1999; 99US-0159294.  
PR 13-OCT-1999; 99US-0159295.  
PR 14-OCT-1999; 99US-0159329.  
PR 14-OCT-1999; 99US-0159330.  
PR 14-OCT-1999; 99US-0159331.  
PR 14-OCT-1999; 99US-0159637.  
PR 14-OCT-1999; 99US-0159638.  
PR 18-OCT-1999; 99US-0159584.  
PR 21-OCT-1999; 99US-0160741.  
PR 21-OCT-1999; 99US-0160767.  
PR 21-OCT-1999; 99US-0160768.  
PR 21-OCT-1999; 99US-0160770.  
PR 21-OCT-1999; 99US-0160814.  
PR 21-OCT-1999; 99US-0160815.  
PR 22-OCT-1999; 99US-0160980.  
PR 22-OCT-1999; 99US-0160981.  
PR 22-OCT-1999; 99US-0160989.  
PR 25-OCT-1999; 99US-0161404.  
PR 25-OCT-1999; 99US-0161405.  
PR 25-OCT-1999; 99US-0161406.  
PR 26-OCT-1999; 99US-0161359.  
PR 26-OCT-1999; 99US-0161360.  
PR 26-OCT-1999; 99US-0161361.  
PR 28-OCT-1999; 99US-0161920.  
PR 28-OCT-1999; 99US-0161992.  
PR 28-OCT-1999; 99US-0161993.  
PR 29-OCT-1999; 99US-0162142.

Query Match 50.6%; Score 39; DB 21; Length 320;  
Best Local Similarity 77.8%; Pred. No. 23;  
Matches 7; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 6 GTDFANORP 14  
| | | | |  
Db 27 grdfndrp 35

## RESULT 10

AAG44528  
ID AAG44528 standard; Protein; 348 AA.

XX AC AAG44528;

XX DT 18-OCT-2000 (first entry)

XX DE Arabidopsis thaliana protein fragment SEQ ID NO: 55789.

XX KW Protein identification; signal transduction pathway; metabolic pathway;  
KW hybridisation assay; genetic mapping; gene expression control; promoter;  
XX termination sequence.

OS Arabidopsis thaliana.

XX PN EP1033405-A2.

XX PD 06-SEP-2000.

XX PF 25-FEB-2000; 2000EP-0301439.

XX PR 25-FEB-1999; 99US-0121825.

XX PR 05-MAR-1999; 99US-0123180.

XX PR 09-MAR-1999; 99US-0123548.

XX PR 23-MAR-1999; 99US-0125788.

XX PR 25-MAR-1999; 99US-0126264.

XX PR 29-MAR-1999; 99US-0126785.

XX PR 01-APR-1999; 99US-0127462.

XX PR 08-APR-1999; 99US-0128234.

XX PR 16-APR-1999; 99US-0129845.

XX PR 19-APR-1999; 99US-0130077.

XX PR 21-APR-1999; 99US-0130449.

XX PR 23-APR-1999; 99US-0130510.

PR 23-APR-1999;	99US-0130891.	PR 20-JUL-1999;	99US-0144884.
PR 28-APR-1999;	99US-0131449.	PR 21-JUL-1999;	99US-0144814.
PR 30-APR-1999;	99US-0132048.	PR 21-JUL-1999;	99US-0145086.
PR 30-APR-1999;	99US-0132407.	PR 21-JUL-1999;	99US-0145088.
PR 04-MAY-1999;	99US-0132484.	PR 22-JUL-1999;	99US-0145085.
PR 05-MAY-1999;	99US-0132485.	PR 22-JUL-1999;	99US-0145087.
PR 06-MAY-1999;	99US-0132486.	PR 22-JUL-1999;	99US-0145089.
PR 07-MAY-1999;	99US-0132487.	PR 22-JUL-1999;	99US-0145192.
PR 11-MAY-1999;	99US-0132863.	PR 23-JUL-1999;	99US-0145145.
PR 11-MAY-1999;	99US-0134256.	PR 23-JUL-1999;	99US-0145218.
PR 14-MAY-1999;	99US-0134218.	PR 23-JUL-1999;	99US-0145224.
PR 14-MAY-1999;	99US-0134219.	PR 26-JUL-1999;	99US-0145276.
PR 14-MAY-1999;	99US-0134221.	PR 27-JUL-1999;	99US-0145913.
PR 14-MAY-1999;	99US-0134370.	PR 27-JUL-1999;	99US-0145918.
PR 18-MAY-1999;	99US-0134376.	PR 27-JUL-1999;	99US-0145919.
PR 19-MAY-1999;	99US-0134941.	PR 28-JUL-1999;	99US-0145951.
PR 20-MAY-1999;	99US-0135124.	PR 02-AUG-1999;	99US-0146386.
PR 21-MAY-1999;	99US-0135353.	PR 02-AUG-1999;	99US-0146388.
PR 24-MAY-1999;	99US-0135629.	PR 03-AUG-1999;	99US-0146389.
PR 25-MAY-1999;	99US-0136021.	PR 03-AUG-1999;	99US-0147038.
PR 27-MAY-1999;	99US-0136392.	PR 04-AUG-1999;	99US-0147204.
PR 28-MAY-1999;	99US-0136782.	PR 04-AUG-1999;	99US-0147302.
PR 01-JUN-1999;	99US-0137222.	PR 05-AUG-1999;	99US-0147192.
PR 03-JUN-1999;	99US-0137528.	PR 05-AUG-1999;	99US-0147260.
PR 04-JUN-1999;	99US-0137502.	PR 06-AUG-1999;	99US-0147303.
PR 07-JUN-1999;	99US-0137724.	PR 06-AUG-1999;	99US-0147416.
PR 08-JUN-1999;	99US-0138094.	PR 09-AUG-1999;	99US-0147493.
PR 10-JUN-1999;	99US-0138540.	PR 09-AUG-1999;	99US-0147935.
PR 10-JUN-1999;	99US-0138847.	PR 09-AUG-1999;	99US-0147935.
PR 14-JUN-1999;	99US-0139119.	PR 10-AUG-1999;	99US-0148171.
PR 16-JUN-1999;	99US-0139452.	PR 11-AUG-1999;	99US-0148319.
PR 16-JUN-1999;	99US-0139453.	PR 12-AUG-1999;	99US-0148341.
PR 17-JUN-1999;	99US-0139453.	PR 13-AUG-1999;	99US-0148565.
PR 17-JUN-1999;	99US-0139492.	PR 13-AUG-1999;	99US-0148684.
PR 18-JUN-1999;	99US-0139454.	PR 15-AUG-1999;	99US-0149368.
PR 18-JUN-1999;	99US-0139455.	PR 17-AUG-1999;	99US-0149175.
PR 18-JUN-1999;	99US-0139456.	PR 18-AUG-1999;	99US-0149426.
PR 18-JUN-1999;	99US-0139457.	PR 20-AUG-1999;	99US-0149722.
PR 18-JUN-1999;	99US-0139458.	PR 20-AUG-1999;	99US-0149723.
PR 18-JUN-1999;	99US-0139459.	PR 20-AUG-1999;	99US-0149929.
PR 18-JUN-1999;	99US-0139460.	PR 23-AUG-1999;	99US-0149902.
PR 18-JUN-1999;	99US-0139461.	PR 23-AUG-1999;	99US-0149930.
PR 18-JUN-1999;	99US-0139462.	PR 25-AUG-1999;	99US-0150566.
PR 18-JUN-1999;	99US-0139463.	PR 26-AUG-1999;	99US-0150884.
PR 18-JUN-1999;	99US-0139750.	PR 27-AUG-1999;	99US-0151065.
PR 18-JUN-1999;	99US-0139763.	PR 27-AUG-1999;	99US-0151066.
PR 21-JUN-1999;	99US-0139817.	PR 27-AUG-1999;	99US-0151080.
PR 22-JUN-1999;	99US-0139899.	PR 30-AUG-1999;	99US-0151303.
PR 23-JUN-1999;	99US-0140353.	PR 31-AUG-1999;	99US-0151438.
PR 23-JUN-1999;	99US-0140354.	PR 01-SEP-1999;	99US-0151930.
PR 24-JUN-1999;	99US-0140695.	PR 07-SEP-1999;	99US-0152363.
PR 28-JUN-1999;	99US-0140823.	PR 10-SEP-1999;	99US-0153070.
PR 29-JUN-1999;	99US-0140991.	PR 13-SEP-1999;	99US-0153758.
PR 30-JUN-1999;	99US-0141287.	PR 13-SEP-1999;	99US-0154018.
PR 01-JUL-1999;	99US-0141842.	PR 16-SEP-1999;	99US-0154039.
PR 01-JUL-1999;	99US-0142154.	PR 20-SEP-1999;	99US-0154779.
PR 02-JUL-1999;	99US-0142055.	PR 22-SEP-1999;	99US-0155139.
PR 06-JUL-1999;	99US-0142290.	PR 23-SEP-1999;	99US-0155486.
PR 08-JUL-1999;	99US-0142803.	PR 24-SEP-1999;	99US-0155659.
PR 09-JUL-1999;	99US-0142920.	PR 28-SEP-1999;	99US-0156458.
PR 12-JUL-1999;	99US-0142977.	PR 29-SEP-1999;	99US-0156596.
PR 13-JUL-1999;	99US-0143342.	PR 04-OCT-1999;	99US-0157117.
PR 14-JUL-1999;	99US-0143624.	PR 05-OCT-1999;	99US-0157753.
PR 15-JUL-1999;	99US-0144005.	PR 06-OCT-1999;	99US-0157865.
PR 16-JUL-1999;	99US-0144085.	PR 07-OCT-1999;	99US-0158029.
PR 16-JUL-1999;	99US-0144086.	PR 08-OCT-1999;	99US-0158232.
PR 19-JUL-1999;	99US-0144325.	PR 12-OCT-1999;	99US-0158369.
PR 19-JUL-1999;	99US-0144331.	PR 13-OCT-1999;	99US-0159293.
PR 19-JUL-1999;	99US-0144332.	PR 13-OCT-1999;	99US-0159294.
PR 19-JUL-1999;	99US-0144333.	PR 13-OCT-1999;	99US-0159295.
PR 19-JUL-1999;	99US-0144334.	PR 14-OCT-1999;	99US-0159329.
PR 19-JUL-1999;	99US-0144335.	PR 14-OCT-1999;	99US-0159330.
PR 20-JUL-1999;	99US-0144352.	PR 14-OCT-1999;	99US-0159331.
PR 20-JUL-1999;	99US-0144632.	PR 14-OCT-1999;	99US-0159637.

PR 14-OCT-1999; 99US-0159638.  
PR 18-OCT-1999; 99US-0159584.  
PR 21-OCT-1999; 99US-0160741.  
PR 21-OCT-1999; 99US-0160767.  
PR 21-OCT-1999; 99US-0160768.  
PR 21-OCT-1999; 99US-0160770.  
PR 21-OCT-1999; 99US-0160814.  
PR 21-OCT-1999; 99US-0160815.  
PR 22-OCT-1999; 99US-0160980.  
PR 22-OCT-1999; 99US-0160981.  
PR 22-OCT-1999; 99US-0160989.  
PR 25-OCT-1999; 99US-0161404.  
PR 25-OCT-1999; 99US-0161405.  
PR 25-OCT-1999; 99US-0161406.  
PR 26-OCT-1999; 99US-0161359.  
PR 26-OCT-1999; 99US-0161360.  
PR 26-OCT-1999; 99US-0161361.  
PR 28-OCT-1999; 99US-0161920.  
PR 28-OCT-1999; 99US-0161992.  
PR 28-OCT-1999; 99US-0161993.  
PR 29-OCT-1999; 99US-0162142.

Query Match 50.6%; Score 39; DB 21; Length 348;  
Best Local Similarity 77.8%; Pred. No. 26;  
Matches 7; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 6 GTDFANQRP 14  
| | | | |  
Db 55 grdfingrp 63

RESULT 11  
AAG44527  
ID AAG44527 standard; Protein; 351 AA.  
XX AC AAG44527;  
XX DT 18-OCT-2000 (first entry)  
XX DE Arabidopsis thaliana protein fragment SEQ ID NO: 55788.  
XX KW Protein identification; signal transduction pathway; metabolic pathway;  
KW hybridisation assay; genetic mapping; gene expression control; promoter;  
KW termination sequence.  
XX OS Arabidopsis thaliana.  
XX PN EP1033405-A2.  
XX PD 06-SEP-2000.  
XX PF 25-FEB-2000; 2000EP-0301439.  
XX PR 25-FEB-1999; 99US-0121825.  
PR 05-MAR-1999; 99US-0123180.  
PR 09-MAR-1999; 99US-0123548.  
PR 23-MAR-1999; 99US-0125788.  
PR 23-MAR-1999; 99US-0126264.  
PR 29-MAR-1999; 99US-0126785.  
PR 01-APR-1999; 99US-0127462.  
PR 06-APR-1999; 99US-0128234.  
PR 08-APR-1999; 99US-0128714.  
PR 16-APR-1999; 99US-0129845.  
PR 19-APR-1999; 99US-0130077.  
PR 21-APR-1999; 99US-0130449.  
PR 23-APR-1999; 99US-0130510.  
PR 28-APR-1999; 99US-0130891.  
PR 30-APR-1999; 99US-0131449.  
PR 30-APR-1999; 99US-0132048.  
PR 04-MAY-1999; 99US-0132407.  
PR 03-MAY-1999; 99US-0132484.  
PR 06-MAY-1999; 99US-0132485.  
PR 06-MAY-1999; 99US-0132486.

PR 06-MAY-1999; 99US-0132487.  
PR 07-MAY-1999; 99US-0132863.  
PR 11-MAY-1999; 99US-0134256.  
PR 14-MAY-1999; 99US-0134218.  
PR 14-MAY-1999; 99US-0134219.  
PR 14-MAY-1999; 99US-0134221.  
PR 14-MAY-1999; 99US-0134370.  
PR 18-MAY-1999; 99US-0134768.  
PR 19-MAY-1999; 99US-0134941.  
PR 20-MAY-1999; 99US-0135124.  
PR 21-MAY-1999; 99US-0135353.  
PR 24-MAY-1999; 99US-0135629.  
PR 25-MAY-1999; 99US-0136021.  
PR 27-MAY-1999; 99US-0136392.  
PR 28-MAY-1999; 99US-0136782.  
PR 01-JUN-1999; 99US-0137222.  
PR 03-JUN-1999; 99US-0137528.  
PR 04-JUN-1999; 99US-0137502.  
PR 07-JUN-1999; 99US-0137724.  
PR 08-JUN-1999; 99US-0138094.  
PR 10-JUN-1999; 99US-0138540.  
PR 10-JUN-1999; 99US-0138847.  
PR 14-JUN-1999; 99US-0139119.  
PR 16-JUN-1999; 99US-0139452.  
PR 16-JUN-1999; 99US-0139453.  
PR 17-JUN-1999; 99US-0139492.  
PR 18-JUN-1999; 99US-0139454.  
PR 18-JUN-1999; 99US-0139455.  
PR 18-JUN-1999; 99US-0139456.  
PR 18-JUN-1999; 99US-0139457.  
PR 18-JUN-1999; 99US-0139458.  
PR 18-JUN-1999; 99US-0139459.  
PR 18-JUN-1999; 99US-0139460.  
PR 18-JUN-1999; 99US-0139461.  
PR 18-JUN-1999; 99US-0139462.  
PR 18-JUN-1999; 99US-0139463.  
PR 18-JUN-1999; 99US-0139750.  
PR 18-JUN-1999; 99US-0139763.  
PR 21-JUN-1999; 99US-0139817.  
PR 22-JUN-1999; 99US-0139899.  
PR 23-JUN-1999; 99US-0140353.  
PR 23-JUN-1999; 99US-0140354.  
PR 24-JUN-1999; 99US-0140695.  
PR 28-JUN-1999; 99US-0140823.  
PR 29-JUN-1999; 99US-0140991.  
PR 30-JUN-1999; 99US-0141287.  
PR 01-JUL-1999; 99US-0141842.  
PR 01-JUL-1999; 99US-0142154.  
PR 02-JUL-1999; 99US-0142055.  
PR 06-JUL-1999; 99US-0142390.  
PR 08-JUL-1999; 99US-0142803.  
PR 09-JUL-1999; 99US-0142920.  
PR 12-JUL-1999; 99US-0142977.  
PR 13-JUL-1999; 99US-0143542.  
PR 14-JUL-1999; 99US-0143624.  
PR 15-JUL-1999; 99US-0144005.  
PR 16-JUL-1999; 99US-0144085.  
PR 16-JUL-1999; 99US-0144086.  
PR 19-JUL-1999; 99US-0144325.  
PR 19-JUL-1999; 99US-0144331.  
PR 19-JUL-1999; 99US-0144332.  
PR 19-JUL-1999; 99US-0144333.  
PR 19-JUL-1999; 99US-0144334.  
PR 19-JUL-1999; 99US-0144335.  
PR 20-JUL-1999; 99US-0144352.  
PR 20-JUL-1999; 99US-0144832.  
PR 20-JUL-1999; 99US-0144884.  
PR 21-JUL-1999; 99US-0144814.  
PR 21-JUL-1999; 99US-0145086.  
PR 21-JUL-1999; 99US-0145088.  
PR 22-JUL-1999; 99US-0145085.  
PR 22-JUL-1999; 99US-0145087.  
PR 22-JUL-1999; 99US-0145089.



```
PR 22-JUL-1999; 99US-0145192.
PR 23-JUL-1999; 99US-0145145.
PR 23-JUL-1999; 99US-0145218.
PR 23-JUL-1999; 99US-0145224.
PR 26-JUL-1999; 99US-0145276.
PR 27-JUL-1999; 99US-0145913.
PR 27-JUL-1999; 99US-0145918.
PR 27-JUL-1999; 99US-0145919.
PR 28-JUL-1999; 99US-0145951.
PR 02-AUG-1999; 99US-0146386.
PR 02-AUG-1999; 99US-0146388.
PR 02-AUG-1999; 99US-0146389.
PR 03-AUG-1999; 99US-0147038.
PR 04-AUG-1999; 99US-0147204.
PR 04-AUG-1999; 99US-0147302.
PR 05-AUG-1999; 99US-0147192.
PR 05-AUG-1999; 99US-0147260.
PR 06-AUG-1999; 99US-0147303.
PR 06-AUG-1999; 99US-0147416.
PR 09-AUG-1999; 99US-0147493.
PR 09-AUG-1999; 99US-0147935.
PR 10-AUG-1999; 99US-0148171.
PR 11-AUG-1999; 99US-0148319.
PR 12-AUG-1999; 99US-0148341.
PR 13-AUG-1999; 99US-0148565.
PR 13-AUG-1999; 99US-0148684.
PR 16-AUG-1999; 99US-0149368.
PR 17-AUG-1999; 99US-0149175.
PR 18-AUG-1999; 99US-0149426.
PR 20-AUG-1999; 99US-0149722.
PR 20-AUG-1999; 99US-0149723.
PR 20-AUG-1999; 99US-0149929.
PR 23-AUG-1999; 99US-0149902.
PR 23-AUG-1999; 99US-0149930.
PR 25-AUG-1999; 99US-0150566.
PR 26-AUG-1999; 99US-0150884.
PR 27-AUG-1999; 99US-0151065.
PR 27-AUG-1999; 99US-0151066.
PR 27-AUG-1999; 99US-0151080.
PR 30-AUG-1999; 99US-0151303.
PR 31-AUG-1999; 99US-0151438.
PR 01-SEP-1999; 99US-0151930.
PR 07-SEP-1999; 99US-0152363.
PR 10-SEP-1999; 99US-0153070.
PR 13-SEP-1999; 99US-0153758.
PR 15-SEP-1999; 99US-0154018.
PR 16-SEP-1999; 99US-0154039.
PR 20-SEP-1999; 99US-0154779.
PR 22-SEP-1999; 99US-0155139.
PR 23-SEP-1999; 99US-0155486.
PR 24-SEP-1999; 99US-0155659.
PR 28-SEP-1999; 99US-0156458.
PR 29-SEP-1999; 99US-0156596.
PR 04-OCT-1999; 99US-0157117.
PR 05-OCT-1999; 99US-0157753.
PR 05-OCT-1999; 99US-0157865.
PR 07-OCT-1999; 99US-0158029.
PR 08-OCT-1999; 99US-0158232.
PR 12-OCT-1999; 99US-0158369.
PR 13-OCT-1999; 99US-0159293.
PR 13-OCT-1999; 99US-0159294.
PR 13-OCT-1999; 99US-0159295.
PR 14-OCT-1999; 99US-0159329.
PR 14-OCT-1999; 99US-0159330.
PR 14-OCT-1999; 99US-0159331.
PR 14-OCT-1999; 99US-0159637.
PR 14-OCT-1999; 99US-0159638.
PR 18-OCT-1999; 99US-0159584.
PR 21-OCT-1999; 99US-0160741.
PR 21-OCT-1999; 99US-0160767.
PR 21-OCT-1999; 99US-0160768.
PR 21-OCT-1999; 99US-0160770.
PR 21-OCT-1999; 99US-0160814.

PR 21-OCT-1999; 99US-0160815.
PR 22-OCT-1999; 99US-0160980.
PR 22-OCT-1999; 99US-0160981.
PR 22-OCT-1999; 99US-0160989.
PR 25-OCT-1999; 99US-0161404.
PR 25-OCT-1999; 99US-0161405.
PR 25-OCT-1999; 99US-0161406.
PR 26-OCT-1999; 99US-0161359.
PR 26-OCT-1999; 99US-0161360.
PR 26-OCT-1999; 99US-0161361.
PR 28-OCT-1999; 99US-0161920.
PR 28-OCT-1999; 99US-0161992.
PR 28-OCT-1999; 99US-0161993.
PR 29-OCT-1999; 99US-0162142.

Query Match 50.6%; Score 39; DB 21; Length 351;
Best Local Similarity 77.8%; Pred. No. 26;
Matches 7; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 6 GTDFANQRP 14
   | | | | |
Db 58 grdfnqrp 66

RESULT 12
AAY53884
ID AAY53884 standard; Protein; 355 AA.
XX
AC AAY53884;
XX
DT 13-MAR-2000 (first entry)
XX
DE
XX
KW Human; suppressor of cytokine signalling protein designated HSCOP-4.
KW cancer; leukaemia; lymphoma; diabetes mellitus; Crohn's disease;
KW immune disorder; AIDS; allergy; atherosclerosis; inflammatory disorder;
KW rheumatoid arthritis; irritable bowel syndrome; multiple sclerosis;
KW ulcerative colitis; neurological disorder; Down's syndrome; amnesia;
KW cerebral neoplasm; Huntington's disease; viral infection; adenovirus;
KW acute respiratory disease; toga virus; rubella.
XX
OS Homo sapiens.
XX
FH Key
FT Modified-site 44 Location/Qualifiers
FT Modified-site 46 /note= "potential phosphorylation site"
FT Modified-site 48 /note= "potential phosphorylation site"
FT Modified-site 48 /note= "potential phosphorylation site"
FT Modified-site 69 /note= "potential phosphorylation site"
FT Modified-site 102 /note= "potential phosphorylation site"
FT Modified-site 111 /note= "potential phosphorylation site"
FT Modified-site 126 /note= "potential glycosylation site"
FT Modified-site 171 /note= "potential phosphorylation site"
FT Modified-site 211 /note= "potential phosphorylation site"
FT Modified-site 264 /note= "potential phosphorylation site"
FT Modified-site 340 /note= "potential phosphorylation site"
FT Modified-site 342 /note= "potential phosphorylation site"
FT /note= "potential phosphorylation site"
XX W09961614-A2.
PD 02-DEC-1999.
```

XX PF 25-MAY-1999; 99WO-US11497.  
 XX PR 28-MAY-1998; 98US-0087104.  
 XX PR 17-DEC-1998; 98US-0216006.  
 XX PA (INCY-) INCYTE PHARM INC.  
 XX PI Lal P, Hillman JL, Gorgone G, Corley NC, Patterson C, Yue H;  
 XX PI Tang YT, Azimzai Y;  
 XX DR WPI; 2000-072621/06.  
 XX DR N-PSDB; AAZ36828.  
 XX PT New purified polypeptide encoding human suppressor of cytokine  
 XX PT signalling (SOCS) proteins useful for diagnosing, treating or preventing  
 XX PT disorders associated with human SOCS proteins  
 XX PS Claim 1; Page 75-76; 90pp; English.  
 XX CC The present sequence represents a human suppressor of cytokine signalling  
 CC (SOCS) protein, designated HSCOP-4. The protein is useful for treating  
 CC and/or preventing a disorder associated with decreased expression or  
 CC activity of HSCOP. The protein antagonist is useful for treating and/or  
 CC preventing a disorder associated with increased expression or activity  
 CC of HSCOP. The human SOCS proteins and polynucleotides encoding them are  
 CC useful in the diagnosis, treatment and prevention of cancer such as  
 CC leukaemia and lymphoma (especially e.g. cancers of the bone, heart and  
 CC skin), diabetes mellitus, Crohn's disease, immune disorders e.g. AIDS,  
 CC allergies and atherosclerosis, inflammatory disorders e.g. rheumatoid  
 CC arthritis, irritable bowel syndrome, multiple sclerosis and ulcerative  
 CC colitis, neurological disorders e.g. Down's syndrome, amnesia, cerebral  
 CC neoplasms and Huntington's disease and infectious diseases such as  
 CC those caused by viral infection e.g. adenoviruses (acute respiratory  
 CC disease) and toga viruses (rubella) as well as those caused by  
 CC bacterial, fungal, parasitic, protozoal and helminthic infections.  
 XX SQ Sequence 355 AA;

Query Match 50.6%; Score 39; DB 21; Length 355;  
 Best Local Similarity 53.8%; Pred. No. 26;  
 Matches 7; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

QY 1 CIGLAGTDFANQR 13  
 |||:| | | |  
 Db 239 c|gvaatk|gnkr 251

RESULT 13  
 AAW73012  
 ID AAW73012 standard; Protein; 462 AA.  
 XX AC AAW73012;  
 XX DT 02-FEB-1999 (first entry)  
 XX DE Cobra venom protease mocarhagin NM-3.  
 XX KW Mocarhagin; snake venom; Mozambiquan spitting cobra; protease;  
 KW inflammation; myocardial infarction; thrombosis; infection;  
 KW metastasis; therapy; NM-3.  
 XX OS Naja mossambica mossambica.  
 XX FH Key Location/Qualifiers  
 FT Peptide 1..61  
 FT /label= Pro\_peptide  
 FT Protein 62..462  
 FT /label= Mat\_protein  
 XX PN W09846771-A2.  
 XX XX

PD 22-OCT-1998.  
 XX PF 14-APR-1998; 98WO-US07998.  
 XX PR 18-FEB-1998; 98US-0026001.  
 XX PR 15-APR-1997; 97US-0843373.  
 XX PR 23-JAN-1998; 98US-0012637.  
 XX PA (GEMY ) GENETICS INST INC.  
 XX PI Boodhoo A, Sako D, Seehra JS, Shaw G;  
 XX PI WPI; 1998-568735/48.  
 XX DR N-PSDB; AAV07900.  
 XX PT Isolated mocarhagin cobra venom protease, and nucleic acids encoding  
 XX PT it - used to develop products for treating e.g. myocardial  
 XX PT infarction, thrombosis, bacterial or viral infection, metastatic  
 XX PT conditions or inflammatory disorders  
 XX PS Claim 70; Page 61-63; 97pp; English.  
 XX CC This is the amino acid sequence of mocarhagin NM-3, a highly  
 CC specific metalloproteinase from the venom of the Mozambiquan  
 CC spitting cobra. The invention provides mocarhagin polypeptides  
 CC (see AAW73007-13) and polynucleotides (see AAV07895-901) encoding them,  
 CC as well as host cells and methods of producing the (especially  
 CC mature) polypeptides. Mocarhagin proteins are capable of cleaving  
 CC anionic polypeptide containing sulphated tyrosine residues.  
 CC P-selectin glycoprotein (GP) ligand-1 (PSGL-1) and Gp1b-alpha  
 CC (claimed). They also inhibit neutrophil/HL60 binding, inhibit  
 CC platelet binding to von Willebrand factor, require Ca2+ and Zn2+  
 CC ions for activity and have activity inhibited by excess EDTA or  
 CC high concentrations of DTP (claimed). They can be used to inhibit  
 CC selectin-mediated binding and to treat inflammatory disease  
 CC (claimed). In particular, they can be used to treat e.g. myocardial  
 CC infarction, vessel restenosis, thrombosis, bacterial or viral  
 CC infection, metastatic conditions, inflammatory disorders such as  
 CC arthritis, acute respiratory distress syndrome, asthma, emphysema,  
 CC delayed type hypersensitivity reaction, systemic lupus  
 CC erythematosus, thermal injury such as burns or frostbite,  
 CC autoimmune thyroiditis, experimental allergic encephalomyelitis,  
 CC multiple sclerosis, multiple organ injury syndrome secondary to  
 CC trauma, diabetes, Reynaud's syndrome, neutrophilic dermatosis  
 CC (Sweet's syndrome), inflammatory bowel disease, Grave's disease,  
 CC glomerulonephritis, gingivitis, periodontitis, haemolytic uremic  
 CC syndrome, ulcerative colitis, Crohn's disease, necrotising  
 CC enterocolitis, granulocyte transfusion associated syndrome,  
 CC cytokine-induced enterocolitis, granulocyte transfusion associated  
 CC syndrome, or cytokine-induced toxicity. Mocarhagin protein may  
 CC also be useful in organ transplantation, both to prepare organs for  
 CC transplantation and to quell organ transplant rejection, to treat  
 CC haemodialysis and leukophoresis patients, or as an inhibitor of P-  
 CC or E-selectin-mediated intercellular adhesion.

Sequence 462 AA;

Query Match 50.6%; Score 39; DB 19; Length 462;  
 Best Local Similarity 77.8%; Pred. No. 35;  
 Matches 7; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 CIGLAGTDF 9  
 || | |||  
 Db 369 cialmgtdf 377

RESULT 14  
 AAE06222  
 ID AAE06222 standard; Protein; 496 AA.  
 XX AC AAE06222;  
 XX XX

DT 25-SEP-2001 (first entry)  
XX Booroola sheep mutant BMP1B receptor.  
XX  
XX Bone morphogenetic protein 1B receptor; BMP1B receptor; ovulation;  
KW FeCB; fecundity; fertility; Booroola; contraceptive; mutant; mutein;  
KW transforming growth factor-beta family; chromosome 6; sheep.  
KW  
XX Ovis aries.  
XX  
XX Key Location/Qualifiers  
FH Domain 127..148  
FT /label= Membrane\_spanning\_domain  
FT Domain 203..496  
FT /label= Intracellular\_kinase\_domain  
FT Misc-difference 249  
FT /note= "Wild type Gln is substituted with Arg"  
XX  
XX WO200148204-A1.  
XX  
XX 05-JUL-2001.  
XX  
XX 22-DEC-2000; 2000WO-NF00259.  
XX  
XX 23-DEC-1999; 99NZ-0502058.  
XX (AGRE-) AGRESEARCH LTD.  
XX  
XX Wilson TM, Wu X;  
PI  
XX WPI; 2001-441717/47.  
DR N-PSDB; AAD11872.  
XX  
XX Novel isolated bone morphogenetic protein 1B receptor polypeptide  
PT useful for modulating the ovulation rate of a female vertebrate -  
PT  
XX  
XX Claim 12; Page 50-52; 53pp; English.  
XX  
XX The invention relates to a bone morphogenetic protein 1B (BMP1B)  
CC receptor polypeptide comprising a sequence which differs from that  
CC of the wild type in that residue 249 is arginine and not glutamine,  
CC or a sequence in which residue 249 is glutamine, but which is otherwise  
CC different from the wild type BMP1B polypeptide sequence and which has  
CC the ability to modulate ovulation in a female mammal. Mutation in  
CC the BMP1B receptor gene is responsible for increased ovulation rate  
CC in sheep derived from Booroola Merino strain that carry an autosomal  
CC mutation in FeCB/Booroola gene. The FeCB gene is mapped to chromosome 6.  
CC The BMP1B receptor of the invention and the polynucleotide encoding  
CC it are useful for modulating the ovulation rate of a female vertebrate.  
CC Identification of mutated BMP1B receptor nucleic acid molecule in a  
CC vertebrate, is useful for assessing fecundity in vertebrate such as  
CC humans and other commercially important mammals and birds including  
CC sheep, cattle, horses, goats, deer, pigs, cats, dogs, possums, and  
CC poultry. The polypeptide is useful to raise antibodies and for reducing  
CC unwanted populations of feral vertebrates. The polynucleotide is useful  
CC for identifying sequence variants in individual animals that are  
CC associated with increased ovulation. The present sequence is mutant  
CC BMP1B receptor from Booroola sheep. The present sequence is a  
CC member of transforming growth factor-beta family.  
XX  
XX Sequence 496 AA;

Query Match 50.6%; Score 39; DB 22; Length 496;  
Best Local Similarity 66.7%; Pred. No. 38;  
Matches 6; Conservative 2; Mismatches 1; Indels 0; Gaps 0;  
QY 1 CIGLAGTDF 9  
Db 71 ciglegsdff 79

RESULT 15

AAR55374  
ID AAR55374 standard; Protein; 502 AA.  
XX  
XX AAR55374;  
XX  
XX 20-JAN-1995 (first entry)  
DT  
XX Mouse Activin receptor-like kinase 6 (mALK-6).  
DE  
XX serine threonine kinases; activin receptors; Act-R; superfamily;  
KW transforming growth factor; TGF; diagnostics; detection; therapy;  
KW rheumatoid arthritis; glomerular nephritis; fibrosis.  
XX  
XX Mus musculus.  
XX  
XX WO9411502-A.  
PN  
XX 26-MAY-1994.  
PD  
XX 17-NOV-1993; 93WO-GB02367.  
XX  
XX 17-NOV-1992; 92GB-0024057.  
PR 08-MAR-1993; 93GB-0004677.  
PR 08-MAR-1993; 93GB-0004680.  
PR 28-MAY-1993; 93GB-0011047.  
PR 02-JUL-1993; 93GB-0013763.  
PR 03-AUG-1993; 93GB-0016099.  
PR 15-OCT-1993; 93GB-0021344.  
XX  
XX (LUDW-) LUDWIG INST CANCER RES.  
XX  
XX Dijke P, Franzen P, Heidin C, Miyazono K, Yamashita H;  
PI  
XX WPI; 1994-183503/22.  
DR N-PSDB; AAQ56642.  
XX  
XX Activin receptor-like kinase(s) with serine/threonine kinase  
PT domains - have activin/TGF beta-type I receptor function and can  
PT be used in diagnosis or therapy of rheumatoid arthritis,  
PT glomerular nephritis, fibrosis, etc.  
XX  
XX Claim 3; Page 75-77; 97pp; English.  
PS  
XX The inventors have identified a new family of receptor kinases  
CC called activin receptor-like kinases (ALK). Their discovery was  
CC based on the realisation that receptor serine/threonine kinases  
CC form a new receptor family, which may include the type II receptors  
CC for other proteins in the transforming growth factor(TGF) beta  
CC superfamily. The activin receptor type II sequences from mouse and  
CC the dafI gene product of C.elegans have high sequence similarity  
CC and were used to design degenerate primers to clone related cDNA's  
CC (see AA066643-49). Six distinct putative receptor serine/threonine  
CC kinases were identified, called ALK (human ALK proteins are shown  
CC in AAR55366-70, mouse ALK are shown in AAR55371-74). Products of the  
CC invention can be used in therapy, eg. to modulate conditions  
CC associated with activin or TGF beta activity. These conditions  
CC include fibrosis, eg. liver cirrhosis and pulmonary fibrosis, cancer,  
CC rheumatoid arthritis and glomeronephritis.  
XX  
XX Sequence 502 AA;

Query Match 50.6%; Score 39; DB 15; Length 502;  
Best Local Similarity 66.7%; Pred. No. 39;  
Matches 6; Conservative 2; Mismatches 1; Indels 0; Gaps 0;  
QY 1 CIGLAGTDF 9  
Db 71 ciglegsdff 79

Search completed: March 26, 2002, 13:38:48

us-09-709-201-100.rag

Tue Mar 26 15:55:28 2002

Job time: 142 sec

1 1 1 1 1

GenCore version 4.5  
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: March 26, 2002, 13:41:28 ; Search time 37.72 Seconds  
(without alignments)  
8.352 Million cell updates/sec

Title: US-09-709-201-100  
Perfect score: 77  
Sequence: 1 CIGLAGTDFANQRP 14

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 212252 seqs, 22503292 residues

Total number of hits satisfying chosen parameters: 212252

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : Issued\_Patents\_AA:\*  
1: /cgn2\_6/ptodata/2/iaa/5A\_COMB.pep.\*  
2: /cgn2\_6/ptodata/2/iaa/5B\_COMB.pep.\*  
3: /cgn2\_6/ptodata/2/iaa/6A\_COMB.pep.\*  
4: /cgn2\_6/ptodata/2/iaa/6B\_COMB.pep.\*  
5: /cgn2\_6/ptodata/2/iaa/PCTUS\_COMB.pep.\*  
6: /cgn2\_6/ptodata/2/iaa/backfiles1.pep.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	DB ID	Description
1	40	51.9	98	6	Patent No. 5459046
2	39	50.6	502	2	US-08-481-337A-8
3	39	50.6	502	4	US-09-382-256-18
4	39	50.6	502	4	US-09-395-115-18
5	39	50.6	502	4	US-08-123-934A-4
6	39	50.6	502	4	US-08-334-179A-14
7	39	50.6	502	5	PCT-US94-10080-4
8	39	50.6	502	5	PCT-US95-05467-8
9	36.5	47.4	358	1	US-08-034-650-10
10	36.5	47.4	358	1	US-08-449-015-10
11	36	46.8	309	2	US-08-849-480A-6
12	36	46.8	1580	2	US-08-804-227C-11
13	36	46.8	1580	2	US-08-804-198-5
14	35	45.5	672	1	US-07-841-651-2
15	35	45.5	672	1	US-07-841-651-3
16	35	45.5	1612	1	US-08-169-927-2
17	34	44.2	176	1	US-08-145-995A-3
18	34	44.2	176	2	US-08-451-747-3
19	34	44.2	176	3	US-09-134-852-3
20	34	44.2	269	4	US-09-028-366-6
21	34	44.2	570	2	US-08-484-993B-16
22	34	44.2	570	2	US-08-484-158B-16
23	34	44.2	570	2	US-08-484-596A-16
24	34	44.2	570	2	US-08-480-150A-16
25	34	44.2	570	3	US-08-458-731-16
26	34	44.2	570	3	US-08-149-223A-16
27	34	44.2	591	1	US-08-145-995A-21

28	34	44.2	591	2	US-08-451-747-21	Sequence 21, Appl
29	34	44.2	591	3	US-09-134-852-21	Sequence 21, Appl
30	34	44.2	659	4	US-09-189-462-4	Sequence 4, Appl
31	33	42.9	526	3	US-08-504-878A-2	Sequence 2, Appl
32	33	42.9	956	3	US-08-772-270A-8	Sequence 8, Appl
33	33	42.9	1127	4	US-08-937-195-3	Sequence 3, Appl
34	33	42.9	1127	4	US-08-915-152-3	Sequence 3, Appl
35	33	42.9	1127	5	PCT-US96-07627-3	Sequence 3, Appl
36	32	41.6	18	2	US-07-876-941A-29	Sequence 29, Appl
37	32	41.6	18	3	US-08-293-728-20	Sequence 20, Appl
38	32	41.6	18	4	US-09-421-868-20	Sequence 20, Appl
39	32	41.6	157	1	US-08-450-065-2	Sequence 2, Appl
40	32	41.6	157	1	US-08-450-595-2	Sequence 2, Appl
41	32	41.6	235	1	US-08-015-985-13	Sequence 13, Appl
42	32	41.6	252	2	US-08-685-992-33	Sequence 33, Appl
43	32	41.6	252	2	US-09-144-925-33	Sequence 33, Appl
44	32	41.6	255	1	US-08-459-264-4	Sequence 4, Appl
45	32	41.6	255	1	US-08-459-263-4	Sequence 4, Appl

ALIGNMENTS

RESULT 1  
5459046-6  
; Patent No. 5459046  
; APPLICANT: KODAMA, TOHRU;IGARASHI, YASUO  
; TITLE OF INVENTION: CYTOCHROME C GENE DERIVED FROM HYDROGEN  
; BACTERIUM  
; NUMBER OF SEQUENCES: 17  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/07/943,140  
; FILING DATE: 10-SEP-1992  
; PRIOR APPLICATION DATA:486,409  
; APPLICATION NUMBER: 28-FEB-1990  
; SEQ ID NO:6:  
; LENGTH: 98  
5459046-6

Query Match 51.9%; Score 40; DB 6; Length 98;  
Best Local Similarity 58.3%; Pred. No. 2.5;  
Matches 7; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 2 IGLAGTDFANQRP 13  
Db 10 VGLAGTDFANQ 21  
:|||||:|:|:|

RESULT 2  
US-08-481-337A-8  
; Sequence 8, Application US/08481337A  
; Patent No. 5863738  
; GENERAL INFORMATION:  
; APPLICANT: TEN DIJKE, Peter  
; APPLICANT: HELDIN, Carl-Henrik  
; APPLICANT: MIYAZONO, Kohei  
; APPLICANT: SAMPATH, Kuber T.  
; TITLE OF INVENTION: Morphogenic Protein-Specific Cell  
; TITLE OF INVENTION: Surface Receptors and Uses Therefor  
; NUMBER OF SEQUENCES: 18  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Testa, Hurwitz & Thibault  
; STREET: 125 High St.  
; CITY: Boston  
; STATE: MA  
; COUNTRY: USA  
; ZIP: 02110.  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30

;; CURRENT APPLICATION DATA:  
;; APPLICATION NUMBER: US/08/481,337A  
;; FILING DATE: 02-JUN-1995  
;; CLASSIFICATION: 435  
;; ATTORNEY/AGENT INFORMATION:  
;; NAME: MEYERS, Thomas C.  
;; REGISTRATION NUMBER: 36,989  
;; REFERENCE/DOCKET NUMBER: CRP-097CP2  
;; TELECOMMUNICATION INFORMATION:  
;; TELEPHONE: (617) 248-7000  
;; TELEFAX: (617) 248-7100  
;; INFORMATION FOR SEQ ID NO: 8:  
;; SEQUENCE CHARACTERISTICS:  
;; LENGTH: 502 amino acids  
;; TYPE: amino acid  
;; TOPOLOGY: linear  
;; MOLECULE TYPE: protein  
;; US-08-481-337A-8

Query Match 50.6%; Score 39; DB 2; Length 502;  
Best Local Similarity 66.7%; Pred. No. 24;  
Matches 6; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1 CIGLAGTDF 9  
Db 71 CLGLEGSDF 79

## RESULT 3

US-09-382-256-18  
; Sequence 18, Application US/09382256A  
; Patent No. 6207814  
; GENERAL INFORMATION:  
; APPLICANT: MIYAZONO, Kohei  
; TEN DIJKE, Peter  
; FRANZEN, Petra  
; YAMASHITA, Hidetoshi  
; HELDIN, Carl-Henrik  
; TITLE OF INVENTION: ACTIVIN RECEPTOR LIKE KINASES, PROTEINS  
; HAVING SERINE THREONINE KINASE DOMAINS,  
; AND THEIR USE  
; NUMBER OF SEQUENCES: 29  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Fulbright & Jaworski L.L.P.  
; STREET: 666 Fifth Avenue  
; CITY: New York City  
; STATE: New York  
; COUNTRY: USA  
; ZIP: 10103  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Diskette, 3.25 inch, 1.44mb  
; COMPUTER: IBM PS/2  
; OPERATING SYSTEM: PC-DOS  
; SOFTWARE: Wordperfect  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/382,256A  
; FILING DATE: 24-Aug-1999  
; CLASSIFICATION: 514  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: PCT/GB93/02367  
; FILING DATE: No. 6207814ember 17, 1993  
; APPLICATION NUMBER: GB 9224057.1  
; FILING DATE: No. 6207814ember 17, 1992  
; APPLICATION NUMBER: GB 9304677.9  
; FILING DATE: March 8, 1993  
; APPLICATION NUMBER: GB 9304680.3  
; FILING DATE: March 8, 1993  
; APPLICATION NUMBER: 9311047.6  
; FILING DATE: May 28, 1993  
; APPLICATION NUMBER: 9313763.6  
; FILING DATE: July 2, 1993  
; APPLICATION NUMBER: 9316099.2

;; FILING DATE: August 3, 1993  
;; APPLICATION NUMBER: 321344.5  
;; FILING DATE: October 15, 1993  
;; ATTORNEY/AGENT INFORMATION:  
;; NAME: No. 6207814man D. Hanson  
;; REGISTRATION NUMBER: 30,946  
;; REFERENCE/DOCKET NUMBER: LUD 5298.1  
;; TELECOMMUNICATION INFORMATION:  
;; TELEPHONE: (212) 318-3000  
;; TELEFAX: (212) 752-5958  
;; INFORMATION FOR SEQ ID NO: 18:  
;; SEQUENCE CHARACTERISTICS:  
;; LENGTH: 502 amino acids  
;; TYPE: amino acid  
;; TOPOLOGY: linear  
;; MOLECULE TYPE: protein  
;; SEQUENCE DESCRIPTION: SEQ ID NO: 18:  
;; US-09-382-256-18

Query Match 50.6%; Score 39; DB 4; Length 502;  
Best Local Similarity 66.7%; Pred. No. 24;  
Matches 6; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1 CIGLAGTDF 9  
Db 71 CLGLEGSDF 79

## RESULT 4

US-09-395-115-18  
; Sequence 18, Application US/09395115  
; Patent No. 6271365  
; GENERAL INFORMATION:  
; APPLICANT: Miyazono, Kohei; Dijke, Peter Ten;  
; APPLICANT: Franzen, Petra; Yamashita, Hidetoshi;  
; TITLE OF INVENTION: Activin Receptor-Like Kinase, Proteins  
; NUMBER OF SEQUENCES: 29  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Felfe & Lynch  
; STREET: 805 Third Avenue  
; CITY: New York City  
; STATE: New York  
; ZIP: 10022  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Diskette, 3.5 inch, 360 kb storage  
; COMPUTER: IBM  
; OPERATING SYSTEM: PC-DOS  
; SOFTWARE: Wordperfect  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/395,115  
; FILING DATE:  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US/08/436,265  
; FILING DATE: 30-October-1995  
; APPLICATION NUMBER: PCT/GB93/02367  
; FILING DATE: 17-No. 6271365ember-1993  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 9224057.1  
; FILING DATE: 17-No. 6271365ember-1992  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 9304677.9  
; FILING DATE: 8-March-1993  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 9304680.3  
; FILING DATE: 8-March-1993  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 9311047.6  
; FILING DATE: 28-May-1993  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 9313763.6

Query Match 50.6%; Score 39; DB 4; Length 502;  
Best Local Similarity 66.7%; Pred. No. 24;  
Matches 6; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1 CIGLAGTDF 9  
Db 71 CLGLEGSDF 79

RESULT 5  
US-08-123-934A-4  
; Sequence 4, Application US/08123934A  
; Patent No. 6291206  
; GENERAL INFORMATION:  
; APPLICANT: WOZNEY, John  
; APPLICANT: CELESTE, Anthony J.  
; APPLICANT: THIES, R. Scott  
; APPLICANT: YAMAJI, No. 6291206oru  
; TITLE OF INVENTION: RECEPTOR PROTEINS  
; NUMBER OF SEQUENCES: 19  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Genetics Institute Inc. - Legal Affairs  
; STREET: 87 CambridgePark Drive  
; CITY: Cambridge  
; STATE: MA  
; COUNTRY: USA  
; ZIP: 02140  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/123,934A  
; FILING DATE: 17-SEP-1993  
; CLASSIFICATION: 530  
; ATTORNEY/AGENT INFORMATION:  
; NAME: LAZAR, Steven R  
; REGISTRATION NUMBER: 32,618  
; REFERENCE/DOCKET NUMBER: 5203  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 617 876 1170  
; TELEFAX: 617 876 5851  
; INFORMATION FOR SEQ ID NO: 4:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 502 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
US-09-395-115-18

Query Match 50.6%; Score 39; DB 4; Length 502;  
Best Local Similarity 66.7%; Pred. No. 24;  
Matches 6; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1 CIGLAGTDF 9  
Db 71 CLGLEGSDF 79

RESULT 5  
US-08-123-934A-4  
; Sequence 4, Application US/08123934A  
; Patent No. 6291206  
; GENERAL INFORMATION:  
; APPLICANT: WOZNEY, John  
; APPLICANT: CELESTE, Anthony J.  
; APPLICANT: THIES, R. Scott  
; APPLICANT: YAMAJI, No. 6291206oru  
; TITLE OF INVENTION: RECEPTOR PROTEINS  
; NUMBER OF SEQUENCES: 19  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Genetics Institute Inc. - Legal Affairs  
; STREET: 87 CambridgePark Drive  
; CITY: Cambridge  
; STATE: MA  
; COUNTRY: USA  
; ZIP: 02140  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/123,934A  
; FILING DATE: 17-SEP-1993  
; CLASSIFICATION: 530  
; ATTORNEY/AGENT INFORMATION:  
; NAME: LAZAR, Steven R  
; REGISTRATION NUMBER: 32,618  
; REFERENCE/DOCKET NUMBER: 5203  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 617 876 1170  
; TELEFAX: 617 876 5851  
; INFORMATION FOR SEQ ID NO: 4:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 502 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
US-08-123-934A-4

Query Match 50.6%; Score 39; DB 4; Length 502;  
Best Local Similarity 66.7%; Pred. No. 24;  
Matches 6; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1 CIGLAGTDF 9  
Db 71 CLGLEGSDF 79

RESULT 6  
US-08-334-179A-14  
; Sequence 14, Application US/08334179A  
; Patent No. 6306622  
; GENERAL INFORMATION:  
; APPLICANT: ROSENBAUM, JAN S.  
; APPLICANT: NOHNO, TSUTOMU  
; TITLE OF INVENTION: CDNA ENCODING A BMP TYPE II RECEPTOR  
; NUMBER OF SEQUENCES: 14  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: THE PROCTER AND GAMBLE COMPANY  
; STREET: 11810 EAST MIAMI RIVER ROAD  
; CITY: ROSS  
; STATE: OH  
; COUNTRY: US  
; ZIP: 45061  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.30, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/334,179A  
; FILING DATE: 04-NOV-1994  
; CLASSIFICATION: 435  
; ATTORNEY/AGENT INFORMATION:  
; NAME: CORSTANJE, BRAHM J.  
; REGISTRATION NUMBER: 34,804  
; REFERENCE/DOCKET NUMBER: 5473  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 513-627-2858  
; TELEFAX: 513-627-0260  
; INFORMATION FOR SEQ ID NO: 14:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 502 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
US-08-334-179A-14

Query Match 50.6%; Score 39; DB 4; Length 502;  
Best Local Similarity 66.7%; Pred. No. 24;  
Matches 6; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1 CIGLAGTDF 9  
Db 71 CLGLEGSDF 79

RESULT 7  
PCT-US94-10080-4  
; Sequence 4, Application PC/TUS9410080  
; GENERAL INFORMATION:  
; APPLICANT: GENETICS INSTITUTE, INC.  
; TITLE OF INVENTION: RECEPTOR PROTEINS  
; NUMBER OF SEQUENCES: 19  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Genetics Institute Inc. - Legal Affairs  
; STREET: 87 CambridgePark Drive  
; CITY: Cambridge  
; STATE: MA

; COUNTRY: USA  
; ZIP: 02140  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: PCT/US94/10080  
; FILING DATE: HEREWITH  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/123,934  
; FILING DATE: 17-SEP-1993  
; CLASSIFICATION:  
; ATTORNEY/AGENT INFORMATION:  
; NAME: LAZAR, Steven R  
; REGISTRATION NUMBER: 32,618  
; REFERENCE/DOCKET NUMBER: 5203-PCT  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (617) 498-8260  
; TELEFAX: (617) 876-5851  
; INFORMATION FOR SEQ ID NO: 4:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 502 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
; PCT-US94-10080-4

Query Match 50.6%; Score 39; DB 5; Length 502;  
Best Local Similarity 66.7%; Pred. No. 24;  
Matches 6; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1 CIGLAGTDF 9  
Db 71 CLGLEGSDF 79

RESULT 8  
PCT-US95-05467-8  
; Sequence 8, Application PC/TUS9505467  
; GENERAL INFORMATION:  
; APPLICANT:  
; APPLICANT:  
; TITLE OF INVENTION: MORPHOGENIC PROTEIN-SPECIFIC CELL  
; SURFACE RECEPTORS AND USES THEREFOR  
; NUMBER OF SEQUENCES: 15  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: PATENT ADMINISTRATOR, TESTA, HURWITZ &  
; ADDRESSEE: THIBEAULT  
; STREET: 53 STATE STREET  
; CITY: BOSTON  
; STATE: MA  
; COUNTRY: USA  
; ZIP: 02109  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: PCT/US95/05467  
; FILING DATE:  
; CLASSIFICATION:  
; ATTORNEY/AGENT INFORMATION:  
; NAME: PITCHER, EDMUND R.  
; REGISTRATION NUMBER: 27,829  
; REFERENCE/DOCKET NUMBER: CRP-097PC  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (617) 248-7000  
; TELEFAX: (617) 248-7100

; INFORMATION FOR SEQ ID NO: 8:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 502 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
; PCT-US95-05467-8

Query Match 50.6%; Score 39; DB 5; Length 502;  
Best Local Similarity 66.7%; Pred. No. 24;  
Matches 6; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1 CIGLAGTDF 9  
Db 71 CLGLEGSDF 79

RESULT 9  
US-08-034-650-10  
; Sequence 10, Application US/08034650  
; Patent No. 5641671  
; GENERAL INFORMATION:  
; APPLICANT: BOS, Jannetje W.  
; APPLICANT: FRENKEN, Leon G.  
; APPLICANT: VERIPS, Cornelis T.  
; APPLICANT: VISSER, Christiaan  
; TITLE OF INVENTION: PRODUCTION OF ACTIVE PSEUDOMONAS GLUMAE  
; TITLE OF INVENTION: LIPASE IN HOMOLOGOUS OR HETEROLOGOUS HOSTS  
; NUMBER OF SEQUENCES: 13  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: CUSHMAN, DARBY & CUSHMAN  
; STREET: 1615 L. Street, N.W.  
; CITY: Washington  
; STATE: D.C.  
; COUNTRY: USA  
; ZIP: 20036-5601  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/034,650  
; FILING DATE:  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/727,235  
; FILING DATE: 03-JUL-1991  
; ATTORNEY/AGENT INFORMATION:  
; NAME: KOKULLIS, Paul N.  
; REGISTRATION NUMBER: 16,773  
; REFERENCE/DOCKET NUMBER: PNK/5970/91731  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (202) 861-3000  
; TELEFAX: (202) 822-0944  
; TELEX: 6714627 CUSH  
; INFORMATION FOR SEQ ID NO: 10:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 358 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
; US-08-034-650-10

Query Match 47.4%; Score 36.5; DB 1; Length 358;  
Best Local Similarity 90.0%; Pred. No. 48;  
Matches 9; Conservative 0; Mismatches 0; Indels 1; Gaps 1;

QY 3 GLAGTD-FAN 11  
Db 55 GLAGTDKFN 64



RESULT 10  
US-08-449-015-10  
; Sequence 10, Application US/08449015  
; Patent No. 5804409  
; GENERAL INFORMATION:  
; APPLICANT: BOS, Jannetje W.  
; APPLICANT: FRENKEN, Leon G.  
; APPLICANT: VERRIPS, Cornelis T.  
; APPLICANT: VISSER, Christiaan  
; TITLE OF INVENTION: PRODUCTION OF ACTIVE PSEUDOMONAS GLUMAE  
; TITLE OF INVENTION: LIPASE IN HOMOLOGOUS OR HETEROLOGOUS HOSTS  
; NUMBER OF SEQUENCES: 13  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: CUSHMAN, DARBY & CUSHMAN  
; STREET: 1615 L. Street, N.W.  
; CITY: Washington  
; STATE: D.C.  
; COUNTRY: USA  
; ZIP: 20036-5601  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/449,015  
; FILING DATE: 24-MAY-1995  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/727,235  
; FILING DATE: 03-JUL-1991  
; ATTORNEY/AGENT INFORMATION:  
; NAME: KOKULIS, Paul N.  
; REGISTRATION NUMBER: 16,773  
; REFERENCE/DOCKET NUMBER: PNK/5970/91731  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (202) 861-3000  
; TELEFAX: (202) 822-0944  
; TELEX: 6714627 CUSH  
; INFORMATION FOR SEQ ID NO: 10:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 358 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
; US-08-449-015-10

Query Match 47.4%; Score 36.5; DB 1; Length 358;  
Best Local Similarity 90.0%; Pred. No. 48;  
Matches 9; Conservative 0; Mismatches 0; Indels 1; Gaps 1;

QY 3 GLAGTD-FAN 11  
| | | | | | | |  
Db 55 GLAGTDKFN 64

RESULT 11  
US-08-849-480A-6  
; Sequence 6, Application US/08849480A  
; Patent No. 5981184  
; GENERAL INFORMATION:  
; APPLICANT: MELCHERS, Klaus  
; TITLE OF INVENTION: SCREENING MODEL  
; NUMBER OF SEQUENCES: 24  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: JACOBSON, PRICE, HOLMAN & STERN, PLLC  
; STREET: 400 - 7th Street, N. W.  
; CITY: Washington  
; STATE: D.C.  
; COUNTRY: USA

ZIP: 20004  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/849,480A  
; FILING DATE: 02-JUN-1997  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: PCT/EP95/04711  
; FILING DATE: 30-NOV-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: DE P4442970.3  
; FILING DATE: 02-DEC-1994  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: DE 19505645.0  
; FILING DATE: 18-FEB-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: AISENBERG, Irwin M.  
; REGISTRATION NUMBER: 19,007  
; REFERENCE/DOCKET NUMBER: 8125/P60984US0  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 202/638-6666  
; TELEFAX: 202/393-5350  
; INFORMATION FOR SEQ ID NO: 6:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 309 amino acids  
; TYPE: amino acid  
; STRANDEDNESS:  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
; HYPOTHEICAL: YES  
; FRAGMENT TYPE: C-terminal  
; ORIGINAL SOURCE:  
; ORGANISM: Helicobacter pylori  
; STRAIN: Helicobacter pylori 69A  
; INDIVIDUAL ISOLATE: Clinical isolate 69A  
; IMMEDIATE SOURCE:  
; LIBRARY: Helicobacter 69A - gene library in vector  
; LIBRARY: PRH160  
; CLONE: PRH948  
; US-08-849-480A-6

Query Match 46.8%; Score 36; DB 2; Length 309;  
Best Local Similarity 77.8%; Pred. No. 50;  
Matches 7; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3 GLAGTD-FAN 11  
| | | | | | | |  
Db 52 GLAGADLAN 60

RESULT 12  
US-08-804-227C-11  
; Sequence 11, Application US/08804227C  
; Patent No. 5876991  
; GENERAL INFORMATION:  
; APPLICANT: DeHoff, Bradley S.  
; APPLICANT: Kuhstoss, Stuart A.  
; APPLICANT: Rostock, Paul R., Jr.  
; APPLICANT: Sutton, Kimberly L.  
; TITLE OF INVENTION: POLYKETIDE SYNTHASE GENES  
; NUMBER OF SEQUENCES: 15  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: THOMAS G. PLANT 1501  
; STREET: LILLY CORPORATE CENTER  
; CITY: INDIANAPOLIS  
; STATE: IN  
; COUNTRY: USA  
; ZIP: 46285

COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: MS-DOS  
SOFTWARE: ASCII(DOS) Text only  
CURRENT APPLICATION DATA:  
FILING DATE: February 21, 1997  
CLASSIFICATION: 435  
ATTORNEY/AGENT INFORMATION:  
NAME: Plant, Thomas, G.  
REGISTRATION NUMBER: 35,784  
REFERENCE/DOCKET NUMBER: X-8231  
TELEPHONE: 317-276-2459  
INFORMATION FOR SEQ ID NO: 11:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 1580 amino acids  
TYPE: amino acid  
TOPOLOGY: unknown  
MOLECULE TYPE: peptide  
US-08-804-227C-11

Query Match 46.8%; Score 36; DB 2; Length 1580;  
Best Local Similarity 63.6%; Pred. No. 3.1e+02;  
Matches 7; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 4 LAGTDFANQRP 14  
Db 752 LAGVDFAGHSP 762

RESULT 13  
US-08-804-198-5  
Sequence 5, Application US/08804198  
Patent No. 5945320  
GENERAL INFORMATION:  
APPLICANT: Burgett, Stanley G.  
APPLICANT: Kuhstoss, Stuart A.  
APPLICANT: Rao, Nagaraja R.  
APPLICANT: Richardson, Mark A.  
TITLE OF INVENTION: PLATENOLIDE SYNTHASE GENE  
NUMBER OF SEQUENCES: 6  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: PAUL R. CANTRELL 1138  
STREET: LILLY CORPORATE CENTER  
CITY: INDIANAPOLIS  
STATE: IN  
COUNTRY: USA  
ZIP: 46285

COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: Macintosh  
OPERATING SYSTEM: Macintosh 7.0  
SOFTWARE: Microsoft Word 5.1  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/804,198  
FILING DATE:  
CLASSIFICATION: 435  
ATTORNEY/AGENT INFORMATION:  
NAME: CANTRELL, PAUL R.  
REGISTRATION NUMBER: 36,470  
REFERENCE/DOCKET NUMBER: P9113  
TELEPHONE: 317-276-3885  
INFORMATION FOR SEQ ID NO: 5:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 1580 amino acids  
TYPE: amino acid  
TOPOLOGY: unknown  
MOLECULE TYPE: peptide

US-08-804-198-5

Query Match 46.8%; Score 36; DB 2; Length 1580;  
Best Local Similarity 63.6%; Pred. No. 3.1e+02;  
Matches 7; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 4 LAGTDFANQRP 14  
Db 752 LAGVDFAGHSP 762

RESULT 14  
US-07-841-651-2  
Sequence 2, Application US/07841651  
Patent No. 5410031  
GENERAL INFORMATION:  
APPLICANT: Pajor, Ana M  
APPLICANT: Wright, Ernest M  
TITLE OF INVENTION: Cloning and Functional Expression of a  
TITLE OF INVENTION: Mammalian Na+/Nucleoside Cotransporter: A Member of the  
TITLE OF INVENTION: SGLT Family  
NUMBER OF SEQUENCES: 4  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Sheldon & Mak  
STREET: 225 South Lake Avenue, Ninth Floor  
CITY: Pasadena  
STATE: California  
COUNTRY: USA  
ZIP: 91101

COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/07/841,651  
FILING DATE: 19920224  
CLASSIFICATION: 435  
ATTORNEY/AGENT INFORMATION:  
NAME: Mandel, Saralynn  
REGISTRATION NUMBER: 31,853  
REFERENCE/DOCKET NUMBER: 8772  
TELEPHONE: (818) 796-4000  
TELEFAX: (818) 795-6321  
INFORMATION FOR SEQ ID NO: 2:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 672 amino acids  
TYPE: AMINO ACID  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
US-07-841-651-2

Query Match 45.5%; Score 35; DB 1; Length 672;  
Best Local Similarity 70.0%; Pred. No. 1.8e+02;  
Matches 7; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 2 IGLAGTDFAN 11  
Db 82 VGLAGTGAAN 91

RESULT 15  
US-07-841-651-3  
Sequence 3, Application US/07841651  
Patent No. 5410031  
GENERAL INFORMATION:  
APPLICANT: Pajor, Ana M  
APPLICANT: Wright, Ernest M  
TITLE OF INVENTION: Cloning and Functional Expression of a  
TITLE OF INVENTION: Mammalian Na+/Nucleoside Cotransporter: A Member of the

;; TITLE OF INVENTION: SGLT Family  
;; NUMBER OF SEQUENCES: 4  
;; CORRESPONDENCE ADDRESS:  
;; ADDRESSEE: Sheldon & Mak  
;; STREET: 225 South Lake Avenue, Ninth Floor  
;; CITY: Pasadena  
;; STATE: California  
;; COUNTRY: USA  
;; ZIP: 91101  
;; COMPUTER READABLE FORM:  
;; MEDIUM TYPE: Floppy disk  
;; COMPUTER: IBM PC compatible  
;; OPERATING SYSTEM: PC-DOS/MS-DOS  
;; SOFTWARE: PatentIn Release #1.0, Version #1.25  
;; CURRENT APPLICATION DATA:  
;; APPLICATION NUMBER: US/07/841,651  
;; FILING DATE: 19920224  
;; CLASSIFICATION: 435  
;; ATTORNEY/AGENT INFORMATION:  
;; NAME: Mandel, Saralynn  
;; REGISTRATION NUMBER: 31,853  
;; REFERENCE/DOCKET NUMBER: 8772  
;; TELECOMMUNICATION INFORMATION:  
;; TELEPHONE: (818) 796-4000  
;; TELEFAX: (818) 795-6321  
;; INFORMATION FOR SEQ ID NO: 3:  
;; SEQUENCE CHARACTERISTICS:  
;; LENGTH: 672 amino acids  
;; TYPE: AMINO ACID  
;; TOPOLOGY: linear  
;; MOLECULE TYPE: protein  
;; HYPOTHETICAL: NO  
;; ORIGINAL SOURCE:  
;; ORGANISM: Oryctolagus cuniculus  
;; US-07-841-651-3

Query Match 45.5%; Score 35; DB 1; Length 672;  
Best Local Similarity 70.0%; Pred. No. 1.8e+02;  
Matches 7; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

OY 2 IGLAGTDFAN 11  
Db 82 VGLAGTGAAN 91

Search completed: March 26, 2002, 13:41:29  
Job time: 303 sec



GenCore version 4.5  
Copyright (c) 1993 - 2000 Compugen Ltd.

OM protein - protein search, using sw model

Run on: March 26, 2002, 13:37:19 ; Search time 42.75 Seconds  
(without alignments)  
24.946 Million cell updates/sec

Title: US-09-709-201-100  
Perfect score: 77  
Sequence: 1 CIGLAGTDFANQRP 14

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 219241 seqs, 76174552 residues

Total number of hits satisfying chosen parameters: 219241

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

PIR\_68: \*  
1: pir1: \*  
2: pir2: \*  
3: pir3: \*  
4: pir4: \*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	68	88.3	392	2 A40371	major outer membra
2	43	55.8	995	2 T50267	probable family 3i
3	41	53.2	1238	2 A64596	hypothetical prote
4	41	53.2	3194	2 D71917	toxin-like outer m
5	40	51.9	98	1 S32485	cytochrome c552 pr
6	39	50.6	289	2 S04407	phytoene synthase
7	39	50.6	324	2 C70785	probable carbohydr
8	39	50.6	377	3 JC7535	chitinase (EC 3.2.
9	39	50.6	502	2 A56683	receptor protein k
10	39	50.6	502	2 A53444	activin receptor-1
11	39	50.6	502	2 JC2491	serine/threonine k
12	39	50.6	660	2 JW0067	chitinase (EC 3.2.
13	39	50.6	743	2 G83726	assimilatory nitra
14	39	50.6	1785	2 T22595	hypothetical prote
15	38	49.4	356	2 F70836	probable ephB prot
16	38	49.4	365	2 T06615	hypothetical prote
17	37	48.1	141	2 JL0103	hypothetical 15.5k
18	37	48.1	276	2 S73410	hypothetical prote
19	37	48.1	547	2 S49814	transferrin-bindin
20	37	48.1	719	2 T33170	hypothetical prote
21	37	48.1	902	2 T49878	respiratory burst
22	37	48.1	926	2 E83375	probable glycosyl
23	37	48.1	1024	2 T46016	hypothetical prote
24	36.5	47.4	358	1 A48952	triacylglycerol li
25	36	46.8	155	2 D72696	riboflavin synthas
26	36	46.8	280	2 T24454	hypothetical prote
27	36	46.8	303	2 B70875	hypothetical prote
28	36	46.8	328	2 S74645	billiverdin reducta
29	36	46.8	354	2 A96596	hypothetical prote

30	36	46.8	371	2 T51695	cell division prot
31	36	46.8	416	2 S76310	hypothetical prote
32	36	46.8	464	2 B64970	hypothetical prote
33	36	46.8	464	2 C85830	hypothetical prote
34	36	46.8	467	2 S15297	hypothetical prote
35	36	46.8	513	2 T28933	hypothetical prote
36	36	46.8	616	2 S64624	alpha-glucoside tr
37	36	46.8	632	2 D71941	ATP-dependent zinc
38	36	46.8	632	2 E64653	cell division prot
39	36	46.8	638	2 T47267	cell cycle protein
40	36	46.8	645	2 G81315	membrane bound zin
41	36	46.8	725	2 T27148	hypothetical prote
42	36	46.8	1050	2 T31853	hypothetical prote
43	36	46.8	1060	2 T31763	hypothetical prote
44	35	45.5	101	2 C31982	Ca2+-transporting
45	35	45.5	104	2 T44890	hypothetical prote

ALIGNMENTS

RESULT 1

A40371

major outer membrane protein precursor - Chlamydomophila psittaci (strain Fpn/pring)  
C:Species: Chlamydomophila psittaci, Chlamydia psittaci  
C:Date: 27-Nov-1991 #sequence\_revision 27-Nov-1991 #text\_change 31-Mar-2000  
C:Accession: I40859; A40371; S16137

R:Storey, C.; Lusher, M.; Yates, P.; Richmond, S.

J. Gen. Microbiol. 139, 2621-2626, 1993

A:Title: Evidence for Chlamydia pneumoniae of non-human origin.

A:Reference number: I40739; MUID:94103736

A:Accession: I40859

A:Status: nucleic acid sequence not shown; translation not shown; translated from GB/

A:Molecule type: DNA

A:Residues: 1-392 <RES>

A:Cross-references: EMBL:X61096; NID:g40564; PIDN:CAA43409.1; PID:g40565

A:Experimental source: strain Fpn

C:Genetics:

A:Gene: MOMP

C:Superfamily: Chlamydia major outer membrane protein

C:Keywords: membrane protein

F:1-22/Domain: signal sequence #status predicted <SIG>

F:23-392/Product: major outer membrane protein #status predicted <MAT>

Query Match 88.3%; Score 68; DB 2: Length 392;  
Best Local Similarity 100.0%; Pred. No. 0.00016;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 IGLAGTDFANQRP 14

|||||

Db 160 IGLAGTDFANQRP 172

RESULT 2

T50267

probable family 3i glucosidase [imported] - fission yeast (Schizosaccharomyces pombe)

C:Species: Schizosaccharomyces pombe

C:Date: 09-Jun-2000 #sequence\_revision 09-Jun-2000 #text\_change 21-Jul-2000

C:Accession: T50267

R:Hunt, C.; Aves, S.; McDougall, R.C.; Rajandream, M.A.; Barrell, B.G.

submitted to the EMBL Data Library, December 1999

A:Reference number: Z25031

A:Accession: T50267

A:Status: preliminary; translated from GB/EMBL/DDBJ

A:Molecule type: DNA

A:Residues: 1-995 <HUN>

A:Cross-references: EMBL:AL133522; PIDN:CA863549.1; GSPDB:GN00066; SPDB:SPAC922.02c

A:Experimental source: strain 972h(-); cosmid c922

C:Genetics:

A:Gene: SPAC1039.11c; SPDB:SPAC922.02c

A:Map position: 1

C:Superfamily: Schwannomyces glucan 1,4-alpha-glucosidase GAMI; sucrase/isomaltase h

Query Match 55.8% Score 43; DB 2; Length 995;  
 Best Local Similarity 57.1%; Pred. No. 14;  
 Matches 8; Conservative 1; Mismatches 5; Indels 0; Gaps 0;

QY 1 CIGLAGTDFANORP 14  
 ||| ||| :||  
 Db 507 CIGSCGTDKLDQNP 520

RESULT 3  
 A64596  
 hypothetical protein HP0609 - Helicobacter pylori (strain 26695)  
 C:Species: Helicobacter pylori  
 C:Date: 09-Aug-1997 #sequence\_revision 09-Aug-1997 #text\_change 08-Oct-1999  
 C:Accession: A64596  
 R:Tomb, J.F.; White, O.; Kerlavage, A.R.; Clayton, R.A.; Sutton, G.G.; Fleischmann, R.D.; Peterson, S.; Loftus, B.; Richardson, D.; Dodson, R.; Khalak, H.G.; Glodek, A.; McKenney, J.D.; Kelley, J.M.; Cotton, M.D.; Weidman, J.M.; Fujii, C.; Bowman, C.; Watthey, L. Nature 388, 539-547, 1997  
 A:Authors: Wallin, E.; Hayes, W.S.; Borodovsky, M.; Karpk, P.D.; Smith, H.O.; Fraser, C.  
 A:Title: The complete genome sequence of the gastric pathogen Helicobacter pylori.  
 A:Reference number: A64520; MUID:97394467  
 A:Accession: A64596  
 A:Status: preliminary; nucleic acid sequence not shown; translation not shown  
 A:Molecule type: DNA  
 A:Residues: 1-1238 <TOM>  
 A:Cross-references: GB:AE000575; GB:AE000511; NID:92313730; PIDN:AAD07677.1; PID:9231373

Query Match 53.2% Score 41; DB 2; Length 1238;  
 Best Local Similarity 53.8%; Pred. No. 39;  
 Matches 7; Conservative 1; Mismatches 5; Indels 0; Gaps 0;

QY 2 IGLAGTDFANORP 14  
 : ||| ||| :  
 Db 207 VNLNTDFGNQTP 219

RESULT 4  
 D71917  
 toxin-like outer membrane protein jhp0556 - Helicobacter pylori (strain J99)  
 C:Species: Helicobacter pylori  
 A:Variety: strain J99  
 C:Date: 12-Feb-1999 #sequence\_revision 12-Feb-1999 #text\_change 08-Oct-1999  
 C:Accession: D71917  
 R:Alm, R.A.; Ling, L.S.L.; Moir, D.T.; King, B.L.; Brown, E.D.; Doig, P.C.; Smith, D.R.; Ives, C.; Gibson, R.; Merberg, D.; Mills, S.D.; Jiang, Q.; Taylor, D.E.; Vovis, G.F.; Nature 397, 176-180, 1999  
 A:Title: Genomic sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori.  
 A:Reference number: A71800; MUID:99120557  
 A:Accession: D71917  
 A:Status: preliminary  
 A:Molecule type: DNA  
 A:Residues: 1-3194 <ARN>  
 A:Cross-references: GB:AE001498; GB:AE001439; NID:94155100; PIDN:AAD06134.1; PID:94155100  
 A:Experimental source: strain J99  
 C:Genetics:  
 A:Gene: jhp0556

Query Match 53.2% Score 41; DB 2; Length 3194;  
 Best Local Similarity 53.8%; Pred. No. 1e+02;  
 Matches 7; Conservative 1; Mismatches 5; Indels 0; Gaps 0;

QY 2 IGLAGTDFANORP 14  
 : ||| ||| :  
 Db 208 VNLNTDFGNQTP 220

RESULT 5  
 S32485

cytochrome c552 precursor - Hydrogenobacter thermophilus  
 C:Species: Hydrogenobacter thermophilus  
 C:Date: 06-Jan-1995 #sequence\_revision 27-Feb-1997 #text\_change 03-Mar-2000  
 C:Accession: S32485; A32226  
 R:Sanbongi, Y.; Yang, J.H.; Igarashi, Y.; Kodama, T. Eur. J. Biochem. 198, 7-12, 1991  
 A:Title: Cloning, nucleotide sequence and expression of the cytochrome c-552 gene from Hydrogenobacter thermophilus  
 A:Reference number: S32485; MUID:91249816  
 A:Accession: S32485  
 A:Status: preliminary  
 A:Molecule type: DNA  
 A:Residues: 1-98 <SAN>  
 A:Cross-references: EMBL:X57735; NID:g43674; PIDN:CAA40902.1; PID:g43675  
 A:Experimental source: strain TK-6  
 R:Sanbongi, Y.; Ishii, M.; Igarashi, Y.; Kodama, T. J. Bacteriol. 171, 65-69, 1989  
 A:Title: Amino acid sequence of cytochrome c-552 from a thermophilic hydrogen-oxidizing bacterium  
 A:Reference number: A32226; MUID:89123087  
 A:Accession: A32226  
 A:Molecule type: protein  
 A:Residues: 15-98 <SA2>  
 A:Experimental source: strain TK-6  
 C:Function:  
 A:Description: primary electron acceptor for molecular hydrogen activated by hydrogenase  
 A:Pathway: hydrogen oxidation  
 C:Superfamily: cytochrome c6; cytochrome c6 homology  
 C:Keywords: chromoprotein; electron transfer; heme; iron; metalloprotein  
 F:1-18/Domain: signal sequence #status predicted <SIG>  
 F:17-94/Domain: cytochrome c6 homology <CYC>  
 F:19-98/Product: cytochrome c552 #status experimental <MAT>  
 F:28,31/Binding site: heme (Cys) (covalent) #status predicted  
 F:32,77/Binding site: heme iron (His, Met) (axial ligands) #status predicted

Query Match 51.9% Score 40; DB 1; Length 98;  
 Best Local Similarity 58.3%; Pred. No. 4.7;  
 Matches 7; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 2 IGLAGTDFANOR 13  
 : ||| ||| :  
 Db 10 VLAGITFANEQ 21

RESULT 6  
 S04407  
 phycoene synthase - Rhodospirillum rubrum  
 C:Species: Rhodospirillum rubrum  
 C:Date: 28-Feb-1990 #sequence\_revision 28-Feb-1990 #text\_change 08-Oct-1999  
 C:Accession: S04407  
 R:Armstrong, G.A.; Alberti, M.; Leach, F.; Hearst, J.E. Mol. Gen. Genet. 216, 254-268, 1989  
 A:Title: Nucleotide sequence, organization, and nature of the protein products of the phycoene synthase gene from Rhodospirillum rubrum  
 A:Reference number: S04407  
 A:Accession: S04407  
 A:Molecule type: DNA  
 A:Residues: 1-289 <ARM>  
 A:Cross-references: EMBL:X52291; NID:g45996; PIDN:CAA36538.1; PID:g46003  
 C:Genetics:  
 A:Gene: crtE  
 C:Superfamily: geranyltransferase  
 C:Keywords: carotenoid biosynthesis

Query Match 50.6% Score 39; DB 2; Length 289;  
 Best Local Similarity 70.0%; Pred. No. 21;  
 Matches 7; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 5 AGTDFANORP 14  
 ||| ||| :||  
 Db 224 AGQDIANERP 233

RESULT 7

## C70785

probable carbohydrate kinase - Mycobacterium tuberculosis (strain H37RV)  
 C:Species: Mycobacterium tuberculosis  
 C:Date: 17-Jul-1998 #sequence\_revision 17-Jul-1998 #text\_change 20-Jun-2000  
 C:Accession: C70785  
 R:Coile, S.T.; Brosch, R.; Parkhill, J.; Garnier, T.; Churcher, C.; Harris, D.; Gordon, S.; Connor, R.; Davies, R.; Devlin, K.; Feltwell, T.; Gentles, S.; Hamlin, N.; Hoiroyd, S.; Rajandream, M.A.; Rogers, J.; Rutter, S.; Seeger, K.; Skelton, S.; Squares, S. Nature 393, 537-544, 1998  
 A:Authors: Soares, R.; Sulston, J.E.; Taylor, K.; Whitehead, S.; Barrell, B.G.  
 A:Title: Deciphering the biology of Mycobacterium tuberculosis from the complete genome  
 A:Reference number: A70500; MUID:98295987  
 A:Accession: C70785  
 A:Status: preliminary; nucleic acid sequence not shown; translation not shown  
 A:Molecule type: DNA  
 A:Residues: 1-324 <COL>  
 A:Cross-references: GB:270283; GB:AL123456; NID:g3261561; PIDN:CAA94245.1; PID:gl237055  
 A:Experimental source: strain H37RV  
 C:Genetics:  
 A:Gene: cbhK  
 C:Superfamily: probable ribokinase

Query Match 50.6%; Score 39; DB 2; Length 324;  
 Best Local Similarity 58.3%; Pred. No. 24;  
 Matches 7; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

## QY 2 IGLAGTDFANOR 13

Db 67 VGAAGADFADYR 78

## RESULT 8

JC7535  
 chitinase (EC 3.2.1.14) 35 - Streptomyces thermoviolaceus  
 C:Species: Streptomyces thermoviolaceus  
 C:Date: 31-Mar-2001 #sequence\_revision 31-Mar-2001 #text\_change 31-Mar-2001  
 C:Accession: JC7535  
 R:Tsujiibo, H.; Okamoto, T.; Hatano, N.; Miyamoto, K.; Watanabe, T.; Mitsutomi, M.; Inanaga  
 Biosci. Biotechnol. Biochem. 64, 2445-2453, 2000  
 A:Title: Family 19 chitinases from Streptomyces thermoviolaceus OPC-520: Molecular cloning  
 A:Reference number: JC7535; MUID:21036907  
 A:Accession: JC7535  
 A:Molecule type: DNA  
 A:Residues: 1-377 <TSU>  
 A:Cross-references: DDBJ:AB016842  
 A:Experimental source: strain OPC-520  
 C:Comment: This enzyme, a member of the family 19 chitinases, is involved in chitin degradation  
 C:Genetics:  
 A:Gene: ch135  
 C:Keywords: hydrolase; glycosidase

Query Match 50.6%; Score 39; DB 3; Length 377;  
 Best Local Similarity 50.0%; Pred. No. 27;  
 Matches 7; Conservative 2; Mismatches 5; Indels 0; Gaps 0;

## QY 1 CIGLAGTDFANORP 14

Db 47 CLDVAGADSANGTP 60

## RESULT 9

A56683  
 receptor protein kinase RPK-1 precursor - chicken  
 C:Species: Gallus gallus (chicken)  
 C:Date: 08-Jul-1995 #sequence\_revision 03-Aug-1995 #text\_change 24-Sep-1999  
 C:Accession: A56683  
 R:Sumitomo, S.; Saito, T.; Nohno, T. DNA Seq. 3, 297-302, 1993  
 A:Title: A new receptor protein kinase from chick embryo related to type II receptor for  
 A:Reference number: A56683; MUID:94003400

A:Accession: A56683

A:Status: preliminary  
 A:Molecule type: mRNA  
 A:Residues: 1-502 <SUM>  
 A:Cross-references: GB:DL13432; NID:g222862; PIDN:BAA02694.1; PID:dl1003199; PID:g22286  
 C:Superfamily: unassigned Ser/Thr or Tyr-specific protein kinases; protein kinase hom  
 C:Keywords: ATP; phosphotransferase; transmembrane protein  
 F:202-498/Domain: protein kinase homology <KIN>  
 F:210-218/Region: protein kinase ATP-binding motif

Query Match 50.6%; Score 39; DB 2; Length 502;  
 Best Local Similarity 66.7%; Pred. No. 36;  
 Matches 6; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

## QY 1 CIGLAGTDF 9

Db 71 CLGLEGSDF 79

## RESULT 10

A53444  
 activin receptor-like kinase 6 precursor - mouse  
 C:Species: Mus musculus (house mouse)  
 C:Date: 19-May-1994 #sequence\_revision 19-May-1994 #text\_change 24-Sep-1999  
 C:Accession: A53444; S40159  
 R:ten Dijke, P.; Yamashita, H.; Ichijo, H.; Franzen, P.; Laiho, M.; Miyazono, K.; Hei  
 Science 264, 101-104, 1994  
 A:Title: Characterization of type I receptors for transforming growth factor-beta and  
 A:Reference number: A53444; MUID:94188705  
 A:Accession: A53444  
 A:Status: preliminary  
 A:Molecule type: mRNA  
 A:Residues: 1-502 <TEN>  
 A:Cross-references: GB:223143; NID:g437870; PIDN:CAA80674.1; PID:g437871  
 R:Miyazono, K.; Moren, A.; Grimsby, S.; Ichijo, H.; Heidlin, C.; ten Dijke, P.  
 Submitted to the EMBL data Library, June 1993  
 A:Description: ALK-3 and ALK-6: the closely related members in the serine/threonine k  
 A:Reference number: S40158  
 A:Accession: S40159  
 A:Status: preliminary  
 A:Molecule type: mRNA  
 A:Residues: 1-502 <MIY>  
 A:Cross-references: EMBL:Z23143; NID:g437870; PIDN:CAA80674.1; PID:g437871  
 C:Superfamily: unassigned Ser/Thr or Tyr-specific protein kinases; protein kinase hom  
 C:Keywords: ATP; serine/threonine-specific protein kinase; transmembrane protein  
 F:202-498/Domain: protein kinase homology <KIN>  
 F:210-218/Region: protein kinase ATP-binding motif

Query Match 50.6%; Score 39; DB 2; Length 502;  
 Best Local Similarity 66.7%; Pred. No. 36;  
 Matches 6; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

## QY 1 CIGLAGTDF 9

Db 71 CLGLEGSDF 79

## RESULT 11

JC2491  
 serine/threonine kinase receptor - rat  
 C:Species: Rattus norvegicus (Norway rat)  
 C:Date: 22-Apr-1995 #sequence\_revision 26-May-1995 #text\_change 10-Sep-1997  
 C:Accession: JC2491  
 R:Yamaji, N.; Celeste, A.J.; Thies, R.S.; Song, J.J.; Bernier, S.M.; Goltzman, D.; Ly  
 Biochem. Biophys. Res. Commun. 205, 1944-1951, 1994  
 A:Title: A mammalian serine/threonine kinase receptor specifically binds BMP-2 and BM  
 A:Reference number: JC2491; MUID:95110346  
 A:Accession: JC2491  
 A:Molecule type: mRNA  
 A:Residues: 1-502 <YAM>  
 C:Superfamily: unassigned Ser/Thr or Tyr-specific protein kinases; protein kinase hom

C:Keywords: ATP; glycoprotein; transmembrane protein  
 F:127-148/Domain: transmembrane #status predicted <TM>  
 F:202-498/Domain: protein kinase homology <KIN>  
 F:210-218/Region: protein kinase ATP-binding motif  
 F:284,343,388/Binding site: carbohydrate (Asn) (covalent) #status predicted

Query Match 50.6%; Score 39; DB 2; Length 502;  
 Best Local Similarity 66.7%; Pred. No. 36;  
 Matches 6; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1 CIGLAGTDF 9  
 I:| | | | |  
 Db 71 CLGLEGSDF 79

## RESULT 12

JW0067  
 chitinase (EC 3.2.1.14) A - Emericella nidulans  
 N:Alternate names: chIA  
 C:Species: Emericella nidulans, Aspergillus nidulans  
 C:Date: 13-Jun-1998 #sequence\_revision 10-Jul-1998 #text\_change 17-Mar-1999  
 C:Accession: JW0067  
 R:Takaya, N.; Yamazaki, D.; Horiuchi, H.; Ohta, A.; Takagi, M.  
 Biosci. Biotechnol. Biochem. 62, 60-65, 1998  
 A:Title: Cloning and characterization of a chitinase-encoding gene (chIA) from Aspergillus  
 A:Reference number: JW0067; MUID:98162139  
 A:Accession: JW0067  
 A:Molecule type: mRNA  
 A:Residues: 1-660 <TAK>  
 A:Cross-references: DDBJ:D87895; NID:g2821948; PID:d1025495; PID:g2828335  
 C:Comment: This enzyme hydrolyzes chitin at beta-1,4 bonds between N-acetylglucosamine  
 C:Genetics:  
 A:Gene: chIA  
 C:Keywords: glycosidase; hydrolase

Query Match 50.6%; Score 39; DB 2; Length 660;  
 Best Local Similarity 70.0%; Pred. No. 48;  
 Matches 7; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 3 GLAGTDFANQ 12  
 I:| | | | |  
 Db 71 GLPGSDFGNQ 80

## RESULT 13

G83726  
 assimilatory nitrate reductase (catalytic subunit) nasC [imported] - Bacillus halodurans  
 C:Species: Bacillus halodurans  
 C:Date: 01-Dec-2000 #sequence\_revision 01-Dec-2000 #text\_change 08-Dec-2000  
 C:Accession: G83726  
 R:Takami, H.; Nakasone, K.; Takaki, Y.; Maeno, G.; Sasaki, R.; Masui, N.; Fujii, F.; Hira  
 Nucleic Acids Res. 28, 4317-4331, 2000  
 A:Title: Complete genome sequence of the alkaliphilic bacterium Bacillus halodurans and  
 A:Reference number: A83650; MUID:20263314  
 A:Accession: G83726  
 A>Status: preliminary  
 A:Molecule type: DNA  
 A:Residues: 1-743 <STO>  
 A:Cross-references: GB:AP001509; GB:BA000004; NID:g10173176; PIDN:BA04334.1; GSPDB:GNOC  
 A:Experimental source: strain C-125  
 C:Genetics:  
 A:Gene: nasC  
 C:Superfamily: formate dehydrogenase

Query Match 50.6%; Score 39; DB 2; Length 743;  
 Best Local Similarity 57.1%; Pred. No. 54;  
 Matches 8; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

QY 1 CIGLAGTDFANORP 14  
 I:| | | | | | | | | |

Db 184 CIVLAGTNLAECOP 197

## RESULT 14

T22595  
 hypothetical protein F53H4.1 - Caenorhabditis elegans  
 C:Species: Caenorhabditis elegans  
 C:Date: 15-Oct-1999 #sequence\_revision 15-Oct-1999 #text\_change 18-Feb-2000  
 C:Accession: T22595  
 R:Dobson, R.  
 submitted to the EMBL Data Library, October 1996  
 A:Reference number: Z19587  
 A:Accession: T22595  
 A>Status: preliminary; translated from GB/EMBL/DDBJ  
 A:Molecule type: DNA  
 A:Residues: 1-1785 <WIL>  
 A:Cross-references: EMBL:281089; PIDN:CAB03135.1; GSPDB:GN00028; CESP:F53H4.1  
 A:Experimental source: clone F53H4  
 C:Genetics:  
 A:Gene: CESP:F53H4.1  
 A:Map position: X  
 A:Introns: 42/2; 196/2; 245/2; 454/3; 562/2; 658/2; 730/3; 790/2; 844/3; 953/1; 1007/

Query Match 50.6%; Score 39; DB 2; Length 1785;  
 Best Local Similarity 50.0%; Pred. No. 1.3e+02;  
 Matches 7; Conservative 1; Mismatches 6; Indels 0; Gaps 0;

QY 1 CIGLAGTDFANORP 14  
 I:| | | | | | | | | |  
 Db 565 CVSLTGADSAARP 578

## RESULT 15

F70636  
 probable ephB protein - Mycobacterium tuberculosis (strain H37RV)  
 C:Species: Mycobacterium tuberculosis  
 C:Date: 17-Jul-1998 #sequence\_revision 17-Jul-1998 #text\_change 20-Jun-2000  
 C:Accession: F70636  
 R:Coile, S.T.; Brosch, R.; Parkhill, J.; Garnier, T.; Churcher, C.; Harris, D.; Gordon  
 ; Connor, R.; Davies, R.; Devlin, K.; Feltwell, T.; Gentles, S.; Hamlin, N.; Holroyd,  
 Rajandream, M.A.; Rogers, J.; Rutter, S.; Seeger, K.; Skelton, S.; Squares, S.  
 Nature 393, 537-544, 1998  
 A:Authors: Squares, R.; Sulston, J.E.; Taylor, K.; Whitehead, S.; Barrell, B.G.  
 A:Title: Deciphering the biology of Mycobacterium tuberculosis from the complete geno  
 A:Reference number: A70500; MUID:98295987  
 A:Accession: F70636  
 A>Status: preliminary; nucleic acid sequence not shown; translation not shown  
 A:Molecule type: DNA  
 A:Residues: 1-356 <COL>  
 A:Cross-references: GB:Z84498; GB:AL123456; NID:g3261701; PIDN:CAB06523.1; PID:g18062  
 A:Experimental source: strain H37RV  
 C:Genetics:  
 A:Gene: ephB  
 C:Superfamily: tropinesterase

Query Match 49.4%; Score 38; DB 2; Length 356;  
 Best Local Similarity 53.8%; Pred. No. 39;  
 Matches 7; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

QY 2 IGLAGTDFANORP 14  
 I:| | | | | | | | | |  
 Db 137 IGLPGSPFGERRP 149

Search completed: March 26, 2002, 13:37:21  
 Job time: 55 sec





Tue Mar 26 15:55:31 2002

```
RESULT 2
C552_HYDTH STANDARD; PRT; 98 AA.
ID C552_HYDTH
AC P13452;
DT 01-APR-1990 (Rel. 14, Created)
DT 01-AUG-1992 (Rel. 23, Last sequence update)
DT 15-JUL-1999 (Rel. 38, Last annotation update)
DE CYTOCHROME C-552 PRECURSOR (C552).
OS Hydrogenobacter thermophilus.
OC Bacteria; Aquificales; Aquificaceae; Hydrogenobacter.
OX NCBI_TaxID=940;
RN [1]
RP SEQUENCE FROM N.A.
RX STRAIN=TK-6;
RX MEDLINE=91249816; PubMed=1645652;
RA Sanbongi Y., Yang J.H., Igarashi Y., Kodama T.;
RT "Cloning, nucleotide sequence and expression of the cytochrome c-552
RT gene from Hydrogenobacter thermophilus.";
RL Eur. J. Biochem. 198;7-12(1991).
RN [2]
RP SEQUENCE OF 19-98.
RX STRAIN=TK-6;
RX MEDLINE=89123087; PubMed=2336668;
RA Sanbongi Y., Ishii M., Igarashi Y., Kodama T.;
RT "Amino acid sequence of cytochrome c-552 from a thermophilic
RT hydrogen-oxidizing bacterium, Hydrogenobacter thermophilus.";
RL J. Bacteriol. 171;65-69(1989).
RN [3]
RP THERMOSTABILITY.
RX MEDLINE=90122832; PubMed=2558725;
RA Sanbongi Y., Igarashi Y., Kodama T.;
RT "Thermostability of cytochrome c-552 from the thermophilic hydrogen-
RT oxidizing bacterium Hydrogenobacter thermophilus.";
RL Biochemistry 28;9574-9578(1989).
RN [4]
RP STRUCTURE BY NMR.
RX STRAIN=TK-6;
RX MEDLINE=98322065; PubMed=9657676;
RA Hasegawa J., Yoshida T., Yamazaki T., Sanbongi Y., Yu Y., Igarashi Y.,
RA Kodama T., Yamazaki K., Kyogoku Y., Kobayashi Y.;
RT "Solution structure of thermostable cytochrome c-552 from
RT Hydrogenobacter thermophilus determined by 1H-NMR spectroscopy.";
RL Biochemistry 37;9641-9649(1998).
CC -!- FUNCTION: REACTS WITH HYDROGENASE.
CC -!- PTM: BINDS ONE HEME GROUP PER MOLECULE.
CC -!- SIMILARITY: 56% WITH P.AERUGINOSA C551.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announcement/
CC or send an email to license@isb-sib.ch).
CC -----
CC EMBL; X57735; CAA40902.1; -
CC DR PIR; A32226; A32226.
CC DR PIR; S32485; S32485.
CC DR PDB; 1AYG; 13-JAN-99.
CC InterPro: IPR000345; CytC_heme_bind.
CC InterPro: IPR003088; Cyt-C1.
CC InterPro: IPR002324; Cyt_C1D.
CC Pfam; PF00034; cytochrome_c; 1.
CC PRINTS; PR00606; CYTOCHROME_C1D.
CC PROSITE; PS00190; CYTOCHROME_C; 1.
CC Electron transport; Heme; Signal; 3D-structure.
CC SIGNAL
CC CHAIN 1 18 CYTOCHROME C-552.
CC BINDING 28 28 HEME (COVALENT).
CC BINDING 31 31 HEME (COVALENT).
CC METAL 32 32 IRON (HEME AXIAL LIGAND).
CC METAL 77 77 IRON (HEME AXIAL LIGAND).
CC SEQUENCE 98 AA; 10431 MW; F49713D829DDE927 CRC64;
CC -----
Query Match 51.9%; Score 40; DB 1; Length 98;
Best Local Similarity 58.3%; Pred. No. 2;
Matches 7; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
QY 2 IGLACTDFANOR 13
DB 10 VGLAGITFANEQ 21
RESULT 3
CRTE_RHOCA STANDARD; PRT; 289 AA.
ID CRTE_RHOCA
AC P17060;
DT 01-AUG-1990 (Rel. 15, Created)
DT 01-AUG-1990 (Rel. 15, Last sequence update)
DT 15-JUL-1999 (Rel. 38, Last annotation update)
DE GERANYLGERANYL PYROPHOSPHATE SYNTHETASE (EC 2.5.1.29) (GGPP
DE SYNTHETASE) (FARNESYLTRANSFERASE).
RN [1]
RP SEQUENCE FROM N.A.
RX STRAIN=SB1003; AND BEC404;
RX MEDLINE=89313663; PubMed=2747617;
RA Armstrong G.A., Alberti M., Leach F., Hearst J.E.;
RT "Nucleotide sequence, organization, and nature of the protein
RT products of the carotenoid biosynthesis gene cluster of Rhodobacter
RT capsulatus.";
RL Mol. Gen. Genet. 216;254-268(1989).
CC -!- CATALYTIC ACTIVITY: TRANS-TRANS-FARNESYL DIPHOSPHATE + ISOPENTENYL
CC DIPHOSPHATE = PYROPHOSPHATE + GERANYLGERANYL DIPHOSPHATE.
CC -!- PATHWAY: CAROTENOID AND CHLOROPHYLL BIOSYNTHESIS.
CC -!- SIMILARITY: BELONGS TO THE FPP/GGPP SYNTHETASES FAMILY.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announcement/
CC or send an email to license@isb-sib.ch).
CC -----
CC EMBL; X52291; CAA36538.1; -
CC DR EMBL; Z11165; CAA77545.1; -
CC DR PIR; S04407; S04407.
CC InterPro: IPR000092; Polyprenyl_synth.
CC Pfam; PF00348; polyprenyl_synth; 1.
CC PROSITE; PS00444; POLYPRENYL_SYNTHET_2; 1.
CC PROSITE; PS00723; POLYPRENYL_SYNTHET_1; 1.
CC DR Photosynthesis; Chlorophyll biosynthesis; Carotenoid biosynthesis;
CC Isoprene biosynthesis; Transferase.
CC SEQUENCE 289 AA; 30043 MW; CF483A26EAC9C859 CRC64;
CC -----
Query Match 50.6%; Score 39; DB 1; Length 289;
Best Local Similarity 70.0%; Pred. No. 9.9;
Matches 7; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
QY 5 AGTDFANORP 14
DB 224 AGQDIANERP 233
RESULT 4
YMO2_MYCTU STANDARD; PRT; 324 AA.
ID YMO2_MYCTU
AC Q10391;
DT 01-OCT-1996 (Rel. 34, Created)
```

```

DT 01-OCT-1996 (Rel. 34, Last sequence update)
DT 20-AUG-2001 (Rel. 40, Last annotation update)
DE HYPOTHEICAL SUGAR KINASE RV2202C.
GN RV2202C OR MT2258 OR MTCV190.13C.
OS Mycobacterium tuberculosis.
OC Bacteria; Firmicutes; Actinobacteria; Actinobacteridae;
OC Actinomycetales; Corynebacterineae; Mycobacteriaceae; Mycobacterium.
OX NCBI_TaxID=1773;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=H37RV;
RX MEDLINE=98295987; PubMed=9634230;
RA Cole S.T., Brosch R., Parkhill J., Garnier T., Churcher C., Harris D.,
RA Gordon S.V., Eiglmeier K., Gas S., Barry C.E. III, Tekala F.,
RA Badcock K., Basham D., Brown D., Chillingworth T., Connor R.,
RA Davies R., Devlin K., Feltwell T., Gentles S., Hamlin N., Holroyd S.,
RA Hornsby T., Jagels K., Krogh A., McLean J., Moule S., Murphy L.,
RA Oliver S., Osborne J., Quail M.A., Rajandream M.A., Rogers J.,
RA Rutter S., Seeger K., Skelton S., Squares S., Squares R.,
RA Sulston J.E., Taylor K., Whitehead S., Barrell B.G.;
RT "Deciphering the biology of Mycobacterium tuberculosis from the
RL complete genome sequence.";
RL Nature 393:537-544 (1998).
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN=CDC 1551 / Oshkosh;
RA Fleischmann R.D., Alland D., Eisen J.A., Carpenter L., White O.,
RA Peterson J., DeBoy R., Dodson R., Gwinn M.L., Haft D., Hickey E.,
RA Kolonay J.F., Nelson W.C., Umayam L.A., Emdolava M.D., Salzberg S.L.,
RA Delcher A., Utterback T., Weidman J., Khouri H., Gill J., Mikula A.,
RA Bishai W.;
RT "Whole genome comparison of Mycobacterium tuberculosis clinical and
RL laboratory strains.";
RL Submitted (APR-2001) to the EMBL/GenBank/DBJ databases.
CC -1- SIMILARITY: BELONGS TO THE PFKB FAMILY OF CARBOHYDRATE KINASES.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
CC EMBL; Z70283; CAA94245.1; -
CC TIGR; MT2258; -
CC TubercuList; RV2202c; -
CC InterPro; IPR002173; pfkb.
CC Pfam; PF00294; pfkb; 1.
CC PROSITE; PS00583; PFKB_KINASES_1; 1.
CC PROSITE; PS00584; PFKB_KINASES_2; FALSE_NEG.
KW Hypothetical protein; Transferase; Kinase; Complete proteome.
SQ SEQUENCE 324 AA; 34472 MW; 0C072206A3210A1D CRC64;
-----
Query Match 50.6%; Score 39; DB 1; Length 324;
Best Local Similarity 58.3%; Pred. No. 11;
Matches 7; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 2 IGLAGTDFANOR 13
Db : | | | | |
67 VGAAGADFADYR 78

RESULT 5
BMRB_CHICK STANDARD; PRT; 502 AA.
ID BMRB_CHICK
AC Q05438;
DT 01-OCT-1996 (Rel. 34, Created)
DT 01-OCT-1996 (Rel. 34, Last sequence update)
DT 20-AUG-2001 (Rel. 40, Last annotation update)
DE BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE IB PRECURSOR (EC 2.7.1.37)

DE (SERINE/THREONINE-PROTEIN KINASE RECEPTOR R6) (SKR6) (ACTIVIN
DE RECEPTOR-LIKE KINASE 6) (ALK-6) (RPK-1).
GN BMRP1B.
OS Gallus gallus (Chicken).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Archosauria; Aves; Neognathae; Galliformes; Phasianidae; Phasianinae;
OC Gallus.
OX NCBI_TaxID=9031;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=94003400; PubMed=8400359;
RA Yamazaki Y., Saito T., Nohno T.;
RT "A new receptor protein kinase from chick embryo related to type II
RL receptor for TGF-beta.";
RL DNA Seq. 3:297-302 (1993).
CC -1- CATALYTIC ACTIVITY: ATP + A PROTEIN - ADP + A PHOSPHOPROTEIN.
CC -1- SUBUNIT: HETERODIMERIZE WITH A TYPE-II RECEPTOR (BY SIMILARITY).
CC -1- SUBCELLULAR LOCATION: TYPE I MEMBRANE PROTEIN.
CC -1- SIMILARITY: BELONGS TO THE SER/THR FAMILY OF PROTEIN KINASES.
CC TGF RECEPTOR SUBFAMILY.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
CC EMBL; D13432; BAA02694.1; -
CC HSSP; P00523; 2PTK.
CC InterPro; IPR000472; Activin_rec.
CC InterPro; IPR000719; Euk_pkinase.
CC InterPro; IPR003605; GS.
CC InterPro; IPR002290; Ser_thr_kin_actsite.
CC Pfam; PF01064; Activin_rec; 1.
CC SMART; SM00467; GS; 1.
CC PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
CC PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
CC PROSITE; PS00011; PROTEIN_KINASE_DOM; 1.
KW Receptor; Transferase; Serine/threonine-protein kinase; ATP-binding;
KW Transmembrane; Glycoprotein; Signal.
FT SIGNAL 1 13
FT CHAIN 14 502 BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE
FT IB.
FT DOMAIN 14 126 EXTRACELLULAR (POTENTIAL).
FT TRANSMEM 127 148 POTENTIAL.
FT DOMAIN 149 502 CYTOPLASMIC (POTENTIAL).
FT DOMAIN 204 494 PROTEIN KINASE.
FT NP_BIND 210 218 ATP (BY SIMILARITY).
FT BINDING 231 231 ATP (BY SIMILARITY).
FT ACT_SITE 332 332 BY SIMILARITY.
FT CARBOHYD 44 44 N-LINKED (GLCNAC...) (POTENTIAL).
FT SEQUENCE 502 AA; 56766 MW; D5D93CCEBFE2A068C CRC64;
-----
Query Match 50.6%; Score 39; DB 1; Length 502;
Best Local Similarity 66.7%; Pred. No. 18;
Matches 6; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1 CIGLAGTDF 9
Db : | | | | |
71 CLGLEGSDF 79

RESULT 6
BMRB_HUMAN STANDARD; PRT; 502 AA.
ID BMRB_HUMAN
AC Q00238; P78366;
DT 30-MAY-2000 (Rel. 39, Created)
DT 30-MAY-2000 (Rel. 39, Last sequence update)
DT 20-AUG-2001 (Rel. 40, Last annotation update)

```



```

Query Match          50.6%; Score 39; DB 1; Length 502;
Best Local Similarity 66.7%; Pred. No. 18;
Matches 6; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1 CIGLAGTDF 9
    :||| |::|
DB 71 CLGLEGSDF 79

RESULT 8
MMOB_METCA STANDARD; PRT; 141 AA.
AC PL8797;
DT 01-NOV-1990 (Rel. 16, Created)
DT 01-NOV-1990 (Rel. 16, Last sequence update)
DT 01-AUG-1991 (Rel. 19, Last annotation update)
DE METHANE MONOOXYGENASE REGULATORY PROTEIN B.
GN MMOB.
OS Methylococcus capsulatus.
OC Bacteria; Proteobacteria; gamma subdivision; Methylococcaceae;
OC Methylococcus.
OX NCBI_TaxID=414;
RN [1]
RP STRAIN=BATH;
RX MEDLINE=89373399; PubMed=2505721;
RA Stainthorpe A.C., Murrell J.C., Salmund G.P.C., Dalton H., Lees V.;
RT "Molecular analysis of methane monooxygenase from Methylococcus
RT capsulatus (Bath).";
RL Arch. Microbiol. 152:154-159(1989).
RN [2]
RP IDENTIFICATION OF PROTEIN, AND SEQUENCE OF 3-19.
RA Pilkington S.J., Salmund G.P.C., Murrell J.C., Dalton H.;
RT "Identification of the gene encoding the regulatory protein B of
RT soluble methane monooxygenase.";
RL FEMS Microbiol. Lett. 72:345-348(1990).
CC -1- FUNCTION: THE B PROTEIN ACTS AS A REGULATOR OF ELECTRON FLOW
CC THROUGH THE SOLUBLE MMO COMPLEX, SWITCHING THE ENZYME FROM AN
CC OXIDASE TO A HYDROXYLASE IN THE PRESENCE OF THE SUBSTRATE.
CC -1- SUBUNIT: M.CAPSULATUS HAS TWO FORMS OF METHANE MONOOXYGENASE,
CC A SOLUBLE AND A MEMBRANE-BOUND TYPE. THE SOLUBLE TYPE CONSISTS
CC OF THREE COMPONENTS (A, B AND C).
PR: JL0103; JL0103.
DR InterPro: IPR003454; MmoB_DmpM.
DR Pfam: PF02406; MmoB_DmpM; 1.
KW Oxidoreductase; Monooxygenase.
SQ SEQUENCE 141 AA; 16018 MW; 45A42A61D6C58406 CRC64;

Query Match          48.1%; Score 37; DB 1; Length 141;
Best Local Similarity 63.8%; Pred. No. 11;
Matches 7; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 2 IGLAGTDFANQ 12
    :||| |::|
DB 13 MGLKGKDFADQ 23

RESULT 9
Y056_MYCPN STANDARD; PRT; 276 AA.
AC P75046;
DT 01-NOV-1997 (Rel. 35, Created)
DT 01-NOV-1997 (Rel. 35, Last sequence update)
DT 20-AUG-2001 (Rel. 40, Last annotation update)
DE HYPOTHETICAL PROTEIN MG056 HOMOLOG (D09_ORF276).
GN MPN071 OR MP084.
OS Mycoplasma pneumoniae.
OC Bacteria; Firmicutes; Bacillus/Clostridium group; Mollicutes;
OC Mycoplasmataceae; Mycoplasma.
OX NCBI_TaxID=2104;

[1]
SEQUENCE FROM N.A.
RP STRAIN=ATCC 29342 / M129;
RX MEDLINE=97105885; PubMed=8948633;
RA Himmelreich R., Hilbert H., Plagens H., Pirkl E., Li B.-C.,
RA Herrmann R.;
RT "Complete sequence analysis of the genome of the bacterium Mycoplasma
RT pneumoniae.";
RL Nucleic Acids Res. 24:4420-4449(1996).
CC -1- SIMILARITY: BELONGS TO THE UPF0011 FAMILY.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@sib-sib.ch).
CC
CC EMBL; AE000010; AAB95732.1;
DR InterPro: IPR000878; Cortin_porph_mthyltrnf.
DR InterPro: IPR000578; UPF0011.
DR Pfam: PF00590; TP_methylase; 1.
DR PRODom; PD007098; UPF0011; 1.
DR PROSITE; PS01296; UPF0011; 1.
KW Hypothetical protein; Complete proteome.
SQ SEQUENCE 276 AA; 31062 MW; 2A071E7A17FCD0CD CRC64;

Query Match          48.1%; Score 37; DB 1; Length 276;
Best Local Similarity 50.0%; Pred. No. 22;
Matches 6; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 2 IGLAGTDFANQR 13
    :||| |::|
DB 43 LGLLGIDFSNQ 54

RESULT 10
LIP_PSEGL STANDARD; PRT; 353 AA.
AC Q05489;
DT 01-OCT-1994 (Rel. 30, Created)
DT 01-OCT-1994 (Rel. 30, Last sequence update)
DT 15-JUL-1999 (Rel. 38, Last annotation update)
DE LIPASE PRECURSOR (EC 3.1.1.3) (TRIACYLGLYCEROL LIPASE).
GN LIPA.
OS Pseudomonas glumae, and Chromobacterium viscosum.
OC Bacteria; Proteobacteria; beta subdivision; Burkholderia group;
OC Burkholderia.
OX NCBI_TaxID=337; 42739;
RN [1]
RP SEQUENCE FROM N.A., SEQUENCE OF 40-61, AND MUTAGENESIS.
RC SPECIES=P. glumae; STRAIN=PG1 / CBS 322.89;
RX MEDLINE=93119130; PubMed=1476423;
RA Frenken L.G.J., Egmond M.R., Batenburg A.M., Bos J.W., Visser C.,
RA Verrips C.T.;
RT "Cloning of the Pseudomonas glumae lipase gene and determination of
RT the active site residues.";
RL Appl. Environ. Microbiol. 58:3787-3791(1992).
RN [2]
RP SEQUENCE OF 40-54, AND CHARACTERIZATION.
RC SPECIES=C. viscosum;
RX MEDLINE=95306500; PubMed=7786905;
RA Taipa M.A., Liebeton K., Costa J.V., Cabral J.M.S., Jaeger K.-E.;
RT "Lipase from Chromobacterium viscosum: biochemical characterization
RT indicating homology to the lipase from Pseudomonas glumae.";
RL Biochim. Biophys. Acta 1256:396-402(1995).
RN [3]
RP X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS).
RC SPECIES=P. glumae;
RX MEDLINE=94009622; PubMed=8405390;
RA Noble M.E.M., Cleasby A., Johnson L.N., Egmond M.R., Frenken L.G.J.;

```

RT "The crystal structure of triacylglycerol lipase from *Pseudomonas*  
 RL glumae reveals a partially redundant catalytic aspartate.";  
 RN [4]  
 RP X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS).  
 RC SPECIES=C.viscosum; STRAIN=ATCC 6918;  
 RX MEDLINE=96275656; PubMed=8683577;  
 RA Lang D., Hofmann B., Haalick L., Hecht H.-J., Spener F., Schmid R.D.,  
 RA Schomburg D.;  
 RT "Crystal structure of a bacterial lipase from *Chromobacterium*  
 RT viscosum ATCC 6918 refined at 1.6-A resolution.";  
 RL J. Mol. Biol. 259:704-717(1996).  
 CC -1- FUNCTION: HYDROLYSIS OF TRIGLYCERIDES.  
 CC -1- CATALYTIC ACTIVITY: TRIACYLGLYCEROL + H(2)O = DIACYLGLYCEROL +  
 CC A FATTY ACID ANION.  
 CC -1- COFACTOR: REQUIRES CALCIUM.  
 CC -1- SUBUNIT: MONOMER.  
 CC -1- SUBCELLULAR LOCATION: SECRETED.  
 CC -1- SIMILARITY: STRONG TO OTHER PSEUDOMONAS LIPASES.  
 CC -1- SIMILARITY: PARTIAL WITH OTHER LIPASES (PANCREATIC, GASTRIC,  
 CC HEPATIC, LINGUAL, LIPOPROTEIN, BACTERIAL, ETC.).  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL Outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announcement/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC -----  
 CC EMBL: X70354; CAA49812.1; -;  
 CC EMBL: A16323; CAA01279.1; -;  
 CC EMBL: A32021; CAA02073.1; -;  
 CC PIR: A48952; A48952.  
 CC PIR: S37291; S37291.  
 CC PDB: 1TAH; 3I-MAY-94.  
 CC InterPro: IPR000073; Abhydrolase.  
 CC InterPro: IPR000379; Est\_lip\_thioest\_actsite.  
 CC Pfam: PF00561; abhydrolase; 1.  
 CC PROSITE: PS00120; LIPASE\_SER; 1.  
 KW Hydrolase; Lipid degradation; Signal; Calcium; 3D-structure.  
 FT SIGNAL 1 39  
 FT CHAIN 40 358 LIPASE.  
 FT ACT\_SITE 126 126 CHARGE RELAY SYSTEM.  
 FT ACT\_SITE 302 302 CHARGE RELAY SYSTEM.  
 FT ACT\_SITE 324 324 CHARGE RELAY SYSTEM.  
 FT DISULFID 229 308  
 FT MUTAGEN 54 54 H->A: NO LOSS OF ACTIVITY.  
 FT MUTAGEN 126 126 S->A: COMPLETE LOSS OF ACTIVITY.  
 FT MUTAGEN 160 160 D->E: NO LOSS OF ACTIVITY.  
 FT MUTAGEN 160 160 D->A: NO LOSS OF ACTIVITY.  
 FT MUTAGEN 280 280 D->E: NO LOSS OF ACTIVITY.  
 FT MUTAGEN 280 280 D->A: COMPLETE LOSS OF ACTIVITY.  
 FT MUTAGEN 302 302 D->E: NO LOSS OF ACTIVITY.  
 FT MUTAGEN 302 302 D->A: 75% LOSS OF ACTIVITY.  
 FT MUTAGEN 324 324 H->A: COMPLETE LOSS OF ACTIVITY.  
 FT CONFLICT 40 40 A -> W (IN REF. 2).  
 SQ SEQUENCE 358 AA; 36928 MW; FE7B5D7A22EC6B4B CRC64;  
 Query Match 47.4%; Score 36.5; DB 1; Length 358;  
 Best Local Similarity 90.0%; Pred. No. 36;  
 Matches 9; Conservative 0; Mismatches 0; Indels 1; Gaps 1;  
 QY 3 GLACTD-FAN 11  
 Db 55 GLACTDRFAN 64  
 RESULT 11  
 RISC\_AERPE STANDARD; PRT; 155 AA.  
 ID

AC Q9YDC5;  
 DT 20-AUG-2001 (Rel. 40, Created)  
 DT 20-AUG-2001 (Rel. 40, Last sequence update)  
 DT 20-AUG-2001 (Rel. 40, Last annotation update)  
 DE RIBOFLAVIN SYNTHASE (EC 2.5.1.9).  
 GN RIBC OR APE0988.  
 OS Aeropyrum pernix.  
 OC Archaea; Crenarchaeota; Desulfurococcales; Desulfurococcaceae;  
 OC Aeropyrum.  
 OX NCBI\_TaxID=56636;  
 RN [1]  
 RN SEQUENCE FROM N.A.  
 RC STRAIN=KI.  
 RX MEDLINE=99310339; PubMed=10382966;  
 RA Kwarabayasi Y., Hino Y., Horikawa H., Yamazaki S., Halkawa Y.,  
 RA Jin-no K., Takahashi M., Sekine M., Baba S.-I., Ankaï A., Kosugi H.,  
 RA Hosoyama A., Fukui S., Nagai Y., Nishijima K., Nakazawa H.,  
 RA Takamiya M., Masuda S., Funahashi T., Tanaka T., Kudoh Y.,  
 RA Yamazaki J., Kushida N., Oguchi A., Aoki K.-I., Kubota K.,  
 RA Nakamura Y., Nomura N., Sako Y., Kikuchi H.;  
 RT "Complete genome sequence of an aerobic hyper-thermophilic  
 RT crenarchaeon, *Aeropyrum pernix* KI.";  
 RL DNA Res. 6:83-101(1999).  
 CC -1- CATALYTIC ACTIVITY: 2 6,7-DIMETHYL-8-(1-D-RIBITYL) LUMAZINE -  
 CC RIBOFLAVIN + 4-(1-D-RIBITYLAMINO)-5-AMINO-2,6-DIHYDROXYPYRIMIDINE.  
 CC -1- COFACTOR: FLAVOPROTEIN (BY SIMILARITY).  
 CC -1- PATHWAY: FINAL STEP OF RIBOFLAVIN SYNTHESIS.  
 CC -1- SIMILARITY: BELONGS TO THE DMRL SYNTHASE FAMILY.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL Outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announcement/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC -----  
 CC EMBL: AP000060; BAA79972.1; -;  
 CC Riboflavin biosynthesis; Transferase; Flavoprotein; Complete proteome.  
 KW SEQUENCE 155 AA; 16576 MW; 644B7A1BD313A4F3 CRC64;  
 Query Match 46.8%; Score 36; DB 1; Length 155;  
 Best Local Similarity 60.0%; Pred. No. 18;  
 Matches 6; Conservative 2; Mismatches 2; Indels 0; Gaps 0;  
 QY 1 CIGLAGTDEFA 10  
 Db 4 CVGVADTTFA 13  
 RESULT 12  
 YGAF\_SHIFL STANDARD; PRT; 300 AA.  
 ID YGAF\_SHIFL  
 AC P37775;  
 DT 01-OCT-1994 (Rel. 30, Created)  
 DT 01-OCT-1994 (Rel. 30, Last sequence update)  
 DT 01-OCT-1994 (Rel. 30, Last annotation update)  
 DE HYPOTHETICAL PROTEIN IN GALF 5' REGION (ORF1X3) (FRAGMENT).  
 OS Shigella flexneri.  
 OC Bacteria; Proteobacteria; gamma subdivision; Enterobacteriaceae;  
 OC Shigella.  
 OX NCBI\_TaxID=623;  
 RN [1]  
 RN SEQUENCE FROM N.A.  
 RC STRAIN=SEROTYPE 2A;  
 RX MEDLINE=94131953; PubMed=7507920;  
 RA Morona R., Mavris M., Fallarino A., Manning P.A.;  
 RT "Characterization of the rfc region of *Shigella flexneri*.";  
 RL J. Bacteriol. 176:733-747(1994).  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL Outstation -

CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC -----

DR EMBL; X71970; CAA50765.1; -  
 KW Hypothetical protein.  
 FT NON\_TER 1  
 SQ SEQUENCE 300 AA; 33367 MW; 4735B2EF93E21325 CRC64;

Query Match 46.8%; Score 36; DB 1; Length 300;  
 Best Local Similarity 53.8%; Pred. No. 36;  
 Matches 7; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

QY 2 IGLAGTDFANQRP 14  
 ||||| : | |  
 Db 73 IGLAGSTYDNNYP 85

RESULT 13  
 GLYA\_MYCLE STANDARD; PRT; 426 AA.  
 ID GLYA\_MYCLE  
 AC Q9X794;  
 DT 30-MAY-2000 (Rel. 39, Created)  
 DT 30-MAY-2000 (Rel. 39, Last sequence update)  
 DT 20-AUG-2001 (Rel. 40, Last annotation update)  
 DE SERINE HYDROXYMETHYLTRANSFERASE (EC 2.1.2.1) (SERINE METHYLASE)  
 DE (SHMT).  
 GN GLYA OR ML1953 OR MLCB1222.22.  
 OS Mycobacterium leprae.  
 OC Bacteria; Firmicutes; Actinobacteria; Actinobacteridae;  
 OC Actinomycetales; Corynebacterineae; Mycobacteriaceae; Mycobacterium.  
 OX NCBI\_TaxID=1769;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=TN;  
 RX MEDLINE=21128732; PubMed=11234002;  
 RA Cole S.T., Eiglmeyer K., Parkhill J., James K.D., Thomson N.R.,  
 RA Wheeler P.R., Honore N., Garnier T., Churcher C., Harris D.,  
 RA Mungall K., Basham D., Brown D., Chillingworth T., Connor R.,  
 RA Davies R.M., Devlin K., Duthoy S., Feltwell T., Fraser A., Hamlin N.,  
 RA Holroyd S., Hornsby T., Jagels K., Lacroix C., Maclean J., Moule S.,  
 RA Murphy L., Oliver K., Quail M.A., Rajandream M.A., Rutherford K.M.,  
 RA Rutter S., Seeger K., Simon S., Simmonds M., Skelton J., Squares R.,  
 RA Squares S., Stevens K., Taylor K., Whitehead S., Woodward J.R.,  
 RA Barrell B.G.;  
 RT "Massive gene decay in the leprosy bacillus";  
 RL Nature 409:1007-1011(2001).  
 CC -!- FUNCTION: INTERCONVERSION OF SERINE AND GLYCINE.  
 CC -!- CATALYTIC ACTIVITY: 5,10-METHYLENETETRAHYDROFOLATE + GLYCINE +  
 CC H(2)O = TETRAHYDROFOLATE + L-SERINE.  
 CC -!- COFACTOR: PYRIDOXAL PHOSPHATE (BY SIMILARITY).  
 CC -!- PATHWAY: KEY ENZYME IN THE BIOSYNTHESIS OF PURINES, LIPIDS,  
 CC HORMONES AND OTHER COMPONENTS.  
 CC -!- SUBUNIT: HOMOTETRAMER (BY SIMILARITY).  
 CC -!- SUBCELLULAR LOCATION: CYTOPLASMIC (BY SIMILARITY).  
 CC -!- SIMILARITY: BELONGS TO THE SHMT FAMILY.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC -----

DR EMBL; AL049491; CAB39828.1; -  
 DR EMBL; AL583923; CAC30908.1; -  
 DR Leproma; ML1953; -  
 DR InterPro; IPR001085; SHMT.  
 DR Pfam; PF00464; SHMT; 1.

DR PROSITE; PS00096; SHMT; FALSE\_NEG.  
 KW Transferase; Pyridoxal phosphate; One-carbon metabolism;  
 KW Complete proteome. 227 PYRIDOXAL PHOSPHATE (BY SIMILARITY).  
 FT BINDING 227  
 SQ SEQUENCE 426 AA; 45224 MW; 27783E2328AF2C98 CRC64;

Query Match 46.8%; Score 36; DB 1; Length 426;  
 Best Local Similarity 63.6%; Pred. No. 53;  
 Matches 7; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 4 LACTDFANQRP 14  
 | | | | | : |  
 Db 82 LFGADFANVQP 92

RESULT 14  
 WCAM\_ECOLI STANDARD; PRT; 464 AA.  
 ID WCAM\_ECOLI  
 AC P71244; P76378;  
 DT 01-NOV-1997 (Rel. 35, Created)  
 DT 01-NOV-1997 (Rel. 35, Last sequence update)  
 DT 20-AUG-2001 (Rel. 40, Last annotation update)  
 DE COLANIC ACID BIOSYNTHESIS PROTEIN WCAM.  
 GN WCAM OR B2043.  
 OS Escherichia coli.  
 OC Bacteria; Proteobacteria; gamma subdivision; Enterobacteriaceae;  
 OC Escherichia.  
 OX NCBI\_TaxID=562;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=K12;  
 RX MEDLINE=96326333; PubMed=8759852;  
 RA Stevenson G., Andrianopoulos K., Hobbs M., Reeves P.R.;  
 RT "Organization of the Escherichia coli K-12 gene cluster responsible  
 RT for production of the extracellular polysaccharide colanic acid.";  
 RL J. Bacteriol. 178:4885-4893(1996).  
 RN [2]  
 RP REVISIONS.  
 RC STRAIN=K12;  
 RA Reeves P.R.;  
 RL Submitted (APR-1998) to the EMBL/GenBank/DBJ databases.  
 RN [3]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=K12 / MGL1655;  
 RX MEDLINE=97426617; PubMed=9278503;  
 RA Blattner F.R., Plunkett G. III, Bloch C.A., Perna N.T., Burland V.,  
 RA Riley M., Collado-Vides J., Glasner J.D., Rode C.K., Mayhew G.F.,  
 RA Gregor J., Davis N.W., Kirkpatrick H.A., Goeden M.A., Rose D.J.,  
 RA Mau B., Shao Y.;  
 RT "The complete genome sequence of Escherichia coli K-12";  
 RL Science 277:1233-1238(1997).  
 RN [4]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=K12;  
 RX MEDLINE=97251358; PubMed=9097040;  
 RA Itoh T., Alba H., Baba T., Fujita K., Hayashi K., Inada T.,  
 RA Isono K., Kasai H., Kimura S., Kitakawa M., Kitagawa M.,  
 RA Makino K., Miki T., Mizobuchi K., Mori H., Mori T., Motomura K.,  
 RA Nakade S., Nakamura Y., Nishimoto H., Nishio Y., Oshima T.,  
 RA Saito N., Sampei G., Seki Y., Sivasubramanian S., Tagami H.,  
 RA Takeda J., Takemoto K., Wada C., Yamamoto Y., Horiuchi T.;  
 RT "A 450-Kb DNA sequence of the Escherichia coli K-12 genome  
 RT corresponding to the 40.1-50.0 min region on the linkage map";  
 RL DNA Res. 3:379-392(1996).  
 CC -!- PATHWAY: INVOLVED IN THE BIOSYNTHESIS OF THE SLIME POLYSACCHARIDE  
 CC COLANIC ACID.  
 CC -----

CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial

CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
CC -----

DR EMBL; U38473; AAC77852.1; -  
DR EMBL; A8000295; AAC75104.1; -  
DR EMBL; D90842; BAA15897.1; -  
DR EcoGene; EGI2651; wcam.  
KW Lipopolysaccharide biosynthesis; Complete proteome.  
SQ SEQUENCE 464 AA; 51315 MW; 72A7655DC07368BE CRC64;

Query Match 46.8%; Score 36; DB 1; Length 464;  
Best Local Similarity 53.8%; Pred. No. 58;  
Matches 7; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

QY 2 IGLAGTDFANQRP 14  
|||||: :| |  
Db 228 IGLAGSTYDNNYP 240

## RESULT 15

ID	WCAW_SALTY	STANDARD;	PRT;	467 AA.
AC	P26389;			
DT	01-AUG-1992 (Rel. 23, Created)			
DT	01-AUG-1992 (Rel. 23, Last sequence update)			
DT	01-NOV-1997 (Rel. 35, Last annotation update)			
DE	COLANIC ACID BIOSYNTHESIS PROTEIN WCAW.			
GN	WCAW.			
OS	Salmonella typhimurium.			
OC	Bacteria; Proteobacteria; gamma subdivision; Enterobacteriaceae;			
OC	Salmonella.			
OX	NCBI_TaxID=602;			
RN	[1]			
RP	SEQUENCE FROM N.A.			
RC	STRAIN-LT2;			
RX	MEDLINE=91260454; PubMed=1710759;			
RA	Jiang X.-M., Neal B., Santiago F., Lee S.J., Romana L.K., Reeves P.R.;			
RT	"Structure and sequence of the rfb (O antigen) gene cluster of			
RT	Salmonella serovar typhimurium (strain LT2).";			
RL	Mol. Microbiol. 5:695-713(1991).			
CC	-1- PATHWAY: INVOLVED IN THE BIOSYNTHESIS OF THE SLIME POLYSACCHARIDE			
CC	COLANIC ACID.			
CC	-----			
CC	This SWISS-PROT entry is copyright. It is produced through a collaboration			
CC	between the Swiss Institute of Bioinformatics and the EMBL outstation -			
CC	the European Bioinformatics Institute. There are no restrictions on its			
CC	use by non-profit institutions as long as its content is in no way			
CC	modified and this statement is not removed. Usage by and for commercial			
CC	entities requires a license agreement (See <a href="http://www.isb-sib.ch/announce/">http://www.isb-sib.ch/announce/</a>			
CC	or send an email to <a href="mailto:license@isb-sib.ch">license@isb-sib.ch</a> ). -----			
DR	EMBL; X56793; CAA40113.1; -			
DR	PIR; S15297; S15297.			
DR	StyGene; SG10448; wcam.			
KW	Lipopolysaccharide biosynthesis.			
SQ	SEQUENCE 467 AA; 50958 MW; 9DCCFD551218E6E8 CRC64;			

Query Match 46.8%; Score 36; DB 1; Length 467;  
Best Local Similarity 53.8%; Pred. No. 58;  
Matches 7; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

QY 2 IGLAGTDFANQRP 14  
|||||: :| |  
Db 231 IGLAGSTYDNNYP 243

Search completed: March 26, 2002, 13:40:45  
Job time: 259 sec



GenCore version 4.5  
Copyright (c) 1993 - 2000 CompuGen Ltd.

# OM protein - protein search, using sw model

Run on: March 26, 2002, 13:40:14 ; Search time 79.01 Seconds  
(without alignments)  
25.918 Million cell updates/sec

Title: US-09-709-201-100  
Perfect score: 77  
Sequence: 1 CIGLAGTDFANQRP 14

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 473505 seqs, 146272329 residues

Total number of hits satisfying chosen parameters: 473505

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%  
Listing first 45 summaries

## Database :

SPTREMBL\_17:\*  
1: sp\_archaea:\*  
2: sp\_bacteria:\*  
3: sp\_fungi:\*  
4: sp\_human:\*  
5: sp\_invertebrate:\*  
6: sp\_mammal:\*  
7: sp\_mhc:\*  
8: sp\_organelle:\*  
9: sp\_phase:\*  
10: sp\_plant:\*  
11: sp\_rodent:\*  
12: sp\_virus:\*  
13: sp\_vertebrate:\*  
14: sp\_unclassified:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	68	88.3	392	2 Q99B0	Q99b0 chlamydia
2	50	64.9	356	2 Q52924	Q52924 chlamydia p
3	50	64.9	390	2 Q9AIJ5	Q9AIJ5 chlamydia p
4	50	64.9	392	2 Q9AIJ4	Q9AIJ4 chlamydia p
5	43	55.8	188	3 Q9HFA9	Q9HFA9 trichosporo
6	43	55.8	995	3 Q9URX4	Q9URX4 schizosacch
7	41	53.2	1238	2 Q25330	Q25330 helicobacte
8	41	53.2	2546	2 Q9AI30	Q9AI30 burkholderi
9	41	53.2	3194	2 Q9ZLM3	Q9ZLM3 helicobacte
10	39	50.6	377	2 Q9RHU5	Q9RHU5 streptomyce
11	39	50.6	382	2 Q9AI11	Q9AI11 streptococc
12	39	50.6	502	6 Q9BDI4	Q9BDI4 ovis aries
13	39	50.6	502	11 Q9QVT7	Q9QVT7 rattus sp.
14	39	50.6	502	13 Q9PUF4	Q9PUF4 coturnix co
15	39	50.6	743	2 Q9KF71	Q9KF71 bacillus ha
16	39	50.6	961	3 Q9Z223	Q9Z223 emericeila
17	39	50.6	1785	5 Q93781	Q93781 caenorhabdi
18	38	49.4	356	2 P95276	P95276 mycobacteri
19	38	49.4	365	10 Q9SZ73	Q9SZ73 arabidopsis

Q9hdz5 schizosacch  
Q9w645 gallus gall  
Q9f4v4 photorhabdu  
Q9lv47 arabidopsis  
Q61604 drosophila  
Q9lct7 methylococc  
Q9ags1 streptomyce  
Q9l9c0 trachemys s  
Q9zj02 streptococc  
Q9kze9 streptomyce  
Q9vpk7 drosophila  
Q9ny99 homo sapien  
Q44167 actinobacill  
Q99ss5 staphylococ  
P91944 drosophila  
Q61862 caenorhabdi  
Q9w4b8 drosophila  
Q81209 arabidopsis  
Q9ly21 arabidopsis  
Q91lv3 pseudomonas  
Q9m2q4 arabidopsis  
Q9vmj5 drosophila  
Q9haz9 homo sapien  
Q66033 cercopitheci  
Q9fa16 acetobacter  
Q9gs30 drosophila

38 49.4 388 3 Q9HDZ5  
38 49.4 543 13 Q9W645  
38 49.4 564 2 Q9F4V4  
38 49.4 614 10 Q9LV47  
38 49.4 640 5 Q61604  
37 48.1 141 2 Q9LCT7  
37 48.1 144 2 Q9AGS1  
37 48.1 170 13 Q9L9C0  
37 48.1 293 2 Q9ZJ02  
37 48.1 479 2 Q9KZE9  
37 48.1 500 5 Q9VPK7  
37 48.1 539 4 Q9NY99  
37 48.1 547 2 Q44167  
37 48.1 553 2 Q99SS5  
37 48.1 619 5 P91944  
37 48.1 719 5 Q61862  
37 48.1 719 5 Q9W4B8  
37 48.1 902 10 Q81209  
37 48.1 902 10 Q9LY21  
37 48.1 926 2 Q91LV3  
40 48.1 1024 10 Q9M2Q4  
41 36.5 47.4 687 5 Q9VMJ5  
42 36 46.8 187 4 Q9H4Z9  
43 36 46.8 187 12 Q66033  
44 36 46.8 205 2 Q9FA16  
45 36 46.8 263 5 Q9GS30

## ALIGNMENTS

RESULT 1  
Q99B0 PRELIMINARY; PRT; 392 AA.  
AC Q99B0;  
DT 01-JUN-2001 (TREMREL. 17, Created)  
DT 01-JUN-2001 (TREMREL. 17, Last sequence update)  
DE 01-JUN-2001 (TREMREL. 17, Last annotation update)  
DE MAJOR OUTER MEMBRANE PROTEIN PRECURSOR.  
GN OMPA.  
OS Chlamydomophila felis.  
OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydomophila.  
OX NCBI\_TaxID=83556;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN=FP BAKER, ATCC VR120, AND FP CELLO;  
RX MEDLINE=21078680; PubMed=11211261;  
RA Bush R.M., Everett K.D.;  
RT "Molecular evolution of the Chlamydiaceae."  
RL Int. J. Syst. Evol. Microbiol. 51:203-220(2001).  
DR EMBL; AF269257; AAK00238.1; -;  
DR EMBL; AF269258; AAK00239.1; -;  
KW Signal.  
FT SIGNAL 1 22 POTENTIAL.  
FT CHAIN 23 392 MAJOR OUTER MEMBRANE PROTEIN.  
SQ SEQUENCE 392 AA; 42051 MW; 88B3C09C1FEE26DB CRC64;

Query Match 88.3%; Score 68; DB 2; Length 392;  
Best Local Similarity 100.0%; Pred. No. 0.00059;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 IGLAGTDFANQRP 14  
|||||  
DB 160 IGLAGTDFANQRP 172

RESULT 2  
Q52924 PRELIMINARY; PRT; 356 AA.  
ID Q52924  
AC Q52924;  
DT 01-JUN-1998 (TREMREL. 06, Created)  
DT 01-JUN-1998 (TREMREL. 06, Last sequence update)

DT 01-JUN-2001 (TrEMBLrel. 17, Last annotation update)  
 DE OUTER MEMBRANE PROTEIN 1 (FRAGMENT).  
 GN OMP1.  
 OS Chlamydia psittaci (Chlamydomphila psittaci).  
 OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydomphila.  
 OX NCBI\_TaxID=83554;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=92-1293, AVIAN SEROVAR D;  
 RA Vanrompay D., Cox E., Goddeeris B.M., Volckaert G.;  
 RL Submitted (FEB-1998) to the EMBL/GenBank/DBJ databases.  
 DR EMBL; Y16562; CAA76286.1; -  
 DR InterPro: IPR000604; Chlamydia\_OMP.  
 DR Pfam: PF01308; Chlamydia\_OMP; 1.  
 DR ProDom: PD001717; Chlamydia\_OMP; 1.  
 KW Outer membrane  
 FT NON\_TER 356  
 SQ SEQUENCE 356 AA; 38396 MW; D51DE06FB46E6F13 CRC64;

Query Match 64.9%; Score 50; DB 2; Length 356;  
 Best Local Similarity 76.9%; Pred. No. 0.8;  
 Matches 10; Conservative 0; Mismatches 3; Indels 3; Gaps 0;

QY 2 IGLAGTDFANQRP 14  
 III IIII III  
 Db 160 IGLKGTDFNNQLP 172

RESULT 3  
 Q9AIJ5 ID Q9AIJ5 PRELIMINARY; PRT; 390 AA.  
 AC Q9AIJ5;  
 DT 01-JUN-2001 (TrEMBLrel. 17, Created)  
 DT 01-JUN-2001 (TrEMBLrel. 17, Last sequence update)  
 DE 01-JUN-2001 (TrEMBLrel. 17, Last annotation update)  
 DE MAJOR OUTER MEMBRANE PROTEIN PRECURSOR (FRAGMENT).  
 GN OMPA.  
 OS Chlamydia psittaci (Chlamydomphila psittaci).  
 OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydomphila.  
 OX NCBI\_TaxID=83554;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=NEW JERSEY 1, NJ1;  
 RX MEDLINE=21078680; PubMed=11211261;  
 RA Bush R.M., Everett K.D.;  
 RT "Molecular evolution of the Chlamydiaceae.";  
 RL Int. J. Syst. Evol. Microbiol. 51:203-220(2001).  
 DR EMBL; AF269266; AAK00247.1; -  
 KW Signal.  
 FT NON\_TER 1  
 FT SIGNAL <1 20 POTENTIAL.  
 FT CHAIN 21 390 MAJOR OUTER MEMBRANE PROTEIN.  
 SQ SEQUENCE 390 AA; 42042 MW; B62858403DBFA4E6 CRC64;

Query Match 64.9%; Score 50; DB 2; Length 390;  
 Best Local Similarity 76.9%; Pred. No. 0.88;  
 Matches 10; Conservative 0; Mismatches 3; Indels 3; Gaps 0;

QY 2 IGLAGTDFANQRP 14  
 III IIII III  
 Db 158 IGLKGTDFNNQLP 170

RESULT 4  
 Q9AIJ4 ID Q9AIJ4 PRELIMINARY; PRT; 392 AA.  
 AC Q9AIJ4;  
 DT 01-JUN-2001 (TrEMBLrel. 17, Created)  
 DT 01-JUN-2001 (TrEMBLrel. 17, Last sequence update)  
 DE 01-JUN-2001 (TrEMBLrel. 17, Last annotation update)  
 DE MAJOR OUTER MEMBRANE PROTEIN PRECURSOR.

GN OMPA.  
 OS Chlamydia psittaci (Chlamydomphila psittaci).  
 OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydomphila.  
 OX NCBI\_TaxID=83554;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=TEXAS TURKEY 3, TT3;  
 RX MEDLINE=21078680; PubMed=11211261;  
 RA Bush R.M., Everett K.D.;  
 RT "Molecular evolution of the Chlamydiaceae.";  
 RL Int. J. Syst. Evol. Microbiol. 51:203-220(2001).  
 DR EMBL; AF269267; AAK00248.1; -  
 KW Signal.  
 FT SIGNAL 1 22 POTENTIAL.  
 FT CHAIN 23 392 MAJOR OUTER MEMBRANE PROTEIN.  
 SQ SEQUENCE 392 AA; 42293 MW; FC31FC051955246C CRC64;

Query Match 64.9%; Score 50; DB 2; Length 392;  
 Best Local Similarity 76.9%; Pred. No. 0.88;  
 Matches 10; Conservative 0; Mismatches 3; Indels 3; Gaps 0;

QY 2 IGLAGTDFANQRP 14  
 III IIII III  
 Db 160 IGLKGTDFNNQLP 172

RESULT 5  
 Q9HFA9 ID Q9HFA9 PRELIMINARY; PRT; 188 AA.  
 AC Q9HFA9;  
 DT 01-MAR-2001 (TrEMBLrel. 16, Created)  
 DT 01-MAR-2001 (TrEMBLrel. 16, Last sequence update)  
 DE 20 KDA PROTEIN HAVING G-X-X-Q-X-W-MOTIF PRECURSOR.  
 OS Trichosporon mucoides.  
 OC Eukaryota; Fungi; Basidiomycota; Hymenomycetes; Tremellomycetidae.  
 OC Trichosporonales; Trichosporon.  
 OX NCBI\_TaxID=82522;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=TIMM 1573;  
 RA Usui Y., Matsunaga Y.;  
 RT "20 kDa protein having G-X-X-Q-X-W motif.";  
 RL Submitted (FEB-2000) to the EMBL/GenBank/DBJ databases.  
 DR EMBL; AB036375; BAB20766.1; -  
 DR InterPro: IPR000772; Ricin\_B\_lectin.  
 DR Pfam; PF00652; Ricin\_B\_lectin; 3.  
 DR SMART; SM00458; RICIN; 1.  
 KW Signal.  
 FT SIGNAL 1 16 POTENTIAL.  
 SQ SEQUENCE 188 AA; 19751 MW; A391173C35A547B1 CRC64;

Query Match 55.8%; Score 43; DB 3; Length 188;  
 Best Local Similarity 50.0%; Pred. No. 7;  
 Matches 7; Conservative 3; Mismatches 4; Indels 4; Gaps 0;

QY 1 CIGLAGTDFANQRP 14  
 I: :II :III I  
 Db 57 CVDVAGANFANGTP 70

RESULT 6  
 Q9URX4 ID Q9URX4 PRELIMINARY; PRT; 995 AA.  
 AC Q9URX4;  
 DT 01-MAY-2000 (TrEMBLrel. 13, Created)  
 DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)  
 DE 01-JUN-2001 (TrEMBLrel. 17, Last annotation update)  
 DE PUTATIVE FAMILY 31 GLUCOSIDASE.  
 GN SPAC922.02C.  
 OS Schizosaccharomyces pombe (Fission yeast).

OC Eukaryota; Fungi; Ascomycota; Schizosaccharomycetes;  
 OC Schizosaccharomycetales; Schizosaccharomycetaceae;  
 OC Schizosaccharomycetes;  
 OX NCBI\_TaxID=4896;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=972H-;  
 RA Hunt C., Aves S., McDougall R.C., Rajandream M.A., Barrell B.G.;  
 RL Submitted (DEC-1999) to the EMBL/GenBank/DBJ databases.  
 DR EMBL: AL133522; CAB63549.1; -;  
 DR InterPro: IPR000322; Glyco\_hydro\_31.  
 DR InterPro: IPR001680; WD40.  
 DR Pfam: PF01055; Glyco\_hydro\_31; 1.  
 DR PROSITE: PS00129; GLYCOSYL-HYDROL\_F31\_1; 1.  
 DR PROSITE: PS00707; GLYCOSYL-HYDROL\_F31\_2; 1.  
 DR PROSITE: PS00678; WD\_REPEATS\_1; UNKNOWN\_1.  
 SQ SEQUENCE 995 AA; 112713 MW; 1EC1D292DC30DBA8 CRC64;

Query Match 55.8%; Score 43; DB 3; Length 995;  
 Best Local Similarity 57.1%; Pred. No. 40;  
 Matches 8; Conservative 1; Mismatches 5; Indels 0; Gaps 0;

Qy 1 CIGLAGTDFANQRP 14  
 :| | | | | :| |  
 Db 507 CIGSGCTDKLDQNP 520

RESULT 7  
 O25330  
 ID 025330 PRELIMINARY; PRT; 1238 AA.  
 AC 025330;  
 DT 01-JAN-1998 (TEMBLrel. 05, Created)  
 DT 01-JAN-1998 (TEMBLrel. 05, Last sequence update)  
 DT 01-JUN-2000 (TEMBLrel. 14, Last annotation update)  
 DE HYPOTHETICAL 135.1 KDA PROTEIN.  
 GN HP0609.  
 OS Helicobacter pylori (Campylobacter pylori).  
 OC Bacteria; Proteobacteria; epsilon subdivision; Helicobacter group;  
 OC Helicobacter  
 OX NCBI\_TaxID=210;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=26695 / ATCC 700392;  
 RX MEDLINE=97394467; PubMed=9252185;  
 RA Tomb J.-P., White O., Kerlavage A.R., Clayton R.A., Sutton G.G.,  
 RA Fleischmann R.D., Ketchum K.A., Klenk H.-P., Gill S., Dougherty B.A.,  
 RA Nelson K., Quackenbush J., Zhou L., Kirkness E.F., Peterson S.,  
 RA Loftus B., Richardson D., Dodson R., Khalak H.G., Glodek A.,  
 RA McKenney K., Fitzgerald L.M., Lee N., Adams M.D., Hickey E.K.,  
 RA Berg D.E., Gocayne J.D., Utterback T.R., Peterson J.D., Kelley J.M.,  
 RA Cotton M.D., Weidman J.M., Fujii C., Bowman C., Watthey L., Wallin E.,  
 RA Hayes W.S., Borodovsky M., Karp P.D., Smith H.O., Fraser C.M.,  
 RA Venter J.C.;  
 RT "The complete genome sequence of the gastric pathogen Helicobacter  
 pylori.";  
 RL Nature 388:539-547(1997).  
 DR EMBL: AE000575; AAD07677.1; -;  
 DR TIGR: HP0609; -;  
 KW Hypothetical protein; Complete proteome.  
 SQ SEQUENCE 1238 AA; 135062 MW; 66DF754EB1BFB173 CRC64;

Query Match 53.2%; Score 41; DB 2; Length 1238;  
 Best Local Similarity 53.8%; Pred. No. 1.1e+02;  
 Matches 7; Conservative 1; Mismatches 5; Indels 0; Gaps 0;

Qy 2 IGLAGTDFANQRP 14  
 :| | | | | :| |  
 Db 207 VNLNTDFGNQTP 219

RESULT 8

Q9AI30  
 ID 09AI30 PRELIMINARY; PRT; 2546 AA.  
 AC 09AI30;  
 DT 01-JUN-2001 (TEMBLrel. 17, Created)  
 DT 01-JUN-2001 (TEMBLrel. 17, Last sequence update)  
 DT 01-JUN-2001 (TEMBLrel. 17, Last annotation update)  
 DE PUTATIVE TYPE I POLYKETIDE SYNTHASE WCBR.  
 GN WCBR.  
 OS Burkholderia mallei (Pseudomonas mallei).  
 OC Bacteria; Proteobacteria; beta subdivision; Burkholderia group;  
 OC Burkholderia.  
 OX NCBI\_TaxID=13373;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=ATCC23344;  
 RA DeShazer D., Haag D.M., Fritz D.L., Woods D.E.;  
 RT "Identification of a Burkholderia mallei polysaccharide gene cluster  
 RT by subtractive hybridization and demonstration that the encoded  
 RT capsule is an essential virulence determinant.";  
 RL Microb. Pathog. 0:0-0(2001).  
 DR EMBL: AF285636; AAK26474.1; -;  
 SQ SEQUENCE 2546 AA; 267597 MW; 55DFD9BC44A5F9BA CRC64;

Query Match 53.2%; Score 41; DB 2; Length 2546;  
 Best Local Similarity 54.5%; Pred. No. 2.4e+02;  
 Matches 6; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy 2 IGLAGTDFANO 12  
 :| | | | | :| |  
 Db 123 VGVAGTDYGNR 133

RESULT 9  
 Q9ZLM3  
 ID 09ZLM3 PRELIMINARY; PRT; 3194 AA.  
 AC 09ZLM3;  
 DT 01-MAY-1999 (TEMBLrel. 10, Created)  
 DT 01-MAY-1999 (TEMBLrel. 10, Last sequence update)  
 DT 01-JUN-2001 (TEMBLrel. 17, Last annotation update)  
 DE PUTATIVE VACUOLATING CYTOTOXIN (VACA) PARALOG.  
 GN JHP0556.  
 OS Helicobacter pylori J99 (Campylobacter pylori J99).  
 OC Bacteria; Proteobacteria; epsilon subdivision; Helicobacter group;  
 OC Helicobacter  
 OX NCBI\_TaxID=85963;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC MEDLINE=99120557; PubMed=9923682;  
 RX Alm R.A., Ling L.-S.L., Moir D.T., King B.L., Dolg P.C.,  
 RA Smith D.R., Noonan B., Guild B.C., deJonge B.L., Carmel G.,  
 RA Tummino P.J., Caruso A., Uria-Nickelsen M., Mills D.M., Ives C.,  
 RA Gibson R., Merberg D., Mills S.D., Jiang Q., Taylor D.E., Vovis G.F.,  
 RA Trust T.J.;  
 RT "Genomic sequence comparison of two unrelated isolates of the human  
 RT gastric pathogen Helicobacter pylori.";  
 RL Nature 397:176-180(1999).  
 DR EMBL: AE001488; AAD06134.1; -;  
 DR InterPro: IPR001589; Actinin\_act\_bind.  
 DR PROSITE: PS00019; ACTININ\_1; UNKNOWN\_1.  
 KW Complete proteome.  
 SQ SEQUENCE 3194 AA; 348350 MW; 26D60C492DBECF0E CRC64;

Query Match 53.2%; Score 41; DB 2; Length 3194;  
 Best Local Similarity 53.8%; Pred. No. 3e+02;  
 Matches 7; Conservative 1; Mismatches 5; Indels 0; Gaps 0;

Qy 2 IGLAGTDFANQRP 14  
 :| | | | | :| |  
 Db 208 VNLNTDFGNQTP 220

```
Db 14 IGLVCKQFAKEQP 26

RESULT 10
Q9RHU5 PRELIMINARY; PRT; 377 AA.
AC Q9RHU5;
DT 01-MAY-2000 (TREMBLrel. 13, Created)
DT 01-MAY-2000 (TREMBLrel. 13, Last sequence update)
DE 01-JUN-2001 (TREMBLrel. 17, Last annotation update)
DE CHI35 PROTEIN.
GN CHI35.
OS Streptomyces thermoviolaceus.
OC Bacteria; Firmicutes; Actinobacteria; Actinobacteridae;
OC Actinomycetales; Streptomycineae; Streptomycetaceae; Streptomycetes.
OX NCBI_TaxID=1952;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN-OPC-520;
RC Tsujibo H.;
RT "Chitinase.";
RL Submitted (AUG-1998) to the EMBL/GenBank/DBJ databases.
DR EMBL; AB016842; BAA88833.1; -
DR HSP; P23951; 2BAA.
DR InterPro: IPR000726; Glyco_hydro_19.
DR InterPro: IPR000772; Ricin_B_lectin.
DR Pfam: PF00182; Glyco_hydro_19; 1.
DR Pfam: PF00652; Ricin_B_lectin; 1.
DR ProDom: PD000574; Glyco_hydro_19; 1.
DR SMART: SM00458; RICIN; 1.
SQ SEQUENCE 377 AA; 39763 MW; 14267B344738562B CRC64;

Query Match 50.6%; Score 39; DB 2; Length 377;
Best Local Similarity 50.0%; Pred. No. 74;
Matches 7; Conservative 2; Mismatches 5; Indels 0; Gaps 0;

QY 1 CIGLAGTDFANQRP 14
   |: || | | | |
Db 47 CLDVAGADSANGTP 60

RESULT 11
Q9A111 PRELIMINARY; PRT; 382 AA.
AC Q9A111;
DT 01-JUN-2001 (TREMBLrel. 17, Created)
DT 01-JUN-2001 (TREMBLrel. 17, Last sequence update)
DT 01-JUN-2001 (TREMBLrel. 17, Last annotation update)
DE PUTATIVE ACETYL-COA C-ACETYLTRANSFERASE (EC 2.3.1.).
DE SPY0524.
OS Streptococcus pyogenes.
OC Bacteria; Firmicutes; Bacillus/Clostridium group; Streptococcaceae;
OC Streptococcus.
OX NCBI_TaxID=1314;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN-SF370;
RX MEDLINE=21192684; PubMed=11296296;
RA Ferretti J.J., McShan W.M., Ajdic D.J., Savic D.J., Savic G., Lyon K.,
RA Primeaux C., Sezate S., Suvorov A.N., Kenton S., Lai H.S., Lin S.P.,
RA Qian Y., Jia H.G., Najjar F.Z., Ren Q., Zhu H., Song L., White J.,
RA Yuan X., Clifton S.W., Roe B.A., McLaughlin R.;
RT "Complete genome sequence of an M1 strain of Streptococcus pyogenes.";
RL Proc. Natl. Acad. Sci. U.S.A. 98:4658-4663(2001).
DR EMBL; AE006510; AAK33520.1; -
KW Transferase; Acyltransferase; Complete proteome.
SQ SEQUENCE 382 AA; 40746 MW; 67755D330D73C2D4 CRC64;

Query Match 50.6%; Score 39; DB 2; Length 382;
Best Local Similarity 53.8%; Pred. No. 75;
Matches 7; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

QY 2 IGLAGTDFANQRP 14
   ||| | | | | |
Db 14 IGLVCKQFAKEQP 26
```

```
Db 14 IGLVCKQFAKEQP 26

RESULT 12
Q9BDI4 PRELIMINARY; PRT; 502 AA.
AC Q9BDI4;
DT 01-JUN-2001 (TREMBLrel. 17, Created)
DT 01-JUN-2001 (TREMBLrel. 17, Last sequence update)
DT 01-JUN-2001 (TREMBLrel. 17, Last annotation update)
DE BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE IB.
GN BMPR-IB.
OS Ovis aries (Sheep).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
OC Bovidae; Caprinae; Ovis.
OX NCBI_TaxID=9940;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE-OVARY;
RA Souza C.J.H., MacDougall C.N., Campbell B.K., McNeilly A.S.,
RA Baird D.T.;
RT "The Booroola (FecB) phenotype is associated with a mutation in the
RT bone morphogenetic receptor type IB (BMPRII) gene.";
RL J. Endocrinol. 0:0-0(2001).
RW EMBL; AF357007; AAK30296.1; -
KW Receptor.
SQ SEQUENCE 502 AA; 56907 MW; 6552124A0A24F35C CRC64;

Query Match 50.6%; Score 39; DB 6; Length 502;
Best Local Similarity 66.7%; Pred. No. 99;
Matches 6; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1 CIGLAGTDF 9
   |: || | | | |
Db 71 CLCGSGSDF 79

RESULT 13
Q9QVT7 PRELIMINARY; PRT; 502 AA.
AC Q9QVT7;
DT 01-MAY-2000 (TREMBLrel. 13, Created)
DT 01-MAY-2000 (TREMBLrel. 13, Last sequence update)
DT 01-JUN-2001 (TREMBLrel. 17, Last annotation update)
DE CFK-43A-BONE MORPHOGENETIC PROTEIN BINDING SERINE/THREONINE KINASE
DE RECEPTOR.
OS Rattus sp.
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
OX NCBI_TaxID=10118;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=95110346; PubMed=7811286;
RA Yamaji N., Celeste A.J., Thies R.S., Song J.J., Bernier S.M.,
RA Goldtman D., Lyons K.M., Nove J., Rosen V., Wozney J.M.;
RT "A mammalian serine/threonine kinase receptor specifically binds BMP-2
RT and BMP-4.";
RL Biochem. Biophys. Res. Commun. 205:1944-1951(1994).
CC -I- SIMILARITY: TO THE SER/THR FAMILY OF PROTEIN KINASES.
DR InterPro: IPR000333; ActivinII_receptor.
DR InterPro: IPR000472; Activin_rec.
DR InterPro: IPR000719; Euk_pkinase.
DR InterPro: IPR003605; GS.
DR InterPro: IPR002290; Ser_thr_kin_actsite.
DR InterPro: IPR001245; Tyr_kin.
DR Pfam: PF01064; Activin_recp; 1.
DR Pfam: PF00069; pkinase; 1.
DR PRINTS; PR00653; ACTIVIN2R.
DR PRINTS; PR00109; TYRKINASE.
DR SMART; SM00467; GS; 1.
DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
```

DR PROSITE; PS50011; PROTEIN\_KINASE\_DOM; 1.  
DR PROSITE; PS00108; PROTEIN\_KINASE\_ST; 1.  
KW ATP-binding; Serine/threonine-protein kinase; Transferase.  
SQ SEQUENCE 502 AA; 56870 MW; E147D1B4477F7573 CRC64;

Query Match 50.6%; Score 39; DB 11; Length 502;  
Best Local Similarity 66.7%; Pred. No. 99;  
Matches 6; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1 CIGLAGTDF 9  
|:|:| |:  
Db 71 CLGLEGSDF 79

## RESULT 14

Q9PUF4 PRELIMINARY; PRT; 502 AA.  
AC Q9PUF4;  
DT 01-MAY-2000 (Tremblrel. 13, Created)  
DT 01-MAY-2000 (Tremblrel. 13, Last sequence update)  
DT 01-JUN-2001 (Tremblrel. 17, Last annotation update)  
DE BONE MORPHOGENETIC PROTEIN RECEPTOR IB.  
GN BMPR-IB.  
OS Coturnix coturnix (common quail).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Archosauria; Aves; Neognathae; Galliformes; Phasianidae;  
OC Coturnix.  
OX NCBI\_TaxID=9091;  
RN [1]  
RP McPherson C.N.A.  
RA McPherson C.E., Varley J.E., Maxwell G.D.;  
RT "Expression and Regulation of the Type I BMP Receptors during Avian  
RL Neural Crest Development";  
RL Submitted (SEP-1999) to the EMBL/GenBank/DBJ databases.  
CC -1- SIMILARITY: TO THE SER/THR FAMILY OF PROTEIN KINASES.  
DR EMBL; AF189778; AAF04583.1;  
DR HSSP; P36897; 1TBI.  
DR InterPro; IPR000333; ActivinII\_receptor.  
DR InterPro; IPR000472; Activin\_rec.  
DR InterPro; IPR000719; Euk\_pkinase.  
DR InterPro; IPR003605; GS.  
DR InterPro; IPR002290; Ser\_thr\_kin\_actsite.  
DR InterPro; IPR001245; Tyr\_kin.  
DR Pfam; PF01064; Activin\_rec; 1.  
DR Pfam; PF00059; pkinase; 1.  
DR PRINTS; PR00653; ACTIVIN2R.  
DR PRINTS; PR00109; TYRKINASE.  
DR SMART; SM00467; GS; 1.  
DR PROSITE; PS00107; PROTEIN\_KINASE\_ATP; 1.  
DR PROSITE; PS50011; PROTEIN\_KINASE\_DOM; 1.  
DR PROSITE; PS00108; PROTEIN\_KINASE\_ST; 1.  
KW ATP-binding; Receptor; Serine/threonine-protein kinase; Transferase.  
SQ SEQUENCE 502 AA; 56886 MW; 6819265085F28422 CRC64;

Query Match 50.6%; Score 39; DB 13; Length 502;  
Best Local Similarity 66.7%; Pred. No. 99;  
Matches 6; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1 CIGLAGTDF 9  
|:|:| |:  
Db 71 CLGLEGSDF 79

## RESULT 15

Q9KF71 PRELIMINARY; PRT; 743 AA.  
AC Q9KF71;  
DT 01-OCT-2000 (Tremblrel. 15, Created)  
DT 01-OCT-2000 (Tremblrel. 15, Last sequence update)  
DT 01-JUN-2001 (Tremblrel. 17, Last annotation update)  
DE ASSIMILATORY NITRATE REDUCTASE (CATALYTIC SUBUNIT).

GN NASC OR BH0615.  
OS Bacillus halodurans.  
OC Bacteria; Firmicutes; Bacillus/Clostridium group;  
OC Bacillus/Staphylococcus group; Bacillus.  
OX NCBI\_TaxID=86665;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN=C-125 / JCM 9153;  
RX MEDLINE=20512582; PubMed=11058132;  
RA Takami H., Nakasone K., Takaki Y., Maeno G., Sasaki R., Masui N.,  
RA Fuji F., Hirama C., Nakamura Y., Ogasawara N., Kuhara S.,  
RA Horikoshi K.;  
RT "Complete genome sequence of the alkaliphilic bacterium Bacillus  
halodurans and genomic sequence comparison with Bacillus subtilis.";  
RL Nucleic Acids Res. 28:4317-4331(2000).  
DR EMBL; AF001509; BAB04334.1; -;  
DR InterPro; IPR001467; Molybdopterin.  
DR Pfam; PF00384; molybdopterin; 1.  
DR Pfam; PF01568; Molybdop\_binding; 1.  
DR PROSITE; PS00551; MOLYBDOPTERIN\_PROK\_1; UNKNOWN\_1.  
DR PROSITE; PS00490; MOLYBDOPTERIN\_PROK\_2; 1.  
KW Complete proteome.  
SQ SEQUENCE 743 AA; 82692 MW; C7221E52CB270E1A CRC64;

Query Match 50.6%; Score 39; DB 2; Length 743;  
Best Local Similarity 57.1%; Pred. No. 1.5e+02;  
Matches 8; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

QY 1 CIGLAGTDFANQRP 14  
|:|:|:| |:  
Db 184 CIVLAGTNLAFCQP 197

Search completed: March 26, 2002, 13:40:15  
Job time: 229 sec



GenCore version 4.5  
Copyright (c) 1993 - 2000 CompuGen Ltd.

# OM protein - protein search, using sw model

Run on: March 26, 2002, 13:38:48 ; Search time 81.51 Seconds  
(without alignments)  
11.814 Million cell updates/sec

Title: US-09-709-201-101

Perfect score: 73

Sequence: 1 COINKFSRKACG 13

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 522463 seqs, 74073290 residues

Total number of hits satisfying chosen parameters: 522463

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

A\_Geneseq\_1101.\*  
1: /SID88/gcgdata/geneseq/geneseq/AA1980.DAT.\*  
2: /SID88/gcgdata/geneseq/geneseq/AA1981.DAT.\*  
3: /SID88/gcgdata/geneseq/geneseq/AA1982.DAT.\*  
4: /SID88/gcgdata/geneseq/geneseq/AA1983.DAT.\*  
5: /SID88/gcgdata/geneseq/geneseq/AA1984.DAT.\*  
6: /SID88/gcgdata/geneseq/geneseq/AA1985.DAT.\*  
7: /SID88/gcgdata/geneseq/geneseq/AA1986.DAT.\*  
8: /SID88/gcgdata/geneseq/geneseq/AA1987.DAT.\*  
9: /SID88/gcgdata/geneseq/geneseq/AA1988.DAT.\*  
10: /SID88/gcgdata/geneseq/geneseq/AA1989.DAT.\*  
11: /SID88/gcgdata/geneseq/geneseq/AA1990.DAT.\*  
12: /SID88/gcgdata/geneseq/geneseq/AA1991.DAT.\*  
13: /SID88/gcgdata/geneseq/geneseq/AA1992.DAT.\*  
14: /SID88/gcgdata/geneseq/geneseq/AA1993.DAT.\*  
15: /SID88/gcgdata/geneseq/geneseq/AA1994.DAT.\*  
16: /SID88/gcgdata/geneseq/geneseq/AA1995.DAT.\*  
17: /SID88/gcgdata/geneseq/geneseq/AA1996.DAT.\*  
18: /SID88/gcgdata/geneseq/geneseq/AA1997.DAT.\*  
19: /SID88/gcgdata/geneseq/geneseq/AA1998.DAT.\*  
20: /SID88/gcgdata/geneseq/geneseq/AA1999.DAT.\*  
21: /SID88/gcgdata/geneseq/geneseq/AA2000.DAT.\*  
22: /SID88/gcgdata/geneseq/geneseq/AA2001.DAT.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match %	ID	Description
1	73	100.0	13	Peptide fragment o
2	73	100.0	343	C. trachomatis ser
3	73	100.0	391	Chlamydia pneumoni
4	67	91.8	93	Chlamydia major o
5	65	89.0	13	Peptide fragment o
6	65	89.0	13	Peptide fragment o
7	59	80.8	13	Peptide fragment o
8	58	79.5	215	Chlamydia psittaci
9	58	79.5	222	Chlamydia psittaci
10	58	79.5	225	Chlamydia psittaci
11	58	79.5	228	Chlamydia psittaci

12	58	79.5	343	20	AAV56769	C. trachomatis ser
13	58	79.5	356	20	AAV56770	C. trachomatis ser
14	58	79.5	389	20	AAW98188	Chlamydia psittaci
15	58	79.5	402	20	AAW98189	Chlamydia psittaci
16	58	79.5	402	20	AAW98187	Chlamydia psittaci
17	58	79.5	525	21	AAW13645	C. pneumoniae sero
18	58	79.5	525	22	AAW83213	Protein encoded by
19	53	72.6	94	20	AAW95308	Chlamydia major o
20	53	72.6	94	20	AAW95310	Chlamydia major o
21	53	72.6	94	20	AAW95311	Chlamydia major o
22	53	72.6	94	20	AAW95312	Chlamydia major o
23	53	72.6	94	20	AAW95316	Chlamydia major o
24	53	72.6	95	20	AAW95313	Chlamydia major o
25	53	72.6	95	20	AAW95314	Chlamydia major o
26	53	72.6	95	20	AAW95314	Chlamydia major o
27	53	72.6	95	20	AAW95317	Chlamydia major o
28	53	72.6	277	21	AAW82393	C. trachomatis MOM
29	53	72.6	349	21	AAW82392	C. trachomatis MOM
30	53	72.6	372	19	AAW76365	C. trachomatis MOM
31	53	72.6	373	19	AAW76362	C. trachomatis JM1
32	53	72.6	374	19	AAW76364	C. trachomatis JM1
33	53	72.6	376	19	AAW76363	C. trachomatis JM1
34	53	72.6	376	19	AAW76366	C. trachomatis JM1
35	53	72.6	387	20	AAV56767	C. trachomatis ser
36	53	72.6	392	20	AAV56760	C. trachomatis ser
37	53	72.6	393	20	AAV56757	C. trachomatis ser
38	53	72.6	393	20	AAV56759	C. trachomatis ser
39	53	72.6	393	22	AAE06646	Chlamydia trachoma
40	53	72.6	394	7	AAW60004	Sequence of a major
41	53	72.6	394	18	AAW15149	Chlamydia trachoma
42	53	72.6	394	19	AAW73141	Chlamydia trachoma
43	53	72.6	394	19	AAW57775	Chlamydia trachoma
44	53	72.6	394	20	AAV56758	C. trachomatis ser
45	53	72.6	394	21	AAW81268	Chlamydia trachoma

## ALIGNMENTS

RESULT 1  
AAW95328  
ID AAW95328 standard; Protein; 13 AA.  
XX  
AC AAW95328;  
XX  
DT 15-MAR-1999 (first entry)  
XX  
DE Peptide fragment of C. pneumoniae CPN342-354.  
XX  
KW Chlamydia; cryptic phase; elementary body phase; replicating; probenicid;  
KW antiporphyrin acid; immune response; infection; diagnostic; assay; MOMP;  
KW major outer membrane protein; autoimmunity; inflammatory; porphyria;  
KW Epstein Barr virus; antioxidant.  
XX  
OS Chlamydia pneumoniae.  
XX  
PN WC9850074-A2.  
XX  
PD 12-NOV-1998.  
XX  
PF 06-MAY-1998; 98WO-US09237.  
XX  
PR 18-FEB-1998; 98US-0025521.  
PR 06-MAY-1997; 97US-0045889.  
PR 06-MAY-1997; 97US-0045739.  
PR 06-MAY-1997; 97US-0045779.  
PR 06-MAY-1997; 97US-0045780.  
PR 06-MAY-1997; 97US-0045784.  
PR 06-MAY-1997; 97US-0045787.  
PR 14-AUG-1997; 97US-0041593.  
PR 18-FEB-1998; 98US-0025174.  
PR 18-FEB-1998; 98US-0025176.  
XX

PA (UYVA-) UNIV VANDERBILT.  
 XX Mitchell WM, Stratton CW;  
 PI WPI: 1999-059653/05.  
 DR  
 XX  
 PT Composition with two agents effective against different stages of  
 PT chlamydial life cycle - comprises agent targetted against cryptic  
 PT phase, against elementary body phase, against replicating phase,  
 PT probenicid and antiporphyric  
 PS Claim 4; Fig 5; 138pp; English.  
 XX  
 CC The invention relates to the diagnosis and management of infections by  
 CC Chlamydia species. The invention provides a composition that comprises  
 CC at least two agents, where each of the agents is effective against a  
 CC different phase of the chlamydial life cycle. The agents are selected  
 CC from: (a) agents targetted against cryptic phase of chlamydial life  
 CC cycle; (b) agents targetted against elementary body phase of chlamydial  
 CC life cycle; (c) agents targetted against replicating phase of chlamydial  
 CC life cycle; (d) probenicid, and (e) antiporphyric acid. The composition  
 CC is used to elicit a protective immune response to Chlamydia infection in  
 CC an animal or human and is applied until the animal or human tests  
 CC negative for Chlamydia infection. It is also used to treat biological  
 CC material infected with Chlamydia. Diagnostic kits for antibody assays  
 CC against recombinant major outer membrane protein (MOMP), and for DNA  
 CC amplification assays for chlamydial genes, are used to diagnose disease,  
 CC e.g. autoimmune disease, an inflammatory disease or a disease that  
 CC occurs in an immuno-compromised individual, associated with Chlamydia  
 CC infection. The kits are used to detect chlamydial elementary bodies in a  
 CC sample. They are also used to monitor and/or modify the course of therapy  
 CC in a patient. The treatment reduces the acellular load of infectious  
 CC Chlamydia virus. The method is also used to treat porphyria, by  
 CC reducing the number of elementary bodies and applying a drug, e.g.  
 CC cimetidine, and antioxidants, to reduce the adverse effects associated  
 CC with porphyria. Sequences AAY5328 to AAY5331 represent peptides  
 CC employed for the construction of peptide based ELISAs with species  
 CC specificity for variable domain 2 (VD2).  
 XX  
 SQ Sequence 13 AA;

Query Match 100.0%; Score 73; DB 20; Length 13;  
 Best Local Similarity 100.0%; Pred. No. 5.3e-06;  
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 CQINKFKSRKACG 13  
 Db 1 cqinkfksrkacg 13  
 |||||

RESULT 2  
 AAY56771  
 ID AAY56771 standard; Protein: 343 AA.  
 AC AAY56771;  
 XX  
 DT 22-FEB-2000 (first entry)  
 XX  
 DE C. trachomatis serovar HuPn MOMP sequence.  
 XX Major outer membrane protein; MOMP; Chlamydia; vaccine; immune response;  
 KW cellular response; immunogen; Th1-like CD4 response; mucosal immunity.  
 KW Chlamydia trachomatis.  
 OS WO9951745-A2.  
 XX  
 PN 14-OCT-1999.  
 XX  
 PD 07-APR-1999; 99WO-CA00292.  
 PF 07-APR-1998; 98US-0055765.  
 PR

XX (UYMA-) UNIV MANITOBA.  
 XX Bruhnam RC;  
 PI WPI: 1999-620205/53.  
 DR Non-replicating vector encoding fragments of the outer membrane protein  
 PT of Chlamydia, useful in vaccines and as immunogen  
 XX  
 PS Disclosure: Fig 10 A-F; 52pp; English.  
 XX  
 CC The invention provides a non-replicating vector that comprises, linked  
 CC to a promoter, a nucleotide sequence that encodes a region containing at  
 CC least one of the conserved domains 2, 3 and 5 of a major outer membrane  
 CC protein (MOMP) of a Chlamydia strain. The vector is used: (a) in  
 CC vaccines to generate a protective immune response (mainly cellular)  
 CC against MOMP, and (b) as immunogens to raise anti-MOMP antibodies, useful  
 CC in standard immunoassays. Immunization with the vector induces a broad  
 CC spectrum of immune responses, including Th1-like CD4 responses and  
 CC mucosal immunity, providing significant protection against subsequent  
 CC challenge. Sequences AAY5675-71 represent MOMP sequences from a variety  
 CC of serovars of C. trachomatis.  
 XX  
 SQ Sequence 343 AA;

Query Match 100.0%; Score 73; DB 20; Length 343;  
 Best Local Similarity 100.0%; Pred. No. 0.00012;  
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 CQINKFKSRKACG 13  
 Db 296 cqinkfksrkacg 308  
 |||||

RESULT 3  
 AAY35319  
 ID AAY35319 standard; Protein: 391 AA.  
 XX  
 AC AAY35319;  
 XX  
 DT 13-SEP-1999 (first entry)  
 XX  
 DE Chlamydia pneumoniae transmembrane protein sequence.  
 XX  
 KW Respiratory disease; pneumonia; bronchitis; heart disease; sarcoidosis;  
 KW sinusitis; purulent otitis media; erythema nodosum; pharyngitis;  
 KW vaccine; neutralising epitope.  
 XX  
 OS Chlamydia pneumoniae.  
 XX  
 PN WO9927105-A2.  
 XX  
 PD 03-JUN-1999.  
 XX  
 PF 20-NOV-1998; 98WO-IB01890.  
 XX  
 PR 04-NOV-1998; 98US-0107078.  
 PR 21-NOV-1997; 97FR-0014673.  
 XX  
 PA (GEST) GENSET.  
 XX  
 PI Griffiths R;  
 XX  
 DR WPI: 1999-357842/30.  
 XX  
 PT Genome sequence of Chlamydia pneumoniae  
 XX  
 PS Page 1130-1131; Disclosure: 1912pp; English.  
 XX  
 CC AAY34584-Y35879 represent the proteins encoded by all the open reading  
 CC frames in the complete genome (see AAY91990) of Chlamydia pneumoniae.



CC C. pneumoniae causes respiratory disease such as pneumonia and  
 CC bronchitis and is thought to be a contributing factor in heart  
 CC disease, sarcoidosis, sinusitis, purulent otitis media, erythema  
 CC nodosum or pharyngitis. The polypeptides encoded by the open reading  
 CC frames of the C. pneumoniae genome (see AAY34584-Y35879) can be used in  
 CC immunogenic compositions as vaccines. Vectors containing C. pneumoniae  
 CC nucleotide sequences can also be used as immunogenic compositions,  
 CC especially where the vector directs the expression of a neutralising  
 CC epitope of C. pneumoniae.  
 XX  
 SQ Sequence 391 AA;

Query Match 100.0%; Score 73; DB 20; Length 391;  
 Best Local Similarity 100.0%; Pred. No. 0.00014;  
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CQINKFKSRKACG 13  
 |||||

Db 344 cqinkfkkrkacg 356  
 |||||

## RESULT 4

AAW95319  
 ID AAW95319 standard; Protein: 93 AA.

XX  
 AC AAW95319;

DT 15-MAR-1999 (first entry)

XX Chlamydia major outer membrane protein (MOMP) PN fragment.

XX Chlamydia; cryptic phase; elementary body phase; replicating; probenicid;  
 KW antiporphyrin acid; immune response; infection; diagnostic; assay; MOMP;  
 KW major outer membrane protein; autoimmune; inflammatory; porphyria;  
 KW Ebstein Barr virus; antioxidant.

XX Chlamydia sp.

XX WO9850074-A2.

XX 12-NOV-1998.

XX 06-MAY-1998; 98WO-US09237.

XX 18-FEB-1998; 98US-0025521.

XX 06-MAY-1997; 97US-0045689.

XX 06-MAY-1997; 97US-0045739.

XX 06-MAY-1997; 97US-0045779.

XX 06-MAY-1997; 97US-0045780.

XX 06-MAY-1997; 97US-0045784.

XX 06-MAY-1997; 97US-0045787.

XX 14-AUG-1997; 97US-0911593.

XX 18-FEB-1998; 98US-0025174.

XX 18-FEB-1998; 98US-0025176.

XX (UYVA-) UNIV VANDERBILT.

XX Mitchell WM, Stratton CW;

XX WPI; 1999-059653/05.

XX Composition with two agents effective against different stages of

PT chlamydial life cycle - comprises agent targeted against cryptic

PT phase, against elementary body phase, against replicating phase,

PT probenicid and antiporphyrin

XX Disclosure; Fig 1A; 138pp; English.

XX The invention relates to the diagnosis and management of infections by

CC Chlamydia species. The invention provides a composition that comprises

CC at least two agents, where each of the agents is effective against a

CC different phase of the chlamydial life cycle. The agents are selected

CC from: (a) agents targeted against cryptic phase of chlamydial life  
 CC cycle; (b) agents targeted against elementary body phase of chlamydial  
 CC life cycle; (c) agents targeted against replicating phase of chlamydial  
 CC life cycle; (d) probenicid; and (e) antiporphyrin acid. The composition  
 CC is used to elicit a protective immune response to Chlamydia infection in  
 CC an animal or human and is applied until the animal or human tests  
 CC negative for Chlamydia infection. It is also used to treat biological  
 CC material infected with Chlamydia. Diagnostic kits for antibody assays  
 CC against recombinant major outer membrane protein (MOMP), and for DNA  
 CC amplification assays for chlamydial genes, are used to diagnose disease,  
 CC e.g. autoimmune disease, an inflammatory disease or a disease that  
 CC occurs in an immuno-compromised individual, associated with Chlamydia  
 CC infection. The kits are used to detect chlamydial elementary bodies in a  
 CC sample. They are also used to monitor and/or modify the course of therapy  
 CC in a patient. The treatment reduces the acellular load of infectious  
 CC Ebstein Barr virus. The method is also used to treat porphyria, by  
 CC reducing the number of elementary bodies and applying a drug, e.g.  
 CC cimetidine, and antioxidants, to reduce the adverse effects associated  
 CC with porphyria. Sequences AAW95272 to AAW95319 represent peptide  
 CC fragments of various Chlamydial MOMPs.  
 XX  
 SQ Sequence 93 AA;

Query Match 91.8%; Score 67; DB 20; Length 93;

Best Local Similarity 100.0%; Pred. No. 0.00037;

Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CQINKFKSRKAC 12

|||||

Db 46 cqinkfkkrkac 57

## RESULT 5

AAW95330

ID AAW95330 standard; Protein: 13 AA.

XX  
 AC AAW95330;

DT 15-MAR-1999 (first entry)

XX Peptide fragment of C. trachomatis CTL342-354.

XX Chlamydia; cryptic phase; elementary body phase; replicating; probenicid;  
 KW antiporphyrin acid; immune response; infection; diagnostic; assay; MOMP;  
 KW major outer membrane protein; autoimmune; inflammatory; porphyria;  
 KW Ebstein Barr virus; antioxidant.

XX Chlamydia trachomatis.

XX WO9850074-A2.

XX 12-NOV-1998.

XX 06-MAY-1998; 98WO-US09237.

XX 18-FEB-1998; 98US-0025521.

XX 06-MAY-1997; 97US-0045689.

XX 06-MAY-1997; 97US-0045739.

XX 06-MAY-1997; 97US-0045779.

XX 06-MAY-1997; 97US-0045780.

XX 06-MAY-1997; 97US-0045784.

XX 06-MAY-1997; 97US-0045787.

XX 14-AUG-1997; 97US-0911593.

XX 18-FEB-1998; 98US-0025174.

XX 18-FEB-1998; 98US-0025176.

XX (UYVA-) UNIV VANDERBILT.

XX Mitchell WM, Stratton CW;

XX WPI; 1999-059653/05.

Composition with two agents effective against different stages of chlamydial life cycle - comprises agent targetted against cryptic phase, against elementary body phase, against replicating phase, probenicid and antiporphyrin

Claim 4; Fig 5; 138pp; English.

The invention relates to the diagnosis and management of infections by Chlamydia species. The invention provides a composition that comprises at least two agents, where each of the agents is effective against a different phase of the chlamydial life cycle. The agents are selected from: (a) agents targetted against cryptic phase of chlamydial life cycle; (b) agents targetted against elementary body phase of chlamydial life cycle; (c) agents targetted against replicating phase of chlamydial life cycle; (d) probenicid, and (e) antiporphyrin acid. The composition is used to elicit a protective immune response to Chlamydia infection in an animal or human and is applied until the animal or human tests negative for Chlamydia infection. It is also used to treat biological material infected with Chlamydia. Diagnostic kits for antibody assays against recombinant major outer membrane protein (MOMP), and for DNA amplification assays for chlamydial genes, are used to diagnose disease, e.g. autoimmune disease, an inflammatory disease or a disease that occurs in an immuno-compromised individual, associated with Chlamydia infection. The kits are used to detect chlamydial elementary bodies in a sample. They are also used to monitor and/or modify the course of therapy in a patient. The treatment reduces the acellular load of infectious Ebsstein Barr virus. The method is also used to treat porphyria, by reducing the number of elementary bodies and applying a drug, e.g. cimetidine, and antioxidants, to reduce the adverse effects associated with porphyria. Sequences AAW95328 to AAW95331 represent peptides employed for the construction of peptide based ELISAs with species specificity for variable domain 2 (VD2).

Sequence 13 AA;

Query Match 89.0%; Score 65; DB 20; Length 13;  
Best Local Similarity 84.6%; Pred. No. 0.00012;  
Matches 11; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1 CQINKFSRKACG 13  
|||:| |||||  
Db 1 cqinkfsrkacg 13

RESULT 6  
AAW95331  
ID AAW95331 standard; Protein; 13 AA.  
AC AAW95331;  
XX  
XX  
DT 15-MAR-1999 (first entry)  
XX  
DE Peptide fragment of C. psittaci CPS342-354.  
XX

Chlamydia; cryptic phase; elementary body phase; replicating; probenicid; antiporphyrin acid; immune response; infection; diagnostic; assay; MOMP; major outer membrane protein; autoimmune; inflammatory; porphyria; Ebsstein Barr virus; antioxidant.

Chlamydia psittaci.  
WO9850074-A2.  
XX  
XX  
XX  
PD 12-NOV-1998.  
XX  
PF 06-MAY-1998; 98WO-0509237.  
XX  
XX 18-FEB-1998; 98US-0025521.  
PR 06-MAY-1997; 97US-0045689.  
PR 06-MAY-1997; 97US-0045739.  
PR 06-MAY-1997; 97US-0045779.  
PR 06-MAY-1997; 97US-0045780.

PR 06-MAY-1997; 97US-0045784.  
PR 06-MAY-1997; 97US-0045787.  
PR 14-AUG-1997; 97US-0041593.  
PR 18-FEB-1998; 98US-0025174.  
PR 18-FEB-1998; 98US-0025176.  
XX  
PA (UYVA-) UNIV VANDERBILT.  
XX  
XX Mitchell WM, Stratton CW;  
PI  
XX  
DR WPI; 1999-059653/05.  
XX

Composition with two agents effective against different stages of chlamydial life cycle - comprises agent targetted against cryptic phase, against elementary body phase, against replicating phase, probenicid and antiporphyrin

Claim 4; Fig 5; 138pp; English.

The invention relates to the diagnosis and management of infections by Chlamydia species. The invention provides a composition that comprises at least two agents, where each of the agents is effective against a different phase of the chlamydial life cycle. The agents are selected from: (a) agents targetted against cryptic phase of chlamydial life cycle; (b) agents targetted against elementary body phase of chlamydial life cycle; (c) agents targetted against replicating phase of chlamydial life cycle; (d) probenicid, and (e) antiporphyrin acid. The composition is used to elicit a protective immune response to Chlamydia infection in an animal or human and is applied until the animal or human tests negative for Chlamydia infection. It is also used to treat biological material infected with Chlamydia. Diagnostic kits for antibody assays against recombinant major outer membrane protein (MOMP), and for DNA amplification assays for chlamydial genes, are used to diagnose disease, e.g. autoimmune disease, an inflammatory disease or a disease that occurs in an immuno-compromised individual, associated with Chlamydia infection. The kits are used to detect chlamydial elementary bodies in a sample. They are also used to monitor and/or modify the course of therapy in a patient. The treatment reduces the acellular load of infectious Ebsstein Barr virus. The method is also used to treat porphyria, by reducing the number of elementary bodies and applying a drug, e.g. cimetidine, and antioxidants, to reduce the adverse effects associated with porphyria. Sequences AAW95328 to AAW95331 represent peptides employed for the construction of peptide based ELISAs with species specificity for variable domain 2 (VD2).

Sequence 13 AA;

Query Match 89.0%; Score 65; DB 20; Length 13;  
Best Local Similarity 92.3%; Pred. No. 0.00012;  
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 CQINKFSRKACG 13  
||||||| |||  
Db 1 cqinkfsrkacg 13

RESULT 7  
AAW95329  
ID AAW95329 standard; Protein; 13 AA.  
AC AAW95329;  
XX  
XX  
DT 15-MAR-1999 (first entry)  
XX  
DE Peptide fragment of C. trachomatis CTP342-354.  
XX

Chlamydia; cryptic phase; elementary body phase; replicating; probenicid; antiporphyrin acid; immune response; infection; diagnostic; assay; MOMP; major outer membrane protein; autoimmune; inflammatory; porphyria; Ebsstein Barr virus; antioxidant.

Chlamydia trachomatis.

XX WO9850074-A2.  
 PN  
 XX  
 XX  
 PD 12-NOV-1998.  
 XX  
 XX  
 PF 06-MAY-1998; 98WO-US09237.  
 XX  
 XX 18-FEB-1998; 98US-0025521.  
 PR 05-MAY-1997; 97US-0045689.  
 PR 06-MAY-1997; 97US-0045739.  
 PR 06-MAY-1997; 97US-0045779.  
 PR 06-MAY-1997; 97US-0045780.  
 PR 06-MAY-1997; 97US-0045784.  
 PR 06-MAY-1997; 97US-0045787.  
 PR 14-AUG-1997; 97US-0911593.  
 PR 18-FEB-1998; 98US-0025174.  
 PR 18-FEB-1998; 98US-0025176.  
 XX  
 XX (UYVA-) UNIV VANDERBILT.  
 XX  
 XX Mitchell WM, Stratton CW;  
 PI  
 XX  
 XX WPI; 1999-059653/05.  
 DR  
 XX  
 XX Composition with two agents effective against different stages of  
 PT chlamydial life cycle - comprises agent targetted against cryptic  
 PT phase, against elementary body phase, against replicating phase,  
 PT probenicid and antiporphyric  
 XX  
 XX Claim 4; Fig 5; 138pp; English.  
 PS  
 XX  
 XX The invention relates to the diagnosis and management of infections by  
 CC Chlamydia species. The invention provides a composition that comprises  
 CC at least two agents, where each of the agents is effective against a  
 CC different phase of the chlamydial life cycle. The agents are selected  
 CC from: (a) agents targetted against cryptic phase of chlamydial life  
 CC cycle; (b) agents targetted against elementary body phase of chlamydial  
 CC life cycle; (c) agents targetted against replicating phase of chlamydial  
 CC life cycle; (d) probenicid, and (e) antiporphyric acid. The composition  
 CC is used to elicit a protective immune response to Chlamydia infection in  
 CC an animal or human and is applied until the animal or human tests  
 CC negative for Chlamydia infection. It is also used to treat biological  
 CC material infected with Chlamydia. Diagnostic kits for antibody assays  
 CC against recombinant major outer membrane protein (MOMP), and for DNA  
 CC amplification assays for chlamydial genes, are used to diagnose disease,  
 CC e.g. autoimmune disease, an inflammatory disease or a disease that  
 CC occurs in an immuno-compromised individual, associated with Chlamydia  
 CC infection. The kits are used to detect chlamydial elementary bodies in a  
 CC sample. They are also used to monitor and/or modify the course of therapy  
 CC in a patient. The treatment reduces the acellular load of infectious  
 CC Ebsstein Barr virus. The method is also used to treat porphyria, by  
 CC reducing the number of elementary bodies and applying a drug, e.g.  
 CC clometidine, and antioxidants, to reduce the adverse effects associated  
 CC with porphyria. Sequences AAW95328 to AAW95331 represent peptides  
 CC employed for the construction of peptide based ELISAs with species  
 CC specificity for variable domain 2 (VD2).  
 XX  
 XX Sequence 13 AA;  
 SQ

Query Match 80.8%; Score 59; DB 20; Length 13;  
 Best Local Similarity 84.6%; Pred. No. 0.0013;  
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 1 CQINKFKSRKACG 13  
 Db 1 CQINKFKSRKACG 13  
 RESULT 8  
 AAW98185  
 ID AAW98185 standard; Protein; 215 AA.  
 XX

AC AAW98185;  
 XX  
 XX 05-JUL-1999 (first entry)  
 XX  
 DE Chlamydia psittaci MOMP (minus VD1 and VD2 region).  
 XX  
 KW Major outer membrane protein; MOMP; psittacosis; infection;  
 KW vaccine; genetic immunisation.  
 XX  
 OS Chlamydia psittaci.  
 XX  
 PN WO9910005-A1.  
 XX  
 PD 04-MAR-1999.  
 XX  
 XX 28-AUG-1998; 98WO-US17943.  
 PF  
 XX  
 XX 28-AUG-1997; 97US-0057147.  
 PR  
 XX  
 XX (LOUU ) UNIV LOUISIANA & AGRIC & MECH COLLEGE.  
 PA  
 XX Baghian A, Chouljenko VN, Kousoulas KS, Tully TN;  
 PI  
 XX WPI; 1999-254214/21.  
 DR  
 XX  
 XX A new vaccine for Chlamydia psittaci infections  
 PT  
 XX  
 XX Claim 28; Page 51; 72pp; English.  
 PS  
 XX  
 XX The present sequence is a major outer membrane protein (MOMP)  
 CC polypeptide of the cockatiel isolate LSJWTKC of Chlamydia psittaci  
 CC (the MOMP gene sequence of this isolate is identical to that of C.  
 CC psittaci Avian Type C). The MOMP polypeptide comprises regions VD3  
 CC and VD4 of native MOMP (see also AAW98137, i.e. it lacks regions VD1  
 CC and VD2 of MOMP. A claimed method of preventing a C. psittaci  
 CC infection in a subject comprises administering an immunising  
 CC amount of an expression vector comprising a eukaryotic promoter  
 CC functionally linked to a nucleic acid encoding a C. psittaci  
 CC MOMP polypeptide lacking regions VD1 and VD2, preferably the  
 CC present sequence or a polypeptide (see also AAW98186) from C.  
 CC psittaci strain B577.  
 XX  
 XX Sequence 215 AA;  
 SQ

Query Match 79.5%; Score 58; DB 20; Length 215;  
 Best Local Similarity 91.7%; Pred. No. 0.027;  
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 2 QINKFKSRKACG 13  
 Db 169 qinkmksrkacg 180  
 RESULT 9  
 AAW98183  
 ID AAW98183 standard; Protein; 222 AA.  
 XX  
 XX AAW98183;  
 AC  
 XX  
 XX 05-JUL-1999 (first entry)  
 DT  
 XX  
 XX Chlamydia psittaci MOMP (minus VD1 and VD2 region).  
 DE  
 XX  
 KW Major outer membrane protein; MOMP; psittacosis; infection;  
 KW vaccine; genetic immunisation.  
 XX  
 OS Chlamydia psittaci.  
 XX  
 XX WO9910005-A1.  
 PN  
 XX  
 XX 04-MAR-1999.  
 PD  
 XX

PF 28-AUG-1998; 98WO-US17943.  
 XX  
 PR 28-AUG-1997; 97US-0057147.  
 XX  
 PA (LOUU ) UNIV LOUISIANA & AGRIC & MECH COLLEGE.  
 XX  
 PI Baghian A, Chouljenko VN, Kousoulas KG, Tully TN;  
 XX  
 XX WPI; 1999-254214/21.  
 DR N-PSDB; AAX25044.  
 XX  
 PT A new vaccine for Chlamydia psittaci infections  
 XX  
 PS Claim 6; Page 41-42; 72pp; English.  
 XX  
 CC The present sequence is a major outer membrane protein (MOMP)  
 CC polypeptide of Chlamydia psittaci strain LSUTCK, a cockatiel  
 CC isolate (the MOMP gene sequence of this isolate is identical to  
 CC that of C. psittaci Avian Type C). The polypeptide comprises  
 CC regions VD3 and VD4 of native MOMP (see also AAW98187), i.e. it lacks  
 CC regions VD1 and VD2 of MOMP. A claimed vaccine composition includes  
 CC the MOMP polypeptide, optionally fused to a maltose binding protein.  
 CC Also claimed are an isolated nucleic acid (see AAX25044) encoding the  
 CC polypeptide, a vector, and a method of preventing C. psittaci  
 CC infection by administering the vaccine containing the MOMP  
 CC polypeptide. Vectors encoding MOMP polypeptides lacking regions  
 CC VD1 and VD2 are useful for genetic (naked nucleic acid) vaccination.  
 CC The vaccines are used to prevent C. psittaci infection, especially  
 CC in birds.  
 XX  
 SQ Sequence 222 AA;

Query Match 79.5%; Score 58; DB 20; Length 222;  
 Best Local Similarity 91.7%; Pred. No. 0.028;  
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2 QINKFKSRKACG 13  
 IIIIIIIIIII  
 Db 176 qinkmksrkacg 187

RESULT 10  
 AAW98186  
 ID AAW98186 standard; Protein; 225 AA.  
 XX  
 AC AAW98186;  
 XX  
 DT 05-JUL-1999 (first entry)  
 XX  
 DE Chlamydia psittaci MOMP (minus VD1 and VD2 region).  
 XX  
 KW Major outer membrane protein; MOMP; psittacosis; infection;  
 XX vaccine; genetic immunisation.  
 OS Chlamydia psittaci.  
 XX  
 PN WO9910005-A1.  
 XX  
 PD 04-MAR-1999.  
 XX  
 PF 28-AUG-1998; 98WO-US17943.  
 XX  
 PR 28-AUG-1997; 97US-0057147.  
 XX  
 PA (LOUU ) UNIV LOUISIANA & AGRIC & MECH COLLEGE.  
 XX  
 PI Baghian A, Chouljenko VN, Kousoulas KG, Tully TN;  
 XX  
 XX WPI; 1999-254214/21.  
 DR N-PSDB; AAX25044.  
 XX  
 PT A new vaccine for Chlamydia psittaci infections  
 XX  
 PS Claim 6; Page 41-42; 72pp; English.  
 XX  
 CC The present sequence is a major outer membrane protein (MOMP)  
 CC polypeptide of Chlamydia psittaci strain LSUTCK, a cockatiel  
 CC isolate (the MOMP gene sequence of this isolate is identical to  
 CC that of C. psittaci Avian Type C). The polypeptide comprises  
 CC regions VD3 and VD4 of native MOMP (see also AAW98187), i.e. it lacks  
 CC regions VD1 and VD2 of MOMP. A claimed vaccine composition includes  
 CC the MOMP polypeptide, optionally fused to a maltose binding protein.  
 CC Also claimed are an isolated nucleic acid (see AAX25044) encoding the  
 CC polypeptide, a vector, and a method of preventing C. psittaci  
 CC infection by administering the vaccine containing the MOMP  
 CC polypeptide. Vectors encoding MOMP polypeptides lacking regions  
 CC VD1 and VD2 are useful for genetic (naked nucleic acid) vaccination.  
 CC The vaccines are used to prevent C. psittaci infection, especially  
 CC in birds.  
 XX  
 SQ Sequence 222 AA;

PS Claim 28; Page 51-52; 72pp; English.  
 XX  
 CC The present sequence is a major outer membrane protein (MOMP)  
 CC polypeptide of Chlamydia psittaci strain B577. It comprises  
 CC regions VD3 and VD4 of native MOMP (see also AAW98187), but lacks  
 CC infection in a subject comprises administering a C. psittaci  
 CC amount of an expression vector comprising a eukaryotic promoter  
 CC functionally linked to a nucleic acid encoding a C. psittaci  
 CC MOMP polypeptide lacking regions VD1 and VD2, preferably the  
 CC present sequence or a polypeptide (see also AAW98186) from C.  
 CC psittaci strain B577.  
 XX  
 SQ Sequence 225 AA;

Query Match 79.5%; Score 58; DB 20; Length 225;  
 Best Local Similarity 91.7%; Pred. No. 0.029;  
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2 QINKFKSRKACG 13  
 IIIIIIIIIII  
 Db 179 qinkmksrkacg 190

RESULT 11  
 AAW98184  
 ID AAW98184 standard; Protein; 228 AA.  
 XX  
 AC AAW98184;  
 XX  
 DT 05-JUL-1999 (first entry)  
 XX  
 DE Chlamydia psittaci MOMP (minus VD1 and VD2 region).  
 XX  
 KW Major outer membrane protein; MOMP; psittacosis; infection;  
 XX vaccine; genetic immunisation.  
 OS Chlamydia psittaci.  
 XX  
 PN WO9910005-A1.  
 XX  
 PD 04-MAR-1999.  
 XX  
 PF 28-AUG-1998; 98WO-US17943.  
 XX  
 PR 28-AUG-1997; 97US-0057147.  
 XX  
 PA (LOUU ) UNIV LOUISIANA & AGRIC & MECH COLLEGE.  
 XX  
 PI Baghian A, Chouljenko VN, Kousoulas KG, Tully TN;  
 XX  
 XX WPI; 1999-254214/21.  
 DR N-PSDB; AAX25044.  
 XX  
 PT A new vaccine for Chlamydia psittaci infections  
 XX  
 PS Claim 6; Page 42-43; 72pp; English.  
 XX  
 CC The present sequence is a major outer membrane protein (MOMP)  
 CC polypeptide of Chlamydia psittaci strain B577. The polypeptide  
 CC comprises regions VD3 and VD4 of the native protein (see also  
 CC AAW98187), but lacks regions VD1 and VD2. A claimed vaccine  
 CC composition includes this MOMP polypeptide, optionally fused to a  
 CC maltose binding protein. Also claimed are an isolated nucleic  
 CC acid (see AAX25044) encoding the polypeptide, a vector, and a method  
 CC of preventing C. psittaci infection by administering the vaccine  
 CC containing the MOMP polypeptide. Vectors encoding MOMP polypeptides  
 CC lacking regions VD1 and VD2 are useful for genetic (naked nucleic  
 CC acid) vaccination. The vaccines are used to prevent C. psittaci  
 CC infection, especially in birds.  
 XX  
 SQ Sequence 228 AA;

Query Match 79.5%; Score 58; DB 20; Length 228;  
 Best Local Similarity 91.7%; Pred. No. 0.029; Mismatches 0; Indels 0; Gaps 0;

QY 2 QINKFKSRKACG 13  
 |||| |||||  
 Db 182 qinkmksrkacg 193

## RESULT 12

AAV56769  
 ID AAY56769 standard; Protein; 343 AA.

XX AC AAY56769;

XX DT 22-FEB-2000 (first entry)

XX DE C. trachomatis serovar GPIC MOMP sequence.

XX KW Major outer membrane protein; MOMP; Chlamydia; vaccine; immune response;  
 XX KW cellular response; immunogen; Th1-like CD4 response; mucosal immunity.

XX OS Chlamydia trachomatis.

XX PN WO9951745-A2.

XX PD 14-OCT-1999.

XX PF 07-APR-1999; 99WO-CA00292.

XX PR 07-APR-1998; 98US-0055765.

XX PA (UYMA-) UNIV MANITOBA.

XX PI Bruhnam RC;

XX DR WPI; 1999-620205/53.

XX PT Non-replicating vector encoding fragments of the outer membrane protein  
 XX PT of Chlamydia, useful in vaccines and as immunogen

XX PS Disclosure; Fig 10 A-F; 52pp; English.

XX CC The invention provides a non-replicating vector that comprises, linked  
 XX CC to a promoter, a nucleotide sequence that encodes a region containing at  
 XX CC least one of the conserved domains 2, 3 and 5 of a major outer membrane  
 XX CC protein (MOMP) of a Chlamydia strain. The vector is used: (a) in  
 XX CC vaccines to generate a protective immune response (mainly cellular)  
 XX CC against MOMP, and (b) as immunogens to raise anti-MOMP antibodies, useful  
 XX CC in standard immunoassays. Immunization with the vector induces a broad  
 XX CC spectrum of immune responses, including Th1-like CD4 responses and  
 XX CC mucosal immunity, providing significant protection against subsequent  
 XX CC challenge. Sequences AAY56757-71 represent MOMP sequences from a variety  
 XX CC of serovars of C. trachomatis.

XX SQ Sequence 343 AA;

Query Match 79.5%; Score 58; DB 20; Length 343;  
 Best Local Similarity 91.7%; Pred. No. 0.043;  
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2 QINKFKSRKACG 13  
 |||| |||||  
 Db 297 qinkmksrkacg 308

## RESULT 13

AAV56770  
 ID AAY56770 standard; Protein; 356 AA.

XX

## AAV56770:

XX DT 22-FEB-2000 (first entry)

XX DE C. trachomatis serovar Mn MOMP sequence.

XX KW Major outer membrane protein; MOMP; Chlamydia; vaccine; immune response;  
 XX KW cellular response; immunogen; Th1-like CD4 response; mucosal immunity.

XX OS Chlamydia trachomatis.

XX PN WO9951745-A2.

XX PD 14-OCT-1999.

XX PF 07-APR-1999; 99WO-CA00292.

XX PR 07-APR-1998; 98US-0055765.

XX PA (UYMA-) UNIV MANITOBA.

XX PI Bruhnam RC;

XX DR WPI; 1999-620205/53.

XX PT Non-replicating vector encoding fragments of the outer membrane protein  
 XX PT of Chlamydia, useful in vaccines and as immunogen

XX PS Disclosure; Fig 10 A-F; 52pp; English.

XX CC The invention provides a non-replicating vector that comprises, linked  
 XX CC to a promoter, a nucleotide sequence that encodes a region containing at  
 XX CC least one of the conserved domains 2, 3 and 5 of a major outer membrane  
 XX CC protein (MOMP) of a Chlamydia strain. The vector is used: (a) in  
 XX CC vaccines to generate a protective immune response (mainly cellular)  
 XX CC against MOMP, and (b) as immunogens to raise anti-MOMP antibodies, useful  
 XX CC in standard immunoassays. Immunization with the vector induces a broad  
 XX CC spectrum of immune responses, including Th1-like CD4 responses and  
 XX CC mucosal immunity, providing significant protection against subsequent  
 XX CC challenge. Sequences AAY56757-71 represent MOMP sequences from a variety  
 XX CC of serovars of C. trachomatis.

XX SQ Sequence 356 AA;

Query Match 79.5%; Score 58; DB 20; Length 356;  
 Best Local Similarity 91.7%; Pred. No. 0.045;  
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2 QINKFKSRKACG 13  
 |||| |||||  
 Db 310 qinkmksrkacg 321

## RESULT 14

AAW98188

ID AAW98188 standard; Protein; 389 AA.

XX AC AAW98188;

XX DT 05-JUL-1999 (first entry)

XX DE Chlamydia psittaci major outer membrane protein.

XX KW Major outer membrane protein; MOMP; psittacosis; infection;  
 XX KW vaccine; genetic immunisation.

XX OS Chlamydia psittaci.

XX PN WO9910005-A1.

XX PD 04-MAR-1999.

XX

```

PF 28-AUG-1998; 98WO-US17943.
XX
XX 28-AUG-1997; 97US-00571147.
XX
XX (LOU ) UNIV LOUISIANA & AGRIC & MECH COLLEGE.
XX
XX Baghian A, Chouljenko VN, Kousoulas KG, Tully TN;
XX WPI; 1999-254214/21.
XX DR N-PSDB; AAX25047.
XX
XX A new vaccine for Chlamydia psittaci infections
XX
XX Disclosure: Page 60-61; 72pp; English.
XX
XX The present sequence is the major outer membrane protein (MOMP)
XX of Chlamydia psittaci strain B577. A claimed MOMP polypeptide (see
XX CAAW98184) comprises regions VD3 and VD4 of B577 MOMP, i.e. it lacks
XX regions VDI and VD2. A claimed vaccine composition includes MOMP
XX polypeptide lacking VDI and VD2, optionally fused to a maltose
XX binding protein. Also claimed are an isolated nucleic acid
XX encoding the polypeptide, a vector, and a method of preventing C.
XX psittaci infection by administering the vaccine containing the
XX MOMP polypeptide. Vectors encoding MOMP polypeptides lacking
XX regions VDI and VD2 are useful for genetic vaccination. The
XX vaccines are used to prevent C. psittaci infection, especially in
XX birds.
XX
XX Sequence 389 AA;
SQ

Query Match 79.5%; Score 58; DB 20; Length 389;
Best Local Similarity 91.7%; Pred. No. 0.048;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2 QINKFKSRKACG 13
Db 343 qinkmksrkacg 354

RESULT 15
AAW98189
ID AAW98189 standard; Protein: 402 AA.
XX
XX AAW98189;
XX
XX 05-JUL-1999 (first entry)
XX
XX Chlamydia psittaci major outer membrane protein.
XX
XX Major outer membrane protein; MOMP; psittacosis; infection;
XX vaccine; genetic immunisation.
XX
XX Chlamydia psittaci.
XX
XX WO9910005-A1.
XX
XX 04-MAR-1999.
XX
XX 28-AUG-1998; 98WO-US17943.
XX
XX 28-AUG-1997; 97US-00571147.
XX
XX (LOU ) UNIV LOUISIANA & AGRIC & MECH COLLEGE.
XX
XX Baghian A, Chouljenko VN, Kousoulas KG, Tully TN;
XX WPI; 1999-254214/21.
XX DR N-PSDB; AAX25048.
XX
XX A new vaccine for Chlamydia psittaci infections
XX
XX Disclosure: Page 65-66; 72pp; English.

```

```

XX
XX The present sequence is the major outer membrane protein (MOMP)
XX of Chlamydia psittaci strain 68C. Claimed MOMP polypeptides (see
XX CAAW98183 and AAW98184) comprise regions VD3 and VD4 of an MOMP, i.e.
XX they lack regions VDI and VD2. Claimed vaccine compositions
XX include such MOMP polypeptides, optionally fused to a maltose
XX binding protein. Also claimed are isolated nucleic acids encoding
XX the polypeptide, a vector, and a method of preventing C. psittaci
XX infection by administering the vaccine containing the MOMP
XX polypeptide. Vectors encoding MOMP polypeptides lacking regions
XX VDI and VD2 are useful for genetic vaccination. The vaccines are
XX used to prevent C. psittaci infection, especially in birds.
XX
XX Sequence 402 AA;
SQ

```

```

Query Match 79.5%; Score 58; DB 20; Length 402;
Best Local Similarity 91.7%; Pred. No. 0.05;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2 QINKFKSRKACG 13
Db 356 qinkmksrkacg 367

```

```

Search completed: March 26, 2002, 13:38:48
Job time: 142 sec

```

GenCore version 4.5  
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: March 26, 2002, 13:41:29 ; Search time 37.72 Seconds  
(without alignments)  
7.756 Million cell updates/sec

Title: US-09-709-201-101  
Perfect score: 73  
Sequence: 1 CQINKFKSRKACG 13

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 212252 seqs, 22503292 residues

Total number of hits satisfying chosen parameters: 212252

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : Issued\_Patents\_AA:\*  
1: /cgn2\_6/ptodata/2/iaa/5A\_COMB.pep.\*  
2: /cgn2\_6/ptodata/2/iaa/5B\_COMB.pep.\*  
3: /cgn2\_6/ptodata/2/iaa/6A\_COMB.pep.\*  
4: /cgn2\_6/ptodata/2/iaa/6B\_COMB.pep.\*  
5: /cgn2\_6/ptodata/2/iaa/PCRUS\_COMB.pep.\*  
6: /cgn2\_6/ptodata/2/iaa/backfiles1.pep.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	40	54.8	58	1	US-08-334-773A-2
2	38	52.1	824	1	US-08-221-750A-3
3	37.5	51.4	19	2	US-08-764-640-158
4	37.5	51.4	19	3	US-08-973-225-158
5	37.5	51.4	19	3	US-09-244-298A-158
6	37.5	51.4	19	4	US-09-516-704-158
7	36	49.3	42	4	US-08-974-549A-141
8	36	49.3	562	3	US-08-851-843A-5
9	36	49.3	562	4	US-08-854-050-5
10	35	47.9	19	2	US-08-764-640-164
11	35	47.9	19	3	US-08-973-225-164
12	35	47.9	19	4	US-09-244-298A-164
13	35	47.9	19	3	US-09-516-704-164
14	35	47.9	68	1	US-07-972-387-40
15	35	47.9	68	1	US-08-431-412-40
16	35	47.9	68	1	US-08-057-971-40
17	35	47.9	68	1	US-08-358-160-125
18	35	47.9	70	1	US-07-791-213D-5
19	35	47.9	70	1	US-08-293-150A-5
20	35	47.9	89	1	US-07-972-387-8
21	35	47.9	89	1	US-07-972-387-10
22	35	47.9	89	1	US-07-972-387-16
23	35	47.9	89	1	US-08-431-412-8
24	35	47.9	89	1	US-08-431-412-10
25	35	47.9	89	1	US-08-431-412-16
26	35	47.9	89	1	US-08-057-971-8
27	35	47.9	89	1	US-08-057-971-10

28	35	47.9	89	1	US-08-057-971-16	Sequence 16, Appl
29	35	47.9	91	1	US-07-791-213D-89	Sequence 89, Appl
30	35	47.9	91	1	US-07-972-387-2	Sequence 2, Appl
31	35	47.9	91	1	US-08-431-412-2	Sequence 2, Appl
32	35	47.9	91	1	US-08-057-971-2	Sequence 2, Appl
33	35	47.9	91	1	US-08-293-150A-89	Sequence 89, Appl
34	35	47.9	101	1	US-07-972-387-28	Sequence 28, Appl
35	35	47.9	101	1	US-08-431-412-28	Sequence 28, Appl
36	35	47.9	101	1	US-08-057-971-28	Sequence 28, Appl
37	35	47.9	540	4	US-09-011-074-4	Sequence 4, Appl
38	35	47.9	595	4	US-08-842-079-6	Sequence 6, Appl
39	35	47.9	595	4	US-08-842-079-17	Sequence 17, Appl
40	34	46.6	58	1	US-08-334-773A-1	Sequence 1, Appl
41	34	46.6	205	1	US-08-450-944-5	Sequence 5, Appl
42	34	46.6	205	5	PCT-US96-07709-5	Sequence 5, Appl
43	34	46.6	221	1	US-08-450-944-2	Sequence 2, Appl
44	34	46.6	221	5	PCT-US96-07709-2	Sequence 2, Appl
45	34	46.6	595	4	US-08-842-079-18	Sequence 18, Appl

ALIGNMENTS

RESULT 1  
US-08-334-773A-2  
; Sequence 2, Application US/08334773A  
; Patent No. 5629176  
; GENERAL INFORMATION:  
; APPLICANT: No. 5629176ris, Fanny  
; APPLICANT: No. 5629176ris, Kjeld  
; APPLICANT: Bjorn, Soren Erik  
; APPLICANT: Petersen, Lars Christian  
; APPLICANT: Olsen, Ole Hvilsted  
; TITLE OF INVENTION: A Human Kunitz-Type Protease Inhibitor  
; TITLE OF INVENTION: Variant  
; NUMBER OF SEQUENCES: 14  
; CORRESPONDENCE ADDRESSES:  
; ADDRESSEE: No. 56291760 No. 5629176disk of No. 5629176th America, Inc.  
; STREET: 405 Lexington Avenue, Suite 5400  
; CITY: New York  
; STATE: New York  
; COUNTRY: U.S.A.  
; ZIP: 10174-6400  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/334,773A  
; FILING DATE: 04-NOV-1994  
; CLASSIFICATION: 435  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Agris, Cheryl H.  
; REGISTRATION NUMBER: 34,086  
; REFERENCE/DOCKET NUMBER: 3695.210-US  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 212 867 0123  
; TELEFAX: 212 878 9655  
; INFORMATION FOR SEQ ID NO: 2:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 58 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
; ORIGINAL SOURCE:  
; ORGANISM: synthetic  
; US-08-334-773A-2

Query Match 54.8%; Score 40; DB 1; Length 58;  
Best Local Similarity 77.8%; Pred. No. 5.4;  
Matches 7; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 4 NKFKSRKAC 12  
| | | | : | |  
Db 43 NKFKSQREC 51

RESULT 2  
US-08-221-750A-3  
; Sequence 3, Application US/08221750A  
; Patent No. 5643747  
; GENERAL INFORMATION:  
; APPLICANT: Baker, Steven M.  
; APPLICANT: Deich, Robert A.  
; TITLE OF INVENTION: Genes for the Export of Pertussis  
; TITLE OF INVENTION: Holotoxin  
; NUMBER OF SEQUENCES: 13  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Hamilton, Brook, Smith & Reynolds, P.C.  
; STREET: Two Militia Drive  
; CITY: Lexington  
; STATE: MA  
; COUNTRY: USA  
; ZIP: 02173  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/221,750A  
; FILING DATE: 31-MAR-1994  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/031,619  
; FILING DATE: 15-MAR-1993  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Carroll, Alice O.  
; REGISTRATION NUMBER: 33,542  
; REFERENCE/DOCKET NUMBER: ACC93-01A  
; TELEPHONE: (617) 861-6240  
; TELEFAX: (617) 861-9540  
; INFORMATION FOR SEQ ID NO: 3:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 824 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
US-08-221-750A-3

Query Match 52.1%; Score 38; DB 1; Length 824;  
Best Local Similarity 53.8%; Pred. No. 1.3e+02;  
Matches 7; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

QY 1 COINKFKSRKAC 13  
| | : | | | | |  
Db 471 COLQKFRSADAG 483

RESULT 3  
US-08-764-640-158  
; Sequence 158, Application US/08764640  
; Patent No. 5869451  
; Patent No. 5869451 5837683  
; GENERAL INFORMATION:  
; APPLICANT: Dower, William J.  
; APPLICANT: Barrett, Ronald W.  
; APPLICANT: Cwirla, Steven E.  
; APPLICANT: Gates, Christian  
; APPLICANT: Schatz, Peter J.  
; APPLICANT: Balasubramanian, Palaniappan  
; APPLICANT: Wagstrom, Christopher R.

; APPLICANT: Hendren, Richard W.  
; APPLICANT: Deprence, Randolph B.  
; APPLICANT: Podduturi, Surekha  
; APPLICANT: Yin, Qun  
; TITLE OF INVENTION: PEPTIDES AND COMPOUNDS THAT BIND TO A  
; TITLE OF INVENTION: RECEPTOR  
; NUMBER OF SEQUENCES: 244  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Glaxo Wellcome  
; STREET: Five Moore Drive, P.O. Box 13398  
; CITY: Research Triangle Park  
; STATE: NC  
; COUNTRY: USA  
; ZIP: 27709  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/764,640  
; FILING DATE: 11-DEC-1996  
; CLASSIFICATION: 514  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Hrubiec, Robert T.  
; REGISTRATION NUMBER: 36,392  
; REFERENCE/DOCKET NUMBER: PK3281  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 919-248-1000  
; INFORMATION FOR SEQ ID NO: 158:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 19 amino acids  
; TYPE: amino acid  
; STRANDEDNESS:  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
US-08-764-640-158

Query Match 51.4%; Score 37.5; DB 2; Length 19;  
Best Local Similarity 61.5%; Pred. No. 4.9;  
Matches 8; Conservative 1; Mismatches 3; Indels 1; Gaps 1;

QY 1 COINKFKSRKAC 13  
| : | | | | | |  
Db 5 CTLNGFKSRH-CG 16

RESULT 4  
US-08-973-225-158  
; Sequence 158, Application US/08973225A  
; Patent No. 6083913  
; GENERAL INFORMATION:  
; APPLICANT: Dower, William J.  
; APPLICANT: Barrett, Ronald W.  
; APPLICANT: Cwirla, Steven E.  
; APPLICANT: Duffin, David J.  
; APPLICANT: Gates, Christian  
; APPLICANT: Haselden, Sherril S.  
; APPLICANT: Mattheakis, Larry C.  
; APPLICANT: Schatz, Peter J.  
; APPLICANT: Wagstrom, Christopher R.  
; APPLICANT: Wrighton, Nicholas C.  
; TITLE OF INVENTION: PEPTIDES AND COMPOUNDS THAT BIND TO A  
; TITLE OF INVENTION: THROMBOPOIETIN RECEPTOR  
; NUMBER OF SEQUENCES: 232  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Glaxo Wellcome  
; STREET: Five Moore Drive, P.O. Box 13398  
; CITY: Research Triangle Park  
; STATE: NC  
; COUNTRY: USA  
; ZIP: 27709



COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/973,225A  
FILING DATE: 04-Dec-1997  
ATTORNEY/AGENT INFORMATION:  
NAME: Hrubiec, Robert T.  
REGISTRATION NUMBER: 36,392  
REFERENCE/DOCKET NUMBER: PK3065USW  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 919-248-1000  
INFORMATION FOR SEQ ID NO: 158:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 19 amino acids  
TYPE: amino acid  
STRANDEDNESS: <Unknown>  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
SEQUENCE DESCRIPTION: SEQ ID NO: 158:  
US-08-973-225-158

Query Match 51.4%; Score 37.5; DB 3; Length 19;  
Best Local Similarity 61.5%; Pred. No. 4.9;  
Matches 8; Conservative 1; Mismatches 3; Indels 1; Gaps 1;

QY 1 COINKFKSRKACG 13  
I : I I I I I I I  
Db 5 CTLNGFKSRH-CG 16

RESULT 5  
US-09-244-298A-158  
; Sequence 158, Application US/09244298A  
; Patent No. 6121238  
; GENERAL INFORMATION:  
; APPLICANT: Dower, William J.  
; APPLICANT: Barrett, Ronald W.  
; APPLICANT: Cwiria, Steven E.  
; APPLICANT: Gates, Christian  
; APPLICANT: Schatz, Peter J.  
; APPLICANT: Balasubramanian, Palaniappan  
; APPLICANT: Wagstrom, Christopher R.  
; APPLICANT: Hendren, Richard W.  
; APPLICANT: Deprience, Randolph B.  
; APPLICANT: Podduturi, Surekha  
; APPLICANT: Yin, Qun  
; TITLE OF INVENTION: PEPTIDES AND COMPOUNDS THAT BIND TO A  
; TITLE OF INVENTION: RECEPTOR  
; NUMBER OF SEQUENCES: 244  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Glaxo Wellcome  
; STREET: Five Moore Drive, P.O. Box 13398  
; CITY: Research Triangle Park  
; STATE: NC  
; COUNTRY: USA  
; ZIP: 27709  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patent Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/244,298A  
; FILING DATE: 11-DEC-1996  
; CLASSIFICATION: 514  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Hrubiec, Robert T.  
; REGISTRATION NUMBER: 36,392  
; REFERENCE/DOCKET NUMBER: PK3281

TELECOMMUNICATION INFORMATION:  
TELEPHONE: 919-248-1000  
INFORMATION FOR SEQ ID NO: 158:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 19 amino acids  
TYPE: amino acid  
STRANDEDNESS:  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
US-09-244-298A-158

Query Match 51.4%; Score 37.5; DB 3; Length 19;  
Best Local Similarity 61.5%; Pred. No. 4.9;  
Matches 8; Conservative 1; Mismatches 3; Indels 1; Gaps 1;

QY 1 COINKFKSRKACG 13  
I : I I I I I I I  
Db 5 CTLNGFKSRH-CG 16

RESULT 6  
US-09-516-704-158  
; Sequence 158, Application US/09516704  
; Patent No. 6251864  
; GENERAL INFORMATION:  
; APPLICANT: Dower, William J.  
; APPLICANT: Barrett, Ronald W.  
; APPLICANT: Cwiria, Steven E.  
; APPLICANT: Gates, Christian  
; APPLICANT: Schatz, Peter J.  
; APPLICANT: Balasubramanian, Palaniappan  
; APPLICANT: Wagstrom, Christopher R.  
; APPLICANT: Hendren, Richard W.  
; APPLICANT: Deprience, Randolph B.  
; APPLICANT: Podduturi, Surekha  
; TITLE OF INVENTION: PEPTIDES AND COMPOUNDS THAT BIND TO A  
; TITLE OF INVENTION: RECEPTOR  
; NUMBER OF SEQUENCES: 244  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Glaxo Wellcome  
; STREET: Five Moore Drive, P.O. Box 13398  
; CITY: Research Triangle Park  
; STATE: NC  
; COUNTRY: USA  
; ZIP: 27709  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patent Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/516,704  
; FILING DATE: 01-Mar-2000  
; CLASSIFICATION: <Unknown>  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Hrubiec, Robert T.  
; REGISTRATION NUMBER: 36,392  
; REFERENCE/DOCKET NUMBER: PK3281  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 919-248-1000  
; INFORMATION FOR SEQ ID NO: 158:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 19 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: <Unknown>  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
; SEQUENCE DESCRIPTION: SEQ ID NO: 158:  
US-09-516-704-158

Query Match 51.4%; Score 37.5; DB 4; Length 19;

Best Local Similarity 61.5%; Pred. No. 4.9;  
Matches 8; Conservative 1; Mismatches 3; Indels 1; Gaps 1;

QY 1 COINFKSRKACG 13  
Db 5 CTJLNGFKSRH-CG 16

## RESULT 7

US-08-974-549A-141  
; Sequence 141, Application US/08974549A  
; Patent No. 6166178

## ; GENERAL INFORMATION:

; APPLICANT: Cech, Thomas R.  
; APPLICANT: Lingner, Joachim  
; APPLICANT: Nakamura, Toru  
; APPLICANT: Chapman, Karen B.  
; APPLICANT: Morin, Gregg B.  
; APPLICANT: Harley, Calvin B.  
; APPLICANT: Andrews, William H.

; TITLE OF INVENTION: Human Telomerase Catalytic Subunit

; NUMBER OF SEQUENCES: 727

## ; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Townsend and Townsend and Crew LLP  
; STREET: Two Embarcadero Center, Eighth Floor  
; CITY: San Francisco  
; STATE: California  
; COUNTRY: USA  
; ZIP: 94111-3834

## ; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS

## ; SOFTWARE: PatentIn Release #1.0, Version #1.30

; CURRENT APPLICATION NUMBER: US/08/974,549A

; FILING DATE: 19-NOV-1997

## ; CLASSIFICATION: 536

; PRIOR APPLICATION NUMBER: US 08/724,643

; FILING DATE: 01-OCT-1996

## ; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: US 08/844,419

; FILING DATE: 18-APR-1997

## ; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: US 08/846,017

; FILING DATE: 25-APR-1997

## ; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: US 08/851,843

; FILING DATE: 06-MAY-1997

## ; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: US 08/854,050

; FILING DATE: 09-MAY-1997

## ; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: US 08/911,312

; FILING DATE: 14-AUG-1997

## ; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: US 08/912,951

; FILING DATE: 14-AUG-1997

## ; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: US 08/915,503

; FILING DATE: 14-AUG-1997

## ; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: WO PCT/US97/17618

; FILING DATE: 01-OCT-1997

## ; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: WO PCT/US97/17885

; FILING DATE: 01-OCT-1997

## ; ATTORNEY/AGENT INFORMATION:

; NAME: Apple, Randolph Ted

; REGISTRATION NUMBER: 36,429

; REFERENCE/DOCKET NUMBER: 015389-002610US

## ; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (415) 576-0200  
; TELEFAX: (415) 576-0300  
; INFORMATION FOR SEQ ID NO: 141:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 42 amino acids  
; TYPE: amino acid  
; STRANDEDNESS:  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
; US-08-974-549A-141

Query Match 49.3%; Score 36; DB 4; Length 42;  
Best Local Similarity 60.0%; Pred. No. 17;  
Matches 6; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 4 NKFKSRKACG 13

Db 8 NPYKKRKNCG 17

## RESULT 8

US-08-851-843A-5

; Sequence 5, Application US/08851843A  
; Patent No. 6093809

## ; GENERAL INFORMATION:

; APPLICANT: Cech, Thomas R.  
; APPLICANT: Lingner, Joachim  
; APPLICANT: Nakamura, Toru  
; APPLICANT: Chapman, Karen B.  
; APPLICANT: Morin, Gregg B.  
; APPLICANT: Harley, Calvin  
; APPLICANT: Andrews, William H.

; TITLE OF INVENTION: No. 6093809el Telomerase

; NUMBER OF SEQUENCES: 225

## ; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Townsend and Townsend and Crew LLP  
; STREET: Two Embarcadero Center, 8th Floor  
; CITY: San Francisco  
; STATE: California  
; COUNTRY: United States of America  
; ZIP: 94111

## ; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: PatentIn Release #1.0, Version #1.30

## ; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/851,843A

; FILING DATE: 06-MAY-1997

## ; CLASSIFICATION:

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: US 08/846,017

; FILING DATE: 25-APR-1997

## ; CLASSIFICATION:

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: US 08/844,419

; FILING DATE: 18-APR-1997

## ; CLASSIFICATION:

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: US 08/724,643

; FILING DATE: 01-OCT-1996

## ; CLASSIFICATION:

; ATTORNEY/AGENT INFORMATION:

; NAME: Apple, Randolph T.

; REGISTRATION NUMBER: 36,429

; REFERENCE/DOCKET NUMBER: 015389-002930US

## ; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (415) 576-0200

; TELEFAX: (415) 576-0300

; INFORMATION FOR SEQ ID NO: 5:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 562 amino acids

;  
; TYPE: amino acid  
; STRANDEDNESS: not relevant  
; TOPOLOGY: not relevant  
; MOLECULE TYPE: protein  
US-08-851-843A-5

Query Match 49.3%; Score 36; DB 3; Length 562;  
Best Local Similarity 60.0%; Pred. No. 1.8e+02;  
Matches 6; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 4 NKFPSRKACG 13  
| : | | | |  
Db 8 NPYKKRKNCG 17

RESULT 9  
US-08-854-050-5  
; Sequence 5, Application US/08854050  
; Patent No. 6261836  
; GENERAL INFORMATION:  
; APPLICANT: Cech, Thomas R.  
; APPLICANT: Lingner, Joachim  
; APPLICANT: Nakamura, Toru  
; APPLICANT: Chapman, Karen B.  
; APPLICANT: Morin, Gregg B.  
; APPLICANT: Harley, Calvin  
; APPLICANT: Andrews, William H.  
; TITLE OF INVENTION: No. 6261836el Telomerase  
; NUMBER OF SEQUENCES: 225  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Townsend and Townsend and Crew LLP  
; STREET: Two Embarcadero Center, 8th Floor  
; CITY: San Francisco  
; STATE: California  
; COUNTRY: United States of America  
; ZIP: 94111  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/854,050  
; FILING DATE: 09-MAY-1997  
; CLASSIFICATION: 536  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/851,843  
; FILING DATE: 06-MAY-1997  
; CLASSIFICATION: 536  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/846,017  
; FILING DATE: 25-APR-1997  
; CLASSIFICATION: 536  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/844,419  
; FILING DATE: 18-APR-1997  
; CLASSIFICATION: 536  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/724,643  
; FILING DATE: 01-OCT-1996  
; CLASSIFICATION: 536  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Apple, Randolph T.  
; REGISTRATION NUMBER: 36,429  
; REFERENCE/DOCKET NUMBER: 015389-002930US  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (415) 576-0200  
; TELEFAX: (415) 576-0300  
; INFORMATION FOR SEQ ID NO: 5:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 562 amino acids  
; TYPE: amino acid

;  
; STRANDEDNESS: not relevant  
; TOPOLOGY: not relevant  
; MOLECULE TYPE: protein  
US-08-854-050-5

Query Match 49.3%; Score 36; DB 4; Length 562;  
Best Local Similarity 60.0%; Pred. No. 1.8e+02;  
Matches 6; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 4 NKFPSRKACG 13  
| : | | | |  
Db 8 NPYKKRKNCG 17

RESULT 10  
US-08-764-640-164  
; Sequence 164, Application US/08764640  
; Patent No. 5869451  
; Patent No. 5869451 5837683  
; GENERAL INFORMATION:  
; APPLICANT: Dower, William J.  
; APPLICANT: Barrett, Ronald W.  
; APPLICANT: Cwirla, Steven E.  
; APPLICANT: Gates, Christian  
; APPLICANT: Schatz, Peter J.  
; APPLICANT: Balasubramanian, Palaniappan  
; APPLICANT: Wegstrom, Christopher R.  
; APPLICANT: Hendren, Richard W.  
; APPLICANT: Deprence, Randolph B.  
; APPLICANT: Podduturi, Surekha  
; APPLICANT: Yin, Qun  
; TITLE OF INVENTION: PEPTIDES AND COMPOUNDS THAT BIND TO A  
; TITLE OF INVENTION: RECEPTOR  
; NUMBER OF SEQUENCES: 244  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Glaxo Wellcome  
; STREET: Five Moore Drive, P.O. Box 13398  
; CITY: Research Triangle Park  
; STATE: NC  
; COUNTRY: USA  
; ZIP: 27709  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/764,640  
; FILING DATE: 11-DEC-1996  
; CLASSIFICATION: 514  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Hrubiec, Robert T.  
; REGISTRATION NUMBER: 36,392  
; REFERENCE/DOCKET NUMBER: PK3281  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 919-248-1000  
; INFORMATION FOR SEQ ID NO: 164:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 19 amino acids  
; TYPE: amino acid  
; STRANDEDNESS:  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
US-08-764-640-164

Query Match 47.9%; Score 35; DB 2; Length 19;  
Best Local Similarity 46.2%; Pred. No. 12;  
Matches 6; Conservative 1; Mismatches 6; Indels 0; Gaps 0;

QY 1 CQINKFSRKACG 13  
| : | | | |

Db 5 CSLAKLKGACG 17

## RESULT 11

US-08-973-225-164  
; Sequence 164, Application US/08973225A  
; Patent No. 6083913  
; GENERAL INFORMATION:

APPLICANT: Dower, William J.  
; Barrett, Ronald W.  
; Cwirla, Steven E.  
; Duffin, David J.  
; Gates, Christian  
; Haselden, Sherril S.  
; Mattheakis, Larry C.  
; Schatz, Peter J.  
; Wagstrom, Christopher R.  
; Wrighton, Nicholas C.

TITLE OF INVENTION: PEPTIDES AND COMPOUNDS THAT BIND TO A  
THROMBOPOIETIN RECEPTOR

NUMBER OF SEQUENCES: 232

CORRESPONDENCE ADDRESS:

ADDRESSEE: Glaxo Wellcome  
STREET: Five Moore Drive, P.O. Box 13398  
CITY: Research Triangle Park  
STATE: NC  
COUNTRY: USA

ZIP: 27709

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: PatentIn Release #1.0, Version #1.30

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/973,225A

FILING DATE: 04-Dec-1997

ATTORNEY/AGENT INFORMATION:

NAME: Hrubiec, Robert T.

REGISTRATION NUMBER: 36,392

REFERENCE/DOCKET NUMBER: PK3065USW

TELECOMMUNICATION INFORMATION:

TELEPHONE: 919-248-1000

INFORMATION FOR SEQ ID NO: 164:

SEQUENCE CHARACTERISTICS:

LENGTH: 19 amino acids

TYPE: amino acid

STRANDEDNESS: <Unknown>

TOPOLOGY: linear

MOLECULE TYPE: peptide

SEQUENCE DESCRIPTION: SEQ ID NO: 164:

US-08-973-225-164

Query Match

Best Local Similarity 47.9%; Score 35; DB 3; Length 19;

Matches 6; Conservative 1; Mismatches 6; Indels 0; Gaps 0;

QY 1 CQINKFKSRKACG 13

I : | | | |

Db 5 CSLAKLKGACG 17

## RESULT 12

US-09-244-298A-164  
; Sequence 164, Application US/09244298A  
; Patent No. 6121238  
; GENERAL INFORMATION:

APPLICANT: Dower, William J.

APPLICANT: Barrett, Ronald W.

APPLICANT: Cwirla, Steven E.

APPLICANT: Gates, Christian

APPLICANT: Schatz, Peter J.

APPLICANT: Balasubramanian, Palaniappan

APPLICANT: Wagstrom, Christopher R.  
; Hendren, Richard W.  
; Deprence, Randolph B.  
; Podduturi, Surekha  
; Yin, Qun  
; TITLE OF INVENTION: PEPTIDES AND COMPOUNDS THAT BIND TO A  
RECEPTOR  
; NUMBER OF SEQUENCES: 244  
; CORRESPONDENCE ADDRESS:  
ADDRESSEE: Glaxo Wellcome  
STREET: Five Moore Drive, P.O. Box 13398  
CITY: Research Triangle Park  
STATE: NC  
COUNTRY: USA

ZIP: 27709

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: PatentIn Release #1.0, Version #1.30

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/244,298A

FILING DATE: 11-DEC-1996

CLASSIFICATION: 514

ATTORNEY/AGENT INFORMATION:

NAME: Hrubiec, Robert T.

REGISTRATION NUMBER: 36,392

REFERENCE/DOCKET NUMBER: PK3281

TELECOMMUNICATION INFORMATION:

TELEPHONE: 919-248-1000

INFORMATION FOR SEQ ID NO: 164:

SEQUENCE CHARACTERISTICS:

LENGTH: 19 amino acids

TYPE: amino acid

STRANDEDNESS:

TOPOLOGY: linear

MOLECULE TYPE: peptide

US-09-244-298A-164

Query Match

Best Local Similarity 47.9%; Score 35; DB 3; Length 19;

Matches 6; Conservative 1; Mismatches 6; Indels 0; Gaps 0;

QY 1 CQINKFKSRKACG 13

I : | | | |

Db 5 CSLAKLKGACG 17

## RESULT 13

US-09-516-704-164

; Sequence 164, Application US/09516704

; Patent No. 6251864

; GENERAL INFORMATION:

APPLICANT: Dower, William J.

APPLICANT: Barrett, Ronald W.

APPLICANT: Cwirla, Steven E.

APPLICANT: Gates, Christian

APPLICANT: Schatz, Peter J.

APPLICANT: Balasubramanian, Palaniappan

APPLICANT: Wagstrom, Christopher R.

APPLICANT: Hendren, Richard W.

APPLICANT: Deprence, Randolph B.

APPLICANT: Podduturi, Surekha

TITLE OF INVENTION: PEPTIDES AND COMPOUNDS THAT BIND TO A  
RECEPTOR

NUMBER OF SEQUENCES: 244

CORRESPONDENCE ADDRESS:

ADDRESSEE: Glaxo Wellcome

STREET: Five Moore Drive, P.O. Box 13398

CITY: Research Triangle Park

STATE: NC

COUNTRY: USA

ZIP: 27709  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/516,704  
FILING DATE: 01-Mar-2000  
CLASSIFICATION: <Unknown>  
ATTORNEY/AGENT INFORMATION:  
NAME: Hrubiec, Robert T.  
REGISTRATION NUMBER: 36,392  
REFERENCE/DOCKET NUMBER: PK3281  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 919-248-1000  
INFORMATION FOR SEQ ID NO: 164:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 19 amino acids  
TYPE: amino acid  
STRANDEDNESS: <Unknown>  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
SEQUENCE DESCRIPTION: SEQ ID NO: 164:  
US-09-516-704-164

Query Match 47.9%; Score 35; DB 4; Length 19;  
Best Local Similarity 46.2%; Pred. No. 12;  
Matches 6; Conservative 1; Mismatches 6; Indels 0; Gaps 0;

QY 1 CQINKFKSRKACG 13  
| : | | | | |  
DB 5 CSLAKLKGACG 17

RESULT 14  
US-07-972-387-40  
; Sequence 40, Application US/07972387  
; Patent No. 5451659  
; GENERAL INFORMATION:  
; APPLICANT: Morishita, Hideaki  
; APPLICANT: Kanamori, Toshinori  
; APPLICANT: No. 5451659uhara, Masahiro  
; TITLE OF INVENTION: Polypeptide, DNA Fragment Encoding the  
; TITLE OF INVENTION: Same, Drug Composition Containing the Same and Process for  
; TITLE OF INVENTION: Producing the Same  
; NUMBER OF SEQUENCES: 76  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Birch, Stewart, Kolasch & Birch  
; STREET: 301 N. Washington St.  
; CITY: Falls Church  
; STATE: Virginia  
; COUNTRY: USA  
; ZIP: 22046-0747  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patentin Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/07/972,387  
; FILING DATE: 19921105  
; CLASSIFICATION: 435  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Murphy Jr., Gerald M.  
; REGISTRATION NUMBER: 28,977  
; REFERENCE/DOCKET NUMBER: 1110-124P  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 703-241-1300  
; TELEFAX: 703-241-2848  
; TELEX: 248345  
; INFORMATION FOR SEQ ID NO: 40:

; SEQUENCE CHARACTERISTICS:  
; LENGTH: 68 amino acids  
; TYPE: AMINO ACID  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
; HYPOTHETICAL: NO  
; FRAGMENT TYPE: C-terminal  
; ORIGINAL SOURCE:  
; ORGANISM: Eschericia coli  
; US-07-972-387-40

Query Match 47.9%; Score 35; DB 1; Length 68;  
Best Local Similarity 66.7%; Pred. No. 39;  
Matches 6; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 4 NKFKSRKAC 12  
| | | | | | |  
DB 41 NKFESEKAC 49

RESULT 15  
US-08-431-412-40  
; Sequence 40, Application US/08431412  
; Patent No. 5589360  
; GENERAL INFORMATION:  
; APPLICANT: Morishita, Hideaki  
; APPLICANT: Kanamori, Toshinori  
; APPLICANT: No. 5589360uhara, Masahiro  
; TITLE OF INVENTION: Polypeptide, DNA Fragment Encoding the  
; TITLE OF INVENTION: Same, Drug Composition Containing the Same and Process for  
; TITLE OF INVENTION: Producing the Same  
; NUMBER OF SEQUENCES: 76  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Birch, Stewart, Kolasch & Birch  
; STREET: 301 N. Washington St.  
; CITY: Falls Church  
; STATE: Virginia  
; COUNTRY: USA  
; ZIP: 22046-0747  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patentin Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/431,412  
; FILING DATE: 28-APR-1995  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/972,387  
; FILING DATE: 05-NOV-1992  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Murphy Jr., Gerald M.  
; REGISTRATION NUMBER: 28,977  
; REFERENCE/DOCKET NUMBER: 1110-124P  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 703-241-1300  
; TELEFAX: 703-241-2848  
; TELEX: 248345  
; INFORMATION FOR SEQ ID NO: 40:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 68 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
; HYPOTHETICAL: NO  
; FRAGMENT TYPE: C-terminal  
; ORIGINAL SOURCE:  
; ORGANISM: Eschericia coli  
; US-08-431-412-40

Query Match 47.9%; Score 35; DB 1; Length 68;  
Best Local Similarity 66.7%; Pred. No. 39;  
Matches 6; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 4 NKFKSRKAC 12  
|||:| |  
Db 41 NAFSEKEC 49

Search completed: March 26, 2002, 13:41:30  
Job time: 304 sec

GenCore version 4.5  
Copyright (c) 1993 - 2000 Compugen Ltd.

OM protein - protein search, using sw model

Run on: March 26, 2002, 13:37:21 ; Search time 42.75 seconds  
(without alignments)  
23.164 Million cell updates/sec

Title: US-09-709-201-101

Perfect score: 73

Sequence: 1 CQINKFKSRKACG 13

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 219241 seqs, 76174552 residues

Total number of hits satisfying chosen parameters: 219241

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

PIR\_58.\*

1: pir1.\*

2: pir2.\*

3: pir3.\*

4: pir4.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

# SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	73	100.0	389	2 A43587	major outer membra
2	73	100.0	389	2 I40864	major outer membra
3	73	100.0	389	2 I40739	major outer membra
4	73	100.0	389	2 D86577	major outer membra
5	58	79.5	389	1 MMCWP3	major outer membra
6	58	79.5	389	2 A50109	major outer membra
7	58	79.5	392	2 A40371	major outer membra
8	58	79.5	402	1 MMCWPM	major outer membra
9	58	79.5	402	2 A60341	major outer membra
10	58	79.5	402	2 B60109	major outer membra
11	58	79.5	402	2 I40740	major outer membra
12	53	72.6	372	2 S11009	major outer membra
13	53	72.6	372	2 B60756	major outer membra
14	53	72.6	374	2 S11007	major outer membra
15	53	72.6	375	2 S11006	major outer membra
16	53	72.6	387	2 J10947	mouse pneumonitis
17	53	72.6	387	2 S16034	major outer membra
18	53	72.6	387	2 C81747	major outer membra
19	53	72.6	393	1 MMCWPE	major outer membra
20	53	72.6	393	2 T01645	major outer membra
21	53	72.6	393	2 S06259	major outer membra
22	53	72.6	393	2 JC1432	major outer membra
23	53	72.6	393	2 H71484	probable major out
24	53	72.6	394	1 MMCWTF	major outer membra
25	53	72.6	394	2 S11012	major outer membra
26	53	72.6	395	1 MMCWTF	major outer membra
27	53	72.6	396	2 S12799	major outer membra
28	53	72.6	397	1 MMCWTH	major outer membra
29	53	72.6	397	1 MMCWTC	major outer membra

## ALIGNMENTS

RESULT 1  
A43587.  
major outer membrane protein, porin CP0051 precursor [imported] - Chlamydomophila pneum  
N:Alternate names: MOMP  
C:Species: Chlamydomophila pneumoniae, Chlamydia pneumoniae  
C:Date: 29-Jan-1993 #sequence\_revision 29-Jan-1993 #text\_change 11-May-2000  
C:Accession: A43587; A49751; A49216; G72044; F81619  
R:Perez Melgosa, M.; Kuo, C.C.; Campbell, L.A.  
Infect. Immun. 59, 2195-2199, 1991  
A:Title: Sequence analysis of the major outer membrane protein gene of Chlamydia pneu  
A:Reference number: A43587; MUID:91244474  
A:Accession: A43587  
A:Molecule type: DNA  
A:Residues: 1-389 <PER>  
A:Cross-references: GB:M69230; NID:gl44540; PIDN:AAA73071.1; PID:gl44541  
R:Cartier, M.W.; Al-Mahdawi, S.A.H.; Giles, I.G.; Trehan, J.D.; Ward, M.E.; Clarke, J. Gen. Microbiol. 137, 465-475, 1991  
A:Title: Nucleotide sequence and taxonomic value of the major outer membrane protein  
A:Reference number: A49751; MUID:91237311  
A:Accession: A49751  
A>Status: preliminary  
A:Molecule type: DNA  
A:Residues: 1-389 <CAR>  
A:Cross-references: GB:M64064; GB:M34942; NID:gl44534; PIDN:AAA23143.1; PID:gl44535  
A:Note: isolate 101-207  
R:Gaydos, C.A.; Quinn, T.C.; Bobo, L.D.; Eiden, J.J.  
Infect. Immun. 60, 5319-5323, 1992  
A:Title: Similarity of Chlamydia pneumoniae strains in the variable domain IV region  
A:Reference number: A49216; MUID:93084388  
A:Accession: A49216  
A>Status: preliminary  
A:Molecule type: DNA  
A:Residues: 297-352 <GAY>  
A:Cross-references: GB:S50607; NID:g260972; PIDN:AAB24363.1; PID:g260973  
A:Note: sequence extracted from NCBI backbone (NCBIN:120604, NCBI:120605)  
R:Kalan, S.; Mitchell, W.; Marathe, R.; Lammel, C.; Fan, J.; Olinger, L.; Grimwood, Nature Genet. 21, 385-389, 1999  
A:Title: Comparative genomes of Chlamydia pneumoniae and C. trachomatis.  
A:Reference number: A72000; MUID:99206606  
A:Accession: G72044  
A:Molecule type: DNA  
A:Residues: 1-389 <ARN>  
A:Cross-references: GB:AE001652; GB:AE001363; NID:g4376997; PIDN:AAD18834.1; PID:g437  
R:Read, T.D.; Brumham, R.C.; Shen, C.; Gill, S.R.; Heidelberg, J.F.; White, O.; Hicke  
C.; Dodson, R.; Gwinn, M.; Nelson, W.; DeBoy, R.; Kolonay, J.; McClarty, G.; Salzbe  
Nucleic Acids Res. 28, 1397-1406, 2000  
A:Title: Genome sequences of Chlamydia trachomatis MoPn and Chlamydia pneumoniae AR39  
A:Reference number: A81500; MUID:20150255  
A:Accession: F81619  
A>Status: preliminary  
A:Molecule type: DNA

30	53	72.6	397	2 JE0413	major outer membra
31	53	72.6	404	2 I40741	major outer membra
32	43	58.9	265	2 D81402	hypothetical prote
33	41	56.2	1154	2 T18525	diacylglycerol kin
34	40	54.8	182	2 T28390	ORF MSV229 leucine
35	39	53.4	862	1 A49346	aldehyde dehydroge
36	39	53.4	894	2 D82127	alcohol dehydrogen
37	38	52.1	444	2 D84948	NADH dehydrogenase
38	38	52.1	824	2 B47301	VitB4 homolog - Bo
39	38	52.1	1330	2 A36373	hypothetical prote
40	38	52.1	1333	2 T38401	retrotransposable
41	37	50.7	235	2 T44466	transposase tnpA [
42	37	50.7	364	2 S43117	transposase - Lept
43	37	50.7	372	2 JC2556	alpha-1-microglobu
44	37	50.7	408	2 T16601	hypothetical prote
45	37	50.7	444	2 H82821	NADH-ubiquinone ox

A:Residues: 1-389 <REA>  
 A:Cross-references: GB:AE002161; NID:g718982; PIDN:AAF37944.1; PID:g718899  
 A:Experimental source: strain AR39, HL cells  
 C:Genetics:

A:Gene: ompA; cp0051  
 C:Superfamily: Chlamydia major outer membrane protein  
 C:Keywords: membrane protein  
 F:1-23/Domain: signal sequence  
 F:24-389/Product: major outer membrane protein #status predicted <MAT>

Query Match 100.0%; Score 73; DB 2; Length 389;  
 Best Local Similarity 100.0%; Pred. No. 2.5e-05;  
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 COINKEFSRKACG 13  
 |||||  
 Db 342 COINKEFSRKACG 354

## RESULT 2

major outer membrane protein - Chlamydia psittaci  
 C:Species: Chlamydia psittaci, Chlamydia psittaci  
 C:Date: 16-Aug-1996 #sequence\_revision 16-Aug-1996 #text\_change 31-Mar-2000  
 C:Accession: I40864; S33465  
 R:Girjes, A.A.; Carrick, F.N.; Lavin, M.F.  
 Gene 138, 139-142, 1994

A:Title: Remarkable sequence relatedness in the DNA encoding the major outer membrane protein  
 A:Reference number: I40864; MUID:94171025  
 A:Accession: I40864

A:Status: preliminary; translated from GB/EMBL/DBJ

A:Molecule type: DNA

A:Residues: 1-389 <RES>

A:Cross-references: EMBL:X72023; NID:g313844; PIDN:CAA50906.1; PID:g313845  
 C:Superfamily: Chlamydia major outer membrane protein

Query Match 100.0%; Score 73; DB 2; Length 389;  
 Best Local Similarity 100.0%; Pred. No. 2.5e-05;  
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 COINKEFSRKACG 13  
 |||||  
 Db 342 COINKEFSRKACG 354

## RESULT 3

major outer membrane protein precursor - Chlamydia pneumoniae (strain equine/N16)  
 C:Species: Chlamydia pneumoniae, Chlamydia pneumoniae  
 A:Variety: strain equine/N16

C:Date: 16-Aug-1996 #sequence\_revision 16-Aug-1996 #text\_change 20-Apr-2000

C:Accession: I40739

R:Storey, C.; Lusher, M.; Yates, P.; Richmond, S.

J. Gen. Microbiol. 139, 2621-2626, 1993

A:Title: Evidence for Chlamydia pneumoniae of non-human origin.

A:Reference number: I40739; MUID:94103736

A:Accession: I40739

A:Status: translated from GB/EMBL/DBJ

A:Molecule type: DNA

A:Residues: 1-389 <STO>

A:Cross-references: GB:L04982; NID:g289840; PIDN:AAAL7397.1; PID:g289841  
 C:Comment: On the basis of the major outer membrane protein the authors classified the  
 the sequence of the genome strain CWL029 and strain strain IOL-207. See PIR:A43587.

## C:Genetics:

A:Gene: omp

C:Superfamily: Chlamydia major outer membrane protein

C:Keywords: membrane protein

F:1-23/Domain: signal sequence #status predicted <SIG>

F:24-389/Product: major outer membrane protein #status predicted <MAT>

Query Match 100.0%; Score 73; DB 2; Length 389;  
 Best Local Similarity 100.0%; Pred. No. 2.5e-05;  
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 COINKEFSRKACG 13  
 |||||  
 Db 342 COINKEFSRKACG 354

## RESULT 4

major outer membrane protein [imported] - Chlamydia pneumoniae (strain J138)  
 C:Species: Chlamydia pneumoniae, Chlamydia pneumoniae  
 C:Date: 02-Mar-2001 #sequence\_revision 02-Mar-2001 #text\_change 23-Mar-2001  
 C:Accession: D86577  
 R:Shirai, M.; Hirakawa, H.; Kimoto, M.; Tabuchi, M.; Kishi, F.; Ouchi, K.; Shiba, T.;  
 Nucleic Acids Res. 28, 2311-2314, 2000  
 A:Title: Comparison of whole genome sequences of chlamydia pneumoniae J138.  
 A:Reference number: A86491; MUID:20330349  
 A:Accession: D86577

A:Status: preliminary

A:Molecule type: DNA

A:Residues: 1-389 <STO>

A:Cross-references: GB:BA000008; NID:g8979067; PIDN:BAA98902.1; GSPDB:GN00142

A:Experimental source: strain J138

C:Genetics:

A:Gene: ompA

C:Superfamily: Chlamydia major outer membrane protein

Query Match 100.0%; Score 73; DB 2; Length 389;  
 Best Local Similarity 100.0%; Pred. No. 2.5e-05;  
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 COINKEFSRKACG 13  
 |||||  
 Db 342 COINKEFSRKACG 354

## RESULT 5

major outer membrane protein precursor - Chlamydia psittaci (strain S26/3)  
 C:Species: Chlamydia psittaci, Chlamydia psittaci  
 C:Date: 31-Dec-1990 #sequence\_revision 31-Dec-1990 #text\_change 31-Mar-2000  
 C:Accession: S08770  
 R:Herring, A.J.; Tan, T.W.; Baxter, S.; Inglis, N.F.; Dunbar, S.  
 FEMS Microbiol. Lett. 65, 153-158, 1989  
 A:Title: Sequence analysis of the major outer membrane protein gene of an ovine abort  
 A:Reference number: S08770

A:Accession: S08770

A:Molecule type: DNA

A:Residues: 1-389 <HER>

A:Cross-references: EMBL:X51859; NID:g40600; PIDN:CAA36152.1; PID:g40601

C:Superfamily: Chlamydia major outer membrane protein

F:1-22/Domain: signal sequence #status predicted <SIG>

F:23-389/Product: major outer membrane protein #status predicted <MAT>

Query Match 79.5%; Score 58; DB 1; Length 389;  
 Best Local Similarity 91.7%; Pred. No. 0.011;  
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2 QINKEFSRKACG 13  
 |||||  
 Db 343 QINKEFSRKACG 354

## RESULT 6

major outer membrane protein precursor - Chlamydia psittaci (strain Guinea pig in  
 C:Species: Chlamydia psittaci, Chlamydia psittaci  
 C:Date: 10-Nov-1992 #sequence\_revision 10-Nov-1992 #text\_change 31-Mar-2000  
 C:Accession: A60109



R:Zhang, Y.X.; Morrison, S.G.; Caldwell, H.D.; Baehr, W.  
Infect. Immun. 57, 1621-1625, 1989  
A:Title: Cloning and sequence analysis of the major outer membrane protein genes of two  
A:Reference number: A60109; MUID:89212917

A:Accession: A60109  
A>Status: not compared with conceptual translation  
A:Molecule type: DNA  
A:Residues: 1-389 <ZHA>  
C:Superfamily: Chlamydia major outer membrane protein  
C:Keywords: membrane protein  
F:1-22/Domain: signal sequence #status predicted <SIG>  
F:23-389/Product: major outer membrane protein #status predicted <MAT>

Query Match 79.5%; Score 58; DB 2; Length 389;  
Best Local Similarity 91.7%; Pred. No. 0.011;  
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2 QINKFKSRKACG 13  
IIII IIIIIII  
DB 343 QINKMKSRKACG 354

## RESULT 7

A40371  
major outer membrane protein precursor - Chlamydomphila psittaci (strain Fpn/pring)

C:Species: Chlamydomphila psittaci, Chlamydia psittaci  
C:Date: 27-Nov-1991 #sequence\_revision 27-Nov-1991 #text\_change 31-Mar-2000

A:Accession: I40859; A40371; S16137

R:Storey, C.; Lusher, M.; Yates, P.; Richmond, S.

J. Gen. Microbiol. 139, 2621-2626, 1993

A:Title: Evidence for Chlamydia pneumoniae of non-human origin.

A:Reference number: I40739; MUID:94103736

A:Accession: I40859  
A>Status: nucleic acid sequence not shown; translation not shown; translated from GB/EMBL  
A:Molecule type: DNA

A:Residues: 1-392 <RES>

A:Cross-references: EMBL:X61096; NID:g40564; PIDN:CAA43409.1; PID:g40565

A:Experimental source: strain Fpn

C:Genetics:

A:Gene: MOMP

C:Superfamily: Chlamydia major outer membrane protein

C:Keywords: membrane protein

F:1-22/Domain: signal sequence #status predicted <SIG>

F:23-392/Product: major outer membrane protein #status predicted <MAT>

Query Match 79.5%; Score 58; DB 2; Length 392;  
Best Local Similarity 91.7%; Pred. No. 0.011;  
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2 QINKFKSRKACG 13  
IIII IIIIIII  
DB 346 QINKMKSRKACG 357

## RESULT 8

M40RPM

major outer membrane protein precursor - Chlamydomphila psittaci (strain A22/W)

C:Species: Chlamydomphila psittaci, Chlamydia psittaci

C:Date: 31-Dec-1990 #sequence\_revision 31-Dec-1990 #text\_change 31-Mar-2000

A:Accession: S05954

R:Pickett, M.A.; Everson, J.S.; Clarke, I.N.

FEMS Microbiol. Lett. 55, 229-234, 1988

A:Title: Chlamydia psittaci ewe abortion agent: complete nucleotide sequence of the major

A:Reference number: S05954

A:Accession: S05954

A:Molecule type: DNA

A:Residues: 1-402 <PIC>

A:Cross-references: EMBL:X12647; NID:g40604; PIDN:CAA31177.1; PID:g40605

C:Superfamily: Chlamydia major outer membrane protein

F:1-22/Domain: signal sequence #status predicted <SIG>

F:23-402/Product: major outer membrane protein #status predicted <MAT>

Query Match 79.5%; Score 58; DB 1; Length 402;  
Best Local Similarity 91.7%; Pred. No. 0.011;  
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2 QINKFKSRKACG 13  
IIII IIIIIII  
DB 356 QINKMKSRKACG 367

## RESULT 9

A60341

major outer membrane protein precursor - Chlamydomphila psittaci (strain 68C)

C:Species: Chlamydomphila psittaci, Chlamydia psittaci

C:Date: 11-Dec-1992 #sequence\_revision 24-Feb-1994 #text\_change 31-Mar-2000

C:Accession: A44565; A60341; B60341

R:Everett, K.D.E.

submitted to the EMBL Data Library, December 1990

A:Reference number: A44565

A:Accession: A44565

A:Molecule type: DNA

A:Residues: 1-402 <EVE>

A:Cross-references: GB:X56980; NID:g40568; PIDN:CAA40300.1; PID:g40569

R:Everett, K.D.E.; Andersen, A.A.; Plaunt, M.; Hatch, T.P.

Infect. Immun. 59, 2853-2855, 1991

A:Title: Cloning and sequence analysis of the major outer membrane protein gene of Ch

A:Reference number: A60341; MUID:91310346

A:Accession: A60341

A:Molecule type: protein

A:Residues: 23-35 <EV2>

A:Accession: B60341

A>Status: nucleic acid sequence not shown

A:Molecule type: DNA

A:Residues: 112-232;317-349 <EV3>

A:Cross-references: GB:X56980

C:Superfamily: Chlamydia major outer membrane protein

C:Keywords: membrane protein

F:1-22/Domain: signal sequence #status predicted <SIG>

F:23-402/Product: major outer membrane protein #status experimental <MAT>

Query Match 79.5%; Score 58; DB 2; Length 402;  
Best Local Similarity 91.7%; Pred. No. 0.011;  
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2 QINKFKSRKACG 13  
IIII IIIIIII  
DB 356 QINKMKSRKACG 367

## RESULT 10

B60109

major outer membrane protein precursor - Chlamydomphila psittaci (strain meningopneumo

C:Species: Chlamydomphila psittaci, Chlamydia psittaci

C:Date: 10-Nov-1992 #sequence\_revision 10-Nov-1992 #text\_change 31-Mar-2000

C:Accession: B60109

R:Zhang, Y.X.; Morrison, S.G.; Caldwell, H.D.; Baehr, W.

Infect. Immun. 57, 1621-1625, 1989

A:Title: Cloning and sequence analysis of the major outer membrane protein genes of t

A:Reference number: A60109; MUID:89212917

A:Accession: B60109

A>Status: not compared with conceptual translation

A:Molecule type: DNA

A:Residues: 1-402 <ZHA>

C:Superfamily: Chlamydia major outer membrane protein

C:Keywords: membrane protein

F:1-22/Domain: signal sequence #status predicted <SIG>

F:23-389/Product: major outer membrane protein #status predicted <MAT>

Query Match 79.5%; Score 58; DB 2; Length 402;  
Best Local Similarity 91.7%; Pred. No. 0.011;

Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2 QINKFKSRKACG 13  
 |||| |||||  
 Db 356 QINKMKSRKACG 367

## RESULT: 11

I40740  
 major outer membrane protein - Chlamydomophila psittaci (strain N352)

C:Species: Chlamydomophila psittaci, Chlamydia psittaci  
 C:Date: 16-Aug-1996 #sequence\_revision 16-Aug-1996 #text\_change 31-Mar-2000  
 C:Accession: I40740

R:Storey, C.; Lusher, M.; Yates, P.; Richmond, S.

J. Gen. Microbiol. 139, 2621-2626, 1993

A:Title: Evidence for Chlamydia pneumoniae of non-human origin.

A:Reference number: I40739; MUID:94103736

A:Accession: I40740

A>Status: nucleic acid sequence not shown; translation not shown; translated from GB/EHE

A:Molecule type: DNA

A:Residues: 1-402 <RES>

A:CrossReferences: GB:L04980; NID:g144544; PIDN:AAA17396.1; PID:g144545

C:Genetics:

A:Gene: omp

C:Superfamily: Chlamydia major outer membrane protein

Query Match 79.5%; Score 58; DB 2; Length 402;

Best Local Similarity 91.7%; Pred. No. 0.011;

Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2 QINKFKSRKACG 13  
 |||| |||||  
 Db 356 QINKMKSRKACG 367

## RESULT 12

S11009  
 major outer membrane protein - Chlamydia trachomatis (serotype B)

C:Species: Chlamydia trachomatis

A:Variety: serotype B

C:Date: 30-Jun-1991 #sequence\_revision 30-Jun-1991 #text\_change 30-Apr-1999

R:Baehr, W.; Zhang, Y.X.; Joseph, T.; Su, H.; Nano, F.E.; Everett, K.D.E.; Caldwell, H.H.

Proc. Natl. Acad. Sci. U.S.A. 85, 4000-4004, 1988

A:Title: Mapping antigenic domains expressed by Chlamydia trachomatis major outer membra

A:Reference number: S11006; MUID:88234546

A:Accession: S11009

A>Status: not compared with conceptual translation

A:Molecule type: DNA

A:Residues: 1-372 <BAE>

A:Experimental source: serovar B

C:Superfamily: Chlamydia major outer membrane protein

C:Keywords: membrane protein

F:1-372/Product: major outer membrane protein #status predicted <MAT>

Query Match 72.6%; Score 53; DB 2; Length 372;

Best Local Similarity 75.0%; Pred. No. 0.082;

Matches 9; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 2 QINKFKSRKACG 13  
 |||| |||||  
 Db 326 QINKMKSRKSCG 337

## RESULT 13

B60756  
 major outer membrane protein - Chlamydia trachomatis (serotype B)

C:Species: Chlamydia trachomatis

C:Date: 03-Jun-1993 #sequence\_revision 24-Feb-1994 #text\_change 07-May-1999

C:Accession: B60756

R:Hayes, E.J.; Pickett, M.A.; Conlan, J.W.; Ferris, S.; Everson, J.S.; Ward, M.E.; Clark

J. Gen. Microbiol. 136, 1559-1566, 1990  
 A:Title: The major outer-membrane proteins of Chlamydia trachomatis serovars A and B: g domains.

A:Reference number: A60756; MUID:91086917

A:Accession: B60756

A>Status: nucleic acid sequence not shown; not compared with conceptual translation

A:Molecule type: DNA

A:Residues: 1-372 <HAY>

A:Experimental source: strain B/Jali-20/OT

C:Superfamily: Chlamydia major outer membrane protein

C:Keywords: membrane protein

Query Match 72.6%; Score 53; DB 2; Length 372;

Best Local Similarity 75.0%; Pred. No. 0.082;

Matches 9; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 2 QINKFKSRKACG 13  
 |||| |||||  
 Db 326 QINKMKSRKSCG 337

## RESULT 14

S11006

major outer membrane protein - Chlamydia trachomatis (serotype A)

C:Species: Chlamydia trachomatis

C:Date: 30-Jun-1991 #sequence\_revision 30-Jun-1991 #text\_change 18-Jun-1993

C:Accession: S11006

R:Baehr, W.; Zhang, Y.X.; Joseph, T.; Su, H.; Nano, F.E.; Everett, K.D.E.; Caldwell,

Proc. Natl. Acad. Sci. U.S.A. 85, 4000-4004, 1988

A:Title: Mapping antigenic domains expressed by Chlamydia trachomatis major outer mem

A:Reference number: S11006; MUID:88234546

A:Accession: S11006

A>Status: not compared with conceptual translation

A:Molecule type: DNA

A:Residues: 1-374 <BAE>

C:Superfamily: Chlamydia major outer membrane protein

C:Keywords: membrane protein

F:1-374/Product: major outer membrane protein #status predicted <MAT>

Query Match 72.6%; Score 53; DB 2; Length 374;

Best Local Similarity 75.0%; Pred. No. 0.082;

Matches 9; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 2 QINKFKSRKACG 13  
 |||| |||||  
 Db 328 QINKMKSRKSCG 339

## RESULT 15

S11007

major outer membrane protein - Chlamydia trachomatis (serotype C)

C:Species: Chlamydia trachomatis

C:Date: 30-Jun-1991 #sequence\_revision 30-Jun-1991 #text\_change 18-Jun-1993

C:Accession: S11007

R:Baehr, W.; Zhang, Y.X.; Joseph, T.; Su, H.; Nano, F.E.; Everett, K.D.E.; Caldwell,

Proc. Natl. Acad. Sci. U.S.A. 85, 4000-4004, 1988

A:Title: Mapping antigenic domains expressed by Chlamydia trachomatis major outer mem

A:Reference number: S11006; MUID:88234546

A:Accession: S11007

A>Status: not compared with conceptual translation

A:Molecule type: DNA

A:Residues: 1-375 <BAE>

C:Superfamily: Chlamydia major outer membrane protein

C:Keywords: membrane protein

F:1-375/Product: major outer membrane protein #status predicted <MAT>

Query Match 72.6%; Score 53; DB 2; Length 375;

Best Local Similarity 75.0%; Pred. No. 0.082;

Matches 9; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 2 QLNKFSRKACG 13  
|:| | | | |  
Db 329 QLNKFSRKSCG 340

Search completed: March 26, 2002, 13:37:21  
Job time: 55 sec



GenCore version 4.5  
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: March 26, 2002, 13:40:45 ; Search time 24.63 Seconds  
(without alignments)  
19.352 Million cell updates/sec

Title: US-09-709-201-101  
Perfect score: 73  
Sequence: 1 CQINKFKSRKACG 13

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 100059 seqs, 36664827 residues

Total number of hits satisfying chosen parameters: 100059

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : SwissProt\_39:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	73	100.0	333	1 OM1K_CHLPN	Q8xbf4 chlamydia p
2	73	100.0	389	1 OM1N_CHLPN	Q07430 chlamydia p
3	73	100.0	389	1 OM1L_CHLPN	P27455 chlamydia p
4	58	79.5	389	1 OM1A_CHLPS	P16567 chlamydia p
5	58	79.5	392	1 OM1P_CHLPS	Q00087 chlamydia p
6	58	79.5	402	1 OM1E_CHLPS	P10332 chlamydia p
7	53	72.6	387	1 OM1L_CHLMU	P75024 chlamydia m
8	53	72.6	393	1 OM1D_CHLTR	Q46409 chlamydia t
9	53	72.6	393	1 OM1E_CHLTR	P17451 chlamydia t
10	53	72.6	393	1 OM1L_CHLTR	P19542 chlamydia t
11	53	72.6	394	1 OM1B_CHLTR	P23421 chlamydia t
12	53	72.6	394	1 OM1M_CHLTR	P06597 chlamydia t
13	53	72.6	395	1 OM1F_CHLTR	P16155 chlamydia t
14	53	72.6	396	1 OM1A_CHLTR	P23732 chlamydia t
15	53	72.6	397	1 OM1C_CHLTR	P08780 chlamydia t
16	53	72.6	397	1 OM1H_CHLTR	P13467 chlamydia t
17	53	72.6	397	1 OM1N_CHLTR	P23114 chlamydia t
18	41	56.2	1154	1 KDGD_MESAU	Q64398 mesocricetu
19	41	56.2	1195	1 KDGD_HUMAN	Q16760 homo sapien
20	39	53.4	862	1 ADHE_CLOAB	P33744 clostridium
21	38	52.1	444	1 NUOF_BUCAI	P57256 buchnera ap
22	38	52.1	1333	1 RDPO_SCHPO	Q05654 schizosacch
23	37	50.7	1075	1 PST2_SCHPO	O13919 schizosacch
24	37	50.7	1419	1 LYS2_SCHPO	P40976 schizosacch
25	37	50.7	1507	1 CADE_DROME	Q42498 drosophila
26	36	49.3	165	1 YSEA_STACA	P47995 staphylococ
27	36	49.3	419	1 CG2B_ORYSA	Q40671 oryza sativ
28	35.5	48.6	139	1 RS12_DROME	P80455 drosophila
29	35	47.9	141	1 LCA_PIG	P18137 sus scrofa
30	35	47.9	172	1 R172_HORVU	P35267 hordeum vul
31	35	47.9	300	1 TFP1_RABIT	P19761 oryctolagus
32	35	47.9	331	1 CATV_NPVBS	Q9ywk4 buzura supp
33	35	47.9	557	1 TKT2_HUMAN	P51854 homo sapien

34 35 47.9 595 1 P2X7\_MOUSE  
35 35 47.9 595 1 P2X7\_RAT  
36 35 47.9 704 1 TRFL\_PIG  
37 35 47.9 884 1 RPOL\_BPT3  
38 35 47.9 2264 1 POLI\_TBRS  
39 34.5 47.3 373 1 EGON\_DROME  
40 34.5 47.3 512 1 DNB2\_ADE04  
41 34.5 47.3 517 1 DNB2\_ADE07  
42 34 46.6 36 1 TXAM\_METSE  
43 34 46.6 146 1 AP4A\_HUMAN  
44 34 46.6 146 1 AP4A\_MOUSE  
45 34 46.6 146 1 AP4A\_PIG

## ALIGNMENTS

RESULT 1  
OM1K\_CHLPN STANDARD; PRT: 333 AA.  
AC Q8XBFA:  
DT 30-MAY-2000 (Rel. 39, Created)  
DT 30-MAY-2000 (Rel. 39, Last sequence update)  
DT 20-AUG-2001 (Rel. 40, Last annotation update)  
DE MAJOR OUTER MEMBRANE PROTEIN (MOMP) (FRAGMENT).  
GN OMPA OR OMPI.  
OS Chlamydia pneumoniae (Chlamydia pneumoniae).  
OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydia phila.  
OX NCBI\_TaxID=83558;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN=KOALA TYPE 1;  
RX MEDLINE=9123168; PubMed=8419295;  
RA Kaltenboeck B., Kousoulas K.G., Storz J.;  
RT "Structures of and allelic diversity and relationships among the major  
outer membrane protein (ompA) genes of the four chlamydial species.";  
RL J. Bacteriol. 175:487-502(1993).  
CC -!- FUNCTION: STRUCTURAL RIGIDITY OF THE OUTER MEMBRANE OF ELEMENTARY  
BODIES AND PORIN FORMING. PERMITTING DIFFUSION OF SOLUTES THROUGH  
THE INTRACELLULAR RETICULATE BODY MEMBRANE.  
CC -!- SUBUNIT: DISULFIDE BOND INTERACTIONS WITHIN AND BETWEEN MOMP  
MOLECULES & OTHER COMPONENTS FORM HIGH MOLECULAR-WEIGHT OLIGOMERS.  
CC -!- SUBCELLULAR LOCATION: INTEGRAL MEMBRANE PROTEIN. OUTER MEMBRANE.  
CC -!- SIMILARITY: BELONGS TO THE CHLAMYDIAL OMP FAMILY.  
CC -----  
CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
between the Swiss Institute of Bioinformatics and the EMBL Outstation  
at the European Bioinformatics Institute. There are no restrictions on its  
use by non-profit institutions as long as its content is in no way  
modified and this statement is not removed. Usage by and for commercial  
entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
CC -----  
CC EMBL; M73038; AAD38210.1;  
DR InterPro; IPR000604; Chlamydia\_OMP.  
DR Pfam; PF01308; Chlamydia\_OMP; 1.  
DR ProDom; PD001717; Chlamydia\_OMP; 1.  
KW Outer membrane; Transmembrane; Porin.  
FT NON\_TER 1  
FT 333 333  
SQ SEQUENCE 333 AA; 35811 MW; 204604512C4C3B3F CRC64;

Query Match 100.0%; Score 73; DB 1; Length 333;  
Best Local Similarity 100.0%; Pred. No. 1e-05;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CQINKFKSRKACG 13

Db 298 CQINKFKSRKACG 310

RESULT 2

Tue Mar 26 15:55:34 2002

```
OMIN_CHLPN
ID OM1N_CHLPN STANDARD; PRT; 389 AA.
AC Q07430;
DT 30-MAY-2000 (Rel. 39, Created)
DT 30-MAY-2000 (Rel. 39, Last sequence update)
DT 20-AUG-2001 (Rel. 40, Last annotation update)
DE MAJOR OUTER MEMBRANE PROTEIN PRECURSOR (MOMP).
GN OMPA OR OMP1.
OS Chlamydia pneumoniae (Chlamydophila pneumoniae).
OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydophila.
OX NCBI_TaxID=83558;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=N16;
RX MEDLINE=94103736; PubMed=8277245;
RA Storey C., Lusher M., Yates P., Richmond S.;
RT "Evidence for Chlamydia pneumoniae of non-human origin.";
RL J. Gen. Microbiol. 139:2621-2626(1993).
CC -1- FUNCTION: STRUCTURAL RIGIDITY OF THE OUTER MEMBRANE OF ELEMENTARY
CC BODIES AND PORIN FORMING, PERMITTING DIFFUSION OF SOLUTES THROUGH
CC THE INTRACELLULAR RETICULATE BODY MEMBRANE.
CC -1- SUBUNIT: DISULFIDE BOND INTERACTIONS WITHIN AND BETWEEN MOMP
CC MOLECULES & OTHER COMPONENTS FORM HIGH MOLECULAR-WEIGHT OLIGOMERS.
CC -1- SUBCELLULAR LOCATION: INTEGRAL MEMBRANE PROTEIN. OUTER MEMBRANE.
CC -1- SIMILARITY: BELONGS TO THE CHLAMYDIAL OMP FAMILY.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; L04982; AAA17397.1;
DR InterPro; IPR000604; Chlamydia_OMP.
DR Pfam; PF01308; Chlamydia_OMP; 1.
DR ProDom; PD001717; Chlamydia_OMP; 1.
DR Outer membrane; Transmembrane; Porin; Signal.
KW SIGNAL 1 23 BY SIMILARITY.
FT CHAIN 24 389 MAJOR OUTER MEMBRANE PROTEIN.
FT SEQUENCE 389 AA; 41628 MW; 801622F05D841967 CRC64;
SQ
Query Match 100.0%; Score 73; DB 1; Length 389;
Best Local Similarity 100.0%; Pred. No. 1.2e-05;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 CQINKFSRKACG 13
| | | | | | | | | | | | | | | | | |
DB 342 CQINKFSRKACG 354
RESULT 3
OMPI_CHLPN
ID OMPI_CHLPN STANDARD; PRT; 389 AA.
AC P27455; O9J0F6;
DT 01-AUG-1992 (Rel. 23, Created)
DT 01-AUG-1992 (Rel. 23, Last sequence update)
DT 20-AUG-2001 (Rel. 40, Last annotation update)
DE MAJOR OUTER MEMBRANE PROTEIN PRECURSOR (MOMP).
GN OMPA OR OMP1 OR CPN0695 OR CPN0051.
OS Chlamydia pneumoniae (Chlamydophila pneumoniae).
OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydophila.
OX NCBI_TaxID=83558;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=IOL-207;
RX MEDLINE=91237311; PubMed=2033374;
RA Carter M.W., Al-Mahdawi S.A.H., Giles I.G., Trehan J.D.,
RA Ward M.E., Clarke I.N.;
RT "Nucleotide sequence and taxonomic value of the major outer membrane
RT protein gene of Chlamydia pneumoniae IOL-207.";
```



RESULT 6  
 OMIE\_CHLPS STANDARD; PRT; 402 AA.  
 AC P10332;  
 DT 01-MAR-1989 (Rel. 10, Created)  
 DT 01-MAR-1989 (Rel. 10, Last sequence update)  
 DT 20-AUG-2001 (Rel. 40, Last annotation update)  
 DE MAJOR OUTER MEMBRANE PROTEIN PRECURSOR (MOMP).  
 GN OMPA OR OMP1.  
 OS Chlamydia psittaci (Chlamydothiophila psittaci).  
 OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydothiophila.  
 OX NCBI\_TaxID=83554;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=EAE A22/M;  
 RA Pickett M.A., Everson S.J., Clarke I.N.;  
 RT "Chlamydia psittaci ewe abortion agent: complete nucleotide sequence  
 of the major outer membrane protein gene.";   
 RL FEMS Microbiol. Lett. 55:229-234(1988).  
 CC -1- FUNCTION: STRUCTURAL RIGIDITY OF THE OUTER MEMBRANE OF ELEMENTARY  
 CC THE INTRACELLULAR RETICULATE BODY MEMBRANE.  
 CC -2- BODIES AND PORIN FORMING, PERMITTING DIFFUSION OF SOLUTES THROUGH  
 CC THE INTRACELLULAR RETICULATE BODY MEMBRANE.  
 CC -3- SUBUNIT: DISULFIDE BOND INTERACTIONS WITHIN AND BETWEEN MOMP  
 CC MOLECULES & OTHER COMPONENTS FORM HIGH MOLECULAR-WEIGHT OLIGOMERS.  
 CC -4- SUBCELLULAR LOCATION: INTEGRAL MEMBRANE PROTEIN. OUTER MEMBRANE.  
 CC -5- SIMILARITY: BELONGS TO THE CHLAMYDIAL OMP FAMILY.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC -----  
 CC ENBL: X12647; CAA31177.1; -;  
 CC EMBL: M36703; AAA23146.1; -;  
 CC PIR: S05954; MMCWPM.  
 CC InterPro: IPR000604; Chlamydia\_OMP.  
 CC Pfam: PF01308; Chlamydia\_OMP; 1.  
 CC ProDom: PD001717; Chlamydia\_OMP; 1.  
 CC Outer membrane; Transmembrane; Porin; Signal.  
 FT SIGNAL 1 22  
 FT CHAIN 23 402 MAJOR OUTER MEMBRANE PROTEIN.  
 SQ SEQUENCE 402 AA; 43277 MW; E6CF00D9DF1EE87A CRC64;  
 Query Match 79.5%; Score 58; DB 1; Length 402;  
 Best Local Similarity 91.7%; Pred. No. 0.0052;  
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 42 QINKFKSRKACG 13  
 DB 356 QINKFKSRKACG 367  
 IIII IIIIIII  
 RESULT 7  
 OMPL\_CHLPU STANDARD; PRT; 387 AA.  
 AC P75024; Q04063; Q9X718;  
 DT 30-MAY-2000 (Rel. 39, Created)  
 DT 30-MAY-2000 (Rel. 39, Last sequence update)  
 DT 20-AUG-2001 (Rel. 40, Last annotation update)  
 DE MAJOR OUTER MEMBRANE PROTEIN PRECURSOR (MOMP).  
 GN OMPA OR OMP1 OR TC0052.  
 OS Chlamydia muridarum.  
 OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydia.  
 OX NCBI\_TaxID=83560;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=MOPN;  
 RC MEDLINE=92039057; PubMed=1937036;

RA Fielder T.J., Pal S., Peterson E.M., la Maza L.M.;  
 RT "Sequence of the gene encoding the major outer membrane protein of the  
 RL mouse pneumonitis biovar of Chlamydia trachomatis.";   
 RN Gene 106:137-138(1991).  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=MOPN;  
 RA MEDLINE=94104488; PubMed=8277858;  
 RA Zhang Y.X., Fox J.G., Ho Y., Zhang L., Stills H.F., Smith T.F.;  
 RT "Comparison of the major outer-membrane protein (MOMP) gene of mouse  
 RL pneumonitis (Mopn) and hamster SPFD strains of Chlamydia trachomatis  
 RT with other Chlamydia strains.";   
 RL Mol. Biol. Evol. 10:1327-1342(1993).  
 RN [3]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=SSP.BV.MOUSE / NIGG II;  
 RA Carter M.W., Giles I., Everson J.S., Clarke I.N.;  
 RT "Chlamydia trachomatis mouse biovar: major outer membrane protein  
 RL gene.";   
 RL (In) Mardh P.A., la Placa M., Ward M. (eds.);  
 RL Proceedings of the European society for chlamydia research and the  
 RL second international symposium of Uppsala university centre for std  
 RL research, pp.38-38, University of Uppsala, Uppsala (1992).  
 RN [4]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=MOPN / NIGG;  
 RA MEDLINE=20150255; PubMed=10684935;  
 RA Read T.D., Brunham R.C., Shen C., Gill S.R., Heidelberg J.F.,  
 RA White O., Linkey E.K., Peterson J., Utterback T., Berry K.,  
 RA Bass S., Linkey K., Weidman J., Khouri H., Craven B., Bowman C.,  
 RA Dodson R., Gwinn M., Nelson W., DeBoy R., Kolonay J., McClarty G.,  
 RA Salzberg S.L., Eisen J., Fraser C.M.;  
 RT "Genome sequences of Chlamydia trachomatis Mopn and Chlamydia  
 RL pneumoniae AR39.";   
 RL Nucleic Acids Res. 28:1397-1406(2000).  
 RN [5]  
 RP SEQUENCE OF 37-375 FROM N.A.  
 RC STRAIN=MOPN;  
 RA MEDLINE=93123168; PubMed=8419295;  
 RA Kallenboeck B., Kousoulas K.G., Storz J.;  
 RT "Structures of and allelic diversity and relationships among the major  
 RT outer membrane protein (ompA) genes of the four chlamydial species.";   
 RL J. Bacteriol. 175:487-502(1993).  
 CC -1- FUNCTION: STRUCTURAL RIGIDITY OF THE OUTER MEMBRANE OF ELEMENTARY  
 CC BODIES AND PORIN FORMING, PERMITTING DIFFUSION OF SOLUTES THROUGH  
 CC THE INTRACELLULAR RETICULATE BODY MEMBRANE.  
 CC -2- SUBUNIT: DISULFIDE BOND INTERACTIONS WITHIN AND BETWEEN MOMP  
 CC MOLECULES & OTHER COMPONENTS FORM HIGH MOLECULAR-WEIGHT OLIGOMERS.  
 CC -3- SUBCELLULAR LOCATION: CELL WALL SURFACE.  
 CC -4- MISCELLANEOUS: MOMP IS RESPONSIBLE FOR THE STRUCTURAL INTEGRITY OF  
 CC THE EXTRA-CELLULAR INFECTIOUS ELEMENTARY BODY & THE DEVELOPMENTAL  
 CC CONVERSION TO THE PLASTIC AND FRAGILE INTRACELLULAR RETICULATE  
 CC BODY.  
 CC -5- SIMILARITY: BELONGS TO THE CHLAMYDIAL OMP FAMILY.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC -----  
 CC EMBL: M64171; AAA23144.1; -;  
 CC EMBL: U60196; AAB07068.1; -;  
 CC EMBL: X63409; CAA45006.1; -;  
 CC EMBL: AE002272; AAF38941.1; -;  
 CC EMBL: M73044; AAD29101.1; -;  
 CC TIGR: TC0052;  
 CC InterPro: IPR000604; Chlamydia\_OMP.  
 CC Pfam: PF01308; Chlamydia\_OMP; 1.  
 CC ProDom: PD001717; Chlamydia\_OMP; 1.  
 CC Outer membrane; Transmembrane; Porin; Signal; Complete proteome.  
 KW



FT SIGNAL 1 22 BY SIMILARITY.  
 FT CHAIN 23 387 MAJOR OUTER MEMBRANE PROTEIN.  
 FT CONFLICT 118 118 F -> Y (IN REF. 5).  
 FT CONFLICT 123 123 Y -> F (IN REF. 5).  
 FT CONFLICT 198 198 L -> F (IN REF. 1).  
 FT CONFLICT 204 204 A -> P (IN REF. 1).  
 SQ SEQUENCE 387 AA; 42009 MW; 4FD6DC23248E0A2 CRC64;

Query Match 72.6%; Score 53; DB 1; Length 387;  
 Best Local Similarity 75.0%; Pred. No. 0.038;  
 Matches 9; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 2 QINKFKSRKACG 13  
 :||| |||||:|

Db 341 QLNKMKSRKSCG 352

## RESULT 8

OMID\_CHLTR STANDARD; PRT; 393 AA.  
 AC Q46409;  
 DT 30-MAY-2000 (Rel. 39, Created)  
 DT 30-MAY-2000 (Rel. 39, Last sequence update)  
 DE 20-AUG-2001 (Rel. 40, Last annotation update)  
 DE MAJOR OUTER MEMBRANE PROTEIN, SEROVAR D PRECURSOR (MOMP).  
 GN OMPA OR OMP1 OR CT681.  
 OS Chlamydia trachomatis.  
 OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydia.  
 OX NCBI\_TaxID=813;  
 [1]  
 RN CHlamydia trachomatis.  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=D/B-120;  
 RX MEDLINE=93013014; PubMed=1398119;  
 RA Sayada C., Denamur E., Elion J.;  
 RT "Complete sequence of the major outer membrane protein-encoding gene  
 of Chlamydia trachomatis serovar Da.";  
 RL Gene 120:129-130(1992).  
 [2]  
 RN CHlamydia trachomatis.  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=D/IU-71960;  
 RX MEDLINE=98339860; PubMed=9673241;  
 RA Scythard D.R., Boguslawski G., Jones R.B.;  
 RT "Phylogenetic analysis of the Chlamydia trachomatis major outer  
 membrane protein and examination of potential pathogenic  
 determinants.";  
 RL Infect. Immun. 66:3618-3625(1998).  
 [3]  
 RN SEQUENCE FROM N.A.  
 RP STRAIN=D/UW-3/CX;  
 RX MEDLINE=99000809; PubMed=9784136;  
 RA Stephens R.S., Kalman S., Lammel C.J., Fan J., Marathe R., Aravind L.,  
 RA Mitchell W.P., Olinger L., Tatusov R.L., Zhao Q., Koonin E.V.,  
 RA Davis R.W.;  
 RT "Genome sequence of an obligate intracellular pathogen of humans:  
 Chlamydia trachomatis.";  
 RL Science 282:754-759(1998).  
 CC -1- FUNCTION: STRUCTURAL RIGIDITY OF THE OUTER MEMBRANE OF ELEMENTARY  
 CC BODIES AND PORIN FORMING, PERMITTING DIFFUSION OF SOLUTES THROUGH  
 CC THE INTRACELLULAR RETICULATE BODY MEMBRANE.  
 CC -1- SUBUNIT: DISULFIDE BOND INTERACTIONS WITHIN AND BETWEEN MOMP  
 CC MOLECULES & OTHER COMPONENTS FORM HIGH MOLECULAR-WEIGHT OLIGOMERS.  
 CC -1- SUBCELLULAR LOCATION: INTEGRAL MEMBRANE PROTEIN. OUTER MEMBRANE.  
 CC -1- SIMILARITY: BELONGS TO THE CHLAMYDIAL OMP FAMILY.  
 CC  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announcement/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).

DR EMBL: X62918; CA44701.1;  
 DR EMBL: AF063195; AAC31436.2;  
 DR EMBL: AE001338; AAC68276.1;  
 DR InterPro: IPR000604; Chlamydia\_OMP.  
 DR Pfam: PF01308; Chlamydia\_OMP; 1.  
 DR ProDom: PD001717; Chlamydia\_OMP; 1.  
 KW Outer membrane; Transmembrane; Porin; Signal; Complete proteome.  
 FT SIGNAL 1 22 BY SIMILARITY.  
 FT CHAIN 23 393 MAJOR OUTER MEMBRANE PROTEIN, SEROVAR D.  
 SQ SEQUENCE 393 AA; 42438 MW; 8CD692FD3EFFF21D6 CRC64;

Query Match 72.6%; Score 53; DB 1; Length 393;  
 Best Local Similarity 75.0%; Pred. No. 0.039;  
 Matches 9; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 2 QINKFKSRKACG 13  
 :||| |||||:|

Db 347 QLNKMKSRKSCG 358

## RESULT 9

OMIE\_CHLTR STANDARD; PRT; 393 AA.  
 AC P17451;  
 DT 01-AUG-1990 (Rel. 15, Created)  
 DT 01-AUG-1990 (Rel. 15, Last sequence update)  
 DT 20-AUG-2001 (Rel. 40, Last annotation update)  
 DE MAJOR OUTER MEMBRANE PROTEIN, SEROVAR E PRECURSOR (MOMP).  
 GN OMPA OR OMP1E.  
 OS Chlamydia trachomatis.  
 OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydia.  
 OX NCBI\_TaxID=813;  
 [1]  
 RN SEQUENCE FROM N.A.  
 RC STRAIN=BOUR / SEROVAR E;  
 RX MEDLINE=90287737; PubMed=2356137;  
 RA Peterson E.M., Markoff B.A., de la Maza L.M.;  
 RT "The major outer membrane protein nucleotide sequence of Chlamydia  
 trachomatis, serovar E.";  
 RL Nucleic Acids Res. 18:3414-3414(1990).  
 CC -1- FUNCTION: STRUCTURAL RIGIDITY OF THE OUTER MEMBRANE OF ELEMENTARY  
 CC BODIES AND PORIN FORMING, PERMITTING DIFFUSION OF SOLUTES THROUGH  
 CC THE INTRACELLULAR RETICULATE BODY MEMBRANE.  
 CC -1- SUBUNIT: DISULFIDE BOND INTERACTIONS WITHIN AND BETWEEN MOMP  
 CC MOLECULES & OTHER COMPONENTS FORM HIGH MOLECULAR-WEIGHT OLIGOMERS.  
 CC -1- SUBCELLULAR LOCATION: INTEGRAL MEMBRANE PROTEIN. OUTER MEMBRANE.  
 CC -1- SIMILARITY: BELONGS TO THE CHLAMYDIAL OMP FAMILY.  
 CC  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announcement/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).

DR EMBL: X52557; CAA36791.1;  
 DR PIR: S10201; MWCWTE.  
 DR InterPro: IPR000604; Chlamydia\_OMP.  
 DR Pfam: PF01308; Chlamydia\_OMP; 1.  
 DR ProDom: PD001717; Chlamydia\_OMP; 1.  
 KW Outer membrane; Transmembrane; Porin; Signal.  
 FT SIGNAL 1 22  
 FT CHAIN 23 393 MAJOR OUTER MEMBRANE PROTEIN, SEROVAR E.  
 SQ SEQUENCE 393 AA; 42424 MW; AB2B82D16027B361 CRC64;

Query Match 72.6%; Score 53; DB 1; Length 393;  
 Best Local Similarity 75.0%; Pred. No. 0.039;  
 Matches 9; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 2 QINKFKSRKACG 13

[1]  
SEQUENCE FROM N.A.  
MEDLINE=87307955; PubMed=3040664;

```

Submitted (SEP-1994) to the SWISS-PROT data bank.
-!- FUNCTION: STRUCTURAL RIGIDITY OF THE OUTER MEMBRANE OF ELEMENTARY BODIES AND PORIN FORMING, PERMITTING DIFFUSION OF SOLUTES THROUGH THE INTRACELLULAR RETICULATE BODY MEMBRANE.
-!- SUBUNIT: DISULFIDE BOND INTERACTIONS WITHIN AND BETWEEN MOMP MOLECULES & OTHER COMPONENTS FORM HIGH MOLECULAR-WEIGHT OLIGOMERS.
-!- SUBCELLULAR LOCATION: INTEGRAL MEMBRANE PROTEIN. OUTER MEMBRANE.
-!- SIMILARITY: BELONGS TO THE CHLAMYDIAL OMP FAMILY.
-----
This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See http://www.isb-sib.ch/announce/ or send an email to license@isb-sib.ch).
-----
EMBL: M14738; AAA23151.1; --
PIR: S11012; S11012.
InterPro: IPR000604; Chlamydia_OMP.
Pfam: PF01308; Chlamydia_OMP.1.
ProDom: PD001717; Chlamydia_OMP.1.
Outer membrane; Transmembrane; Porin; Signal.
SIGNAL 1 32
CHAIN 23 394
SEQUENCE 394 AA; 42550 MW; BB587B80EB289CA5 CRC64;
-----
Query Match 72.6%; Score 53; DB 1; Length 394;
Best Local Similarity 75.1%; Pred. NO. 0.039;
Matches 9; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
-----
QY 2 QINKFKSRKACG 13
DB 348 QLNKMKSRKSCG 359
-----
::: ||| ::::: ||
-----
RESULT 13
OM1F_CHLTR OM1F_CHLTR STANDARD; PRT; 395 AA.
ID OM1F_CHLTR
AC P16155;
AT 01-APR-1990 (Rel. 14, Created)
DT 01-APR-1990 (Rel. 14, Last sequence update)
DT 20-AUG-2001 (Rel. 40, Last annotation update)
DE MAJOR OUTER MEMBRANE PROTEIN, SEROVAR F PRECURSOR (MOMP).
DE OMPA OR OM1F.
OS Chlamydia trachomatis.
OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydia.
OX NCBI_Taxid=813;
RN [1]
RS SEQUENCE FROM N.A.
RC STRAIN-IC-CAL3 / SEROVAR F;
RC MEDLINE=90192102; PubMed=2315025;
RA Zhang Y.X., Morrison S.G., Caldwell H.D.;
RT "The nucleotide sequence of major outer membrane protein gene of Chlamydia trachomatis serovar F.";
RL Nucleic Acids Res. 18:1061-1061(1990).
CC -!- FUNCTION: STRUCTURAL RIGIDITY OF THE OUTER MEMBRANE OF ELEMENTARY BODIES AND PORIN FORMING, PERMITTING DIFFUSION OF SOLUTES THROUGH THE INTRACELLULAR RETICULATE BODY MEMBRANE.
CC -!- SUBUNIT: DISULFIDE BOND INTERACTIONS WITHIN AND BETWEEN MOMP MOLECULES & OTHER COMPONENTS FORM HIGH MOLECULAR-WEIGHT OLIGOMERS.
CC -!- SUBCELLULAR LOCATION: INTEGRAL MEMBRANE PROTEIN. OUTER MEMBRANE.
CC -!- SIMILARITY: BELONGS TO THE CHLAMYDIAL OMP FAMILY.
-----
This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See http://www.isb-sib.ch/announce/ or send an email to license@isb-sib.ch).
-----

```

Db 350 QLNKMKSRKSCG 361

```

RESULT 15
OMIC_CHLTR
ID OMIC_CHLTR STANDARD; PRT; 397 AA.
AC P08780;
DT 01-NOV-1988 (Rel. 09, Created)
DT 01-NOV-1988 (Rel. 09, Last sequence update)
DT 20-AUG-2001 (Rel. 40, Last annotation update)
DE MAJOR OUTER MEMBRANE PROTEIN, SEROVAR C PRECURSOR (MOMP).
GN OMPA OR OMP1 OR OMP1C.
OS Chlamydia trachomatis.
OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydia.
OX NCBI_TaxID=813;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=87307955; PubMed=3040664;
RA Stephens R.S., Sanchez-Pescador R., Wagar E.A., Inouye C., Urdea M.S.;
RT "Diversity of Chlamydia trachomatis major outer membrane protein
genes.";
RL J. Bacteriol. 169:3879-3885(1987).
RN [2]
RP SEQUENCE FROM N.A.
RX STRAIN=C/TW3;
RA Dean D., Suchland R.J., Stamm W.E.;
RT "Evidence for long-term cervical persistence of Chlamydia trachomatis
by omp1 genotyping.";
RL J. Infect. Dis. 182:909-916(2000).
CC -1- FUNCTION: STRUCTURAL RIGIDITY OF THE OUTER MEMBRANE OF ELEMENTARY
BODIES AND PORIN FORMING, PERMITTING DIFFUSION OF SOLUTES THROUGH
THE INTRACELLULAR RETICULATE BODY MEMBRANE.
CC -1- SUBUNIT: DISULFIDE BOND INTERACTIONS WITHIN AND BETWEEN MOMP
MOLECULES & OTHER COMPONENTS FORM HIGH MOLECULAR-WEIGHT OLIGOMERS.
CC -1- SUBCELLULAR LOCATION: INTEGRAL MEMBRANE PROTEIN. OUTER MEMBRANE.
CC -1- SIMILARITY: BELONGS TO THE CHLAMYDIAL OMP FAMILY.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
between the Swiss Institute of Bioinformatics and the EMBL outstation -
the European Bioinformatics Institute. There are no restrictions on its
use by non-profit institutions as long as its content is in no way
modified and this statement is not removed. Usage by and for commercial
entities requires a license agreement (See http://www.isb-sib.ch/announce/
or send an email to license@isb-sib.ch).
CC -----
EMBL: M17343; AAA23156.1; -.
DR EMBL; AF202455; AAG09443.1; -.
DR PIR; S11011; MMCWTC.
DR InterPro; IPR000604; Chlamydia_OMP.
DR Pfam; PF01308; Chlamydia_OMP; 1.
DR ProDom; PD001717; Chlamydia_OMP; 1.
KW Outer membrane; Transmembrane; Porin; Signal.
FT SIGNAL 1
FT CHAIN 23 397 MAJOR OUTER MEMBRANE PROTEIN, SEROVAR C.
SQ SEQUENCE 397 AA; 42892 MW; 0047BCDB108E5309 CRC64;

```

```

Query Match 72.6%; Score 53; DB 1; Length 397;
Best Local Similarity 75.0%; Pred. No. 0.039;
Matches 9; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 2 QLNKMKSRKACG 13
   1:11 1111111
Db 351 QLNKMKSRKSCG 362

```

Search completed: March 26, 2002, 13:40:46  
Job time: 260 sec

GenCore version 4.5  
Copyright (c) 1993 - 2000 Compugen Ltd.

OM protein - protein search, using sw model

Run on: March 26, 2002, 13:40:15 ; Search time 79.01 Seconds  
(without alignments)  
24.067 Million cell updates/sec

Title: US-09-709-201-101  
Perfect score: 73  
Sequence: 1 CQINKFSRKACG 13

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 473505 seqs, 146272329 residues

Total number of hits satisfying chosen parameters: 473505

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

#### Database :

SPTREMBL\_17.\*  
1: sp\_archaea.\*  
2: sp\_bacteria.\*  
3: sp\_fungi.\*  
4: sp\_human.\*  
5: sp\_invertebrate.\*  
6: sp\_mammal.\*  
7: sp\_mhc.\*  
8: sp\_organelle.\*  
9: sp\_phase.\*  
10: sp\_plant.\*  
11: sp\_protein.\*  
12: sp\_virus.\*  
13: sp\_vertebrate.\*  
14: sp\_unclassified.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match %	Length	DB ID	Description
1	73	100.0	389	2 Q08085	Q08085 chlamydia p
2	67	91.8	336	2 Q9XB5	Q9XB5 chlamydia p
3	58	79.5	326	2 Q9K5C5	Q9K5C5 chlamydia p
4	58	79.5	330	2 Q9XB3	Q9XB3 chlamydia p
5	58	79.5	337	2 Q9XB6	Q9XB6 chlamydia p
6	58	79.5	340	2 Q9XB2	Q9XB2 chlamydia p
7	58	79.5	341	2 Q9X717	Q9X717 chlamydia p
8	58	79.5	380	2 Q9A111	Q9A111 chlamydia p
9	58	79.5	381	2 Q9A112	Q9A112 chlamydia p
10	58	79.5	382	2 Q9A1J9	Q9A1J9 chlamydia p
11	58	79.5	388	2 Q9A1K1	Q9A1K1 chlamydia p
12	58	79.5	388	2 Q9A1K0	Q9A1K0 chlamydia p
13	58	79.5	389	2 Q9APM4	Q9APM4 chlamydia p
14	58	79.5	389	2 Q9A1H9	Q9A1H9 chlamydia p
15	58	79.5	390	2 Q9A1J5	Q9A1J5 chlamydia p
16	58	79.5	391	2 Q46235	Q46235 chlamydia p
17	58	79.5	391	2 Q9A1J2	Q9A1J2 chlamydia p
18	58	79.5	392	2 Q9A1J4	Q9A1J4 chlamydia p
19	58	79.5	392	2 Q99QB0	Q99QB0 chlamydia p

20	58	79.5	395	2 Q9A1J7	Q9A1J7 chlamydia p
21	58	79.5	397	2 Q9A1J8	Q9A1J8 chlamydia p
22	58	79.5	402	2 Q46203	Q46203 chlamydia p
23	58	79.5	402	2 Q46236	Q46236 chlamydia p
24	58	79.5	402	2 Q46193	Q46193 chlamydia p
25	58	79.5	402	2 Q9A1I0	Q9A1I0 chlamydia p
26	55	75.3	322	2 Q9XB1	Q9XB1 chlamydia s
27	55	75.3	376	2 Q9A1I9	Q9A1I9 chlamydia s
28	55	75.3	385	2 Q9A1I7	Q9A1I7 chlamydia s
29	55	75.3	385	2 Q9A1I6	Q9A1I6 chlamydia s
30	55	75.3	386	2 Q9A1I5	Q9A1I5 chlamydia s
31	55	75.3	387	2 Q9A1J1	Q9A1J1 chlamydia s
32	55	75.3	387	2 Q9A1J0	Q9A1J0 chlamydia s
33	55	75.3	389	2 Q9A1I4	Q9A1I4 chlamydia s
34	55	75.3	391	2 Q9A1I3	Q9A1I3 chlamydia s
35	55	75.3	396	2 Q9A1I8	Q9A1I8 chlamydia s
36	55	75.3	402	2 Q9A1J6	Q9A1J6 chlamydia p
37	55	75.3	402	2 Q9A1J3	Q9A1J3 chlamydia p
38	53	72.6	103	2 Q9S6E6	Q9S6E6 chlamydia t
39	53	72.6	106	2 Q9S6E9	Q9S6E9 chlamydia t
40	53	72.6	107	2 Q9S6E7	Q9S6E7 chlamydia t
41	53	72.6	108	2 Q9X4V8	Q9X4V8 chlamydia t
42	53	72.6	108	2 Q9S6F2	Q9S6F2 chlamydia t
43	53	72.6	108	2 Q9S6E8	Q9S6E8 chlamydia t
44	53	72.6	108	2 Q9S6E1	Q9S6E1 chlamydia t
45	53	72.6	109	2 Q9ZFE8	Q9ZFE8 chlamydia t

#### ALIGNMENTS

RESULT 1

Q08085 ID Q08085 PRELIMINARY; PRT; 389 AA.  
AC Q08085;  
DT 01-NOV-1996 (Tremblrel. 01, Created)  
DT 01-NOV-1996 (Tremblrel. 01, Last sequence update)  
DE 01-JUN-2001 (Tremblrel. 17, Last annotation update)  
DE MAJOR OUTER MEMBRANE PROTEIN PRECURSOR (MOMP).  
OS Chlamydia psittaci (Chlamydia psittaci).  
OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydia.  
OX NCBI\_TaxID=83554;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN=KOALA TYPE 1;  
RX MEDLINE=94:71025; PubMed=8125292;  
RA Girjes A.A., Carrick F.N., Lavin M.F.;  
RT Remarkable sequence relatedness in the DNA encoding the major outer membrane protein of Chlamydia psittaci (koala type I) and Chlamydia pneumoniae.  
RL Gene 138:139-142(1994).  
CC -!- FUNCTION: STRUCTURAL RIGIDITY OF THE OUTER MEMBRANE OF ELEMENTARY BODIES AND PORIN FORMING, PERMITTING DIFFUSION OF SOLUTES THROUGH THE INTRACELLULAR RETICULATE BODY MEMBRANE.  
CC -!- SUBUNIT: DISULFIDE BOND INTERACTIONS WITHIN AND BETWEEN MOMP MOLECULES & OTHER COMPONENTS FORM HIGH MOLECULAR-WEIGHT OLIGOMERS.  
CC -!- SUBCELLULAR LOCATION: INTEGRAL MEMBRANE PROTEIN. OUTER MEMBRANE. EMBL; X72023; CAAS0906.1; -!  
DR InterPro; IPR000604; Chlamydia\_OMP.  
DR Pfam; PF01308; Chlamydia\_OMP; 1.  
DR PRINTS; PR01334; CHLAMIDIAOMP.  
DR ProDom; PD001717; Chlamydia\_OMP; 1.  
KW Outer membrane; Transmembrane; Porin; Signal.  
FT SIGNAL 1 23 BY SIMILARITY.  
FT CHAIN 24 389 MAJOR OUTER MEMBRANE PROTEIN.  
SQ SEQUENCE 389 AA; 41579 MW; 5DC50E85A6F4E50F CRC64;

Query Match 100.0%; Score 73; DB 2; Length 389;  
Best Local Similarity 100.0%; Pred. No. 8e-06;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CQINKFSRKACG 13

```

Db 342 QINKFKSRKACG 354
|||||
RESULT 2
Q9XBF5 PRELIMINARY; PRT; 336 AA.
AC Q9XBF5
DT 01-NOV-1999 (TREMBlrel. 12, Created)
DT 01-NOV-1999 (TREMBlrel. 12, Last sequence update)
DE 01-JUN-2001 (TREMBlrel. 17, Last annotation update)
DE OUTER MEMBRANE PROTEIN (FRAGMENT).
OS Chlamydomophila pecorum.
OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydomophila.
OX NCBI_TaxID=85991;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=66P130;
RX MEDLINE=93123168; PubMed=8419295;
RA "Kaltenboeck B., Kousoulas K.G., Storz J.;
RT "Structures of and allelic diversity and relationships among the major
RL J. Bacteriol. 175:487-502(1993).
DR EMBL; M73034; AAD38209.1;
DR InterPro; IPR000604; Chlamydia_OMP.
DR Pfam; PF01308; Chlamydia_OMP; 1.
DR ProDom; PD001717; Chlamydia_OMP; 1.
FT NON_TER 1
FT NON_TER 336
SQ SEQUENCE 336 AA; 36698 MW; 0AC8C33EB3E0A61A CRC64;

Query Match 91.8%; Score 67; DB 2; Length 336;
Best Local Similarity 92.3%; Pred. No. 9.5e-05;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 QINKFKSRKACG 13
|||||
Db 301 QINKLKSRRKACG 313

RESULT 3
Q9K5C5 PRELIMINARY; PRT; 326 AA.
AC Q9K5C5
DT 01-OCT-2000 (TREMBlrel. 15, Created)
DT 01-OCT-2000 (TREMBlrel. 15, Last sequence update)
DE 01-JUN-2001 (TREMBlrel. 17, Last annotation update)
DE OUTER MEMBRANE PROTEIN 1 (FRAGMENT).
OS Chlamydia psittaci (Chlamydomophila psittaci).
OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydomophila.
OX NCBI_TaxID=83554;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=RS4;
RX PubMed=10919838;
RA "Hermann B., Rahman R., Bergstrom S., Bonnedahl J., Olsen B.;
RT "Chlamydomophila abortus in a Brown Skua (Catharacta antarctica
RL (Lomborg)) from a Subantarctic Island.";
DR Appl. Environ. Microbiol. 66:3654-3656(2000).
DR EMBL; A243525; CAB96859.1;
DR InterPro; IPR000604; Chlamydia_OMP.
DR Pfam; PF01308; Chlamydia_OMP; 1.
DR PRINTS; PR01334; CHLAMIDITAO.
DR ProDom; PD001717; Chlamydia_OMP; 1.
FT NON_TER 1
FT NON_TER 326
SQ SEQUENCE 326 AA; 35345 MW; 6C5A20C8913743C8 CRC64;

Query Match 79.5%; Score 58; DB 2; Length 326;
Best Local Similarity 91.7%; Pred. No. 0.0046;

QY 1 QINKFKSRKACG 13
|||||
Db 301 QINKLKSRRKACG 313

RESULT 4
Q9XBF3 PRELIMINARY; PRT; 330 AA.
AC Q9XBF3
DT 01-NOV-1999 (TREMBlrel. 12, Created)
DT 01-NOV-1999 (TREMBlrel. 12, Last sequence update)
DE 01-JUN-2001 (TREMBlrel. 17, Last annotation update)
DE OUTER MEMBRANE PROTEIN (FRAGMENT).
OS Chlamydomophila pecorum.
OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydomophila.
OX NCBI_TaxID=85991;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=L71;
RX MEDLINE=93123168; PubMed=8419295;
RA "Kaltenboeck B., Kousoulas K.G., Storz J.;
RT "Structures of and allelic diversity and relationships among the major
RL J. Bacteriol. 175:487-502(1993).
DR EMBL; M73039; AAD38211.1;
DR InterPro; IPR000604; Chlamydia_OMP.
DR Pfam; PF01308; Chlamydia_OMP; 1.
DR ProDom; PD001717; Chlamydia_OMP; 1.
FT NON_TER 1
FT NON_TER 330
SQ SEQUENCE 330 AA; 35834 MW; FCB6D9332991BB09 CRC64;

Query Match 79.5%; Score 58; DB 2; Length 330;
Best Local Similarity 91.7%; Pred. No. 0.0046;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2 QINKFKSRKACG 13
|||||
Db 296 QINKLKSRRKACG 307

RESULT 5
Q9XBF6 PRELIMINARY; PRT; 337 AA.
AC Q9XBF6
DT 01-NOV-1999 (TREMBlrel. 12, Created)
DT 01-NOV-1999 (TREMBlrel. 12, Last sequence update)
DE 01-JUN-2001 (TREMBlrel. 17, Last annotation update)
DE OUTER MEMBRANE PROTEIN (FRAGMENT).
OS Chlamydomophila pecorum.
OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydomophila.
OX NCBI_TaxID=85991;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=L710S;
RX MEDLINE=93123168; PubMed=8419295;
RA "Kaltenboeck B., Kousoulas K.G., Storz J.;
RT "Structures of and allelic diversity and relationships among the major
RL J. Bacteriol. 175:487-502(1993).
DR EMBL; M73033; AAD38208.1;
DR InterPro; IPR000604; Chlamydia_OMP.
DR Pfam; PF01308; Chlamydia_OMP; 1.
DR ProDom; PD001717; Chlamydia_OMP; 1.
FT NON_TER 1
FT NON_TER 337
SQ SEQUENCE 337 AA; 36817 MW; A173FB2597C84E6B CRC64;

Query Match 79.5%; Score 58; DB 2; Length 337;

```

Best Local Similarity 91.7%; Pred. NO. 0.0047; Mismatches 0; Gaps 0; Indels 1;

Matches 11; Conservative 0; Mismatches 1; Indels 1; Gaps 0;

QY 2 QINKFKSRKACG 13  
 DB 303 QINKLKSRRKACG 314

## RESULT 6

Q9XBF2 PRELIMINARY; PRT; 340 AA.  
 AC Q9XBF2;  
 DT 01-NOV-1999 (TReMBLrel. 12, Created)  
 DT 01-NOV-1999 (TReMBLrel. 12, Last sequence update)  
 DT 01-JUN-2001 (TReMBLrel. 17, Last annotation update)  
 DE OUTER MEMBRANE PROTEIN (FRAGMENT).  
 OS Chlamydomophila pecorum.  
 OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydomophila.  
 NCBI\_TaxID=85991;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=LW613;  
 RX MEDLINE=93123168; PubMed=8419295;  
 RA Kaltenboeck B., Kousoulas K.G., Storz J.;  
 RT "Structures of and allelic diversity and relationships among the major  
 RT outer membrane protein (ompA) genes of the four chlamydial species.";  
 RL J. Bacteriol. 175:487-502(1993).  
 DR EMBL; W73042; AAD38212.1;  
 DR InterPro: IPR000604; Chlamydia\_OMP.  
 DR Pfam: PF01308; Chlamydia\_OMP; 1.  
 DR ProDom; PD001717; Chlamydia\_OMP; 1.  
 FT NON\_TER 1  
 FT NON\_TER 340  
 FT NON\_TER 340  
 SQ SEQUENCE 340 AA; 36968 MW; F571E822DIDE0AA3 CRC64;

Query Match 79.5%; Score 58; DB 2; Length 340;

Best Local Similarity 91.7%; Pred. NO. 0.0047; Mismatches 0; Gaps 0; Indels 1;

QY 2 QINKFKSRKACG 13  
 DB 306 QINKLKSRRKACG 317

## RESULT 7

Q9X717 PRELIMINARY; PRT; 341 AA.  
 AC Q9X717;  
 DT 01-NOV-1999 (TReMBLrel. 12, Created)  
 DT 01-NOV-1999 (TReMBLrel. 12, Last sequence update)  
 DT 01-JUN-2001 (TReMBLrel. 17, Last annotation update)  
 DE MAJOR OUTER MEMBRANE PROTEIN PRECURSOR (FRAGMENT).  
 GN OMPA.  
 OS Chlamydomophila abortus.  
 OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydomophila.  
 NCBI\_TaxID=83555;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=LW508;  
 RX MEDLINE=93123168; PubMed=8419295;  
 RA Kaltenboeck B., Kousoulas K.G., Storz J.;  
 RT "Structures of and allelic diversity and relationships among the major  
 RT outer membrane protein (ompA) genes of the four chlamydial species.";  
 RL J. Bacteriol. 175:487-502(1993).  
 DR EMBL; W73040; AAD29103.1;  
 DR InterPro: IPR000604; Chlamydia\_OMP.  
 DR Pfam: PF01308; Chlamydia\_OMP; 1.  
 DR ProDom; PD001717; Chlamydia\_OMP; 1.  
 FT NON\_TER 1  
 FT NON\_TER 341  
 FT NON\_TER 341  
 SQ SEQUENCE 341 AA; 36762 MW; B5933C9BF6AAFI71 CRC64;

Query Match 79.5%; Score 58; DB 2; Length 341;

Best Local Similarity 91.7%; Pred. NO. 0.0048; Mismatches 0; Gaps 0; Indels 1;

QY 2 QINKFKSRKACG 13  
 DB 307 QINKMKSRRKACG 318

## RESULT 8

Q9AII1 PRELIMINARY; PRT; 380 AA.  
 AC Q9AII1;  
 DT 01-JUN-2001 (TReMBLrel. 17, Created)  
 DT 01-JUN-2001 (TReMBLrel. 17, Last sequence update)  
 DT 01-JUN-2001 (TReMBLrel. 17, Last annotation update)  
 DE MAJOR OUTER MEMBRANE PROTEIN PRECURSOR (FRAGMENT).  
 GN OMPA.  
 OS Chlamydomophila pecorum.  
 OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydomophila.  
 NCBI\_TaxID=85991;  
 RN [1]  
 RP SEQUENCE OF 40-352 FROM N.A.  
 RC STRAIN=L71;  
 RX MEDLINE=93123168; PubMed=8419295;  
 RA Kaltenboeck B., Kousoulas K.G., Storz J.;  
 RT "Structures of and allelic diversity and relationships among the major  
 RT outer membrane protein (ompA) genes of the four chlamydial species.";  
 RL J. Bacteriol. 175:487-502(1993).  
 RN [2]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=L71;  
 RX MEDLINE=21078680; PubMed=11211261;  
 RA Bush R.M., Everett K.D.;  
 RT "Molecular evolution of the Chlamydiaceae.";  
 RL Int. J. Syst. Evol. Microbiol. 51:203-220(2001).  
 RN [3]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=L71;  
 RA Everett K.D.E., Hambly W.A., Andersen A.A.;  
 RL Submitted (MAY-2000) to the EMBL/GenBank/DBJ databases.  
 DR EMBL; AF269280; AAK00261.1;  
 KW Signal.  
 FT NON\_TER 1  
 FT SIGNAL <1  
 FT CHAIN 16  
 FT SEQUENCE 380 AA; 41047 MW; 829A18D3CSA85008 CRC64;

Query Match 79.5%; Score 58; DB 2; Length 380;

Best Local Similarity 91.7%; Pred. NO. 0.0052; Mismatches 0; Gaps 0; Indels 1;

QY 2 QINKFKSRKACG 13  
 DB 334 QINKLKSRRKACG 345

## RESULT 9

Q9AII2 PRELIMINARY; PRT; 381 AA.  
 AC Q9AII2;  
 DT 01-JUN-2001 (TReMBLrel. 17, Created)  
 DT 01-JUN-2001 (TReMBLrel. 17, Last sequence update)  
 DT 01-JUN-2001 (TReMBLrel. 17, Last annotation update)  
 DE MAJOR OUTER MEMBRANE PROTEIN PRECURSOR (FRAGMENT).  
 GN OMPA.  
 OS Chlamydomophila pecorum.  
 OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydomophila.  
 NCBI\_TaxID=85991;  
 RN [1]  
 RP SEQUENCE OF 34-369 FROM N.A.

RC STRAIN=1710S;  
 RX MEDLINE=93123168; PubMed=8419295;  
 RA Kaltenboeck B., Kousoulas K.G., Storz J.;  
 RT "Structures of and allelic diversity and relationships among the major  
 RT outer membrane protein (ompA) genes of the four chlamydial species.";  
 RL J. Bacteriol. 175:487-502(1993).  
 RN [2]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=1710S;  
 RX MEDLINE=21078680; PubMed=11211261;  
 RA Bush R.M., Everett K.D.;  
 RT "Molecular evolution of the Chlamydiaceae.";  
 RL Int. J. Syst. Evol. Microbiol. 51:203-220(2001).  
 RN [3]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=1710S;  
 RX MEDLINE=21078680; PubMed=11211261;  
 RA Everett K.D.E., Hambly W.A., Andersen A.A.;  
 RT Submitted (MAY-2000) to the EMBL/GenBank/DBJ databases.  
 DR EMBL; AF269279; AAK00260.1; -;  
 KW Signal.  
 FT NON\_TER 1 15 POTENTIAL.  
 FT SIGNAL <1 15  
 FT CHAIN 16 381 MAJOR OUTER MEMBRANE PROTEIN.  
 FT SEQUENCE 381 AA; 41332 MW; 29406725CF9D3512 CRC64;

Query Match 79.5%; Score 58; DB 2; Length 381;  
 Best Local Similarity 91.7%; Pred. No. 0.0052;  
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 2 QINKFKSRKACG 13  
 DB 335 QINKLKSRRKACG 346  
 IIII IIIIIII

RESULT 10  
 Q9AIJ9 PRELIMINARY; PRT; 382 AA.  
 AC Q9AIJ9;  
 DT 01-JUN-2001 (TReMBLrel. 17, Created)  
 DT 01-JUN-2001 (TReMBLrel. 17, Last sequence update)  
 DT 01-JUN-2001 (TReMBLrel. 17, Last annotation update)  
 DE MAJOR OUTER MEMBRANE PROTEIN PRECURSOR (FRAGMENT).  
 GN OMPA.  
 OS Chlamydia psittaci (Chlamydia phila psittaci).  
 OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydia phila.  
 OX NCBI\_TaxID=83554;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=MENINGOPNEUMONITIS, MN, ATCC VR122;  
 RX MEDLINE=21078680; PubMed=11211261;  
 RA Bush R.M., Everett K.D.;  
 RT "Molecular evolution of the Chlamydiaceae.";  
 RL Int. J. Syst. Evol. Microbiol. 51:203-220(2001).  
 DR EMBL; AF269262; AAK00243.1; -;  
 KW Signal.  
 FT NON\_TER 1 1 POTENTIAL.  
 FT SIGNAL <1 2  
 FT CHAIN 3 382 MAJOR OUTER MEMBRANE PROTEIN.  
 FT SEQUENCE 382 AA; 41231 MW; 69171719A69303B CRC64;

Query Match 79.5%; Score 58; DB 2; Length 382;  
 Best Local Similarity 91.7%; Pred. No. 0.0053;  
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 2 QINKFKSRKACG 13  
 DB 336 QINKMKSRKACG 347  
 IIII IIIIIII

RESULT 11  
 Q9AIK1 PRELIMINARY; PRT; 389 AA.

ID Q9AIK1 PRELIMINARY; PRT; 388 AA.  
 AC Q9AIK1;  
 DT 01-JUN-2001 (TReMBLrel. 17, Created)  
 DT 01-JUN-2001 (TReMBLrel. 17, Last sequence update)  
 DT 01-JUN-2001 (TReMBLrel. 17, Last annotation update)  
 DE MAJOR OUTER MEMBRANE PROTEIN PRECURSOR (FRAGMENT).  
 GN OMPA.  
 OS Chlamydia psittaci (Chlamydia phila psittaci).  
 OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydia phila.  
 OX NCBI\_TaxID=83554;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=VS225;  
 RX MEDLINE=21078680; PubMed=11211261;  
 RA Bush R.M., Everett K.D.;  
 RT "Molecular evolution of the Chlamydiaceae.";  
 RL Int. J. Syst. Evol. Microbiol. 51:203-220(2001).  
 DR EMBL; AF269259; AAK00240.1; -;  
 KW Signal.  
 FT NON\_TER 1 19 POTENTIAL.  
 FT SIGNAL <1 19  
 FT CHAIN 20 388 MAJOR OUTER MEMBRANE PROTEIN.  
 FT SEQUENCE 388 AA; 41573 MW; 8E232D22C9B9948D CRC64;

Query Match 79.5%; Score 58; DB 2; Length 388;  
 Best Local Similarity 91.7%; Pred. No. 0.0053;  
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 2 QINKFKSRKACG 13  
 DB 342 QINKMKSRKACG 353  
 IIII IIIIIII

RESULT 12  
 Q9AIK0 PRELIMINARY; PRT; 388 AA.  
 AC Q9AIK0;  
 DT 01-JUN-2001 (TReMBLrel. 17, Created)  
 DT 01-JUN-2001 (TReMBLrel. 17, Last sequence update)  
 DT 01-JUN-2001 (TReMBLrel. 17, Last annotation update)  
 DE MAJOR OUTER MEMBRANE PROTEIN PRECURSOR (FRAGMENT).  
 GN OMPA.  
 OS Chlamydia psittaci (Chlamydia phila psittaci).  
 OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydia phila.  
 OX NCBI\_TaxID=83554;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=CALIFORNIA TURKEY 1, CTL;  
 RX MEDLINE=21078680; PubMed=11211261;  
 RA Bush R.M., Everett K.D.;  
 RT "Molecular evolution of the Chlamydiaceae.";  
 RL Int. J. Syst. Evol. Microbiol. 51:203-220(2001).  
 DR EMBL; AF269260; AAK00241.1; -;  
 KW Signal.  
 FT NON\_TER 1 1 POTENTIAL.  
 FT SIGNAL <1 19  
 FT CHAIN 20 388 MAJOR OUTER MEMBRANE PROTEIN.  
 FT SEQUENCE 388 AA; 42053 MW; 96E675B3F69F708B CRC64;

Query Match 79.5%; Score 58; DB 2; Length 388;  
 Best Local Similarity 91.7%; Pred. No. 0.0053;  
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 2 QINKFKSRKACG 13  
 DB 342 QINKMKSRKACG 353  
 IIII IIIIIII

RESULT 13  
 Q9APM4 PRELIMINARY; PRT; 389 AA.



Q9APM4;  
 DT 01-JUN-2001 (TReMBLrel. 17, Created)  
 DT 01-JUN-2001 (TReMBLrel. 17, Last sequence update)  
 DT 01-JUN-2001 (TReMBLrel. 17, Last annotation update)  
 DE MAJOR OUTER MEMBRANE PROTEIN PRECURSOR.  
 GN OMPL.  
 OS Chlamydomydia abortus.  
 OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydomydia.  
 OX NCBI\_TaxID=83355;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=LLG;  
 RX MEDLINE=20569239; PubMed=111119563;  
 RA Vretou E., Psarrou E., Kaisar M., Vlisidou I., Salti-Montesanto V.,  
 RA Longbottom D.;  
 RT "Identification of protective epitopes by sequencing of the major  
 RT outer membrane protein gene of a variant strain of Chlamydia psittaci  
 RT serotype 1.";  
 RL Infect. Immun. 69:607-612(2001).  
 DR EMBL; AF272945; AAG53881.1; -.  
 KW Signal.  
 FT SIGNAL 1 22 POTENTIAL.  
 FT CHAIN 23 389 MAJOR OUTER MEMBRANE PROTEIN.  
 SQ SEQUENCE 389 AA; 41897 MW; 2051369C7DBAAF5 CRC64;

Query Match 79.5%; Score 58; DB 2; Length 389;  
 Best Local Similarity 91.7%; Pred. No. 0.0053;  
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2 QINKKSRKACG 13  
 IIII IIIIIII  
 Db 343 QINKKSRKACG 354

RESULT 14  
 Q9AIH9  
 ID Q9AIH9 PRELIMINARY; PRT; 389 AA.  
 AC Q9AIH9;  
 DT 01-JUN-2001 (TReMBLrel. 17, Created)  
 DT 01-JUN-2001 (TReMBLrel. 17, Last sequence update)  
 DT 01-JUN-2001 (TReMBLrel. 17, Last annotation update)  
 DE MAJOR OUTER MEMBRANE PROTEIN PRECURSOR.  
 GN OMPA.  
 OS Chlamydomydia caviae.  
 OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydomydia.  
 OX NCBI\_TaxID=833557;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=GUINEA PIG INCLUSION CONJUNCTIVITIS, GPIC, ATCC VR813;  
 RX MEDLINE=89212917; PubMed=2707861;  
 RA Zhang Y.X., Morrison S.G., Caldwell H.D., Baehr W.;  
 RT "Cloning and sequence analysis of the major outer membrane protein  
 RT genes of two Chlamydia psittaci strains.";  
 RL Infect. Immun. 57:1621-1625(1989).  
 DR EMBL; AF269282; AAK00263.1; -.  
 KW Signal.  
 FT SIGNAL 1 22 POTENTIAL.  
 FT CHAIN 23 389 MAJOR OUTER MEMBRANE PROTEIN.  
 SQ SEQUENCE 389 AA; 41932 MW; 2527A820C76F8310 CRC64;

Query Match 79.5%; Score 58; DB 2; Length 389;  
 Best Local Similarity 91.7%; Pred. No. 0.0053;  
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2 QINKKSRKACG 13  
 IIII IIIIIII  
 Db 343 QINKKSRKACG 354

RESULT 15  
 Q9AIJ5  
 ID Q9AIJ5 PRELIMINARY; PRT; 390 AA.  
 AC Q9AIJ5;  
 DT 01-JUN-2001 (TReMBLrel. 17, Created)  
 DT 01-JUN-2001 (TReMBLrel. 17, Last sequence update)  
 DT 01-JUN-2001 (TReMBLrel. 17, Last annotation update)  
 DE MAJOR OUTER MEMBRANE PROTEIN PRECURSOR (FRAGMENT).  
 GN OMPA.  
 OS Chlamydia psittaci (Chlamydomydia psittaci).  
 OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydomydia.  
 OX NCBI\_TaxID=83354;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=NEW JERSEY 1, NJ1;  
 RX MEDLINE=21078680; PubMed=11211261;  
 RA Bush R.M., Everett K.D.;  
 RT "Molecular evolution of the Chlamydiaceae.";  
 RL Int. J. Syst. Evol. Microbiol. 51:203-220(2001).  
 DR EMBL; AF269266; AAK00247.1; -.  
 KW Signal.  
 FT NON\_TER 1 1  
 FT SIGNAL <1 20 POTENTIAL.  
 FT CHAIN 21 390 MAJOR OUTER MEMBRANE PROTEIN.  
 SQ SEQUENCE 390 AA; 42042 MW; B62858403DBFA4E6 CRC64;

Query Match 79.5%; Score 58; DB 2; Length 390;  
 Best Local Similarity 91.7%; Pred. No. 0.0054;  
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2 QINKKSRKACG 13  
 IIII IIIIIII  
 Db 344 QINKKSRKACG 355

Search completed: March 26, 2002, 13:40:16  
 Job time: 230 sec

